FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Slavov, SN
   Silveira, RM
   Hespanhol, MR
   Sauvage, V
   Rodrigues, ES
   Krause, LF
   Bittencourt, HT
   Caro, V
   Laperche, S
   Covas, DT
   Kashima, S
AF Slavov, S. N.
   Maraninchi Silveira, R.
   Hespanhol, M. R.
   Sauvage, V.
   Rodrigues, E. S.
   Fontanari Krause, L.
   Bittencourt, H. T.
   Caro, V.
   Laperche, S.
   Covas, D. T.
   Kashima, S.
TI Human pegivirus-1 (HPgV-1) RNA prevalence and genotypes in volunteer
   blood donors from the Brazilian Amazon
SO TRANSFUSION CLINIQUE ET BIOLOGIQUE
LA English
DT Article
DE Human Pegivirus-1; HPgV-1; Blood donors; Prevalence; Genotype; Brazilian
   Amazon
ID GB-VIRUS-C; HEPATITIS-G VIRUS; C/HEPATITIS-G VIRUS; HIV-1-INFECTED
   PATIENTS; TRANSPLANT RECIPIENTS; PHYLOGENETIC ANALYSIS; INFECTION; HIV;
   TRANSMISSION; C/HGV
AB Objectives. - The objectives of this study were to evaluate the prevalence of Human Pegivirus-1 (HPgV-1) viremia and genotype diversity among healthy blood donors from the Eastern Brazilian Amazon (city of Macapa, State of Amapa). There is little information for prevalence and circulation of HPgV-1 in this remote Brazilian region.
   Materials and methods. - We conducted a study evaluating the HPgV-1 RNA prevalence and circulating genotypes in 431 volunteer blood donors originating from the Eastern Brazilian Amazon. The obtained HPgV-1 positive samples were submitted to sequencing and genotyping analysis in order to examine the genotype diversity of this virus in the Brazilian Amazon.
   Results. - Our results demonstrated a prevalence of HPgV-1 RNA in 9.5% of the tested blood donors. The phylogenetic analyses of the detected positive samples showed the presence of HPgV-1 genotypes 1, 2 and 3. The most frequently detected genotype was 2 (78.0% of the cases) represented by sub-genotypes 2A (39.0%) and 2B (39.0%). At lower rates, genotypes 1 (14.6%) and 3 (7.4%) were also detected.
   Conclusion. - Our results revealed the presence of genotypes with European, Asiatic and African endemicity in Amazonian blood donors, probably due to the complex miscegenation processes that took place in this Brazilian region. More investigations, including information for the prevalence of HPgV-1 RNA in blood donors from other Latin American countries are needed to estimate the viremic rates and genotype distribution of this virus in a highly diverse continent like South America. (C) 2019 Societe francaise de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.
C1 [Slavov, S. N.; Maraninchi Silveira, R.; Hespanhol, M. R.; Rodrigues, E. S.; Covas, D. T.; Kashima, S.] Univ Sao Paulo, Fac Med Ribeirao Preto, Reg Blood Ctr Ribeirao Preto, BR-14051140 Ribeirao Preto, SP, Brazil.
   [Slavov, S. N.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Internal Med, BR-14051140 Ribeirao Preto, SP, Brazil.
   [Sauvage, V.; Laperche, S.] Ctr Natl Reference Risques Infect Transfus, INTS, Dept Etud Agents Transmissibles Sang DATS, F-75015 Paris, France.
   [Fontanari Krause, L.] Franciscan Univ, Lab Biosci, BR-97010030 Santa Maria, RS, Brazil.
   [Bittencourt, H. T.] Inst Hematol & Hemotherapy Amapa, BR-68900074 Macapa, Amapa, Brazil.
   [Caro, V.] Inst Pasteur, Environm & Infect Risks Res & Expertise Unit, Lab Urgent Response Biol Threats, PGP, F-75724 Paris, France.
RP Slavov, SN (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Reg Blood Ctr Ribeirao Preto, Lab Mol Biol, Rua Tenente Catao Roxo 2501, BR-14051140 Ribeirao Preto, SP, Brazil.
EM svetoslay.slavov@hemocentro.fmrp.usp.br
RI ; Kashima, Simone/G-4876-2012
OI Silveira, Roberta/0000-0002-7745-7274; Kashima,
   Simone/0000-0002-1487-0141
FU Fundacao de Amparo e Pesquisa do Estado de Sao Paulo-FAPESP, Brazil
   [2009/16623-1, CTC-2013/081352, 2017/23205-8,
   INCTC-FAPESP-2014/50947-7]; Conselho Nacional do Desenvolvimento
   Cientifico e Tecnologico, Brazil [INCTC-465539/2014-9, 455503/2014-1];
   FINEP, BrazilCiencia Tecnologia e Inovacao (FINEP) [245/2016]
FX This study was supported by Fundacao de Amparo e Pesquisa do Estado de
   Sao Paulo-FAPESP, Brazil (Grants 2009/16623-1, CTC-2013/081352,
   2017/23205-8, INCTC-FAPESP-2014/50947-7), Conselho Nacional do
   Desenvolvimento Cientifico e Tecnologico, Brazil (INCTC-465539/2014-9;
   455503/2014-1), and FINEP, Brazil (245/2016).
CR Abraham P, 2003, J CLIN VIROL, V28, P59, DOI 10.1016/S1386-6532(02)00239-1
   Abu Odeh R, 2010, INTERVIROLOGY, V53, P402, DOI 10.1159/000317290
   AbuOdeh RO, 2015, J MED VIROL, V87, P2074, DOI 10.1002/jmv.24289
   Alcalde R, 2010, VIRUS RES, V151, P148, DOI 10.1016/j.virusres.2010.04.008
   Asim M, 2008, DIGEST DIS SCI, V53, P1383, DOI 10.1007/s10620-007-0004-1
   Byrnes JJ, 1996, LANCET, V348, P472, DOI 10.1016/S0140-6736(05)64562-X
   Castelain S, 2004, J MED VIROL, V73, P596, DOI 10.1002/jmv.20131
   Crespo J, 1999, POSTGRAD MED J, V75, P159, DOI 10.1136/pgmj.75.881.159
   Da Mota LD, 2019, J MED VIROL, V91, P31, DOI 10.1002/jmv.25291
   Van Nguyen D, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10030102
   Ernst D, 2014, HIV MED, V15, P245, DOI 10.1111/hiv.12094
   Frey SE, 2002, CLIN INFECT DIS, V34, P1033, DOI 10.1086/339206
   Giret MTM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018407
   Goubau P, 1999, TROP MED INT HEALTH, V4, P365, DOI 10.1046/j.1365-3156.1999.00407.x
   Iles JC, 2013, INFECT GENET EVOL, V19, P386, DOI 10.1016/j.meegid.2013.01.021
   Jogeda EL, 2017, J MED VIROL, V89, P632, DOI 10.1002/jmv.24683
   Kapoor A, 2013, J VIROL, V87, P7185, DOI 10.1128/JVI.00324-13
   Kennedy N, 1998, J INFECTION, V37, P140, DOI 10.1016/S0163-4453(98)80168-0
   Konomi N, 1999, J CLIN MICROBIOL, V37, P3291, DOI 10.1128/JCM.37.10.3291-3295.1999
   Lampe E, 1998, J MED VIROL, V56, P39, DOI 10.1002/(SICI)1096-9071(199809)56:1&lt;39::AID-JMV7&gt;3.0.CO;2-O
   Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A
   Lee CK, 2014, J MED VIROL, V86, P737, DOI 10.1002/jmv.23893
   Lei D, 2019, VIRUS GENES, V55, P248, DOI 10.1007/s11262-018-1624-6
   Levi José Eduardo, 2003, Rev. Inst. Med. trop. S. Paulo, V45, P75, DOI 10.1590/S0036-46652003000200004
   Li CY, 2006, AIDS, V20, P1458, DOI 10.1097/01.aids.0000233583.02586.14
   Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505
   Lu L, 2001, VIRUS RES, V73, P131, DOI 10.1016/S0168-1702(00)00231-8
   MIAO ZJ, 2017, VIRUSES-BASEL, V9, DOI DOI 10.3390/V9050100
   Muerhoff AS, 2003, J MED VIROL, V70, P141, DOI 10.1002/jmv.10375
   N'Guessan KF, 2018, VIRUS GENES, V54, P361, DOI 10.1007/s11262-018-1555-2
   Naito H, 2001, J VIROL METHODS, V91, P3, DOI 10.1016/S0166-0934(00)00207-X
   Neibecker M, 2011, J MED VIROL, V83, P685, DOI 10.1002/jmv.22029
   Ng KT, 2015, SCI REP, V5, P1
   Nishiya Anna S., 2003, Rev. Inst. Med. trop. S. Paulo, V45, P213, DOI 10.1590/S0036-46652003000400007
   Oliveira LA, 2002, MEM I OSWALDO CRUZ, V97, P953, DOI 10.1590/S0074-02762002000700005
   Pinho JRR, 1999, J CLIN MICROBIOL, V37, P1634, DOI 10.1128/JCM.37.5.1634-1637.1999
   Ramia S, 2004, INT J STD AIDS, V15, P463, DOI 10.1258/0956462041211180
   Ramos R, 2004, MEM I OSWALDO CRUZ, V99, P639, DOI 10.1590/S0074-02762004000600019
   Sahni H, 2014, J MED VIROL, V86, P426, DOI 10.1002/jmv.23845
   Santos LM, 2017, INT J GYNECOL OBSTET, V138, P113, DOI 10.1002/ijgo.12175
   Shah SAR, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-30
   Sibley SD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098569
   SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564
   Stapleton JT, 2011, J GEN VIROL, V92, P233, DOI 10.1099/vir.0.027490-0
   Supapol WB, 2009, J INFECT DIS, V200, P227, DOI 10.1086/599793
   Tuveri R, 2000, AM J TROP MED HYG, V63, P192, DOI 10.4269/ajtmh.2000.63.192
   Vieira DS, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-165
   Watanabe MAE, 2003, RENAL FAILURE, V25, P67, DOI 10.1081/JDI-120017469
   Woelfle J, 1998, J PEDIATR GASTR NUTR, V26, P402, DOI 10.1097/00005176-199804000-00008
   Xiang JH, 2005, J INFECT DIS, V192, P2147, DOI 10.1086/498170
NR 50
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 1246-7820
J9 TRANSFUS CLIN BIOL
JI Transfu. Clin. Biol.
PD NOV
PY 2019
VL 26
IS 4
BP 234
EP 239
DI 10.1016/j.tracli.2019.06.005
PG 6
WC Hematology; Immunology
SC Hematology; Immunology
GA JY4ET
UT WOS:000504370600008
PM 31277987
DA 2020-11-26
ER

PT J
AU Slavov, SN
   Maconetto, JDM
   Martinez, EZ
   Silva-Pinto, AC
   Covas, DT
   Eis-Hubinger, AM
   Kashima, S
AF Slavov, Svetoslav N.
   Maconetto, Juliana D. M.
   Martinez, Edson Z.
   Silva-Pinto, Ana Cristina
   Covas, Dimas T.
   Eis-Huebinger, Anna Maria
   Kashima, Simone
TI Prevalence of hepatitis E virus infection in multiple transfused
   Brazilian patients with thalassemia and sickle cell disease
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE HEV; multiple transfusion; real-time PCR; seroprevalence; thalassemia
ID BLOOD-DONORS; TRANSMISSION; ANTIBODIES; SEROPREVALENCE
AB Hepatitis E virus (HEV) is a leading cause of acute hepatitis worldwide. The virus is acquired by fecal-oral route; however, it can also be transmitted by blood transfusion. The objective of the study was to examine anti-HEV immunoglobulin G and HEV RNA prevalence in multiple transfused patients with thalassemia and sickle cell disease (SCD), and in blood donors. The HEV seroprevalence in the patients was 13% (20% in thalassemics; 7.7% in SCD), and 11% in blood donors. No positive result for HEV RNA was obtained. This is a pioneer study examining HEV circulation in Brazilian patients with hemoglobinopathies.
C1 [Slavov, Svetoslav N.; Maconetto, Juliana D. M.; Silva-Pinto, Ana Cristina; Covas, Dimas T.; Kashima, Simone] Univ Sao Paulo, Fac Med Ribeirao Preto, Blood Ctr Ribeirao Preto, Lab Mol Biol, 2501 Tenente Catao Roxo St, BR-14051140 Ribeirao Preto, SP, Brazil.
   [Slavov, Svetoslav N.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Internal Med, Ribeirao Preto, SP, Brazil.
   [Martinez, Edson Z.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Social Med, Ribeirao Preto, SP, Brazil.
   [Covas, Dimas T.] Butantan Inst, Sao Paulo, Brazil.
   [Eis-Huebinger, Anna Maria] Univ Bonn, Inst Virol, Med Ctr, Bonn, Germany.
RP Slavov, SN (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Blood Ctr Ribeirao Preto, Lab Mol Biol, 2501 Tenente Catao Roxo St, BR-14051140 Ribeirao Preto, SP, Brazil.
EM svetoslav.slavov@hemocentro.fmrp.usp.br
RI Kashima, Simone/G-4876-2012; Martinez, Edson Zangiacomi/A-3638-2008
OI Kashima, Simone/0000-0002-1487-0141; Martinez, Edson
   Zangiacomi/0000-0002-0949-3222; Slavov, Svetoslav/0000-0003-0805-6140
FU Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq)
   [465539/2014-9]; Financiadora de Estudos e ProjetosCiencia Tecnologia e
   Inovacao (FINEP) [245/2016]; Fundacao de Amparo a Pesquisa do Estado de
   Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2009/16623-1, 2013/081352, 2017/23205-8, 2014/50947-7]
FX Conselho Nacional de Desenvolvimento Cientifico e Tecnologico,
   Grant/Award Number: 465539/2014-9; Financiadora de Estudos e Projetos,
   Grant/Award Number: 245/2016; Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo, Grant/Award Numbers: 2009/16623-1, 2013/081352, 2017/23205-8,
   2014/50947-7
CR Abdelmawla D, 2019, BRAZ J INFECT DIS, V23, P40, DOI 10.1016/j.bjid.2019.01.007
   Alberts CJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208522
   AlFawaz I, 1996, J VIRAL HEPATITIS, V3, P203, DOI 10.1111/j.1365-2893.1996.tb00096.x
   Belliere J, 2017, TRANSPL INFECT DIS, V19, DOI 10.1111/tid.12784
   Bendall R, 2010, J MED VIROL, V82, P799, DOI 10.1002/jmv.21656
   Bortoliero André Luiz, 2006, Rev. Inst. Med. trop. S. Paulo, V48, P87, DOI 10.1590/S0036-46652006000200006
   Colson P, 2007, EMERG INFECT DIS, V13, P648, DOI 10.3201/eid1304.061387
   Dimeglio C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208934
   Grabarczyk P, 2018, TRANSFUSION, V58, P1245, DOI 10.1111/trf.14531
   Guo QS, 2010, J CLIN MICROBIOL, V48, P317, DOI 10.1128/JCM.01466-09
   Hauser L, 2014, BLOOD, V123, P796, DOI 10.1182/blood-2013-09-524348
   Hewitt PE, 2014, LANCET, V384, P1766, DOI 10.1016/S0140-6736(14)61034-5
   Horvatits T, 2018, LIVER INT, V38, P1951, DOI 10.1111/liv.13859
   Huzly D, 2014, EUROSURVEILLANCE, V19, P11, DOI 10.2807/1560-7917.ES2014.19.21.20812
   Irshad Mohammad, 2002, Indian J Gastroenterol, V21, P183
   Jothikumar N, 2006, J VIROL METHODS, V131, P65, DOI 10.1016/j.jviromet.2005.07.004
   Katiyar H, 2018, INDIAN J GASTROENTER, V37, P342, DOI 10.1007/s12664-018-0880-7
   Khuroo MS, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8090253
   Mansuy JM, 2011, EMERG INFECT DIS, V17, P2309, DOI 10.3201/eid1712.110371
   Matsubayashi K, 2008, TRANSFUSION, V48, P1368, DOI 10.1111/j.1537-2995.2008.01722.x
   Mooij SH, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3078-9
   Nanmoku K, 2019, TRANSPL INFECT DIS, V21, DOI 10.1111/tid.13033
   Nasrallah GK, 2017, TRANSFUSION, V57, P1801, DOI 10.1111/trf.14116
   Niederhauser C, 2018, EUROSURVEILLANCE, V23, P15, DOI 10.2807/1560-7917.ES.2018.23.35.1700616
   Parana R, 1997, AM J TROP MED HYG, V57, P60, DOI 10.4269/ajtmh.1997.57.60
   Passos-Castilho AM, 2017, BRAZ J INFECT DIS, V21, P535, DOI 10.1016/j.bjid.2017.05.004
   Passos-Castilho AM, 2016, J MED VIROL, V88, P361, DOI 10.1002/jmv.24336
   Pisano MB, 2018, LIVER INT, V38, P1536, DOI 10.1111/liv.13881
   Riveiro-Barciela M, 2017, TRANSFUSION, V57, P244, DOI 10.1111/trf.13876
   Slot E, 2013, EUROSURVEILLANCE, V18, P23, DOI 10.2807/1560-7917.ES2013.18.31.20550
   Sotoodeh Jahromi Abdolreza, 2016, Glob J Health Sci, V8, P53885, DOI 10.5539/gjhs.v8n9p245
   Tedder RS, 2016, TRANSFUSION, V56, P1529, DOI 10.1111/trf.13498
   Vollmer T, 2016, EUROSURVEILLANCE, V21, P32, DOI 10.2807/1560-7917.ES.2016.21.35.30332
   Xu CY, 2013, TRANSFUSION, V53, P2505, DOI 10.1111/trf.12326
NR 34
TC 0
Z9 0
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD SEP
PY 2019
VL 91
IS 9
BP 1693
EP 1697
DI 10.1002/jmv.25498
PG 5
WC Virology
SC Virology
GA IR5CL
UT WOS:000481450500016
PM 31066064
DA 2020-11-26
ER

PT J
AU Slavov, SN
   Christova, IS
   Ferreira, AR
   Rodrigues, ES
   Bianquini, ML
   Hespanhol, MR
   Covas, DT
   Kashima, S
AF Slavov, S. N.
   Christova, I. S.
   Ferreira, A. R.
   Rodrigues, E. S.
   Bianquini, M. L.
   Hespanhol, M. R.
   Covas, D. T.
   Kashima, S.
TI Serological evidence of Borrelia circulation among blood donors in the
   Sao Paulo state, Brazil
SO TRANSFUSION MEDICINE
LA English
DT Article
DE blood donors; borrelia; seroprevalence; western blot
ID LYME BORRELIOSIS; BURGDORFERI; SEROPREVALENCE; PROTEIN; POPULATION;
   PREVALENCE; FLAGELLIN; AREA; OSPC
AB Objective The objective of this study was to examine the Borrelia seroprevalence among blood donors in Southeast Brazil. Background There is evidence that Borrelia spirochetes are circulating in Brazil; however, there are no studies that characterise these bacteria and investigate their seroprevalence in the Brazilian population. Such a situation, combined with a recent outbreak of tick-borne Rocky Mountain spotted fever in the Sao Paulo state demonstrates the increasing role of ticks as arthropod vectors in Brazil. Methods For the purpose of the study, 452 blood donors from Ribeirao Preto city, Sao Paulo state were tested using anti-Borrelia immunoglobulin G (IgG) assay. The positive results were also confirmed by Western blot for anti-borrelia IgM/IgG. Results The anti-Borrelia IgG enzyme-linked immunosorbent assay (ELISA) showed nine positive and nine borderline reactive samples, giving a total seroprevalence of 2 center dot 0% of anti-Borrelia IgG among Brazilian blood donors. The confirmation of the seropositive and borderline samples by Borrelia Western blot was demonstrated by IgG-positive results in 16 samples (a seroprevalence of 3.5%). Anti-Borrelia IgM antibodies were also detected in one sample. Conclusions Our results demonstrate that Borrelia-like spirochetes may be circulating among blood donors from the Sao Paulo State and that the ticks have an important epidemiological role as vectors of bacterial infections in this Brazilian region. These results not only alert us to possible actions that might be undertaken in order to completely characterise the aetiological agents of Lyme-like syndromes in Brazil but also the possible impact that these bacterial agents might have on haemotherapy practices.
C1 [Slavov, S. N.; Ferreira, A. R.; Rodrigues, E. S.; Bianquini, M. L.; Hespanhol, M. R.; Covas, D. T.; Kashima, S.] Univ Sao Paulo, Fac Med Ribeirao Preto, Blood Ctr Ribeirao Preto, Sao Paulo, Brazil.
   [Slavov, S. N.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Internal Med, Sao Paulo, Brazil.
   [Christova, I. S.] Natl Ctr Infect & Parasit Dis, Dept Microbiol, Sofia, Bulgaria.
RP Slavov, SN (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Blood Ctr Ribeirao Preto, Lab Mol Biol, 2501 Tenente Catao Roxo St, BR-14051060 Ribeirao Preto, SP, Brazil.
EM svetoslav.slavov@hemocentro.fmrp.usp.br
RI Kashima, Simone/G-4876-2012
OI Kashima, Simone/0000-0002-1487-0141; Slavov,
   Svetoslav/0000-0003-0805-6140
FU Fundacao de Amparo e Pesquisa do Estado de Sao Paulo-FAPESP, Brazil
   [CTC-2013/081352, 2017/23205-8, INCTC-FAPESP-2014/50947-7]; Conselho
   Nacional do Desenvolvimento Cientifico e Tecnologico, Brazil
   [INCTC-465539/2014-9, 455503/2014-1]; FINEP, BrazilCiencia Tecnologia e
   Inovacao (FINEP) [245/2016]
FX We are grateful to all blood donors who donated their samples for the
   realisation of this study. We thank Sandra Navarro Bresciani for the
   excellent artwork. This study was supported by Fundacao de Amparo e
   Pesquisa do Estado de Sao Paulo-FAPESP, Brazil (Grants CTC-2013/081352,
   2017/23205-8, INCTC-FAPESP-2014/50947-7); Conselho Nacional do
   Desenvolvimento Cientifico e Tecnologico, Brazil (INCTC-465539/2014-9;
   455503/2014-1); and FINEP, Brazil (245/2016). SNS authored the
   manuscript, performed the formal analysis and supervised the working
   process; I.S.C., A.R.F., E.S.R., M.L.B. and M.R.E performed the formal
   analysis, analysed the data and executed the methodology; and D.T.C. and
   S.K. participated in funding acquisition and formal analysis.
CR Branda JA, 2013, CLIN INFECT DIS, V57, P333, DOI 10.1093/cid/cit235
   Carrasco SE, 2015, INFECT IMMUN, V83, P4848, DOI 10.1128/IAI.01215-15
   De Keukeleire M, 2017, VECTOR-BORNE ZOONOT, V17, P108, DOI 10.1089/vbz.2016.1954
   DRESSLER F, 1994, J INFECT DIS, V169, P313, DOI 10.1093/infdis/169.2.313
   EPTV, 2018, NUMB DEATHS SPOTT FE
   FAHRER H, 1991, J INFECT DIS, V163, P305, DOI 10.1093/infdis/163.2.305
   Socoloski SNG, 2018, TROP ANIM HEALTH PRO, V50, P831, DOI 10.1007/s11250-017-1504-4
   Ginzburg Y, 2013, TRANSFUSION, V53, P2822, DOI 10.1111/trf.12116
   Goncalves DD, 2013, BRAZ J MICROBIOL, V44, P125, DOI 10.1590/S1517-83822013005000011
   Hristea A, 2001, EUR J EPIDEMIOL, V17, P891, DOI 10.1023/A:1015600729900
   Jovanovic D, 2015, BRAZ J MICROBIOL, V46, P807, DOI 10.1590/S1517-838246320140698
   LUFT BJ, 1993, RES MICROBIOL, V144, P251, DOI 10.1016/0923-2508(93)90009-Q
   M. of H, 2018, CONF CAS SPOTT FEV
   M. of H, 2018, DEATHS SPOTT FEV
   McFee RB, 2018, DM-DIS MON, V64, P163, DOI 10.1016/j.disamonth.2018.01.002
   Mhalu FS, 1996, E AFR MED J, V73, P583
   Perez CA, 2008, REV BRAS PARASITOL V, V17, P210, DOI 10.1590/S1984-29612008000400008
   PIERER K, 1993, ZBL BAKT-INT J MED M, V279, P239
   SANTINO I, 1995, MICROBIOLOGICA, V18, P391
   Stanek G, 2012, LANCET, V379, P461, DOI 10.1016/S0140-6736(11)60103-7
   Tilly K, 2006, INFECT IMMUN, V74, P3554, DOI 10.1128/IAI.01950-05
   Tokarska-Rodak M., 2012, LYME DIS SEROLOGY DI
NR 22
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0958-7578
EI 1365-3148
J9 TRANSFUSION MED
JI Transfus. Med.
PD OCT
PY 2019
VL 29
IS 5
BP 358
EP 363
DI 10.1111/tme.12627
EA AUG 2019
PG 6
WC Hematology
SC Hematology
GA JE9VK
UT WOS:000484258500001
PM 31468639
DA 2020-11-26
ER

PT J
AU Slavov, SN
   Rodrigues, ES
   Sauvage, V
   Caro, V
   Diefenbach, CF
   Zimmermann, AM
   Covas, DT
   Laperche, S
   Kashima, S
AF Slavov, Svetoslav N.
   Rodrigues, Evandra S.
   Sauvage, Virginie
   Caro, Valerie
   Diefenbach, Cristiane F.
   Zimmermann, Ana M.
   Covas, Dimas T.
   Laperche, Syria
   Kashima, Simone
TI Parvovirus B19 seroprevalence, viral load, and genotype characterization
   in volunteer blood donors from southern Brazil
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE blood donors; genotypes; parvovirus B19; real-time polymerase chain
   reaction; seroprevalence
ID SICKLE-CELL-DISEASE; HEPATITIS-A VIRUS; IMMUNOCOMPETENT INDIVIDUALS;
   INFECTION; PREVALENCE; DNA; VIREMIA; IDENTIFICATION; TRANSFUSION;
   THALASSEMIA
AB Usually transmitted via respiratory droplets, parvovirus B19 (B19V) can also be acquired by blood transfusion especially because of viral persistence, resistance to blood treatment procedures, and high viral load during the early infection phase. This is particularly problematic in immunocompromised or anemic patients where the infection can have a severe outcome. As B19V DNA was detected in blood donations from South Brazil during a viral metagenomic survey performed by Next-Generation Sequencing, the objective of this retrospective study was to evaluate the seroprevalence, B19V DNA presence and circulating genotypes in a Hospital Blood Transfusion Service in Santa Maria city in South Brazil (Rio Grande do Sul state). Among 480 volunteer blood donors, 53.9% (n = 258 of 479) were anti-B19V IgG-positive, and 9 (1.9%) plasma samples presented B19V DNA. In almost all cases (n = 7 of 9, 77.8%), B19V DNA load was accompanied by the presence of anti-B19V IgG suggesting a persistent infection. The sequencing of the strains demonstrated that all belong to genotype 1 which is the most prevalent worldwide. The analysis of the recipient information of the positive for B19V DNA units revealed no related posttransfusion adverse effects. Our results demonstrate for the first time, B19V seroprevalence, viral load, and genotypes among blood donors from South Brazil and give a light for the circulation and impact of this B19V in this part of the country.
C1 [Slavov, Svetoslav N.; Rodrigues, Evandra S.; Covas, Dimas T.; Kashima, Simone] Univ Sao Paulo, Fac Med Ribeirao Preto, Blood Ctr Ribeirao Preto, Lab Mol Biol, Rua Tenente Catao Roxo 2501, BR-14051140 Ribeirao Preto, SP, Brazil.
   [Slavov, Svetoslav N.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Internal Med, Ribeirao Preto, SP, Brazil.
   [Sauvage, Virginie; Laperche, Syria] INTS, Dept Etud Agents Transmissibles Sang DATS, Ctr Natl Reference Risques Infect Transfus, Paris, France.
   [Caro, Valerie] Inst Pasteur, PGP, Lab Urgent Response Biol Threats, Environm & Infect Risks Res & Expertise Unit, Paris, France.
   [Diefenbach, Cristiane F.] Univ Fed Santa Maria, Univ Hosp Santa Maria, Dept Internal Med, Santa Maria, RS, Brazil.
   [Zimmermann, Ana M.] Hosp Dr Astrogildo de Azevedo, Hemotherapy Serv, Hematol Dept, Santa Maria, RS, Brazil.
RP Slavov, SN (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Blood Ctr Ribeirao Preto, Lab Mol Biol, Rua Tenente Catao Roxo 2501, BR-14051140 Ribeirao Preto, SP, Brazil.
EM svetoslav.slavov@hemocentro.fmrp.usp.br
RI ; Kashima, Simone/G-4876-2012
OI Slavov, Svetoslav/0000-0003-0805-6140; Kashima,
   Simone/0000-0002-1487-0141
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2009/16623-1,
   INCTC-FAPESP-2014/50947-7, 2017/23205-8, CTC-2013/081352]; Conselho
   Nacional de Desenvolvimento Cientifico e TecnologicoNational Council for
   Scientific and Technological Development (CNPq) [INCTC-465539/2014-9,
   455503/2014-1]; Financiadora de Estudos e ProjetosCiencia Tecnologia e
   Inovacao (FINEP) [245/2016]
FX Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Grant/Award
   Numbers: 2009/16623-1, INCTC-FAPESP-2014/50947-7, 2017/23205-8,
   CTC-2013/081352; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico, Grant/Award Numbers: INCTC-465539/2014-9, 455503/2014-1;
   Financiadora de Estudos e Projetos, Grant/Award Number: 245/2016
CR Candotti D, 2004, J VIROL, V78, P12169, DOI 10.1128/JVI.78.22.12169-12178.2004
   European Commission, PHARM SUBST HUM ORG
   Han T, 2015, TRANSFUSION MED, V25, P406, DOI 10.1111/tme.12259
   Heegaard ED, 2002, CLIN MICROBIOL REV, V15, P485, DOI 10.1128/CMR.15.3.485-505.2002
   Henriques I, 2005, TRANSFUS APHER SCI, V33, P305, DOI 10.1016/j.transci.2005.06.002
   Jia JT, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0396-z
   Juhl D, 2014, TRANSFUS MED HEMOTH, V41, P52, DOI 10.1159/000357650
   Ke L, 2011, TRANSFUSION, V51, P1909, DOI 10.1111/j.1537-2995.2011.03067.x
   Kleinman SH, 2007, TRANSFUSION, V47, P1756, DOI 10.1111/j.1537-2995.2007.01341.x
   Kooistra K, 2011, VOX SANG, V100, P261, DOI 10.1111/j.1423-0410.2010.01423.x
   Lefrere JJ, 2005, BLOOD, V106, P2890, DOI 10.1182/blood-2005-03-1053
   Lindblom A, 2005, CLIN INFECT DIS, V41, P1201, DOI 10.1086/444503
   de Azevedo KML, 2009, MEM I OSWALDO CRUZ, V104, P901, DOI 10.1590/S0074-02762009000600014
   Maple PAC, 2014, J CLIN MICROBIOL, V52, P947, DOI 10.1128/JCM.02613-13
   Matsukura H, 2008, TRANSFUSION, V48, P1036, DOI 10.1111/j.1537-2995.2008.01704.x
   Nagaharu K, 2017, TRANSFUSION, V57, P1414, DOI 10.1111/trf.14088
   Oh DJ, 2010, KOREAN J LAB MED, V30, P58, DOI 10.3343/kjlm.2010.30.1.58
   Qiu JM, 2017, CLIN MICROBIOL REV, V30, P43, DOI 10.1128/CMR.00040-16
   Sakata H, 2013, TRANSFUSION, V53, P2556, DOI 10.1111/j.1537-2995.2012.03949.x
   Satake M, 2011, TRANSFUSION, V51, P1887, DOI 10.1111/j.1537-2995.2010.03047.x
   Sauvage V, 2016, TRANSFUS CLIN BIOL, V23, P28, DOI 10.1016/j.tracli.2015.12.002
   Schmidt M, 2007, TRANSFUSION, V47, P1775, DOI 10.1111/j.1537-2995.2007.01443.x
   Servant-Delmas A, 2010, J VIROL, V84, P9658, DOI 10.1128/JVI.00684-10
   Slavou SN, 2013, BRAZ J INFECT DIS, V17, P97, DOI 10.1016/j.bjid.2012.06.026
   Slavov SN, 2011, FEMS IMMUNOL MED MIC, V62, P247, DOI 10.1111/j.1574-695X.2011.00819.x
   Slavov SN, 2016, INDIAN J HEMATOL BLO, V32, pS323, DOI 10.1007/s12288-015-0607-1
   Slavov SN, 2012, J MED VIROL, V84, P1652, DOI 10.1002/jmv.23358
   Zaaijer HL, 2004, EPIDEMIOL INFECT, V132, P1161, DOI 10.1017/S0950268804002730
   Zadsar M, 2018, J MED VIROL, V90, P1318, DOI 10.1002/jmv.25195
NR 29
TC 4
Z9 5
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD JUL
PY 2019
VL 91
IS 7
BP 1224
EP 1231
DI 10.1002/jmv.25453
PG 8
WC Virology
SC Virology
GA ID5ZD
UT WOS:000471755300007
PM 30851123
DA 2020-11-26
ER

PT J
AU Tozatto-Maio, K
   Girot, R
   Ly, ID
   Rocha, V
   Pinto, ACS
   Diagne, I
   Benzerara, Y
   Dinardo, CL
   Kashima, S
   Leston-Araujo, I
   Kenzey, C
   Fonseca, GHH
   Rodrigues, ES
   Volt, F
   Jarduli, LR
   Ruggeri, A
   Mariaselvam, CM
   Gualandro, SFM
   Elayoubi, H
   Cunha, R
   Cappelli, B
   Malmegrim, KCR
   Simoes, BP
   Gluckman, E
   Tamouza, R
AF Tozatto-Maio, Karina
   Girot, Robert
   Ly, Indou D.
   Rocha, Vanderson
   Pinto, Ana C. Silva
   Diagne, Ibrahima
   Benzerara, Yahia
   Dinardo, Carla L.
   Kashima, Simone
   Leston-Araujo, Itaua
   Kenzey, Chantal
   Fonseca, Guilherme H. H.
   Rodrigues, Evandra S.
   Volt, Fernanda
   Jarduli, Luciana R.
   Ruggeri, Annalisa
   Mariaselvam, Christina M.
   Gualandro, Sandra F. M.
   Elayoubi, Hanadi
   Cunha, Renato
   Cappelli, Barbara
   Malmegrim, Kelen C. R.
   Simoes, Belinda P.
   Gluckman, Eliane
   Tamouza, Ryad
TI A Toll-like receptor 2 genetic variant modulates occurrence of bacterial
   infections in patients with sickle cell disease
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE sickle cell disease; bacterial infections; Toll-like receptor;
   rs4696480; immunogenetics
ID PULMONARY INFLAMMATION; CHILDREN; POLYMORPHISMS; HLA; SUSCEPTIBILITY;
   ALLELES; ALLOIMMUNIZATION; TUBERCULOSIS; ASSOCIATION; EXPRESSION
AB Despite adequate immunization and penicillin prophylaxis, bacterial infections remain a leading cause of morbidity and mortality in patients with sickle cell disease (SCD). Besides hyposplenism, inflammatory and genetic factors might modulate their susceptibility to bacterial infections. We performed a candidate gene association of single nucleotide polymorphisms (SNPs) located in Toll-like receptor (TLR) genes, encoding prominent molecules for innate immune responses, with the occurrence of bacterial infections in patients with SCD. A cohort followed in centres in Brazil, France and Senegal (n=430) was divided in two groups: patients who presented at least one episode of bacterial infection (n=235) and patients who never had bacterial infections (n=195). There were no differences in gender or age distribution among the groups. The frequency of the TLR2 rs4696480 TA genotype was significantly lower in the infected group (50% vs. 67%, odds ratio [OR]=050, 95% confidence interval [CI] 034-075, P<0001), and the TT genotype was significantly higher in the infected group (15% vs. 5%, OR=318, 95% CI 153-661, P<0001). Previous reports demonstrated higher secretion of inflammatory factors in cells from AA individuals, lower occurrence and severity of immune diseases in T carriers. The rs4696480 TA genotype might stand between deleterious effects of over inflammatory response (AA genotype) and inefficient responses (TT genotype) to infectious agents in SCD settings.
C1 [Tozatto-Maio, Karina; Rocha, Vanderson; Kenzey, Chantal; Volt, Fernanda; Ruggeri, Annalisa; Elayoubi, Hanadi; Cappelli, Barbara; Gluckman, Eliane] Ctr Sci Monaco, Monacord, Monaco, Monaco.
   [Tozatto-Maio, Karina; Rocha, Vanderson; Kenzey, Chantal; Volt, Fernanda; Ruggeri, Annalisa; Elayoubi, Hanadi; Cappelli, Barbara; Gluckman, Eliane] Univ Paris Diderot, Sorbonne Paris Cite, Inst Univ Hematol, Eurocord,Hop St Louis, Paris, France.
   [Tozatto-Maio, Karina; Pinto, Ana C. Silva; Kashima, Simone; Rodrigues, Evandra S.; Cunha, Renato; Malmegrim, Kelen C. R.; Simoes, Belinda P.] Univ Sao Paulo, Ribeirao Preto Med Sch, Blood Ctr Ribeirao Preto, Ctr Cell Based Therapy, Ribeirao Preto, Brazil.
   [Tozatto-Maio, Karina; Rocha, Vanderson; Dinardo, Carla L.; Fonseca, Guilherme H. H.; Gualandro, Sandra F. M.] Univ Sao Paulo, Sch Med, Clin Hosp, Dept Haematol, Sao Paulo, Brazil.
   [Girot, Robert] Hop Univ Est Parisien, Hop Tenon, Paris, France.
   [Ly, Indou D.] Cheikh Anta Diop Univ, Ctr Hosp Natl Enfants Albert Royer, Pediat Unit, Dakar, Senegal.
   [Rocha, Vanderson] Univ Oxford, Churchill Hosp, Dept Haematol, Oxford, England.
   [Diagne, Ibrahima] Univ Gaston Berger, St Louis, Senegal.
   [Benzerara, Yahia] Hop Univ Est Parisien, Dept Bacteriol, Paris, France.
   [Leston-Araujo, Itaua] Univ Paris Diderot, Sorbonne Paris Cite, Inst Univ Hematol, INSERM 1160,Alloimmun Autoimmun Transplantat, Paris, France.
   [Jarduli, Luciana R.] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Ribeirao Preto, Brazil.
   [Ruggeri, Annalisa] EBMT, Cellular Therapy & Immunobiol Working Party, Rome, Italy.
   [Ruggeri, Annalisa] Osped Pediat Bambino Gesu, Rome, Italy.
   [Mariaselvam, Christina M.; Tamouza, Ryad] Ctr Hosp Univ Henri Mondor, INSERM, U955, Creteil, France.
   [Malmegrim, Kelen C. R.] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Anal Toxicol & Food Sci, Sao Paulo, Brazil.
RP Tozatto-Maio, K (corresponding author), Eurocord 1 Ave Claude Vellefaux, F-75010 Paris, France.
EM karina.tmaio@usp.br
RI Malmegrim, Kelen/H-1016-2015; Mariaselvam, Christina/AAS-6408-2020;
   Guerino-Cunha, Renato/AAA-4299-2019; Simoes, Belinda P/M-7469-2016;
   Rocha, Vanderson/AAO-1691-2020; ruggeri, annalisa/K-5203-2018; Kashima,
   Simone/G-4876-2012; DINARDO, CARLA LUANA/A-1062-2013
OI Malmegrim, Kelen/0000-0002-9303-0086; Guerino-Cunha,
   Renato/0000-0003-3936-0129; ruggeri, annalisa/0000-0002-7261-2765;
   Kashima, Simone/0000-0002-1487-0141; DINARDO, CARLA
   LUANA/0000-0002-0453-7863
FU Centre Scientifique de Monaco; Brazilian Coordination for the
   Improvement of Higher Education Personnel (CAPES)CAPES
FX This work was supported by the Centre Scientifique de Monaco and the
   Brazilian Coordination for the Improvement of Higher Education Personnel
   (CAPES). The authors thank the Centre Scientifique de Monaco, CAPES, all
   patients and their families.
CR Adekile A, 2005, AM J HEMATOL, V79, P8, DOI 10.1002/ajh.20311
   Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Allen SJ, 1997, P NATL ACAD SCI USA, V94, P14736, DOI 10.1073/pnas.94.26.14736
   Ballas SK, 2010, AM J HEMATOL, V85, P6, DOI 10.1002/ajh.21550
   Bank S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098815
   Booth C, 2010, INT J INFECT DIS, V14, pE2, DOI 10.1016/j.ijid.2009.03.010
   Brousse V, 2014, BRIT J HAEMATOL, V166, P165, DOI 10.1111/bjh.12950
   Bulat-Kardum LJ, 2015, SCAND J IMMUNOL, V82, P63, DOI 10.1111/sji.12300
   David S, 2018, IMMUNOGENETICS, V70, P37, DOI 10.1007/s00251-017-1013-7
   Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374
   Fertrin KY, 2010, EXPERT REV HEMATOL, V3, P443, DOI [10.1586/ehm.10.44, 10.1586/EHM.10.44]
   Godefroy E, 2016, HAEMATOLOGICA, V101, P1028, DOI 10.3324/haematol.2016.147181
   Gopalakrishnan A, 2016, CURR OPIN IMMUNOL, V42, P76, DOI 10.1016/j.coi.2016.06.003
   Hoppe C, 2003, BLOOD, V101, P2865, DOI 10.1182/blood-2002-09-2791
   Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531
   Kato GJ, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.10
   Kerkhof M, 2010, THORAX, V65, P690, DOI 10.1136/thx.2009.119636
   Khor CC, 2007, NAT GENET, V39, P523, DOI 10.1038/ng1976
   Kormann MS, 2008, J ALLERGY CLIN IMMUN, V122, pe1
   Lin Y, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-2943-x
   Loft ND, 2018, PHARMACOGENOMICS J, V18, P494, DOI 10.1038/tpj.2017.31
   Miedema KGE, 2012, LEUKEMIA, V26, P1203, DOI 10.1038/leu.2011.341
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Moresco EMY, 2011, CURR BIOL, V21, pR488, DOI 10.1016/j.cub.2011.05.039
   Morrissey BJ, 2015, HEMOGLOBIN, V39, P316, DOI 10.3109/03630269.2015.1065419
   Neonato MG, 1999, EUR J HUM GENET, V7, P679, DOI 10.1038/sj.ejhg.5200360
   Norris CF, 1996, J PEDIATR-US, V128, P813, DOI 10.1016/S0022-3476(96)70334-7
   Ntoufa S, 2016, SEMIN CANCER BIOL, V39, P15, DOI 10.1016/j.semcancer.2016.07.001
   Oh DY, 2009, ALLERGY, V64, P1608, DOI 10.1111/j.1398-9995.2009.02066.x
   Oliveira J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119702
   Oteng-Ntim E, 2015, BLOOD, V125, P3316, DOI 10.1182/blood-2014-11-607317
   Piel FB, 2017, NEW ENGL J MED, V376, P1561, DOI 10.1056/NEJMra1510865
   Pitanga TN, 2016, CYTOKINE, V83, P75, DOI 10.1016/j.cyto.2016.03.016
   Sanders MS, 2011, CLIN INFECT DIS, V52, P475, DOI 10.1093/cid/ciq155
   Sippert EA, 2017, TRANSFUSION, V57, P379, DOI 10.1111/trf.13920
   Sobota A, 2015, BRIT J HAEMATOL, V170, P757, DOI 10.1111/bjh.13526
   Sole X, 2006, BIOINFORMATICS, V22, P1928, DOI 10.1093/bioinformatics/btl268
   Stuart MJ, 2004, LANCET, V364, P1343, DOI 10.1016/S0140-6736(04)17192-4
   Styles LA, 2000, BLOOD, V95, P3562, DOI 10.1182/blood.V95.11.3562.011k49_3562_3567
   Tamouza R, 2002, HUM IMMUNOL, V63, P194, DOI 10.1016/S0198-8859(01)00378-0
   Tatari-Calderone Z, 2016, HUM IMMUNOL, V77, P35, DOI 10.1016/j.humimm.2015.10.010
   vansWell G.T.J., 2012, PLOS ONE, V7
   Veltkamp M, 2007, CLIN EXP IMMUNOL, V149, P453, DOI 10.1111/j.1365-2249.2007.03428.x
   Vingert B, 2015, EUR J IMMUNOL, V45, P1868, DOI 10.1002/eji.201445187
   Wallace KL, 2010, BLOOD, V116, P5010, DOI 10.1182/blood-2010-06-290643
   Wallace KL, 2009, BLOOD, V114, P667, DOI 10.1182/blood-2009-02-205492
   Wambua S, 2006, PLOS MED, V3, P643, DOI 10.1371/journal.pmed.0030158
   Yawn BP, 2014, JAMA-J AM MED ASSOC, V312, P1033, DOI 10.1001/jama.2014.10517
NR 48
TC 2
Z9 2
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD JUN
PY 2019
VL 185
IS 5
BP 918
EP 924
DI 10.1111/bjh.15875
PG 7
WC Hematology
SC Hematology
GA IE2SD
UT WOS:000472233600012
PM 30908604
DA 2020-11-26
ER

PT J
AU Ferreira, AF
   Ferreira, FU
   da Costa, PNM
   Catelli, LF
   Macedo, MDF
   dos Santos, TPM
   Leopoldino, AM
   Picanco-Castro, V
   Kashima, S
   Covas, DT
AF Ferreira, Aline Fernanda
   Ferreira, Fernanda Ursoli
   Mendes da Costa, Pericles Natan
   Catelli, Lucas Ferrioli
   Favarin Macedo, Maria do Carmo
   dos Santos, Talita P. M.
   Leopoldino, Andreia Machado
   Picanco-Castro, Virginia
   Kashima, Simone
   Covas, Dimas Tadeu
TI Generation of integration-free induced pluripotent stem cells from
   blood-derived cells isolated from patient with severe haemophilia A
SO HAEMOPHILIA
LA English
DT Letter
C1 [Ferreira, Aline Fernanda; Ferreira, Fernanda Ursoli; Mendes da Costa, Pericles Natan; Catelli, Lucas Ferrioli; Favarin Macedo, Maria do Carmo; Picanco-Castro, Virginia; Kashima, Simone; Covas, Dimas Tadeu] Univ Sao Paulo, Sch Med Ribeirao Preto, Reg Blood Ctr, Ctr Cell Based Therapy, Ribeirao Preto, Brazil.
   [dos Santos, Talita P. M.; Leopoldino, Andreia Machado; Kashima, Simone] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Ribeirao Preto, Brazil.
RP Kashima, S (corresponding author), Univ Sao Paulo, Sch Med Ribeirao Preto, Reg Blood Ctr, Lab Mol Biol, Ribeirao Preto, Brazil.
EM skashima@hemocentro.fmrp.usp.br
RI Leopoldino, Andreia M/E-9926-2012; Picanco-Castro,
   Virginia/AAC-7242-2019; Kashima, Simone/G-4876-2012
OI Leopoldino, Andreia M/0000-0002-8313-4754; Picanco-Castro,
   Virginia/0000-0001-8474-4610; Costa, Pericles/0000-0003-2860-6429;
   Kashima, Simone/0000-0002-1487-0141
FU CAPES scholarshipCAPES [1535985]; FAPESPFundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2013/08135-2]; CNPqNational Council for
   Scientific and Technological Development (CNPq) [465539/2014-9]
FX We are grateful to CAPES scholarship (1535985), FAPESP (2013/08135-2)
   and CNPq (465539/2014-9) for funding, Sandra Navarro Bresciani,
   Alexander Rodrigo Ferreira and Yann Lamarre for the figure formatting,
   Josiane Serrano for histological analysis, Camila C.O.M. Bonaldo for
   immunophenotyping analysis, Cleide Silva for mice experiments and Andy
   Alastair Cumming for assistance in the English review.
CR Abujarour R, 2013, SCI REP-UK, V3, DOI 10.1038/srep01179
   Albesiano E, 2003, BLOOD, V102, P3333, DOI 10.1182/blood-2003-05-1585
   Bharathan SP, 2017, BIOL OPEN, V6, P100, DOI 10.1242/bio.022111
   Ebert AD, 2012, J CARDIOVASC PHARM, V60, P408, DOI 10.1097/FJC.0b013e318247f642
   Jia B, 2014, LIFE SCI, V108, P22, DOI 10.1016/j.lfs.2014.05.004
   Reis LCJ, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/7492914
   Lee AS, 2013, NAT MED, V19, P998, DOI 10.1038/nm.3267
   Mali P, 2008, STEM CELLS, V26, P1998, DOI 10.1634/stemcells.2008-0346
   Mannucci PM, 2001, NEW ENGL J MED, V344, P1773, DOI 10.1056/NEJM200106073442307
   Sabapathy V, 2016, J CELL MOL MED, V20, P1571, DOI 10.1111/jcmm.12839
NR 10
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-8216
EI 1365-2516
J9 HAEMOPHILIA
JI Haemophilia
PD MAY
PY 2019
VL 25
IS 3
BP E195
EP E199
DI 10.1111/hae.13716
PG 5
WC Hematology
SC Hematology
GA IC4IO
UT WOS:000470929100012
PM 30866120
DA 2020-11-26
ER

PT J
AU Slavov, SN
   Ferreira, FU
   Rodrigues, ES
   Gomes, R
   Covas, DT
   Kashima, S
AF Slavov, Svetoslav Nanev
   Ferreira, Fernando Ursoli
   Rodrigues, Evandra Strazza
   Gomes, Rogerio
   Covas, Dimas Tadeu
   Kashima, Simone
TI Simultaneous zika and dengue serotype-4 viral detection and isolation
   from a donor plasma unit
SO JOURNAL OF VECTOR BORNE DISEASES
LA English
DT Article
DE Coinfection; dengue virus; serotyping; zika virus
ID VIRUS; TRANSMISSION; OUTBREAK
AB During zika and dengue viruse (ZIKV and DENV) outbreaks. the majority of the infected individuals remain clinically asymptomatic. Such asymptomatic individuals may occasionally acquire both arboviruses, donate blood, and contaminate haemoderivatives. The aim of this study was to characterize a ZIKViDENV-4 coinfection in asymptomatic blood donor who donated blood during a large mixed ZIKV/DENV outbreak in the Sao Paulo State, Brazil. On the basis of post-donation information, one blood donor sample was found positive for ZIKV and DENV RNA. The DENV molecular serotyping was performed by molecular testing. The sample was also titrated on VERO E6 cells in order to define the presence of infectious arboviruses. The real-time PCR testing of the blood donor sample demonstrated very high viral load for both ZIKV and DENV. Further, molecular serotyping of DENV showed that the presence of DENV-4. The viral titration in cell culture indicated a titre of 2.75 x10(6) PFU/ml which was concordant with the presence of infectious viruses in the blood donation. This is an interesting report for the simultaneous presence of infectious ZIKV and DENV-4 in asymptomatic blood sample. Special attention must be paid during mixed arboviral outbreaks for the possibility of transfusion-transmission of multiple arboviral agents.
C1 [Slavov, Svetoslav Nanev; Ferreira, Fernando Ursoli; Rodrigues, Evandra Strazza; Gomes, Rogerio; Covas, Dimas Tadeu; Kashima, Simone] Univ Sao Paulo, Fac Med Ribeirao Preto, Reg Blood Ctr Ribeirao Preto, Ribeirao Preto, SP, Brazil.
   [Slavov, Svetoslav Nanev; Covas, Dimas Tadeu] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Internal Med, Ribeirao Preto, SP, Brazil.
RP Slavov, SN (corresponding author), Univ Sao Paulo, Blood Ctr Ribeirao Preto, Lab Mol Biol, BR-14051140 Ribeirao Preto, SP, Brazil.
EM svetoslay.slavov@hemocentro.fmrp.usp.br
RI Gomes, Rogerio/B-7689-2013; Kashima, Simone/G-4876-2012
OI Gomes, Rogerio/0000-0002-0126-1742; Kashima, Simone/0000-0002-1487-0141
FU Fundacao de Amparo e Pesquisa do Estado de Sao Paulo-FAPESP, Brazil
   [2009/16623-1, CTC-2013/081352]; Conselho Nacional do Desenvolvimento
   Cientifico e Tecnologico, Brazil [INCTC-573.754/2008-0,
   INCTC-2008/57.877-3]; FINEP, BrazilCiencia Tecnologia e Inovacao (FINEP)
   [245/2016]
FX The authors are grateful to Sandra Navarro Bresciani for the graphical
   designs. This study was supported by Fundacao de Amparo e Pesquisa do
   Estado de Sao Paulo-FAPESP, Brazil (Grant No. 2009/16623-1,
   CTC-2013/081352), Conselho Nacional do Desenvolvimento Cientifico e
   Tecnologico, Brazil (INCTC-573.754/2008-0 and INCTC-2008/57.877-3), and
   FINEP, Brazil (245/2016).
CR Coelho SVA, 2017, J VIROL METHODS, V246, P65, DOI 10.1016/j.jviromet.2017.04.011
   Cherabuddi Kartikeya, 2016, JMM Case Rep, V3, pe005072, DOI 10.1099/jmmcr.0.005072
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Eldin C, 2019, TRAVEL MED INFECT DI, V28, P100, DOI 10.1016/j.tmaid.2019.01.002
   Huhtamo E, 2010, J CLIN VIROL, V47, P49, DOI 10.1016/j.jcv.2009.11.001
   Ingelbeen B, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0007029
   Iovine NM, 2017, CLIN INFECT DIS, V64, P72, DOI 10.1093/cid/ciw667
   Johnson BW, 2005, J CLIN MICROBIOL, V43, P4977, DOI 10.1128/JCM.43.10.4977-4983.2005
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Levi JE, 2016, J INFECT DIS, V213, P689, DOI 10.1093/infdis/jiv322
   Mavrouli M, 2019, AM J TROP MED HYG, V100, P420, DOI 10.4269/ajtmh.18-0339
   Motta IJF, 2016, NEW ENGL J MED, V375, P1101, DOI 10.1056/NEJMc1607262
   Rahman M, 2019, EMERG INFECT DIS, V25, P370, DOI 10.3201/eid2502.180188
   Ruckert C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15412
   Stramer SL, 2012, TRANSFUSION, V52, P1657, DOI 10.1111/j.1537-2995.2012.03566.x
   Vairo F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208896
   Laredo-Tiscareno SV, 2018, AM J TROP MED HYG, V99, P1308, DOI 10.4269/ajtmh.18-0426
   Laredo-Tiscareno SV, 2018, AM J TROP MED HYG, V99, P191, DOI 10.4269/ajtmh.18-0117
NR 18
TC 0
Z9 0
U1 0
U2 1
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0972-9062
J9 J VECTOR DIS
JI J. Vector Borne Dis.
PD APR-JUN
PY 2019
VL 56
IS 2
BP 166
EP 169
AR PMID 31397393
DI 10.4103/0972-9062.263724
PG 4
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA IS2SH
UT WOS:000482003800012
PM 31397393
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Slavov, SN
   de Noronha, LAG
   Gonzaga, FAC
   Pimentel, BMS
   Kashima, S
   Haddad, R
AF Slavov, Svetoslav Nanev
   Goncalves de Noronha, Lorena Aparecida
   Carvalho Gonzaga, Filipe Almeida
   Sidou Pimentel, Barbara Maciel
   Kashima, Simone
   Haddad, Rodrigo
TI Low human parvovirus B19 (B19V) DNA prevalence in blood donors from
   Central-West Brazil
SO JOURNAL OF MEDICAL MICROBIOLOGY
LA English
DT Article
DE parvovirus B19; prevalence; viral load; blood donors
ID TRANSFUSION; PERSISTENCE; ANTIBODIES
AB Parvovirus B19 (B19V) transmission may occur through blood transfusion as a result of asymptomatic viral persistence in blood donors. Our study evaluated the prevalence and viral load of B19V in blood donors from Brasilia, Federal District, Central-West Brazil. B19V DNA detection and quantification were performed in 477 blood donors. The positive samples were also tested for anti-B19V IgG and haemoderivative recipients were investigated for adverse effects following transfusion. B19V DNA prevalence was 0.21 % (n=1/477). The positive B19V DNA sample was also anti-B19 IgG-positive (probably persistent infection). The viral load was low and no adverse effects following blood transfusion were registered in the recipients. This study demonstrated that the B19V DNA prevalence in blood donors from Central-West Brazil is low. Nevertheless, the mere presence of B19V DNA in blood donors strengthens the need for viral molecular screening, especially in haemoderivatives that that will go to susceptible recipients.
C1 [Slavov, Svetoslav Nanev; Kashima, Simone] Univ Sao Paulo, Fac Med Ribeirao Preto, Blood Ctr Ribeirao Preto, Ribeirao Preto, SP, Brazil.
   [Slavov, Svetoslav Nanev] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Internal Med, Ribeirao Preto, SP, Brazil.
   [Goncalves de Noronha, Lorena Aparecida; Carvalho Gonzaga, Filipe Almeida; Haddad, Rodrigo] Univ Brasilia, Fac Ceilandia, Brasilia, DF, Brazil.
   [Carvalho Gonzaga, Filipe Almeida; Sidou Pimentel, Barbara Maciel; Haddad, Rodrigo] Univ Brasilia, Ctr Trop Med, Brasilia, DF, Brazil.
   [Sidou Pimentel, Barbara Maciel] Blood Ctr Brasilia, Brasilia, DF, Brazil.
   [Kashima, Simone] Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, Dept Clin Toxicol & Bromatol Anal, Ribeirao Preto, SP, Brazil.
RP Haddad, R (corresponding author), Univ Brasilia, Fac Ceilandia, Brasilia, DF, Brazil.; Haddad, R (corresponding author), Univ Brasilia, Ctr Trop Med, Brasilia, DF, Brazil.
EM haddad@unb.br
RI Haddad, Rodrigo/A-3460-2013; Kashima, Simone/G-4876-2012
OI Haddad, Rodrigo/0000-0003-4699-164X; Kashima,
   Simone/0000-0002-1487-0141; Gonzaga, Filipe Almeida
   Carvalho/0000-0002-3680-4284; Slavov, Svetoslav/0000-0003-0805-6140
FU Financiadora de Estudos eProjetos - FINEP, BrazilCiencia Tecnologia e
   Inovacao (FINEP) [245/2016]; Fundacao de Apoio a Pesquisado Distrito
   Federal, Federal District, Brazil - FAPDF [0193001014/2015]; Conselho
   Nacional d DesenvolvimentoCientifico e Tecnologico CNPq, Brazil
   [453906/2014-01]
FX This project was supported financially by Financiadora de Estudos
   eProjetos -FINEP, Brazil (245/2016), Fundacao de Apoio a Pesquisado
   Distrito Federal, Federal District, Brazil - FAPDF(0193001014/2015) and
   Conselho Nacional d DesenvolvimentoCientifico e Tecnologico CNPq, Brazil
   (453906/2014-01).
CR *BLOOD PROD ADV CO, 1999, NUCL AC TEST BLOOD D
   de Blas I, 2006, P 11 INT S VET EP EC
   Gama BE, 2017, TRANSPLANT DIRECT, V3, DOI 10.1097/TXD.0000000000000731
   Heegaard ED, 2002, CLIN MICROBIOL REV, V15, P485, DOI 10.1128/CMR.15.3.485-505.2002
   Juhl D, 2014, VOX SANG, V107, P226, DOI 10.1111/vox.12162
   Juhl D, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00004
   Ke L, 2011, TRANSFUSION, V51, P1909, DOI 10.1111/j.1537-2995.2011.03067.x
   Kleinman SH, 2007, TRANSFUSION, V47, P1756, DOI 10.1111/j.1537-2995.2007.01341.x
   Lee TH, 2011, TRANSFUSION, V51, P1896, DOI 10.1111/j.1537-2995.2010.03035.x
   Nagaharu K, 2017, TRANSFUSION, V57, P1414, DOI 10.1111/trf.14088
   Schmidt M, 2007, TRANSFUSION, V47, P1775, DOI 10.1111/j.1537-2995.2007.01443.x
   Sergeant ESG, 2016, EPITOOLS EPIDEMIOLOG
   Silva NFA, 2018, J BRAS PATOL MED LAB, V54, P206
   Slavov SN, 2014, TRANSFUSION MED, V24, P130, DOI 10.1111/tme.12113
   Slavov SN, 2016, INDIAN J HEMATOL BLO, V32, pS323, DOI 10.1007/s12288-015-0607-1
   Slavov SN, 2012, J MED VIROL, V84, P1652, DOI 10.1002/jmv.23358
   Thomas I, 2003, VOX SANG, V84, P300, DOI 10.1046/j.1423-0410.2003.00299.x
   Zadsar M, 2018, J MED VIROL, V90, P1318, DOI 10.1002/jmv.25195
   Zhang W, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-194
NR 19
TC 2
Z9 2
U1 0
U2 0
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-2615
EI 1473-5644
J9 J MED MICROBIOL
JI J. Med. Microbiol.
PD APR
PY 2019
VL 68
IS 4
BP 622
EP 626
DI 10.1099/jmm.0.000957
PG 5
WC Microbiology
SC Microbiology
GA IB2FD
UT WOS:000470084200014
PM 30843782
OA Bronze
DA 2020-11-26
ER

PT J
AU Slavov, SN
   Silveira, RM
   Rodrigues, ES
   Diefenbach, CF
   Zimmermann, AM
   Covas, DT
   Kashima, S
AF Slavov, Svetoslav Nanev
   Silveira, Roberta Maraninchi
   Rodrigues, Evandra Strazza
   Diefenbach, Cristiane Fracao
   Zimmermann, Ana Maria
   Covas, Dimas Tadeu
   Kashima, Simone
TI Human pegivirus-1 pegivirus-1 (HPgV-1, GBV-C) RNA prevalence and
   genotype diversity among volunteer blood donors from an intra-hospital
   hemotherapy service in Southern Brazil
SO TRANSFUSION AND APHERESIS SCIENCE
LA English
DT Article
DE Pegivirus; HPgV-1; Blood donors; PCR; Genotypes
ID C/HEPATITIS-G-VIRUS; HEPATITIS-G-VIRUS; MOTHER-TO-INFANT; INFECTION;
   C/HGV; TRANSMISSION; RECOMBINATION; EPIDEMIOLOGY; HIV
AB Objective: Human pegivirus (HPgV-1, GBV-C) is classified within the Pegivirus genus of the Flaviviriade family. The natural history of HPgV-1 infection is still unclear, however, the main route of viral transmission seems to be the parenteral one. The detection of HPgV-1 viremia in blood donors without parenteral exposure demonstrates that other routes of HPgV-1 transmission might also exist. The objective of the present study was to evaluate the prevalence of HPgV-1 RNA and circulating genotypes among blood donors from a intra-hospital Hemotherapy Service localized in the Santa Maria city, central part of the Rio Grande do Sul State in the extreme South of Brazil.
   Methods: Blood samples were obtained from 373 volunteer blood donors and tested for the presence of HPgV-1 RNA. All positive for RNA samples were submitted to sequencing and phylogenetic analysis.
   Results: The prevalence of the HPgV-1 RNA was 5.9% (22/373). The performed phylogenetic analysis demonstrated a predominant detection of genotype 2 with its both subgenotype forms (95.5% of all isolates i.e 54.5% belonging to subgenotype 2 A and 40.9% belonging to subgenotype 2B). Only one sequence was classified as genotype 3 (1/22, 4.5%).
   Conclusions: Our study demonstrates the circulation pattern and genotypes of HPgV-1 among volunteer blood donors of South Brazil, and adds to the global knowledge of the natural history and possible transmission routes of this viral agent with putative impact on the area of hemotherapy.
C1 [Slavov, Svetoslav Nanev; Silveira, Roberta Maraninchi; Rodrigues, Evandra Strazza; Covas, Dimas Tadeu; Kashima, Simone] Univ Sao Paulo, Fac Med Ribeirao Preto, Blood Ctr Ribeirao Preto, BR-14051140 Ribeirao Preto, SP, Brazil.
   [Slavov, Svetoslav Nanev] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Internal Med, BR-14051140 Ribeirao Preto, SP, Brazil.
   [Diefenbach, Cristiane Fracao] Univ Fed Santa Maria, Univ Hosp Santa Maria, Hematol & Oncol Serv, BR-97105340 Santa Maria, RS, Brazil.
   [Zimmermann, Ana Maria] Hosp Dr Astrogildo de Azevedo, Hemotherapy Serv, BR-97015372 Santa Maria, RS, Brazil.
RP Slavov, SN (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Blood Ctr Ribeirao Preto, Mol Biol Lab, Ribeirao Preto, Brazil.
EM svetoslav.slavov@hemocentro.fmrp.usp.br
RI ; Kashima, Simone/G-4876-2012
OI Silveira, Roberta/0000-0002-7745-7274; Kashima,
   Simone/0000-0002-1487-0141
FU Fundacao de Amparo e Pesquisa do Estado de Sao Paulo-FAPESP, Brazil
   [2009/16623-1, CTC-2013/081352, 2017/23205-8,
   INCTC-FAPESP-2014/50947-7]; Conselho Nacional do Desenvolvimento
   Cientifico e Tecnologico, Brazil [INCTC-465539/2014-9, 455503/2014-1];
   FINEP, BrazilCiencia Tecnologia e Inovacao (FINEP) [245/2016]
FX This study was supported by Fundacao de Amparo e Pesquisa do Estado de
   Sao Paulo-FAPESP, Brazil (Grants 2009/16623-1, CTC-2013/081352,
   2017/23205-8, INCTC-FAPESP-2014/50947-7), Conselho Nacional do
   Desenvolvimento Cientifico e Tecnologico, Brazil (INCTC-465539/2014-9;
   455503/2014-1), and FINEP, Brazil (245/2016).
CR Abraham P, 2001, VOX SANG, V81, P264, DOI 10.1046/j.1423-0410.2001.00109.x
   Adams MJ, 2013, ARCH VIROL, V158, P2023, DOI 10.1007/s00705-013-1688-5
   Alcalde R, 2010, VIRUS RES, V151, P148, DOI 10.1016/j.virusres.2010.04.008
   Barusruk Sahapat, 2006, Southeast Asian Journal of Tropical Medicine and Public Health, V37, P289
   Blackard JT, 2016, J GEN VIROL, V97, P1537, DOI 10.1099/jgv.0.000477
   Christensen PB, 2003, J MED VIROL, V70, P156, DOI 10.1002/jmv.10359
   Da Mota LD, 2019, J MED VIROL, V91, P31, DOI 10.1002/jmv.25291
   Giret MTM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018407
   Giulivi A, 2000, VOX SANG, V79, P201, DOI 10.1159/000056731
   Goubau P, 1999, TROP MED INT HEALTH, V4, P365, DOI 10.1046/j.1365-3156.1999.00407.x
   Jogeda EL, 2017, J MED VIROL, V89, P632, DOI 10.1002/jmv.24683
   Jordier F, 2019, J MED VIROL, V91, P38, DOI 10.1002/jmv.25290
   Kennedy N, 1998, J INFECTION, V37, P140, DOI 10.1016/S0163-4453(98)80168-0
   Lee CK, 2014, J MED VIROL, V86, P737, DOI 10.1002/jmv.23893
   Lefrere JJ, 2000, TRANSFUSION, V40, P602, DOI 10.1046/j.1537-2995.2000.40050602.x
   Levi José Eduardo, 2003, Rev. Inst. Med. trop. S. Paulo, V45, P75, DOI 10.1590/S0036-46652003000200004
   Lu L, 2001, VIRUS RES, V73, P131, DOI 10.1016/S0168-1702(00)00231-8
   MIAO ZJ, 2017, VIRUSES-BASEL, V9, DOI DOI 10.3390/V9050100
   N'Guessan KF, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx222
   Naito H, 2001, J VIROL METHODS, V91, P3, DOI 10.1016/S0166-0934(00)00207-X
   Neibecker M, 2011, J MED VIROL, V83, P685, DOI 10.1002/jmv.22029
   Nishiya Anna S., 2003, Rev. Inst. Med. trop. S. Paulo, V45, P213, DOI 10.1590/S0036-46652003000400007
   Ohto H, 2000, TRANSFUSION, V40, P725, DOI 10.1046/j.1537-2995.2000.40060725.x
   Oliveira LA, 2002, MEM I OSWALDO CRUZ, V97, P953, DOI 10.1590/S0074-02762002000700005
   Pinho JRR, 1999, J CLIN MICROBIOL, V37, P1634, DOI 10.1128/JCM.37.5.1634-1637.1999
   Ramos R, 2004, MEM I OSWALDO CRUZ, V99, P639, DOI 10.1590/S0074-02762004000600019
   SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401
   Stapleton JT, 2011, J GEN VIROL, V92, P233, DOI 10.1099/vir.0.027490-0
   Vitrenko Y, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0837-y
   Xiang JH, 2005, J INFECT DIS, V192, P2147, DOI 10.1086/498170
NR 30
TC 5
Z9 5
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1473-0502
J9 TRANSFUS APHER SCI
JI Transfus. Apher. Sci.
PD APR
PY 2019
VL 58
IS 2
BP 174
EP 178
DI 10.1016/j.transci.2019.01.002
PG 5
WC Hematology
SC Hematology
GA HZ3AO
UT WOS:000468720100013
PM 30709590
DA 2020-11-26
ER

PT J
AU Santos, FLS
   Cuter, TB
   Rodrigues, ES
   Bettarello, EC
   Ubiali, EMA
   Castilho, LM
   Kashima, S
   Covas, DT
AF Souza Santos, Flavia Leite
   Cuter, Talitha Baldin
   Rodrigues, Evandra Strazza
   Bettarello, Emile Cristina
   Amorim Ubiali, Eugenia Maria
   Castilho, Lilian Maria
   Kashima, Simone
   Covas, Dimas Tadeu
TI "Molecular analysis of the rare S-s- red blood cell phenotype in blood
   donors and patients in south-east Brazil"
SO VOX SANGUINIS
LA English
DT Article
DE anti-U; GYPB; MNS blood group
ID HEMOLYTIC TRANSFUSION REACTION; GYPB
AB Background and objectives The rare S-s- phenotype has two main molecular backgrounds. GYPB deletions give rise to the S-s-U- phenotype, which loses the expression of the U antigen, while variant GYPB alleles usually lead to the S-s-U+var phenotype, which express a variant U antigen. The S-s- phenotype is typically found in people of African origin and represents a challenge in transfusion sets, especially when S-s- patients develop anti-U. Molecular analysis is the most reliable method for determining U antigen status. We studied the molecular basis of the S-s- phenotype in donors and patients at Regional Blood Center of Ribeirao Preto. Material and Methods Five patients and 25 donors with the S-s- phenotype were investigated through real-time PCR for the GYPB*S/s polymorphism, followed by an allele-specific/RFLP-PCR for GYPB deletion (GYPB*Null) and for its main variants: GYPB*P2 and GYPB*NY. DNA sequencing was conducted in one sample. Results Two samples were heterozygous GYPB*P2/GYPB*NY, eight were homozygous/hemizygous for GYPB*P2 and 19 samples were homozygous for GYPB*Null. A hybrid gene (GYPB-E-B.Ros) was found in one sample after discrepant results in the initial tests. Conclusion GYPB deletion is the main mechanism responsible for the S-s- phenotype in our donors and patients. It is essential to evaluate the main GYPB variant alleles when genotyping in order to obtain the correct prediction of the phenotype. Hybrid genes lead to discrepancies between genotype and phenotype and may not be detected by conventional molecular assays.
C1 [Souza Santos, Flavia Leite; Cuter, Talitha Baldin; Rodrigues, Evandra Strazza; Bettarello, Emile Cristina; Amorim Ubiali, Eugenia Maria; Castilho, Lilian Maria; Kashima, Simone; Covas, Dimas Tadeu] Hemoctr Ribeirao Preto, Reg Blood Ctr Ribeirao Preto, Ribeirao Preto, Brazil.
RP Santos, FLS (corresponding author), Hemoctr Ribeirao Preto, Rua Tenente Catao Roxo,2510 Monte Alegre, BR-14051140 Ribeirao Preto, SP, Brazil.
EM flavia.leite@hemocentro.fmrp.usp.br
RI Kashima, Simone/G-4876-2012
OI Kashima, Simone/0000-0002-1487-0141; Santos, Flavia/0000-0002-7911-4128
FU CNPq UniversalNational Council for Scientific and Technological
   Development (CNPq) [422118/2016-8]; Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) - Center for Cell-based Therapy (CTC)
   [2013/08135-2]; Conselho Nacional do Desenvolvimento Cientifico e
   Tecnologico, Brazil [INCTC-465539/2014-9]
FX This work was supported by CNPq Universal (Process no. 422118/2016-8),
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) - Center
   for Cell-based Therapy (CTC) (Process no. 2013/08135-2) and Conselho
   Nacional do Desenvolvimento Cientifico e Tecnologico, Brazil
   (INCTC-465539/2014-9).
CR Castilho Lilian, 2016, Immunohematology, V32, P11
   Daniels G, 2013, HUMAN BLOOD GROUPS
   Ramos BRD, 2016, GENETICA, V144, P259, DOI 10.1007/s10709-016-9894-1
   Faria Marina Alves, 2012, Rev. Bras. Hematol. Hemoter., V34, P212, DOI 10.5581/1516-8484.20120052
   Gassner C, 2018, VOX SANG, V113, P5
   Gassner C, 2018, VOX SANG, V70, P6343
   HUANG CH, 1987, BLOOD, V70, P1830
   Leffler EM, 2017, SCIENCE, V356, DOI 10.1126/science.aam6393
   Lins TC, 2010, AM J HUM BIOL, V22, P187, DOI 10.1002/ajhb.20976
   Meyer S, 2016, BRIT J HAEMATOL, V174, P624, DOI 10.1111/bjh.14095
   Novaretti Marcia Cristina Zago, 2003, Rev. Hosp. Clin., V58, P320, DOI 10.1590/S0041-87812003000600006
   Omoto R, 2008, Immunohematology, V24, P148
   RAHUEL C, 1991, AM J HEMATOL, V37, P57, DOI 10.1002/ajh.2830370115
   Reid M E, 2009, Immunohematology, V25, P95
   ROTHMAN IK, 1976, TRANSFUSION, V16, P357
   Storry JR, 2003, TRANSFUSION, V43, P1738, DOI 10.1046/j.0041-1132.2003.00585.x
   Storry JR, 1996, TRANSFUSION, V36, P512, DOI 10.1046/j.1537-2995.1996.36696269509.x
   WIENER AS, 1953, JAMA-J AM MED ASSOC, V153, P1444, DOI 10.1001/jama.1953.02940330028010
   WIENER AS, 1954, SCIENCE, V119, P734, DOI 10.1126/science.119.3099.734
   Willemetz A, 2015, VOX SANG, V108, P410, DOI 10.1111/vox.12244
NR 20
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0042-9007
EI 1423-0410
J9 VOX SANG
JI Vox Sang.
PD APR
PY 2019
VL 114
IS 3
BP 262
EP 267
DI 10.1111/vox.12751
PG 6
WC Hematology
SC Hematology
GA HU2GU
UT WOS:000465090200010
PM 30784083
DA 2020-11-26
ER

PT J
AU Slavov, SN
   Ciliao-Alves, DC
   Gonzaga, FAC
   Moura, DR
   de Moura, ACAM
   de Noronha, LAG
   Cassemiro, EM
   Pimentel, BMS
   Costa, FJQ
   da Silva, GA
   Ramos, DDR
   de Araujo, WN
   Kashima, S
   Haddad, R
AF Slavov, Svetoslav Nanev
   Ciliao-Alves, Daiani Cristina
   Carvalho Gonzaga, Filipe Almeida
   Moura, Drielly Rodrigues
   Alves Melo de Moura, Ana Carolina
   Goncalves de Noronha, Lorena Aparecida
   Cassemiro, Evelin Mota
   Sidou Pimentel, Barbara Maciel
   Queiroz Costa, Fabiano Jose
   da Silva, Grasiela Araujo
   Rabello Ramos, Doralina do Amaral
   de Araujo, Wildo Navegantes
   Kashima, Simone
   Haddad, Rodrigo
TI Dengue seroprevalence among asymptomatic blood donors during an epidemic
   outbreak in Central-West Brazil
SO PLOS ONE
LA English
DT Article
ID VIRUS; VIREMIA; INFECTION; DIAGNOSIS; REGION; RNA
AB Dengue virus (DENV) transmission by blood transfusion is an important route of viral acquisition during outbreaks. The prevalence of DENV markers (viral RNA, NS1, anti-DENV IgM, and IgG) among blood donors in Central-West Brazil has never been evaluated. Our aim was to evaluate the full set of serological and molecular markers for DENV among blood donors of the Federal District of Brazil during an extensive outbreak in 2016. We found an anti-DENV IgM prevalence of 6.74% (n = 32/475). Of 475, 20 samples (4.21%) were also anti-DENV IgG positive. All samples were non-reactive for NS1 and DENV RNA. Our results imply that a significant proportion of the tested donors had experienced asymptomatic infection. More studies are necessary to evaluate the real prevalence of DENV viremia in blood donors from the Federal District of Brazil and if specific measures are needed to routinely test the blood donors for DENV RNA during outbreaks.
C1 [Slavov, Svetoslav Nanev; Kashima, Simone] Univ Sao Paulo, Fac Med Ribeirao Preto, Blood Ctr Ribeirao Preto, Ribeirao Preto, SP, Brazil.
   [Slavov, Svetoslav Nanev] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Internal Med, Ribeirao Preto, SP, Brazil.
   [Ciliao-Alves, Daiani Cristina] Euroamer Univ Ctr UNIEURO, Brasilia, DF, Brazil.
   [Carvalho Gonzaga, Filipe Almeida; Moura, Drielly Rodrigues; Alves Melo de Moura, Ana Carolina; Goncalves de Noronha, Lorena Aparecida; Cassemiro, Evelin Mota; de Araujo, Wildo Navegantes; Haddad, Rodrigo] Univ Brasilia, Fac Ceilandia, Brasilia, DF, Brazil.
   [Carvalho Gonzaga, Filipe Almeida; Cassemiro, Evelin Mota; de Araujo, Wildo Navegantes; Haddad, Rodrigo] Univ Brasilia, Ctr Trop Med, Brasilia, DF, Brazil.
   [Sidou Pimentel, Barbara Maciel] Blood Ctr Brasilia, Brasilia, DF, Brazil.
   [Queiroz Costa, Fabiano Jose; da Silva, Grasiela Araujo] Cent Publ Hlth Lab Fed Dist LACEN DF, Brasilia, DF, Brazil.
   [Rabello Ramos, Doralina do Amaral] Univ Brasilia, Fac Hlth Sci & Med, Lab Mol Pathol Canc, Brasilia, DF, Brazil.
   [Kashima, Simone] Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, Dept Clin Toxicol & Bromatol Anal, Ribeirao Preto, SP, Brazil.
RP Haddad, R (corresponding author), Univ Brasilia, Fac Ceilandia, Brasilia, DF, Brazil.; Haddad, R (corresponding author), Univ Brasilia, Ctr Trop Med, Brasilia, DF, Brazil.
EM haddad@unb.br
RI Haddad, Rodrigo/A-3460-2013; Rabello, Doralina/E-9900-2013; Kashima,
   Simone/G-4876-2012
OI Haddad, Rodrigo/0000-0003-4699-164X; Rabello,
   Doralina/0000-0002-6272-6558; Gonzaga, Filipe Almeida
   Carvalho/0000-0002-3680-4284; Kashima, Simone/0000-0002-1487-0141
FU Financiadora de Estudos e Projetos - FINEP, BrazilCiencia Tecnologia e
   Inovacao (FINEP) [245/2016]; Fundacao de Apoio a Pesquisa do Distrito
   Federal, Federal District, Brazil - FAPDF [0193000416/2016]; Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq,
   BrazilNational Council for Scientific and Technological Development
   (CNPq) [453906/2014-01]; Coordenacao Geral de Laboratorios de Saude
   Publica (CGLAB/SVS/MS)
FX This project was supported financially by Financiadora de Estudos e
   Projetos - FINEP, Brazil (245/2016) (www.finep.gov.br), Fundacao de
   Apoio a Pesquisa do Distrito Federal, Federal District, Brazil - FAPDF
   (0193000416/2016) (www.fap.df.gov.br), Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico - CNPq, Brazil
   (453906/2014-01)(www.cnpq.br) and and Coordenacao Geral de Laboratorios
   de Saude Publica (CGLAB/SVS/MS). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ashshi AM, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0768-7
   Busch MP, 2016, J INFECT DIS, V214, P49, DOI 10.1093/infdis/jiw122
   Chen J, 2015, TROP MED, V15, P1014
   Chuang Vivien W. M., 2008, Hong Kong Medical Journal, V14, P170
   da Costa AG, 2011, REV SOC BRAS MED TRO, V44, P471, DOI 10.1590/S0037-86822011000400014
   deBlas I, WINEPI WORKING EPIDE
   Dias LL, 2012, TRANSFUSION, V52, P1667, DOI 10.1111/j.1537-2995.2012.03729.x
   Faddy HM, 2013, EMERG INFECT DIS, V19, P787, DOI 10.3201/eid1905.121664
   Huhtamo E, 2010, J CLIN VIROL, V47, P49, DOI 10.1016/j.jcv.2009.11.001
   Karim F, 2017, TRANSFUS APHER SCI, V56, P151, DOI 10.1016/j.transci.2016.10.013
   KUNO G, 1987, AM J TROP MED HYG, V36, P153, DOI 10.4269/ajtmh.1987.36.153
   Lavezzo LC, 2010, TRANSFUSION MED, V20, P278, DOI 10.1111/j.1365-3148.2010.00996.x
   Levi JE, 2015, TRANSFUSION, V55, P961, DOI 10.1111/trf.12944
   Linnen JM, 2008, TRANSFUSION, V48, P1355, DOI 10.1111/j.1537-2995.2008.01772.x
   Low SL, 2015, AM J TROP MED HYG, V93, P40, DOI 10.4269/ajtmh.14-0671
   Matos D, 2016, TRANSFUSION, V56, P215, DOI 10.1111/trf.13288
   Mohammed H, 2008, TRANSFUSION, V48, P1348, DOI 10.1111/j.1537-2995.2008.01771.x
   Muller DA, 2017, J INFECT DIS, V215, pS89, DOI 10.1093/infdis/jiw649
   Ranjan P, 2016, J CLIN DIAGN RES, V10, pDC8, DOI 10.7860/JCDR/2016/21262.8711
   Rothman AL, 2004, J CLIN INVEST, V113, P946, DOI 10.1172/JCI200421512
   Sabino EC, 2016, J INFECT DIS, V213, P694, DOI 10.1093/infdis/jiv326
   Slavov SN, 2018, TRANSFUSION MED, V28, P465, DOI 10.1111/tme.12521
   Stramer SL, 2012, TRANSFUSION, V52, P1657, DOI 10.1111/j.1537-2995.2012.03566.x
   Tambyah PA, 2008, NEW ENGL J MED, V359, P1526, DOI 10.1056/NEJMc0708673
   Teixeira MG, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002520
   WHO, 2015, DENG HAEM FEV DIAGN
   Zeng P, 2018, TRANSFUSION MED, V28, P468, DOI 10.1111/tme.12551
NR 27
TC 2
Z9 2
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 25
PY 2019
VL 14
IS 3
AR e0213793
DI 10.1371/journal.pone.0213793
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HQ1KV
UT WOS:000462157600019
PM 30908528
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Rodrigues, ES
   de Macedo, MD
   Orellana, MD
   Takayanagui, OM
   Palma, PVB
   Pinto, MT
   de Oliveira, GLV
   Malmegrim, KCR
   Slavov, SN
   Covas, DT
   Kashima, S
AF Rodrigues, Evandra Strazza
   de Macedo, Mayra Dorigan
   Orellana, Maristela Delgado
   Takayanagui, Osvaldo Massaiti
   Bonini Palma, Patricia Vianna
   Pinto, Mariana Tomazini
   Vilela de Oliveira, Gislane Lelis
   Ribeiro Malmegrim, Kelen Cristina
   Slavov, Svetoslav Nanev
   Covas, Dimas Tadeu
   Kashima, Simone
TI Short Communication: Human Bone Marrow Stromal Cells Exhibit
   Immunosuppressive Effects on Human T Lymphotropic Virus Type 1 T
   Lymphocyte from Infected Individuals
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
DE MSC; HTLV-1; immunoregulation; gene expression
ID MESENCHYMAL STEM-CELLS; IN-VITRO; INHIBIT
AB Human multipotent mesenchymal stromal cells (MSCs) display immunoregulatory functions that can modulate innate and adaptive cellular immune responses. The suppressive and immunomodulatory activities of MSCs occur through the action of soluble factors that are constitutively produced and released by these cells or, alternatively, after MSC induction by stimuli of inflammatory microenvironments. However, to date the contribution of MSCs in the inflammatory microenvironment resulting from viral infection is unknown. In our study, we evaluated the MSC immunosuppressive effect on human T lymphotropic virus type 1 (HTLV-1) infected T lymphocytes. To evaluate if MSC immunoregulation can influence the proliferation of HTLV-1 infected T lymphocytes, we compared the proliferation of lymphocytes obtained from HTLV-1 infected and healthy individuals cocultured in the presence of MSCs. It was observed that the lymphoproliferative inhibition by MSCs on infected lymphocytes was similar compared to the cells obtained from healthy individuals. In addition, this suppressive effect was related to a significant increase of indoleamine-2,3-dioxygenase and prostaglandin E2 gene expression (p <= .05). Furthermore, the HTLV-1 pol gene was less expressed after coculturing with MSCs, suggesting that the MSC immunoregulation can have effective suppression on HTLV-1 infected T cells. In conclusion, this study suggests that MSCs could be involved in the immunomodulation of the HTLV-1 infected T lymphocytes.
C1 [Rodrigues, Evandra Strazza; de Macedo, Mayra Dorigan; Orellana, Maristela Delgado; Bonini Palma, Patricia Vianna; Pinto, Mariana Tomazini; Ribeiro Malmegrim, Kelen Cristina; Slavov, Svetoslav Nanev; Covas, Dimas Tadeu; Kashima, Simone] Univ Sao Paulo, Sch Med Ribeirao Preto, Reg Blood Ctr Ribeirao Preto, Ctr Cell Based Res, Ribeirao Preto, Brazil.
   [Rodrigues, Evandra Strazza; de Macedo, Mayra Dorigan; Ribeiro Malmegrim, Kelen Cristina] Fac Pharmaceut Sci Ribeirao Preto, Dept Clin Toxicol & Bromatol Anal, Ribeirao Preto, Brazil.
   [Orellana, Maristela Delgado; Takayanagui, Osvaldo Massaiti; Covas, Dimas Tadeu; Kashima, Simone] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Clin Med, Ribeirao Preto, Brazil.
   [Vilela de Oliveira, Gislane Lelis] Sao Paulo State Univ UNESP, Inst Biosci Humanities & Exact Sci IBILCE, Sao Jose Do Rio Preto, SP, Brazil.
RP Kashima, S (corresponding author), Univ Sao Paulo, Ctr Cell Based Res, Sch Med Ribeirao Preto, Ave Tenente Catao Roxo 2501, BR-14051140 Ribeirao Preto, SP, Brazil.
EM skashima@hemocentro.fmrp.usp.br
RI Malmegrim, Kelen/H-1016-2015; de Oliveira, Gislane L. V./I-4896-2013;
   Kashima, Simone/G-4876-2012
OI Malmegrim, Kelen/0000-0002-9303-0086; de Oliveira, Gislane L.
   V./0000-0002-0269-9973; Kashima, Simone/0000-0002-1487-0141; Lelis
   Vilela de Oliveira, Gislane/0000-0002-8883-5541
CR Dotoli GM, 2017, BONE MARROW TRANSPL, V52, P859, DOI 10.1038/bmt.2017.35
   Karlsson H, 2008, BLOOD, V112, P532, DOI 10.1182/blood-2007-10-119370
   Kinpara S, 2009, J VIROL, V83, P5101, DOI 10.1128/JVI.02564-08
   Le Blanc K, 2012, NAT REV IMMUNOL, V12, P383, DOI 10.1038/nri3209
   Liotta F, 2008, STEM CELLS, V26, P279, DOI 10.1634/stemcells.2007-0454
   Lucchini G, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/690236
   Meisel R, 2004, BLOOD, V103, P4619, DOI 10.1182/blood-2003-11-3909
   Nagai K, 2008, INT J HEMATOL, V88, P551, DOI 10.1007/s12185-008-0207-z
   Opitz CA, 2009, STEM CELLS, V27, P909, DOI 10.1002/stem.7
   Prockop DJ, 2013, STEM CELLS, V31, P2042, DOI 10.1002/stem.1400
NR 10
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD FEB 1
PY 2019
VL 35
IS 2
BP 164
EP 168
DI 10.1089/aid.2018.0066
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA HR2AW
UT WOS:000462938900008
PM 30351194
DA 2020-11-26
ER

PT J
AU Slavov, SN
   Hespanhol, MR
   Ferreira, AR
   Rodrigues, ES
   Covas, DT
   Kashima, S
AF Slavov, S. N.
   Hespanhol, M. R.
   Ferreira, A. R.
   Rodrigues, E. S.
   Covas, D. T.
   Kashima, S.
TI Silent dengue virus circulation among asymptomatic blood donors from a
   hyperendemic Brazilian region
SO TRANSFUSION MEDICINE
LA English
DT Letter
ID PCR
C1 [Slavov, S. N.; Hespanhol, M. R.; Ferreira, A. R.; Rodrigues, E. S.; Covas, D. T.; Kashima, S.] Univ Sao Paulo, Blood Ctr Ribeirao Preto, Fac Med Rbeirao Preto, Ribeirao Preto, SP, Brazil.
   [Slavov, S. N.; Covas, D. T.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Internal Med, Ribeirao Preto, SP, Brazil.
RP Slavov, SN (corresponding author), Univ Sao Paulo, Blood Ctr Ribeirao Preto, Mol Biol Lab, Rua Tenente Catao Roxo 2501, BR-14015160 Ribeirao Preto, SP, Brazil.
EM svetoslav.slavov@hemocentro.fmrp.usp.br
RI Ferreira, Alexander/R-1439-2017; Ferreira, Alexander/X-3802-2019;
   Kashima, Simone/G-4876-2012
OI Ferreira, Alexander/0000-0003-1175-8127; Ferreira,
   Alexander/0000-0003-1175-8127; Slavov, Svetoslav/0000-0003-0805-6140;
   Kashima, Simone/0000-0002-1487-0141
FU Fundacao de Amparo e Pesquisa do Estado de Sao Paulo-FAPESP, Brazil
   [2009/16623-1, CTC-2013/081352]; Conselho Nacional do Desenvolvimento
   Cientifico e Tecnologico, Brazil [INCTC-573.754/2008-0,
   INCTC-2008/57.877-3]; FINEP, BrazilCiencia Tecnologia e Inovacao (FINEP)
   [245/2016]
FX This study was supported by Fundacao de Amparo e Pesquisa do Estado de
   Sao Paulo-FAPESP, Brazil (Grant. 2009/16623-1, CTC-2013/081352);
   Conselho Nacional do Desenvolvimento Cientifico e Tecnologico, Brazil
   (INCTC-573.754/2008-0 and INCTC-2008/57.877-3); and FINEP, Brazil
   (245/2016).
CR Amarilla AA, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-113
   Huhtamo E, 2010, J CLIN VIROL, V47, P49, DOI 10.1016/j.jcv.2009.11.001
   Johnson BW, 2005, J CLIN MICROBIOL, V43, P4977, DOI 10.1128/JCM.43.10.4977-4983.2005
   Sabino EC, 2016, J INFECT DIS, V213, P694, DOI 10.1093/infdis/jiv326
   Stramer SL, 2012, TRANSFUSION, V52, P1657, DOI 10.1111/j.1537-2995.2012.03566.x
NR 5
TC 2
Z9 2
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0958-7578
EI 1365-3148
J9 TRANSFUSION MED
JI Transfus. Med.
PD DEC
PY 2018
VL 28
IS 6
BP 465
EP 467
DI 10.1111/tme.12521
PG 3
WC Hematology
SC Hematology
GA HE3VF
UT WOS:000453289300013
PM 29542218
DA 2020-11-26
ER

PT J
AU Otaguiri, KK
   dos Santos, DF
   Slavov, SN
   Depieri, LV
   Palma, PVB
   Meirelles, FV
   Covas, DT
   da Silveira, JC
   Kashima, S
AF Otaguiri, Katia Kaori
   dos Santos, Daiane Fernanda
   Slavov, Svetoslav Nanev
   Depieri, Livia Vieira
   Bonini Palma, Patricia Vianna
   Meirelles, Flavio Vieira
   Covas, Dimas Tadeu
   da Silveira, Juliano Coelho
   Kashima, Simone
TI TAX-mRNA-Carrying Exosomes from Human T Cell Lymphotropic Virus Type
   1-Infected Cells Can Induce Interferon-Gamma Production In Vitro
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
DE exosomes; HTLV-1; HAM; TSP; Tax; interferon-gamma
ID MYELOPATHY/TROPICAL SPASTIC PARAPARESIS; BLOOD MONONUCLEAR-CELLS;
   PROVIRAL DNA LOAD; EXTRACELLULAR VESICLES; CYTOKINE PRODUCTION;
   IMMUNE-RESPONSES; VIRAL-RNA; HTLV-1; EXPRESSION; MICROVESICLES
AB Human T cell lymphotropic virus type 1 (HTLV-1) is the etiological agent of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and adult T cell leukemia/lymphoma. The development of HAM/TSP, a chronic neuroinflammatory disease, is correlated to complex interaction between the host immune response and the infecting virus. Tax expression plays an important role in HAM/TSP pathogenesis by activating various cellular genes, including the cytokines interferon-gamma (IFN-) and tumor necrosis factor-alpha (TNF-). Exosomes have emerged as an important factor of cell-to-cell communication contributing to diverse cellular processes, including immune modulation. Considering the potential role of exosomes in modulating the immune response and inflammation, the main objective of this study was to examine if HTLV-1-infected cells produce exosomes carrying viral proteins or inflammatory molecules, which can participate in the chronic inflammation that is observed in patients with HAM/TSP. Exosomes were isolated from HTLV-1-infected cell line, evaluated for the tax mRNA presence, and tested for the ability to activate peripheral mononuclear cells (PBMC) in inducing an inflammatory immune response. We observed that the proinflammatory cytokines, IFN- and TNF-, were upregulated in T cells after treatment of the PBMC with Tax-carrying exosomes compared to the negative control. Interleukin-4, Granzyme B, and Perforin did not show alterations. Taken together, these results suggest that exosomes carrying tax-mRNA isolated from HTLV-1-infected cells might induce the production of proinflammatory cytokines and activate T helper (Th)(1), and not Th-2-immune response. If this finding is further confirmed, this study may have impact on investigations on the pathogenesis of HAM-TSP and the inflammatory response involved in this disease.
C1 [Otaguiri, Katia Kaori; dos Santos, Daiane Fernanda; Kashima, Simone] Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, Dept Clin Toxicol & Bromatol Anal, Ribeirao Preto, Brazil.
   [Otaguiri, Katia Kaori; dos Santos, Daiane Fernanda; Slavov, Svetoslav Nanev; Bonini Palma, Patricia Vianna; Covas, Dimas Tadeu; Kashima, Simone] Univ Sao Paulo, Reg Blood Ctr Ribeirao Preto, Fac Med Ribeirao Preto, Ribeirao Preto, Brazil.
   [Depieri, Livia Vieira] Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, Dept Pharmaceut Sci, Ribeirao Preto, Brazil.
   [Meirelles, Flavio Vieira; Covas, Dimas Tadeu] Univ Sao Paulo, Fac Anim Sci & Food Engn, Dept Vet Med, Pirassununga, Brazil.
   [da Silveira, Juliano Coelho] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Internal Med, Ribeirao Preto, Brazil.
RP Kashima, S (corresponding author), Fdn Hemoctr Ribeirao Preto, Lab Biol Mol, Rua Tenente Catao Roxo 2501, BR-14051140 Ribeirao Preto, SP, Brazil.
EM skashima@hemocentro.fmrp.usp.br
RI Meirelles, Flavio V/B-5048-2010; Da Silveira, Juliano/B-3086-2013;
   Kashima, Simone/G-4876-2012
OI Meirelles, Flavio V/0000-0003-0372-4920; Da Silveira,
   Juliano/0000-0002-4796-6393; Kashima, Simone/0000-0002-1487-0141
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo-FAPESP,
   BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [CTC-1998/14.247-6, INCTC-2008/57.877-3, 2014/22887-0, 2015/16985-1,
   2015/21829]; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico-CNPq, BrazilNational Council for Scientific and
   Technological Development (CNPq) [INCTC-573.754/2008-0]
FX We are grateful to the Laboratory of Electron Microscopy of the
   Department of Cellular and Molecular Biology of the School of Medicine
   of Ribeirao Preto, University of Sao Paulo (Ribeirao Preto, Sao Paulo,
   Brazil), for the Transmission Electron Microscopy analysis of the
   exosomes. We are also grateful to the Laboratory of Molecular
   Morphophysiology and Development of Department of Veterinary Medicine of
   Faculty of Animal Sciences and Food Engineering, University of Sao Paulo
   (Pirassununga, Sao Paulo, Brazil), for the Nanoparticle Tracking
   Analysis of the exosomes. Finally, we are grateful to the Laboratory of
   Flow Cytometry of the Regional Blood Center of General Clinical
   Hospital, Faculty of Medicine of Ribeirao Preto (Ribeirao Preto, Sao
   Paulo, Brazil), for performing the flow cytometry analysis. This work
   was supported financially by the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo-FAPESP, Brazil (grant numbers CTC-1998/14.247-6,
   INCTC-2008/57.877-3, 2014/22887-0, 2015/16985-1, 2015/21829), and the
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-CNPq,
   Brazil (INCTC-573.754/2008-0).
CR Akers JC, 2013, J NEURO-ONCOL, V113, P1, DOI 10.1007/s11060-013-1084-8
   Araya N, 2014, J CLIN INVEST, V124, P3431, DOI 10.1172/JCI75250
   Buzas EI, 2014, NAT REV RHEUMATOL, V10, P356, DOI 10.1038/nrrheum.2014.19
   Cowan EP, 1997, J VIROL, V71, P6982, DOI 10.1128/JVI.71.9.6982-6989.1997
   Demontis MA, 2015, J MED VIROL, V87, P2130, DOI 10.1002/jmv.24264
   DETHE G, 1993, AIDS RES HUM RETROV, V9, P381, DOI 10.1089/aid.1993.9.381
   DHIBJALBUT S, 1994, ANN NEUROL, V36, P787, DOI 10.1002/ana.410360516
   Dreux M, 2012, CELL HOST MICROBE, V12, P558, DOI 10.1016/j.chom.2012.08.010
   Furukawa Y, 2003, J INFECT DIS, V187, P1116, DOI 10.1086/368379
   Greening DW, 2015, SEMIN CELL DEV BIOL, V40, P72, DOI 10.1016/j.semcdb.2015.02.009
   Gross C, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8030074
   Jaworski E, 2014, J BIOL CHEM, V289, P22284, DOI 10.1074/jbc.M114.549659
   Martin F, 2014, EXPERT REV CLIN IMMU, V10, P1531, DOI 10.1586/1744666X.2014.966690
   Matsuura E, 2010, J NEUROIMMUNE PHARM, V5, P310, DOI 10.1007/s11481-010-9216-9
   Medina F, 2016, J MED VIROL, V88, P521, DOI 10.1002/jmv.24342
   Miley WJ, 2000, AIDS RES HUM RETROV, V16, P665, DOI 10.1089/088922200308891
   Muller L, 2016, SCI REP-UK, V6, DOI 10.1038/srep20254
   Munoz JL, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.60
   Nagai M, 1998, J NEUROVIROL, V4, P586, DOI 10.3109/13550289809114225
   Nagai M, 2001, ANN NEUROL, V50, P807, DOI 10.1002/ana.10065
   Okayama Akihiko, 2005, Rinsho Byori, V53, P837
   Oliere S, 2011, CYTOKINE GROWTH F R, V22, P197, DOI 10.1016/j.cytogfr.2011.08.002
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   Ramirez E, 2007, J MED VIROL, V79, P782, DOI 10.1002/jmv.20844
   Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138
   RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990
   Robbins PD, 2014, NAT REV IMMUNOL, V14, P195, DOI 10.1038/nri3622
   Sampey GC, 2016, J BIOL CHEM, V291, P1251, DOI 10.1074/jbc.M115.662171
   Schageman J, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/253957
   Tattermusch S, 2012, TRENDS MICROBIOL, V20, P494, DOI 10.1016/j.tim.2012.07.004
   Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30
   UMEHARA F, 1994, J NEUROPATH EXP NEUR, V53, P72, DOI 10.1097/00005072-199401000-00009
   Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129
   Yamano Y, 2002, BLOOD, V99, P88, DOI 10.1182/blood.V99.1.88
   Yari A, 2014, IRAN J BASIC MED SCI, V17, P531
   Yuana Y, 2013, BLOOD REV, V27, P31, DOI 10.1016/j.blre.2012.12.002
NR 36
TC 2
Z9 2
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD DEC 1
PY 2018
VL 34
IS 12
BP 1075
EP 1082
DI 10.1089/aid.2018.0115
EA NOV 2018
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA HE2BG
UT WOS:000448919000001
PM 30229663
DA 2020-11-26
ER

PT J
AU Iragorri, MAL
   El Hoss, S
   Brousse, V
   Lefevre, SD
   Dussiot, M
   Xu, TY
   Ferreira, AR
   Lamarre, Y
   Pinto, ACS
   Kashima, S
   Lapoumeroulie, C
   Covas, DT
   Le Van Kim, C
   Colin, Y
   Elion, J
   Francais, O
   Le Pioufle, B
   El Nemer, W
AF Iragorri, Maria Alejandra Lizarralde
   El Hoss, Sara
   Brousse, Valentine
   Lefevre, Sophie D.
   Dussiot, Michael
   Xu, Tieying
   Ferreira, Alexander Rodrigo
   Lamarre, Yann
   Silva Pinto, Ana Cristina
   Kashima, Simone
   Lapoumeroulie, Claudine
   Covas, Dimas Tadeu
   Le Van Kim, Caroline
   Colin, Yves
   Elion, Jacques
   Francais, Olivier
   Le Pioufle, Bruno
   El Nemer, Wassim
TI A microfluidic approach to study the effect of mechanical stress on
   erythrocytes in sickle cell disease
SO LAB ON A CHIP
LA English
DT Article
ID RED-BLOOD-CELL; FETAL-HEMOGLOBIN; F-CELLS; IN-VIVO; DEFORMABILITY;
   VASOOCCLUSION; HEREDITARY; FREQUENCY; OCCLUSION; DYNAMICS
AB The human red blood cell is a biconcave disc of 6-8 x 2 mu m that is highly elastic. This capacity to deform enables it to stretch while circulating through narrow capillaries to ensure its main function of gas exchange. Red cell shape and deformability are altered in membrane disorders because of defects in skeletal or membrane proteins affecting protein-protein interactions. Red cell properties are also altered in other pathologies such as sickle cell disease. Sickle cell disease is a genetic hereditary disorder caused by a single point mutation in the beta-globin gene generating sickle haemoglobin (HbS). Hypoxia drives HbS polymerisation that is responsible for red cell sickling and reduced deformability. The main clinical features of sickle cell disease are vaso-occlusive crises and haemolytic anaemia. Foetal haemoglobin (HbF) inhibits HbS polymerisation and positively impacts red cell survival in the circulation but the mechanism through which it exerts this action is not fully characterized. In this study, we designed a microfluidic biochip mimicking the dimensions of human capillaries to measure the impact of repeated mechanical stress on the survival of red cells at the single cell scale under controlled pressure. We show that mechanical stress is a critical parameter underlying intravascular haemolysis in sickle cell disease and that high intracellular levels of HbF protect against lysis. The biochip is a promising tool to address red cell deformability in pathological situations and to screen for molecules positively impacting this parameter in order to improve red cell survival in the circulation.
C1 [Iragorri, Maria Alejandra Lizarralde; El Hoss, Sara; Brousse, Valentine; Lefevre, Sophie D.; Le Van Kim, Caroline; Colin, Yves; Elion, Jacques; El Nemer, Wassim] Univ Antilles, Univ La Reunion, Sorbonne Paris Cite,Biol Integree Globule Rouge, INSERM,Univ Paris Diderot,INTS,UMR S1134, 6 Rue Alexandre Cabanel, F-75015 Paris, France.
   [Iragorri, Maria Alejandra Lizarralde; El Hoss, Sara; Brousse, Valentine; Lefevre, Sophie D.; Lapoumeroulie, Claudine; Le Van Kim, Caroline; Colin, Yves; Elion, Jacques; El Nemer, Wassim] Inst Natl Transfus Sanguine, F-75015 Paris, France.
   [Iragorri, Maria Alejandra Lizarralde; El Hoss, Sara; Brousse, Valentine; Lefevre, Sophie D.; Lapoumeroulie, Claudine; Le Van Kim, Caroline; Colin, Yves; Elion, Jacques; El Nemer, Wassim] Lab Excellence GR Ex, Paris, France.
   [Brousse, Valentine] Hop Necker Enfants Malad, AP HP, Serv Pediat Gen, Ctr Reference Drepanocytose, Paris, France.
   [Dussiot, Michael] Univ Paris 05, Univ Sorbonne Paris Cite, Lab Cellular & Mol Mech Hematol Disorders & Thera, INSERM,Lab Excellence GR Ex,CNRS,Inst Imagine, Paris, France.
   [Xu, Tieying; Le Pioufle, Bruno] Univ Paris Saclay, ENS Paris Saclay, Inst dAlembert, CNRS,SATIE, Ile De France, France.
   [Ferreira, Alexander Rodrigo; Lamarre, Yann; Silva Pinto, Ana Cristina; Kashima, Simone; Covas, Dimas Tadeu] Hemoctr Ribeirao Preto, Ctr Cell Based Therapy, Sao Paulo, Brazil.
   [Covas, Dimas Tadeu] Univ Sao Paulo, Ribeirao Preto Med Sch, Ribeirao Preto, SP, Brazil.
   [Francais, Olivier] Univ Paris Est, ESYCOM EA2552, ESIEE Paris, Noisy Le Grand, France.
RP El Nemer, W (corresponding author), Univ Antilles, Univ La Reunion, Sorbonne Paris Cite,Biol Integree Globule Rouge, INSERM,Univ Paris Diderot,INTS,UMR S1134, 6 Rue Alexandre Cabanel, F-75015 Paris, France.; El Nemer, W (corresponding author), Inst Natl Transfus Sanguine, F-75015 Paris, France.; El Nemer, W (corresponding author), Lab Excellence GR Ex, Paris, France.
EM wassim.el-nemer@inserm.fr
RI El Nemer, Wassim/N-4247-2017; Ferreira, Alexander/X-3802-2019; Lefevre,
   Sophie D./AAO-2773-2020; Ferreira, Alexander/R-1439-2017; Lamarre,
   Yann/ABC-2074-2020; Elion, Jacques/A-1048-2014; Lefevre, Sophie
   D/G-7713-2015; Lapoumeroulie, Claudine/P-3515-2018; Le Pioufle,
   Bruno/B-6951-2013; Kashima, Simone/G-4876-2012
OI Ferreira, Alexander/0000-0003-1175-8127; Lefevre, Sophie
   D./0000-0002-7504-1881; Ferreira, Alexander/0000-0003-1175-8127; Elion,
   Jacques/0000-0002-8407-1783; Lefevre, Sophie D/0000-0002-7504-1881; Le
   Pioufle, Bruno/0000-0002-0010-2475; El Hoss, Sara/0000-0003-1711-2829;
   Kashima, Simone/0000-0002-1487-0141; LAPOUMEROULIE,
   Claudine/0000-0001-6665-3598
FU Institut National de la Sante et de la Recherche Medicale
   (Inserm)Institut National de la Sante et de la Recherche Medicale
   (Inserm); Institut National de la Transfusion Sanguine; Laboratory of
   Excellence GR-Ex [ANR-11-LABX-0051]; Laboratory of Excellence LaSIPS
   [ANR-10-LABX-0040-Lasips]; FAPESPFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [CTC 2013/08135-2]; program "Investissements
   d'avenir" of the French National Research AgencyFrench National Research
   Agency (ANR) [ANR-11-IDEX-0005-02]; Ministere de l'Enseignement
   Superieur et de la Recherche (Ecole Doctorale BioSPC); Club du Globule
   Rouge et du Fer; Societe Francaise d'Hematologie
FX We thank Mr Mickael Marin and Mr Leonardo Molina Cancino for technical
   support. The work was supported by the Institut National de la Sante et
   de la Recherche Medicale (Inserm), the Institut National de la
   Transfusion Sanguine, the Laboratory of Excellence GR-Ex, reference
   ANR-11-LABX-0051, the Laboratory of Excellence LaSIPS
   (ANR-10-LABX-0040-Lasips), and FAPESP grant for Center for Cell-based
   Therapy (CTC 2013/08135-2). GR-Ex is funded by the program
   "Investissements d'avenir" of the French National Research Agency,
   reference ANR-11-IDEX-0005-02. Sara El Hoss and Maria Alejandra
   Lizarralde Iragorri were funded by the Ministere de l'Enseignement
   Superieur et de la Recherche (Ecole Doctorale BioSPC); they received
   financial support from: Club du Globule Rouge et du Fer and Societe
   Francaise d'Hematologie.
CR Alapan Y, 2016, TECHNOLOGY, V4, P71, DOI 10.1142/S2339547816400045
   Bagriantsev SN, 2014, J BIOL CHEM, V289, P31673, DOI 10.1074/jbc.R114.612697
   Barabino GA, 2010, ANNU REV BIOMED ENG, V12, P345, DOI 10.1146/annurev-bioeng-070909-105339
   Bartolucci P, 2010, BLOOD, V116, P2152, DOI 10.1182/blood-2009-12-257444
   Bosman GJCGM, 2008, TRANSFUSION MED, V18, P335, DOI 10.1111/j.1365-3148.2008.00892.x
   BOYER SH, 1975, JOHNS HOPKINS MED J, V137, P105
   BOYER SH, 1977, AM J HUM GENET, V29, P256
   BOYER SH, 1975, SCIENCE, V188, P361, DOI 10.1126/science.804182
   BRUGNARA C, 1986, SCIENCE, V232, P388, DOI 10.1126/science.3961486
   BRUGNARA C, 1989, BLOOD, V74, P487
   Connes P, 2016, BLOOD REV, V30, P111, DOI 10.1016/j.blre.2015.08.005
   Dobbe JGG, 2002, BLOOD CELL MOL DIS, V28, P373, DOI 10.1006/bcmd.2002.0528
   Dominical VM, 2015, EXP HEMATOL, V43, P223, DOI 10.1016/j.exphem.2014.10.015
   DOVER GJ, 1978, NEW ENGL J MED, V299, P1428, DOI 10.1056/NEJM197812282992603
   Du E, 2015, P NATL ACAD SCI USA, V112, P1422, DOI 10.1073/pnas.1424111112
   Dupire J, 2012, P NATL ACAD SCI USA, V109, P20808, DOI 10.1073/pnas.1210236109
   Franco RS, 2006, BLOOD, V108, P1073, DOI 10.1182/blood-2005-09-008318
   Franco RS, 1998, J CLIN INVEST, V101, P2730, DOI 10.1172/JCI2484
   Gallagher PG, 2013, CURR OPIN HEMATOL, V20, P201, DOI 10.1097/MOH.0b013e32835f6870
   Goodman SR, 2004, CELL MOL BIOL, V50, P53
   Higgins JM, 2007, P NATL ACAD SCI USA, V104, P20496, DOI 10.1073/pnas.0707122105
   Kaul DK, 2000, J CLIN INVEST, V106, P411, DOI 10.1172/JCI9225
   KAUL DK, 1986, BLOOD, V68, P1162
   Kaul DK, 2004, MICROCIRCULATION, V11, P153, DOI 10.1080/10739680490278457
   KAUL DK, 1989, P NATL ACAD SCI USA, V86, P3356, DOI 10.1073/pnas.86.9.3356
   Lubin B, 1981, Prog Clin Biol Res, V56, P171
   Lux SE, 2016, BLOOD, V127, P187, DOI 10.1182/blood-2014-12-512772
   MAIERREDELSPERGER M, 1994, BLOOD, V84, P3182, DOI 10.1182/blood.V84.9.3182.bloodjournal8493182
   MARVA E, 1994, BLOOD, V83, P242
   McDonald JC, 2002, ACCOUNTS CHEM RES, V35, P491, DOI 10.1021/ar010110q
   MOHANDAS N, 1980, J CLIN INVEST, V66, P563, DOI 10.1172/JCI109888
   MOHANDAS N, 1989, ANN NY ACAD SCI, V554, P217, DOI 10.1111/j.1749-6632.1989.tb22423.x
   Narla J, 2017, INT J LAB HEMATOL, V39, P47, DOI 10.1111/ijlh.12657
   PAULING L, 1949, SCIENCE, V109, P443
   Piel FB, 2017, NEW ENGL J MED, V376, P1561, DOI 10.1056/NEJMra1510865
   POWARS DR, 1984, BLOOD, V63, P921, DOI 10.1182/blood.V63.4.921.921
   Quinn DJ, 2011, ANN BIOMED ENG, V39, P1041, DOI 10.1007/s10439-010-0232-y
   Rabai M, 2014, BIORHEOLOGY, V51, P159, DOI 10.3233/BIR-140660
   Ribeil JA, 2017, NEW ENGL J MED, V376, P848, DOI 10.1056/NEJMoa1609677
   Sankaran VG, 2010, BRIT J HAEMATOL, V149, P181, DOI 10.1111/j.1365-2141.2010.08105.x
   SEWCHAND LS, 1983, BLOOD CELLS, V9, P147
   Stuart MJ, 2004, LANCET, V364, P1343, DOI 10.1016/S0140-6736(04)17192-4
   Tomaiuolo G, 2016, MED ENG PHYS, V38, P11, DOI 10.1016/j.medengphy.2015.05.007
   Tsai M, 2012, J CLIN INVEST, V122, P408, DOI 10.1172/JCI58753
   Turhan A, 2002, P NATL ACAD SCI USA, V99, P3047, DOI 10.1073/pnas.052522799
   van Beers EJ, 2014, AM J HEMATOL, V89, P598, DOI 10.1002/ajh.23699
   Voskou S, 2015, REDOX BIOL, V6, P226, DOI 10.1016/j.redox.2015.07.018
   Ware RE, 2017, LANCET, V390, P311, DOI 10.1016/S0140-6736(17)30193-9
   Wood DK, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002738
   WOOD WG, 1975, BLOOD, V46, P671
NR 50
TC 12
Z9 12
U1 4
U2 41
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1473-0197
EI 1473-0189
J9 LAB CHIP
JI Lab Chip
PD OCT 7
PY 2018
VL 18
IS 19
BP 2975
EP 2984
DI 10.1039/c8lc00637g
PG 10
WC Biochemical Research Methods; Chemistry, Multidisciplinary; Chemistry,
   Analytical; Nanoscience & Nanotechnology; Instruments & Instrumentation
SC Biochemistry & Molecular Biology; Chemistry; Science & Technology -
   Other Topics; Instruments & Instrumentation
GA GY3AA
UT WOS:000448415500009
PM 30168832
DA 2020-11-26
ER

PT J
AU Rodrigues, ES
   Favarin, MD
   de Macedo, MD
   Otaguiri, KK
   Orellana, MD
   Takayanagui, OM
   Palma, PVB
   Slavov, SN
   Covas, DT
   Kashima, S
AF Rodrigues, Evandra Strazza
   Favarin, Maria do Carmo
   de Macedo, Mayra Dorigan
   Otaguiri, Katia Kaori
   Orellana, Maristela Delgado
   Takayanagui, Osvaldo Massaiti
   Bonini Palma, Patricia Vianna
   Slavov, Svetoslav Nanev
   Covas, Dimas Tadeu
   Kashima, Simone
TI Detection of HTLV-1 proviral DNA in BM mononuclear cells and cultured
   mesenchymal stromal cells isolated from patients with HTLV-1 infection
SO VIROLOGY
LA English
DT Article
DE HTLV-1; Provirus; Human mesenchymal stromal cell; MSC; Virus infection
ID VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; BONE-MARROW-TRANSPLANTATION;
   STEM-CELLS; T-LYMPHOCYTE; CYTOMEGALOVIRUS-INFECTION; LEUKEMIA-LYMPHOMA;
   VITRO; DIFFERENTIATION; PROLIFERATION
AB The bone marrow (BM) biology during HTLV-1 infection is obscure. In this study, we investigated BM mononuclear cells and mesenchymal stromal cells (MSC) from HTLV-1 asymptomatic and symptomatic individuals. An infiltration of CD4(+)T-cell lymphocytes in the BM of HTLV-1-infected individuals was observed when compared to healthy controls. The provirus detection in the BM CD4(+)T cells confirmed the presence of integrated HTLV DNA. In regard to MSC, we observed that the number of fibroblast progenitor cells was lower in HTLV-1 infected individuals than in healthy controls. Isolated HTLV-1 infected BM-MSC demonstrated surface expression markers and in vitro differentiation potential similar to uninfected individuals. The presence of HTLV-1 proviral DNA in the BM-MSC of HTLV-1-infected patients was demonstrated but no p19 antigen was detected in supernatant from cultured MSC. We suppose that HTLV-1 infects human MSC probably by cell-to-cell contact from the infected CD4(+)T-lymphocytes infiltrated into the bone marrow.
C1 [Rodrigues, Evandra Strazza; Favarin, Maria do Carmo; de Macedo, Mayra Dorigan; Otaguiri, Katia Kaori; Orellana, Maristela Delgado; Bonini Palma, Patricia Vianna; Slavov, Svetoslav Nanev; Covas, Dimas Tadeu; Kashima, Simone] Univ Sao Paulo, Reg Blood Ctr Ribeirao Preto, Sao Paulo, Brazil.
   [Rodrigues, Evandra Strazza; de Macedo, Mayra Dorigan; Otaguiri, Katia Kaori; Kashima, Simone] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Toxicol & Bromatol Anal, Sao Paulo, Brazil.
   [Orellana, Maristela Delgado; Takayanagui, Osvaldo Massaiti; Slavov, Svetoslav Nanev; Covas, Dimas Tadeu] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Internal Med, Sao Paulo, Brazil.
RP Kashima, S (corresponding author), Reg Blood Ctr Ribeirao Preto, Rua Tenente Catao Roxo 2501, Ribeirao Preto, SP, Brazil.
EM skashima@hemocentro.fmrp.usp.br
RI Covas, Dimas T/C-5431-2013; N, Svetoslav/M-5416-2017; Kashima,
   Simone/G-4876-2012
OI Covas, Dimas T/0000-0002-7364-2595; Kashima, Simone/0000-0002-1487-0141
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [454155/2014-0]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) - Center for Cell-based Therapy (CTC) [2013/08135-2]; Conselho
   Nacional do Desenvolvimento Cientifico e Tecnologico, Brazil
   [INCTC-465539/2014-9]; Fundacao Hemocentro de Ribeirao Preto (FUNDHERP)
FX This work was supported by CNPq Universal (Process no. 454155/2014-0),
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) - Center
   for Cell-based Therapy (CTC) (Process no. 2013/08135-2), the Conselho
   Nacional do Desenvolvimento Cientifico e Tecnologico, Brazil
   (INCTC-465539/2014-9) and Fundacao Hemocentro de Ribeirao Preto
   (FUNDHERP).
CR Akimoto M, 2007, J MED VIROL, V79, P977, DOI 10.1002/jmv.20807
   Albesiano E, 2003, BLOOD, V102, P3333, DOI 10.1182/blood-2003-05-1585
   Bernardo ME, 2009, CYTOTHERAPY, V11, P825, DOI 10.3109/14653240903121260
   Bianco P, 2011, BLOOD, V117, P5281, DOI 10.1182/blood-2011-01-315069
   Cheng K, 2013, EXP CELL RES, V319, P2266, DOI 10.1016/j.yexcr.2013.06.008
   Choudhary S, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/264350
   Cotter EJ, 2007, AIDS RES HUM RETROV, V23, P1521, DOI 10.1089/aid.2007.0112
   Cotter EJ, 2011, AIDS RES HUM RETROV, V27, P187, DOI 10.1089/aid.2010.0114
   Cotter EJ, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-33
   Di Rosa F, 2009, IMMUNOL CELL BIOL, V87, P20, DOI 10.1038/icb.2008.84
   FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267
   Furuta R, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006722
   Gessain A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00388
   Gibellini D, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-40
   Hishizawa M, 2010, BLOOD, V116, P1369, DOI 10.1182/blood-2009-10-247510
   Ishida T, 2013, BIOL BLOOD MARROW TR, V19, P1731, DOI 10.1016/j.bbmt.2013.09.014
   ITOYAMA Y, 1988, NEUROLOGY, V38, P1302, DOI 10.1212/WNL.38.8.1302
   Kawa K, 1998, LANCET, V352, P1034, DOI 10.1016/S0140-6736(05)60077-3
   Kikuchi H, 2000, BONE MARROW TRANSPL, V26, P1235, DOI 10.1038/sj.bmt.1702698
   KOYANAGI Y, 1993, VIROLOGY, V196, P25, DOI 10.1006/viro.1993.1451
   Larghero J, 2008, ANN RHEUM DIS, V67, P443, DOI 10.1136/ard.2007.071233
   Levin MC, 1997, BLOOD, V89, P346
   LUNARDIISKANDAR Y, 1993, J EXP MED, V177, P741, DOI 10.1084/jem.177.3.741
   MACATONIA SE, 1992, AIDS RES HUM RETROV, V8, P1699, DOI 10.1089/aid.1992.8.1699
   NAGAFUJI K, 1993, BLOOD, V82, P2823, DOI 10.1182/blood.V82.9.2823.bloodjournal8292823
   Osame M, 1997, J NEUROVIROL, V3, pS50
   Parsons CH, 2004, BLOOD, V104, P2736, DOI 10.1182/blood-2004-02-0693
   Pinto MT, 2016, REV SOC BRAS MED TRO, V49, P232, DOI 10.1590/0037-8682-0282-2015
   Pinto MT, 2012, REV INST MED TROP SP, V54, P123, DOI 10.1590/S0036-46652012000300002
   RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990
   Rodrigues ES, 2014, VIROLOGY, V449, P190, DOI 10.1016/j.virol.2013.11.022
   Rollin R, 2007, OSTEOARTHR CARTILAGE, V15, P475, DOI 10.1016/j.joca.2006.11.007
   Shiratori S, 2008, BIOL BLOOD MARROW TR, V14, P817, DOI 10.1016/j.bbmt.2008.04.014
   Smirnov SV, 2007, VIROLOGY, V360, P6, DOI 10.1016/j.virol.2006.09.017
   Sundin M, 2006, BONE MARROW TRANSPL, V37, P1051, DOI 10.1038/sj.bmt.1705368
   Sundin M, 2008, BIOL BLOOD MARROW TR, V14, P1172, DOI 10.1016/j.bbmt.2008.08.003
   Tamai Y, 2013, J IMMUNOL, V190, P4382, DOI 10.4049/jimmunol.1202971
   Tiwari V., 2011, J BIOMED BIOTECHNOL
   Utsunomiya Atae, 2016, Rinsho Ketsueki, V57, P2190
   Wang LX, 2002, AIDS RES HUM RETROV, V18, P917, DOI 10.1089/088922202760265597
   Wei G, 2011, TRANSPL P, V43, P1944, DOI 10.1016/j.transproceed.2010.12.053
   ZACHAROPOULOS VR, 1992, J VIROL, V66, P4601, DOI 10.1128/JVI.66.7.4601-4605.1992
NR 42
TC 0
Z9 0
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD JUN
PY 2018
VL 519
BP 145
EP 155
DI 10.1016/j.virol.2018.04.014
PG 11
WC Virology
SC Virology
GA GJ3VX
UT WOS:000435228000016
PM 29723784
OA Bronze
DA 2020-11-26
ER

PT J
AU Amorim, FG
   Boldrini-Franca, J
   Bordon, KD
   Cardoso, IA
   De Pauw, E
   Quinton, L
   Kashima, S
   Arantes, EC
AF Amorim, Fernanda Gobbi
   Boldrini-Franca, Johara
   Figueiredo Bordon, Karla de Castro
   Cardoso, Iara Aime
   De Pauw, Edwin
   Quinton, Louc
   Kashima, Simone
   Arantes, Eliane Candiani
TI Heterologous expression of rTsHyal-1: the first recombinant
   hyaluronidase of scorpion venom produced in Pichia pastoris system
SO APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Article
DE Tityus serrulatus; Scorpion venom; Hyaluronidase; Heterologous
   expression; Pichia pastoris
ID ANTIGENIC CROSS-REACTIVITY; ESCHERICHIA-COLI; PROTEIN EXPRESSION; INSECT
   CELLS; MOLECULAR CHARACTERIZATION; ALLERGEN HYALURONIDASE;
   MASS-SPECTROMETRY; BUTHUS-MARTENSI; CLONING; PURIFICATION
AB In general, hyaluronidases have a broad potential application on medicine and esthetics fields. Hyaluronidases from animal venoms cleave hyaluronan present in the extracellular matrix, acting as spreading factors of toxins into the tissues of the victim. However, the in-depth characterization of hyaluronidase from animal venoms has been neglected due to its instability and low concentration in the venom, which hamper its isolation. Thus, heterologous expression of hyaluronidase acts as a biotechnological tool in the obtainment of enough amounts of the enzyme for structural and functional studies. Therefore, this study produced a recombinant hyaluronidase from Tityus serrulatus scorpion venom, designated as rTsHyal-1, in the Pichia pastoris system. Thus, a gene for TsHyal-1 (gb|KF623285.1) was synthesized and cloned into the pPICZ alpha A vector (GenScript Corporation) for heterologous expression in P. pastoris. rTsHyal-1 was expressed in laboratorial scale in a buffered minimal medium containing methanol (BMM) for 96 h with daily addition of methanol. Expression of rTsHyal-1 resulted in a total protein yield of 0.266 mg/mL. rTsHyal-1 partially purified through cation exchange chromatography presented a specific activity of 1097 TRU/mg, against 838 TRU/mg for the final expressed material, representing a 1.31-fold purification. rTsHyal-1 has molecular mass of 49.5 kDa, and treatment with PNGase F and analysis by mass spectrometry (MALDI-TOF) indicated a potential N-glycosylation of 4.5 kDa. Additionally, de novo sequencing of rTsHyal-1, performed in MALDI-TOF and Q Exactive Orbitrap MS, resulted in 46.8% of protein sequence coverage. rTsHyal-1 presents the highest substrate specificity to hyaluronan followed by chondroitin-6-sulfate, chondroitin-4-sulfate, and dermatan sulfate and showed an optimum activity at pH 6.0 and 40 A degrees C. These results validate the biotechnological process for the heterologous expression of rTsHyal-1. This is the first recombinant hyaluronidase from scorpion venoms expressed in the P. pastoris system with preserved enzyme activity.
C1 [Amorim, Fernanda Gobbi; Boldrini-Franca, Johara; Figueiredo Bordon, Karla de Castro; Cardoso, Iara Aime; Arantes, Eliane Candiani] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Chem & Phys, Av Cafe S-N, BR-14040903 Ribeirao Preto, Brazil.
   [De Pauw, Edwin; Quinton, Louc] Univ Liege, Dept Chem, Liege, Belgium.
   [Kashima, Simone] Univ Sao Paulo, Ribeirao Preto Med Sch, Reg Ctr Hemotherapy Ribeirao Preto, Sao Paulo, Brazil.
RP Amorim, FG; Arantes, EC (corresponding author), Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Chem & Phys, Av Cafe S-N, BR-14040903 Ribeirao Preto, Brazil.
EM fernandagamorim@gmail.com; ecabraga@fcfrp.usp.br
RI Bordon, Karla C. F./G-7393-2012; Arantes, Eliane Candiani/D-9604-2012;
   Cardoso, Iara Aime/Y-9177-2019; Kashima, Simone/G-4876-2012
OI Bordon, Karla C. F./0000-0001-6540-2295; Arantes, Eliane
   Candiani/0000-0002-6712-6033; Cardoso, Iara Aime/0000-0002-0288-4706;
   Kashima, Simone/0000-0002-1487-0141; Loic, Quinton/0000-0001-8153-9590
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Sao Paulo
   Research Foundation)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2011/12317-3, 2013/26083-0, 2012/14996-8]; Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico (CNPq, The National Council
   for Scientific and Technological Development)National Council for
   Scientific and Technological Development (CNPq) [402508/2012-2,
   303689/2013-7, 449960/2014-5]; Support Nucleus for Research on Animal
   Toxins (NAP-TOXAN-USP) [12-125432.1.3]
FX This study received financial support from Fundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP, Sao Paulo Research Foundation,
   scholarship to FGA, n. 2011/12317-3 and 2013/26083-0; grant to ECA, n.
   2012/14996-8), Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq, The National Council for Scientific and Technological
   Development, grants n. 402508/2012-2, n. 303689/2013-7, and n.
   449960/2014-5), and the Support Nucleus for Research on Animal Toxins
   (NAP-TOXAN-USP, grant n. 12-125432.1.3).
CR Amorim FG, 2017, TOXICON, V140, P105, DOI 10.1016/j.toxicon.2017.10.025
   Bakke M, 2011, FEBS LETT, V585, P115, DOI 10.1016/j.febslet.2010.11.021
   Batista CVF, 2007, COMP BIOCHEM PHYS C, V146, P147, DOI 10.1016/j.cbpc.2006.12.004
   BERRY AM, 1994, INFECT IMMUN, V62, P1101, DOI 10.1128/IAI.62.3.1101-1108.1994
   BHASKARANNAIR R, 1975, BIOCHIM BIOPHYS ACTA, V381, P165, DOI 10.1016/0304-4165(75)90198-1
   Bordon KCF, 2015, J VENOM ANIM TOXINS, V21, DOI 10.1186/s40409-015-0042-7
   Bordon KCF, 2012, BIOCHIMIE, V94, P2740, DOI 10.1016/j.biochi.2012.08.014
   Brondyk WH, 2009, METHOD ENZYMOL, V463, P131, DOI 10.1016/S0076-6879(09)63011-1
   Calvete JJ, 2017, BIOCHEM J, V474, P611, DOI 10.1042/BCJ20160577
   Cereghino JL, 2000, FEMS MICROBIOL REV, V24, P45, DOI 10.1111/j.1574-6976.2000.tb00532.x
   CEVALLOS MA, 1992, TOXICON, V30, P925, DOI 10.1016/0041-0101(92)90392-I
   Chen KJ, 2016, J BIOSCI BIOENG, V122, P673, DOI 10.1016/j.jbiosc.2016.06.007
   Clement H, 2012, TOXICON, V60, P1223, DOI 10.1016/j.toxicon.2012.08.018
   Cologna CT, 2009, PROTEIN PEPTIDE LETT, V16, P920, DOI 10.2174/092986609788923329
   Cregg JM, 2000, MOL BIOTECHNOL, V16, P23, DOI 10.1385/MB:16:1:23
   Daly R, 2005, J MOL RECOGNIT, V18, P119, DOI 10.1002/jmr.687
   Feng L, 2008, COMP BIOCHEM PHYS C, V148, P250, DOI 10.1016/j.cbpc.2008.06.003
   Ferrer VP, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002206
   Frost GI, 1997, BIOCHEM BIOPH RES CO, V236, P10, DOI 10.1006/bbrc.1997.6773
   Gao MJ, 2015, APPL BIOCHEM BIOTECH, V176, P493, DOI 10.1007/s12010-015-1590-6
   GMACHL M, 1993, P NATL ACAD SCI USA, V90, P3569, DOI 10.1073/pnas.90.8.3569
   Goto Y, 2014, FEBS OPEN BIO, V4, P554, DOI 10.1016/j.fob.2014.06.001
   Heimo H, 1997, PROTEIN EXPRES PURIF, V10, P70, DOI 10.1006/prep.1996.0713
   Hofinger ESA, 2007, GLYCOBIOLOGY, V17, P444, DOI 10.1093/glycob/cwm003
   Jung Y, 2010, PROTEIN EXPRES PURIF, V74, P181, DOI 10.1016/j.pep.2010.06.003
   Jacomini DLJ, 2014, TOXICON, V82, P104, DOI 10.1016/j.toxicon.2014.02.016
   Kang Z, 2016, APPL MICROBIOL BIOT, V100, P707, DOI 10.1007/s00253-015-7056-5
   King TP, 1996, J ALLERGY CLIN IMMUN, V98, P588, DOI 10.1016/S0091-6749(96)70093-3
   Kuhn-Nentwig L, 2003, CELL MOL LIFE SCI, V60, P2651, DOI 10.1007/s00018-003-3106-8
   LAEMMLI UK, 1970, J MOL BIOL, V47, P69, DOI 10.1016/0022-2836(70)90402-X
   Lambers H., 2006, International Journal of Cosmetic Science, V28, P359, DOI 10.1111/j.1467-2494.2006.00344.x
   Li HR, 2014, PROTEIN EXPRES PURIF, V103, P23, DOI 10.1016/j.pep.2014.03.007
   Li MW, 2002, J ANDROL, V23, P211
   LU G, 1995, J BIOL CHEM, V270, P4457, DOI 10.1074/jbc.270.9.4457
   Macauley-Patrick S, 2005, YEAST, V22, P249, DOI 10.1002/yea.1208
   Mechref Yehia, 2012, Curr Protoc Protein Sci, VChapter 12, DOI 10.1002/0471140864.ps1211s68
   Mergulhao FJM, 2005, BIOTECHNOL ADV, V23, P177, DOI 10.1016/j.biotechadv.2004.11.003
   Morelle W, 2007, NAT PROTOC, V2, P1585, DOI 10.1038/nprot.2007.227
   Morey SS, 2006, TOXICON, V47, P188, DOI 10.1016/j.toxicon.2005.10.014
   Ng HC, 2005, GENE, V346, P71, DOI 10.1016/j.gene.2004.09.024
   Ohman H, 1998, J INVEST DERMATOL, V111, P674, DOI 10.1046/j.1523-1747.1998.00356.x
   Pessini AC, 2001, TOXICON, V39, P1495, DOI 10.1016/S0041-0101(01)00122-2
   Pucca MB, 2015, TOXICON, V108, P272, DOI 10.1016/j.toxicon.2015.10.015
   Pucca MB, 2014, TOXICON, V90, P326, DOI 10.1016/j.toxicon.2014.08.064
   PUKRITTAYAKAMEE S, 1988, TOXICON, V26, P629, DOI 10.1016/0041-0101(88)90245-0
   RAMANAIAH M, 1990, BIOCHEM INT, V20, P301
   Horta CCR, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002693
   Reitinger S, 2008, PROTEIN EXPRES PURIF, V57, P226, DOI 10.1016/j.pep.2007.10.001
   Rodriguez-Ravelo R, 2013, J VENOM ANIM TOXINS, V19, DOI 10.1186/1678-9199-19-13
   SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7
   Skov LK, 2006, ACTA CRYSTALLOGR D, V62, P595, DOI 10.1107/S0907444906010687
   Soldatova LN, 1998, J ALLERGY CLIN IMMUN, V101, P691, DOI 10.1016/S0091-6749(98)70179-4
   Soldatova LN, 2007, ALLERGY ASTHMA PROC, V28, P210, DOI 10.2500/aap.2007.28.2947
   Sreekrishna K, 1997, GENE, V190, P55, DOI 10.1016/S0378-1119(96)00672-5
   Tan CH, 2016, J PROTEOMICS, V132, P1, DOI 10.1016/j.jprot.2015.11.014
   Venancio EJ, 2013, TOXICON, V69, P180, DOI 10.1016/j.toxicon.2013.02.012
   Wiezel GA, 2015, TOXICON, V107, P359, DOI 10.1016/j.toxicon.2015.08.029
   Wingfield Paul T, 2015, Curr Protoc Protein Sci, V80, DOI 10.1002/0471140864.ps0601s80
   Wohlrab J, 2014, SKIN PHARMACOL PHYS, V27, P276, DOI 10.1159/000360545
   Xia XC, 2014, GENE, V547, P338, DOI 10.1016/j.gene.2014.06.045
   Zaia J, 2004, MASS SPECTROM REV, V23, P161, DOI 10.1002/mas.10073
NR 61
TC 7
Z9 7
U1 0
U2 15
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0175-7598
EI 1432-0614
J9 APPL MICROBIOL BIOT
JI Appl. Microbiol. Biotechnol.
PD APR
PY 2018
VL 102
IS 7
BP 3145
EP 3158
DI 10.1007/s00253-018-8821-z
PG 14
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA FZ4RN
UT WOS:000427579600018
PM 29455388
DA 2020-11-26
ER

PT J
AU Berzoti-Coelho, MG
   Ferreira, AF
   Nunes, ND
   Pinto, MT
   Rocha, MC
   Simoes, BP
   Martinez-A, C
   Souto, EX
   Panepucci, RA
   Covas, DT
   Kashima, S
   Castro, FA
AF Berzoti-Coelho, Maria Gabriela
   Ferreira, Aline Fernanda
   Nunes, Natalia de Souza
   Pinto, Mariana Tomazini
   Rocha Junior, Mauricio Cristiano
   Simoes, Belinda Pinto
   Martinez-A, Carlos
   Souto, Elizabeth Xisto
   Panepucci, Rodrigo Alexandre
   Covas, Dimas Tadeu
   Kashima, Simone
   Castro, Fabiola Attie
TI The expression of Death Inducer-Obliterator (DIDO) variants in
   Myeloproliferative Neoplasms (vol 59, pg 25, 2016)
SO BLOOD CELLS MOLECULES AND DISEASES
LA English
DT Correction
C1 [Berzoti-Coelho, Maria Gabriela; Ferreira, Aline Fernanda; Nunes, Natalia de Souza; Pinto, Mariana Tomazini; Rocha Junior, Mauricio Cristiano; Kashima, Simone; Castro, Fabiola Attie] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Anal Toxicol & Food Sci, Sao Paulo, Brazil.
   [Ferreira, Aline Fernanda; Pinto, Mariana Tomazini; Rocha Junior, Mauricio Cristiano; Simoes, Belinda Pinto; Panepucci, Rodrigo Alexandre; Covas, Dimas Tadeu; Kashima, Simone; Castro, Fabiola Attie] Ctr Cell Based Therapy, Ribeirao Preto, Brazil.
   [Simoes, Belinda Pinto; Panepucci, Rodrigo Alexandre; Covas, Dimas Tadeu] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Internal Med, Sao Paulo, Brazil.
   [Martinez-A, Carlos] Univ Autonoma Madrid, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, Madrid, Spain.
   [Souto, Elizabeth Xisto] Hosp Transplantes Euryclides de Jesus Zerbini, Sao Paulo, Brazil.
RP Ferreira, AF (corresponding author), Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Sao Paulo, Brazil.
EM gabrielaberzoti@usp.br; alineferreira591@gmail.com
RI CASTRO, FABIOLA/D-4693-2012; Panepucci, Rodrigo A/C-2365-2012; Covas,
   Dimas T/C-5431-2013; Pinto, Mariana/B-6129-2017; Kashima,
   Simone/G-4876-2012
OI Panepucci, Rodrigo A/0000-0002-1119-4352; Covas, Dimas
   T/0000-0002-7364-2595; Pinto, Mariana/0000-0002-5176-7776; Kashima,
   Simone/0000-0002-1487-0141
CR Berzoti-Coelho MG, 2016, BLOOD CELL MOL DIS, V59, P25, DOI 10.1016/j.bcmd.2016.03.008
NR 1
TC 0
Z9 0
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1079-9796
EI 1096-0961
J9 BLOOD CELL MOL DIS
JI Blood Cells Mol. Dis.
PD MAR
PY 2018
VL 69
BP 123
EP 123
DI 10.1016/j.bcmd.2017.08.013
PG 1
WC Hematology
SC Hematology
GA FW0QI
UT WOS:000424999700022
PM 28882478
DA 2020-11-26
ER

PT J
AU Ferreira, AF
   Calin, GA
   Picanco-Castro, V
   Kashima, S
   Covas, DT
   de Castro, FA
AF Ferreira, Aline F.
   Calin, George A.
   Picanco-Castro, Virginia
   Kashima, Simone
   Covas, Dimas T.
   de Castro, Fabiola A.
TI Hematopoietic stem cells from induced pluripotent stem cells -
   considering the role of microRNA as a cell differentiation regulator
SO JOURNAL OF CELL SCIENCE
LA English
DT Review
DE HSC; iPSC; miRNA; Cell reprogramming
ID RED-BLOOD-CELLS; IPS CELLS; TRANSCRIPTION FACTORS; EPIGENETIC MEMORY;
   KIT RECEPTOR; MOUSE; GENERATION; MODEL; ERYTHROPOIESIS; TUMORIGENESIS
AB Although hematopoietic stem cell (HSC) therapy for hematological diseases can lead to a good outcome from the clinical point of view, the limited number of ideal donors, the comorbidity of patients and the increasing number of elderly patients may limit the application of this therapy. HSCs can be generated from induced pluripotent stem cells (iPSCs), which requires the understanding of the bone marrow and liver niches components and function in vivo. iPSCs have been extensively applied in several studies involving disease models, drug screening and cellular replacement therapies. However, the somatic reprogramming by transcription factors is a low-efficiency process. Moreover, the reprogramming process is also regulated by microRNAs (miRNAs), which modulate the expression of the transcription factors OCT-4 (also known as POU5F1), SOX-2, KLF-4 and MYC, leading somatic cells to a pluripotent state. In this Review, we present an overviewof the challenges of cell reprogramming protocols with regard to HSC generation from iPSCs, and highlight the potential role of miRNAs in cell reprogramming and in the differentiation of induced pluripotent stem cells.
C1 [Ferreira, Aline F.; de Castro, Fabiola A.] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin Anal Toxicol & Food Sci, BR-14040903 Ribeirao Preto, SP, Brazil.
   [Calin, George A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77054 USA.
   [Picanco-Castro, Virginia; Kashima, Simone; Covas, Dimas T.] Reg Blood Ctr Ribeirao Preto, Ctr Cell Therapy, BR-14051140 Ribeirao Preto, SP, Brazil.
   [Covas, Dimas T.] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Internal Med, BR-14049900 Ribeirao Preto, SP, Brazil.
RP de Castro, FA (corresponding author), Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin Anal Toxicol & Food Sci, BR-14040903 Ribeirao Preto, SP, Brazil.
EM castrofabiola@hotmail.com
RI Picanco-Castro, Virginia/AAC-7242-2019; Castro, Virginia/H-2904-2015;
   CASTRO, FABIOLA/D-4693-2012; Calin, George/E-9390-2011; Covas, Dimas
   T/C-5431-2013; Kashima, Simone/G-4876-2012
OI Picanco-Castro, Virginia/0000-0001-8474-4610; Castro,
   Virginia/0000-0001-8474-4610; Covas, Dimas T/0000-0002-7364-2595;
   Kashima, Simone/0000-0002-1487-0141; Calin, George/0000-0002-7427-0578;
   Calin, George/0000-0001-6704-5615
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2013/08135-2,
   2015/21237-4]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   SuperiorCAPES [1535985]; Conselho Nacional de Desenvolvimento Cientifico
   e TecnologicoNational Council for Scientific and Technological
   Development (CNPq)
FX We are grateful to Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) (2013/08135-2 and 2015/21237-4), Coordenacao de Aperfeicoamento
   de Pessoal de Nivel Superior (1535985) and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico.
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   An NF, 2016, EXP HEMATOL ONCOL, V5, P1, DOI 10.1186/s40164-016-0060-3
   Anokye-Danso F, 2011, CELL STEM CELL, V8, P376, DOI 10.1016/j.stem.2011.03.001
   Aoi T, 2008, SCIENCE, V321, P699, DOI 10.1126/science.1154884
   Araki R, 2013, NATURE, V494, P100, DOI 10.1038/nature11807
   Bar-Nur O, 2011, CELL STEM CELL, V9, P17, DOI 10.1016/j.stem.2011.06.007
   Baron F, 2017, EXPERT OPIN BIOL TH, V17, P163, DOI 10.1080/14712598.2017.1269167
   Brickman JM, 2017, WIRES DEV BIOL, V6, DOI 10.1002/wdev.259
   BROXMEYER HE, 1991, CANCER CELL-MON REV, V3, P480
   Card DAG, 2008, MOL CELL BIOL, V28, P6426, DOI 10.1128/MCB.00359-08
   Carotta S, 2004, BLOOD, V104, P1873, DOI 10.1182/blood-2004-02-0570
   Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30
   Chaudhuri AA, 2012, P NATL ACAD SCI USA, V109, P4233, DOI 10.1073/pnas.1200677109
   Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903
   Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804
   Choi HW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170735
   Chou BK, 2011, CELL RES, V21, P518, DOI 10.1038/cr.2011.12
   Chung BH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042011
   de Lazaro I, 2014, J CONTROL RELEASE, V185, P37, DOI 10.1016/j.jconrel.2014.04.011
   Dowey SN, 2012, NAT PROTOC, V7, P2013, DOI 10.1038/nprot.2012.121
   Ebina W, 2015, EMBO J, V34, P694, DOI 10.15252/embj.201490804
   Eckfeldt CE, 2005, NAT REV MOL CELL BIO, V6, P726, DOI 10.1038/nrm1713
   Elliott S, 2008, EXP HEMATOL, V36, P1573, DOI 10.1016/j.exphem.2008.08.003
   Fan XL, 2017, BIOMED PHARMACOTHER, V88, P507, DOI 10.1016/j.biopha.2017.01.058
   Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023
   Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102
   Georgantas RW, 2007, P NATL ACAD SCI USA, V104, P2750, DOI 10.1073/pnas.0610983104
   Giani FC, 2016, CELL STEM CELL, V18, P73, DOI 10.1016/j.stem.2015.09.015
   Goh PA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081622
   Hamazaki T, 2017, STEM CELLS, V35, P545, DOI 10.1002/stem.2570
   Hanna J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092
   Hawkins KE, 2013, REGEN MED, V8, P771, DOI 10.2217/rme.13.71
   Henao-Mejia J, 2013, IMMUNITY, V38, P984, DOI 10.1016/j.immuni.2013.02.021
   Hu SJ, 2013, STEM CELLS, V31, P259, DOI 10.1002/stem.1278
   Hysolli E, 2016, STEM CELL REP, V7, P43, DOI 10.1016/j.stemcr.2016.05.014
   Jaramillo S, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.45
   Judson RL, 2009, NAT BIOTECHNOL, V27, P459, DOI 10.1038/nbt.1535
   Kim K, 2010, NATURE, V467, P285, DOI 10.1038/nature09342
   Kim SJ, 2017, BLOOD RES, V52, P37, DOI 10.5045/br.2017.52.1.37
   Kitajima K, 2003, METHOD ENZYMOL, V365, P72
   Kotini AG, 2015, NAT BIOTECHNOL, V33, P646, DOI 10.1038/nbt.3178
   Kozakowska M, 2014, ANTIOXID REDOX SIGN, V20, P1827, DOI 10.1089/ars.2013.5341
   Lacaud G, 2017, EXP HEMATOL, V49, P19, DOI 10.1016/j.exphem.2016.12.009
   Li QJ, 2007, CELL, V129, P147, DOI 10.1016/j.cell.2007.03.008
   Li ZH, 2011, EMBO J, V30, P823, DOI 10.1038/emboj.2011.2
   Liang GY, 2013, CELL STEM CELL, V13, P149, DOI 10.1016/j.stem.2013.07.001
   Loh YH, 2010, CELL STEM CELL, V7, P15, DOI 10.1016/j.stem.2010.06.004
   Lu SJ, 2008, BLOOD, V112, P4475, DOI 10.1182/blood-2008-05-157198
   Lu W, 2016, ONCOTARGET, V7, P62364, DOI 10.18632/oncotarget.11634
   Maherali N, 2008, CELL STEM CELL, V3, P595, DOI 10.1016/j.stem.2008.11.008
   Masouridi-Levrat S, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00362
   Meng XM, 2012, MOL THER, V20, P408, DOI 10.1038/mt.2011.258
   Menon S, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010141
   Metcalf D, 2008, BLOOD, V111, P485, DOI 10.1182/blood-2007-03-079681
   Miyamoto T, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004476
   Miyoshi N, 2011, CELL STEM CELL, V8, P633, DOI 10.1016/j.stem.2011.05.001
   Nakagawa M, 2014, SCI REP-UK, V4, DOI 10.1038/srep03594
   Nakano T, 1996, INT J HEMATOL, V65, P1
   Nishimori M, 2014, HUM CELL, V27, P29, DOI 10.1007/s13577-013-0078-3
   Ong S.-G., 2016, ADV DRUG DELIV REV, V1, P3
   Palis J, 2008, CURR OPIN HEMATOL, V15, P155, DOI 10.1097/MOH.0b013e3282f97ae1
   Park CY, 2014, P NATL ACAD SCI USA, V111, P9253, DOI 10.1073/pnas.1323941111
   Patel M, 2010, STEM CELL REV REP, V6, P367, DOI 10.1007/s12015-010-9123-8
   Pfaff N, 2017, STEM CELL RES, V20, P70, DOI 10.1016/j.scr.2017.03.003
   Philonenko ES, 2017, ACTA NATURAE, V9, P68, DOI 10.32607/20758251-2017-9-1-68-74
   Polo JM, 2010, NAT BIOTECHNOL, V28, P848, DOI 10.1038/nbt.1667
   Rowe RG, 2016, CELL STEM CELL, V18, P707, DOI 10.1016/j.stem.2016.05.016
   Saha K, 2009, CELL STEM CELL, V5, P584, DOI 10.1016/j.stem.2009.11.009
   Sakaki-Yumoto M., 2013, EUR REV MED PHARMACO, V20, P4390
   Schlaeger TM, 2015, NAT BIOTECHNOL, V33, P58, DOI 10.1038/nbt.3070
   Seiler K, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/895086
   Shaham L, 2012, LEUKEMIA, V26, P2011, DOI 10.1038/leu.2012.90
   Shepard KA, 2014, STEM CELL TRANSL MED, V3, P775, DOI 10.5966/sctm.2014-0104
   Slamecka J, 2016, CELL CYCLE, V15, P234, DOI 10.1080/15384101.2015.1121332
   Smith BW, 2013, BLOOD, V122, P376, DOI 10.1182/blood-2012-11-466722
   Stadtfeld M, 2008, CURR BIOL, V18, P890, DOI 10.1016/j.cub.2008.05.010
   Sun G, 2017, CANCER GENE THER, V24, P194, DOI 10.1038/cgt.2014.82
   Sweeney CL, 2016, STEM CELLS, V34, P1513, DOI 10.1002/stem.2332
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Takayama N, 2010, J EXP MED, V207, P2817, DOI 10.1084/jem.20100844
   Teng SS, 2014, TISSUE ENG PART B-RE, V20, P328, DOI [10.1089/ten.TEB.2013.0301, 10.1089/ten.teb.2013.0301]
   Timmins NE, 2011, TISSUE ENG PART C-ME, V17, P1131, DOI [10.1089/ten.tec.2011.0207, 10.1089/ten.TEC.2011.0207]
   Tiyaboonchai A, 2014, STEM CELL RES, V12, P630, DOI 10.1016/j.scr.2014.02.004
   Tsiftsoglou AS, 2009, IUBMB LIFE, V61, P800, DOI 10.1002/iub.226
   Tsiftsoglou AS, 2009, PHARMACOL THERAPEUT, V122, P264, DOI 10.1016/j.pharmthera.2009.03.001
   Undi RB, 2016, INDIAN J HEMATOL BLO, V32, P123, DOI 10.1007/s12288-015-0585-3
   van Bekkum DW, 2012, ANN NY ACAD SCI, V1266, P179, DOI 10.1111/j.1749-6632.2012.06629.x
   Vitaloni M, 2014, J BIOL CHEM, V289, P2084, DOI 10.1074/jbc.M113.538702
   Wang H, 2015, DIFFERENTIATION, V90, P69, DOI 10.1016/j.diff.2015.10.002
   Warren L., 2013, CURR PROTOC STEM CEL, V27
   Wojtowicz EE, 2016, CELL STEM CELL, V19, P383, DOI 10.1016/j.stem.2016.06.008
   Wojtowicz EE, 2014, EXP HEMATOL, V42, P909, DOI 10.1016/j.exphem.2014.06.010
   Yang CS, 2011, RNA, V17, P1451, DOI 10.1261/rna.2664111
   Yang CT, 2017, STEM CELLS, V35, P886, DOI 10.1002/stem.2562
   Yao SM, 2016, BIOL PROCED ONLINE, V18, DOI 10.1186/s12575-016-0037-y
   Ye BX, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/5210459
   Yildirim S, 2016, SCI REP-UK, V6, DOI 10.1038/srep22110
   Zhang GC, 2012, STEM CELLS DEV, V21, P955, DOI 10.1089/scd.2011.0649
   Zhang Xiao-Bing, 2013, Genomics Proteomics & Bioinformatics, V11, P264, DOI 10.1016/j.gpb.2013.09.001
NR 99
TC 9
Z9 10
U1 1
U2 7
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 0021-9533
EI 1477-9137
J9 J CELL SCI
JI J. Cell Sci.
PD FEB
PY 2018
VL 131
IS 4
AR jcs203018
DI 10.1242/jcs.203018
PG 8
WC Cell Biology
SC Cell Biology
GA FX8PC
UT WOS:000426356000005
PM 29467236
OA Bronze
DA 2020-11-26
ER

PT J
AU Souza, LEB
   Beckenkamp, LR
   Sobral, LM
   Fantacini, DMC
   Melo, FUF
   Borges, JS
   Leopoldino, AM
   Kashima, S
   Covas, DT
AF Souza, Lucas E. B.
   Beckenkamp, Liziane R.
   Sobral, Lays M.
   Fantacini, Daianne M. C.
   Melo, Fernanda U. F.
   Borges, Josiane S.
   Leopoldino, Andreia M.
   Kashima, Simone
   Covas, Dimas Tadeu
TI Pre-culture in endothelial growth medium enhances the angiogenic
   properties of adipose-derived stem/stromal cells
SO ANGIOGENESIS
LA English
DT Article
DE Angiogenesis; Cell therapy; Perivascular cells; Adipose-derived stem
   cells
ID MESENCHYMAL STEM-CELLS; STROMAL CELLS; IN-VITRO; DISEASE; MECHANISMS;
   EXPANSION; THERAPY; TISSUE
AB Considerable progress has been made on the development of adipose-derived stem/stromal cells (ASCs) as pro-angiogenic therapeutic tools. However, variable clinical results highlight the need for devising strategies to enhance their therapeutic efficacy. Since ASCs proliferate and stabilize newly formed vessels during the angiogenic phase of adipose tissue formation, we hypothesized that mimicking an angiogenic milieu during culture of ASCs would enhance their capacity to support endothelial cell survival and angiogenesis. To test this, we compared the effect of an endothelial growth medium (EGM-2) and conventional media (alpha MEM) on the progenitor and angiogenic properties of ASCs. ASCs cultured in EGM-2 (ASC-EGM) displayed the highest clonogenic efficiency, proliferative potential and multilineage potential. After co-culture under growth factor starvation, only ASC-EGM attenuated luciferase-expressing human umbilical vein endothelial cells (HUVECluc) apoptosis and supported the formation of endothelial cords in a dose-dependent manner. These effects were recapitulated by the conditioned medium of ASC-EGM, which displayed a 100-fold higher expression of hepatocyte growth factor in comparison with ASC-alpha MEM. Next, HUVECluc and ASCs were co-transplanted subcutaneously into immunodeficient mice, and the survival of HUVECluc was monitored by bioluminescent imaging. After 60 days, the survival of HUVECluc transplanted alone was equivalent to that of HUVECluc co-transplanted with ASC-alpha MEM (15.0 +/- 0.7 vs. 13.0 +/- 0.5%). Strikingly, co-transplantation with ASC-EGM increased HUVECluc survival to 105.0 +/- 3.5%, and the resulting organoids displayed functional vasculature with the highest human-derived vascular area. These findings demonstrate that pre-conditioning of ASCs in endothelial growth medium augment their pro-angiogenic properties and could enhance their therapeutic efficacy against ischemic diseases.
C1 [Souza, Lucas E. B.; Beckenkamp, Liziane R.; Fantacini, Daianne M. C.; Covas, Dimas Tadeu] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Clin Med, 3900 Bandeirantes Ave, BR-14048900 Ribeirao Preto, SP, Brazil.
   [Souza, Lucas E. B.; Beckenkamp, Liziane R.; Fantacini, Daianne M. C.; Melo, Fernanda U. F.; Borges, Josiane S.; Kashima, Simone; Covas, Dimas Tadeu] Natl Inst Sci & Technol Stem Cells & Cell Therapy, Ribeirao Preto, SP, Brazil.
   [Sobral, Lays M.; Leopoldino, Andreia M.] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Anal Toxicol & Food Sci, Cafe Ave, BR-14040903 Ribeirao Preto, SP, Brazil.
RP Souza, LEB (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Clin Med, 3900 Bandeirantes Ave, BR-14048900 Ribeirao Preto, SP, Brazil.; Souza, LEB (corresponding author), Natl Inst Sci & Technol Stem Cells & Cell Therapy, Ribeirao Preto, SP, Brazil.
EM lucas.edubs@gmail.com
RI Fantacini, Daianne Maciely C/N-9703-2018; de Souza, Lucas E.
   B./F-8743-2015; Covas, Dimas T/C-5431-2013; Souza, Lucas E.
   B./W-7139-2019; Leopoldino, Andreia M/E-9926-2012; beckenkamp,
   Liziane/AAG-3982-2020; Kashima, Simone/G-4876-2012
OI Fantacini, Daianne Maciely C/0000-0003-2694-0132; de Souza, Lucas E.
   B./0000-0003-4254-7509; Covas, Dimas T/0000-0002-7364-2595; Souza, Lucas
   E. B./0000-0003-4254-7509; Leopoldino, Andreia M/0000-0002-8313-4754;
   Sobral, Lays/0000-0002-8731-850X; Ursoli, Fernanda/0000-0002-8499-000X;
   Kashima, Simone/0000-0002-1487-0141
FU Sao Paulo Research Foundation (FAPESP, Brazil)Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP); Coordination for Improvement
   of Higher Education Personnel (CAPES, Brazil)CAPES; National Counsel of
   Technological and Scientific Development (CNPq, Brazil)National Council
   for Scientific and Technological Development (CNPq)
FX The authors would like to thank Dr. Marina Rosique for providing us the
   samples of human adipose tissue as well as Patricia Palma and Camila
   Menezes for their support with the acquisition of flow cytometry data.
   This work was funded with resources from Sao Paulo Research Foundation
   (FAPESP, Brazil), Coordination for Improvement of Higher Education
   Personnel (CAPES, Brazil) and from the National Counsel of Technological
   and Scientific Development (CNPq, Brazil).
CR de Souza LEB, 2016, STEM CELLS DEV, V25, P1843, DOI 10.1089/scd.2016.0109
   BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629
   Eming SA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009337
   Freiman A, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-015-0251-6
   GRONTHOS S, 1995, BLOOD, V85, P929, DOI 10.1182/blood.V85.4.929.bloodjournal854929
   Han J, 2011, DEVELOPMENT, V138, P5027, DOI 10.1242/dev.067686
   Hu XY, 2008, J THORAC CARDIOV SUR, V135, P799, DOI 10.1016/j.jtcvs.2007.07.071
   Karantalis V, 2015, CIRC RES, V116, P1413, DOI 10.1161/CIRCRESAHA.116.303614
   Lin RZ, 2012, ANGIOGENESIS, V15, P443, DOI 10.1007/s10456-012-9272-2
   Locatelli P, 2015, GENE THER, V22, P449, DOI 10.1038/gt.2015.28
   Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002
   Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Sanina C, 2015, CIRC RES, V117, P229, DOI 10.1161/CIRCRESAHA.117.306306
   Schellenberg A, 2012, CYTOTHERAPY, V14, P401, DOI 10.3109/14653249.2011.640669
   Suga H, 2007, CYTOTHERAPY, V9, P738, DOI 10.1080/14653240701679873
   Trounson A, 2015, CELL STEM CELL, V17, P11, DOI 10.1016/j.stem.2015.06.007
   Yang F, 2010, P NATL ACAD SCI USA, V107, P3317, DOI 10.1073/pnas.0905432106
   Zhu XY, 2013, STEM CELLS, V31, P117, DOI 10.1002/stem.1263
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105
   Zwezdaryk KJ, 2007, EXP HEMATOL, V35, P640, DOI 10.1016/j.exphem.2007.01.044
NR 21
TC 29
Z9 30
U1 1
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0969-6970
EI 1573-7209
J9 ANGIOGENESIS
JI Angiogenesis
PD FEB
PY 2018
VL 21
IS 1
BP 15
EP 22
DI 10.1007/s10456-017-9579-0
PG 8
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FW4JP
UT WOS:000425279800002
PM 28988272
DA 2020-11-26
ER

PT J
AU Pinto, MT
   Melo, FUF
   Malta, TM
   Rodrigues, ES
   Placa, JR
   Silva, WAJ
   Panepucci, RA
   Covas, DT
   Rodrigues, CD
   Kashima, S
AF Pinto, Mariana Tomazini
   Ferreira Melo, Fernanda Ursoli
   Malta, Tathiane Maistro
   Rodrigues, Evandra Strazza
   Placa, Jessica Rodrigues
   Jr Silva, Wilson Araujo
   Panepucci, Rodrigo Alexandre
   Covas, Dimas Tadeu
   Rodrigues, Claudia de Oliveira
   Kashima, Simone
TI Endothelial cells from different anatomical origin have distinct
   responses during SNAIL/TGF-beta 2-mediated endothelial-mesenchymal
   transition
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Endothelial-mesenchymal transition (EndMT); endothelial cells; SNAIL;
   transforming growth factor beta 2 (TGF-beta 2)
ID FIBROBLAST ACTIVATION PROTEIN; BETA-CATENIN; TGF-BETA; EXPRESSION;
   CARCINOMA; CANCER; FIBROSIS; SNAIL; CONTRIBUTES; INDUCTION
AB Background: Endothelial-mesenchymal transition (EndMT) is a complex process whereby differentiated endothelial cells undergo phenotypic transition to mesenchymal cells. EndMT can be stimulated by several factors and the most common are the transforming growth factor-beta (TGF-beta) and SNAIL transcription factor. Given the diversity of the vascular system, it is unclear whether endothelial cells lining different vessels are able to undergo EndMT through the same mechanisms. Here we evaluate the molecular and functional changes that occur in different types of endothelial cells following induction of EndMT by overexpression of SNAIL and TGF-beta 2. Results: We found that responses to induction by SNAIL are determined by cell origin and marker expression. Human coronary endothelial cells (HCAECs) showed the greatest EndMT responses evidenced by significant reciprocal changes in the expression of mesenchymal and endothelial markers, effects that were potentiated by a combination of SNAIL and TGF-132. Key molecular events associated with EndMT driven by SNAIL/TGF-beta 2 involved extracellular-matrix remodeling and inflammation (IL-8, IL-12, IGF-1, and TREM-1 signaling). Notch signaling pathway members DLL4, NOTCH3 and NOTCH4 as well as members of the Wnt signaling pathway FZD2, FZD9, and WNT5B were altered in the combination treatment strategy, implicating Notch and Wnt signaling pathways in the induction process. Conclusion: Our results provide a foundation for understanding the roles of specific signaling pathways in mediating EndMT in endothelial cells from different anatomical origins.
C1 [Pinto, Mariana Tomazini; Ferreira Melo, Fernanda Ursoli; Malta, Tathiane Maistro; Rodrigues, Evandra Strazza; Placa, Jessica Rodrigues; Jr Silva, Wilson Araujo; Panepucci, Rodrigo Alexandre; Covas, Dimas Tadeu; Kashima, Simone] Ctr Cell Based Therapy & Reg Blood Ctr Ribeirao P, Natl Inst Sci & Technol Stem Cell & Cell Therapy, Tenente Catao Roxo St 2501, BR-14051140 Ribeirao Preto, SP, Brazil.
   [Pinto, Mariana Tomazini; Kashima, Simone] Univ Sao Paulo, Fac Pharmaceut Sci, Ribeirao Preto, Brazil.
   [Jr Silva, Wilson Araujo; Panepucci, Rodrigo Alexandre; Covas, Dimas Tadeu] Univ Sao Paulo, Fac Med Ribeirao Preto, Ribeirao Preto, Brazil.
   [Pinto, Mariana Tomazini] Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, SP, Brazil.
   [Rodrigues, Claudia de Oliveira] Univ Miami, Leonard M Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL USA.
   [Rodrigues, Claudia de Oliveira] Univ Miami, Leonard M Miller Sch Med, Interdisciplinary Stem Cell Inst, Miami, FL USA.
RP Kashima, S (corresponding author), Ctr Cell Based Therapy & Reg Blood Ctr Ribeirao P, Natl Inst Sci & Technol Stem Cell & Cell Therapy, Tenente Catao Roxo St 2501, BR-14051140 Ribeirao Preto, SP, Brazil.
EM skashima@hemocentro.fmrp.usp.br
RI Panepucci, Rodrigo A/C-2365-2012; Malta, Tathiane/N-1686-2013; Kashima,
   Simone/G-4876-2012
OI Panepucci, Rodrigo A/0000-0002-1119-4352; Malta,
   Tathiane/0000-0003-1129-5791; Kashima, Simone/0000-0002-1487-0141
FU Center for Cell-based Therapy-CTC CEPID (FAPESP) [2013/08135-2];
   Fundacao Hemocentro de Ribeirao Preto (FUNDHERP); Centro Regional de
   Hemoterapia de Ribeirao Preto (CRH); Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP); Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES)CAPES; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq); FAPESPFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [2011/21740-7]
FX We would like to thank Dr. Keith A. Webster for critical reading and
   editing of this manuscript. We thank Ms. Patricia V.B. Palma for
   assistance with flow cytometry and Ms. Amelia G. de Araujo for
   assistance with the microarray technique. We thank Dr. Robert A.
   Weinberg and Dr. Leonardo Rodrigues, Whitehead Institute for Biomedical
   Research, Cambridge, MA, for kindly providing us with the plasmid DNA
   used for generation of SNAIL lentivirus. This work was supported by
   Center for Cell-based Therapy-CTC CEPID (FAPESP/no 2013/08135-2),
   Fundacao Hemocentro de Ribeirao Preto (FUNDHERP), Centro Regional de
   Hemoterapia de Ribeirao Preto (CRH), Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP), Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior (CAPES), and Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq). Pinto, M.T. was a fellow of the FAPESP
   (FAPESP/no 2011/21740-7).
CR Albanese I, 2017, ARTERIOSCL THROM VAS, V37, P543, DOI 10.1161/ATVBAHA.116.308394
   Armstrong EJ, 2004, CIRC RES, V95, P459, DOI 10.1161/01.RES.0000141146.95728.da
   Azhar M, 2009, DEV DYNAM, V238, P431, DOI 10.1002/dvdy.21854
   Chi JT, 2003, P NATL ACAD SCI USA, V100, P10623, DOI 10.1073/pnas.1434429100
   EISENBERG LM, 1995, CIRC RES, V77, P1, DOI 10.1161/01.RES.77.1.1
   Ge D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099378
   Ghersi G, 2002, J BIOL CHEM, V277, P29231, DOI 10.1074/jbc.M202770200
   Good RB, 2015, AM J PATHOL, V185, P1850, DOI 10.1016/j.ajpath.2015.03.019
   Graham TR, 2008, CANCER RES, V68, P2479, DOI 10.1158/0008-5472.CAN-07-2559
   Hashimoto N, 2010, AM J RESP CELL MOL, V43, P161, DOI 10.1165/rcmb.2009-0031OC
   He JH, 2013, CLIN EXP NEPHROL, V17, P488, DOI 10.1007/s10157-013-0781-0
   Henriksson ML, 2011, AM J PATHOL, V178, P1387, DOI 10.1016/j.ajpath.2010.12.008
   Jia SQ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175058
   Kokudo T, 2008, J CELL SCI, V121, P3317, DOI 10.1242/jcs.028282
   Kowal RC, 1999, CIRC RES, V84, P1166, DOI 10.1161/01.RES.84.10.1166
   Lee JG, 2006, INVEST OPHTH VIS SCI, V47, P1376, DOI 10.1167/iovs.05-1223
   Lee WJ, 2015, WOUND REPAIR REGEN, V23, P435, DOI 10.1111/wrr.12300
   Lee YH, 2008, CARCINOGENESIS, V29, P2243, DOI 10.1093/carcin/bgn199
   Levy MT, 2002, LIVER, V22, P93, DOI 10.1034/j.1600-0676.2002.01503.x
   Li HM, 2015, ONCOL LETT, V9, P143, DOI 10.3892/ol.2014.2687
   Liebner S, 2004, J CELL BIOL, V166, P359, DOI 10.1083/jcb.200403050
   Medici D, 2008, MOL BIOL CELL, V19, P4875, DOI 10.1091/mbc.E08-05-0506
   Medici D, 2012, SEMIN CANCER BIOL, V22, P379, DOI 10.1016/j.semcancer.2012.04.004
   Medici D, 2011, BIOCHEM J, V437, P515, DOI 10.1042/BJ20101500
   Nakamura T, 1999, J BIOL CHEM, V274, P22476, DOI 10.1074/jbc.274.32.22476
   Noseda M, 2004, CIRC RES, V94, P910, DOI 10.1161/01.RES.0000124300.76171.C9
   Osta WA, 2004, CANCER RES, V64, P5818, DOI 10.1158/0008-5472.CAN-04-0754
   Parker BS, 2004, CANCER RES, V64, P7857, DOI 10.1158/0008-5472.CAN-04-1976
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Piera-Velazquez S, 2011, AM J PATHOL, V179, P1074, DOI 10.1016/j.ajpath.2011.06.001
   Pinto MT, 2016, BIOL PROCED ONLINE, V18, DOI 10.1186/s12575-016-0040-3
   Potenta S, 2008, BRIT J CANCER, V99, P1375, DOI 10.1038/sj.bjc.6604662
   SCANLAN MJ, 1994, P NATL ACAD SCI USA, V91, P5657, DOI 10.1073/pnas.91.12.5657
   Schwock J, 2010, BMC CLIN PATHOL, V10, DOI 10.1186/1472-6890-10-1
   Walsh LA, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-10
   Wang RY, 2016, ONCOL RES, V24, P225, DOI 10.3727/096504016X14648701447931
   Wang SH, 2017, ONCOGENE, V36, P1503, DOI 10.1038/onc.2016.317
   Wang XM, 2008, FRONT BIOSCI-LANDMRK, V13, P3168, DOI 10.2741/2918
   Zeisberg EM, 2007, CANCER RES, V67, P10123, DOI 10.1158/0008-5472.CAN-07-3127
   Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613
   Zeisberg EM, 2008, J AM SOC NEPHROL, V19, P2282, DOI 10.1681/ASN.2008050513
   Zhang ZQ, 2015, CELL PHYSIOL BIOCHEM, V35, P1643, DOI 10.1159/000373978
   Zhou N, 2016, ONCOL LETT, V12, P1915, DOI 10.3892/ol.2016.4900
   Zidar N, 2008, VIRCHOWS ARCH, V453, P267, DOI 10.1007/s00428-008-0649-y
NR 44
TC 6
Z9 6
U1 0
U2 4
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2018
VL 10
IS 12
BP 4065
EP 4081
PG 17
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA HI7YE
UT WOS:000456671500015
PM 30662651
DA 2020-11-26
ER

PT J
AU Slavov, SN
   Hespanhol, MR
   Rodrigues, ES
   Levi, JE
   Ubiali, EMA
   Covas, DT
   Kashima, S
AF Slavov, Svetoslav N.
   Hespanhol, Marta R.
   Rodrigues, Evandra S.
   Levi, Jose E.
   Ubiali, Eugenia M. A.
   Covas, Dimas T.
   Kashima, Simone
TI Zika virus RNA detection in asymptomatic blood donors during an outbreak
   in the northeast region of Sao Paulo State, Brazil, 2016
SO TRANSFUSION
LA English
DT Article
AB BACKGROUND: In 2015, there was a large Zika virus (ZIKV) outbreak in Brazil. The proportion of asymptomatic infections is very high, and it is possible for transfusion-transmitted ZIKV (TT-ZIKV) infection to occur. The prevalence of asymptomatic ZIKV infection among Brazilian blood donors during this epidemic outbreak is unknown.
   STUDY DESIGN AND METHODS: Plasma samples obtained between October 2015 and May 2016 from 1393 volunteer blood donors were tested for ZIKV RNA. The viral load was quantified using an in-house standard curve. Additionally, positive ZIKV RNA samples were tested for anti-ZIKV immunoglobulin (Ig)M and anti-ZIKV IgG.
   RESULTS: Of the 1393 blood samples, ZIKV RNA was detected in 37 (n = 37/1393; 2.7%). The median infection viral load detected was 7714 copies/mL (ranging from 135-124,220 copies/mL). The majority of the positive samples (70.3%) exhibited a viral load of approximately 10(3) copies/mL. Six samples that were positive for ZIKV RNA were also positive for anti-ZIKV IgM and IgG (n = 6/37; 13.5%).
   CONCLUSION: This is the first study evaluating the prevalence of ZIKV RNA among Brazilian blood donors, which was relatively high and might lead to TT-ZIKV infection. It is unclear whether the simultaneous presence of anti-ZIKV IgM and IgG in RNA-positive donations or the viral load influences transfusion transmission of the infection. This study also adds to the global understanding of ZIKV prevalence in blood donors during outbreaks and the transfusion impact of the infection.
C1 [Slavov, Svetoslav N.; Hespanhol, Marta R.; Rodrigues, Evandra S.; Ubiali, Eugenia M. A.; Covas, Dimas T.; Kashima, Simone] Univ Sao Paulo, Fac Med Ribeirao Preto, Blood Ctr Ribeirao Preto, Sao Paulo, Brazil.
   [Levi, Jose E.] Univ Sao Paulo, Virol Lab, Inst Trop Med, Sao Paulo, Brazil.
   [Kashima, Simone] Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, Sao Paulo, Brazil.
RP Slavov, SN (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Blood Ctr Ribeirao Preto, Lab Mol Biol, 2501 Tenente Catao Roxo St, BR-14051140 Sao Paulo, Brazil.
EM svetoslav.slavov@hemocentro.fmrp.usp.br
RI Covas, Dimas T/C-5431-2013; Rodrigues, Evandra/L-6094-2017; N,
   Svetoslav/M-5416-2017; Kashima, Simone/G-4876-2012
OI Covas, Dimas T/0000-0002-7364-2595; Rodrigues,
   Evandra/0000-0003-0964-9554; Kashima, Simone/0000-0002-1487-0141
FU Fundacao de Amparo e Pesquisa do Estado de Sao Paulo-FAPESP, Brazil
   [2009/16623-1, CTC-2013/081352]; Conselho Nacional do Desenvolvimento
   Cientifico e Tecnologico, Brazil [INCTC-573.754/2008-0,
   INCTC-2008/57.877-3]; FINEP, BrazilCiencia Tecnologia e Inovacao (FINEP)
   [245/2016]
FX This study was supported by the Fundacao de Amparo e Pesquisa do Estado
   de Sao Paulo-FAPESP, Brazil (Grant 2009/16623-1, CTC-2013/081352); the
   Conselho Nacional do Desenvolvimento Cientifico e Tecnologico, Brazil
   (INCTC-573.754/2008-0 and INCTC-2008/57.877-3); and FINEP, Brazil
   (245/2016).
NR 0
TC 11
Z9 12
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD DEC
PY 2017
VL 57
IS 12
BP 2897
EP 2901
DI 10.1111/trf.14322
PG 5
WC Hematology
SC Hematology
GA FP5AW
UT WOS:000417630900012
PM 28921551
OA Bronze
DA 2020-11-26
ER

PT J
AU Colaco, CS
   de Matos, AR
   Estrela, MS
   Rocha, MC
   Otaguiri, KK
   Rodrigues, ES
   Takayanagui, OM
   Covas, DT
   Kashima, S
   Silva, FP
   Haddad, R
AF Colaco, Camila Schoueri
   de Matos, Adriano Reis
   Estrela, Martha Silva
   Rocha-Junior, Mauricio Cristiano
   Otaguiri, Katia Kaori
   Rodrigues, Evandra Strazza
   Takayanagui, Osvaldo Massaiti
   Covas, Dimas Tadeu
   Kashima, Simone
   Silva, Fabio Pittella
   Haddad, Rodrigo
TI Downregulation of histone methyltransferase EHMT2 in CD4(+) T-cells may
   protect HTLV-1-infected individuals against HAM/TSP development
SO ARCHIVES OF VIROLOGY
LA English
DT Article
DE HTLV-1; HAM/TSP; Histone methyltransferases
ID DIAGNOSTIC-CRITERIA; HTLV-1 INFECTION; PROVIRAL LOAD; TAX; INTERACTS;
   GLP
AB Approximately 5% of human T-cell leukemia virus type 1 (HTLV-1)-infected individuals will develop one of the HTLV-1-related diseases, such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) or adult T-cell leukemia. However, the mechanisms responsible for the appearance of symptoms have not been fully clarified. It is believed that viral factors, host genetic and epigenetic mechanisms are implicated in this process. Studies have shown the involvement of histone methyltransferases in retrovirus infection, but no study observed their expression in HTLV-1-infected patients. Among them, euchromatic histone-lysine N-methyltransferase (EHMT)-1 and EHMT-2 were related to retroviral latency in HIV-1 infection. We investigated whether histone methyltransferases EHMT1 and EHMT2 exert any influence on HAM/TSP development by assessing their expression levels in CD4(+) T-cells from HTLV-1-infected patients. CD4(+) T-cells were immunomagnetically isolated from peripheral blood mononuclear cells of HTLV-1-infected or non-infected individuals and the expression levels of EHMT1 and EHMT2 were determined by RT-qPCR. We observed that EHMT2 was negatively regulated in HTLV-1 asymptomatic carriers compared to non-infected individuals. No difference was observed for EHMT1. These results suggest that EHMT2 downregulation in CD4(+) T-cells may be linked to a protection mechanism against the development of HAM/TSP.
C1 [Colaco, Camila Schoueri; de Matos, Adriano Reis; Estrela, Martha Silva; Silva, Fabio Pittella; Haddad, Rodrigo] Univ Brasilia UnB, Fac Hlth Sci, Lab Mol Pathol Canc, Brasilia, DF, Brazil.
   [Haddad, Rodrigo] Univ Brasilia UnB, Trop Med Unit, Brasilia, DF, Brazil.
   [Haddad, Rodrigo] Univ Brasilia UnB, Fac Ceilandia, Brasilia, DF, Brazil.
   [Rocha-Junior, Mauricio Cristiano; Otaguiri, Katia Kaori; Rodrigues, Evandra Strazza; Covas, Dimas Tadeu; Kashima, Simone] Univ Sao Paulo, Hemotherapy Ctr Ribeirao Preto, Sao Paulo, Brazil.
   [Takayanagui, Osvaldo Massaiti] Univ Sao Paulo, Med Sch Ribeirao Preto, Sao Paulo, Brazil.
RP Haddad, R (corresponding author), Univ Brasilia UnB, Fac Hlth Sci, Lab Mol Pathol Canc, Brasilia, DF, Brazil.; Haddad, R (corresponding author), Univ Brasilia UnB, Trop Med Unit, Brasilia, DF, Brazil.; Haddad, R (corresponding author), Univ Brasilia UnB, Fac Ceilandia, Brasilia, DF, Brazil.
EM haddad@unb.br
RI Rodrigues, Evandra/L-6094-2017; Silva, Fabio Pittella/B-2621-2013;
   Covas, Dimas T/C-5431-2013; Haddad, Rodrigo/A-3460-2013; Kashima,
   Simone/G-4876-2012
OI Rodrigues, Evandra/0000-0003-0964-9554; Silva, Fabio
   Pittella/0000-0002-9644-7098; Covas, Dimas T/0000-0002-7364-2595;
   Haddad, Rodrigo/0000-0003-4699-164X; Kashima, Simone/0000-0002-1487-0141
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/04122-5];
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [453906/2014]; Centro de Terapia Celular da Fundacao Hemocentro
   de Ribeirao Preto (CTC/FUND-HERP); Fundacao de Amparo a Pesquisa do
   Distrito Federal (FAPDF) [193.001.014/2015]
FX This study was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP, process 2012/04122-5), Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq, process 453906/2014),
   Centro de Terapia Celular da Fundacao Hemocentro de Ribeirao Preto
   (CTC/FUND-HERP), and Fundacao de Amparo a Pesquisa do Distrito Federal
   (FAPDF, process 193.001.014/2015).
CR Asquith B, 2007, IMMUNOL CELL BIOL, V85, P280, DOI 10.1038/sj.icb.7100050
   Dasgupta A, 2008, J VIROL, V82, P49, DOI 10.1128/JVI.01497-07
   De Castro-Costa CM, 2006, AIDS RES HUM RETROV, V22, P931, DOI 10.1089/aid.2006.22.931
   Ding DL, 2013, VIROLOGY, V440, P182, DOI 10.1016/j.virol.2013.02.022
   Gessain A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00388
   Haddad R, 2011, AIDS RES HUM RETROV, V27, P283, DOI 10.1089/aid.2010.0165
   Hamamoto R, 2016, CANCER SCI, V107, P377, DOI 10.1111/cas.12884
   He S, 2013, IMMUNOTHERAPY-UK, V5, P989, DOI 10.2217/imt.13.101
   Imai K, 2010, J BIOL CHEM, V285, P16538, DOI 10.1074/jbc.M110.103531
   Jeong SJ, 2006, J VIROL, V80, P10036, DOI 10.1128/JVI.00186-06
   Kamoi K, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-5
   Lezin A, 2007, BLOOD, V110, P3722, DOI 10.1182/blood-2007-04-085076
   Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111
   Nagai M, 1998, J NEUROVIROL, V4, P586, DOI 10.3109/13550289809114225
   Panfil AR, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8010007
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Grassi MFR, 2011, J MED VIROL, V83, P1269, DOI 10.1002/jmv.22087
   Shinkai Y, 2011, GENE DEV, V25, P781, DOI 10.1101/gad.2027411
   Yamamoto K, 2011, CANCER SCI, V102, P260, DOI 10.1111/j.1349-7006.2010.01752.x
   Yamano Y, 2002, BLOOD, V99, P88, DOI 10.1182/blood.V99.1.88
   Yasunaga J, 2011, INT J HEMATOL, V94, P435, DOI 10.1007/s12185-011-0937-1
NR 21
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0304-8608
EI 1432-8798
J9 ARCH VIROL
JI Arch. Virol.
PD OCT
PY 2017
VL 162
IS 10
BP 3131
EP 3136
DI 10.1007/s00705-017-3428-8
PG 6
WC Virology
SC Virology
GA FH1OL
UT WOS:000410909200021
PM 28608127
DA 2020-11-26
ER

PT J
AU Slavov, SN
   Otaguiri, KK
   Smid, J
   de Oliveira, ACP
   Casseb, J
   Martinez, EZ
   Covas, DT
   Eis-Hubinger, AM
   Kashima, S
AF Slavov, Svetoslav Nanev
   Otaguiri, Katia Kaori
   Smid, Jerusa
   Penalva de Oliveira, Augusto Cesar
   Casseb, Jorge
   Martinez, Edson Zangiacomi
   Covas, Dimas Tadeu
   Eis-Huebinger, Anna Maria
   Kashima, Simone
TI Human Parvovirus 4 Prevalence Among HTLV-1/2 Infected Individuals in
   Brazil
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE PARV4; HTLV-1/2; coinfections; parenteral transmission; HAM/TSP
ID SUB-SAHARAN AFRICA; PARV4; ANTIBODIES; TRANSMISSION; HEMOPHILIA;
   CHILDREN
AB Human parvovirus 4 (PARV4), a Tetraparvovirus, has been largely found in HIV, HBV, or HCV infected individuals. However, there is no data for the PARV4 occurrence in Human T-lymphotropic virus (HTLV-1/2) infected individuals, despite similar transmission routes. Here, PARV4 viremia was evaluated in 130 HTLV infected patients under care of a Brazilian HTLV outpatient clinic. PARV4 viremia was detected in 6.2% of the HTLV-1 infected patients. Most PARV4 positives showed no evidence for parenterally transmitted infections. It is suggested that in Brazil, transmission routes of PARV4 are more complex than in Europe and North America and resemble those in Africa. (C) 2016 Wiley Periodicals, Inc.
C1 [Slavov, Svetoslav Nanev; Otaguiri, Katia Kaori; Covas, Dimas Tadeu; Kashima, Simone] Univ Sao Paulo, Fac Med Ribeirao Preto, Blood Ctr Ribeirao Preto, Sao Paulo, Brazil.
   [Slavov, Svetoslav Nanev; Covas, Dimas Tadeu] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Sao Paulo, Brazil.
   [Otaguiri, Katia Kaori; Kashima, Simone] Univ Sao Paulo, Fac Pharmaceut Sci, Dept Clin Toxicol & Bromatol Anal, Sao Paulo, Brazil.
   [Smid, Jerusa; Penalva de Oliveira, Augusto Cesar; Casseb, Jorge] Inst Infect Dis Emilio Ribas, HTLV Outpatient Clin, Sao Paulo, Brazil.
   [Casseb, Jorge] Inst Trop Med Sao Paulo, Lab Med Invest 56, Sao Paulo, Brazil.
   [Martinez, Edson Zangiacomi] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Social Med, Sao Paulo, Brazil.
   [Eis-Huebinger, Anna Maria] Univ Bonn, Med Ctr, Inst Virol, Bonn, Germany.
RP Slavov, SN (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Mol Biol Lab, Blood Ctr Ribeirao Preto, BR-05508 Sao Paulo, Brazil.
EM svetoslav.slavov@hemocentro.fmrp.usp.br
RI N, Svetoslav/M-5416-2017; Covas, Dimas T/C-5431-2013; Martinez, Edson
   Zangiacomi/A-3638-2008; casseb, jorge/X-5219-2019; Kashima,
   Simone/G-4876-2012; CTC USP, CEPID 13 18/J-8951-2014
OI Covas, Dimas T/0000-0002-7364-2595; Martinez, Edson
   Zangiacomi/0000-0002-0949-3222; casseb, jorge/0000-0002-4553-2559;
   Kashima, Simone/0000-0002-1487-0141; Slavov,
   Svetoslav/0000-0003-0805-6140; CTC USP, CEPID 13 18/0000-0002-7123-9524
FU Fundacao de Amparo e Pesquisa do Estado de Sao Paulo-FAPESP, Brazil
   [2009/16623-1, CTC-1998/14.247-6, INCTC-2008/57.877-3]; Conselho
   Nacional do Desenvolvimento Cientifico e Tecnologico, Brazil
   [INCTC-573.754/2008-0]
FX Grant sponsor: Fundacao de Amparo e Pesquisa do Estado de Sao
   Paulo-FAPESP, Brazil; Grant numbers: 2009/16623-1; CTC-1998/14.247-6;
   INCTC-2008/57.877-3; Grant sponsor: Conselho Nacional do Desenvolvimento
   Cientifico e Tecnologico, Brazil; Grant number: INCTC-573.754/2008-0
CR Canuti M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029140
   Catalan-Soares Bernadette, 2005, Cad. Saúde Pública, V21, P926, DOI 10.1590/S0102-311X2005000300027
   Chen MY, 2011, EMERG INFECT DIS, V17, P1954, DOI 10.3201/eid1710.101841
   Cotmore SF, 2014, ARCH VIROL, V159, P1239, DOI 10.1007/s00705-013-1914-1
   Drexler JF, 2012, EMERG INFECT DIS, V18, P1650, DOI 10.3201/eid1810.111373
   Fryer JF, 2007, VOX SANG, V93, P341, DOI 10.1111/j.1423-0410.2007.00979.x
   GESSAIN A, 1985, LANCET, V2, P407
   HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476
   Jones MS, 2005, J VIROL, V79, P8230, DOI 10.1128/JVI.79.13.8230-8236.2005
   Lahtinen A, 2011, EMERG INFECT DIS, V17, P79, DOI 10.3201/eid1701.100750
   Matthews PC, 2015, EMERG INFECT DIS, V21, P713, DOI 10.3201/eid2104.141545
   Novoa P, 2007, J MED VIROL, V79, P182, DOI 10.1002/jmv.20775
   Panning M, 2010, EMERG INFECT DIS, V16, P1143, DOI 10.3201/eid1607.100025
   Rocha M. F. J., 2014, THESIS
   Sharp CP, 2012, TRANSFUSION, V52, P1482, DOI 10.1111/j.1537-2995.2011.03420.x
   Sharp CP, 2010, EMERG INFECT DIS, V16, P1605, DOI 10.3201/eid1610.101001
   Sharp CP, 2009, J INFECT DIS, V200, P1119, DOI 10.1086/605646
   Simmonds P, 2008, J GEN VIROL, V89, P2299, DOI 10.1099/vir.0.2008/001180-0
   Simmons R, 2013, J VIROL, V87, P3087, DOI 10.1128/JVI.02793-12
   Simmons R, 2012, J INFECT DIS, V205, P1816, DOI 10.1093/infdis/jis291
   Slavov SN, 2015, HAEMOPHILIA, V21, pE86, DOI 10.1111/hae.12564
NR 21
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD APR
PY 2017
VL 89
IS 4
BP 748
EP 752
DI 10.1002/jmv.24673
PG 5
WC Virology
SC Virology
GA EK4KH
UT WOS:000393895000024
PM 27589576
DA 2020-11-26
ER

PT J
AU de Oliveira, GLV
   Ferreira, AF
   Gasparotto, EPL
   Kashima, S
   Covas, DT
   Guerreiro, CT
   Brum, DG
   Barreira, AA
   Voltarelli, JC
   Simoes, BP
   Oliveira, MC
   de Castro, FA
   Malmegrim, KCR
AF de Oliveira, G. L. V.
   Ferreira, A. F.
   Gasparotto, E. P. L.
   Kashima, S.
   Covas, D. T.
   Guerreiro, C. T.
   Brum, D. G.
   Barreira, A. A.
   Voltarelli, J. C.
   Simoes, B. P.
   Oliveira, M. C.
   de Castro, F. A.
   Malmegrim, K. C. R.
TI Defective expression of apoptosis-related molecules in multiple
   sclerosis patients is normalized early after autologous haematopoietic
   stem cell transplantation
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE apoptosis-related molecules; autologous haematopoietic stem cell
   transplantation; autoreactive cells; immune tolerance; multiple
   sclerosis
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ENVIRONMENTAL RISK-FACTORS;
   BCL-2 FAMILY PROTEINS; T-CELLS; PERIPHERAL-BLOOD; UP-REGULATION;
   MONONUCLEAR-CELLS; DISEASE-ACTIVITY; NERVOUS-SYSTEM; B-CELLS
AB Defective apoptosis might be involved in the pathogenesis of multiple sclerosis (MS). We evaluated apoptosis-related molecules in MS patients before and after autologous haematopoietic stem cell transplantation (AHSCT) using BCNU, Etoposide, AraC and Melphalan (BEAM) or cyclophosphamide (CY)-based conditioning regimens. Patients were followed for clinical and immunological parameters for 2 years after AHSCT. At baseline, MS patients had decreased proapoptotic BAD, BAX and FASL and increased A1 gene expression when compared with healthy counterparts. In the BEAM group, BAK, BIK, BIMEL, FAS, FASL, A1, BCL2, BCLXL, CFLIPL and CIAP2 genes were up-regulated after AHSCT. With the exception of BIK, BIMEL and A1, all genes reached levels similar to controls at day + 720 post-transplantation. Furthermore, in these patients, we observed increased CD8(+) Fas(+) T cell frequencies after AHSCT when compared to baseline. In the CY group, we observed increased BAX, BCLW, CFLIPL and CIAP1 and decreased BIK and BID gene expressions after transplantation. At day 1 720 post-AHSCT, the expression of BAX, FAS, FASL, BCL2, BCLXL and CIAP1 was similar to that of controls. Protein analyses showed increased Bcl-2 expression before transplantation. At 1 year post-AHSCT, expression of Bak, Bim, Bcl-2, Bcl-xL and cFlip-L was decreased when compared to baseline values. In summary, our findings suggest that normalization of apoptosis-related molecules is associated with the early therapeutic effects of AHSCT in MS patients. These mechanisms may be involved in the re-establishment of immune tolerance during the first 2 years post-transplantation.
C1 [de Oliveira, G. L. V.; Ferreira, A. F.; Gasparotto, E. P. L.; Voltarelli, J. C.; de Castro, F. A.; Malmegrim, K. C. R.] Fac Pharmaceut Sci Ribeirao Preto, Dept Clin Toxicol & Bromatol Anal, Sao Paulo, Brazil.
   [de Oliveira, G. L. V.; Ferreira, A. F.; Kashima, S.; Covas, D. T.; Simoes, B. P.; Oliveira, M. C.; Malmegrim, K. C. R.] Univ Sao Paulo, Reg Blood Ctr Ribeirao Preto, Ctr Cell Based Res, Sao Paulo, Brazil.
   [de Oliveira, G. L. V.; Ferreira, A. F.; Kashima, S.; Covas, D. T.; Simoes, B. P.; Oliveira, M. C.; Malmegrim, K. C. R.] Univ Sao Paulo, Ribeirao Preto, SP, Brazil.
   [Covas, D. T.; Brum, D. G.] Univ State Sao Paulo, UNESP, Dept Neurol Psicol & Psiquiatry, Sch Med Botucatu, Botucatu, SP, Brazil.
   [Covas, D. T.; Guerreiro, C. T.; Barreira, A. A.; Voltarelli, J. C.; Simoes, B. P.; Oliveira, M. C.] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Clin Med, Ribeirao Preto, SP, Brazil.
RP Malmegrim, KCR (corresponding author), Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Ave Cafe S-N, BR-14040903 Ribeirao Preto, SP, Brazil.
EM kelenfarias@fcfrp.usp.br
RI CASTRO, FABIOLA/D-4693-2012; de Oliveira, Gislane L. V./I-4896-2013;
   Malmegrim, Kelen/H-1016-2015; Simoes, Belinda P/M-7469-2016; Brum,
   Doralina/A-1225-2015; Rodrigues, Maria Carolina Oliveira/A-2302-2012;
   Covas, Dimas T/C-5431-2013; CTC USP, CEPID 13 18/J-8951-2014; Kashima,
   Simone/G-4876-2012
OI de Oliveira, Gislane L. V./0000-0002-0269-9973; Malmegrim,
   Kelen/0000-0002-9303-0086; Brum, Doralina/0000-0002-9050-3319;
   Rodrigues, Maria Carolina Oliveira/0000-0003-0691-2222; Covas, Dimas
   T/0000-0002-7364-2595; CTC USP, CEPID 13 18/0000-0002-7123-9524;
   Barreira, Amilton/0000-0002-4791-223X; Lelis Vilela de Oliveira,
   Gislane/0000-0002-8883-5541; Kashima, Simone/0000-0002-1487-0141
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2008/58387,
   2008/57877-3]; Coordenacao de Aperfeicoa-mento de Pessoal de Nivel
   Superior (CAPES)CAPES; Fundacao Hemocentro de Ribeirao Preto (FUNDHERP,
   Ribeirao Preto Blood Bank Foundation)
FX The study was supported by Brazilian governmental agencies, as follows:
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Foundation
   for the Support of Research in the State of Sao Paulo; Processes numbers
   2008/58387 and 2008/57877-3), Coordenacao de Aperfeicoa-mento de Pessoal
   de Nivel Superior (CAPES, Coordination of the Advancement of Higher
   Education) and Fundacao Hemocentro de Ribeirao Preto (FUNDHERP, Ribeirao
   Preto Blood Bank Foundation).
CR Abrahamsson S, 2008, AUTOIMMUNITY, V41, P577, DOI 10.1080/08916930802197081
   Abrahamsson SV, 2013, BRAIN, V136, P2888, DOI 10.1093/brain/awt182
   Achiron A, 2007, ANN NY ACAD SCI, V1107, P155, DOI 10.1196/annals.1381.017
   Albesiano E, 2003, BLOOD, V102, P3333, DOI 10.1182/blood-2003-05-1585
   Arruda LCM, 2015, BONE MARROW TRANSPL, V50, P380, DOI 10.1038/bmt.2014.277
   Ascherio A, 2007, ANN NEUROL, V61, P504, DOI 10.1002/ana.21141
   Ascherio A, 2007, ANN NEUROL, V61, P288, DOI 10.1002/ana.21117
   Bomprezzi R, 2003, HUM MOL GENET, V12, P2191, DOI 10.1093/hmg/ddg221
   Bouillet P, 2009, NAT REV IMMUNOL, V9, P514, DOI 10.1038/nri2570
   Bowen JD, 2012, BONE MARROW TRANSPL, V47, P946, DOI 10.1038/bmt.2011.208
   Buckner JH, 2010, NAT REV IMMUNOL, V10, P849, DOI 10.1038/nri2889
   Burt RK, 2015, JAMA-J AM MED ASSOC, V313, P275, DOI 10.1001/jama.2014.17986
   Burt RK, 2012, MULT SCLER J, V18, P772, DOI 10.1177/1352458512442993
   Burt RK, 2009, LANCET NEUROL, V8, P244, DOI 10.1016/S1474-4422(09)70017-1
   Comi C, 2012, AUTOIMMUN REV, V12, P150, DOI 10.1016/j.autrev.2011.08.011
   Curro D, 2015, MULT SCLER J, V21, P1423, DOI 10.1177/1352458514564484
   de Oliveira GLV, 2012, CLIN EXP IMMUNOL, V168, P291, DOI 10.1111/j.1365-2249.2012.04583.x
   Decallonne B, 2003, J AUTOIMMUN, V20, P219, DOI 10.1016/S0896-8411(03)00025-8
   Dendrou CA, 2015, NAT REV IMMUNOL, V15, P545, DOI 10.1038/nri3871
   Dubey S, 2003, ANN HEMATOL, V82, P496, DOI 10.1007/s00277-003-0645-x
   Eguchi K, 2001, INTERNAL MED, V40, P275, DOI 10.2169/internalmedicine.40.275
   Farjam M, 2015, J NEUROL SCI, V358, P22, DOI 10.1016/j.jns.2015.09.346
   Fassas A, 1997, BONE MARROW TRANSPL, V20, P631, DOI 10.1038/sj.bmt.1700944
   Gatzka M, 2007, AUTOIMMUNITY, V40, P442, DOI 10.1080/08916930701464962
   Genestier L, 1998, BLOOD, V91, P2360, DOI 10.1182/blood.V91.7.2360.2360_2360_2368
   GIORDANO C, 1995, DIABETOLOGIA, V38, P1449, DOI 10.1007/BF00400606
   Gomes AC, 2003, J NEUROIMMUNOL, V135, P126, DOI 10.1016/S0165-5728(02)00437-X
   Gronski Matthew A., 2006, Review of Diabetic Studies, V3, P88, DOI 10.1900/RDS.2006.3.88
   Grullich C, 2009, BIOL BLOOD MARROW TR, V15, P173, DOI 10.1016/j.bbmt.2008.11.014
   Hafler DA, 2007, NEW ENGL J MED, V357, P851, DOI 10.1056/NEJMoa073493
   Hamerschlak N, 2010, BONE MARROW TRANSPL, V45, P239, DOI 10.1038/bmt.2009.127
   Hayashi T, 2001, APOPTOSIS, V6, P31, DOI 10.1023/A:1009667926296
   Hebb ALO, 2008, MULT SCLER J, V14, P577, DOI 10.1177/1352458507087468
   Kinnunen T, 2013, J CLIN INVEST, V123, P2737, DOI 10.1172/JCI68775
   Krammer PH, 2007, NAT REV IMMUNOL, V7, P532, DOI 10.1038/nri2115
   Lev N, 2004, NEUROSCI LETT, V359, P139, DOI 10.1016/j.neulet.2004.01.076
   Lim SY, 2010, INT J CLIN PRACT, V64, P637, DOI 10.1111/j.1742-1241.2009.02261.x
   Liphaus BL, 2007, J RHEUMATOL, V34, P1580
   Liu HT, 2003, CURR OPIN PHARMACOL, V3, P317, DOI 10.1016/S1471-4892(03)00037-7
   Mancardi GL, 2012, MULT SCLER J, V18, P835, DOI 10.1177/1352458511429320
   Mancardi GL, 2015, NEUROLOGY, V84, P981, DOI 10.1212/WNL.0000000000001329
   Maniati E, 2008, J PATHOL, V214, P190, DOI 10.1002/path.2270
   Munoz LE, 2008, LUPUS, V17, P371, DOI 10.1177/0961203308089990
   Muraro PA, 2005, J EXP MED, V201, P805, DOI 10.1084/jem.20041679
   Muraro PA, 2015, NEUROLOGY, V84, P968, DOI 10.1212/WNL.0000000000001347
   Muraro PA, 2010, CURR OPIN INVEST DR, V11, P1265
   Nylander A, 2012, J CLIN INVEST, V122, P1180, DOI 10.1172/JCI58649
   Okuda Y, 2006, J NEUROIMMUNOL, V171, P163, DOI 10.1016/j.jneuroim.2005.09.020
   Okuda Y, 2002, J NEUROIMMUNOL, V131, P115, DOI 10.1016/S0165-5728(02)00267-9
   Opferman JT, 2008, CELL DEATH DIFFER, V15, P234, DOI 10.1038/sj.cdd.4402182
   Pope RM, 2002, NAT REV IMMUNOL, V2, P527, DOI 10.1038/nri846
   POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302
   Reichardt HM, 2012, CURR PHARM DESIGN, V18, P4453
   Rinta S, 2008, J NEUROIMMUNOL, V205, P135, DOI 10.1016/j.jneuroim.2008.09.002
   Saccardi R, 2012, MULT SCLER J, V18, P825, DOI 10.1177/1352458512438454
   Satoh J, 2005, NEUROBIOL DIS, V18, P537, DOI 10.1016/j.nbd.2004.10.007
   Sharief MK, 2003, J NEUROIMMUNOL, V134, P158, DOI 10.1016/S0165-5728(02)00400-9
   Sharief MK, 2002, J NEUROIMMUNOL, V125, P155, DOI 10.1016/S0165-5728(02)00024-3
   Sharief MK, 2001, J NEUROIMMUNOL, V119, P350, DOI 10.1016/S0165-5728(01)00365-4
   Snowden JA, 2012, BONE MARROW TRANSPL, V47, P770, DOI 10.1038/bmt.2011.185
   Stys PK, 2012, NAT REV NEUROSCI, V13, P507, DOI 10.1038/nrn3275
   Su X, 2000, J IMMUNOL, V164, P2523, DOI 10.4049/jimmunol.164.5.2523
   Tischner D, 2010, Cell Death Dis, V1, pe48, DOI 10.1038/cddis.2010.27
   Tramacere I, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011381.pub2
   Tseveleki V, 2004, J IMMUNOL, V173, P6619, DOI 10.4049/jimmunol.173.11.6619
   Waiczies S, 2002, J NEUROIMMUNOL, V126, P213, DOI 10.1016/S0165-5728(02)00067-X
   Zucchelli S, 2005, IMMUNITY, V22, P385, DOI 10.1016/j.immuni.2005.01.015
NR 67
TC 7
Z9 7
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
EI 1365-2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD MAR
PY 2017
VL 187
IS 3
BP 383
EP 398
DI 10.1111/cei.12895
PG 16
WC Immunology
SC Immunology
GA EK5OX
UT WOS:000393976800007
PM 28008595
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Slavov, SN
   Otaguiri, KK
   Pinto, MT
   Valente, VB
   Ubiali, EMA
   Covas, DT
   Kashima, S
AF Slavov, Svetoslav Nanev
   Otaguiri, Katia Kaori
   Pinto, Mariana Tomazini
   Valente, Vanderleia Barbaro
   Amorim Ubiali, Eugenia Maria
   Covas, Dimas Tadeu
   Kashima, Simone
TI Prevalence of Trypanosoma Cruzi antibodies in blood donors from the Sao
   Paulo State, Brazil, between 2012 and 2014
SO JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
LA English
DT Article
DE Blood donors; Trypanosoma cruzi; seroprevalence; blood transfusion
ID CHAGAS-DISEASE; NONENDEMIC AREA; INFECTION
AB Introduction: American tripanosomiasis (Chagas disease), the second most neglected disease in the world, is caused by the protozoan parasite Trypanosoma cruzi. Though natural transmission by insect vectors has been controlled, there is significant risk of T. cruzi transmission by blood transfusion in non-endemic regions, generally due to immigration processes from endemic areas.
   Methodology: The objective of this study was to evaluate anti-T. cruzi seroprevalence in blood donors from the western part of Sao Paulo State, Brazil, by serologic and immunofluorescence confirmation tests for the period between 2012 and 2014. Currently, this region is regarded as a non-endemic area for Chagas disease.
   Results: The confirmed overall T. cruzi seroprevalence among blood donors was 0.10%, which can be considered low compared to other Brazilian regions. Nevertheless, the distribution of the anti-T. cruzi antibodies within the examined region was uneven, and some areas of significantly higher prevalence were observed.
   Conclusions: We could consider two tendencies in the prevalence of T. cruzi: (i) residual older undiagnosed cases from Sao Paulo State, and (ii) immigration from endemic Brazilian or South American regions. The discordance obtained for T. cruzi prevalence by serologic and immunofluorescence methods demonstrates that more specific routine diagnosis is needed to diminish the cost of the assays and the loss of blood supply once all seropositive blood bags are immediately discarded.
C1 [Slavov, Svetoslav Nanev; Otaguiri, Katia Kaori; Pinto, Mariana Tomazini; Valente, Vanderleia Barbaro; Amorim Ubiali, Eugenia Maria; Covas, Dimas Tadeu; Kashima, Simone] Univ Sao Paulo, Fac Med Ribeirao Preto, Blood Ctr Ribeirao Preto, Ribeirao Preto, SP, Brazil.
   [Slavov, Svetoslav Nanev; Covas, Dimas Tadeu] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Ribeirao Preto, SP, Brazil.
   [Otaguiri, Katia Kaori; Kashima, Simone] Univ Sao Paulo, Fac Pharmaceut Sci, Dept Clin Toxicol & Bromatol Anal, Ribeirao Preto, SP, Brazil.
RP Slavov, SN (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Blood Ctr Ribeirao Preto, Lab Mol Biol, Rua Tenente Catao Roxo 2501, BR-14051140 Ribeirao Preto, SP, Brazil.
EM svetoslav.slavov@hemocentro.fmrp.usp.br
RI Pinto, Mariana/B-6129-2017; Covas, Dimas T/C-5431-2013; N,
   Svetoslav/M-5416-2017; Kashima, Simone/G-4876-2012; CTC USP, CEPID 13
   18/J-8951-2014
OI Pinto, Mariana/0000-0002-5176-7776; Covas, Dimas T/0000-0002-7364-2595;
   Kashima, Simone/0000-0002-1487-0141; CTC USP, CEPID 13
   18/0000-0002-7123-9524; Slavov, Svetoslav/0000-0003-0805-6140
FU Fundacao de Amparo e Pesquisa do Estado de Sao Paulo-FAPESP, Brazil
   [2009/16623-1, CTC-1998/14.247-6, INCTC2008/57.877-3]; Conselho Nacional
   do Desenvolvimento Cientifico e Tecnologico, Brazil
   [INCTC-573.754/2008-0]
FX We are grateful to Sandra Navarro Bresciani for the artwork. The study
   was supported by the Fundacao de Amparo e Pesquisa do Estado de Sao
   Paulo-FAPESP, Brazil (Grant. 2009/16623-1, CTC-1998/14.247-6 and
   INCTC2008/57.877-3), and the Conselho Nacional do Desenvolvimento
   Cientifico e Tecnologico, Brazil (INCTC-573.754/2008-0).
CR Angheben A, 2015, BLOOD TRANSFUS-ITALY, V13, P540, DOI 10.2450/2015.0040-15
   Araujo AB, 2008, BRAZ J INFECT DIS, V12, P480, DOI 10.1590/S1413-86702008000600007
   Barjas-Castro MD, 1998, TRANSFUSION, V38, P611
   Bern C, 2011, CLIN MICROBIOL REV, V24, P655, DOI 10.1128/CMR.00005-11
   Blejer J L, 2001, Int J Infect Dis, V5, P89, DOI 10.1016/S1201-9712(01)90032-3
   Cancino-Faure B, 2015, TRANSFUSION, V55, P1249, DOI 10.1111/trf.12989
   CARRASCO R, 1990, MEM I OSWALDO CRUZ, V85, P69, DOI 10.1590/S0074-02761990000100011
   Castro E, 2009, TRANSFUSION MED, V19, P16, DOI 10.1111/j.1365-3148.2009.00915.x
   de Lima LM, 2012, REV SOC BRAS MED TRO, V45, P723, DOI 10.1590/S0037-86822012000600013
   Holmes P., 2015, INV OV GLOB IMP NEGL
   Leite Odair F., 2001, Revista da Sociedade Brasileira de Medicina Tropical, V34, P437, DOI 10.1590/S0037-86822001000500006
   Martin DL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095398
   Massad E, 2008, EPIDEMIOL INFECT, V136, P1153, DOI 10.1017/S0950268807009879
   Mendonca VJ, 2015, AM J TROP MED HYG, V92, P1076, DOI 10.4269/ajtmh.14-0556
   Reiche Edna Maria Vissoci, 1996, Revista do Instituto de Medicina Tropical de Sao Paulo, V38, P233, DOI 10.1590/S0036-46651996000300014
   Remesar M, 2015, TRANSFUSION, V55, P2499, DOI 10.1111/trf.13180
   Sabino EC, 2003, TRANSFUSION, V43, P853, DOI 10.1046/j.1537-2995.2003.t01-2-00432.x
   Sanchez-Guillen MC, 2002, MEM I OSWALDO CRUZ, V97, P947, DOI 10.1590/S0074-02762002000700004
   Silveira HJ, 2003, REV SAUDE PUBL, V37, P807, DOI [10.1590/S0034-89102003000600018, 10.1590/s0034-89102003000600018]
   Sobreira A C, 2001, Rev Soc Bras Med Trop, V34, P193
   Stanaway JD, 2015, GLOB HEART, V10, P139, DOI 10.1016/j.gheart.2015.06.001
   Wendel S, 2010, ACTA TROP, V115, P28, DOI 10.1016/j.actatropica.2009.12.006
NR 22
TC 5
Z9 7
U1 0
U2 0
PU J INFECTION DEVELOPING COUNTRIES
PI TRAMANIGLIO
PA JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO
   CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY
SN 1972-2680
J9 J INFECT DEV COUNTR
JI J. Infect. Dev. Ctries.
PD MAR
PY 2017
VL 11
IS 3
BP 277
EP 281
DI 10.3855/jidc.8169
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA ER7UF
UT WOS:000399018600010
PM 28368863
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Slavov, S
   Matsuno, A
   Yamamoto, A
   Otaguiri, K
   Cervi, M
   Covas, D
   Kashima, S
AF Slavov, Svetoslav
   Matsuno, Alessandra
   Yamamoto, Aparecida
   Otaguiri, Katia
   Cervi, Maria
   Covas, Dimas
   Kashima, Simone
TI Zika virus infection in a pediatric patient with acute gastrointestinal
   involvement
SO PEDIATRIC REPORTS
LA English
DT Article
DE Zika virus; ZIKV; abdominal pain; viral load
ID DENGUE; DIAGNOSIS
AB Zika virus (ZIKV) is a mosquito-borne flavivirus, which has been related to severe neurological complications in neonates. However, many clinical aspects of the infection remain unclear, especially in pediatric patients. In this case report we describe the uncommon presentation of ZIKV infection in a pediatric patient with acute gastrointestinal involvement hospitalized in a Brazilian Emergency Unit. Dengue hemorrhagic fever was initially suspected, however, the molecular result for Dengue was negative. Molecular testing for other arboviruses (ZIKV and Chikungunya), revealed positive for ZIKV RNA result in both blood and saliva. The ZIKV load in saliva (6.947 copies/mL) was higher than the vetected ZIKV RNA in plasma (1.945 copies/mL). Additionally, the performed abdominal ultrasound revealed mesenteric lymphadenitis without abdominal retention of fluids. The presentation of this case demonstrates that ZIKV can be involved in a broader range of clinical conditions than currently assumed, including pediatric emergencies, especially in regions with extensive ZIKV outbreaks.
C1 [Slavov, Svetoslav; Otaguiri, Katia; Covas, Dimas; Kashima, Simone] Univ Sao Paulo, Blood Ctr Ribeirao Preto, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
   [Slavov, Svetoslav; Covas, Dimas] Univ Sao Paulo, Dept Internal Med, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
   [Matsuno, Alessandra; Yamamoto, Aparecida; Cervi, Maria] Univ Sao Paulo, Dept Pediat, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
   [Otaguiri, Katia; Kashima, Simone] Univ Sao Paulo, Dept Clin Toxicol & Bromatol Anal, Fac Pharmaceut Sci Ribeirao Preto, Sao Paulo, Brazil.
RP Slavov, S (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Mol Biol Lab, Blood Ctr Ribeirao Preto, Sao Paulo, Brazil.
EM svetoslav.slavov@hemocentro.fmrp.usp.br
RI Cervi, Maria Celia/P-2567-2016; Covas, Dimas T/C-5431-2013; Matsuno,
   Alessandra K/H-9507-2012; Kashima, Simone/G-4876-2012
OI Cervi, Maria Celia/0000-0002-6563-6507; Covas, Dimas
   T/0000-0002-7364-2595; Matsuno, Alessandra K/0000-0002-3491-1641;
   Kashima, Simone/0000-0002-1487-0141
FU Sao Paulo Research Foundation (FAPESP), BrazilFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2009/16623-1, 13/08135-2];
   Conselho Nacional do Desenvolvimento Cientifico e Tecnologico, Brazil
   [INCTC-465539/2014]; Financiadora de Estudos e ProjetosCiencia
   Tecnologia e Inovacao (FINEP) [0245/2016]; PPSUS [2016/150493]
FX the Sao Paulo Research Foundation (FAPESP), Brazil (Grants No
   2009/16623-1, 13/08135-2), the Conselho Nacional do Desenvolvimento
   Cientifico e Tecnologico, Brazil (INCTC-465539/2014), the Financiadora
   de Estudos e Projetos (0245/2016) and the PPSUS, 2016/150493.
CR Huhtamo E, 2010, J CLIN VIROL, V47, P49, DOI 10.1016/j.jcv.2009.11.001
   Khor BS, 2006, AM J TROP MED HYG, V74, P901, DOI 10.4269/ajtmh.2006.74.901
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lanciotti RS, 2007, EMERG INFECT DIS, V13, P764, DOI 10.3201/eid1305.070015
   Lazear HM, 2016, J VIROL, V90, P4864, DOI 10.1128/JVI.00252-16
   Macari M, 2002, AM J ROENTGENOL, V178, P853, DOI 10.2214/ajr.178.4.1780853
   Musso D, 2015, J CLIN VIROL, V68, P53, DOI 10.1016/j.jcv.2015.04.021
   Patel NB, 2015, RADIOL CLIN N AM, V53, P1159, DOI 10.1016/j.rcl.2015.06.004
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Trunfio M, 2017, INFECTION, V45, P1, DOI 10.1007/s15010-016-0927-6
   Ventura CV, 2016, LANCET, V387, P2502, DOI 10.1016/S0140-6736(16)30776-0
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 12
TC 4
Z9 4
U1 0
U2 0
PU PAGEPRESS PUBL
PI PAVIA
PA MEDITGROUP, VIA G BELLI, 4, PAVIA, 27100, ITALY
SN 2036-749X
EI 2036-7503
J9 PEDIATRIC REP
JI Pediatric Rep.
PY 2017
VL 9
IS 4
BP 78
EP 80
AR 7341
DI 10.4081/pr.2017.7341
PG 3
WC Pediatrics
SC Pediatrics
GA FU9SI
UT WOS:000424196700006
PM 29383222
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU de Souza, LEB
   Malta, TM
   Haddad, SK
   Covas, DT
AF Botelho de Souza, Lucas Eduardo
   Malta, Tathiane Maistro
   Haddad, Simone Kashima
   Covas, Dimas Tadeu
TI Mesenchymal Stem Cells and Pericytes: To What Extent Are They Related?
SO STEM CELLS AND DEVELOPMENT
LA English
DT Review
DE mesenchymal stem cell; pericytes; adventitial cells; tissue-specific
   stem cells; niche
ID HUMAN BONE-MARROW; STROMAL CELLS; IN-VIVO; PROGENITOR CELLS;
   GROWTH-FACTOR; MICROVASCULAR PERICYTES; INTERNATIONAL-SOCIETY;
   ENDOTHELIAL-CELLS; BETA-RECEPTOR; PDGFR-BETA
AB Mesenchymal stem cells (MSCs) were initially identified as progenitors of skeletal tissues within mammalian bone marrow and cells with similar properties were also obtained from other tissues such as adipose and dental pulp. Although MSCs have been extensively investigated, their native behavior and in vivo identity remain poorly defined. Uncovering the in vivo identity of MSCs has been challenging due to the lack of exclusive cell markers, cellular alterations caused by culture methods, and extensive focus on in vitro properties for characterization. Although MSC site of origin influences their functional properties, these mesenchymal progenitors can be found in the perivascular space in virtually all organs from where they were obtained. However, the precise identity of MSCs within the vascular wall is highly controversial. The recurrent concept that MSCs correspond to pericytes in vivo has been supported mainly by their perivascular localization and expression of some molecular markers. However, this view has been a subject of controversy, in part, due to the application of loose criteria to define pericytes and due to the lack of a marker able to unequivocally identify these cells. Furthermore, recent evidences indicate that subpopulations of MSCs can be found at extravascular sites such as the endosteum. In this opinion review, we bring together the advances and pitfalls on the search for the in vivo identity of MSCs and highlight the recent evidences that suggest that perivascular MSCs are adventitial cells, acting as precursors of pericytes and other stromal cells during tissue homeostasis.
C1 [Botelho de Souza, Lucas Eduardo; Covas, Dimas Tadeu] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Clin Med, 3900 Bandeirantes Ave, BR-14048900 Ribeirao Preto, SP, Brazil.
   [Botelho de Souza, Lucas Eduardo; Malta, Tathiane Maistro; Haddad, Simone Kashima; Covas, Dimas Tadeu] Natl Inst Sci & Technol Stem Cell & Cell Therapy, Ribeirao Preto, Brazil.
   [Malta, Tathiane Maistro] Univ Sao Paulo, Dept Genet, Ribeirao Preto Med Sch, Ribeirao Preto, Brazil.
RP Covas, DT (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Clin Med, 3900 Bandeirantes Ave, BR-14048900 Ribeirao Preto, SP, Brazil.
EM dimas@fmrp.usp.br
RI Souza, Lucas E. B./W-7139-2019; Covas, Dimas T/C-5431-2013; Malta,
   Tathiane/N-1686-2013; de Souza, Lucas E. B./F-8743-2015; CTC USP, CEPID
   13 18/J-8951-2014; Kashima, Simone/G-4876-2012
OI Souza, Lucas E. B./0000-0003-4254-7509; Covas, Dimas
   T/0000-0002-7364-2595; Malta, Tathiane/0000-0003-1129-5791; de Souza,
   Lucas E. B./0000-0003-4254-7509; CTC USP, CEPID 13
   18/0000-0002-7123-9524; Kashima, Simone/0000-0002-1487-0141
FU Co-ordination for the Improvement of Higher Level Education
   (CAPES)CAPES; Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP); National Counsel of
   Technological and Scientific Development (CNPq), BrazilNational Council
   for Scientific and Technological Development (CNPq)
FX This work was supported with grants from the Co-ordination for the
   Improvement of Higher Level Education (CAPES), Sao Paulo Research
   Foundation (FAPESP), and National Counsel of Technological and
   Scientific Development (CNPq), Brazil.
CR Aguzzi A, 2014, TRENDS IMMUNOL, V35, P105, DOI 10.1016/j.it.2013.11.001
   Andreeva ER, 1998, TISSUE CELL, V30, P127, DOI 10.1016/S0040-8166(98)80014-1
   Anjos-Afonso F, 2004, J CELL SCI, V117, P5655, DOI 10.1242/jcs.01488
   Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001
   Barlow S, 2008, STEM CELLS DEV, V17, P1095, DOI 10.1089/scd.2007.0154
   Battula VL, 2010, STEM CELLS, V28, P1435, DOI 10.1002/stem.467
   Berry R, 2013, NAT CELL BIOL, V15, P302, DOI 10.1038/ncb2696
   Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Birbrair A, 2013, STEM CELLS DEV, V22, P2298, DOI 10.1089/scd.2012.0647
   Boxall SA, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/975871
   Brocher J, 2013, STEM CELL RES, V11, P1393, DOI 10.1016/j.scr.2013.07.008
   Buhring HJ, 2009, ANN NY ACAD SCI, V1176, P124, DOI 10.1111/j.1749-6632.2009.04564.x
   Burlacu A, 2008, EUR J CELL BIOL, V87, P173, DOI 10.1016/j.ejcb.2007.09.003
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Caplan AI, 2008, CELL STEM CELL, V3, P229, DOI 10.1016/j.stem.2008.08.008
   Caplan AI, 2011, CELL STEM CELL, V9, P11, DOI 10.1016/j.stem.2011.06.008
   CATTORETTI G, 1993, BLOOD, V81, P1726
   Chan CKF, 2015, CELL, V160, P285, DOI 10.1016/j.cell.2014.12.002
   Chan J, 2006, STEM CELLS, V24, P1879, DOI 10.1634/stemcells.2005-0564
   Chong JJH, 2011, CELL STEM CELL, V9, P527, DOI 10.1016/j.stem.2011.10.002
   Corselli M, 2012, STEM CELLS DEV, V21, P1299, DOI 10.1089/scd.2011.0200
   Covas DT, 2008, EXP HEMATOL, V36, P642, DOI 10.1016/j.exphem.2007.12.015
   Covas DT, 2005, EXP CELL RES, V309, P340, DOI 10.1016/j.yexcr.2005.06.005
   Covas DT, 2003, BRAZ J MED BIOL RES, V36, P1179, DOI 10.1590/S0100-879X2003000900006
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932
   Diaz-Flores L, 2009, HISTOL HISTOPATHOL, V24, P909, DOI 10.14670/HH-24.909
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Dore-Duffy P, 2006, J CEREBR BLOOD F MET, V26, P613, DOI 10.1038/sj.jcbfm.9600272
   FRIEDENSTEIN AJ, 1987, CELL TISSUE KINET, V20, P263, DOI 10.1111/j.1365-2184.1987.tb01309.x
   FRIEDENSTEIN AJ, 1974, TRANSPLANTATION, V17, P331, DOI 10.1097/00007890-197404000-00001
   FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365-2184.1970.tb00347.x
   Gimble JM, 2003, CYTOTHERAPY, V5, P362, DOI 10.1080/14653240310003026
   Grcevic D, 2012, STEM CELLS, V30, P187, DOI 10.1002/stem.780
   Gronthos S, 2003, J CELL SCI, V116, P1827, DOI 10.1242/jcs.00369
   Haniffa MA, 2009, HAEMATOL-HEMATOL J, V94, P258, DOI 10.3324/haematol.13699
   Heldin CH, 1999, PHYSIOL REV, V79, P1283
   Hellstrom M, 1999, DEVELOPMENT, V126, P3047
   Hennig T, 2007, J CELL PHYSIOL, V211, P682, DOI 10.1002/jcp.20977
   Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234
   Hoshino A, 2008, BIOCHEM BIOPH RES CO, V368, P305, DOI 10.1016/j.bbrc.2008.01.090
   Howson KM, 2005, AM J PHYSIOL-CELL PH, V289, pC1396, DOI 10.1152/ajpcell.00168.2005
   Hsiao STF, 2012, STEM CELLS DEV, V21, P2189, DOI 10.1089/scd.2011.0674
   Hu YH, 2011, ARTERIOSCL THROM VAS, V31, P1523, DOI 10.1161/ATVBAHA.110.221176
   Hu YH, 2004, J CLIN INVEST, V113, P1258, DOI 10.1172/JCI200419628
   Ieronimakis N, 2013, J MOL CELL CARDIOL, V63, P122, DOI 10.1016/j.yjmcc.2013.07.014
   Isenmann S, 2009, STEM CELLS, V27, P2457, DOI 10.1002/stem.181
   Jansen BJH, 2010, STEM CELLS DEV, V19, P481, DOI 10.1089/scd.2009.0288
   Kassem M, 2015, CELL, V160, P17, DOI 10.1016/j.cell.2014.12.034
   Kieslinger M, 2005, DEV CELL, V9, P757, DOI 10.1016/j.devcel.2005.10.009
   Kostallari E, 2015, DEVELOPMENT, V142, P1242, DOI 10.1242/dev.115386
   Kovacic JC, 2012, CIRCULATION, V125, P1795, DOI 10.1161/CIRCULATIONAHA.111.040352
   Krautler NJ, 2012, CELL, V150, P194, DOI 10.1016/j.cell.2012.05.032
   Langhans TH., 1866, VIRCHOWS ARCH, V36, P226
   Lin G, 2008, STEM CELLS DEV, V17, P1053, DOI 10.1089/scd.2008.0117
   Mabuchi Y, 2016, INT J HEMATOL, V103, P138, DOI 10.1007/s12185-015-1921-y
   Mabuchi Y, 2013, STEM CELL REP, V1, P152, DOI 10.1016/j.stemcr.2013.06.001
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Medici D, 2010, NAT MED, V16, P1400, DOI 10.1038/nm.2252
   Mendez-Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Moreno PR, 2006, CURR MOL MED, V6, P457, DOI 10.2174/156652406778018635
   NEHLS V, 1993, HISTOCHEMISTRY, V99, P1, DOI 10.1007/BF00268014
   NEHLS V, 1992, CELL TISSUE RES, V270, P469, DOI 10.1007/BF00645048
   Neng LL, 2013, NAT PROTOC, V8, P709, DOI 10.1038/nprot.2013.033
   Noth U, 2002, J ORTHOP RES, V20, P1060, DOI 10.1016/S0736-0266(02)00018-9
   Olson LE, 2011, DEV CELL, V20, P815, DOI 10.1016/j.devcel.2011.04.019
   OWEN M, 1988, CIBA F SYMP, V136, P42
   Phinney DG, 2011, STEM CELLS, V29, P3, DOI 10.1002/stem.553
   Pinho S, 2013, J EXP MED, V210, P1351, DOI 10.1084/jem.20122252
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Pla P, 2001, J CELL PHYSIOL, V189, P121, DOI 10.1002/jcp.10008
   Potenta S, 2008, BRIT J CANCER, V99, P1375, DOI 10.1038/sj.bjc.6604662
   Pusztaszeri MP, 2006, J HISTOCHEM CYTOCHEM, V54, P385, DOI 10.1369/jhc.4A6514.2005
   Qian H, 2013, MOL CELL BIOL, V33, P661, DOI 10.1128/MCB.01287-12
   Reis JS, 2006, MODERN PATHOL, V19, P307, DOI 10.1038/modpathol.3800542
   Rouget C., 1873, ARCH PHYSL NORM PATH, V5, P603
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Seifert RA, 1998, KIDNEY INT, V54, P731, DOI 10.1046/j.1523-1755.1998.00046.x
   SHCHELKUNOV SI, 1977, MAIN PRINCIPLES CELL
   Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696
   SIMS DE, 1986, TISSUE CELL, V18, P153, DOI 10.1016/0040-8166(86)90026-1
   Tang W, 2008, SCIENCE, V322, P583, DOI 10.1126/science.1156232
   TAVASSOLI M, 1968, SCIENCE, V161, P54, DOI 10.1126/science.161.3836.54
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Tintut Y, 2003, CIRCULATION, V108, P2505, DOI 10.1161/01.CIR.0000096485.64373.C5
   Tormin A, 2011, BLOOD, V117, P5067, DOI 10.1182/blood-2010-08-304287
   Trounson A, 2015, CELL STEM CELL, V17, P11, DOI 10.1016/j.stem.2015.06.007
   Tuan RS, 2003, ARTHRITIS RES THER, V5, P32, DOI 10.1186/ar614
   Ueno H, 2006, DEV CELL, V11, P519, DOI 10.1016/j.devcel.2006.08.001
   Winkler EA, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-32
   Worthley DL, 2015, CELL, V160, P269, DOI 10.1016/j.cell.2014.11.042
   Zannettino ACW, 2008, J CELL PHYSIOL, V214, P413, DOI 10.1002/jcp.21210
   Zeisberg EM, 2007, CANCER RES, V67, P10123, DOI 10.1158/0008-5472.CAN-07-3127
   Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613
   Zengin E, 2006, DEVELOPMENT, V133, P1543, DOI 10.1242/dev.02315
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zhao H, 2014, CELL STEM CELL, V14, P160, DOI 10.1016/j.stem.2013.12.013
NR 99
TC 44
Z9 44
U1 0
U2 21
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547-3287
EI 1557-8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD DEC 15
PY 2016
VL 25
IS 24
BP 1843
EP 1852
DI 10.1089/scd.2016.0109
PG 10
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA EE1AH
UT WOS:000389312100001
PM 27702398
DA 2020-11-26
ER

PT J
AU Meirelles, LD
   Wagatsuma, VMD
   Malta, TM
   Palma, PVB
   Araujo, AG
   Panepucci, RA
   Silva, WA
   Kashima, S
   Covas, DT
AF Meirelles, Lindolfo da Silva
   Wagatsuma, Virginia Mara de Deus
   Malta, Tathiane Maistro
   Palma, Patricia Viana Bonini
   Araujo, Amelia Goes
   Panepucci, Rodrigo Alexandre
   Silva, Wilson Araujo, Jr.
   Kashima, Simone
   Covas, Dimas Tadeu
TI The gene expression profile of non-cultured, highly purified human
   adipose tissue pericytes: Transcriptomic evidence that pericytes are
   stem cells in human adipose tissue
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Pericytes; Mesenchymal stromal cells; Mesenchymal stem cells; Adipose
   tissue; Gene expression
ID MESENCHYMAL STROMAL CELLS; FACTOR RECEPTOR ANTIBODIES; HUMAN
   SKELETAL-MUSCLE; BONE-MARROW; GROWTH-FACTOR; IN-VIVO; PERIVASCULAR
   CELLS; MICROVASCULAR PERICYTES; STEM/PROGENITOR CELLS; SATELLITE CELLS
AB Pericytes (PCs) are a subset of perivascular cells that can give rise to mesenchymal stromal cells (MSCs) when culture-expanded, and are postulated to give rise to MSC-like cells during tissue repair in vivo. PCs have been suggested to behave as stem cells (SCs) in situ in animal models, although evidence for this role in humans is lacking. Here, we analyzed the transcriptomes of highly purified, non-cultured adipose tissue (AT)-derived PCs (ATPCs) to detect gene expression changes that occur as they acquire MSC characteristics in vitro, and evaluated the hypothesis that human ATPCs exhibit a gene expression profile compatible with an AT SC phenotype. The results showed ATPCs are non-proliferative and express genes characteristic not only of PCs, but also of AT stem/progenitor cells. Additional analyses defined a gene expression signature for ATPCs, and revealed putative novel ATPC markers. Almost all AT stem/progenitor cell genes differentially expressed by ATPCs were not expressed by ATMSCs or culture-expanded ATPCs. Genes expressed by ATMSCs but not by ATPCs were also identified. These findings strengthen the hypothesis that PCs are SCs in vascularized tissues, highlight gene expression changes they undergo as they assume an MSC phenotype, and provide new insights into PC biology.
C1 [Meirelles, Lindolfo da Silva; Wagatsuma, Virginia Mara de Deus; Malta, Tathiane Maistro; Palma, Patricia Viana Bonini; Silva, Wilson Araujo, Jr.; Kashima, Simone; Covas, Dimas Tadeu] Univ Sao Paulo, Reg Ctr Hemotherapy Ribeirao Preto, Ctr Cell Based Therapy CEPID FAPESP, Rua Tenente Catao Roxo 2501, BR-14051140 Ribeirao Preto, SP, Brazil.
   [Meirelles, Lindolfo da Silva] Univ Luterana Brasil, PPGBioSaude, Lab Stem Cells & Tissue Engn, Av Farroupilha 8001, BR-92425900 Canoas, RS, Brazil.
   [Araujo, Amelia Goes; Panepucci, Rodrigo Alexandre] Univ Sao Paulo, Reg Ctr Hemotherapy Ribeiraao Preto, Lab Large Scale Funct Biol LLSFBio, Rua Tenente Catao Roxo 2501, BR-14051140 Ribeirao Preto, SP, Brazil.
   [Silva, Wilson Araujo, Jr.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Genet, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
   [Covas, Dimas Tadeu] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Clin Med, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
RP Meirelles, LD (corresponding author), Univ Luterana Brasil, PPGBioSaude, Lab Stem Cells & Tissue Engn, Av Farroupilha 8001, BR-92425900 Canoas, RS, Brazil.
EM lindolfomeirelles@gmail.com
RI Covas, Dimas T/C-5431-2013; Silva, Wilson Araujo/E-9487-2011; Panepucci,
   Rodrigo A/C-2365-2012; Malta, Tathiane/N-1686-2013; Wagatsuma,
   Virginia/F-1643-2013; da Silva Meirelles, Lindolfo/B-3451-2008; Kashima,
   Simone/G-4876-2012
OI Covas, Dimas T/0000-0002-7364-2595; Silva, Wilson
   Araujo/0000-0001-9364-2886; Panepucci, Rodrigo A/0000-0002-1119-4352;
   Malta, Tathiane/0000-0003-1129-5791; Wagatsuma,
   Virginia/0000-0003-3801-3280; da Silva Meirelles,
   Lindolfo/0000-0001-5775-2869; Kashima, Simone/0000-0002-1487-0141
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2013/08135-2]; University of Sao Paulo
   [12.1.25441.01.2]; Brazilian National Council for Scientific and
   Technological Development (CNPq)National Council for Scientific and
   Technological Development (CNPq) [477806/2008-2, 573754/2008-0,
   131371/2011-8]
FX The authors are indebted to the team of Divisao de Cirurgia Plastica e
   Queimaduras of Hospital das Clinicas de Ribeirao Preto for providing
   adipose tissue samples, and Ms. Aline Magro Bueno for technical
   assistance. This work has been funded by Sao Paulo Research Foundation
   (FAPESP; Grant number 2013/08135-2); University of Sao Paulo (Grant
   number 12.1.25441.01.2); and Brazilian National Council for Scientific
   and Technological Development (CNPq; Grant numbers 477806/2008-2,
   573754/2008-0, and 131371/2011-8).
CR Alliot F, 1999, J NEUROSCI RES, V58, P367
   Avolio E, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002043
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19-3-180
   Bianco P, 1999, EXP CELL RES, V251, P257, DOI 10.1006/excr.1999.4592
   Birbrair A, 2013, STEM CELL RES, V10, P67, DOI 10.1016/j.scr.2012.09.003
   Bondjers C, 2003, AM J PATHOL, V162, P721, DOI 10.1016/S0002-9440(10)63868-0
   Bondjers C, 2006, FASEB J, V20, P1703, DOI 10.1096/fj.05-4944fje
   Boneberg EM, 2009, MICROVASC RES, V78, P325, DOI 10.1016/j.mvr.2009.06.012
   Brachvogel B, 2005, DEVELOPMENT, V132, P2657, DOI 10.1242/dev.01846
   Campagnolo P, 2010, CIRCULATION, V121, P1735, DOI 10.1161/CIRCULATIONAHA.109.899252
   Caplan AI, 2011, CELL STEM CELL, V9, P11, DOI 10.1016/j.stem.2011.06.008
   CATTORETTI G, 1993, BLOOD, V81, P1726
   Cherry HM, 2014, EUR CELLS MATER, V27, P185, DOI 10.22203/eCM.v027a14
   Claeskens A, 2000, BRIT J CANCER, V82, P1123, DOI 10.1054/bjoc.1999.1051
   Corselli M, 2013, BLOOD, V121, P2891, DOI 10.1182/blood-2012-08-451864
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   CROCKER DJ, 1970, EXP MOL PATHOL, V13, P51, DOI 10.1016/0014-4800(70)90084-5
   Dellavalle A, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1508
   Dellavalle A, 2007, NAT CELL BIOL, V9, P255, DOI 10.1038/ncb1542
   Diaz-Flores L, 2009, HISTOL HISTOPATHOL, V24, P909, DOI 10.14670/HH-24.909
   Dore-Duffy P, 2008, CURR PHARM DESIGN, V14, P1581, DOI 10.2174/138161208784705469
   Esteve D, 2015, STEM CELLS, V33, P1277, DOI 10.1002/stem.1916
   Feng JF, 2011, P NATL ACAD SCI USA, V108, P6503, DOI 10.1073/pnas.1015449108
   Flores-Figueroa E, 2012, LAB INVEST, V92, P1330, DOI 10.1038/labinvest.2012.93
   Frazier T. P., 2016, STEM CELLS
   Galli R, 2002, DEVELOPMENT, V129, P1633
   Geevarghese A, 2014, TRANSL RES, V163, P296, DOI 10.1016/j.trsl.2014.01.011
   Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441-003-0745-x
   Gesta S, 2011, P NATL ACAD SCI USA, V108, P2771, DOI 10.1073/pnas.1019704108
   Gupta RK, 2012, CELL METAB, V15, P230, DOI 10.1016/j.cmet.2012.01.010
   Hammarstedt A, 2013, P NATL ACAD SCI USA, V110, P2563, DOI 10.1073/pnas.1211255110
   Hayashi T, 2007, J THROMB HAEMOST, V5, P1477, DOI 10.1111/j.1538-7836.2007.02594.x
   Hu L, 2015, STEM CELLS, V33, P2483, DOI 10.1002/stem.2052
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Humphreys BD, 2010, AM J PATHOL, V176, P85, DOI 10.2353/ajpath.2010.090517
   Iwaisako K, 2008, J HEPATOL, V49, P768, DOI 10.1016/j.jhep.2008.05.026
   Kane R, 2008, MOL VIS, V14, P1138
   Karagiannis ED, 2007, BIOCHEM BIOPH RES CO, V359, P63, DOI 10.1016/j.bbrc.2007.05.041
   Kramann R, 2015, CELL STEM CELL, V16, P51, DOI 10.1016/j.stem.2014.11.004
   Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242
   Lindroos J, 2013, CELL METAB, V18, P62, DOI 10.1016/j.cmet.2013.05.020
   Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0
   LYFORD GL, 1995, NEURON, V14, P433, DOI 10.1016/0896-6273(95)90299-6
   Mabuchi Y, 2013, STEM CELL REP, V1, P152, DOI 10.1016/j.stemcr.2013.06.001
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   MANDARINO LJ, 1993, EXP EYE RES, V57, P609, DOI 10.1006/exer.1993.1166
   Martella E, 2014, CYTOTHERAPY, V16, P1476, DOI 10.1016/j.jcyt.2014.05.005
   Meirelles LD, 2008, STEM CELLS, V26, P2287, DOI 10.1634/stemcells.2007-1122
   Meirelles LD, 2016, FRONT BIOSCI-LANDMRK, V21, P130, DOI 10.2741/4380
   Meirelles LD, 2015, STEM CELLS DEV, V24, P2822, DOI 10.1089/scd.2015.0153
   Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002
   Mendez-Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Midwood KS, 2004, INT J BIOCHEM CELL B, V36, P1031, DOI 10.1016/j.biocel.2003.12.003
   Mikami Y, 2011, STEM CELLS DEV, V20, P901, DOI 10.1089/scd.2010.0299
   NAYAK RC, 1988, J EXP MED, V167, P1003, DOI 10.1084/jem.167.3.1003
   NEHLS V, 1991, J CELL BIOL, V113, P147, DOI 10.1083/jcb.113.1.147
   Peppiatt CM, 2006, NATURE, V443, P700, DOI 10.1038/nature05193
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Quirici N, 2002, EXP HEMATOL, V30, P783, DOI 10.1016/S0301-472X(02)00812-3
   Quirici N, 2010, STEM CELLS DEV, V19, P915, DOI 10.1089/scd.2009.0408
   Ramchandran R, 1999, BIOCHEM BIOPH RES CO, V255, P735, DOI 10.1006/bbrc.1999.0248
   RICHARDSON RL, 1982, ACTA ANAT, V114, P41
   Rocnik EF, 2006, J BIOL CHEM, V281, P22855, DOI 10.1074/jbc.M513463200
   Rodeheffer MS, 2008, CELL, V135, P240, DOI 10.1016/j.cell.2008.09.036
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Sarjeant JM, 2003, ARTERIOSCL THROM VAS, V23, P2172, DOI 10.1161/01.ATV.0000100404.05459.39
   SCHLINGEMANN RO, 1990, AM J PATHOL, V136, P1393
   Schutyser E, 2003, CYTOKINE GROWTH F R, V14, P409, DOI 10.1016/S1359-6101(03)00049-2
   SHEPRO D, 1993, FASEB J, V7, P1031
   Shukunami C, 2005, BIOCHEM BIOPH RES CO, V333, P299, DOI 10.1016/j.bbrc.2005.05.133
   SIMS DE, 1986, TISSUE CELL, V18, P153, DOI 10.1016/0040-8166(86)90026-1
   Stapor PC, 2012, MICROVASC RES, V83, P257, DOI 10.1016/j.mvr.2011.09.003
   Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016
   Sundberg C, 2002, LAB INVEST, V82, P387, DOI 10.1038/labinvest.3780433
   Tang W, 2008, SCIENCE, V322, P583, DOI 10.1126/science.1156232
   Tonami K, 2011, J CELL SCI, V124, P1214, DOI 10.1242/jcs.072561
   Traktuev DO, 2008, CIRC RES, V102, P77, DOI 10.1161/CIRCRESAHA.107.159475
   Uezumi A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.161
   van der Horst A, 2009, CELL CYCLE, V8, P3742, DOI 10.4161/cc.8.22.10047
   Varma MJO, 2007, STEM CELLS DEV, V16, P91, DOI 10.1089/scd.2006.0026
   Wang M, 2016, MOL CELL ENDOCRINOL, V426, P136, DOI 10.1016/j.mce.2016.02.020
   Wendel M, 1998, J CELL BIOL, V141, P839, DOI 10.1083/jcb.141.3.839
   WESTEN H, 1979, J EXP MED, V150, P919, DOI 10.1084/jem.150.4.919
   Xiang W, 2011, J CELL MOL MED, V15, P359, DOI 10.1111/j.1582-4934.2009.00961.x
   Yanagida A., 1812, BIOCHIM BIOPHYS ACTA, V2011, P1403
   Zhang J, 2013, J CARDIOVASC SURG, V54, P511
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
NR 87
TC 11
Z9 11
U1 0
U2 5
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD DEC 10
PY 2016
VL 349
IS 2
BP 239
EP 254
DI 10.1016/j.yexer.2016.10.017
PG 16
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA ED9AU
UT WOS:000389163200005
PM 27789253
DA 2020-11-26
ER

PT J
AU Moura, LG
   Tognon, R
   Nunes, NS
   Rodrigues, LC
   Ferreira, AF
   Kashima, S
   Covas, DT
   Santana, M
   Souto, EX
   Perobelli, L
   Simoes, BP
   Dias-Baruffi, M
   Castro, FA
AF Moura, L. G.
   Tognon, R.
   Nunes, N. S.
   Cataldi Rodrigues, L.
   Ferreira, A. F.
   Kashima, S.
   Covas, D. T.
   Santana, M.
   Souto, E. X.
   Perobelli, L.
   Simoes, B. P.
   Dias-Baruffi, M.
   Castro, F. A.
TI Different expression patterns of LGALS1 and LGALS3 in polycythemia vera,
   essential thrombocythemia and primary myelofibrosis
SO JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article
DE CANCER GENETICS; HAEMATO-ONCOLOGY; GENE AMPLIFICATION
ID GALECTIN-3; INVOLVEMENT; PATHWAY; CELLS
AB Despite all the knowledge, the cellular and molecular mechanisms involved in myeloproliferative neoplasm (MPN) pathophysiology remain unclear. Authors have shown galectin-1 (Gal-1) and 3 playing roles in tumour angiogenesis and fibrosis, which were correlated with poor prognosis in patients with MPN. In the present study LGALS1 and LGALS3 were differently expressed between polycythemia vera, essential thrombocythemia (ET) and primary myelofibrosis (PMF) diseases. Increased LGALS3 expression was associated with a negative JAK2 V617F status mutation in leucocytes from PMF but not in patients with ET without this mutation. However, a positive Janus kinase 2 (JAK2) V617F cell line established from patients with ET (SET-2 cells) when treated with JAK inhibitor presented high levels of LGALS3. Additionally, high LGALS1 expression was found in CD34(+) cells but not in leucocytes from patients with PMF, in absence of JAK2 V617F mutation, and also in SET-2 cells treated with JAK inhibitor. Thus, our findings indicate that differential expression of LGALS1 and/or LGALS3 in patients with MPN is linked with JAK2 V617F status mutation in these diseases and state of cell differentiation.
C1 [Moura, L. G.; Nunes, N. S.; Cataldi Rodrigues, L.; Ferreira, A. F.; Dias-Baruffi, M.; Castro, F. A.] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Dept Anal Clin Toxicol & Bromatol, BR-14040903 Sao Paulo, Brazil.
   [Tognon, R.] Univ Fed Juiz de Fora, Dept Farm, Campus Governador Valadares, Governador Valadares, MG, Brazil.
   [Kashima, S.; Covas, D. T.] Univ Sao Paulo, Fac Med Ribeirao Preto, Hosp Clin, Hemoctr Ribeirao Preto, Sao Paulo, Brazil.
   [Covas, D. T.; Simoes, B. P.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Sao Paulo, Brazil.
   [Santana, M.; Souto, E. X.; Perobelli, L.] Hosp Estadual Transplantes Euryclides Jesus Zerbi, Sao Paulo, Brazil.
RP Moura, LG (corresponding author), Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Dept Anal Clin Toxicol & Bromatol, BR-14040903 Sao Paulo, Brazil.
EM livia.moura@cemaden.gov.br
RI CASTRO, FABIOLA/D-4693-2012; Baruffi, Marcelo D/I-7199-2015; Covas,
   Dimas T/C-5431-2013; Simoes, Belinda P/M-7469-2016; SIMOES,
   BELINDA/A-1896-2014; CTC USP, CEPID 13 18/J-8951-2014; Kashima,
   Simone/G-4876-2012
OI Baruffi, Marcelo D/0000-0002-2039-1884; Covas, Dimas
   T/0000-0002-7364-2595; SIMOES, BELINDA/0000-0003-4508-8934; CTC USP,
   CEPID 13 18/0000-0002-7123-9524; Kashima, Simone/0000-0002-1487-0141
FU FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo-Brazil)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2010/11905-6]; CNPQ (Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico-Brazil)National Council for Scientific and
   Technological Development (CNPq) [467646/2014-7]; NAPDIN (Nucleo de
   Apoio a Pesquisa em Doencas Inflamatorias) [11.1.21625.01.0]
FX We acknowledge the financial support and fellowships from FAPESP
   (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo-Brazil) process
   number 2010/11905-6; CNPQ (Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico-Brazil) process number 467646/2014-7 and NAPDIN
   (Nucleo de Apoio a Pesquisa em Doencas Inflamatorias process number
   11.1.21625.01.0).
CR Asgarian-Omran H, 2010, CANCER INVEST, V28, P717, DOI 10.3109/07357907.2010.494319
   Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9
   Califice S, 2004, INT J ONCOL, V25, P983
   Cedeno-Laurent F, 2012, BLOOD, V119, P3534, DOI 10.1182/blood-2011-12-396457
   Croci DO, 2013, LEUKEMIA, V27, P1413, DOI 10.1038/leu.2012.315
   Demydenko D., 2009, Experimental Oncology, V31, P74
   Fischer I, 2011, J REPROD IMMUNOL, V90, P35, DOI 10.1016/j.jri.2011.04.004
   Iacovazzi PA, 2010, IMMUNOPHARM IMMUNOT, V32, P160, DOI 10.1080/08923970902936880
   Jeon SB, 2010, J IMMUNOL, V185, P7037, DOI 10.4049/jimmunol.1000154
   Koopmans SM, 2012, AM J BLOOD RES, V2, P119
   Leffler H, 2001, Results Probl Cell Differ, V33, P57
   Nakamura M, 1999, INT J ONCOL, V15, P143
   Satelli A, 2008, ONCOL REP, V19, P587
   Tefferi A, 2007, BLOOD, V110, P1092, DOI 10.1182/blood-2007-04-083501
   Tognon R, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-2
   Tognon R, 2011, J CLIN PATHOL, V64, P75, DOI 10.1136/jcp.2010.080895
   Uozumi K, 2000, LEUKEMIA, V14, P142, DOI 10.1038/sj.leu.2401608
   Vainchenker W, 2011, BLOOD, V118, P1723, DOI 10.1182/blood-2011-02-292102
   Vannucchi AM, 2008, LEUKEMIA, V22, pCP5, DOI 10.1038/leu.2008.113
NR 19
TC 2
Z9 2
U1 0
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0021-9746
EI 1472-4146
J9 J CLIN PATHOL
JI J. Clin. Pathol.
PD OCT
PY 2016
VL 69
IS 10
BP 926
EP 929
DI 10.1136/jclinpath-2016-203948
PG 4
WC Pathology
SC Pathology
GA DX8ZJ
UT WOS:000384681400015
PM 27402956
DA 2020-11-26
ER

PT J
AU Alves, DCC
   Haddad, R
   Rocha, MC
   Wagatsuma, VMD
   Martelli-Palomino, G
   Marques, AA
   Takayanagui, OM
   Covas, DT
   Kashima, S
   Donadi, EA
AF Ciliao Alves, Daiani Cristina
   Haddad, Rodrigo
   Rocha-Junior, Mauricio Cristiano
   de Deus Wagatsuma, Virginia Mara
   Martelli-Palomino, Gustavo
   Marques, Adriana Aparecida
   Takayanagui, Osvaldo Massaiti
   Covas, Dimas Tadeu
   Kashima, Simone
   Donadi, Eduardo Antonio
TI HLA-G 3 '-untranslated region polymorphisms are associated with HTLV-1
   infection, proviral load and HTLV-associated myelopathy/tropical spastic
   paraparesis development
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID LYMPHOTROPIC VIRUS TYPE-1; 3' UNTRANSLATED REGION; G MESSENGER-RNA;
   14-BP INSERTION/DELETION POLYMORPHISM; HUMAN-PAPILLOMAVIRUS INFECTION;
   CYTOMEGALOVIRUS-INFECTION; G MOLECULES; ANTIGEN-G; SUSCEPTIBILITY;
   POPULATION
AB Most human T-lymphotropic virus type 1 (HTLV-1)-infected patients remain asymptomatic throughout life. The factors associated with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) development have not been fully elucidated; immunological and genetic factors may be involved. The association of 14 bp INS/DEL HLA-G polymorphism with HTLV-1 infection susceptibility has been reported previously. Here, other polymorphic sites at the HLA-G 3-UTR (14-bp D/I, + 3003C/T, + 3010C/G, + 3027A/C, + 3035C/T, + 3142C/G, + 3187A/G and + 3196C/G) were evaluated in 37 HTLV-1-infected individuals exhibiting HAM/TSP, 45 HTLV-1 asymptomatic carriers (HAC) and 153 uninfected individuals, followed up at University Hospital of the Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Brazil. It was observed that: (i) 14bpDI genotype is a risk factor for HTLV-1 infection, while the 14bpDD and +3142CC genotypes were associated with protection against infection; (ii) the +3142C allele and the +3003CT and +3142CC genotypes were associated with susceptibility, while 14bpII and +3003TT genotypes were associated with protection against HAM/TSP development; and (iii) the 14bpII, +3010CC, +3142GG and +3187AA genotypes were associated with lower HTLV-1 proviral load compared to respective counterpart genotypes. Findings that HLA-G has a well-recognized immunomodulatory role and that the genetic variability at HLA-G 3-UTR may post-transcriptionally modify HLA-G production indicate a differential genetic susceptibility to: (i) the development of HTLV-1 infection, (ii) the magnitude of HTLV-1 proviral load and (iii) HAM/TSP development.
C1 [Ciliao Alves, Daiani Cristina; Martelli-Palomino, Gustavo; Takayanagui, Osvaldo Massaiti; Covas, Dimas Tadeu; Donadi, Eduardo Antonio] Univ Sao Paulo, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil.
   [Haddad, Rodrigo] Univ Brasilia UnB, Fac Ceilandia, BR-72220900 Brasilia, DF, Brazil.
   [Haddad, Rodrigo] Univ Brasilia UnB, Nucleo Med Trop, BR-70904970 Brasilia, DF, Brazil.
   [Rocha-Junior, Mauricio Cristiano; de Deus Wagatsuma, Virginia Mara; Marques, Adriana Aparecida; Covas, Dimas Tadeu; Kashima, Simone] Univ Sao Paulo, Fundacao Hemoctr Ribeirao Preto, BR-14051140 Ribeirao Preto, SP, Brazil.
   [Rocha-Junior, Mauricio Cristiano; Kashima, Simone] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, BR-14040903 Ribeirao Preto, SP, Brazil.
RP Alves, DCC (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil.
EM daianicristina@yahoo.com.br
RI donadi, eduardo A/H-7080-2013; Covas, Dimas T/C-5431-2013; Haddad,
   Rodrigo/A-3460-2013; Wagatsuma, Virginia/F-1643-2013; Kashima,
   Simone/G-4876-2012; CTC USP, CEPID 13 18/J-8951-2014
OI donadi, eduardo A/0000-0002-9457-9601; Covas, Dimas
   T/0000-0002-7364-2595; Haddad, Rodrigo/0000-0003-4699-164X; Wagatsuma,
   Virginia/0000-0003-3801-3280; Kashima, Simone/0000-0002-1487-0141; CTC
   USP, CEPID 13 18/0000-0002-7123-9524
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); Centro de Terapia
   Celular da Fundacao Hemocentro de Ribeirao Preto (CTC/FUNDHERP);
   Instituto Nacional de Celulas Tronco e Terapia Celular (INCTC)
FX This study was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP), Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq), Centro de Terapia Celular da Fundacao Hemocentro de
   Ribeirao Preto (CTC/FUNDHERP) and Instituto Nacional de Celulas Tronco e
   Terapia Celular (INCTC). The authors declare that the study was
   conducted in the absence of any commercial or financial relationship
   that could be interpreted as a potential conflict of interest.
CR Aceti Antonio, 2015, World J Virol, V4, P198, DOI 10.5501/wjv.v4.i3.198
   Asquith B, 2005, J GEN VIROL, V86, P1515, DOI 10.1099/vir.0.80766-0
   Asquith B, 2007, IMMUNOL CELL BIOL, V85, P280, DOI 10.1038/sj.icb.7100050
   Bangham CRM, 2003, J GEN VIROL, V84, P3177, DOI 10.1099/vir.0.19334-0
   Bermingham J, 2000, BIOCHEM SOC T, V28, P215, DOI 10.1042/bst0280215
   Bortolotti D, 2014, TISSUE ANTIGENS, V83, P113, DOI 10.1111/tan.12281
   Bortolotti Daria, 2014, World J Methodol, V4, P11, DOI 10.5662/wjm.v4.i1.11
   Carosella ED, 2003, ADV IMMUNOL, V81, P199, DOI 10.1016/S0065-2776(03)81006-4
   Carosella ED, 2011, IMMUNOL LETT, V138, P22, DOI 10.1016/j.imlet.2011.02.011
   Castelli EC, 2010, GENES IMMUN, V11, P134, DOI 10.1038/gene.2009.74
   Cordero EAA, 2009, TISSUE ANTIGENS, V74, P308, DOI 10.1111/j.1399-0039.2009.01331.x
   Donadi EA, 2011, CELL MOL LIFE SCI, V68, P369, DOI 10.1007/s00018-010-0580-7
   Excoffier L, 1998, AM J HUM GENET, V62, P171, DOI 10.1086/301674
   Excoffier L, 2005, EVOL BIOINFORM, V1, P47, DOI 10.1177/117693430500100003
   Fabris A, 2009, AIDS, V23, P177, DOI 10.1097/QAD.0b013e32832027bf
   Gessain A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00388
   Goncalves Denise U., 2008, Inflammation & Allergy Drug Targets, V7, P98, DOI 10.2174/187152808785107642
   GUO SW, 1992, BIOMETRICS, V48, P361, DOI 10.2307/2532296
   Haddad R, 2011, AIDS RES HUM RETROV, V27, P283, DOI 10.1089/aid.2010.0165
   Hviid TVF, 2003, IMMUNOGENETICS, V55, P63, DOI 10.1007/s00251-003-0547-z
   Jiang YT, 2011, DNA CELL BIOL, V30, P1027, DOI 10.1089/dna.2011.1238
   Jin ZK, 2012, TRANSPL IMMUNOL, V27, P69, DOI 10.1016/j.trim.2012.06.008
   Kashima S, 2009, J GEN VIROL, V90, P927, DOI 10.1099/vir.0.008367-0
   Manns A, 1999, J INFECT DIS, V180, P1487, DOI 10.1086/315088
   Martelli-Palomino G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071742
   Moreau P, 2009, J CELL MOL MED, V13, P2973, DOI 10.1111/j.1582-4934.2009.00800.x
   Nagai M, 1998, J NEUROVIROL, V4, P586, DOI 10.3109/13550289809114225
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   Ratner L, 2005, CURR OPIN ONCOL, V17, P469, DOI 10.1097/01.cco.0000174037.84903.fb
   RAYMOND M, 1995, J HERED, V86, P248, DOI 10.1093/oxfordjournals.jhered.a111573
   Rizzo R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00592
   Rocha MC, 2012, TISSUE ANTIGENS, V80, P143, DOI 10.1111/j.1399-0039.2012.01887.x
   Rousseau P, 2003, HUM IMMUNOL, V64, P1005, DOI 10.1016/j.humimm.2003.08.347
   Sabouri AH, 2005, J GEN VIROL, V86, P773, DOI 10.1099/vir.0.80509-0
   Segat L, 2014, TISSUE ANTIGENS, V83, P161, DOI 10.1111/tan.12296
   Soriano V, 2012, J ANTIMICROB CHEMOTH, V67, P523, DOI 10.1093/jac/dkr506
   Costa GCS, 2009, J MED VIROL, V81, P552, DOI 10.1002/jmv.21421
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Tan Z, 2007, AM J HUM GENET, V81, P829, DOI 10.1086/521200
   Trevino A, 2013, J NEUROL, V260, P2551, DOI 10.1007/s00415-013-7014-z
   Tripathi P, 2007, AIDS, V21, P1395, DOI 10.1097/QAD.0b013e32810c8bbc
   Verdonck K, 2007, LANCET INFECT DIS, V7, P266, DOI 10.1016/S1473-3099(07)70081-6
   Wang L, 2016, J NANOMATER, V2016, DOI 10.1155/2016/8078165
   Xu HH, 2014, TISSUE ANTIGENS, V84, P216, DOI 10.1111/tan.12359
   Yamano Y, 2002, BLOOD, V99, P88, DOI 10.1182/blood.V99.1.88
   Yang YC, 2014, EUR J CANCER, V50, P469, DOI 10.1016/j.ejca.2013.10.018
   Yie SM, 2008, MOL HUM REPROD, V14, P649, DOI 10.1093/molehr/gan059
   Zheng XQ, 2009, TISSUE ANTIGENS, V74, P317, DOI 10.1111/j.1399-0039.2009.01312.x
NR 48
TC 3
Z9 3
U1 0
U2 0
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD OCT
PY 2016
VL 97
BP 2742
EP 2752
DI 10.1099/jgv.0.000559
PN 10
PG 11
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA EA8GA
UT WOS:000386872100026
PM 27449667
OA Bronze
DA 2020-11-26
ER

PT J
AU Slavov, SN
   Otaguiri, KK
   de Figueiredo, GG
   Yamamoto, AY
   Mussi-Pinhata, MM
   Kashima, S
   Covas, DT
AF Slavov, Svetoslav Nanev
   Otaguiri, Katia Kaori
   de Figueiredo, Glauciane Garcia
   Yamamoto, Aparecida Yulie
   Mussi-Pinhata, Marisa Marcia
   Kashima, Simone
   Covas, Dimas Tadeu
TI Development and Optimization of a Sensitive TaqMan (R) Real-Time PCR
   With Synthetic Homologous Extrinsic Control for Quantitation of Human
   cytomegalovirus Viral Load
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE HCMV; molecular detection; optimization; internal controls
ID TRANSPLANT RECIPIENTS; CLINICAL UTILITY; RAPID DETECTION; WHOLE-BLOOD;
   CMV PCR; INFECTION; PLASMA; DNA; URINE; ASSAY
AB Human cytomegalovirus (Human herpesvirus 5, HCMV) causes frequent asymptomatic infections in the general population. However, in immunosuppressed patients or congenitally infected infants, HCMV is related to high morbidity and mortality. In such cases, a rapid viral detection is crucial for monitoring the clinical outcome and the antiviral treatment. In this study, we optimized a sensitive biplex TaqMan (R) real-time PCR for the simultaneous detection and differentiation of a partial HCMV UL97 sequence and homologous extrinsic control (HEC) in the same tube. HEC was represented by a plasmid containing a modified HCMV sequence retaining the original primer binding sites, while the probe sequence was substituted by a phylogenetically divergent one (chloroplast CF0 subunit plant gene). It was estimated that the optimal HEC concentration, which did not influence the HCMV amplification is 1,000 copies/reaction. The optimized TaqMan (R) PCR demonstrated high analytical sensitivity (6.97 copies/ reaction, CI = 95%) and specificity (100%). Moreover, the reaction showed adequate precision (repeatability, CV = 0.03; reproducibility, CV = 0.0027) and robustness (no carry-over or cross-contamination). The diagnostic sensitivity (100%) and specificity (97.8%) were adequate for the clinical application of the molecular platform. The optimized TaqMan (R) real-time PCR is suitable for HCMV detection and quantitation in predisposed patients and monitoring of the applied antiviral therapy. (C) 2016 Wiley Periodicals, Inc.
C1 [Slavov, Svetoslav Nanev; Otaguiri, Katia Kaori; Kashima, Simone; Covas, Dimas Tadeu] Univ Sao Paulo, Blood Ctr Ribeirao Preto, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
   [Slavov, Svetoslav Nanev; Covas, Dimas Tadeu] Univ Sao Paulo, Dept Clin Med, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
   [Otaguiri, Katia Kaori; Kashima, Simone] Univ Sao Paulo, Dept Clin Toxicol & Bromatol Analyses, Fac Pharmaceut Sci, Sao Paulo, Brazil.
   [de Figueiredo, Glauciane Garcia; Yamamoto, Aparecida Yulie; Mussi-Pinhata, Marisa Marcia] Univ Sao Paulo, Dept Pediat, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
RP Slavov, SN (corresponding author), Univ Sao Paulo, Mol Biol Lab, Blood Ctr Ribeirao Preto, Fac Med Ribeirao Preto, Rua Tentente Catao Roxo 2501, BR-14051140 Sao Paulo, Brazil.
EM svetoslav.slavov@hemocentro.fmrp.usp.br
RI de Figueiredo, Glauciane Garcia/Q-6674-2019; Glauciane Figueiredo, GG
   Garcia de Figueiredo/J-9557-2013; N, Svetoslav/M-5416-2017; Covas, Dimas
   T/C-5431-2013; Mussi-Pinhata, Marisa/G-6568-2012; Kashima,
   Simone/G-4876-2012; CTC USP, CEPID 13 18/J-8951-2014
OI de Figueiredo, Glauciane Garcia/0000-0003-4136-9608; Glauciane
   Figueiredo, GG Garcia de Figueiredo/0000-0003-4136-9608; Covas, Dimas
   T/0000-0002-7364-2595; Mussi-Pinhata, Marisa/0000-0001-8985-1570;
   Kashima, Simone/0000-0002-1487-0141; CTC USP, CEPID 13
   18/0000-0002-7123-9524; Slavov, Svetoslav/0000-0003-0805-6140
CR Abu Al-Soud W, 2000, J CLIN MICROBIOL, V38, P345
   Babady NE, 2015, J CLIN MICROBIOL, V53, P1252, DOI 10.1128/JCM.03435-14
   Caliendo AM, 2000, J CLIN MICROBIOL, V38, P2122
   Garrigue I, 2008, J CLIN MICROBIOL, V46, P493, DOI 10.1128/JCM.01499-07
   Gullett JC, 2015, CLIN CHEM, V61, P72, DOI 10.1373/clinchem.2014.223289
   Halwachs-Baumann G, 2007, EXPERT REV ANTI-INFE, V5, P427, DOI 10.1586/14787210.5.3.427
   Hayden RT, 2015, J CLIN MICROBIOL, V53, P1500, DOI 10.1128/JCM.03375-14
   Hoorfar J, 2004, J CLIN MICROBIOL, V42, P1863, DOI 10.1128/JCM.42.5.1863-1868.2004
   Kearns AM, 2002, J CLIN VIROL, V24, P131, DOI 10.1016/S1386-6532(01)00240-2
   KHAN G, 1991, J CLIN PATHOL, V44, P360, DOI 10.1136/jcp.44.5.360
   Kohda C, 2014, J VIROL METHODS, V208, P160, DOI 10.1016/j.jviromet.2014.07.034
   Li W, 2015, JPN J INFECT DIS, V68, P135, DOI 10.7883/yoken.JJID.2014.017
   Lisboa LF, 2011, TRANSPLANTATION, V91, P231, DOI 10.1097/TP.0b013e3181ff8719
   Loens K, 2003, J CLIN MICROBIOL, V41, P4915, DOI 10.1128/JCM.41.11.4915-4923.2003
   Madi N, 2015, TRANSPL P, V47, P1802, DOI 10.1016/j.transproceed.2015.05.007
   Mussi-Pinhata MM, 2009, CLIN INFECT DIS, V49, P522, DOI 10.1086/600882
   Paixao P, 2012, EUR J PEDIATR, V171, P125, DOI 10.1007/s00431-011-1496-4
   Piiparinen H, 2002, J CLIN MICROBIOL, V40, P2945, DOI 10.1128/JCM.40.8.2945-2952.2002
   Pillet S, 2014, EXPERT REV ANTI-INFE, V12, P193, DOI 10.1586/14787210.2014.870887
   Revello MG, 2002, CLIN MICROBIOL REV, V15, P680, DOI 10.1128/CMR.15.4.680-715.2002
   Ross S A, 2011, Infect Disord Drug Targets, V11, P466
   Sanchez JL, 2002, J CLIN MICROBIOL, V40, P2381, DOI 10.1128/JCM.40.7.2381-2386.2002
   Schalasta G, 2000, J CLIN VIROL, V19, P175, DOI 10.1016/S1386-6532(00)00116-5
   Schrader C, 2012, J APPL MICROBIOL, V113, P1014, DOI 10.1111/j.1365-2672.2012.05384.x
   Slavov SN, 2015, BRAZ J MED BIOL RES, V48, P777, DOI 10.1590/1414-431X20154507
   Slavov SN, 2015, VIRAL IMMUNOL, V28, P123, DOI 10.1089/vim.2014.0057
   Tung YC, 2014, CLIN LAB, V60, P1895, DOI 10.7754/Clin.Lab.2014.140111
   von Muller L, 2002, J CLIN MICROBIOL, V40, P2285, DOI 10.1128/JCM.40.6.2285-2287.2002
   Waggoner J, 2012, J CLIN MICROBIOL, V50, P2378, DOI 10.1128/JCM.06800-11
   Wakabayashi H, 2012, AM J PERINAT, V29, P377, DOI 10.1055/s-0031-1300971
   Yamamoto AY, 2011, PEDIATR INFECT DIS J, V30, P1043, DOI 10.1097/INF.0b013e31822d9640
   Ziemann M, 2010, J VIROL METHODS, V170, P155, DOI 10.1016/j.jviromet.2010.09.020
NR 32
TC 2
Z9 2
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD SEP
PY 2016
VL 88
IS 9
BP 1604
EP 1612
DI 10.1002/jmv.24499
PG 9
WC Virology
SC Virology
GA DZ3BN
UT WOS:000385718800017
PM 26890091
DA 2020-11-26
ER

PT J
AU Berzoti-Coelho, MG
   Ferreira, AF
   Nunes, ND
   Pinto, MT
   Rocha, MC
   Simoes, BP
   Martinez-A, C
   Souto, EX
   Panepucci, RA
   Covas, DT
   Kashima, S
   Castro, FA
AF Berzoti-Coelho, Maria Gabriela
   Ferreira, Aline Fernanda
   Nunes, Natalia de Souza
   Pinto, Mariana Tomazini
   Rocha Junior, Maur-Cio Cristiano
   Simoes, Belinda Pinto
   Martinez-A, Carlos
   Souto, Elizabeth Xisto
   Panepucci, Rodrigo Alexandre
   Covas, Dimas Tadeu
   Kashima, Simone
   Castro, Fabiola Attie
TI The expression of Death Inducer-Obliterator (DIDO) variants in
   Myeloproliferative Neoplasms
SO BLOOD CELLS MOLECULES AND DISEASES
LA English
DT Article
DE Myeloproliferative Neoplasms; DIDO; Apoptosis; JAK2(V617F); BCR-ABL1
ID WORLD-HEALTH-ORGANIZATION; APOPTOSIS-RELATED GENES; JAK2 MUTATION;
   PRIMARY MYELOFIBROSIS; MYELOID NEOPLASMS; ALLELE BURDEN; IN-VITRO;
   DISORDERS; CELLS; LEUKEMIA
AB Chronic Myeloid Leukemia (CML), Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF) are Myeloproliferative Neoplasms (MPN) characterized by clonal myeloproliferation without cell maturation impairment. CML pathogenesis is associated with the Ph chromosome leading to BCR-ABL tyrosine-kinase constitutive expression. The Ph negative MPN (PV, ET and PMF) are characterized by the mutation JAK2(V617F) of the JAK2 protein in the auto-inhibitory JH2 domain, which is found in most PV patients and in approximately half of ET and PMF patients. Considerable effort is beingmade to understand the role of JAK2(V617F) at the MPN initiation and to clarify the pathogenesis and apoptosis resistance in CML, PV, ET and PMF patients. In the present investigation, we evaluated the Death Inducer-Obliterator (DIDO) (variants DIDO 1, 2 and 3) levels in CML, PV, ET and PMF patients. Our data reported the DIDO1, 2 and 3 differential expressions in Myeloproliferative Neoplasms. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Berzoti-Coelho, Maria Gabriela; Ferreira, Aline Fernanda; Nunes, Natalia de Souza; Pinto, Mariana Tomazini; Rocha Junior, Maur-Cio Cristiano; Kashima, Simone; Castro, Fabiola Attie] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Anal Toxicol & Food Sci, BR-09500900 Sao Paulo, Brazil.
   [Ferreira, Aline Fernanda; Pinto, Mariana Tomazini; Rocha Junior, Maur-Cio Cristiano; Simoes, Belinda Pinto; Panepucci, Rodrigo Alexandre; Covas, Dimas Tadeu; Kashima, Simone; Castro, Fabiola Attie] Ctr Cell Based Therapy, Ribeirao Preto, Brazil.
   [Simoes, Belinda Pinto; Panepucci, Rodrigo Alexandre; Covas, Dimas Tadeu] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Internal Med, BR-09500900 Sao Paulo, Brazil.
   [Martinez-A, Carlos] Univ Autonoma Madrid, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, Madrid, Spain.
   [Souto, Elizabeth Xisto] Hosp Transplantes Euryclides Jesus Zerbini, Sao Paulo, Brazil.
RP Ferreira, AF (corresponding author), Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, BR-09500900 Sao Paulo, Brazil.
EM alineferreira591@gmail.com
RI Panepucci, Rodrigo A/C-2365-2012; Pinto, Mariana/B-6129-2017; Simoes,
   Belinda P/M-7469-2016; Covas, Dimas T/C-5431-2013; CASTRO,
   FABIOLA/D-4693-2012; CTC USP, CEPID 13 18/J-8951-2014; Kashima,
   Simone/G-4876-2012
OI Panepucci, Rodrigo A/0000-0002-1119-4352; Pinto,
   Mariana/0000-0002-5176-7776; Covas, Dimas T/0000-0002-7364-2595; CTC
   USP, CEPID 13 18/0000-0002-7123-9524; Kashima,
   Simone/0000-0002-1487-0141
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2011/20135-2]; CNPqNational Council for Scientific and Technological
   Development (CNPq); CAPES (PNPD)CAPES; Center for Cell-based Therapy;
   CEPID [201308135-2]
FX We first wish to thank the patients who participated in this study. This
   work was supported by FAPESP (2011/20135-2), CNPq, and CAPES (PNPD)
   Grants, Center for Cell-based Therapy and CEPID (201308135-2).
CR Bellanne-Chantelot C, 2006, BLOOD, V108, P346, DOI 10.1182/blood-2005-12-4852
   Braig S, 2013, ONCOGENE, V32, P837, DOI 10.1038/onc.2012.115
   Ferreira AF, 2015, ACTA HAEMATOL-BASEL, V133, P354, DOI 10.1159/000369446
   Fleischman AG, 2011, BLOOD, V118, P6392, DOI 10.1182/blood-2011-04-348144
   Futterer A, 2012, CELL DEATH DIFFER, V19, P132, DOI 10.1038/cdd.2011.62
   Futterer A, 2005, J CLIN INVEST, V115, P2351, DOI 10.1172/JCI24177
   Garcia-Domingo D, 2003, MOL CELL BIOL, V23, P3216, DOI 10.1128/MCB.23.9.3216-3225.2003
   Garcia-Domingo D, 1999, P NATL ACAD SCI USA, V96, P7992, DOI 10.1073/pnas.96.14.7992
   Gatchalian J, 2013, CELL REP, V4, P148, DOI 10.1016/j.celrep.2013.06.014
   Gotoh A, 1997, Curr Opin Hematol, V4, P3
   Guglielmelli P, 2009, BLOOD, V114, P1477, DOI 10.1182/blood-2009-04-216044
   Huang R., 2015, CURR CANC DRUG TARGE
   Iqbal Zafar, 2014, Indian J Hum Genet, V20, P64, DOI 10.4103/0971-6866.132758
   James C, 2005, TRENDS MOL MED, V11, P546, DOI 10.1016/j.molmed.2005.10.003
   James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546
   Lacout C, 2006, BLOOD, V108, P1652, DOI 10.1182/blood-2006-02-002030
   Pardanani A, 2006, BLOOD, V107, P4572, DOI 10.1182/blood-2005-12-4988
   Park SJ, 2009, BIOCHEM J, V420, P73, DOI 10.1042/BJ20082131
   Pietra D, 2008, BLOOD, V111, P1686, DOI 10.1182/blood-2007-07-101576
   Rumi E, 2007, J CLIN ONCOL, V25, P5630, DOI 10.1200/JCO.2007.12.6896
   Spivak JL, 2004, SEMIN HEMATOL, V41, P1, DOI 10.1053/j.seminhematol.2004.02.011
   Staerk Judith, 2012, JAKSTAT, V1, P184, DOI 10.4161/jkst.22071
   Tefferi A, 2008, LEUKEMIA, V22, P756, DOI 10.1038/sj.leu.2405097
   Tefferi A, 2008, LEUKEMIA, V22, P14, DOI 10.1038/sj.leu.2404955
   Tognon R, 2013, EINSTEIN-SAO PAULO, V11, P540, DOI 10.1590/S1679-45082013000400025
   Tognon R, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-2
   Tognon R, 2011, J CLIN PATHOL, V64, P75, DOI 10.1136/jcp.2010.080895
   Trachana V, 2007, P NATL ACAD SCI USA, V104, P2691, DOI 10.1073/pnas.0611132104
   Vardiman JW, 2009, BLOOD, V114, P937, DOI 10.1182/blood-2009-03-209262
   Xia DY, 2014, BRAZ J MED BIOL RES, V47, P1096, DOI 10.1590/1414-431X20143734
   Ye ZH, 2009, BLOOD, V114, P5473, DOI 10.1182/blood-2009-04-217406
NR 31
TC 5
Z9 5
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1079-9796
EI 1096-0961
J9 BLOOD CELL MOL DIS
JI Blood Cells Mol. Dis.
PD JUL
PY 2016
VL 59
BP 25
EP 30
DI 10.1016/j.bcmd.2016.03.008
PG 6
WC Hematology
SC Hematology
GA DN9AI
UT WOS:000377371000004
PM 27282563
DA 2020-11-26
ER

PT J
AU Slavov, SN
   Otaguiri, KK
   Covas, DT
   Kashima, S
AF Slavov, Svetoslav Nanev
   Otaguiri, Katia Kaori
   Covas, Dimas Tadeu
   Kashima, Simone
TI Prevalence and Viral Load of Human Parvovirus B19 (B19V) Among Blood
   Donors in South-East Brazil
SO INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
LA English
DT Letter
DE Human parvovirus B19; B19V; Viral quantitation; Blood donors
ID SICKLE-CELL-DISEASE; DNA; PERSISTENCE; INFECTION; ANTIBODIES; GENOTYPES
AB The infection of human parvovirus B19 (B19V) is a common event in the general population, including volunteer blood donors. In some cases it can be asymptomatic and can remain persistent for a long period of time. The objective of this study was to examine the B19V DNA prevalence and viral load in first-time volunteer blood donors. Blood samples were collected from 91 primary blood donors at the Regional Blood Center of Ribeirao Preto, Southeast Brazil. Viral detection and quantitation was performed by an in-house TaqMan (R) real-time PCR with high sensitivity. B19V DNA was detected in one male blood donor (1.0 %) and was characterized by a very low viral load (537.36 copies/mL). Our studies demonstrate that B19V DNA at low titer may be present in apparently healthy individuals. Sensitive molecular diagnostic tools can be applied for the screening of fresh blood derived products in order to prevent transfusion-transmitted B19V infection.
C1 [Slavov, Svetoslav Nanev; Otaguiri, Katia Kaori; Covas, Dimas Tadeu; Kashima, Simone] Univ Sao Paulo, Mol Biol Lab, Fac Med Ribeirao Preto, Reg Blood Ctr Ribeirao Preto, Rua Tenente Catao Roxo 2501, BR-14051140 Sao Paulo, Brazil.
   [Slavov, Svetoslav Nanev; Covas, Dimas Tadeu] Univ Sao Paulo, Dept Clin Med, Fac Med Ribeirao Preto, Ribeirao Preto, Brazil.
   [Otaguiri, Katia Kaori; Kashima, Simone] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin Toxicol & Bromatol Anal, Ribeirao Preto, Brazil.
RP Slavov, SN (corresponding author), Univ Sao Paulo, Mol Biol Lab, Fac Med Ribeirao Preto, Reg Blood Ctr Ribeirao Preto, Rua Tenente Catao Roxo 2501, BR-14051140 Sao Paulo, Brazil.; Slavov, SN (corresponding author), Univ Sao Paulo, Dept Clin Med, Fac Med Ribeirao Preto, Ribeirao Preto, Brazil.
EM svetoslav.slavov@hemocentro.fmrp.usp.br
RI Covas, Dimas T/C-5431-2013; N, Svetoslav/M-5416-2017; Kashima,
   Simone/G-4876-2012; CTC USP, CEPID 13 18/J-8951-2014
OI Covas, Dimas T/0000-0002-7364-2595; Kashima, Simone/0000-0002-1487-0141;
   Slavov, Svetoslav/0000-0003-0805-6140; CTC USP, CEPID 13
   18/0000-0002-7123-9524
CR Corcioli F, 2008, J MED VIROL, V80, P2005, DOI 10.1002/jmv.21289
   Corcoran A, 2004, J MED MICROBIOL, V53, P459, DOI 10.1099/jmm.0.05485-0
   [Food and Drug Administration Center for Biologics Evaluation and Research US Department of Health and Human Services], 2009, NUCL AC TEST NAT RED
   Heegaard ED, 2002, CLIN MICROBIOL REV, V15, P485, DOI 10.1128/CMR.15.3.485-505.2002
   Juhl D, 2014, VOX SANG, V107, P226, DOI 10.1111/vox.12162
   Juhl D, 2014, TRANSFUS MED HEMOTH, V41, P52, DOI 10.1159/000357650
   Ke L, 2011, TRANSFUSION, V51, P1909, DOI 10.1111/j.1537-2995.2011.03067.x
   Kleinman SH, 2007, TRANSFUSION, V47, P1756, DOI 10.1111/j.1537-2995.2007.01341.x
   Kooistra K, 2011, VOX SANG, V100, P261, DOI 10.1111/j.1423-0410.2010.01423.x
   Lee TH, 2011, TRANSFUSION, V51, P1896, DOI 10.1111/j.1537-2995.2010.03035.x
   Lefrere JJ, 2005, BLOOD, V106, P2890, DOI 10.1182/blood-2005-03-1053
   Matsukura H, 2008, TRANSFUSION, V48, P1036, DOI 10.1111/j.1537-2995.2008.01704.x
   Slavov SN, 2012, J MED VIROL, V84, P1652, DOI 10.1002/jmv.23358
   Thomas I, 2003, VOX SANG, V84, P300, DOI 10.1046/j.1423-0410.2003.00299.x
   Tsitsikas DA, 2014, BLOOD REV, V28, P23, DOI 10.1016/j.blre.2013.12.002
NR 15
TC 10
Z9 12
U1 0
U2 3
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001,
   INDIA
SN 0971-4502
EI 0974-0449
J9 INDIAN J HEMATOL BLO
JI Indian J. Hematol. Blood Transfus.
PD JUN
PY 2016
VL 32
SU 1
BP S323
EP S325
DI 10.1007/s12288-015-0607-1
PG 3
WC Hematology
SC Hematology
GA DQ1XG
UT WOS:000378993400085
PM 27408426
OA Green Published
DA 2020-11-26
ER

PT J
AU Pinto, MT
   Covas, DT
   Kashima, S
   Rodrigues, CO
AF Pinto, Mariana T.
   Covas, Dimas T.
   Kashima, Simone
   Rodrigues, Claudia O.
TI Endothelial Mesenchymal Transition: Comparative Analysis of Different
   Induction Methods
SO BIOLOGICAL PROCEDURES ONLINE
LA English
DT Article
DE Endothelial-mesenchymal transition; TGF-beta; Hypoxia
ID INDUCED PULMONARY-FIBROSIS; CARDIAC FIBROSIS; IN-VITRO; VASCULAR
   ENDOTHELIUM; CELLS UNDERGO; SNAIL; FIBROBLASTS; PROMOTES;
   TRANSDIFFERENTIATION; ACTIVATION
AB Background: Endothelial-Mesenchymal-Transition (EndMT) plays an essential role in cardiovascular development, and recently became an attractive therapeutic target based on evidence supporting its involvement in fibrosis and cancer. Important questions that remain to be answered are related to the molecular mechanisms that control EndMT in different organs and distinct pathological conditions. The lack of a detailed protocol for induction of EndMT and the assumption that TGF-beta isoforms play similar roles on different types of endothelial cells, limit progress in the field. The aim of this study was to compare the induction of EndMT by TGF-beta isoforms in endothelial cells of different sources, and define a detailed protocol for EndMT assessment in vitro.
   Results: We compared the dose-dependent effect of TGF-beta isoforms, under normoxia and hypoxia, on the induction of EndMT in human coronary and pulmonary artery endothelial cells. Our results suggest that endothelial cells undergo spontaneous EndMT with time in culture under the conditions tested. The extent of EndMT induction by TGF-beta was dependent on the dose and endothelial cell type. Furthermore, the potential of TGF-beta to induce EndMT was reduced under hypoxia relative to normoxia.
   Conclusions: Our work suggests that the response of endothelial cells to TGF-beta is intrinsic to the dose, cell type and environment. Optimization of induction conditions may be essential, as pathways triggering EndMT may vary during development and pathological conditions. Therefore, caution is needed regarding indiscriminate use of TGF-beta to induce EndMT for mechanistic studies.
C1 [Pinto, Mariana T.; Rodrigues, Claudia O.] Univ Miami, Leonard M Miller Sch Med, Interdisciplinary Stem Cell Inst, Biomed Res Bldg,1501 NW 10th Ave,Room 826, Miami, FL 33136 USA.
   [Pinto, Mariana T.; Covas, Dimas T.; Kashima, Simone] Inst Nacl Ciencia & Tecnol Celulas Tronco & Terap, Ribeirao Preto, SP, Brazil.
   [Pinto, Mariana T.; Covas, Dimas T.; Kashima, Simone] Fundacao Hemoctr Ribeirao Preto, Ribeirao Preto, SP, Brazil.
   [Pinto, Mariana T.; Kashima, Simone] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
   [Covas, Dimas T.] Univ Sao Paulo, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
   [Rodrigues, Claudia O.] Univ Miami, Leonard M Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA.
RP Rodrigues, CO (corresponding author), Univ Miami, Leonard M Miller Sch Med, Interdisciplinary Stem Cell Inst, Biomed Res Bldg,1501 NW 10th Ave,Room 826, Miami, FL 33136 USA.; Rodrigues, CO (corresponding author), Univ Miami, Leonard M Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA.
EM CRodrigues@med.miami.edu
RI Covas, Dimas T/C-5431-2013; Pinto, Mariana/B-6129-2017; CTC USP, CEPID
   13 18/J-8951-2014; Kashima, Simone/G-4876-2012
OI Covas, Dimas T/0000-0002-7364-2595; Pinto, Mariana/0000-0002-5176-7776;
   CTC USP, CEPID 13 18/0000-0002-7123-9524; Kashima,
   Simone/0000-0002-1487-0141
FU Interdisciplinary Stem Cell Institute, University of Miami Miller School
   of Medicine, Miami, FL; Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2011/21740-7]
FX This work was supported by discretionary funds from the
   Interdisciplinary Stem Cell Institute, University of Miami Miller School
   of Medicine, Miami, FL, to Claudia O. Rodrigues. M.T.P. was a fellow of
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP),
   fellowship number 2011/21740-7. We would like to thank Dr. Keith Webster
   for critical reading of this manuscript.
CR ARCINIEGAS E, 1992, J CELL SCI, V103, P521
   Arciniegas E, 2007, AM J PHYSIOL-LUNG C, V293, pL1, DOI 10.1152/ajplung.00378.2006
   BERANEK JT, 1995, LAB INVEST, V72, P771
   Bijkerk Roel, 2012, Microrna, V1, P2
   Chi JT, 2003, P NATL ACAD SCI USA, V100, P10623, DOI 10.1073/pnas.1434429100
   Choi SH, 2015, CLIN CANCER RES, V21, P3716, DOI 10.1158/1078-0432.CCR-14-3193
   Copple BL, 2009, LIVER INT, V29, P1010, DOI 10.1111/j.1478-3231.2009.02015.x
   Diez M, 2010, CARDIOVASC RES, V88, P502, DOI 10.1093/cvr/cvq236
   Florea V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073146
   Frid MG, 2002, CIRC RES, V90, P1189, DOI 10.1161/01.RES.0000021432.70309.28
   Ghosh AK, 2012, CELL SIGNAL, V24, P1031, DOI 10.1016/j.cellsig.2011.12.024
   Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189
   Goumans MJ, 2008, TRENDS CARDIOVAS MED, V18, P293, DOI 10.1016/j.tcm.2009.01.001
   Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743
   Hashimoto N, 2010, AM J RESP CELL MOL, V43, P161, DOI 10.1165/rcmb.2009-0031OC
   He JH, 2013, CLIN EXP NEPHROL, V17, P488, DOI 10.1007/s10157-013-0781-0
   Higgins DF, 2007, J CLIN INVEST, V117, P3810, DOI 10.1172/JCI30487
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kokudo T, 2008, J CELL SCI, V121, P3317, DOI 10.1242/jcs.028282
   Kumarswamy R, 2012, ARTERIOSCL THROM VAS, V32, P361, DOI 10.1161/ATVBAHA.111.234286
   Lee SW, 2013, MOL THER, V21, P1767, DOI 10.1038/mt.2013.146
   Lin F, 2012, IUBMB LIFE, V64, P717, DOI 10.1002/iub.1059
   Mahler GJ, 2013, ARTERIOSCL THROM VAS, V33, P121, DOI 10.1161/ATVBAHA.112.300504
   MARKWALD RR, 1977, AM J ANAT, V148, P85, DOI 10.1002/aja.1001480108
   Medici D, 2011, BIOCHEM J, V437, P515, DOI 10.1042/BJ20101500
   Mihira H, 2012, J BIOCHEM, V151, P145, DOI 10.1093/jb/mvr121
   Paranya G, 2001, AM J PATHOL, V159, P1335, DOI 10.1016/S0002-9440(10)62520-5
   Pardali E, 2010, TRENDS CELL BIOL, V20, P556, DOI 10.1016/j.tcb.2010.06.006
   Paruchuri S, 2006, CIRC RES, V99, P861, DOI 10.1161/01.RES.0000245188.41002.2c
   Piera-Velazquez S, 2012, FIBROGENESIS TISSUE, V5, DOI 10.1186/1755-1536-5-S1-S7
   Piera-Velazquez S, 2011, AM J PATHOL, V179, P1074, DOI 10.1016/j.ajpath.2011.06.001
   Potenta S, 2008, BRIT J CANCER, V99, P1375, DOI 10.1038/sj.bjc.6604662
   Shaikh D, 2012, CELL SIGNAL, V24, P2396, DOI 10.1016/j.cellsig.2012.08.007
   Xu XB, 2015, J BIOL CHEM, V290, P16653, DOI 10.1074/jbc.M115.636944
   Zeisberg EM, 2007, CANCER RES, V67, P10123, DOI 10.1158/0008-5472.CAN-07-3127
   Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613
   Zeisberg EM, 2008, J AM SOC NEPHROL, V19, P2282, DOI 10.1681/ASN.2008050513
NR 37
TC 18
Z9 20
U1 1
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1480-9222
J9 BIOL PROCED ONLINE
JI Biol. Proced. Online
PD APR 27
PY 2016
VL 18
AR 10
DI 10.1186/s12575-016-0040-3
PG 8
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA DK7IC
UT WOS:000375097400001
PM 27127420
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Palma, CD
   Grassi, ML
   Thome, CH
   Ferreira, GA
   Albuquerque, D
   Pinto, MT
   Melo, FUF
   Kashima, S
   Covas, DT
   Pitteri, SJ
   Faca, VM
AF Palma, Camila de Souza
   Grassi, Mariana Lopes
   Thome, Carolina Hassibe
   Ferreira, Germano Aguiar
   Albuquerque, Daniele
   Pinto, Mariana Tomazini
   Ferreira Melo, Fernanda Ursoli
   Kashima, Simone
   Covas, Dimas Tadeu
   Pitteri, Sharon J.
   Faca, Vitor M.
TI Proteomic Analysis of Epithelial to Mesenchymal Transition (EMT) Reveals
   Cross-talk between SNAIL and HDAC1 Proteins in Breast Cancer Cells
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Article
ID TRANSCRIPTIONAL REPRESSOR SNAIL; STATISTICAL-MODEL; MESSENGER-RNA;
   PROGRESSION; EXPRESSION; RECRUITMENT; METASTASIS; INDUCTION; MIGRATION;
   NETWORKS
AB Epithelial to mesenchymal transition (EMT)(1) occurs naturally during embryogenesis, tissue repair, cancer progression, and metastasis. EMT induces cellular and microenvironmental changes resulting in loss of epithelial and acquisition of mesenchymal phenotypes, which promotes cellular invasive and migratory capabilities. EMT can be triggered by extracellular factors, including TGF-, HGF, and EGF. Overexpression of transcription factors, such as SNAIL, SLUG, ZEB1/2, and TWIST1, also induces EMT and is correlated to cancer aggressiveness. Here, the breast adenocarcinoma cell line MCF7 was transduced with SNAIL to identify specific mechanisms controlled by this transcription factor during EMT. Overexpression of SNAIL led to EMT, which was thoroughly validated by molecular, morphological, and functional experiments. Subcellular proteome enrichment followed by GEL-LC-MS/MS was performed to provide extensive protein fractionation and in-depth proteomic analysis. Quantitative analysis relied on a SILAC strategy, using the invasive breast cancer cell line MDA-MB-231 as a reference for quantitation. Subsets of proteins enriched in each subcellular compartment led to a complementary list of 4289 proteins identified with high confidence. A subset of differentially expressed proteins was validated by Western blot, including regulation in specific cellular compartments, potentially caused by protein translocation. Protein network analysis highlighted complexes involved in cell cycle control and epigenetic regulation. Flow cytometry analysis indicated that SNAIL overexpression led to cell cycle arrest in G(0)/G(1) phases. Furthermore, down-regulation of HDAC1 was observed, supporting the involvement of epigenetic processes in SNAIL-induced EMT. When HDAC1 activity was inhibited, MCF7 not only apparently initiated EMT but also up-regulated SNAIL, indicating the cross-talk between these two proteins. Both HDAC1 inhibition and SNAIL overexpression activated the AKT pathway. These molecular mechanisms appear to be essential to EMT and therefore for cancer metastasis. Specific control of such epigenetic processes might then represent effective approaches for clinical management of metastatic cancer.
C1 [Palma, Camila de Souza; Grassi, Mariana Lopes; Thome, Carolina Hassibe; Albuquerque, Daniele; Faca, Vitor M.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Biochem & Immunol, Av Bandeirantes,3900 Monte Alegre, BR-14049900 Ribeirao Preto, SP, Brazil.
   [Palma, Camila de Souza; Grassi, Mariana Lopes; Thome, Carolina Hassibe; Ferreira, Germano Aguiar; Pinto, Mariana Tomazini; Ferreira Melo, Fernanda Ursoli; Kashima, Simone; Covas, Dimas Tadeu; Faca, Vitor M.] Univ Sao Paulo, Ribeirao Preto Med Sch, Ribeirao Preto Blood Ctr, Cell Based Therapy Ctr, BR-14049900 Ribeirao Preto, SP, Brazil.
   [Pitteri, Sharon J.] Stanford Univ, Sch Med, Canary Ctr Stanford Canc Early Detect, Dept Radiol, Stanford, CA 94305 USA.
RP Faca, VM (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Biochem & Immunol, Av Bandeirantes,3900 Monte Alegre, BR-14049900 Ribeirao Preto, SP, Brazil.
EM vitor.faca@fmrp.usp.br
RI Faca, Vitor/A-3989-2013; Ferreira, Germano/M-4789-2014; Palma,
   Camila/A-8206-2017; Covas, Dimas T/C-5431-2013; Pinto,
   Mariana/B-6129-2017; Kashima, Simone/G-4876-2012; CTC USP, CEPID 13
   18/J-8951-2014
OI Ferreira, Germano/0000-0002-3149-3077; Palma,
   Camila/0000-0002-4868-8540; Covas, Dimas T/0000-0002-7364-2595; Pinto,
   Mariana/0000-0002-5176-7776; Ursoli, Fernanda/0000-0002-8499-000X;
   Kashima, Simone/0000-0002-1487-0141; FACA, VITOR
   MARCEL/0000-0003-3205-7944; Pitteri, Sharon/0000-0002-3119-873X; CTC
   USP, CEPID 13 18/0000-0002-7123-9524
FU FAPESP Young Scientist Grant [2011/09740-1]; CNPqNational Council for
   Scientific and Technological Development (CNPq); Center for Cell-based
   Therapy-CTC-CEPID; FAPESP GrantFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [2013/08135-2]; CISBi-NAP
FX This work was supported in part by FAPESP Young Scientist Grant
   2011/09740-1, CNPq, Center for Cell-based Therapy-CTC-CEPID, FAPESP
   Grant 2013/08135-2, and CISBi-NAP.
CR Adam RM, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-30
   Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI [10.1089/ars.2008.2270, 10.1089/ARS.2008.2270]
   Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907
   Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416
   Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6
   Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265
   CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Chen JZ, 2014, CANCER RES, V74, P4353, DOI 10.1158/0008-5472.CAN-14-0181
   Dhasarathy A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026514
   Dreger M, 2003, EUR J BIOCHEM, V270, P589, DOI 10.1046/j.1432-1033.2003.03426.x
   Faca V, 2006, J PROTEOME RES, V5, P2009, DOI 10.1021/pr060102+
   Faca VM, 2008, PLOS MED, V5, P953, DOI 10.1371/journal.pmed.0050123
   Franci C, 2006, ONCOGENE, V25, P5134, DOI 10.1038/sj.onc.1209519
   Geiger T, 2010, NAT METHODS, V7, P383, DOI 10.1038/nmeth.1446
   Gong C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6406
   Guo H, 2011, J BIOL CHEM, V286, P208, DOI 10.1074/jbc.M110.149013
   Guo SC, 2005, CANCER RES, V65, P3011, DOI 10.1158/0008-5472.CAN-04-3624
   Gupta P, 2014, MOL ONCOL, V8, P1532, DOI 10.1016/j.molonc.2014.06.006
   Javaid S, 2013, CELL REP, V5, P1679, DOI 10.1016/j.celrep.2013.11.034
   Jiang GM, 2013, BBA-MOL CELL RES, V1833, P663, DOI 10.1016/j.bbamcr.2012.12.002
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h
   Kiesslich T, 2013, MOL CLIN ONCOL, V1, P3, DOI 10.3892/mco.2012.28
   Kurozumi A, 2016, CANCER SCI, V107, P84, DOI 10.1111/cas.12842
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lakshmaiah KC, 2014, J CANCER RES THER, V10, P469, DOI 10.4103/0973-1482.137937
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lindsey S, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00358
   MacLean B, 2006, BIOINFORMATICS, V22, P2830, DOI 10.1093/bioinformatics/btl379
   Masuda S, 2005, GENE DEV, V19, P1512, DOI 10.1101/gad.1302205
   Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009
   Naber HPH, 2013, BIOCHEM BIOPH RES CO, V435, P58, DOI 10.1016/j.bbrc.2013.04.037
   Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Rauch A, 2006, J PROTEOME RES, V5, P112, DOI 10.1021/pr0503533
   Salton M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023882
   SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409
   Sugimachi K, 2003, CLIN CANCER RES, V9, P2657
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Thome CH, 2012, MOL CELL PROTEOMICS, V11, P1898, DOI 10.1074/mcp.M112.019661
   Uhlen M, 2005, MOL CELL PROTEOMICS, V4, P1920, DOI 10.1074/mcp.M500279-MCP200
   Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104
   Verghese ET, 2013, J PATHOL, V231, P388, DOI 10.1002/path.4248
   Vetter G, 2009, BIOCHEM BIOPH RES CO, V385, P485, DOI 10.1016/j.bbrc.2009.05.025
   Vizcaino JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839
   Wang SC, 2005, ANN NY ACAD SCI, V1059, P11, DOI 10.1196/annals.1339.002
   Wang ZW, 2010, CURR STEM CELL RES T, V5, P74, DOI 10.2174/157488810790442813
   Wu CY, 2012, TRENDS GENET, V28, P454, DOI 10.1016/j.tig.2012.05.005
   Zhang L, 2015, MOL MED REP, V12, P7869, DOI 10.3892/mmr.2015.4443
   Zheng H, 2014, ONCOGENE, V33, P1755, DOI 10.1038/onc.2013.128
   Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173
NR 57
TC 22
Z9 24
U1 0
U2 14
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 1535-9476
EI 1535-9484
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD MAR
PY 2016
VL 15
IS 3
SI SI
BP 906
EP 917
DI 10.1074/mcp.M115.052910
PG 12
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA DG2KB
UT WOS:000371894700013
PM 26764010
OA Bronze, Green Published
DA 2020-11-26
ER

PT J
AU Pinto, MT
   Slavov, SN
   Valente, VB
   Ubiali, EMA
   Covas, DT
   Kashima, S
AF Pinto, Mariana Tomazini
   Slavov, Svetoslav Nanev
   Valente, Vanderleia Barbaro
   Amorim Ubiali, Eugenia Maria
   Covas, Dimas Tadeu
   Kashima, Simone
TI Evaluation of human T-lymphotropic virus prevalence/co-infection rates
   for a four-year period in a non-metropolitan blood center in Southeast
   Brazil
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA English
DT Article
DE HTLV-1/2 seroprevalence; HTLV-1/2 co-infection; Brazil
ID HTLV-I; DONORS
AB Introduction: Human T-lymphotropic virus types 1/2 (HTLV-1/2) are distributed worldwide and are endemic in specific regions. Methods: Serological evaluation of the HTLV-1/2 prevalence and co-infection rate [human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), Chagas disease, and syphilis)] for 2011-2014 was performed with volunteer blood donors from the western part of Sao Paulo State. Results: Serrana and Aracatuba had higher HTLV seroprevalence rates (0.1%); while Franca, Olimpia, and Bebedouro had lower seroprevalences (0.04%). Co-infection (HBV and syphilis) was present in 12.3% of HTLV-infected blood donors. Conclusions: Our findings provide data for the prevalence of HTLV in Brazil and demonstrate the importance of regional and global hemovigilance.
C1 [Pinto, Mariana Tomazini; Slavov, Svetoslav Nanev; Valente, Vanderleia Barbaro; Amorim Ubiali, Eugenia Maria; Covas, Dimas Tadeu; Kashima, Simone] Univ Sao Paulo, Fac Med Ribeirao Preto, Fundacao Hemoctr Ribeirao Preto, Sao Paulo, Brazil.
   [Pinto, Mariana Tomazini; Kashima, Simone] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Biociencias Aplicadas Farm, Sao Paulo, Brazil.
   [Covas, Dimas Tadeu] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Sao Paulo, Brazil.
RP Kashima, S (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Fundacao Hemoctr Ribeirao Preto, Sao Paulo, Brazil.; Kashima, S (corresponding author), Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Biociencias Aplicadas Farm, Sao Paulo, Brazil.
EM skashima@hemocentro.fmrp.usp.br
RI Covas, Dimas T/C-5431-2013; Pinto, Mariana/B-6129-2017; N,
   Svetoslav/M-5416-2017; Kashima, Simone/G-4876-2012; CTC USP, CEPID 13
   18/J-8951-2014
OI Covas, Dimas T/0000-0002-7364-2595; Pinto, Mariana/0000-0002-5176-7776;
   Kashima, Simone/0000-0002-1487-0141; Slavov,
   Svetoslav/0000-0003-0805-6140; CTC USP, CEPID 13 18/0000-0002-7123-9524
FU Fundacao Hemocentro de Ribeirao Preto (FUNDHERP); Centro Regional de
   Hemoterapia de Ribeirao Preto (CRH); Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP); Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES)CAPES; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq)
FX This work was supported by Fundacao Hemocentro de Ribeirao Preto
   (FUNDHERP), Centro Regional de Hemoterapia de Ribeirao Preto (CRH),
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP),
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), and
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq).
CR Bandeira LM, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003691
   Catalan-Soares BC, 2001, REV BRAS EPIDEMIOL, V4, P81
   Chenari M, 2014, J MED VIROL, V86, P1861, DOI 10.1002/jmv.24046
   Gadelha SR, 2014, RETROVIROLOGY S1, V11, pP49
   GalvaoCastro B, 1997, TRANSFUSION, V37, P242, DOI 10.1046/j.1537-2995.1997.37297203532.x
   Gessain A, 2011, Bull Soc Pathol Exot, V104, P167, DOI 10.1007/s13149-011-0174-4
   GESSAIN A, 1985, LANCET, V2, P407
   Goncalves DU, 2010, CLIN MICROBIOL REV, V23, P577, DOI 10.1128/CMR.00063-09
   Inaba S, 1999, TRANSFUSION, V39, P1104, DOI 10.1046/j.1537-2995.1999.39101104.x
   Laperche S, 2009, VOX SANG, V96, P104, DOI 10.1111/j.1423-0410.2008.01136.x
   Paiva A, 2015, REV INST MED TROP SP, V57, P1, DOI 10.1590/S0036-46652015000100001
   Pinto MT, 2012, REV INST MED TROP SP, V54, P123, DOI 10.1590/S0036-46652012000300002
   Ribeiro D, 2012, SEX TRANSM INFECT, V88, P32, DOI 10.1136/sextrans-2011-050066
   Verdonck K, 2007, LANCET INFECT DIS, V7, P266, DOI 10.1016/S1473-3099(07)70081-6
NR 14
TC 5
Z9 5
U1 0
U2 4
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PD MAR-APR
PY 2016
VL 49
IS 2
BP 232
EP 236
DI 10.1590/0037-8682-0282-2015
PG 5
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA DM9AU
UT WOS:000376656800014
PM 27192594
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Slavov, SN
   Otaguiri, KK
   Kashima, S
   Covas, DT
AF Slavov, S. N.
   Otaguiri, K. K.
   Kashima, S.
   Covas, D. T.
TI Overview of Zika virus (ZIKV) infection in regards to the Brazilian
   epidemic
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE Zika virus; ZIKV; Transmission; Epidemiology; Congenital infection;
   Brazil
ID GUILLAIN-BARRE-SYNDROME; TRANSMISSION; INFLUENZA; MOSQUITOS; HUMANS;
   BRAIN
AB Zika virus (ZIKV), a mosquito-borne flavivirus, belongs to the Flaviviridae family, genus Flavivirus. ZIKV was initially isolated in 1947 from a sentinel monkey in the Zika forest, Uganda. Little clinical importance was attributed to ZIKV, once only few symptomatic cases were reported in some African and Southeast Asiatic countries. This situation changed in 2007, when a large outbreak was registered on the Yap Island, Micronesia, caused by the Asian ZIKV lineage. Between 2013 and 2014, ZIKV spread explosively and caused many outbreaks in different islands of the Southern Pacific Ocean and in 2015 autochthonous transmission was reported in Brazil. Currently, Brazil is the country with the highest number of ZIKV-positive cases in Latin America. Moreover, for the first time after the discovery of ZIKV, the Brazilian scientists are studying the possibility for the virus to cause severe congenital infection related to microcephaly and serious birth defects due to the time-spatial coincidence of the alarming increase of newborns with microcephaly and the Brazilian ZIKV epidemic. The present review summarizes recent information for ZIKV epidemiology, clinical picture, transmission, diagnosis and the consequences of this emerging virus in Brazil.
C1 [Slavov, S. N.; Otaguiri, K. K.; Kashima, S.; Covas, D. T.] Univ Sao Paulo, Fac Med Ribeirao Preto, Hemoctr Ribeirao Preto, Ribeirao Preto, SP, Brazil.
   [Slavov, S. N.; Covas, D. T.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Ribeirao Preto, SP, Brazil.
   [Otaguiri, K. K.; Kashima, S.] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin Toxicol & Bromatol, Ribeirao Preto, SP, Brazil.
RP Slavov, SN (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Hemoctr Ribeirao Preto, Ribeirao Preto, SP, Brazil.; Slavov, SN (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Ribeirao Preto, SP, Brazil.
EM svetoslav.slavov@hemocentro.fmrp.usp.br
RI N, Svetoslav/M-5416-2017; Covas, Dimas T/C-5431-2013; CTC USP, CEPID 13
   18/J-8951-2014; Kashima, Simone/G-4876-2012
OI Covas, Dimas T/0000-0002-7364-2595; CTC USP, CEPID 13
   18/0000-0002-7123-9524; Slavov, Svetoslav/0000-0003-0805-6140; Kashima,
   Simone/0000-0002-1487-0141
FU Fundacao de Amparo e Pesquisa do Estado de Sao Paulo-FAPESP, Brazil
   [2009/16623-1]; CTC [1998/14. 247-6]; INCTC [2008/57.877-3]; Conselho
   Nacional do Desenvolvimento Cientifico e Tecnologico, Brazil (INCTC)
   [573.754/2008-0]
FX We are grateful to Sandra Navarro Bresciani for the artwork. We are also
   grateful to the funding agencies Fundacao de Amparo e Pesquisa do Estado
   de Sao Paulo-FAPESP, Brazil (#2009/16623-1, CTC-#1998/14. 247-6 and
   INCTC-#2008/57.877-3), and the Conselho Nacional do Desenvolvimento
   Cientifico e Tecnologico, Brazil (INCTC-#573.754/2008-0).
CR Ali M, 2005, AM J NEURORADIOL, V26, P289
   Ang CW, 2004, TRENDS IMMUNOL, V25, P61, DOI 10.1016/j.it.2003.12.004
   [Anonymous], 2016, Wkly Epidemiol Rec, V91, P73
   Besnard M., 2014, EURO SURVEILL, V19
   Brasil P, 2016, N ENGL J MED
   Calvet G, 2016, LANCET INFECT DIS
   Campos RD, 2016, J CLIN VIROL, V77, P69, DOI 10.1016/j.jcv.2016.02.009
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   CaoLormeau VM, 2016, GUILLAIN BARRE SYNDR, DOI [10.1016/S01406736(16)005626, DOI 10.1016/S0140-6736(16)00562-6]
   Chan JF, 2016, J INFECT
   Chippaux A, 1981, Med Trop (Mars), V41, P53
   Cook S, 2006, ARCH VIROL, V151, P309, DOI 10.1007/s00705-005-0626-6
   Costa F, 2016, IDEAS OPINIONS EMERG
   Coulombier D, 2015, RAPID RISK ASSESMENT
   de Paula Freitas B, 2016, JAMA OPHTHALMOL, P1
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   European Centre for Disease Prevention and Control, 2016, COMM DIS THREAT REP
   Faye O, 2008, J CLIN VIROL, V43, P96, DOI 10.1016/j.jcv.2008.05.005
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   Faye O, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-311
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   GESER A, 1970, Bulletin of the World Health Organization, V43, P539
   Gourinat AC, 2015, EMERG INFECT DIS, V21, P84, DOI 10.3201/eid2101.140894
   Grard G, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002681
   Grimaldi-Bensouda L, 2011, AM J EPIDEMIOL, V174, P326, DOI 10.1093/aje/kwr072
   HADDOW AJ, 1964, B WORLD HEALTH ORGAN, V31, P57
   Haddow AD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001477
   JAN C, 1978, B SOC PATHOL EXOT, V71, P140
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Larik A, 2012, BMJ CASE REP, V2012
   Lehmann HC, 2010, LANCET INFECT DIS, V10, P643, DOI 10.1016/S1473-3099(10)70140-7
   MACNAMARA FN, 1954, T ROY SOC TROP MED H, V48, P139, DOI 10.1016/0035-9203(54)90006-1
   MARCHETTE NJ, 1969, AM J TROP MED HYG, V18, P411, DOI 10.4269/ajtmh.1969.18.411
   Marcondes CB, 2016, REV SOC BRAS MED TRO, V49, P4, DOI 10.1590/0037-8682-0220-2015
   Marrs C, 2016, AM J PERINATOL
   Martin DA, 2000, J CLIN MICROBIOL, V38, P1823, DOI 10.1128/JCM.38.5.1823-1826.2000
   Martines RB, 2016, MMWR-MORBID MORTAL W, V65, P159, DOI 10.15585/mmwr.mm6506e1
   McGrogan A, 2009, NEUROEPIDEMIOLOGY, V32, P150, DOI 10.1159/000184748
   Mecharles S, 2016, LANCET
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   MONLUN E, 1993, B SOC PATHOL EXOT, V86, P21
   Musso D, 2014, CLIN MICROBIOL INFEC, V20, pO595, DOI 10.1111/1469-0691.12707
   Musso D, 2015, EMERG INFECT DIS, V21, P1887, DOI 10.3201/eid2110.151125
   Musso D, 2015, J CLIN VIROL, V68, P53, DOI 10.1016/j.jcv.2015.04.021
   Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363
   Oehler E, 2014, EUROSURVEILLANCE, V19, DOI [0.2807/1560-7917.es2014.19.9.20720, DOI 10.2807/1560-7917.ES2014.19.9.20720, 10.2807/1560-7917.ES2014.19.9.20720]
   OLSON JG, 1983, ANN TROP MED PARASIT, V77, P131, DOI 10.1080/00034983.1983.11811687
   OLSON JG, 1981, T ROY SOC TROP MED H, V75, P389, DOI 10.1016/0035-9203(81)90100-0
   Pyke Alyssa T, 2014, PLoS Curr, V6, DOI 10.1371/currents.outbreaks.4635a54dbffba2156fb2fd76dc49f65e
   Robin Y., 1975, Bulletin Soc Path Exot, V68, P249
   SALUZZO JF, 1981, B SOC PATHOL EXOT, V74, P490
   SALUZZO JF, 1982, B SOC PATHOL EXOT, V75, P262
   Sarno M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004517
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Shinohara K, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/tav011
   Tam CC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000344
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   Tappe D, 2014, EURO SURVEILL, V19
   Ventura CV, 2016, LANCET, V387, P228, DOI 10.1016/S0140-6736(16)00006-4
   Verma R, 2012, BMJ CASE REP, V2012, pxx
   Wolfe ND, 2001, AM J TROP MED HYG, V64, P310, DOI 10.4269/ajtmh.2001.64.310
   Wong PSJ, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002348
   Yuki N, 2012, NEW ENGL J MED, V366, P2294, DOI 10.1056/NEJMra1114525
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 66
TC 36
Z9 36
U1 0
U2 27
PU ASSOC BRAS DIVULG CIENTIFICA
PI RIBEIRAO PRETO
PA FACULDADE MEDICINA, CASA 10, 14049 RIBEIRAO PRETO, RIBEIRAO PRETO, SP
   14049, BRAZIL
SN 0100-879X
EI 1678-4510
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PY 2016
VL 49
IS 5
AR e5420
DI 10.1590/1414-431X20165420
PG 11
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA DM9KF
UT WOS:000376684000010
PM 27143174
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Ferreira, AF
   Moura, LG
   Tojal, I
   Ambrosio, L
   Pinto-Simoes, B
   Hamerschlak, N
   Calin, GA
   Ivan, C
   Covas, DT
   Kashima, S
   Castro, FA
AF Ferreira, A. F.
   Moura, L. G.
   Tojal, I.
   Ambrosio, L.
   Pinto-Simoes, B.
   Hamerschlak, N.
   Calin, G. A.
   Ivan, C.
   Covas, D. T.
   Kashima, S.
   Castro, F. A.
TI ApoptomiRs expression modulated by BCR-ABL is linked to CML progression
   and imatinib resistance (vol 53, pg 47, 2014)
SO BLOOD CELLS MOLECULES AND DISEASES
LA English
DT Correction
C1 [Ferreira, A. F.; Moura, L. G.; Ambrosio, L.; Castro, F. A.] Univ Sao Paulo, Fac Ciencias Farmacaut Ribeirao Preto, Dept Anal Clin Toxicol & Bromatol, BR-05508 Sao Paulo, Brazil.
   [Tojal, I.; Covas, D. T.; Kashima, S.] Ctr Reg Hemoterapia Ribeirao Preto, Ribeirao Preto, Brazil.
   [Pinto-Simoes, B.; Covas, D. T.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, BR-05508 Sao Paulo, Brazil.
   [Hamerschlak, N.] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Calin, G. A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.
   [Ivan, C.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNAs, Houston, TX 77030 USA.
RP Ferreira, AF (corresponding author), Univ Sao Paulo, Fac Ciencias Farmacaut Ribeirao Preto, Dept Anal Clin Toxicol & Bromatol, BR-05508 Sao Paulo, Brazil.
EM alineferreira591@gmail.com
RI Covas, Dimas T/C-5431-2013; Kashima, Simone/G-4876-2012; CTC USP, CEPID
   13 18/J-8951-2014
OI Covas, Dimas T/0000-0002-7364-2595; Kashima, Simone/0000-0002-1487-0141;
   CTC USP, CEPID 13 18/0000-0002-7123-9524; Calin,
   George/0000-0002-7427-0578; Ivan, Cristina/0000-0002-4848-0168
CR Ferreira AF, 2014, BLOOD CELL MOL DIS, V53, P47, DOI 10.1016/j.bcmd.2014.02.008
NR 1
TC 0
Z9 0
U1 0
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1079-9796
EI 1096-0961
J9 BLOOD CELL MOL DIS
JI Blood Cells Mol. Dis.
PD DEC
PY 2015
VL 55
IS 4
BP 420
EP 420
DI 10.1016/j.bcmd.2015.08.005
PG 1
WC Hematology
SC Hematology
GA CU2MR
UT WOS:000363358100024
OA Bronze
DA 2020-11-26
ER

PT J
AU Meirelles, LD
   Malta, TM
   Wagatsuma, VMD
   Palma, PVB
   Araujo, AG
   Malmegrim, KCR
   de Oliveira, FM
   Panepucci, RA
   Silva, WA
   Haddad, SK
   Covas, DT
AF Meirelles, Lindolfo da Silva
   Malta, Tathiane Maistro
   de Deus Wagatsuma, Virginia Mara
   Bonini Palma, Patricia Viana
   Araujo, Amelia Goes
   Ribeiro Malmegrim, Kelen Cristina
   Morato de Oliveira, Fabio
   Panepucci, Rodrigo Alexandre
   Silva, Wilson Araujo, Jr.
   Haddad, Simone Kashima
   Covas, Dimas Tadeu
TI Cultured Human Adipose Tissue Pericytes and Mesenchymal Stromal Cells
   Display a Very Similar Gene Expression Profile
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID ANTIBODY (3G5)-DEFINED GANGLIOSIDE; STEM-CELLS; ENDOTHELIAL-CELLS;
   BONE-MARROW; IN-VITRO; MICROVASCULAR PERICYTES; DENTAL-PULP; ANTIGEN;
   3G5; SURFACE
AB Mesenchymal stromal cells (MSCs) are cultured cells that can give rise to mature mesenchymal cells under appropriate conditions and secrete a number of biologically relevant molecules that may play an important role in regenerative medicine. Evidence indicates that pericytes (PCs) correspond to mesenchymal stem cells in vivo and can give rise to MSCs when cultured, but a comparison between the gene expression profiles of cultured PCs (cPCs) and MSCs is lacking. We have devised a novel methodology to isolate PCs from human adipose tissue and compared cPCs to MSCs obtained through traditional methods. Freshly isolated PCs expressed CD34, CD140b, and CD271 on their surface, but not CD146. Both MSCs and cPCs were able to differentiate along mesenchymal pathways in vitro, displayed an essentially identical surface immunophenotype, and exhibited the ability to suppress CD3(+) lymphocyte proliferation in vitro. Microarray expression data of cPCs and MSCs formed a single cluster among other cell types. Further analyses showed that the gene expression profiles of cPCs and MSCs are extremely similar, although MSCs differentially expressed endothelial cell (EC)-specific transcripts. These results confirm, using the power of transcriptomic analysis, that PCs give rise to MSCs and suggest that low levels of ECs may persist in MSC cultures established using traditional protocols.
C1 [Meirelles, Lindolfo da Silva; Malta, Tathiane Maistro; de Deus Wagatsuma, Virginia Mara; Bonini Palma, Patricia Viana; Morato de Oliveira, Fabio; Silva, Wilson Araujo, Jr.; Haddad, Simone Kashima; Covas, Dimas Tadeu] Univ Sao Paulo, Ctr Cell Based Therapy CEPID FAPESP, Reg Ctr Hemotherapy Ribeirao Preto, Ribeirao Preto, Brazil.
   [Meirelles, Lindolfo da Silva] Univ Luterana Brasil, Lab Stem Cells & Tissue Engn, PPGBioSaude, BR-92425900 Canoas, Brazil.
   [Araujo, Amelia Goes; Panepucci, Rodrigo Alexandre] Univ Sao Paulo, Reg Ctr Hemotherapy Ribeirao Preto, Lab Large Scale Funct Biol LLSFBio, BR-14049 Ribeirao Preto, Brazil.
   [Ribeiro Malmegrim, Kelen Cristina] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, BR-14049 Ribeirao Preto, Brazil.
   [Silva, Wilson Araujo, Jr.] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Genet, BR-14049 Ribeirao Preto, Brazil.
   [Covas, Dimas Tadeu] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Clin Med, BR-14049 Ribeirao Preto, Brazil.
RP Meirelles, LD (corresponding author), Univ Luterana Brasil, Lab Stem Cells & Tissue Engn, PPGBioSaude, Av Farroupilha 8001, BR-92425900 Canoas, Brazil.
EM lindolfomeirelles@gmail.com
RI Panepucci, Rodrigo A/C-2365-2012; Covas, Dimas T/C-5431-2013; Malmegrim,
   Kelen/H-1016-2015; Silva, Wilson Araujo/E-9487-2011; da Silva Meirelles,
   Lindolfo/B-3451-2008; Malta, Tathiane/N-1686-2013; Kashima,
   Simone/G-4876-2012; CTC USP, CEPID 13 18/J-8951-2014; Wagatsuma,
   Virginia/F-1643-2013
OI Panepucci, Rodrigo A/0000-0002-1119-4352; Covas, Dimas
   T/0000-0002-7364-2595; Malmegrim, Kelen/0000-0002-9303-0086; Silva,
   Wilson Araujo/0000-0001-9364-2886; da Silva Meirelles,
   Lindolfo/0000-0001-5775-2869; Malta, Tathiane/0000-0003-1129-5791;
   Kashima, Simone/0000-0002-1487-0141; CTC USP, CEPID 13
   18/0000-0002-7123-9524; Wagatsuma, Virginia/0000-0003-3801-3280
FU NICHDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD); Sao Paulo
   Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [2013/08135-2]; Research Support of the University of
   Sa Paulo, CISBi-NAP; Brazilian National Council for Scientific and
   Technological Development (CNPq)National Council for Scientific and
   Technological Development (CNPq) [477806/2008-2, 573754/2008-0,
   131371/2011-8]; USP [12.1.25441.01.2]
FX The authors are indebted to the team of Divisao de Cirurgia Plastica e
   Queimaduras of Hospital das Clinicas de Ribeirao Preto for providing AT
   samples and Ms. Aline Magro Bueno for technical assistance. The P2B1
   hybridoma developed by Elizabeth A. Wayner and Gregory Vercellotti was
   obtained from the Developmental Studies Hybridoma Bank developed under
   the auspices of the NICHD and maintained by the University of Iowa,
   Department of Biology, Iowa City, IA. This work has been funded by the
   following grants: #2013/08135-2, Sao Paulo Research Foundation (FAPESP);
   USP #12.1.25441.01.2, Research Support of the University of Sa Paulo,
   CISBi-NAP; and grants #477806/2008-2, #573754/2008-0, and
   #131371/2011-8, Brazilian National Council for Scientific and
   Technological Development (CNPq).
CR Ahn SJ, 2013, J ENDODONT, V39, P1562, DOI 10.1016/j.joen.2013.07.037
   Bardin N, 1996, TISSUE ANTIGENS, V48, P531, DOI 10.1111/j.1399-0039.1996.tb02666.x
   Boneberg EM, 2009, MICROVASC RES, V78, P325, DOI 10.1016/j.mvr.2009.06.012
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471-4914(01)02016-0
   Chen WCW, 2014, JOVE-J VIS EXP, DOI 10.3791/51195
   Conway DE, 2010, AM J PHYSIOL-HEART C, V298, pH367, DOI 10.1152/ajpheart.00565.2009
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   Dellavalle A, 2007, NAT CELL BIOL, V9, P255, DOI 10.1038/ncb1542
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Fiedler E, 2004, AM J DERMATOPATH, V26, P200, DOI 10.1097/00000372-200406000-00005
   FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365-2184.1970.tb00347.x
   Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193
   Geevarghese A, 2014, TRANSL RES, V163, P296, DOI 10.1016/j.trsl.2014.01.011
   Gushi A, 2008, J CUTAN PATHOL, V35, P278, DOI 10.1111/j.1600-0560.2007.00809.x
   Helmbold P, 2001, J CUTAN PATHOL, V28, P206, DOI 10.1034/j.1600-0560.2001.028004206.x
   Helmbold P, 2001, MICROVASC RES, V61, P160, DOI 10.1006/mvre.2000.2292
   Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858
   Jong HL, 2013, PHYSIOL GENOMICS, V45, P256, DOI 10.1152/physiolgenomics.00071.2012
   Kramann R, 2015, CELL STEM CELL, V16, P51, DOI 10.1016/j.stem.2014.11.004
   Lennon DP, 2006, EXP HEMATOL, V34, P1604, DOI 10.1016/j.exphem.2006.07.014
   Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415
   Medici D, 2010, NAT MED, V16, P1400, DOI 10.1038/nm.2252
   Meirelles LD, 2008, STEM CELLS, V26, P2287, DOI 10.1634/stemcells.2007-1122
   Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002
   Nakamura S, 2010, BIOCHEM BIOPH RES CO, V391, P846, DOI 10.1016/j.bbrc.2009.11.150
   NAYAK RC, 1988, J EXP MED, V167, P1003, DOI 10.1084/jem.167.3.1003
   NAYAK RC, 1992, KIDNEY INT, V41, P1638, DOI 10.1038/ki.1992.236
   OWEN M, 1988, J CELL SCI, P63
   POWERS AC, 1984, ENDOCRINOLOGY, V114, P1338, DOI 10.1210/endo-114-4-1338
   RABINOWE SL, 1987, J EXP MED, V165, P1436, DOI 10.1084/jem.165.5.1436
   Rajashekhar G, 2008, STEM CELLS, V26, P2674, DOI 10.1634/stemcells.2008-0277
   Royer-Pokora B, 2010, HUM MOL GENET, V19, P1651, DOI 10.1093/hmg/ddq042
   SCHILTZ PM, 1993, HISTOCHEM J, V25, P642, DOI 10.1007/BF00157878
   SCHLINGEMANN RO, 1990, AM J PATHOL, V136, P1393
   Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696
   Stramer BM, 2004, INVEST OPHTH VIS SCI, V45, P807, DOI 10.1167/iovs.03-0256
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tesar PJ, 2007, NATURE, V448, P196, DOI 10.1038/nature05972
   van Balkom BWM, 2013, BLOOD, V121, P3997, DOI 10.1182/blood-2013-02-478925
   Varma MJO, 2007, STEM CELLS DEV, V16, P91, DOI 10.1089/scd.2006.0026
   Zannettino ACW, 2008, J CELL PHYSIOL, V214, P413, DOI 10.1002/jcp.21210
   Zhou XX, 2011, AM J RESP CELL MOL, V45, P1256, DOI 10.1165/rcmb.2011-0065OC
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 44
TC 21
Z9 21
U1 0
U2 13
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547-3287
EI 1557-8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD DEC 1
PY 2015
VL 24
IS 23
BP 2822
EP 2840
DI 10.1089/scd.2015.0153
PG 19
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA CW1ZN
UT WOS:000364790800009
PM 26192741
OA Green Published
DA 2020-11-26
ER

PT J
AU Pinto, MT
   Malta, TM
   Rodrigues, ES
   Takayanagui, OM
   Tanaka, Y
   Covas, DT
   Kashima, S
AF Pinto, Mariana Tomazini
   Malta, Tathiane Maistro
   Rodrigues, Evandra Strazza
   Takayanagui, Osvaldo Massaiti
   Tanaka, Yuetsu
   Covas, Dimas Tadeu
   Kashima, Simone
TI T cell receptor signaling pathway is overexpressed in CD4(+) T cells
   from HAM/TSP individuals
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HTLV-1; HAM/TSP; CD4(+) T cell activation; Gene expression
ID VIRUS TYPE-I; MYELOPATHY/TROPICAL SPASTIC PARAPARESIS; ZAP-70 TYROSINE
   KINASE; INFECTED INDIVIDUALS; ANTIGEN RECEPTOR; ALTERED EXPRESSION;
   GENE-EXPRESSION; PROVIRAL LOAD; TAX PROTEIN; ZETA-CHAIN
AB Human T-lymphotropic virus type 1 (HTLV-1) is a human retrovirus related to the chronic neuroinflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). CD4(+) T cells activation appears to play a key role on HTLV-1 infection. Here we investigated the expression of genes associated to T cell activation CD3e molecule, epsilon CD3 epsilon), lymphocyte-specific protein tyrosine kinase LCK), vav 1 guanine nucleotide exchange factor VAV1), and zeta-chain TCR) associated protein kinase 70 kDa ZAP70) on T lymphocytes of HTLV-1-infected individuals and compared to healthy uninfected individuals (CT). We observed that CD3 epsilon, LCK, ZAP70, and VAV1 gene expression were increased in CD4(+) T cells from HAM/TSP group compared to HTLV-1 asymptomatic patients HAC). Moreover, ZAP70 and VAV1 were also upregulated in HAM/TSP compared to CT group. We detected a positive correlation among all these genes. We also observed that CD3 epsilon, LCK, and VAV1 genes had a positive correlation with the proviral load (PVL) and Tax expression. These results suggest that PVL and Tax protein could drive CD3 epsilon, LCK, and VAV1 gene expression in CD4(+) T cells, and these genes function on a synchronized way on the CD4(+) T cell activation. The elucidation of the mechanisms underlying T cell receptor signaling pathway is of considerable interest and might lead to new insights into the mechanism of HAM/TSP. (C) 2015 Elsevier Editora Ltda. All rights reserved.
C1 [Pinto, Mariana Tomazini; Malta, Tathiane Maistro; Rodrigues, Evandra Strazza; Covas, Dimas Tadeu; Kashima, Simone] Inst Nacl Ciencias & Tecnol Celulas Tronco & Tera, Ctr Terapia Celular, Ribeirao Preto, SP, Brazil.
   [Pinto, Mariana Tomazini; Malta, Tathiane Maistro; Rodrigues, Evandra Strazza; Covas, Dimas Tadeu; Kashima, Simone] Ctr Reg Hemoterapia Ribeirao Preto, Ribeirao Preto, SP, Brazil.
   [Pinto, Mariana Tomazini; Kashima, Simone] Univ Sao Paulo, Fac Ciencias Farmaceut, BR-14049 Ribeirao Preto, SP, Brazil.
   [Pinto, Mariana Tomazini; Kashima, Simone] Univ Sao Paulo, Fac Ciencias Farmaceut, BR-14049 Ribeirao Preto, SP, Brazil.
   [Takayanagui, Osvaldo Massaiti; Covas, Dimas Tadeu] Univ Sao Paulo, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
   [Tanaka, Yuetsu] Univ Ryukyus, Grad Sch Med, Dept Immunol, Nishihara, Okinawa 90301, Japan.
RP Kashima, S (corresponding author), Reg Blood Ctr Ribeirao Preto, Tenente Catao Roxo St 2501, BR-14051140 Sao Paulo, Brazil.
EM skashima@hemocentro.fmrp.usp.br
RI Rodrigues, Evandra/L-6094-2017; Malta, Tathiane/N-1686-2013; Pinto,
   Mariana/B-6129-2017; Takayanagui, Osvaldo M/C-8159-2013; Covas, Dimas
   T/C-5431-2013; Kashima, Simone/G-4876-2012; CTC USP, CEPID 13
   18/J-8951-2014
OI Rodrigues, Evandra/0000-0003-0964-9554; Malta,
   Tathiane/0000-0003-1129-5791; Pinto, Mariana/0000-0002-5176-7776;
   Takayanagui, Osvaldo M/0000-0002-8190-0275; Covas, Dimas
   T/0000-0002-7364-2595; Kashima, Simone/0000-0002-1487-0141; CTC USP,
   CEPID 13 18/0000-0002-7123-9524
FU Fundacao Hemocentro de Ribeirao Preto (FUNDHERP); Centro Regional de
   Hemoterapia de Ribeirao Preto (CRH); Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP); Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES)CAPES; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq)
FX The authors thank Prof. Charles Bangham for Tax expression analysis.
   They are also grateful to the patients. This work was supported by
   Fundacao Hemocentro de Ribeirao Preto (FUNDHERP), Centro Regional de
   Hemoterapia de Ribeirao Preto (CRH), Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP), Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior (CAPES), and Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq).
CR Araujo AQC, 2006, LANCET NEUROL, V5, P1068, DOI 10.1016/S1474-4422(06)70628-7
   Barda-Saad M, 2005, NAT IMMUNOL, V6, P80, DOI 10.1038/ni1143
   Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646
   Blanchard N, 2002, IMMUNITY, V17, P389, DOI 10.1016/S1074-7613(02)00421-1
   CAYOTA A, 1994, INT IMMUNOL, V6, P611, DOI 10.1093/intimm/6.4.611
   CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7
   De Castro-Costa CM, 2006, AIDS RES HUM RETROV, V22, P931, DOI 10.1089/aid.2006.22.931
   Fischer A, 2010, SEMIN IMMUNOPATHOL, V32, P107, DOI 10.1007/s00281-010-0196-x
   GESSAIN A, 1985, LANCET, V2, P407
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   LINETTE GP, 1988, SCIENCE, V241, P573, DOI 10.1126/science.2899908
   Malta TM, 2013, AIDS RES HUM RETROV, V29, P826, DOI [10.1089/aid.2012.0205, 10.1089/AID.2012.0205]
   MASUR H, 1981, NEW ENGL J MED, V305, P1431, DOI 10.1056/NEJM198112103052402
   Mesnard JM, 1999, VIROLOGY, V257, P277, DOI 10.1006/viro.1999.9685
   Mustelin T, 2003, BIOCHEM J, V371, P15, DOI 10.1042/BJ20021637
   Nagai M, 1998, J NEUROVIROL, V4, P586, DOI 10.3109/13550289809114225
   Nagai M, 2001, J INFECT DIS, V183, P197, DOI 10.1086/317932
   OSAME M, 1986, LANCET, V1, P1031
   PEREZBLAS M, 1992, CLIN EXP IMMUNOL, V89, P83
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pinto MT, 2014, AIDS RES HUM RETROV, V30, P610, DOI [10.1089/aid.2013.0109, 10.1089/AID.2013.0109]
   Pinto MT, 2012, REV INST MED TROP SP, V54, P123, DOI 10.1590/S0036-46652012000300002
   RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990
   Satou Y, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-46
   SCHELLEKENS PTA, 1990, J CLIN IMMUNOL, V10, P121, DOI 10.1007/BF00918194
   Segura I, 1999, J VIROL, V73, P5207, DOI 10.1128/JVI.73.6.5207-5213.1999
   SMALL CB, 1983, AM J MED, V74, P433, DOI 10.1016/0002-9343(83)90970-1
   Soede RDM, 1998, J CELL BIOL, V142, P1371, DOI 10.1083/jcb.142.5.1371
   Stefanova I, 1996, J CLIN INVEST, V98, P1290, DOI 10.1172/JCI118915
   STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523
   Ticchioni M, 2002, BLOOD, V99, P3111, DOI 10.1182/blood.V99.9.3111
   TIMON M, 1993, CLIN EXP IMMUNOL, V94, P38
   Toulza F, 2008, BLOOD, V111, P5047, DOI 10.1182/blood-2007-10-118539
   Trimble LA, 1998, BLOOD, V91, P585, DOI 10.1182/blood.V91.2.585.585_585_594
   UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Vine AM, 2004, J IMMUNOL, V173, P5121, DOI 10.4049/jimmunol.173.8.5121
   WANGE RL, 1992, J BIOL CHEM, V267, P11685
   Weil R, 1999, J VIROL, V73, P3709, DOI 10.1128/JVI.73.5.3709-3717.1999
   Yamamoto-Taguchi N, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003630
   Yamano Y, 2002, BLOOD, V99, P88, DOI 10.1182/blood.V99.1.88
   Yasunaga J, 2001, BLOOD, V97, P3177, DOI 10.1182/blood.V97.10.3177
   Zhang YB, 2012, IMMUNOLOGY, V135, P268, DOI 10.1111/j.1365-2567.2011.03549.x
NR 43
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD NOV-DEC
PY 2015
VL 19
IS 6
BP 578
EP 584
DI 10.1016/j.bjid.2015.07.008
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA CX7GX
UT WOS:000365871300004
PM 26358743
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Santos, LA
   Gray, RR
   Monteiro-Cunha, JP
   Strazza, E
   Kashima, S
   Santos, ED
   Araujo, THA
   Goncalves, MD
   Salemi, M
   Alcantara, LCJ
AF Santos, Luciane Amorim
   Gray, Rebecca R.
   Monteiro-Cunha, Joana Paixao
   Strazza, Evandra
   Kashima, Simone
   Santos, Edson de Souza
   Almeida Araujo, Thessika Hialla
   Goncalves, Marilda de Souza
   Salemi, Marco
   Junior Alcantara, Luiz Carlos
TI Short Communication: Phylodynamics Analysis of the Human
   Immunodeficiency Virus Type 1 Envelope Gene in Mother and Child Pairs
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID EVOLUTIONARY DYNAMICS; STATISTICAL TEST; ENV GENE; HIV-1; POPULATION;
   TRANSMISSION; LIKELIHOOD; SEQUENCES; ALGORITHM; DISEASE
AB Characterizing the impact of HIV transmission routes on viral genetic diversity can improve the understanding of the mechanisms of virus evolution and adaptation. HIV vertical transmission can occur in utero, during delivery, or while breastfeeding. The present study investigated the phylodynamics of the HIV-1 env gene in mother-to-child transmission by analyzing one chronically infected pair from Brazil and three acutely infected pairs from Zambia, with three to five time points. Sequences from 25 clones from each sample were obtained and aligned using Clustal X. ML trees were constructed in PhyML using the best evolutionary model. Bayesian analyses testing the relaxed and strict molecular clock were performed using BEAST and a Bayesian Skyline Plot (BSP) was construed. The genetic variability of previously described epitopes was investigated and compared between each individual time point and between mother and child sequences. The relaxed molecular clock was the best-fitted model for all datasets. The tree topologies did not show differentiation in the evolutionary dynamics of the virus circulating in the mother from the viral population in the child. In the BSP, the effective population size was more constant in time in the chronically infected patients while in the acute patients it was possible to detect bottlenecks. The genetic variability within viral epitopes recognized by the human immune system was considerably higher among the chronically infected pair in comparison with acutely infected pairs. These results contribute to a better understanding of HIV-1 evolutionary dynamics in mother-to-child transmission.
C1 [Santos, Luciane Amorim; Monteiro-Cunha, Joana Paixao; Santos, Edson de Souza; Almeida Araujo, Thessika Hialla; Goncalves, Marilda de Souza; Junior Alcantara, Luiz Carlos] Fundacao Oswaldo Cruz, Ctr Pesquisa Goncalo Moniz, Lab Hematol Genet & Biol Computac, Salvador, BA, Brazil.
   [Gray, Rebecca R.; Salemi, Marco] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL USA.
   [Monteiro-Cunha, Joana Paixao] Univ Fed Bahia, BR-41170290 Salvador, BA, Brazil.
   [Strazza, Evandra; Kashima, Simone] Univ Sao Paulo, Hemoctr Ribeirao Preto, Sao Paulo, Brazil.
RP Alcantara, LCJ (corresponding author), LASP CPqGM FIOCRUZ, Rua Waldemar Falcao 121, BR-40296710 Salvador, BA, Brazil.
EM lalcan@bahia.fiocruz.br
RI Kashima, Simone/G-4876-2012
OI Kashima, Simone/0000-0002-1487-0141; Alcantara, Luiz/0000-0002-6769-9931
FU Brazilian Ministry of Heath Centro Nacional de Pesquisa (CNPq)
FX We thank the Brazilian Ministry of Heath Centro Nacional de Pesquisa
   (CNPq) for funding of the master student L.A.S.
CR Achaz G, 2004, MOL BIOL EVOL, V21, P1902, DOI 10.1093/molbev/msh196
   Bette Korber T, HIV MOL IMMUNOLOGY 2
   Brown AJL, 1997, P NATL ACAD SCI USA, V94, P1862, DOI 10.1073/pnas.94.5.1862
   Bruen TC, 2006, GENETICS, V172, P2665, DOI 10.1534/genetics.105.048975
   Derdeyn CA, 2004, SCIENCE, V303, P2019, DOI 10.1126/science.1093137
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Grenfell BT, 2004, SCIENCE, V303, P327, DOI 10.1126/science.1090727
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Hoffmann FG, 2008, AIDS, V22, P817, DOI 10.1097/QAD.0b013e3282f486af
   HUDSON RR, 1992, MOL BIOL EVOL, V9, P138
   Huson D, 2006, MOL BIOL EVOL, V9, P138
   Lemey P, 2006, AIDS REV, V8, P125
   Salemi M, 2008, MOL PHYLOGENET EVOL, V49, P618, DOI 10.1016/j.ympev.2008.08.017
   Seo TK, 2002, GENETICS, V160, P1283
   Shriner D, 2004, GENETICS, V166, P1155, DOI 10.1534/genetics.166.3.1155
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Williamson S, 2003, MOL BIOL EVOL, V20, P1318, DOI 10.1093/molbev/msg144
   WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316
   Zhang H, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-67
   Zhang H, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-73
NR 20
TC 1
Z9 1
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD SEP 1
PY 2015
VL 31
IS 9
BP 913
EP 920
DI 10.1089/aid.2014.0352
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA CQ1VJ
UT WOS:000360388000011
PM 26123053
OA Green Published
DA 2020-11-26
ER

PT J
AU Slavov, SN
   Vilar, FC
   Wagatsuma, VMD
   Santana, RC
   Machado, AA
   da Fonseca, BAL
   Kashima, S
   Covas, DT
AF Slavov, S. N.
   Vilar, F. C.
   Wagatsuma, V. M. D.
   Santana, R. C.
   Machado, A. A.
   da Fonseca, B. A. L.
   Kashima, S.
   Covas, D. T.
TI Late emergence of A594V and L595W mutations related to ganciclovir
   resistance in a patient with HCMV retinitis and long-term HIV
   progression
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE Human cytomegalovirus; HCMV; Ganciclovir; Resistance; AIDS
ID CYTOMEGALOVIRUS ISOLATES RESISTANT; STEM-CELL TRANSPLANTATION;
   DRUG-RESISTANCE; UL54 GENES; UL97; SUSCEPTIBILITY; SENSITIVITY;
   INFECTION; FOSCARNET; THERAPY
AB The emergence of ganciclovir (GCV) resistance during the treatment of human cytomegalovirus (HCMV) infection is a serious clinical challenge, and is associated with high morbidity and mortality. In this case report, we describe the emergence of two consecutive mutations (A594V and L595W) related to GCV resistance in a patient with HCMV retinitis and long-term HIV progression after approximately 240 days of GCV use. Following the diagnosis of retinitis, the introduction of GCV did not result in viral load reduction. The detected mutations appeared late in the treatment, and we propose that other factors (high initial HCMV load, previous GCV exposure, low CD4(+) cell count), in addition to the presence of resistance mutations, may have contributed to the treatment failure of HCMV infection in this patient.
C1 [Slavov, S. N.; Kashima, S.; Covas, D. T.] Univ Sao Paulo, Hemoctr Ribeirao Preto, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
   [Vilar, F. C.; Santana, R. C.; Machado, A. A.; da Fonseca, B. A. L.] Univ Sao Paulo, Div Molestias Infecciosas & Trop, Dept Clin Med, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
   [Wagatsuma, V. M. D.] Univ Sao Paulo, Lab Hematol Expt, Dept Clin Med, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
   [Kashima, S.] Univ Sao Paulo, Dept Analises Clin Toxicol & Bromatol, Fac Ciencias Farmaceut Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
   [Covas, D. T.] Univ Sao Paulo, Dept Cli Med, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
RP Slavov, SN (corresponding author), Univ Sao Paulo, Hemoctr Ribeirao Preto, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
EM svetoslav.slavov@hemocentro.fmrp.usp.br
RI Covas, Dimas T/C-5431-2013; Vilar, Fernando Crivelenti/AAK-4233-2020; N,
   Svetoslav/M-5416-2017; de C Santana, Rodrigo/C-4429-2014; CTC USP, CEPID
   13 18/J-8951-2014; Fonseca, Benedito/F-3252-2012; Kashima,
   Simone/G-4876-2012; Wagatsuma, Virginia/F-1643-2013
OI Covas, Dimas T/0000-0002-7364-2595; de C Santana,
   Rodrigo/0000-0002-5887-8663; vilar, fernando
   crivelenti/0000-0001-8232-5375; CTC USP, CEPID 13
   18/0000-0002-7123-9524; Slavov, Svetoslav/0000-0003-0805-6140; Fonseca,
   Benedito/0000-0003-3159-5687; Kashima, Simone/0000-0002-1487-0141;
   Wagatsuma, Virginia/0000-0003-3801-3280
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2009/16623-1, CTC-1998/14.247-6, INCTC-2008/57.877-3]; CNPqNational
   Council for Scientific and Technological Development (CNPq)
   [INCTC-573.754/2008-0]
FX We are grateful to Dr. Joao Marcello Fortes Furtado, Ophthalmology
   Department, Clinical Hospital of the University of Sao Paulo School of
   Medicine at Ribeirao Preto for the ophthalmologic images and their
   interpretation. We are also grateful to Sandra Navarro Bresciani for the
   artwork. Research supported by FAPESP (#2009/16623-1, #CTC-1998/14.247-6
   and #INCTC-2008/57.877-3), and CNPq (#INCTC-573.754/2008-0).
CR Almyroudis NG, 2007, TRANSPL INFECT DIS, V9, P286, DOI 10.1111/j.1399-3062.2007.00235.x
   Bakshi NK, 2012, EYE, V26, P759, DOI 10.1038/eye.2012.17
   Boutolleau D, 2012, J CLIN VIROL, V54, P194, DOI 10.1016/j.jcv.2012.02.008
   Bowen EF, 1997, J VIROL METHODS, V68, P225
   Buyck HCE, 2010, J CLIN VIROL, V49, P32, DOI 10.1016/j.jcv.2010.06.018
   Chevillotte M, 2010, ANTIVIR RES, V85, P318, DOI 10.1016/j.antiviral.2009.10.004
   Chou S, 2002, J INFECT DIS, V185, P162, DOI 10.1086/338362
   Chou SW, 2011, ANTIMICROB AGENTS CH, V55, P382, DOI 10.1128/AAC.01259-10
   da Cunha-Bang C, 2013, AM J TRANSPLANT, V13, P458, DOI 10.1111/ajt.12042
   Drew WL, 2006, J CLIN VIROL, V37, P124, DOI 10.1016/j.jcv.2006.07.010
   Foulongne V, 2004, ACTA VIROL, V48, P51
   Hakki M, 2011, CURR OPIN INFECT DIS, V24, P605, DOI 10.1097/QCO.0b013e32834cfb58
   Imai Y, 2004, J INFECT DIS, V189, P611, DOI 10.1086/381394
   Jabs DA, 2010, OPHTHALMOLOGY, V117, P128, DOI 10.1016/j.ophtha.2009.06.016
   Kedhar Sanjay R, 2007, Herpes, V14, P66
   Kuo IC, 2003, AM J OPHTHALMOL, V135, P20, DOI 10.1016/S0002-9394(02)01758-0
   Lurain NS, 2010, CLIN MICROBIOL REV, V23, P689, DOI 10.1128/CMR.00009-10
   Martin BK, 2007, CLIN INFECT DIS, V44, P1001, DOI 10.1086/512368
   Oshima K, 2008, J MED VIROL, V80, P1769, DOI 10.1002/jmv.21277
   Smith IL, 1997, J INFECT DIS, V176, P69, DOI 10.1086/514041
NR 20
TC 2
Z9 2
U1 0
U2 2
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, 00, BRAZIL
SN 0100-879X
EI 1678-4510
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD SEP
PY 2015
VL 48
IS 9
BP 777
EP 781
DI 10.1590/1414-431X20154507
PG 5
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA CQ3KQ
UT WOS:000360501400002
PM 26270327
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Rodrigues, ES
   de Macedo, MD
   de Melo, FU
   Rocha, MC
   Wagatsuma, VMD
   Toledo, R
   Ubiali, EMA
   Brunetta, DM
   Covas, DT
   Kashima, S
AF Rodrigues, E. S.
   de Macedo, M. D.
   de Melo, F. U.
   Rocha-Junior, M. C.
   de Deus Wagatsuma, V. M.
   Toledo, R.
   Ubiali, E. M. A.
   Brunetta, D. M.
   Covas, D. T.
   Kashima, S.
TI Rapid blood group genotyping by allelic discriminative real-time PCR in
   multiply-transfused patients
SO TRANSFUSION MEDICINE
LA English
DT Letter
ID ANTIGEN
C1 [Rodrigues, E. S.; de Macedo, M. D.; de Melo, F. U.; Rocha-Junior, M. C.; de Deus Wagatsuma, V. M.; Toledo, R.; Ubiali, E. M. A.; Brunetta, D. M.; Covas, D. T.; Kashima, S.] Univ Sao Paulo, Reg Blood Ctr Ribeirao Preto, Sao Paulo, Brazil.
   [Rodrigues, E. S.; de Macedo, M. D.; Rocha-Junior, M. C.; Kashima, S.] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Sao Paulo, Brazil.
   [de Melo, F. U.; Covas, D. T.] Univ Sao Paulo, Sch Med Ribeirao Preto, Sao Paulo, Brazil.
RP Kashima, S (corresponding author), Reg Blood Ctr Ribeirao Preto, Sao Paulo, Brazil.
EM skashima@hemocentro.fmrp.usp.br
RI Rodrigues, Evandra/L-6094-2017; Covas, Dimas T/C-5431-2013; Kashima,
   Simone/G-4876-2012; Wagatsuma, Virginia/F-1643-2013; Brunetta,
   Denise/A-8712-2013; CTC USP, CEPID 13 18/J-8951-2014
OI Rodrigues, Evandra/0000-0003-0964-9554; Covas, Dimas
   T/0000-0002-7364-2595; Kashima, Simone/0000-0002-1487-0141; Ursoli,
   Fernanda/0000-0002-8499-000X; Wagatsuma, Virginia/0000-0003-3801-3280;
   Brunetta, Denise/0000-0001-7382-8712; CTC USP, CEPID 13
   18/0000-0002-7123-9524
CR Araujo F, 2002, Immunohematology, V18, P59
   Atamaniuk J, 2009, J CLIN LAB ANAL, V23, P24, DOI 10.1002/jcla.20282
   Denomme GA, 2005, TRANSFUSION, V45, P660, DOI 10.1111/j.1537-2995.2005.04365.x
   Kalman LV, 2013, ARCH PATHOL LAB MED, V137, P983, DOI 10.5858/arpa.2012-0311-RA
   Novaretti M C Z, 2010, Immunohematology, V26, P66
   Polin H, 2008, VOX SANG, V95, P125, DOI 10.1111/j.1423-0410.2008.01067.x
   Reid ME, 2011, TRANSFUS APHER SCI, V44, P65, DOI 10.1016/j.transci.2010.12.011
   Guelsin GAS, 2010, J CLIN LAB ANAL, V24, P311, DOI 10.1002/jcla.20407
   Sousa TN, 2007, VOX SANG, V92, P373, DOI 10.1111/j.1423-0410.2007.00902.x
   Westhoff CM, 2006, CURR OPIN HEMATOL, V13, P471, DOI 10.1097/01.moh.0000245695.77758.3d
NR 10
TC 0
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0958-7578
EI 1365-3148
J9 TRANSFUSION MED
JI Transfus. Med.
PD APR
PY 2015
VL 25
IS 2
BP 111
EP 114
DI 10.1111/tme.12186
PG 4
WC Hematology
SC Hematology
GA CJ1ME
UT WOS:000355246900008
PM 25823878
DA 2020-11-26
ER

PT J
AU Slavov, SN
   Kashima, S
   Wagatsuma, VMD
   Silva-Pinto, AC
   Martinez, EZ
   Favarin, MD
   Covas, DT
AF Slavov, Svetoslav N.
   Kashima, Simone
   Wagatsuma, Virginia M. D.
   Silva-Pinto, Ana Cristina
   Martinez, Edson Z.
   Favarin, Maria do Carmo
   Covas, Dimas T.
TI Glycoprotein B Genotyping of Human Cytomegalovirus Strains Isolated from
   Brazilian Patients with Sickle Cell Disease and Beta-Thalassemia Major
SO VIRAL IMMUNOLOGY
LA English
DT Article
ID TRANSPLANT RECIPIENTS; VIRAL-INFECTIONS; VIRUS; BLOOD; LOAD;
   SEROPREVALENCE; INDIVIDUALS; ASSOCIATION; RETINITIS; MULTIPLE
AB The role of the human cytomegalovirus (HCMV) infection in individuals with hemoglobinopathies is unclear. Our objective was to examine the molecular and genotypic characteristics of HCMV in patients with sickle cell disease, beta-thalassemia major, and volunteer blood donors by viral load quantitation, glycoprotein B (gB) genotyping, and phylogenetic analysis. The patients with sickle cell disease demonstrated the highest HCMV DNA prevalence (13.8%), followed by the patients with beta-thalassemia major (7.6%), and the blood donors (3%). The infection was characterized by a low mean viral load (3.8x10(3) copies/mL), but infections with higher copy numbers were also observed. Genotype gB2 was detected in the majority of cases (90.9%), followed by genotype gB1 (9.1%). No gB3/gB4 genotype was detected. No statistical significance was observed between HCMV DNAemia/gB genotype and hematological alterations or severity of the disease. The high number of sickle cell disease patients with HCMV DNAemia could be due to their partial immune dysfunction (multiple transfusions, spleen dysfunction, hydroxyurea treatment). The extensive HCMV gB2 prevalence in patients with hemoglobinopathies is probably due to HCMV epidemiologic characteristics in the examined region, and can be important during the clinical management of these patients.
C1 [Slavov, Svetoslav N.; Kashima, Simone; Silva-Pinto, Ana Cristina; Favarin, Maria do Carmo; Covas, Dimas T.] Univ Sao Paulo, Ribeirao Preto Med Sch, Reg Blood Ctr Ribeirao Preto, BR-14051140 Sao Paulo, Brazil.
   [Wagatsuma, Virginia M. D.] Univ Sao Paulo, Ribeirao Preto Med Sch, Lab Expt Hematol, BR-14051140 Sao Paulo, Brazil.
   [Martinez, Edson Z.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Social Med, BR-14051140 Sao Paulo, Brazil.
   [Covas, Dimas T.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Clin Med, BR-14051140 Sao Paulo, Brazil.
   [Kashima, Simone] Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, BR-14049 Ribeirao Preto, Brazil.
RP Slavov, SN (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Reg Blood Ctr Ribeirao Preto, Mol Biol Lab, Rua Tenente Catao Roxo 2501, BR-14051140 Sao Paulo, Brazil.
EM svetoslav.slavov@hemocentro.fmrp.usp.br
RI N, Svetoslav/M-5416-2017; Martinez, Edson Zangiacomi/A-3638-2008; Covas,
   Dimas T/C-5431-2013; Wagatsuma, Virginia/F-1643-2013; Kashima,
   Simone/G-4876-2012; CTC USP, CEPID 13 18/J-8951-2014
OI Martinez, Edson Zangiacomi/0000-0002-0949-3222; Covas, Dimas
   T/0000-0002-7364-2595; Wagatsuma, Virginia/0000-0003-3801-3280; Slavov,
   Svetoslav/0000-0003-0805-6140; Pinto, Ana/0000-0002-4104-2296; Kashima,
   Simone/0000-0002-1487-0141; CTC USP, CEPID 13 18/0000-0002-7123-9524
FU Fundacao de Amparo e Pesquisa do Estado de Sao Paulo-FAPESP, Brazil
   [2009/16623-1, CTC-1998/14.247-6, INCTC-2008/57.877-3]; Conselho
   Nacional do Desenvolvimento Cientifico e Tecnologico, Brazil
   [INCTC-573.754/2008-0]
FX We are grateful to Aparecida Yamamoto, MD, PhD for providing the HCMV
   strain AD169, which was used to control the molecular detection methods
   and the genotyping. This study was supported by grants awarded by the
   Fundacao de Amparo e Pesquisa do Estado de Sao Paulo-FAPESP, Brazil
   (Grant nos. 2009/16623-1, CTC-1998/14.247-6, and INCTC-2008/57.877-3),
   and the Conselho Nacional do Desenvolvimento Cientifico e Tecnologico,
   Brazil (INCTC-573.754/2008-0).
CR Ariza-Heredia EJ, 2014, CANCER LETT, V342, P1, DOI 10.1016/j.canlet.2013.09.004
   Baronciani D, 1990, BONE MARROW TRANSPL, V5, P67
   Buddeberg F, 2008, BEST PRACT RES-CLIN, V22, P503, DOI 10.1016/j.bpa.2008.05.003
   Carraro E, 2003, J MED VIROL, V70, P240, DOI 10.1002/jmv.10383
   Chernyshev AV, 2008, J THEOR BIOL, V251, P93, DOI 10.1016/j.jtbi.2007.10.016
   CHOU SW, 1991, J INFECT DIS, V163, P1229, DOI 10.1093/infdis/163.6.1229
   Correia-Silva JF, 2011, ORAL DIS, V17, P530, DOI 10.1111/j.1601-0825.2011.01801.x
   de Matos SB, 2011, J MED VIROL, V83, P298, DOI 10.1002/jmv.21965
   dos Santos CJ, 2014, J MED VIROL, V86, P1953, DOI 10.1002/jmv.23820
   Drew WL, 2002, J INFECT DIS, V186, P114, DOI 10.1086/341071
   Dumont LJ, 2001, BLOOD, V97, P3640, DOI 10.1182/blood.V97.11.3640
   ERGAZAKI M, 1994, ONCOL REP, V1, P813
   Fauquet CM, 2005, VIRUS TAXONOMY, P203
   Felsenstein J, 1997, SYST BIOL, V46, P101, DOI 10.2307/2413638
   GERMENIS A, 1989, ACTA HAEMATOL-BASEL, V82, P57
   Gilbert C, 1999, J MED VIROL, V59, P98, DOI 10.1002/(SICI)1096-9071(199909)59:1&lt;98::AID-JMV16&gt;3.0.CO;2-A
   Gorzer I, 2010, J CLIN VIROL, V48, P100, DOI 10.1016/j.jcv.2010.03.005
   HADDAD JD, 1984, CHEST, V86, P265, DOI 10.1378/chest.86.2.265
   Martin-Gandul C, 2014, TRANSPL INT, V27, P1060, DOI 10.1111/tri.12378
   Mayaphi SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093702
   NIGRO G, 1990, TRANSFUSION, V30, P808, DOI 10.1046/j.1537-2995.1990.30991048786.x
   Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357
   Palmer S, 2005, J CLIN MICROBIOL, V43, P406, DOI 10.1128/JCM.43.1.406-413.2005
   Rasmussen L, 2003, J GEN VIROL, V84, P1853, DOI 10.1099/vir.0.18896-0
   Souza MA, 2010, REV SOC BRAS MED TRO, V43, P359, DOI 10.1590/S0037-86822010000400004
   Toro AI, 1996, RES VIROLOGY, V147, P233, DOI 10.1016/0923-2516(96)89654-3
   TorokStorb B, 1997, BLOOD, V90, P2097, DOI 10.1182/blood.V90.5.2097
   Trincado DE, 2000, J MED VIROL, V61, P481, DOI 10.1002/1096-9071(200008)61:4&lt;481::AID-JMV11&gt;3.0.CO;2-H
   Xia X, 2001, J HERED, V92, P371, DOI 10.1093/jhered/92.4.371
   YADAV S, 1993, J TROP PEDIATRICS, V39, P243, DOI 10.1093/tropej/39.4.243
   Yamamoto AY, 2007, J MED VIROL, V79, P1164, DOI 10.1002/jmv.20903
   YOHANNAN MD, 1990, ACTA PAEDIATR SCAND, V79, P201, DOI 10.1111/j.1651-2227.1990.tb11439.x
NR 32
TC 2
Z9 2
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0882-8245
EI 1557-8976
J9 VIRAL IMMUNOL
JI Viral Immunol.
PD MAR 1
PY 2015
VL 28
IS 2
BP 123
EP 129
DI 10.1089/vim.2014.0057
PG 7
WC Immunology; Virology
SC Immunology; Virology
GA CB2QG
UT WOS:000349472100008
PM 25420197
OA Green Published
DA 2020-11-26
ER

PT J
AU Ferreira, AF
   de Oliveira, GLV
   Tognon, R
   Collassanti, MDS
   Zanichelli, MA
   Hamerschlak, N
   de Souza, AM
   Covas, DT
   Kashima, S
   de Castro, FA
AF Ferreira, Aline Fernanda
   de Oliveira, Gislane L. V.
   Tognon, Raquel
   Collassanti, Maria Dulce S.
   Zanichelli, Maria Aparecida
   Hamerschlak, Nelson
   de Souza, Ana Maria
   Covas, Dimas Tadeu
   Kashima, Simone
   de Castro, Fabiola Attie
TI Apoptosis-Related Gene Expression Profile in Chronic Myeloid Leukemia
   Patients after Imatinib Mesylate and Dasatinib Therapy
SO ACTA HAEMATOLOGICA
LA English
DT Article
DE Apoptosis; BCR-ABL; Chronic myeloid leukemia; Gene expression; Tyrosine
   kinase inhibitors
ID CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; TYROSINE
   KINASE INHIBITOR; ABL-MEDIATED RESISTANCE; BCR-ABL; UP-REGULATION;
   DRUG-RESISTANCE; BCL-2 PROTEIN; CELLS; SURVIVAL
AB Background/Aims: We investigated the effects of tyrosine kinase inhibitors (TKIs) on the expression of apoptosis-related genes (BCL-2 and death receptor family members) in chronic myeloid leukemia (CML) patients. Methods: Peripheral blood mononuclear cells from 32 healthy subjects and 26 CML patients were evaluated before and after treatment with imatinib mesylate (IM) and dasatinib (DAS) by quantitative PCR. Results: Anti-apoptotic genes (c-FLIP and MCL-1) were overexpressed and the pro-apoptotic BIK was reduced in CML patients. Expression of BMF, A1, c-FLIP, MCL-1, CIAP-2 and CIAP-1 was modulated by DAS. In IM-resistant patients, expression of A1, c-FLIP, CIAP-1 and MCL-1 was upregulated, and BCL-2, CIAP-2, BAK, BAX, BIK and FASL expression was downregulated. Conclusion: Taken together, our results point out that, in CML, DAS interferes with the apoptotic machinery regulation. In addition, the data suggest that apoptosis-related gene expression profiles are associated with primary resistance to IM. (C) 2015 S. Karger AG, Basel
C1 [Ferreira, Aline Fernanda; de Oliveira, Gislane L. V.; Tognon, Raquel; de Souza, Ana Maria; de Castro, Fabiola Attie] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Dept Anal Clin Toxicol & Bromatol, BR-14040903 Ribeirao Preto, SP, Brazil.
   [Covas, Dimas Tadeu] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, BR-14040903 Ribeirao Preto, SP, Brazil.
   [Kashima, Simone] Ctr Reg Hemoterapia Ribeirao Preto, Mol Biol Lab, Ribeirao Preto, Brazil.
   [Covas, Dimas Tadeu; Kashima, Simone] Inst Nacl Ciencia & Tecnol Celulas Tronco & Terap, INCTC, Ribeirao Preto, Brazil.
   [Collassanti, Maria Dulce S.; Zanichelli, Maria Aparecida] Inst Tratamento Canc Infantil ITACI, Sao Paulo, Brazil.
   [Hamerschlak, Nelson] Hosp Albert Einstein Sao Paulo, Soc Beneficente Israelita & Brasileira, Sao Paulo, Brazil.
RP Ferreira, AF (corresponding author), Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Dept Anal Clin Toxicol & Bromatol, Ave Cafe S-N, BR-14040903 Ribeirao Preto, SP, Brazil.
EM alineferreira591@gmail.com
RI Hamerschlak, Nelson/M-8060-2015; CASTRO, FABIOLA/D-4693-2012; de
   Oliveira, Gislane L. V./I-4896-2013; Covas, Dimas T/C-5431-2013;
   Kashima, Simone/G-4876-2012; CTC USP, CEPID 13 18/J-8951-2014
OI Hamerschlak, Nelson/0000-0002-5140-5310; de Oliveira, Gislane L.
   V./0000-0002-0269-9973; Covas, Dimas T/0000-0002-7364-2595; Lelis Vilela
   de Oliveira, Gislane/0000-0002-8883-5541; Kashima,
   Simone/0000-0002-1487-0141; CTC USP, CEPID 13 18/0000-0002-7123-9524
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2005/57746-8]
FX We first wish to thank the CML patients who participated in this study.
   We are grateful to Zita Gregorio for her technical assistance and help
   in collecting peripheral blood samples. This work was supported by
   FAPESP grant 2005/57746-8.
CR Aichberger KJ, 2005, BLOOD, V105, P3303, DOI 10.1182/blood-2004-02-0749
   Albesiano E, 2003, BLOOD, V102, P3333, DOI 10.1182/blood-2003-05-1585
   Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705
   Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664
   Bewry NN, 2008, MOL CANCER THER, V7, P3169, DOI 10.1158/1535-7163.MCT-08-0314
   BOYUM A, 1977, LYMPHOLOGY, V10, P71
   BRADBURY DA, 1995, BRIT J HAEMATOL, V91, P374, DOI 10.1111/j.1365-2141.1995.tb05306.x
   Brumatti G, 2003, FEBS LETT, V541, P57, DOI 10.1016/S0014-5793(03)00299-0
   Bueno-da-Silva AEB, 2003, CELL DEATH DIFFER, V10, P592, DOI 10.1038/sj.cdd.4401210
   CAMPOS L, 1993, BLOOD, V81, P3091
   Cools J, 2005, DRUG RESIST UPDATE, V8, P119, DOI 10.1016/j.drup.2005.04.005
   Deininger MWN, 2000, CANCER RES, V60, P2049
   Del Poeta G, 2008, CURR CANCER DRUG TAR, V8, P207
   DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291
   Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194
   Di Bacco A, 2000, Oncologist, V5, P405, DOI 10.1634/theoncologist.5-5-405
   Doggrel SA, 2005, EXPERT OPIN BIOL TH, V305, P399
   Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083
   Faderl S, 1999, ANN INTERN MED, V131, P207, DOI 10.7326/0003-4819-131-3-199908030-00008
   Frazer R, 2006, ULSTER MED J, V76, P8
   Handa H, 1997, LEUKEMIA RES, V21, P479, DOI 10.1016/S0145-2126(97)00006-4
   Hehlmann R, 2007, LANCET, V370, P342, DOI 10.1016/S0140-6736(07)61165-9
   KANTARJIAN HM, 1995, ANN INTERN MED, V122, P254, DOI 10.7326/0003-4819-122-4-199502150-00003
   Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000
   Kuroda J, 2007, CELL DEATH DIFFER, V14, P1667, DOI 10.1038/sj.cdd.4402168
   Mackus WJM, 2005, LEUKEMIA, V19, P427, DOI 10.1038/sj.leu.2403623
   Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079
   MAUNG ZT, 1994, BRIT J HAEMATOL, V88, P105, DOI 10.1111/j.1365-2141.1994.tb04984.x
   Melo JV, 2007, NAT REV CANCER, V7, P441, DOI 10.1038/nrc2147
   Moller GMO, 2007, FEBS LETT, V581, P1329, DOI 10.1016/j.febslet.2007.02.048
   Munzert G, 2002, BLOOD, V100, P3749, DOI 10.1182/blood.V100.10.3749
   Nelson EA, 2008, BLOOD, V112, P5095, DOI 10.1182/blood-2007-12-129718
   PORWITMACDONALD A, 1995, LEUKEMIA, V9, P1191
   Riccioni R, 2007, BRIT J HAEMATOL, V139, P194, DOI 10.1111/j.1365-2141.2007.06757.x
   Snead JL, 2009, BLOOD, V114, P3459, DOI 10.1182/blood-2007-10-113969
   Stamatovic D, 2012, VOJNOSANIT PREGL, V69, P37, DOI 10.2298/VSP1201037S
   Steinberg M, 2007, CLIN THER, V29, P2289, DOI 10.1016/j.clinthera.2007.11.005
   Thomas RK, 2002, AM J PATHOL, V160, P1521, DOI 10.1016/S0002-9440(10)62578-3
   Tipping AJ, 2003, EXP HEMATOL, V31, P1073, DOI 10.1016/j.exphem.2003.08.006
   Valdez BC, 2008, LEUKEMIA RES, V32, P1684, DOI 10.1016/j.leukres.2008.01.016
   Weisberg E, 2007, NAT REV CANCER, V7, P345, DOI 10.1038/nrc2126
   Yasui K, 2004, CANCER RES, V64, P1403, DOI 10.1158/0008-5472.CAN-3263-2
NR 42
TC 12
Z9 12
U1 0
U2 14
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0001-5792
EI 1421-9662
J9 ACTA HAEMATOL-BASEL
JI Acta Haematol.
PY 2015
VL 133
IS 4
BP 354
EP 364
DI 10.1159/000369446
PG 11
WC Hematology
SC Hematology
GA CI8HX
UT WOS:000355013700006
PM 25721555
DA 2020-11-26
ER

PT J
AU Slavov, SN
   Kashima, S
   Rocha, MC
   Silva-Pinto, AC
   Oliveira, LC
   Eis-Hubinger, AM
   Covas, DT
AF Slavov, S. N.
   Kashima, S.
   Rocha-Junior, M. C.
   Silva-Pinto, A. C.
   Oliveira, L. C.
   Eis-Huebinger, A. M.
   Covas, D. T.
TI Human parvovirus 4 in Brazilian patients with haemophilia,
   beta-thalassaemia major and volunteer blood donors
SO HAEMOPHILIA
LA English
DT Letter
ID PLASMA; TRANSMISSION; INFECTION; EXPOSURE; PARV4
C1 [Slavov, S. N.; Kashima, S.; Rocha-Junior, M. C.; Silva-Pinto, A. C.; Oliveira, L. C.; Covas, D. T.] Univ Sao Paulo, Fac Med Ribeirao Preto, Reg Blood Ctr Ribeirao Preto, Sao Paulo, Brazil.
   [Kashima, S.; Rocha-Junior, M. C.] Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, Sao Paulo, Brazil.
   [Eis-Huebinger, A. M.] Univ Bonn, Med Ctr, Inst Virol, Bonn, Germany.
   [Covas, D. T.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, 3R-41051140 Sao Paulo, Brazil.
RP Slavov, SN (corresponding author), Univ Sao Paulo, Ctr Reg Hemoterapia HCFMRP, Rua Tenente Catao Roxo 2501, 3R-41051140 Sao Paulo, Brazil.
EM svetoslav.slavov@hemocentro.fmrp.usp.br
RI Covas, Dimas T/C-5431-2013; N, Svetoslav/M-5416-2017; CTC USP, CEPID 13
   18/J-8951-2014; Kashima, Simone/G-4876-2012
OI Covas, Dimas T/0000-0002-7364-2595; CTC USP, CEPID 13
   18/0000-0002-7123-9524; Slavov, Svetoslav/0000-0003-0805-6140; Kashima,
   Simone/0000-0002-1487-0141
CR Baylis SA, 2013, TRANSFUSION, V53, P2585, DOI 10.1111/trf.12372
   Delwart E, 2012, TRANSFUSION, V52, P1398, DOI 10.1111/j.1537-2995.2012.03721.x
   Eis-Hubinger AM, 2010, TRANSFUSION, V50, P266, DOI 10.1111/j.1537-2995.2009.02433.x
   Fryer JF, 2007, TRANSFUSION, V47, P1054, DOI 10.1111/j.1537-2995.2007.01235.x
   Lahtinen A, 2011, EMERG INFECT DIS, V17, P79, DOI 10.3201/eid1701.100750
   Maple PAC, 2013, TRANSFUSION, V53, P2575, DOI 10.1111/trf.12278
   Sharp CP, 2012, TRANSFUSION, V52, P1482, DOI 10.1111/j.1537-2995.2011.03420.x
   Sharp CP, 2010, EMERG INFECT DIS, V16, P1605, DOI 10.3201/eid1610.101001
   Sharp CP, 2009, J INFECT DIS, V200, P1119, DOI 10.1086/605646
   Touinssi M, 2010, EMERG INFECT DIS, V16, P165, DOI 10.3201/eid1601.090517
NR 10
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-8216
EI 1365-2516
J9 HAEMOPHILIA
JI Haemophilia
PD JAN
PY 2015
VL 21
IS 1
BP E86
EP E88
DI 10.1111/hae.12564
PG 3
WC Hematology
SC Hematology
GA AX5RU
UT WOS:000346985600017
PM 25311656
DA 2020-11-26
ER

PT J
AU Slavov, SN
   Otaguiri, KK
   Macedo, MD
   Rocha, MC
   Silva-Pinto, AC
   Kashima, S
   Covas, DT
AF Slavov, Svetoslav Nanev
   Otaguiri, Katia Kaori
   Macedo, Mayra Dorigan
   Rocha-Junior, Mauricio Cristiano
   Silva-Pinto, Ana Cristina
   Kashima, Simone
   Covas, Dimas Tadeu
TI No evidence of xenotropic murine leukemia virus-related virus infection
   in Brazilian multiply transfused patients with sickle cell disease and
   beta-thalassemia major
SO NEW MICROBIOLOGICA
LA English
DT Article
DE Xenotropic murine leukemia virus-related virus; XMRV; Sickle cell
   disease; Beta-thalassemia major; Blood donors
ID CHRONIC-FATIGUE-SYNDROME; PROSTATE-CANCER PATIENTS; BLOOD-DONORS;
   GENE-SEQUENCES; UNITED-STATES; MOUSE DNA; XMRV; CONTAMINATION;
   RETROVIRUS; ABSENCE
AB Although xenotropic murine leukemia virus-related virus (XMRV) has been regarded as a laboratory contaminant, it remains one of the most controversial viruses. The objective of the study was to determine if XMRV is present in 44 patients with beta-thalassemia major, 48 with sickle cell disease, and 89 volunteer blood donors. After RNA/DNA extraction from plasma/buffy coat the samples were screened for XMRV sequences by conserved nested GAG primers. None of the RNA samples showed a positive result. Surprisingly, four DNA samples obtained from blood donors were positive for XMRV provirus. The subsequent phylogenetic analysis revealed that these sequences are identical to the positive control (murine leukemia retrovirus) and are probably consistent with laboratory contamination. XMRV infection (provirus and viral RNA) was absent in multiply transfused patients and volunteer blood donors. The positive result obtained from some blood donors probably reflects laboratory contamination. We believe that XMRV does not pose risk to blood transfusion.
C1 [Slavov, Svetoslav Nanev; Otaguiri, Katia Kaori; Macedo, Mayra Dorigan; Rocha-Junior, Mauricio Cristiano; Silva-Pinto, Ana Cristina; Kashima, Simone; Covas, Dimas Tadeu] Univ Sao Paulo, Fac Med Ribeirao Preto, Reg Blood Ctr Ribeirao Preto, Sao Paulo, Brazil.
   [Otaguiri, Katia Kaori; Macedo, Mayra Dorigan; Rocha-Junior, Mauricio Cristiano] Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, Sao Paulo, Brazil.
   [Covas, Dimas Tadeu] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Sao Paulo, Brazil.
RP Slavov, SN (corresponding author), HCFMRP USP, Ctr Reg Hemoterapia, Rua Tenente Catao Roxo 2501, BR-41051140 Sao Paulo, Brazil.
EM svetoslav.slavov@hemocentro.fmrp.usp.br
RI N, Svetoslav/M-5416-2017; Covas, Dimas T/C-5431-2013; CTC USP, CEPID 13
   18/J-8951-2014; Kashima, Simone/G-4876-2012
OI Covas, Dimas T/0000-0002-7364-2595; CTC USP, CEPID 13
   18/0000-0002-7123-9524; Slavov, Svetoslav/0000-0003-0805-6140; Kashima,
   Simone/0000-0002-1487-0141; Pinto, Ana/0000-0002-4104-2296
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo-FAPESP,
   BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2009/16623-1, CTC-1998/14.247-6, INCTC-2008/57.877-3]; Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico, BrazilNational
   Council for Scientific and Technological Development (CNPq)
   [INC-TC-573.754/2008-0]
FX The study was supported by the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo-FAPESP, Brazil (Grants N. 2009/16623-1, CTC-1998/14.247-6
   and INCTC-2008/57.877-3), and the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico, Brazil (INC-TC-573.754/2008-0). We are also
   grateful to Sandra Navarro Bresciani for the artwork.
CR Alberts B, 2011, SCIENCE, V334, P1636, DOI 10.1126/science.334.6063.1636-a
   Ali MA, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-450
   Arnold RS, 2010, UROLOGY, V75, P755, DOI 10.1016/j.urology.2010.01.038
   Bacich Dean J, 2011, BMC Res Notes, V4, P457, DOI 10.1186/1756-0500-4-457
   Danielson BP, 2010, J INFECT DIS, V202, P1470, DOI 10.1086/656146
   Dodd RY, 2012, TRANSFUSION, V52, P298, DOI 10.1111/j.1537-2995.2011.03450.x
   Dolgin E, 2010, NAT MED, V16, P832, DOI 10.1038/nm0810-832a
   Dong B, 2007, P NATL ACAD SCI USA, V104, P1655, DOI 10.1073/pnas.0610291104
   Erlwein O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023484
   Erlwein O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008519
   Fischera N, 2008, J CLIN VIROL, V43, P277, DOI 10.1016/j.jcv.2008.04.016
   Furuta RA, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-20
   Gingaras C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031398
   Gray ER, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018096
   He XT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047208
   Hohn O, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-92
   Hong P, 2012, VIRUS RES, V167, P1, DOI 10.1016/j.virusres.2012.04.004
   Hong P, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-224
   Hue S, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-111
   Kaiser J, 2011, SCIENCE, V331, P17, DOI 10.1126/science.331.6013.17
   Knox K, 2011, SCIENCE, V333, P94, DOI 10.1126/science.1204963
   Korn K, 2012, INFECTION, V40, P181, DOI 10.1007/s15010-012-0249-2
   Lo SC, 2010, P NATL ACAD SCI USA, V107, P15874, DOI 10.1073/pnas.1006901107
   Lombardi VC, 2009, SCIENCE, V326, P585, DOI 10.1126/science.1179052
   Maggi F, 2012, INT J IMMUNOPATH PH, V25, P523, DOI 10.1177/039463201202500224
   Matsumoto C, 2012, JPN J INFECT DIS, V65, P334, DOI 10.7883/yoken.65.334
   Mi ZQ, 2012, TRANSFUSION, V52, P326, DOI 10.1111/j.1537-2995.2011.03267.x
   Oakes B, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-109
   Oltra E, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-332
   Rezaei SD, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-20
   Robinson MJ, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-108
   Sakuma T, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-23
   Sato E, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-110
   Schlaberg R, 2009, P NATL ACAD SCI USA, V106, P16351, DOI 10.1073/pnas.0906922106
   Tang SX, 2011, TRANSFUSION, V51, P463, DOI 10.1111/j.1537-2995.2010.02932.x
   Touinssi M, 2012, BLOOD TRANSFUS-ITALY, V10, P553, DOI 10.2450/2012.0137-11
   Urisman A, 2006, PLOS PATHOG, V2, P211, DOI 10.1371/journal.ppat.0020025
   van Kuppeveld FJM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1018
   Wolff D, 2011, CLIN LAB, V57, P631
   Yang JW, 2011, ONCOTARGET, V2, P358
   Zheng HQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029050
NR 41
TC 1
Z9 1
U1 0
U2 1
PU EDIZIONI INT SRL
PI PAVIA
PA DIV EDIMES, EDIZIONI MEDICO SCIENTIFICHE PAVIA, VIA RIVIERA, PAVIA,
   39-27100, ITALY
SN 1121-7138
J9 NEW MICROBIOL
JI New Microbiol.
PD OCT
PY 2014
VL 37
IS 4
BP 543
EP 550
PG 8
WC Microbiology
SC Microbiology
GA AU6QO
UT WOS:000345727300013
PM 25387292
DA 2020-11-26
ER

PT J
AU Pinto, MT
   Malta, TM
   Rodrigues, ES
   Pinheiro, DG
   Panepucci, RA
   de Farias, KCRM
   Sousa, AD
   Takayanagui, OM
   Tanaka, Y
   Covas, DT
   Kashima, S
AF Pinto, Mariana Tomazini
   Malta, Tathiane Maistro
   Rodrigues, Evandra Strazza
   Pinheiro, Daniel Guariz
   Panepucci, Rodrigo Alexandre
   Ribeiro Malmegrim de Farias, Kelen Cristina
   Sousa, Alessandra De Paula
   Takayanagui, Osvaldo Massaiti
   Tanaka, Yuetsu
   Covas, Dimas Tadeu
   Kashima, Simone
TI Genes Related to Antiviral Activity, Cell Migration, and Lysis Are
   Differentially Expressed in CD4(+) T Cells in Human T Cell Leukemia
   Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis Patients
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID I-ASSOCIATED MYELOPATHY; PROINFLAMMATORY CYTOKINE PRODUCTION;
   PERIPHERAL-BLOOD LYMPHOCYTES; TRANSCRIPTION FACTOR FOXP3; SPINAL-CORD
   LESIONS; HEPATITIS-C VIRUS; HTLV-I; MESSENGER-RNA; GRANZYME-B; RT-PCR
AB Human T cell leukemia virus type 1 (HTLV-1) preferentially infects CD4(+) T cells and these cells play a central role in HTLV-1 infection. In this study, we investigated the global gene expression profile of circulating CD4(+) T cells from the distinct clinical status of HTLV-1-infected individuals in regard to TAX expression levels. CD4(+) T cells were isolated from asymptomatic HTLV-1 carrier (HAC) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients in order to identify genes involved in HAM/TSP development using a microarray technique. Hierarchical clustering analysis showed that healthy control (CT) and HTLV-1-infected samples clustered separately. We also observed that the HAC and HAM/TSP groups clustered separately regardless of TAX expression. The gene expression profile of CD4(+) T cells was compared among the CT, HAC, and HAM/TSP groups. The paxillin (Pxn), chemokine (C-X-C motif) receptor 4 (Cxcr4), interleukin 27 (IL27), and granzyme A (Gzma) genes were differentially expressed between the HAC and HAM/TSP groups, regardless of TAX expression. The perforin 1 (Prf1) and forkhead box P3 (Foxp3) genes were increased in the HAM/TSP group and presented a positive correlation to the expression of TAX and the proviral load (PVL). The frequency of CD4(+)FOXP3(+) regulatory T cells (Treg) was higher in HTLV-1-infected individuals. Foxp3 gene expression was positively correlated with cell lysis-related genes (Gzma, Gzmb, and Prf1). These findings suggest that CD4(+) T cell activity is distinct between the HAC and HAM/TSP groups.
C1 [Pinto, Mariana Tomazini; Malta, Tathiane Maistro; Rodrigues, Evandra Strazza; Pinheiro, Daniel Guariz; Panepucci, Rodrigo Alexandre; Ribeiro Malmegrim de Farias, Kelen Cristina; Sousa, Alessandra De Paula; Covas, Dimas Tadeu; Kashima, Simone] Natl Inst Sci & Technol Stem Cell & Cell Therapy, Ctr Cell Based Therapy, Ribeirao Preto, Brazil.
   [Pinto, Mariana Tomazini; Malta, Tathiane Maistro; Rodrigues, Evandra Strazza; Pinheiro, Daniel Guariz; Panepucci, Rodrigo Alexandre; Ribeiro Malmegrim de Farias, Kelen Cristina; Sousa, Alessandra De Paula; Covas, Dimas Tadeu; Kashima, Simone] Natl Inst Sci & Technol Stem Cell & Cell Therapy, Reg Blood Ctr Ribeirao Preto, Ribeirao Preto, Brazil.
   [Pinto, Mariana Tomazini; Malta, Tathiane Maistro; Rodrigues, Evandra Strazza; Ribeiro Malmegrim de Farias, Kelen Cristina; Kashima, Simone] Univ Sao Paulo, Fac Pharmaceut Sci, BR-14049 Ribeirao Preto, Brazil.
   [Pinheiro, Daniel Guariz] Univ Sao Paulo, Dept Genet, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, Brazil.
   [Panepucci, Rodrigo Alexandre; Takayanagui, Osvaldo Massaiti; Covas, Dimas Tadeu] Univ Sao Paulo, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, Brazil.
   [Tanaka, Yuetsu] Univ Ryukyus, Grad Sch Med, Dept Immunol, Okinawa, Japan.
RP Kashima, S (corresponding author), Reg Blood Ctr Ribeirao Preto, Rua Tenente Catao Roxo 2501, BR-14051140 Sao Paulo, Brazil.
EM skashima@hemocentro.fmrp.usp.br
RI Rodrigues, Evandra/L-6094-2017; Malmegrim, Kelen/H-1016-2015; Pinheiro,
   Daniel/H-4604-2012; Panepucci, Rodrigo A/C-2365-2012; Takayanagui,
   Osvaldo M/C-8159-2013; Covas, Dimas T/C-5431-2013; Pinto,
   Mariana/B-6129-2017; Malta, Tathiane/N-1686-2013; Kashima,
   Simone/G-4876-2012; CTC USP, CEPID 13 18/J-8951-2014
OI Rodrigues, Evandra/0000-0003-0964-9554; Malmegrim,
   Kelen/0000-0002-9303-0086; Pinheiro, Daniel/0000-0001-7062-5936;
   Panepucci, Rodrigo A/0000-0002-1119-4352; Takayanagui, Osvaldo
   M/0000-0002-8190-0275; Covas, Dimas T/0000-0002-7364-2595; Pinto,
   Mariana/0000-0002-5176-7776; Malta, Tathiane/0000-0003-1129-5791;
   Kashima, Simone/0000-0002-1487-0141; CTC USP, CEPID 13
   18/0000-0002-7123-9524
FU Fundacao Hemocentro de Ribeirao Preto (FUNDHERP); Sao Paulo Research
   Foundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2011/21740-7]
FX The authors thank Rochele Azevedo for quantification of the proviral
   load, Patricia Vianna Bonini Palma for flow cytometry analysis, Amelia
   Goes de Araujo for her assistance with the microarray technique,
   Mauricio Cristiano Rocha Junior for help in writing the paper, and Prof.
   Charles Bangham for TAX expression analysis. They are also grateful to
   the patients. This work was supported by Fundacao Hemocentro de Ribeirao
   Preto (FUNDHERP) and Sao Paulo Research Foundation (FAPESP-Process
   number: 2011/21740-7)
CR Amadi-Obi A, 2007, NAT MED, V13, P711, DOI 10.1038/nm1585
   Arai M, 1998, VIROLOGY, V241, P298, DOI 10.1006/viro.1997.8968
   Araujo AQC, 2006, LANCET NEUROL, V5, P1068, DOI 10.1016/S1474-4422(06)70628-7
   Batten M, 2006, NAT IMMUNOL, V7, P929, DOI 10.1038/ni1375
   Best I, 2009, IMMUNOLOGY, V128, pe777, DOI 10.1111/j.1365-2567.2009.03082.x
   Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023
   Cao XF, 2007, IMMUNITY, V27, P635, DOI 10.1016/j.immuni.2007.08.014
   Catalan-Soares Bernadette, 2005, Cad. Saúde Pública, V21, P926, DOI 10.1590/S0102-311X2005000300027
   Chang SC, 2000, J VIROL, V74, P9732, DOI 10.1128/JVI.74.20.9732-9737.2000
   Chuaqui RF, 2002, NAT GENET, V32, P509, DOI 10.1038/ng1034
   Corti B, 2005, TRANSPL P, V37, P4467, DOI 10.1016/j.transproceed.2005.11.035
   De Castro-Costa CM, 2006, AIDS RES HUM RETROV, V22, P931, DOI 10.1089/aid.2006.22.931
   Dourado I, 2003, JAIDS-J ACQ IMM DEF, V34, P527, DOI 10.1097/00126334-200312150-00013
   Fakruddin JM, 2007, BLOOD, V109, P1841, DOI 10.1182/blood-2006-02-001578
   Fernandis AZ, 2004, ONCOGENE, V23, P157, DOI 10.1038/sj.onc.1206910
   Fontenot JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179
   Frank AC, 2010, J INTERF CYTOK RES, V30, P427, DOI 10.1089/jir.2009.0093
   Freeman WM, 1999, BIOTECHNIQUES, V26, P112, DOI 10.2144/99261rv01
   Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169
   GESSAIN A, 1985, LANCET, V2, P407
   Ghazalpour A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001393
   Goon PKC, 2004, J IMMUNOL, V172, P1735, DOI 10.4049/jimmunol.172.3.1735
   Goon PKC, 2002, BLOOD, V99, P3335, DOI 10.1182/blood.V99.9.3335
   Greenbaum D, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-117
   Greenwell-Wild T, 2009, BLOOD, V114, P1864, DOI 10.1182/blood-2009-03-211540
   Grossman WJ, 2004, IMMUNITY, V21, P589, DOI 10.1016/j.immuni.2004.09.002
   Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720
   Hamano S, 2003, IMMUNITY, V19, P657, DOI 10.1016/S1074-7613(03)00298-X
   Hartmann TN, 2005, ONCOGENE, V24, P4462, DOI 10.1038/sj.onc.1208621
   Hashimoto K, 1998, J NEUROL SCI, V159, P67, DOI 10.1016/S0022-510X(98)00138-5
   Hayashi D, 2008, J NEUROIMMUNOL, V200, P115, DOI 10.1016/j.jneuroim.2008.06.005
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929
   Imamichi T, 2008, AIDS, V22, P39, DOI 10.1097/QAD.0b013e3282f3356c
   Jazin EE, 1997, J NEUROIMMUNOL, V79, P148, DOI 10.1016/S0165-5728(97)00117-3
   KAPLAN TA, 1990, PHYS REV B, V41, P6882, DOI 10.1103/PhysRevB.41.6882
   Kawaguchi A, 2009, BLOOD, V114, P2961, DOI 10.1182/blood-2008-11-189308
   Kubota R, 1998, J IMMUNOL, V161, P482
   LAGRENADE L, 1990, LANCET, V336, P1345
   Larousserie F, 2005, AM J PATHOL, V166, P1217, DOI 10.1016/S0002-9440(10)62340-1
   Lima MASD, 2005, J NEUROL NEUROSUR PS, V76, P294, DOI 10.1136/jnnp.2004.035709
   Luker KE, 2006, CANCER LETT, V238, P30, DOI 10.1016/j.canlet.2005.06.021
   Malec M, 2004, LEUKEMIA, V18, P1630, DOI 10.1038/sj.leu.2403444
   Malta TM, 2013, AIDS RES HUM RETROV, V29, P826, DOI [10.1089/aid.2012.0205, 10.1089/AID.2012.0205]
   Mariette X, 2000, CLIN EXP RHEUMATOL, V18, P341
   Matsuura E, 2010, J NEUROIMMUNE PHARM, V5, P310, DOI 10.1007/s11481-010-9216-9
   Miyazaki Y, 2008, BIOCHEM BIOPH RES CO, V373, P397, DOI 10.1016/j.bbrc.2008.06.038
   Mochizuki M, 1996, J ACQ IMMUN DEF SYND, V13, pS50, DOI 10.1097/00042560-199600001-00010
   Moepps B, 1997, EUR J IMMUNOL, V27, P2102, DOI 10.1002/eji.1830270839
   MORGAN OS, 1989, LANCET, V2, P1184
   MURPHY EL, 1989, ANN INTERN MED, V111, P555, DOI 10.7326/0003-4819-111-7-555
   Nagai M, 1998, J NEUROVIROL, V4, P586, DOI 10.3109/13550289809114225
   NAKAGAWA M, 1995, J NEUROVIROL, V1, P50, DOI 10.3109/13550289509111010
   Niedbala W, 2008, ANN RHEUM DIS, V67, P1474, DOI 10.1136/ard.2007.083360
   NISHIOKA K, 1989, LANCET, V1, P441
   Nose H, 2007, J INFECT DIS, V196, P1761, DOI 10.1086/522966
   Oh U, 2006, J INFECT DIS, V193, P1557, DOI 10.1086/503874
   Oliere S, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001177
   OSAME M, 1986, LANCET, V1, P1031
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pflanz S, 2002, IMMUNITY, V16, P779, DOI 10.1016/S1074-7613(02)00324-2
   Pinto MT, 2012, REV INST MED TROP SP, V54, P123, DOI 10.1590/S0036-46652012000300002
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990
   Roncador G, 2005, LEUKEMIA, V19, P2247, DOI 10.1038/sj.leu.2403965
   Sarwal MM, 2001, HUM IMMUNOL, V62, P21, DOI 10.1016/S0198-8859(00)00228-7
   Satou Y, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-46
   Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098
   Shi RL, 2004, TRANSPL IMMUNOL, V12, P103, DOI 10.1016/j.trim.2003.11.002
   Shin GT, 2005, NEPHRON CLIN PRACT, V100, pC63, DOI 10.1159/000085050
   Stumhofer JS, 2006, NAT IMMUNOL, V7, P937, DOI 10.1038/ni1376
   TACHIBANA N, 1988, INT J CANCER, V42, P829, DOI 10.1002/ijc.2910420605
   Tan PK, 2003, NUCLEIC ACIDS RES, V31, P5676, DOI 10.1093/nar/gkg763
   Taylor JM, 2008, APOPTOSIS, V13, P733, DOI 10.1007/s10495-008-0208-7
   Toulza F, 2008, BLOOD, V111, P5047, DOI 10.1182/blood-2007-10-118539
   UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481
   UMEHARA F, 1994, J NEUROPATH EXP NEUR, V53, P72, DOI 10.1097/00005072-199401000-00009
   UMEHARA F, 1993, J NEUROPATH EXP NEUR, V52, P424, DOI 10.1097/00005072-199307000-00010
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   VERNANT JC, 1987, ANN NEUROL, V21, P123, DOI 10.1002/ana.410210204
   Vine AM, 2004, J IMMUNOL, V173, P5121, DOI 10.4049/jimmunol.173.8.5121
   Vlad G, 2007, TRANSPL IMMUNOL, V18, P13, DOI 10.1016/j.trim.2007.03.001
   Vogel C, 2012, NAT REV GENET, V13, P227, DOI 10.1038/nrg3185
   Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941
   Wang JH, 2008, J AUTOIMMUN, V30, P222, DOI 10.1016/j.jaut.2007.10.001
   Wurmbach E, 2003, METHODS, V31, P306, DOI 10.1016/S1046-2023(03)00161-0
   Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15
   Yauk CL, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh123
   YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534
   Yoshimura T, 2006, J IMMUNOL, V177, P5377, DOI 10.4049/jimmunol.177.8.5377
   Zhao DM, 2006, BLOOD, V107, P3925, DOI 10.1182/blood-2005-11-4502
   Zhu BM, 2005, GENOMICS, V85, P657, DOI 10.1016/j.ygeno.2005.02.012
   Ziegler SF, 2006, ANNU REV IMMUNOL, V24, P209, DOI 10.1146/annurev.immunol.24.021605.090547
NR 93
TC 5
Z9 5
U1 0
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD JUN
PY 2014
VL 30
IS 6
BP 610
EP 622
DI 10.1089/aid.2013.0109
PG 13
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AI9CE
UT WOS:000337224400015
PM 24041428
OA Green Published
DA 2020-11-26
ER

PT J
AU Ferreira, AF
   Moura, LG
   Tojal, I
   Ambrosio, L
   Pinto-Simoes, B
   Hamerschlak, N
   Calin, GA
   Ivan, C
   Covas, DT
   Kashima, S
   Castro, FA
AF Ferreira, A. F.
   Moura, L. G.
   Tojal, I.
   Ambrosio, L.
   Pinto-Simoes, B.
   Hamerschlak, N.
   Calin, G. A.
   Ivan, C.
   Covas, D. T.
   Kashima, S.
   Castro, F. A.
TI ApoptomiRs expression modulated by BCR-ABL is linked to CML progression
   and imatinib resistance
SO BLOOD CELLS MOLECULES AND DISEASES
LA English
DT Article
DE MicroRNA; Chronic myeloid leukemia; Apoptosis; Imatinib response
ID CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; APOPTOSIS;
   CELLS; INHIBITOR; MCL-1
AB Background: Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by the presence of Philadelphia chromosome (Ph) leading to expression of a BCR-ABL1 fusion oncogene. The BCR-ABL protein has a constitutive tyrosine kinase activity which is responsible for CML pathogenesis by promoting cell apoptosis resistance; however, the cellular and molecular mechanisms associated with BCR-ABL expression and apoptosis impairment in CML leukemic cells have not been fully elucidated.
   Methods: This study evaluated apoptomiRs and their predicted apoptotic genes in BCR-ABL(+) cells from patients in different phases of CML treated with tyrosine kinase inhibitor (TKI) according to their imatinib (IM) response by qPCR Phosphotyrosine and c-ABL expressions in HL-60.BCR-ABL cells treated with TKI were done by Western blot.
   Results: We found that dasatinib (DAS) modulated miR-let-7d, miR-let-7e, miR-15a, miR-16, miR-21, miR-130a and miR-142-3p expressions while IM modulated miR-15a and miR-130a levels. miR-16, miR-130a and miR-145 expressions were modulated by nilotinib (NIL). We observed higher miR-15a, miR-130b and miR-145; and lower miR-16, miR-26a and miR-146a expressions in CML-CP in comparison with controls. CML-AP patients showed low miR-let-7d, miR-15a, miR-16, miR-29c, miR-142-3p, miR-145, and miR-146a levels in comparison with CML-CP. We noted that the miR-26a, miR-29c, miR-130b and miR-146a expressions were downregulated in IM resistant patients in comparison with IM responsive patients.
   Conclusions: This study showed the modulation of apoptomiRs by BCR-ABL kinase activity and the deregulation of apoptomiRs and their predicted apoptotic target genes in different CML phases and after treatment with TK inhibitors. ApoptomiRs may be involved in the BCR-ABL+ cell apoptosis regulation. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Ferreira, A. F.; Moura, L. G.; Ambrosio, L.; Castro, F. A.] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeiro Preto, Dept Anal Clin Toxicol & Bromatolog, BR-05508 Sao Paulo, Brazil.
   [Tojal, I.; Covas, D. T.; Kashima, S.] Ctr Reg Hemoterapia Ribeirao Preto, Sao Paulo, Brazil.
   [Pinto-Simoes, B.; Covas, D. T.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, BR-05508 Sao Paulo, Brazil.
   [Hamerschlak, N.] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Calin, G. A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.
   [Ivan, C.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNAs, Houston, TX 77030 USA.
RP Ferreira, AF (corresponding author), Univ Sao Paulo, Fac Ciencias Farmaceut Ribeiro Preto, Dept Anal Clin Toxicol & Bromatolog, BR-05508 Sao Paulo, Brazil.
EM alineferreira591@gmail.com
RI Simoes, Belinda P/M-7469-2016; Covas, Dimas T/C-5431-2013; Calin,
   George/E-9390-2011; Hamerschlak, Nelson/M-8060-2015; CTC USP, CEPID 13
   18/J-8951-2014; Kashima, Simone/G-4876-2012
OI Covas, Dimas T/0000-0002-7364-2595; Hamerschlak,
   Nelson/0000-0002-5140-5310; Ivan, Cristina/0000-0002-4848-0168; Calin,
   George/0000-0001-6704-5615; CTC USP, CEPID 13 18/0000-0002-7123-9524;
   Kashima, Simone/0000-0002-1487-0141; Calin, George/0000-0002-7427-0578
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2005/57746-8, 2008/ 52049-5, 2011/20135-2]; CNPqNational Council for
   Scientific and Technological Development (CNPq)
FX We first wish to thank the CML patients who participated in this study.
   We are grateful to Zita Gregorio for her technical assistance and help
   in collecting peripheral blood samples. We thank to Dr. Gustavo Amarante
   Mendes for giving us the HL-60.BCR-ABL cell line. This work was
   supported by FAPESP Grant Numbers 2005/57746-8, 2008/ 52049-5,
   2011/20135-2 and CNPq.
CR Aichberger KJ, 2005, BLOOD, V105, P3303, DOI 10.1182/blood-2004-02-0749
   Amarante-Mendes GP, 1999, BRAZ J MED BIOL RES, V32, P1053, DOI 10.1590/S0100-879X1999000900001
   Beverly LJ, 2009, ONCOGENE, V28, P1274, DOI 10.1038/onc.2008.466
   Brieger A, 2004, BIOCHEM PHARMACOL, V68, P85, DOI 10.1016/j.bcp.2004.02.028
   Bueno-da-Silva AEB, 2003, CELL DEATH DIFFER, V10, P592, DOI 10.1038/sj.cdd.4401210
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Careta F.P., 2007, THESIS RIBEIERAO PRE
   Cheng YH, 2007, AM J PATHOL, V170, P1831, DOI 10.2353/ajpath.2007.061170
   Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102
   Deininger MWN, 2000, CANCER RES, V60, P2049
   Eneriz E.S.J., 2009, MOL CANCER, V8, P69
   Faderl S, 1999, ONCOLOGY-NY, V13, P169
   Flamant S, 2010, HAEMATOL-HEMATOL J, V95, P1325, DOI 10.3324/haematol.2009.020636
   Guo WC, 2012, MOL PHARMACOL, V82, P938, DOI 10.1124/mol.112.079889
   Gutierrez-Castellanos S, 2004, EUR J HAEMATOL, V72, P231, DOI 10.1046/j.0902-4441.2003.00201.x
   Hochhaus A, 2002, LEUKEMIA, V16, P2190, DOI 10.1038/sj.leu.2402741
   Melo JV, 2007, NAT REV CANCER, V7, P441, DOI 10.1038/nrc2147
   Metais JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048267
   Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436
   Nuovo GJ, 2012, MODERN PATHOL, V25, P1333, DOI 10.1038/modpathol.2012.95
   Perrotti D, 2007, CLIN CANCER RES, V13, P1638, DOI 10.1158/1078-0432.CCR-06-2320
   Rokah OH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035501
   Seca H, 2010, EUR J CANCER, V46, P1520, DOI 10.1016/j.ejca.2010.03.031
   Spinello I., BLOOD CANC J, V1
   Suresh S, 2011, J CELL COMMUN SIGNAL, V5, P183, DOI 10.1007/s12079-011-0139-x
   Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103
   Wei W, 2013, APOPTOSIS, V18, P1060, DOI 10.1007/s10495-013-0854-2
   Xiong YJ, 2010, HEPATOLOGY, V51, P836, DOI 10.1002/hep.23380
   Zanette DL, 2007, BRAZ J MED BIOL RES, V40, P1435, DOI 10.1590/S0100-879X2007001100003
NR 29
TC 16
Z9 18
U1 0
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1079-9796
EI 1096-0961
J9 BLOOD CELL MOL DIS
JI Blood Cells Mol. Dis.
PD JUN-AUG
PY 2014
VL 53
IS 1-2
BP 47
EP 55
DI 10.1016/j.bcmd.2014.02.008
PG 9
WC Hematology
SC Hematology
GA AH8VJ
UT WOS:000336416000009
PM 24629639
DA 2020-11-26
ER

PT J
AU Garcia, FB
   Kashima, S
   Rodrigues, ES
   Silva, IT
   Malta, TM
   Nicolete, LDD
   Haddad, R
   Moraes-Souza, H
   Covas, DT
AF Garcia, F. B.
   Kashima, S.
   Rodrigues, E. S.
   Silva, I. T.
   Malta, T. M.
   de Figueiredo Nicolete, L. D.
   Haddad, R.
   Moraes-Souza, H.
   Covas, D. T.
TI Novel polymorphisms in the promoter region of the perforin gene among
   distinct Brazilian populations and their functional impact
SO INTERNATIONAL JOURNAL OF IMMUNOGENETICS
LA English
DT Article
ID MEDIATED CYTOTOXICITY; REGULATORY SEQUENCES; EXPRESSION; CELLS;
   LYMPHOCYTES; ACTIVATION; DEATH; SURVEILLANCE; MECHANISMS; HAPLOTYPES
AB Cytotoxic T lymphocytes and natural killer cells play a crucial role in eliminating tumour and virus-infected cells. The perforin is a key part of the arsenal that these cells use to destroy their targets. In this study, we characterized single-nucleotide polymorphisms (SNPs) located in the promoter region of the perforin gene among distinct Brazilian ethnic groups. The study was carried out by sequencing this region in three groups: European, African and Asian descents. We demonstrated for the first time the occurrence of three new polymorphisms in the promoter region of gene PRF1: 494A/G (rs78058707), 720G/A (rs75925789) and 1176C/T (rs75183511). Three other SNPs already described in the literature 63A/G (rs35401316), 112A/G (rs10999428) and 1012C/T (rs35069510) were also detected. The SNPs are distributed differently in the ethnic groups studied. The 112G allele was observed at high frequency, especially among Asian descents (48.1%). The 1012T allele was detected only among European descents, the 494G allele only among Asian descents and 1176T allele only in African descents. Based on the association between the polymorphisms described, ten new haplotypes were originated. In functional analysis, we noticed that SNPs present in most common haplotypes cannot induce significant differences in expression levels of perforin alone. In conclusion, this study demonstrates for the first time the existence of three new polymorphisms in perforin promoter and, contrary to what was stated, the presence of these SNPs does not alter the levels of protein expression.
C1 [Garcia, F. B.] Univ Fed Triangulo Mineiro, BR-38025440 Uberaba, MG, Brazil.
   [Kashima, S.; Rodrigues, E. S.; Silva, I. T.; Malta, T. M.; de Figueiredo Nicolete, L. D.; Covas, D. T.] Univ Sao Paulo, Ctr Reg Hemoterapia, Sao Paulo, Brazil.
   [Kashima, S.; Malta, T. M.] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Sao Paulo, Brazil.
   [Silva, I. T.; Covas, D. T.] Univ Sao Paulo, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
   [Haddad, R.] Univ Brasilia, Fac Ceilandia, Brasilia, DF, Brazil.
   [Moraes-Souza, H.] Fundacao Hemominas, Hemoctr Reg Uberaba, Uberaba, MG, Brazil.
RP Garcia, FB (corresponding author), Univ Fed Triangulo Mineiro, Discipline Hematol & Hemotherapy, Ave Getulio Guarita 250, BR-38025440 Uberaba, MG, Brazil.
EM nandadel-li@yahoo.com.br
RI Covas, Dimas T/C-5431-2013; Moraes-Souza, Helio/O-7720-2015; Silva,
   Israel T/N-3858-2014; Malta, Tathiane/N-1686-2013; Rodrigues,
   Evandra/L-6094-2017; Haddad, Rodrigo/A-3460-2013; Kashima,
   Simone/G-4876-2012; CTC USP, CEPID 13 18/J-8951-2014
OI Covas, Dimas T/0000-0002-7364-2595; Silva, Israel T/0000-0002-4687-1499;
   Malta, Tathiane/0000-0003-1129-5791; Rodrigues,
   Evandra/0000-0003-0964-9554; Haddad, Rodrigo/0000-0003-4699-164X;
   Kashima, Simone/0000-0002-1487-0141; Moraes-Souza,
   Helio/0000-0001-8049-348X; CTC USP, CEPID 13 18/0000-0002-7123-9524
CR Albesiano E, 2003, BLOOD, V102, P3333, DOI 10.1182/blood-2003-05-1585
   Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819
   Chen HJ, 2005, HUM MUTAT, V25, P150, DOI 10.1002/humu.20127
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   Excoffier L, 1998, AM J HUM GENET, V62, P171, DOI 10.1086/301674
   EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921
   Excoffier L, 2005, EVOL BIOINFORM, V1, P47, DOI 10.1177/117693430500100003
   FINK TM, 1992, GENOMICS, V13, P1300, DOI 10.1016/0888-7543(92)90050-3
   GARCIASANZ JA, 1993, EUR J IMMUNOL, V23, P1877, DOI 10.1002/eji.1830230822
   Glimcher LH, 2004, NAT REV IMMUNOL, V4, P900, DOI 10.1038/nri1490
   GUO SW, 1992, BIOMETRICS, V48, P361, DOI 10.2307/2532296
   HENKART P, 1985, ADV EXP MED BIOL, V184, P121
   HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X
   Johnatty SE, 2002, BRIT J PHARMACOL, V137, P1213, DOI 10.1038/sj.bjp.0704935
   KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614
   Kagi D, 1996, ANNU REV IMMUNOL, V14, P207, DOI 10.1146/annurev.immunol.14.1.207
   LICHTENHELD MG, 1992, J IMMUNOL, V149, P2619
   LICHTENHELD MG, 1995, J IMMUNOL, V154, P2153
   LICHTENHELD MG, 1989, J IMMUNOL, V143, P4267
   McIlroy D, 2006, INT J IMMUNOGENET, V33, P73, DOI 10.1111/j.1744-313X.2006.00571.x
   NAKATA M, 1992, INT IMMUNOL, V4, P1049, DOI 10.1093/intimm/4.9.1049
   Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745
   Pipkin ME, 2007, CURR OPIN IMMUNOL, V19, P301, DOI 10.1016/j.coi.2007.04.011
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Smyth MJ, 2000, J EXP MED, V192, P755, DOI 10.1084/jem.192.5.755
   Stepp SE, 1999, SCIENCE, V286, P1957, DOI 10.1126/science.286.5446.1957
   Trapani JA, 2002, NAT REV IMMUNOL, V2, P735, DOI 10.1038/nri911
   vandenBroek MF, 1996, J EXP MED, V184, P1781, DOI 10.1084/jem.184.5.1781
   Zhang J, 1999, J EXP MED, V190, P1297, DOI 10.1084/jem.190.9.1297
   Zhang YG, 1997, J IMMUNOL, V158, P1734
NR 31
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1744-3121
EI 1744-313X
J9 INT J IMMUNOGENET
JI Int. J. Immunogenet.
PD JUN
PY 2014
VL 41
IS 3
BP 198
EP 205
DI 10.1111/iji.12103
PG 8
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA AH6RY
UT WOS:000336259600003
PM 24321052
DA 2020-11-26
ER

PT J
AU Picanco-Castro, V
   Moreira, LF
   Kashima, S
   Covas, DT
AF Picanco-Castro, Virginia
   Moreira, Lilian F.
   Kashima, Simone
   Covas, Dimas T.
TI Can Pluripotent Stem Cells Be Used in Cell-Based Therapy?
SO CELLULAR REPROGRAMMING
LA English
DT Review
ID HEPATOCYTE-LIKE CELLS; HUMAN FIBROBLASTS; SOMATIC-CELLS;
   DIFFERENTIATION; GENERATION; INDUCTION; IMMUNOGENICITY; VECTOR; LINES
AB Pluripotent stem cells, both embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), have the ability to differentiate into several cell types that can be used in drug testing and also in the study and treatment of diseases. These cells can be differentiated by in vitro systems, which may serve as models for human diseases and for cell transplantation. In this review, we address the pluripotent cell types, how to obtain and characterize these cells, and differentiation assays. We also focus on the potential of these cells in clinical trials, and we describe the clinical trials that are underway.
C1 [Picanco-Castro, Virginia; Moreira, Lilian F.; Kashima, Simone; Covas, Dimas T.] Blood Ctr Ribeirao Preto, BR-14022000 Ribeirao Preto, Brazil.
RP Picanco-Castro, V (corresponding author), Blood Ctr Ribeirao Preto, Rua Tenente Catao Roxo 2501, BR-14022000 Ribeirao Preto, Brazil.
EM virginia.picanco.castro@gmail.com
RI Castro, Virginia/H-2904-2015; Covas, Dimas T/C-5431-2013; Moreira,
   Lilian/H-4907-2015; Picanco-Castro, Virginia/AAC-7242-2019; CTC USP,
   CEPID 13 18/J-8951-2014; Kashima, Simone/G-4876-2012
OI Castro, Virginia/0000-0001-8474-4610; Covas, Dimas
   T/0000-0002-7364-2595; Moreira, Lilian/0000-0001-8108-2703;
   Picanco-Castro, Virginia/0000-0001-8474-4610; CTC USP, CEPID 13
   18/0000-0002-7123-9524; Kashima, Simone/0000-0002-1487-0141
CR Agarwal S, 2008, STEM CELLS, V26, P1117, DOI 10.1634/stemcells.2007-1102
   Araki R, 2013, NATURE, V494, P100, DOI 10.1038/nature11807
   Assady S, 2001, DIABETES, V50, P1691, DOI 10.2337/diabetes.50.8.1691
   BONGSO A, 1994, HUM REPROD, V9, P2110, DOI 10.1093/oxfordjournals.humrep.a138401
   Brolen GKC, 2005, DIABETES, V54, P2867, DOI 10.2337/diabetes.54.10.2867
   Carey BW, 2009, P NATL ACAD SCI USA, V106, P157, DOI 10.1073/pnas.0811426106
   Chen YF, 2012, HEPATOLOGY, V55, P1193, DOI 10.1002/hep.24790
   Choi YJ, 2011, NAT CELL BIOL, V13, P1353, DOI 10.1038/ncb2366
   De Felici M, 2009, CURR STEM CELL RES T, V4, P87
   Duan YY, 2010, STEM CELLS, V28, P674, DOI 10.1002/stem.315
   Fairchild PJ, 2010, NAT REV IMMUNOL, V10, P868, DOI 10.1038/nri2878
   Feng B, 2009, NAT CELL BIOL, V11, P197, DOI 10.1038/ncb1827
   Fusaki N, 2009, P JPN ACAD B-PHYS, V85, P348, DOI 10.2183/pjab.85.348
   Gilbert S. F., 2006, DEV BIOL, V8
   Guha P, 2013, CELL STEM CELL, V12, P407, DOI 10.1016/j.stem.2013.01.006
   Heng JCD, 2010, CELL STEM CELL, V6, P167, DOI 10.1016/j.stem.2009.12.009
   Ichida JK, 2009, CELL STEM CELL, V5, P491, DOI 10.1016/j.stem.2009.09.012
   James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706
   Kadereit S, 2011, SEMIN IMMUNOPATHOL, V33, P551, DOI 10.1007/s00281-011-0265-9
   Kaufman DS, 2001, P NATL ACAD SCI USA, V98, P10716, DOI 10.1073/pnas.191362598
   Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0
   Kehat I, 2001, J CLIN INVEST, V108, P407, DOI 10.1172/JCI12131
   Keirstead HS, 2005, J NEUROSCI, V25, P4694, DOI 10.1523/JNEUROSCI.0311-05.2005
   Kim JB, 2009, NATURE, V461, P649, DOI 10.1038/nature08436
   Kim K, 2010, NATURE, V467, P285, DOI 10.1038/nature09342
   Lavon N, 2005, J CELL BIOCHEM, V96, P1193, DOI 10.1002/jcb.20590
   Levenberg S, 2002, P NATL ACAD SCI USA, V99, P4391, DOI 10.1073/pnas.032074999
   Liu SR, 2004, CELL TISSUE RES, V318, P525, DOI 10.1007/s00441-004-0990-7
   Maekawa M, 2011, NATURE, V474, P225, DOI 10.1038/nature10106
   Maherali N, 2009, CURR BIOL, V19, P1718, DOI 10.1016/j.cub.2009.08.025
   MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634
   Martin MJ, 2005, NAT MED, V11, P228, DOI 10.1038/nm1181
   Morizane A, 2013, STEM CELL REP, V1, P283, DOI 10.1016/j.stemcr.2013.08.007
   Nishikawa S, 2008, NAT REV MOL CELL BIO, V9, P725, DOI 10.1038/nrm2466
   Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270
   Picanco-Castro V, 2011, STEM CELLS DEV, V20, P169, DOI 10.1089/scd.2009.0424
   Rambhatla L, 2003, CELL TRANSPLANT, V12, P1, DOI 10.3727/000000003783985179
   Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134
   Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399
   Samavarchi-Tehrani P, 2010, CELL STEM CELL, V7, P64, DOI 10.1016/j.stem.2010.04.015
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Segev H, 2004, STEM CELLS, V22, P265, DOI 10.1634/stemcells.22-3-265
   Sokol SY, 2011, DEVELOPMENT, V138, P4341, DOI 10.1242/dev.066209
   Sommer CA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051711
   Sommer CA, 2009, STEM CELLS, V27, P543, DOI 10.1634/stemcells.2008-1075
   Stadtfeld M, 2008, SCIENCE, V322, P945, DOI 10.1126/science.1162494
   Stadtfeld M, 2010, GENE DEV, V24, P2239, DOI 10.1101/gad.1963910
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Thanasegaran S., 2013, BIOMED RES INT, V2013, P1
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   van Vranken BE, 2005, TISSUE ENG, V11, P1177
   Vergano D., 2010, 2 HUMAN EMBRYONIC ST
   Walsh F., 2012, BBC NEWS
   Wang D, 2007, P NATL ACAD SCI USA, V104, P4449, DOI 10.1073/pnas.0700052104
   Wang JH, 2008, NAT BIOTECHNOL, V26, P901, DOI 10.1038/nbt.1484
   Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012
   Woltjen K, 2009, NATURE, V458, P766, DOI 10.1038/nature07863
   Yamanaka S, 2008, PHILOS T R SOC B, V363, P2079, DOI 10.1098/rstb.2008.2261
   Yi F, 2012, PROTEIN CELL, V3, P855, DOI 10.1007/s13238-012-2064-z
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Yu JY, 2009, SCIENCE, V324, P797, DOI 10.1126/science.1172482
   Yusa K, 2009, NAT METHODS, V6, P363, DOI [10.1038/NMETH.1323, 10.1038/nmeth.1323]
   Zeng XM, 2004, STEM CELLS, V22, P925, DOI 10.1634/stemcells.22-6-925
   Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129
   Zhao R, 2008, J CELL BIOCHEM, V105, P949, DOI 10.1002/jcb.21871
   Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135
   Zhao Y, 2008, CELL STEM CELL, V3, P475, DOI 10.1016/j.stem.2008.10.002
   Zhou WB, 2009, STEM CELLS, V27, P2667, DOI 10.1002/stem.201
NR 69
TC 10
Z9 10
U1 0
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2152-4971
EI 2152-4998
J9 CELL REPROGRAM
JI Cell. Reprogramm.
PD APR 1
PY 2014
VL 16
IS 2
BP 98
EP 107
DI 10.1089/cell.2013.0072
PG 10
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Genetics & Heredity
SC Cell Biology; Biotechnology & Applied Microbiology; Genetics & Heredity
GA AD4UV
UT WOS:000333247600002
PM 24606201
OA Green Published
DA 2020-11-26
ER

PT J
AU Slavov, SN
   Kashima, S
   Rocha-Junior, MC
   Oliveira, LC
   Silva-Pinto, AC
   Yamamoto, AY
   Covas, DT
AF Slavov, S. N.
   Kashima, S.
   Rocha-Junior, M. C.
   Oliveira, L. C.
   Silva-Pinto, A. C.
   Yamamoto, A. Y.
   Covas, D. T.
TI Frequent human parvovirus B19 DNA occurrence and high seroprevalence in
   haemophilic patients from a non-metropolitan blood centre, Brazil
SO TRANSFUSION MEDICINE
LA English
DT Letter
ID HUMAN PARVOVIRUS B19; INFECTION
C1 [Slavov, S. N.; Kashima, S.; Rocha-Junior, M. C.; Oliveira, L. C.; Silva-Pinto, A. C.; Covas, D. T.] Univ Sao Paulo, Fac Med Ribeirao Preto, Reg Blood Ctr Ribeirao Preto, Sao Paulo, Brazil.
   [Kashima, S.; Rocha-Junior, M. C.] Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, Sao Paulo, Brazil.
   [Yamamoto, A. Y.] Univ Sao Paulo, Dept Pediat, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
   [Covas, D. T.] Univ Sao Paulo, Dept Clin Med, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
RP Slavov, SN (corresponding author), HCFMRP USP, Ctr Reg Hemoterapia, Rua Tenente Catao Roxo 2501, BR-41051140 Sao Paulo, Brazil.
EM svetoslav.slavov@hemocentro.fmrp.usp.br
RI Covas, Dimas T/C-5431-2013; N, Svetoslav/M-5416-2017; Kashima,
   Simone/G-4876-2012; CTC USP, CEPID 13 18/J-8951-2014
OI Covas, Dimas T/0000-0002-7364-2595; Kashima, Simone/0000-0002-1487-0141;
   Pinto, Ana/0000-0002-4104-2296; CTC USP, CEPID 13
   18/0000-0002-7123-9524; Slavov, Svetoslav/0000-0003-0805-6140
CR Corcoran A, 2004, J MED MICROBIOL, V53, P459, DOI 10.1099/jmm.0.05485-0
   GROSSEBLEY A, 1994, THROMB HAEMOSTASIS, V72, P503
   KOCH WC, 1990, J CLIN MICROBIOL, V28, P65, DOI 10.1128/JCM.28.1.65-69.1990
   Ragni MV, 1996, TRANSFUSION, V36, P238, DOI 10.1046/j.1537-2995.1996.36396182142.x
   Rubinstein R, 2000, HAEMOPHILIA, V6, P93
   Slavov SN, 2012, J MED VIROL, V84, P1652, DOI 10.1002/jmv.23358
   Thammasri K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067179
   Zakrzewska K, 2001, J MED VIROL, V65, P402, DOI 10.1002/jmv.2048
NR 8
TC 6
Z9 8
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0958-7578
EI 1365-3148
J9 TRANSFUSION MED
JI Transfus. Med.
PD APR
PY 2014
VL 24
IS 2
BP 130
EP 132
DI 10.1111/tme.12113
PG 3
WC Hematology
SC Hematology
GA AE0QX
UT WOS:000333672300014
PM 24684574
DA 2020-11-26
ER

PT J
AU Rodrigues, ES
   de Macedo, MD
   Pinto, MT
   Orellana, MD
   Rocha, MC
   de Magalhaes, DAR
   Tanaka, Y
   Takayanagui, OM
   Covas, DT
   Kashima, S
AF Rodrigues, Evandra Strazza
   de Macedo, Mayra Dorigan
   Pinto, Mariana Tomazini
   Orellana, Maristela Delgado
   Rocha Junior, Mauricio Cristiano
   Rosa de Magalhaes, Danielle Aparecida
   Tanaka, Yuetsu
   Takayanagui, Osvaldo Massaiti
   Covas, Dimas Tadeu
   Kashima, Simone
TI HTLV-1 infects human mesenchymal stromal cell in vitro and modifies
   their phenotypic characteristics
SO VIROLOGY
LA English
DT Article
DE HTLV-1; Human mesenchymal stromal cells; MSC differentiation; MSC virus
   infection
ID VIRUS TYPE-I; MYELOPATHY/TROPICAL SPASTIC PARAPARESIS; SPINAL-CORD
   LESIONS; STEM-CELLS; BONE-MARROW; LEUKEMIA-VIRUS;
   CYTOMEGALOVIRUS-INFECTION; PROVIRAL LOAD; DIFFERENTIATION; TYPE-1
AB The typical characteristics of mesenchymal stem cells (MSCs) can be affected by inflammatory microenvironment; however, the exact contribution of HTLV-1 to MSC dysfunction remains to be elucidated. In this study, we demonstrated that MSC cell surface molecules VCAM-1 and ICAM-1 are upregulated by contact with HTLV-1, and HLA-DR was most highly expressed in MSCs co-cultured with MT2 cells. The expression levels of VCAM-1 and HLA-DR were increased in MSCs cultured in the presence of PBMCs isolated from HTLV-1-infected symptomatic individuals compared with those cultured with cells from asymptomatic infected individuals or healthy subjects. HTLV-1 does not impair the MSC differentiation process into osteocytes and adipocytes. In addition, MSCs were efficiently infected with HTLV-1 in vitro through direct contact with HTLV-1-infected cells; however, cell-free virus particles were not capable of causing infection. In summary, HTLV-1 can alter MSC function, and this mechanism may contribute to the pathogenesis of this viral infection. (C) 2013 Published by Elsevier Inc.
C1 [Rodrigues, Evandra Strazza; de Macedo, Mayra Dorigan; Pinto, Mariana Tomazini; Orellana, Maristela Delgado; Rocha Junior, Mauricio Cristiano; Rosa de Magalhaes, Danielle Aparecida; Covas, Dimas Tadeu; Kashima, Simone] Univ Sao Paulo, Reg Blood Ctr Ribeirao Preto, BR-05508 Sao Paulo, Brazil.
   [Rodrigues, Evandra Strazza; de Macedo, Mayra Dorigan; Pinto, Mariana Tomazini; Rocha Junior, Mauricio Cristiano; Kashima, Simone] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, BR-05508 Sao Paulo, Brazil.
   [Orellana, Maristela Delgado; Takayanagui, Osvaldo Massaiti; Covas, Dimas Tadeu] Univ Sao Paulo, Sch Med Ribeirao Preto, BR-05508 Sao Paulo, Brazil.
   [Tanaka, Yuetsu] Univ Ryukyus, Nishihara, Okinawa 90301, Japan.
RP Kashima, S (corresponding author), Reg Blood Ctr Ribeirao Preto, Ave Tenente Catao Roxo 2501, Ribeirao Preto, SP, Brazil.
EM skashima@hemocentro.fmrp.usp.br
RI Rodrigues, Evandra/L-6094-2017; Orellana, Maristela/L-5542-2014; Covas,
   Dimas T/C-5431-2013; Takayanagui, Osvaldo M/C-8159-2013; Pinto,
   Mariana/B-6129-2017; Kashima, Simone/G-4876-2012; CTC USP, CEPID 13
   18/J-8951-2014
OI Rodrigues, Evandra/0000-0003-0964-9554; Orellana,
   Maristela/0000-0003-0159-4472; Covas, Dimas T/0000-0002-7364-2595;
   Takayanagui, Osvaldo M/0000-0002-8190-0275; Pinto,
   Mariana/0000-0002-5176-7776; Kashima, Simone/0000-0002-1487-0141; CTC
   USP, CEPID 13 18/0000-0002-7123-9524
FU CNPq UniversalNational Council for Scientific and Technological
   Development (CNPq) [477126/2009-0]; Center for Cell-based Therapy (CTC);
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Fundacao Hemocentro
   de Ribeirao Preto (FUNDHERP)
FX This study was supported by CNPq Universal (Process number
   477126/2009-0). Center for Cell-based Therapy (CTC), Fundacao de Amparo
   a Pesquisa do Estado de Sao Paulo (FAPESP) and Fundacao Hemocentro de
   Ribeirao Preto (FUNDHERP). We are grateful to the staff and blood donors
   of Regional Blood Center of Ribeirao Preto and patients from the
   Neurology Department of the University Hospital. The authors thank
   Leonardo Lira do Amaral for the assistance in cell irradiation and
   Patricia Vianna Bonini Palma for cytometry analyses. The authors
   acknowledge Svetoslav Nanev Slavov for scientific contribution and
   Fernanda Udinal for English language support. We also thank Sandra
   Navarro Bresciani for preparing the figures and Josiane Serrano Borges
   for technical support with glass coverslips.
CR Albesiano E, 2003, BLOOD, V102, P3333, DOI 10.1182/blood-2003-05-1585
   ARAUJO AD, 1995, J NEUROL SCI, V129, P147
   Auletta JJ, 2012, BLOOD, V119, P1801, DOI 10.1182/blood-2011-10-384354
   Avanzi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071412
   Barnard AL, 2005, BLOOD, V106, P988, DOI 10.1182/blood-2004-07-2850
   Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301-472X(01)00769-X
   Starling ALB, 2013, ACTA TROP, V125, P75, DOI 10.1016/j.actatropica.2012.09.012
   Castilho-Fernandes A, 2011, EXP MOL PATHOL, V91, P664, DOI 10.1016/j.yexmp.2011.09.002
   Cheng K, 2013, EXP CELL RES, V319, P2266, DOI 10.1016/j.yexcr.2013.06.008
   Choudhary S, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/264350
   Cotter EJ, 2007, AIDS RES HUM RETROV, V23, P1521, DOI 10.1089/aid.2007.0112
   Cotter EJ, 2011, AIDS RES HUM RETROV, V27, P187, DOI 10.1089/aid.2010.0114
   Cotter EJ, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-33
   Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932
   Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   DONEGAN E, 1994, TRANSFUSION, V34, P478, DOI 10.1046/j.1537-2995.1994.34694295061.x
   FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267
   Gibellini D, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-40
   Grant C, 2002, J CELL PHYSIOL, V190, P133, DOI 10.1002/JCP.10053
   Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115
   JACOBSON S, 1992, ANN NEUROL, V32, P651, DOI 10.1002/ana.410320508
   Jacobson Steven, 1997, Leukemia (Basingstoke), V11, P73
   Jones KS, 2008, NAT MED, V14, P429, DOI 10.1038/nm1745
   KIYOKAWA T, 1987, CANCER, V59, P1187, DOI 10.1002/1097-0142(19870315)59:6<1187::AID-CNCR2820590626>3.0.CO;2-8
   LAGRENADE L, 1990, LANCET, V336, P1345
   Manns A, 1999, J INFECT DIS, V180, P1487, DOI 10.1086/315088
   MARANDIN A, 1995, VIROLOGY, V213, P245, DOI 10.1006/viro.1995.1565
   Mariette X, 2000, CLIN EXP RHEUMATOL, V18, P341
   Montanheito PA, 2005, BRAZ J MED BIOL RES, V38, P1643, DOI 10.1590/S0100-879X2005001100011
   NAGAFUJI K, 1993, BLOOD, V82, P2823, DOI 10.1182/blood.V82.9.2823.bloodjournal8292823
   Nagai M, 1998, J NEUROVIROL, V4, P586, DOI 10.3109/13550289809114225
   Oh U, 2008, NEUROL CLIN, V26, P781, DOI 10.1016/j.ncl.2008.03.008
   OSAME M, 1986, LANCET, V1, P1031
   Pinto MT, 2012, REV INST MED TROP SP, V54, P123, DOI 10.1590/S0036-46652012000300002
   Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014
   Ren GW, 2010, J IMMUNOL, V184, P2321, DOI 10.4049/jimmunol.0902023
   Romieu-Mourez R, 2007, J IMMUNOL, V179, P1549, DOI 10.4049/jimmunol.179.3.1549
   SCADDEN DT, 1990, BLOOD, V76, P317
   Smirnov SV, 2007, VIROLOGY, V360, P6, DOI 10.1016/j.virol.2006.09.017
   SODERBERG C, 1993, J VIROL, V67, P6576
   Stagg J, 2006, BLOOD, V107, P2570, DOI 10.1182/blood-2005-07-2793
   Sundin M, 2006, BONE MARROW TRANSPL, V37, P1051, DOI 10.1038/sj.bmt.1705368
   Tang SW, 2013, J VIROL, V87, P1699, DOI 10.1128/JVI.02147-12
   TENDLER CL, 1991, J CELL BIOCHEM, V46, P302, DOI 10.1002/jcb.240460405
   Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15
   UMEHARA F, 1994, J NEUROPATH EXP NEUR, V53, P72, DOI 10.1097/00005072-199401000-00009
   UMEHARA F, 1993, J NEUROPATH EXP NEUR, V52, P424, DOI 10.1097/00005072-199307000-00010
   Wang LX, 2002, AIDS RES HUM RETROV, V18, P917, DOI 10.1089/088922202760265597
   Waterman RS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010088
   Wei G, 2011, TRANSPL P, V43, P1944, DOI 10.1016/j.transproceed.2010.12.053
   YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534
NR 52
TC 8
Z9 8
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD JAN 20
PY 2014
VL 449
BP 190
EP 199
DI 10.1016/j.virol.2013.11.022
PG 10
WC Virology
SC Virology
GA 295CL
UT WOS:000330094100021
PM 24418552
OA Bronze
DA 2020-11-26
ER

PT J
AU Nunes, NS
   Tognon, R
   Moura, LG
   Kashima, S
   Covas, DT
   Santana, M
   Souto, EX
   Zanichelli, MA
   Simoes, BP
   Souza, AM
   Castro, FA
AF Nunes, Natalia S.
   Tognon, Raquel
   Moura, Livia G.
   Kashima, Simone
   Covas, Dimas T.
   Santana, Mary
   Souto, Elizabeth X.
   Zanichelli, Maria A.
   Simoes, Belinda P.
   Souza, Ana M.
   Castro, Fabiola A.
TI Differential expression of apoptomiRs in myeloproliferative neoplasms
SO LEUKEMIA & LYMPHOMA
LA English
DT Letter
ID APOPTOSIS-RELATED GENES; POLYCYTHEMIA-VERA; DEREGULATION; MICRORNAS;
   PROTEINS; BCL-2
C1 [Nunes, Natalia S.; Tognon, Raquel; Moura, Livia G.; Souza, Ana M.; Castro, Fabiola A.] Univ Sao Paulo, Dept Clin Toxicol & Bromatol Anal, Ribeirao Preto Sch Pharmaceut Sci, BR-14040903 Ribeirao Preto, Brazil.
   [Kashima, Simone; Covas, Dimas T.] Univ Sao Paulo, Reg Blood Ctr Ribeirao Preto, Ribeirao Preto Sch Med, Clin Hosp, BR-14040903 Ribeirao Preto, Brazil.
   [Santana, Mary; Souto, Elizabeth X.] Brigadeiro Hosp Sao Paulo, Sao Paulo, Brazil.
   [Zanichelli, Maria A.] Inst Canc Treatment Children ITACI, Sao Paulo, Brazil.
   [Covas, Dimas T.; Simoes, Belinda P.] Univ Sao Paulo, Dept Clin Med, Ribeirao Preto Sch Med, BR-14040903 Ribeirao Preto, Brazil.
   [Castro, Fabiola A.] INCT IF CNPq, Campinas, SP, Brazil.
RP Nunes, NS (corresponding author), Univ Sao Paulo, Dept Clin Toxicol & Bromatol Anal, Ave Cafe S-N, BR-14040903 Ribeirao Preto, Brazil.
EM nsnunes@fcfrp.usp.br
RI SIMOES, BELINDA/A-1896-2014; Simoes, Belinda P/M-7469-2016; Covas, Dimas
   T/C-5431-2013; Kashima, Simone/G-4876-2012; CTC USP, CEPID 13
   18/J-8951-2014
OI SIMOES, BELINDA/0000-0003-4508-8934; Covas, Dimas T/0000-0002-7364-2595;
   Kashima, Simone/0000-0002-1487-0141; CTC USP, CEPID 13
   18/0000-0002-7123-9524
CR Bortoluzzi S, 2012, BLOOD, V119, pE120, DOI 10.1182/blood-2011-07-368001
   Bruchova H, 2009, BLOOD CELL MOL DIS, V43, P81, DOI 10.1016/j.bcmd.2009.02.001
   Calin GA, 2008, P NATL ACAD SCI USA, V105, P5166, DOI 10.1073/pnas.0800121105
   Dejean LM, 2010, BBA-BIOENERGETICS, V1797, P1231, DOI 10.1016/j.bbabio.2010.01.007
   Guglielmelli P, 2007, EXP HEMATOL, V35, P1708, DOI 10.1016/j.exphein.2007.08.020
   Jazbutyte V, 2010, CURR DRUG TARGETS, V11, P926, DOI 10.2174/138945010791591403
   Li G, 2011, BLOOD, V114, P416
   Gasparotto EPL, 2011, BRAZ J PHARM SCI, V47, P873, DOI 10.1590/S1984-82502011000400025
   Reilly JT, 2008, LEUKEMIA, V22, P1818, DOI 10.1038/leu.2008.218
   Rhyasen GW, 2012, LEUKEMIA, V26, P13, DOI 10.1038/leu.2011.221
   Schotte D, 2012, LEUKEMIA, V26, P1, DOI 10.1038/leu.2011.151
   Selcuklu SD, 2009, BIOCHEM SOC T, V37, P918, DOI 10.1042/BST0370918
   Stenvang Jan, 2012, Silence, V3, P1, DOI 10.1186/1758-907X-3-1
   Tognon R, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-2
   Tognon R, 2011, J CLIN PATHOL, V64, P75, DOI 10.1136/jcp.2010.080895
   Vecchione A, 2010, ENDOCR-RELAT CANCER, V17, pF37, DOI 10.1677/ERC-09-0163
NR 16
TC 4
Z9 4
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1042-8194
EI 1029-2403
J9 LEUKEMIA LYMPHOMA
JI Leuk. Lymphoma
PD SEP
PY 2013
VL 54
IS 9
BP 2047
EP 2051
DI 10.3109/10428194.2013.767453
PG 5
WC Oncology; Hematology
SC Oncology; Hematology
GA 206BY
UT WOS:000323492400032
PM 23394459
DA 2020-11-26
ER

PT J
AU Pinto, MT
   Nicolete, LDF
   Rodrigues, ES
   Palma, PVB
   Orellana, MD
   Kashima, S
   Covas, DT
AF Pinto, M. T.
   Nicolete, L. D. F.
   Rodrigues, E. S.
   Palma, P. V. B.
   Orellana, M. D.
   Kashima, S.
   Covas, D. T.
TI Overexpression of hsa-miR-125b during osteoblastic differentiation does
   not influence levels of Runx2, osteopontin, and ALPL gene expression
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE Multipotent mesenchymal stromal cells; Osteoblastic differentiation;
   hsa-miR-125b
ID MESENCHYMAL STEM-CELLS; BIOGENESIS; MICRORNAS; MIR-125B; BLOOD
AB Multipotent mesenchymal stromal cells (MSCs) were first isolated from bone marrow and then from various adult tissues including placenta, cord blood, deciduous teeth, and amniotic fluid. MSCs are defined or characterized by their ability to adhere to plastic, to express specific surface antigens, and to differentiate into osteogenic, chondrogenic, adipogenic, and myogenic lineages. Although the molecular mechanisms that control MSC proliferation and differentiation are not well understood, the involvement of microRNAs has been reported. In the present study, we investigated the role of miR-125b during osteoblastic differentiation in humans. We found that miR-125b increased during osteoblastic differentiation, as well as Runx2 and ALPL genes. To study whether the gain or loss of miR-125b function influenced osteoblastic differentiation, we transfected MSCs with pre-miR-125b or anti-miR-125b and cultured the transfected cells in an osteoblastic differentiation medium. After transfection, no change was observed in osteoblastic differentiation, and Runx2, OPN, and ALPL gene expression were not changed. These results suggest that the gain or loss of miR-125b function does not influence levels of Runx2, OPN, and ALPL during osteoblastic differentiation.
C1 [Pinto, M. T.; Nicolete, L. D. F.; Rodrigues, E. S.; Palma, P. V. B.; Orellana, M. D.; Kashima, S.; Covas, D. T.] Ctr Reg Hemoterapia Ribeirao Preto, Inst Nacl Ciencia & Tecnol Celulas Tronco & Terap, BR-14051140 Ribeirao Preto, SP, Brazil.
   [Pinto, M. T.; Rodrigues, E. S.; Kashima, S.] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Dept Analises Clin Toxicol & Bromatol, Ribeirao Preto, SP, Brazil.
   [Covas, D. T.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Ribeirao Preto, SP, Brazil.
RP Kashima, S (corresponding author), Ctr Reg Hemoterapia Ribeirao Preto, Rua Tenente Catao Roxo 2501, BR-14051140 Ribeirao Preto, SP, Brazil.
EM skashima@hemocentro.fmrp.usp.br
RI Pinto, Mariana/B-6129-2017; Covas, Dimas T/C-5431-2013; Rodrigues,
   Evandra/L-6094-2017; Orellana, Maristela/L-5542-2014; Kashima,
   Simone/G-4876-2012; CTC USP, CEPID 13 18/J-8951-2014
OI Pinto, Mariana/0000-0002-5176-7776; Covas, Dimas T/0000-0002-7364-2595;
   Rodrigues, Evandra/0000-0003-0964-9554; Orellana,
   Maristela/0000-0003-0159-4472; Kashima, Simone/0000-0002-1487-0141; CTC
   USP, CEPID 13 18/0000-0002-7123-9524
FU Fundacao Hemocentro de Ribeirao Preto (FUNDHERP); Centro Regional de
   Hemoterapia de Ribeirao Preto (CRH)
FX The authors thank Samia Rigotto Caruso, Karina Rosa Solano, and Taisa
   Risque Fernandes for the isolation of MSCs. They are also grateful to
   the healthy donors who participated in this study. Research supported by
   Fundacao Hemocentro de Ribeirao Preto (FUNDHERP) and Centro Regional de
   Hemoterapia de Ribeirao Preto (CRH).
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bieback K, 2004, STEM CELLS, V22, P625, DOI 10.1634/stemcells.22-4-625
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Du TT, 2005, DEVELOPMENT, V132, P4645, DOI 10.1242/dev.02070
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   in 'tAnker PS, 2003, BLOOD, V102, P1548, DOI 10.1182/blood-2003-04-1291
   LI CD, 2005, PLACENTA
   LURIA EA, 1971, TRANSFUSION, V11, P345, DOI 10.1111/j.1537-2995.1971.tb04426.x
   Mizuno Y, 2008, BIOCHEM BIOPH RES CO, V368, P267, DOI 10.1016/j.bbrc.2008.01.073
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   PUCHTLER H, 1978, HISTOCHEMISTRY, V56, P177, DOI 10.1007/BF00495978
   Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200
   Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   Yang Z, 2011, STEM CELLS DEV, V20, P259, DOI 10.1089/scd.2010.0072
   Zhang JF, 2011, MOL BIOL CELL, V22, P3955, DOI 10.1091/mbc.E11-04-0356
   Zhang Y., 2012, SCI WORLD J, V2012, P793
NR 18
TC 6
Z9 7
U1 0
U2 5
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, 00, BRAZIL
SN 0100-879X
EI 1678-4510
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD AUG
PY 2013
VL 46
IS 8
BP 676
EP 680
DI 10.1590/1414-431X20132896
PG 5
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 220HP
UT WOS:000324573800005
PM 24036939
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Kashima, SKH
   Rodrigues, ESR
   Dorigan, MDM
   de Melo, FUM
   Rocha, MC
   Wagatsuma, VMDW
   Toledo, RST
   Eugenia, EMAU
   Brunetta, DMB
   Covas, DTC
AF Kashima, S. K. H.
   Rodrigues, E. S. R.
   Dorigan, M. D. M.
   de Melo, F. U. M.
   Rocha Junior, M. C.
   Wagatsuma, V. M. D. W.
   Toledo, R. S. T.
   Eugenia, E. M. A. U.
   Brunetta, D. M. B.
   Covas, D. T. C.
TI RAPID AND SENSITIVE TEST FOR BLOOD GROUP GENOTYPING IN MULTIPLE
   TRANSFUSED PATIENTS: COST AND BENEFITS
SO VOX SANGUINIS
LA English
DT Meeting Abstract
C1 [Kashima, S. K. H.; Rodrigues, E. S. R.; Dorigan, M. D. M.; de Melo, F. U. M.; Rocha Junior, M. C.; Wagatsuma, V. M. D. W.; Toledo, R. S. T.; Eugenia, E. M. A. U.; Brunetta, D. M. B.; Covas, D. T. C.] Hemoctr Ribeirao Preto, Ribeirao Preto, Brazil.
RI Covas, Dimas T/C-5431-2013; CTC USP, CEPID 13 18/J-8951-2014
OI Covas, Dimas T/0000-0002-7364-2595; CTC USP, CEPID 13
   18/0000-0002-7123-9524
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0042-9007
J9 VOX SANG
JI Vox Sang.
PD JUN
PY 2013
VL 105
SU 1
SI SI
BP 232
EP 232
PG 1
WC Hematology
SC Hematology
GA 148FH
UT WOS:000319228100623
DA 2020-11-26
ER

PT J
AU Malta, TM
   Silva, IT
   Pinheiro, DG
   Santos, ARD
   Pinto, MT
   Panepucci, RA
   Takayanagui, OM
   Tanaka, Y
   Covas, DT
   Kashima, S
AF Malta, Tathiane M.
   Silva, Israel T.
   Pinheiro, Daniel G.
   Santos, Anemarie R. D.
   Pinto, Mariana T.
   Panepucci, Rodrigo A.
   Takayanagui, Osvaldo M.
   Tanaka, Yuetsu
   Covas, Dimas T.
   Kashima, Simone
TI Altered Expression of Degranulation-Related Genes in CD8(+) T Cells in
   Human T Lymphotropic Virus Type I Infection
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID LEUKEMIA-VIRUS; INTERLEUKIN-10 PROMOTER; SPASTIC PARAPARESIS;
   IMMUNE-RESPONSE; SERIAL ANALYSIS; PROVIRAL LOAD; MYELOPATHY; RISK;
   HTLV-1; POLYMORPHISMS
AB Human T lymphotropic virus type I (HTLV-1) is the etiological agent of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). CD8(+) T cells may contribute to the protection or development of HAM/TSP. In this study we used SAGE methodology to screen for differentially expressed genes in CD8(+) T cells isolated from HTLV-1 asymptomatic carriers (HAC) and from HAM/TSP patients to identify genes involved in HAM/TSP development. SAGE analysis was conducted by pooling samples according to clinical status. The comparison of gene expression profiles between HAC and HAM/TSP libraries identified 285 differentially expressed tags. We focus on cytotoxicity and cytokine-related genes due to their potential biological role in HTLV-1 infection. Our results showed that patients with HAM/TSP have high expression levels of degranulation-related genes, namely GZMH and PRF1, and of the cytoskeletal adaptor PXN. We found that GZMB and ZAP70 were overexpressed in HTLV-infected patients compared to the noninfected group. We also detected that CCL5 was higher in the HAM/TSP group compared to the HAC and CT groups. Our findings showed that CD8(+) T cells of HAM/TSP patients have an inflammatory and active profile. PXN and ZAP70 overexpression in HTLV-1-infected patients was described for the first time here and reinforces this concept. However, although active and abundant, CD8(+) T cells are not able to completely eliminate infected cells and prevent the development of HAM/TSP and, moreover, these cells might contribute to the pathogenesis of the disease by migrating to the central nervous system (CNS). These results should be further tested with biological functional assays to increase our understanding on the role of these molecules in the development of HTLV-1-related diseases.
C1 [Malta, Tathiane M.; Silva, Israel T.; Pinheiro, Daniel G.; Santos, Anemarie R. D.; Pinto, Mariana T.; Panepucci, Rodrigo A.; Covas, Dimas T.; Kashima, Simone] Natl Inst Sci & Technol Stem Cell & Cell Therapy, Ctr Cell Therapy, Ribeirao Preto, SP, Brazil.
   [Malta, Tathiane M.; Silva, Israel T.; Pinheiro, Daniel G.; Santos, Anemarie R. D.; Pinto, Mariana T.; Panepucci, Rodrigo A.; Covas, Dimas T.; Kashima, Simone] Blood Ctr Ribeirao Preto, Reg Blood Ctr, BR-14051140 Ribeirao Preto, SP, Brazil.
   [Malta, Tathiane M.; Pinto, Mariana T.; Kashima, Simone] Univ Sao Paulo, Fac Pharmaceut Sci, BR-14049 Ribeirao Preto, SP, Brazil.
   [Panepucci, Rodrigo A.; Takayanagui, Osvaldo M.; Covas, Dimas T.] Univ Sao Paulo, Fac Med, BR-14049 Ribeirao Preto, SP, Brazil.
   [Tanaka, Yuetsu] Univ Ryukyus, Grad Sch Med, Dept Immunol, Nishihara, Okinawa 90301, Japan.
RP Kashima, S (corresponding author), Reg Blood Ctr Ribeirao Preto, Tenente Catao Roxo St 2501, BR-14051140 Ribeirao Preto, SP, Brazil.
EM skashima@hemocentro.fmrp.usp.br
RI Pinto, Mariana/B-6129-2017; Takayanagui, Osvaldo M/C-8159-2013;
   Panepucci, Rodrigo A/C-2365-2012; Silva, Israel T/N-3858-2014; Malta,
   Tathiane/N-1686-2013; Pinheiro, Daniel/H-4604-2012; Covas, Dimas
   T/C-5431-2013; CTC USP, CEPID 13 18/J-8951-2014; Kashima,
   Simone/G-4876-2012
OI Pinto, Mariana/0000-0002-5176-7776; Takayanagui, Osvaldo
   M/0000-0002-8190-0275; Panepucci, Rodrigo A/0000-0002-1119-4352; Silva,
   Israel T/0000-0002-4687-1499; Malta, Tathiane/0000-0003-1129-5791;
   Pinheiro, Daniel/0000-0001-7062-5936; Covas, Dimas
   T/0000-0002-7364-2595; CTC USP, CEPID 13 18/0000-0002-7123-9524;
   Kashima, Simone/0000-0002-1487-0141
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Centro de Terapia
   Celular/Fundacao Hemocentro de Ribeirao Preto (CTC/FUNDHERP); Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq),
   BrazilNational Council for Scientific and Technological Development
   (CNPq)
FX We thank Rochele Azevedo, Larissa Deadame de Figueiredo Nicolete,
   Rodrigo Haddad, Adriana Aparecida Marques, and Patricia Viana Bonini
   Palma for their assistance in laboratory techniques. We also thank Prof.
   Charles Bangham for training us in Tax expression analysis. The authors
   are also grateful to the patients. This work was supported by Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Centro de Terapia
   Celular/Fundacao Hemocentro de Ribeirao Preto (CTC/FUNDHERP), and
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq),
   Brazil.
CR Audic S, 1997, GENOME RES, V7, P986, DOI 10.1101/gr.7.10.986
   Bangham CRM, 2005, ONCOGENE, V24, P6035, DOI 10.1038/sj.onc.1208970
   Bangham CRM, 2000, J CLIN PATHOL, V53, P581, DOI 10.1136/jcp.53.8.581
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bieganowska K, 1999, J IMMUNOL, V162, P1765
   Brown C, 2011, J MOL BIOL, V410, P761, DOI 10.1016/j.jmb.2011.03.076
   De Castro-Costa CM, 2006, AIDS RES HUM RETROV, V22, P931, DOI 10.1089/aid.2006.22.931
   DETHE G, 1993, AIDS RES HUM RETROV, V9, P381, DOI 10.1089/aid.1993.9.381
   Fischer A, 2010, SEMIN IMMUNOPATHOL, V32, P107, DOI 10.1007/s00281-010-0196-x
   Gadelha SR, 2008, J MED VIROL, V80, P2141, DOI 10.1002/jmv.21341
   GESSAIN A, 1985, LANCET, V2, P407
   Goon PKC, 2002, BLOOD, V99, P3335, DOI 10.1182/blood.V99.9.3335
   Hashimoto S, 1999, BLOOD, V94, P837, DOI 10.1182/blood.V94.3.837.413k02_837_844
   HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476
   Jacobson S, 2002, J INFECT DIS, V186, pS187, DOI 10.1086/344269
   KAPLAN JE, 1990, J ACQ IMMUN DEF SYND, V3, P1096
   Kashima S, 2009, J GEN VIROL, V90, P927, DOI 10.1099/vir.0.008367-0
   LAGRENADE L, 1990, LANCET, V336, P1345
   LEE B, 1989, TOHOKU J EXP MED, V157, P1, DOI 10.1620/tjem.157.1
   Miley WJ, 2000, AIDS RES HUM RETROV, V16, P665, DOI 10.1089/088922200308891
   Mochizuki M, 1996, J ACQ IMMUN DEF SYND, V13, pS50, DOI 10.1097/00042560-199600001-00010
   Montanheiro P, 2007, J NEUROIMMUNOL, V188, P138, DOI 10.1016/j.jneuroim.2007.05.015
   MORGAN OS, 1989, LANCET, V2, P1184
   Mori N, 2004, INT J CANCER, V111, P548, DOI 10.1002/ijc.20266
   Mosley AJ, 2005, VIRAL IMMUNOL, V18, P293, DOI 10.1089/vim.2005.18.293
   MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214
   Nogalski MT, 2011, J VIROL, V85, P1360, DOI 10.1128/JVI.02090-10
   OSAME M, 1986, LANCET, V1, P1031
   PARKER CE, 1992, VIROLOGY, V188, P628, DOI 10.1016/0042-6822(92)90517-S
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pinheiro DG, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-170
   Pinto MT, 2012, REV INST MED TROP SP, V54, P123, DOI 10.1590/S0036-46652012000300002
   Robertson LK, 2005, J IMMUNOL, V175, P8138, DOI 10.4049/jimmunol.175.12.8138
   Sabouri AH, 2004, J INFECT DIS, V190, P1279, DOI 10.1086/423942
   Sabouri AH, 2008, BLOOD, V112, P2411, DOI 10.1182/blood-2008-02-140335
   Takenouchi N, 2003, J NEUROVIROL, V9, P29, DOI 10.1080/13550280390173418
   Tanaka M, 2008, NEUROLOGY, V71, P974, DOI 10.1212/01.wnl.0000326589.57128.c3
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484
   Vine AM, 2004, J IMMUNOL, V173, P5121, DOI 10.4049/jimmunol.173.8.5121
   YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534
NR 41
TC 2
Z9 2
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD MAY
PY 2013
VL 29
IS 5
BP 826
EP 836
DI 10.1089/aid.2012.0205
PG 11
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 132NA
UT WOS:000318074200013
PM 23301858
DA 2020-11-26
ER

PT J
AU Slavou, SN
   Kashima, S
   Silva-Pinto, AC
   Amarilla, AA
   Aquino, VH
   Covas, DT
AF Slavou, Svetoslav Nanev
   Kashima, Simone
   Silva-Pinto, Ana Cristina
   Amarilla, Alberto Anastacio
   Aquino, Victor Hugo
   Covas, Dimas Tadeu
TI Molecular and clinical evaluation of the acute human parvovirus B19
   infection: comparison of two cases in children with sickle cell disease
   and discussion of the literature
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Human parvovirus B19; Viral load; Aplastic crisis; Subgenotypes
ID TRANSIENT APLASTIC CRISIS
AB Human parvovirus B19 is a well-known cause of severe conditions in patients with sickle cell disease, but the molecular mechanisms of the infection are insufficiently understood. The different clinical outcome of the acute parvovirus B19 infection in two pediatric patients with sickle cell disease has been examined. One of them developed life-threatening condition requiring emergency transfusions, while the other had asymptomatic infection, diagnosed occasionally. Both cases had high viral load and identical subgenotype, indicating that the viral molecular characteristics play a minimal role in the infection outcome. (C) 2013 Elsevier Editora Ltda. All rights reserved.
C1 [Slavou, Svetoslav Nanev; Kashima, Simone; Silva-Pinto, Ana Cristina; Covas, Dimas Tadeu] Univ Sao Paulo, Fac Med Ribeirao Preto, Hemotherapy Ctr Ribeirao Preto, BR-05508 Sao Paulo, Brazil.
   [Kashima, Simone] Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, BR-05508 Sao Paulo, Brazil.
   [Amarilla, Alberto Anastacio; Aquino, Victor Hugo] Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, Dept Clin Toxicol & Bromatol Anal, Virol Lab, BR-05508 Sao Paulo, Brazil.
   [Covas, Dimas Tadeu] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, BR-05508 Sao Paulo, Brazil.
RP Slavou, SN (corresponding author), Rua Tenente Catao Roxo 2501, BR-14051140 Sao Paulo, Brazil.
EM svetlyosf@yahoo.com
RI Ortiz, Alberto Anastacio Amarilla/C-3112-2012; Aquino, Victor
   Hugo/C-1922-2012; N, Svetoslav/M-5416-2017; Covas, Dimas T/C-5431-2013;
   Kashima, Simone/G-4876-2012; CTC USP, CEPID 13 18/J-8951-2014
OI Ortiz, Alberto Anastacio Amarilla/0000-0002-4151-2024; Aquino, Victor
   Hugo/0000-0003-1910-0776; Covas, Dimas T/0000-0002-7364-2595; Kashima,
   Simone/0000-0002-1487-0141; Pinto, Ana/0000-0002-4104-2296; Slavov,
   Svetoslav/0000-0003-0805-6140; CTC USP, CEPID 13 18/0000-0002-7123-9524
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   CNPqNational Council for Scientific and Technological Development
   (CNPq); INCTC
FX We are grateful to FAPESP, CNPq and INCTC for the financial support. We
   are also grateful to Virginia Wagatsuma for the technical assistance.
CR Bakhshi S, 2002, ARCH DIS CHILD, V87, P541, DOI 10.1136/adc.87.6.541
   Borsato M L, 2000, J Pediatr (Rio J), V76, P458
   Broliden K, 2006, J INTERN MED, V260, P285, DOI 10.1111/j.1365-2796.2006.01697.x
   Fattet S, 2004, J PEDIAT HEMATOL ONC, V26, P497, DOI 10.1097/01.mph.0000134463.09543.99
   Freitas RB, 2008, J CLIN VIROL, V43, P60, DOI 10.1016/j.jcv.2008.03.033
   Hemauer A, 1996, J GEN VIROL, V77, P1781, DOI 10.1099/0022-1317-77-8-1781
   KOCH WC, 1990, J CLIN MICROBIOL, V28, P65, DOI 10.1128/JCM.28.1.65-69.1990
   MALLOUH AA, 1995, PEDIATR INFECT DIS J, V14, P31, DOI 10.1097/00006454-199501000-00006
   Quek L, 2010, BRIT J HAEMATOL, V149, P289, DOI 10.1111/j.1365-2141.2009.08062.x
   Rao SP, 1996, J PEDIAT HEMATOL ONC, V18, P175, DOI 10.1097/00043426-199605000-00016
   Rayburg M, 2010, AM J HEMATOL, V85, P182, DOI 10.1002/ajh.21605
   Servant A, 2002, J VIROL, V76, P9124, DOI 10.1128/JVI.76.18.9124-9134.2002
   Slavov SN, 2012, CAN J MICROBIOL, V58, P200, DOI [10.1139/w11-119, 10.1139/W11-119]
   Yates AM, 2009, PEDIATR BLOOD CANCER, V53, P479, DOI 10.1002/pbc.22035
   Zimmerman SA, 2003, J PEDIAT HEMATOL ONC, V25, P387, DOI 10.1097/00043426-200305000-00007
NR 15
TC 5
Z9 6
U1 0
U2 0
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD JAN-FEB
PY 2013
VL 17
IS 1
BP 97
EP 101
DI 10.1016/j.bjid.2012.06.026
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA 091RT
UT WOS:000315068200017
PM 23290473
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Rodrigues, ES
   Picanco-Castro, V
   Espanhol, MR
   de Andrade, LAM
   Palma, PVB
   Kashima, S
   Fontes, AM
   Covas, DT
AF Rodrigues, Evandra Strazza
   Picanco-Castro, Virginia
   Espanhol, Marta Regina
   Martins de Andrade, Luiz Alberto
   Bonini Palma, Patricia Vianna
   Kashima, Simone
   Fontes, Aparecida Maria
   Covas, Dimas Tadeu
TI Quantitative correlation between transcriptional levels of ER chaperone,
   peroximal protein and FVIII productivity in human Hek-293 cell line
SO SPRINGERPLUS
LA English
DT Article
DE ER BIP chaperone; Factor VIII; Hemophilia A; PAHX gene expression and
   Recombinant Factor VIII Delta B
ID COAGULATION-FACTOR-VIII; EXPRESSION; SECRETION; STRESS; ROLES
AB Hek-293 cell line presents good production platform for recombinant therapeutic proteins, however little is known about the components that contribute to the cellular control of recombinant protein production. In this study, we generated a Hek-293 producing recombinant factor VIII (FVIII) and we evaluated the immunoglobulin-binding protein (BiP) and phytanoil-CoA a-hydroxylase (PAHX) expression levels which are known for diminishing FVIII production. Our analyses showed that the recombinant cell population expresses 3.1 +/- 1.4 fold of BIP mRNA (P = 0.0054) and 97.8 +/- 0.5 fold of PAHX mRNA (P = 0.0016) compared to nontransduced cells. The amount of these proteins was inversely correlated to the secreted FVIII. In conclusion, BIP and PAHX expression are augmented in human cells producing FVIII and they antagonize the amount of therapeutic factor VIII in the cell culture.
C1 [Rodrigues, Evandra Strazza; Picanco-Castro, Virginia; Espanhol, Marta Regina; Martins de Andrade, Luiz Alberto; Bonini Palma, Patricia Vianna; Kashima, Simone; Fontes, Aparecida Maria; Covas, Dimas Tadeu] Univ Sao Paulo, FMRP, Hemotherapy Ctr Ribeirao Preto, Sao Paulo, Brazil.
   [Fontes, Aparecida Maria; Covas, Dimas Tadeu] Univ Sao Paulo, FMRP, Sao Paulo, Brazil.
   [Rodrigues, Evandra Strazza; Kashima, Simone] Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto FCFRP, Sao Paulo, Brazil.
   [Rodrigues, Evandra Strazza; Kashima, Simone; Covas, Dimas Tadeu] Natl Inst Sci & Technol Stem Cell & Cell Therapy, Hemoctr Ribeirao Preto, BR-14051140 Sao Paulo, Brazil.
RP Rodrigues, ES (corresponding author), Univ Sao Paulo, FMRP, Hemotherapy Ctr Ribeirao Preto, Sao Paulo, Brazil.
EM evandra@hemocentro.fmrp.usp.br
RI Castro, Virginia/H-2904-2015; Picanco-Castro, Virginia/AAC-7242-2019;
   Rodrigues, Evandra/L-6094-2017; Fontes, Aparecida M/F-5627-2013; Fontes,
   Aparecida Maria/ABF-2892-2020; Kashima, Simone/G-4876-2012; Covas,
   Dimas/C-5431-2013
OI Castro, Virginia/0000-0001-8474-4610; Picanco-Castro,
   Virginia/0000-0001-8474-4610; Rodrigues, Evandra/0000-0003-0964-9554;
   Fontes, Aparecida M/0000-0002-4878-417X; Fontes, Aparecida
   Maria/0000-0002-4878-417X; Kashima, Simone/0000-0002-1487-0141; Covas,
   Dimas/0000-0002-7364-2595
FU Center for Cell-based Therapy (CTC); Fundaco de Amparo a Pesquisa do
   Estado de Sao Paulo - FAPESPFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP)
FX This study was supported by the Center for Cell-based Therapy (CTC) and
   Fundaco de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP. The
   authors acknowledge Dr. Garry P. Nolan for contributing with the pBMN-I
   - GFP vector and David Marco Antonio for statistical support. We thank
   Fernanda Udinal and Alessandra Almeida for English language support. We
   also thank Sandra Navarro Bresciani for preparing the figures.
CR Albesiano E, 2003, BLOOD, V102, P3333, DOI 10.1182/blood-2003-05-1585
   Antunes SV, 2003, HAEMOPHILIA, V9, P573, DOI 10.1046/j.1365-2516.2003.00789.x
   Baxter, 2010, ADV PRESCR INF
   Becker S, 2004, THROMB HAEMOSTASIS, V92, P23, DOI 10.1160/th03-06-0360
   Brown HC, 2011, J BIOL CHEM, V286, P24451, DOI 10.1074/jbc.M111.238758
   Burton M, 1999, P NATL ACAD SCI USA, V96, P12725, DOI 10.1073/pnas.96.22.12725
   Chen C, 2001, J BIOL CHEM, V276, P46340, DOI 10.1074/jbc.M106124200
   DORNER AJ, 1994, BIOLOGICALS, V22, P103, DOI 10.1006/biol.1994.1016
   DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x
   Durocher Y, 2002, NUCLEIC ACIDS RES, V15, P30
   Durocher Y, 2009, CURR OPIN BIOTECH, V20, P700, DOI 10.1016/j.copbio.2009.10.008
   Ghosh K, 2004, CLIN LAB HAEMATOL, V26, P243, DOI 10.1111/j.1365-2257.2004.00590.x
   HealthCare B, 2009, KOG PRESCR INF
   Herlitschka SE, 1998, J BIOTECHNOL, V61, P165, DOI 10.1016/S0168-1656(98)00035-2
   Invitrogen Corporation, 2007, US MAN FREE STYL TM
   Jiang R, 2002, HAEMOPHILIA, V8, P1, DOI 10.1046/j.1351-8216.2001.00115.x
   Kannicht C, 2013, THROMB RES, V131, P78, DOI 10.1016/j.thromres.2012.09.011
   Lee C, 1999, THROMB HAEMOSTASIS, V82, P516
   Lenting PJ, 2010, HAEMOPHILIA, V16, P6, DOI 10.1111/j.1365-2516.2008.01864.x
   LIND P, 1995, EUR J BIOCHEM, V232, P19, DOI 10.1111/j.1432-1033.1995.tb20776.x
   MARQUETTE KA, 1995, J BIOL CHEM, V270, P10297, DOI 10.1074/jbc.270.17.10297
   MEULIEN P, 1988, PROTEIN ENG, V2, P301, DOI 10.1093/protein/2.4.301
   Miao HZ, 2004, BLOOD, V103, P3412, DOI 10.1182/blood-2003-10-3591
   Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327
   Neidhardt E, 2005, HAEMOPHILIA, V11, P319, DOI 10.1111/j.1365-2516.2005.01094.x
   Picanco V, 2007, CYTOTHERAPY, V9, P785, DOI 10.1080/14653240701656053
   Pipe SW, 2009, HAEMOPHILIA, V15, P1187, DOI 10.1111/j.1365-2516.2009.02026.x
   Shen BW, 2008, BLOOD, V111, P1240, DOI 10.1182/blood-2007-08-109918
   Srour MA, 2008, ANN HEMATOL, V87, P107, DOI 10.1007/s00277-007-0380-9
   Stanley SL, 2006, SEMIN HEMATOL, V43, pS17, DOI 10.1053/j.seminhematol.2006.02.004
   Swiech K, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-114
   Thomas Philip, 2005, Journal of Pharmacological and Toxicological Methods, V51, P187, DOI 10.1016/j.vascn.2004.08.014
   TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939
   Wyeth Pharma (Pfizer), 2007, REFACTO PRESCR INF
   ZAGO MA, 1987, HAEMATOLOGIA, V20, P57
NR 35
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-1801
J9 SPRINGERPLUS
JI SpringerPlus
PY 2013
VL 2
AR 328
DI 10.1186/2193-1801-2-328
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V40FR
UT WOS:000209465000126
PM 25530931
OA Green Published, Other Gold
DA 2020-11-26
ER

PT J
AU Trindade, BC
   Sorgi, CA
   Nicolete, LDD
   Malta, TM
   Pinto, MT
   Takayanagui, OM
   Covas, DT
   Martins, OA
   Kashima, S
   Faccioli, LH
AF Trindade, Bruno Caetano
   Sorgi, Carlos Arterio
   de Figueiredo Nicolete, Larissa Deadame
   Malta, Tathiane Maistro
   Pinto, Mariana Tomazini
   Takayanagui, Osvaldo Massaiti
   Covas, Dimas Tadeu
   Martins Filho, Olindo Assis
   Kashima, Simone
   Faccioli, Lucia Helena
TI Leukotrienes Are Upregulated and Associated with Human T-Lymphotropic
   Virus Type 1 (HTLV-1)-Associated Neuroinflammatory Disease
SO PLOS ONE
LA English
DT Article
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELOPATHY/TROPICAL SPASTIC
   PARAPARESIS; PROVIRAL LOAD; CEREBROSPINAL-FLUID; CYSTEINYL-LEUKOTRIENES;
   HAM/TSP PATIENTS; INFECTION; RECEPTORS; RELEASE; TUBERCULOSIS
AB Leukotrienes (LTs) are lipid mediators involved in several inflammatory disorders. We investigated the LT pathway in human T-lymphotropic virus type 1 (HTLV-1) infection by evaluating LT levels in HTLV-1-infected patients classified according to the clinical status as asymptomatic carriers (HACs) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients. Bioactive LTB4 and CysLTs were both increased in the plasma and in the supernatant of peripheral blood mononuclear cell cultures of HTLV-1-infected when compared to non-infected. Interestingly, CysLT concentrations were increased in HAM/TSP patients. Also, the concentration of plasma LTB4 and LTC4 positively correlated with the HTLV-1 proviral load in HTLV-1-infected individuals. The gene expression levels of LT receptors were differentially modulated in CD4(+) and CD8(+) T cells of HTLV-1-infected patients. Analysis of the overall plasma signature of immune mediators demonstrated that LT and chemokine amounts were elevated during HTLV-1 infection. Importantly, in addition to CysLTs, IP-10 was also identified as a biomarker for HAM/TSP activity. These data suggest that LTs are likely to be associated with HTLV-1 infection and HAM/TSP development, suggesting their putative use for clinical monitoring.
C1 [Trindade, Bruno Caetano; Sorgi, Carlos Arterio; Faccioli, Lucia Helena] Univ Sao Paulo, Lab Inflamacao & Imunol Parasitoses, Fac Ciencias Farmaceut Ribeirao Preto, Sao Paulo, Brazil.
   [Trindade, Bruno Caetano; Martins Filho, Olindo Assis] Fundacao Oswaldo Cruz, Lab Biomarcadores Diagnost & Monitoracao, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil.
   [de Figueiredo Nicolete, Larissa Deadame; Malta, Tathiane Maistro; Pinto, Mariana Tomazini; Covas, Dimas Tadeu; Kashima, Simone] Inst Nacl Ciencia & Tecnol Celulas Tronco & Terap, Sao Paulo, Brazil.
   [Takayanagui, Osvaldo Massaiti] Univ Sao Paulo, Dept Neurociencias & Ciencias Comportamento, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
   [Covas, Dimas Tadeu] Univ Sao Paulo, Dept Clin Med, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
RP Faccioli, LH (corresponding author), Univ Sao Paulo, Lab Inflamacao & Imunol Parasitoses, Fac Ciencias Farmaceut Ribeirao Preto, Sao Paulo, Brazil.
EM faccioli@fcfrp.usp.br
RI Malta, Tathiane/N-1686-2013; Takayanagui, Osvaldo M/C-8159-2013; Sorgi,
   Carlos Arterio/AAA-6284-2020; Sorgi, Carlos/ABE-4246-2020; Sorgi,
   Carlos/O-2839-2017; Covas, Dimas T/C-5431-2013; Lucia,
   Faccioli/G-8976-2015; Pinto, Mariana/B-6129-2017; Kashima,
   Simone/G-4876-2012
OI Malta, Tathiane/0000-0003-1129-5791; Takayanagui, Osvaldo
   M/0000-0002-8190-0275; Sorgi, Carlos Arterio/0000-0001-7528-9935; Sorgi,
   Carlos/0000-0001-7528-9935; Covas, Dimas T/0000-0002-7364-2595; Lucia,
   Faccioli/0000-0002-4999-8305; Pinto, Mariana/0000-0002-5176-7776;
   Kashima, Simone/0000-0002-1487-0141; Martins-Filho, Olindo
   Assis/0000-0002-5494-4889
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP); Fundacao de Amparo a Pesquisa
   do Estado de Minas GeraisMinas Gerais State Research Foundation
   (FAPEMIG); Conselho Nacional de Desenvolvimento Cientifico e
   TecnologicoNational Council for Scientific and Technological Development
   (CNPq); Fundacao Hemocentro de Ribeirao Preto; CNPqNational Council for
   Scientific and Technological Development (CNPq)
FX Funding provided by Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo, Fundacao de Amparo a Pesquisa do Estado de Minas Gerais, Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico and Fundacao
   Hemocentro de Ribeirao Preto. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.; We would like to thank Virginia Mara de Deus Wagatsuma and
   Evandra Strazza Rodrigues, from the Hemocentro Foundation of Ribeirao
   Preto, for their technical assistance. LHF, OAMF, DTC and OMT are
   thankful to CNPq for the PQ fellowship Program.
CR AHMADZADEH N, 1991, INFLAMMATION, V15, P497, DOI 10.1007/BF00923346
   Best I, 2006, CLIN EXP IMMUNOL, V146, P226, DOI 10.1111/j.1365-2249.2006.03208.x
   Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8
   Cannas A, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-333
   Capra V, 2007, MED RES REV, V27, P469, DOI 10.1002/med.20071
   Carvalho EM, 2001, J ACQ IMMUN DEF SYND, V27, P1, DOI 10.1097/00126334-200105010-00001
   CLAESSON HE, 1992, INT J IMMUNOPHARMACO, V14, P441, DOI 10.1016/0192-0561(92)90174-J
   Coffey MJ, 1999, BLOOD, V94, P3897, DOI 10.1182/blood.V94.11.3897.423k12_3897_3905
   Cooper Sarah A, 2009, Pract Neurol, V9, P16, DOI 10.1136/jnnp.2008.167155
   de Souza JG, 2011, J CLIN VIROL, V50, P13, DOI 10.1016/j.jcv.2010.09.007
   Flamand L, 2004, J INFECT DIS, V189, P2001, DOI 10.1086/386374
   Flamand L, 2007, J IMMUNOL, V178, P8036, DOI 10.4049/jimmunol.178.12.8036
   Flamand N, 2007, CELL MOL LIFE SCI, V64, P2657, DOI 10.1007/s00018-007-7228-2
   FROLDI M, 1992, J NEUROIMMUNOL, V38, P155, DOI 10.1016/0165-5728(92)90100-Y
   Gaudreault E, 2008, J IMMUNOL, V180, P6211, DOI 10.4049/jimmunol.180.9.6211
   Goncalves DU, 2010, CLIN MICROBIOL REV, V23, P577, DOI 10.1128/CMR.00063-09
   GOUT O, 1990, NEW ENGL J MED, V322, P383, DOI 10.1056/NEJM199002083220607
   Guerreiro JB, 2006, CLIN EXP IMMUNOL, V145, P296, DOI 10.1111/j.1365-2249.2006.03150.x
   Haddad R, 2011, AIDS RES HUM RETROV, V27, P283, DOI 10.1089/aid.2010.0165
   Ichiyama T, 2005, CLIN EXP ALLERGY, V35, P1214, DOI 10.1111/j.1365-2222.2005.02323.x
   Izumo S, 2010, NEUROPATHOLOGY, V30, P480, DOI 10.1111/j.1440-1789.2010.01135.x
   Kabeer BSA, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-135
   Keating SM, 2011, AIDS, V25, P1823, DOI 10.1097/QAD.0b013e3283489d1f
   Kihara Y, 2010, BIOCHEM BIOPH RES CO, V394, P673, DOI 10.1016/j.bbrc.2010.03.049
   LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312
   Luiza-Silva M, 2011, J INFECT DIS, V204, P873, DOI 10.1093/infdis/jir439
   Machado ER, 2005, J IMMUNOL, V175, P3892, DOI 10.4049/jimmunol.175.6.3892
   Matsuo M, 1996, PEDIATR NEUROL, V14, P121, DOI 10.1016/0887-8994(96)83272-3
   Matsuzaki T, 2001, J NEUROVIROL, V7, P228
   Medeiros AI, 2004, INFECT IMMUN, V72, P1637, DOI 10.1128/IAI.72.3.1637-1644.2004
   Medeiros AI, 2008, J IMMUNOL, V181, P8544, DOI 10.4049/jimmunol.181.12.8544
   Moriuchi M, 2001, J VIROL, V75, P192, DOI 10.1128/JVI.75.1.192-198.2001
   Nassar GM, 1997, KIDNEY INT, V51, P1520, DOI 10.1038/ki.1997.209
   NEU I, 1992, ACTA NEUROL SCAND, V86, P586, DOI 10.1111/j.1600-0404.1992.tb05491.x
   Okubo M, 2010, GLIA, V58, P599, DOI 10.1002/glia.20948
   Okunishi K, 2011, BBA-GEN SUBJECTS, V1810, P1096, DOI 10.1016/j.bbagen.2011.02.005
   Olindo S, 2005, J NEUROL SCI, V237, P53, DOI 10.1016/j.jns.2005.05.010
   Peres CM, 2007, MICROBES INFECT, V9, P483, DOI 10.1016/j.micinf.2007.01.006
   Peres-Buzalaf C, 2011, PROSTAG LEUKOTR ESS, V85, P75, DOI 10.1016/j.plefa.2011.04.024
   Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371
   POULIOT M, 1994, J IMMUNOL, V152, P851
   Santos SB, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-7
   Takenouchi N, 2003, J NEUROVIROL, V9, P29, DOI 10.1080/13550280390173418
   Toulza F, 2010, J IMMUNOL, V185, P183, DOI 10.4049/jimmunol.0903846
   Umehara F, 2003, GANN MONOGR CANC RES, P141
   Verdonck K, 2007, LANCET INFECT DIS, V7, P266, DOI 10.1016/S1473-3099(07)70081-6
   Wang LF, 2011, J IMMUNOL, V187, P2336, DOI 10.4049/jimmunol.1100333
   Watanabe T, 1997, INT J HEMATOL, V66, P257
   Yoshikawa K, 2011, PROSTAG LEUKOTR ESS, V85, P43, DOI 10.1016/j.plefa.2011.04.022
NR 49
TC 4
Z9 4
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 20
PY 2012
VL 7
IS 12
AR e51873
DI 10.1371/journal.pone.0051873
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 060RA
UT WOS:000312794500058
PM 23284797
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Nicolete, LDDF
   Nicolete, R
   Haddad, R
   Azevedo, R
   de Castro, FA
   Tanaka, Y
   Takayanagui, OM
   Covas, DT
   Kashima, S
AF de Figueiredo Nicolete, Larissa Deadame
   Nicolete, Roberto
   Haddad, Rodrigo
   Azevedo, Rochele
   de Castro, Fabiola Attie
   Tanaka, Yuetsu
   Takayanagui, Osvaldo Massaiti
   Covas, Dimas Tadeu
   Kashima, Simone
TI Upregulation of hsa-miR-125b in HTLV-1 asymptomatic carriers and
   HTLV-1-associated myelopathy/tropical spastic paraparesis patients
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE HAM/TSP; hsa-miR-125b; upregulation
ID T-CELLS; MICRORNAS; NAIVE; PCR
AB The retrovirus human T lymphotropic virus type 1 (HTLV-1) promotes spastic paraparesis, adult T cell leukaemia and other diseases. Recently, some human microRNAs (miRNAs) have been described as important factors in host-virus interactions. This study compared miRNA expression in control individuals, asymptomatic HTLV-1 carriers and HTLV-1 associated myelopathy (HAM)/tropical spastic paraparesis patients. The proviral load and Tax protein expression were measured in order to characterize the patients. hsa-miR-125b expression was significantly higher in patients than in controls (p = 0.0285) or in the HAM group (p = 0.0312). Therefore, our findings suggest that miR-125b expression can be used to elucidate the mechanisms of viral replication and pathogenic processes.
C1 [de Figueiredo Nicolete, Larissa Deadame; de Castro, Fabiola Attie; Kashima, Simone] Univ Sao Paulo, Dept Anal Clin Toxicol & Bromatol, Fac Ciencias Farmaceut Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
   [de Figueiredo Nicolete, Larissa Deadame; Haddad, Rodrigo; Azevedo, Rochele; Covas, Dimas Tadeu; Kashima, Simone] Univ Sao Paulo, Fundacao Hemoctr Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
   [Haddad, Rodrigo; Takayanagui, Osvaldo Massaiti; Covas, Dimas Tadeu; Kashima, Simone] Univ Sao Paulo, Fac Med Ribeirao Preto, Ribeirao Preto, SP, Brazil.
   [de Figueiredo Nicolete, Larissa Deadame; Nicolete, Roberto] Fiocruz Rondonia, Porto Velho, RO, Brazil.
   [Tanaka, Yuetsu] Univ Ryukyus, Dept Immunol, Grad Sch, Nishihara, Okinawa 90301, Japan.
   [Tanaka, Yuetsu] Univ Ryukyus, Fac Med, Nishihara, Okinawa 90301, Japan.
RP Nicolete, LDD (corresponding author), Univ Sao Paulo, Dept Anal Clin Toxicol & Bromatol, Fac Ciencias Farmaceut Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
EM larissanicolete@gmail.com
RI Covas, Dimas T/C-5431-2013; Haddad, Rodrigo/A-3460-2013; Takayanagui,
   Osvaldo M/C-8159-2013; Kashima, Simone/G-4876-2012
OI Covas, Dimas T/0000-0002-7364-2595; Haddad, Rodrigo/0000-0003-4699-164X;
   Takayanagui, Osvaldo M/0000-0002-8190-0275; Kashima,
   Simone/0000-0002-1487-0141
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [06/59388-4]; CNPqNational Council for Scientific and Technological
   Development (CNPq); FUNDHERP
FX Financial support: FAPESP (06/59388-4), CNPq, FUNDHERP
CR Asquith B, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-75
   Bellon M, 2009, BLOOD, V113, P4914, DOI 10.1182/blood-2008-11-189845
   Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178
   Dehee A, 2002, J VIROL METHODS, V102, P37, DOI 10.1016/S0166-0934(01)00445-1
   GESSAIN A, 1985, LANCET, V2, P407
   Lambeth LS, 2009, J GEN VIROL, V90, P1164, DOI 10.1099/vir.0.007831-0
   Le MTN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002242
   Ma F, 2011, NAT IMMUNOL, V12, P861, DOI 10.1038/ni.2073
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   Rajaram MVS, 2011, P NATL ACAD SCI USA, V108, P17408, DOI 10.1073/pnas.1112660108
   Rossi RL, 2011, NAT IMMUNOL, V12, P796, DOI 10.1038/ni.2057
   Salvatori Beatrice, 2011, Genes Cancer, V2, P585, DOI 10.1177/1947601911416357
   Scaria V, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-68
   Taylor JM, 2008, APOPTOSIS, V13, P733, DOI 10.1007/s10495-008-0208-7
   Tomita M, 2012, INT J CANCER, V130, P2300, DOI 10.1002/ijc.25115
   Wu HQ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001020
   Yamano Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006517
   Yeung ML, 2008, CANCER RES, V68, P8976, DOI 10.1158/0008-5472.CAN-08-0769
NR 18
TC 3
Z9 3
U1 0
U2 0
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD SEP
PY 2012
VL 107
IS 6
BP 824
EP 827
PG 4
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 008FX
UT WOS:000308943900020
PM 22990976
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Lins, L
   de Carvalho, VJU
   Rego, FFD
   Azevedo, R
   Kashima, S
   Gallazi, VNO
   Xavier, MT
   Galvao-Castro, B
   Alcantara, LCJ
AF Lins, Liliane
   Uchoa de Carvalho, Victor Jose
   de Almeida Rego, Filipe Ferreira
   Azevedo, Rochele
   Kashima, Simone
   Olavarria Gallazi, Viviana Nilla
   Xavier, Marcia Tosta
   Galvao-Castro, Bernardo
   Junior Alcantara, Luiz Carlos
TI Oral health profile in patients infected with HTLV-1: Clinical findings,
   proviral load, and molecular analysis from HTLV-1 in saliva
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE oral health; saliva; HTLV-1
ID VIRUS TYPE-I; SJOGRENS-SYNDROME; ANTIBODIES; GLANDS
AB Human T-lymphotropic virus type 1 (HTLV-1) is associated with adult T-cell leukemia (ATL) and HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) and has also been implicated in several disorders, including periodontal disease. The proviral load is an important biological marker for understanding HTLV-1 pathogenesis and elucidating whether or not the virus is related to the clinical manifestation of the disease. This study describes the oral health profile of HTLV-1 carriers and HAM/TSP patients in order to investigate the association between the proviral load in saliva and the severity of the periodontal disease and to examine virus intra-host variations from peripheral blood mononuclear cells and saliva cells. It is a cross-sectional analytical study of 90 individuals carried out from November 2006 to May 2008. Of the patients, 60 were HTLV-1 positive and 30 were negative. Individuals from the HTLV-1 positive and negative groups had similar mean age and social-economic status. Data were analyzed using two available statistical software packages, STATA 8.0 and SPSS 11.0 to conduct frequency analysis. Differences of P?<?0.05 were considered statistically significant. HTLV-1 patients had poorer oral health status when compared to seronegative individuals. A weak positive correlation between blood and saliva proviral loads was observed. The mean values of proviral load in blood and saliva in patients with HAM/TSP was greater than those in HTLV-1 carriers. The HTLV-1 molecular analysis from PBMC and saliva specimens suggests that HTLV-1 in saliva is due to lymphocyte infiltration from peripheral blood. A direct relationship between the proviral load in saliva and oral manifestations was observed. J. Med. Virol. 84:1428-1436, 2012. (c) 2012 Wiley Periodicals, Inc.
C1 [Uchoa de Carvalho, Victor Jose; de Almeida Rego, Filipe Ferreira; Olavarria Gallazi, Viviana Nilla; Galvao-Castro, Bernardo; Junior Alcantara, Luiz Carlos] Fundacao Oswaldo Cruz, Goncalo Moniz Res Ctr, BR-40296610 Salvador, BA, Brazil.
   [Lins, Liliane; Uchoa de Carvalho, Victor Jose; de Almeida Rego, Filipe Ferreira; Olavarria Gallazi, Viviana Nilla; Xavier, Marcia Tosta; Galvao-Castro, Bernardo; Junior Alcantara, Luiz Carlos] Bahiana Sch Med & Publ Hlth, Salvador, BA, Brazil.
   [Lins, Liliane] Fed Univ Bahia UFBA, Sch Med, Salvador, BA, Brazil.
   [Azevedo, Rochele; Kashima, Simone] Univ Sao Paulo, Sch Med, Natl Inst Sci & Technol Stem Cells & Cell Theraph, Sao Paulo, Brazil.
RP Alcantara, LCJ (corresponding author), Fundacao Oswaldo Cruz, Goncalo Moniz Res Ctr, Rua Waldemar Falcao 121, BR-40296610 Salvador, BA, Brazil.
EM lalcan@bahia.fiocruz.br
RI Lins-Kusterer, Liliane/Q-5191-2019; Kashima, Simone/G-4876-2012
OI Lins-Kusterer, Liliane/0000-0003-3736-0002; Kashima,
   Simone/0000-0002-1487-0141; Alcantara, Luiz/0000-0002-6769-9931
FU FAPESB [303/03]; Brazilian Ministry of Health [306/04, 307/04]
FX Grant sponsor: FAPESB; Grant number: 303/03; Grant sponsor: Brazilian
   Ministry of Health; Grant numbers: 306/04. 307/04.
CR Alcantara LCJ, 2006, AIDS, V20, P780, DOI 10.1097/01.aids.0000216383.14808.13
   Belec L, 1996, AIDS RES HUM RETROV, V12, P157, DOI 10.1089/aid.1996.12.157
   Catalan-Soares BC, 2001, REV BRAS EPIDEMIOL, V4, P81
   Cruz Boris A., 2005, Rev. Bras. Reumatol., V45, P71, DOI 10.1590/S0482-50042005000200005
   Dehee A, 2002, J VIROL METHODS, V102, P37, DOI 10.1016/S0166-0934(01)00445-1
   Dourado I, 2003, JAIDS-J ACQ IMM DEF, V34, P527, DOI 10.1097/00126334-200312150-00013
   Ferraz-Chaoui AK, 2010, RHEUMATOL INT, V30, P775, DOI 10.1007/s00296-009-1066-5
   GalvaoCastro B, 1997, TRANSFUSION, V37, P242, DOI 10.1046/j.1537-2995.1997.37297203532.x
   Garlet GP, 2010, CLIN INFECT DIS, V50, pE11, DOI 10.1086/649871
   GESSAIN A, 1985, LANCET, V2, P407
   Giozza SP., 2006, THESIS U FEDERAL BAH
   Gushi Lívia Litsue, 2005, J. Appl. Oral Sci., V13, P305, DOI 10.1590/S1678-77572005000300019
   Haddad SK., 2004, THESIS U SAO PAULO S
   Jorge AOC., 1998, MICROBIOLOGIA BUCAL, P21
   Jovino-Silveira Renata Cimoes, 2005, Oral Health Prev Dent, V3, P151
   Korn Gustavo Polacow, 2002, Rev. Bras. Otorrinolaringol., V68, P624, DOI 10.1590/S0034-72992002000500004
   Krasse B., 1998, RISCO CARIE GUIA PRA, P113
   KUMAR S, 1994, COMPUT APPL BIOSCI, V10, P189
   La Grenade L, 1998, ARCH DERMATOL, V134, P439, DOI 10.1001/archderm.134.4.439
   Mariette X, 2000, CLIN EXP RHEUMATOL, V18, P341
   Mochizuki M, 1996, J ACQ IMMUN DEF SYND, V13, pS50, DOI 10.1097/00042560-199600001-00010
   Mota Augusto, 2006, Rev. Bras. Hematol. Hemoter., V28, P120, DOI 10.1590/S1516-84842006000200011
   Nakamura H, 2000, J LAB CLIN MED, V135, P139, DOI 10.1067/mlc.2000.103429
   Nicholas KB, 1997, EMBNEW NEWS, V4, P14
   OSAME M, 1986, LANCET, V1, P1031
   OSAME M, 1990, HUMAN RETROVIROLOGY : HTLV, P191
   Peres Marco Aurélio, 2003, Rev. bras. epidemiol., V6, P293, DOI 10.1590/S1415-790X2003000400004
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Proietti FA, 2005, ONCOGENE, V24, P6058, DOI 10.1038/sj.onc.1208968
   Ragghianti Mariana Schützer, 2004, J. Appl. Oral Sci., V12, P273, DOI 10.1590/S1678-77572004000400004
   Swofford DL, 1998, PAUP PHYLOGENETIC AN
   Tangy F, 1999, J INFECT DIS, V179, P497, DOI 10.1086/314588
   TERADA K, 1994, LANCET, V344, P1116, DOI 10.1016/S0140-6736(94)90630-0
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Thylstrup A, 2001, CARIOLOGIA CLIN, P421
   World Health Organization (WHO), 1999, LAB MAN EX HUM SEM S, P68
   Yakova M, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-4
   YAMAMOTO T, 1995, J CLIN MICROBIOL, V33, P1510, DOI 10.1128/JCM.33.6.1510-1515.1995
NR 39
TC 7
Z9 7
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD SEP
PY 2012
VL 84
IS 9
BP 1428
EP 1436
DI 10.1002/jmv.23327
PG 9
WC Virology
SC Virology
GA 977IA
UT WOS:000306648800014
PM 22825822
OA Green Published
DA 2020-11-26
ER

PT J
AU Rocha, MC
   Haddad, R
   Alves, DCC
   Wagatsuma, VMD
   Mendes, CT
   Deghaide, NHS
   Takayanagui, OM
   Covas, DT
   Donadi, EA
   Kashima, S
AF Rocha-Junior, M. C.
   Haddad, R.
   Ciliao Alves, D. C.
   de Deus Wagatsuma, V. M.
   Mendes-Junior, C. T.
   Deghaide, N. H. S.
   Takayanagui, O. M.
   Covas, D. T.
   Donadi, E. A.
   Kashima, S.
TI Interleukin-18 and interferon-gamma polymorphisms are implicated on
   proviral load and susceptibility to human T-lymphotropic virus type 1
   infection
SO TISSUE ANTIGENS
LA English
DT Article
DE human T-cell leukemia virus type 1 infection; interleukin-18;
   interferon-gamma; polymorphisms
ID CHRONIC HEPATITIS-B; MYELOPATHY/TROPICAL SPASTIC PARAPARESIS;
   I-ASSOCIATED MYELOPATHY; HTLV-I; GENE POLYMORPHISMS; PROMOTER
   POLYMORPHISM; HIV-1 INFECTION; IL-18 PROMOTER; ASSOCIATION; RISK
AB Interleukin-18 (IL-18) and interferon-gamma (IFN-?) exert important functions in both innate and adaptive immune responses against intracellular pathogens and viruses. Previous studies suggested that host genetic factors, including cytokines gene polymorphisms, could be involved in the pathogenesis of human T-cell leukemia virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Thus, we analyzed -137C/G and -607A/C of the IL-18 promoter and +874T/A of the IFN-? in DNA samples from 98 HTLV-1-infected individuals exhibiting or not clinical symptoms and 150 healthy control individuals. The IL-18 promoter -607CC genotype was significantly lower in HTLV-1 asymptomatic carriers (HAC) and HTLV-1-infected individuals (HAC + HAM/TSP) than healthy control group. In contrast, the -607AC genotype was significantly higher in HAC and HTLV-1-infected individuals group compared to the healthy control group. The -137G/-607A IL-18 haplotype was higher in infected group than healthy control group, and the -137C/-607C IL-18 haplotype was increased in the healthy control group compared to the others. Finally, the IFN-? polymorphism analysis showed that the HTLV-1-infected individuals with +874AT genotype presented higher proviral load than +874AA genotype. These data indicate that the IL-18-607AC genotype and -137G/-607A haplotype could be a risk factor for HTLV-1 infection, whereas the protective effect could be conferred by -607CC genotype and -137C/-607C haplotype. Also, the IFN-? could be implicated on the proviral load levels.
C1 [Rocha-Junior, M. C.; Haddad, R.; de Deus Wagatsuma, V. M.; Covas, D. T.; Kashima, S.] Univ Sao Paulo, Hemoctr Ribeirao Preto, BR-14051140 Sao Paulo, Brazil.
   [Rocha-Junior, M. C.; Deghaide, N. H. S.; Kashima, S.] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, BR-14040903 Sao Paulo, Brazil.
   [Haddad, R.; Ciliao Alves, D. C.; Takayanagui, O. M.; Covas, D. T.; Donadi, E. A.] Univ Sao Paulo, Fac Med Ribeirao Preto, BR-14049900 Sao Paulo, Brazil.
   [Mendes-Junior, C. T.] Univ Sao Paulo, Dept Quim, Fac Filosofia Ciencias & Letras Ribeirao Preto, BR-14040901 Sao Paulo, Brazil.
RP Kashima, S (corresponding author), Fundacao Hemoctr Ribeirao Preto, Mol Biol Lab, Rua Tenente Catao Roxo 2501, BR-14051140 Sao Paulo, Brazil.
EM skashima@hemocentro.fmrp.usp.br
RI Takayanagui, Osvaldo M/C-8159-2013; Mendes-Junior, Celso
   Teixeira/B-1994-2010; donadi, eduardo A/H-7080-2013; Haddad,
   Rodrigo/A-3460-2013; Covas, Dimas T/C-5431-2013; Wagatsuma,
   Virginia/F-1643-2013; Kashima, Simone/G-4876-2012
OI Takayanagui, Osvaldo M/0000-0002-8190-0275; Mendes-Junior, Celso
   Teixeira/0000-0002-7337-1203; donadi, eduardo A/0000-0002-9457-9601;
   Haddad, Rodrigo/0000-0003-4699-164X; Covas, Dimas T/0000-0002-7364-2595;
   Wagatsuma, Virginia/0000-0003-3801-3280; Kashima,
   Simone/0000-0002-1487-0141
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); Centro de Terapia
   Celular da Fundacao Hemocentro de Ribeirao Preto (CTC/FUNDHERP);
   Instituto Nacional de Celulas Tronco e Terapia Celular (INCTC)
FX This work was funded by Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP), Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq), Centro de Terapia Celular da Fundacao Hemocentro de
   Ribeirao Preto (CTC/FUNDHERP), and Instituto Nacional de Celulas Tronco
   e Terapia Celular (INCTC).
CR An P, 2008, J INFECT DIS, V198, P1159, DOI 10.1086/592047
   Arend WP, 2008, IMMUNOL REV, V223, P20, DOI 10.1111/j.1600-065X.2008.00624.x
   Arimitsu J, 2006, BIOCHEM BIOPH RES CO, V342, P1413, DOI 10.1016/j.bbrc.2006.02.096
   Bangham CRM, 2003, J GEN VIROL, V84, P3177, DOI 10.1099/vir.0.19334-0
   Best I, 2009, IMMUNOLOGY, V128, pe777, DOI 10.1111/j.1365-2567.2009.03082.x
   Bouzgarrou N, 2008, J MED VIROL, V80, P607, DOI 10.1002/jmv.21079
   Castelar L, 2010, TISSUE ANTIGENS, V76, P126, DOI 10.1111/j.1399-0039.2010.01471.x
   Cheong JY, 2010, DIGEST DIS SCI, V55, P1113, DOI 10.1007/s10620-009-0819-z
   Dai CY, 2006, TRANSL RES, V148, P128, DOI 10.1016/j.trsl.2006.04.005
   Dinarello CA, 2003, J INFECT DIS, V187, pS370, DOI 10.1086/374751
   Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X
   Dinarello CA, 2007, SEMIN NEPHROL, V27, P98, DOI 10.1016/j.semnephrol.2006.09.013
   Gadelha SR, 2008, J MED VIROL, V80, P2141, DOI 10.1002/jmv.21341
   Gao QJ, 2009, WORLD J GASTROENTERO, V15, P5610, DOI 10.3748/wjg.15.5610
   GESSAIN A, 1985, LANCET, V2, P407
   Giedraitis V, 2001, J NEUROIMMUNOL, V112, P146, DOI 10.1016/S0165-5728(00)00407-0
   Haas SL, 2009, J CLIN IMMUNOL, V29, P620, DOI 10.1007/s10875-009-9302-z
   Haddad R, 2011, AIDS RES HUM RETROV, V27, P283, DOI 10.1089/aid.2010.0165
   Hirankarn N, 2007, TISSUE ANTIGENS, V70, P160, DOI 10.1111/j.1399-0039.2007.00865.x
   Kim YS, 2009, DIGEST DIS SCI, V54, P2722, DOI 10.1007/s10620-009-0970-6
   LaGrenade L, 1996, J ACQ IMMUN DEF SYND, V13, pS46, DOI 10.1097/00042560-199600001-00009
   Manohar K, 2009, HEPATOL INT, V3, P371, DOI 10.1007/s12072-009-9127-0
   Mariette X, 2000, CLIN EXP RHEUMATOL, V18, P341
   Migita K, 2009, TRANSL RES, V153, P91, DOI 10.1016/j.trsl.2008.11.008
   Mochizuki M, 1996, J ACQ IMMUN DEF SYND, V13, pS50, DOI 10.1097/00042560-199600001-00010
   Montanheiro PA, 2009, SCAND J IMMUNOL, V70, P403, DOI 10.1111/j.1365-3083.2009.02291.x
   MORGAN OS, 1989, LANCET, V2, P1184
   MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214
   Nagai M, 2003, J NEUROVIROL, V9, P228, DOI 10.1080/13550280390194028
   Nagai M, 1998, J NEUROVIROL, V4, P586, DOI 10.3109/13550289809114225
   Nakahira M, 2002, J IMMUNOL, V168, P1146, DOI 10.4049/jimmunol.168.3.1146
   Nishimura M, 2002, HUM IMMUNOL, V63, P696, DOI 10.1016/S0198-8859(02)00419-6
   NISHIOKA K, 1989, LANCET, V1, P441
   Nolan KF, 1998, GENOMICS, V51, P161, DOI 10.1006/geno.1998.5336
   Okamoto M, 2002, BLOOD, V99, P1289, DOI 10.1182/blood.V99.4.1289
   OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0
   Okazawa A, 2004, CLIN EXP IMMUNOL, V136, P269, DOI 10.1111/j.1365-2249.2004.02431.x
   Orland JR, 2003, NEUROLOGY, V61, P1588, DOI 10.1212/01.WNL.0000096011.92542.DA
   OSAME M, 1986, LANCET, V1, P1031
   Perrey C, 1998, TRANSPL IMMUNOL, V6, P193, DOI 10.1016/S0966-3274(98)80045-2
   Pravica V, 2000, HUM IMMUNOL, V61, P863, DOI 10.1016/S0198-8859(00)00167-1
   RAYMOND M, 1995, J HERED, V86, P248, DOI 10.1093/oxfordjournals.jhered.a111573
   Robinson D, 1997, IMMUNITY, V7, P571, DOI 10.1016/S1074-7613(00)80378-7
   Sabouri AH, 2005, J GEN VIROL, V86, P773, DOI 10.1099/vir.0.80509-0
   Sabouri AH, 2004, J INFECT DIS, V190, P1279, DOI 10.1086/423942
   Sailer CA, 2007, J INFECT DIS, V195, P734, DOI 10.1086/511435
   Segat L, 2006, IMMUNOGENETICS, V58, P471, DOI 10.1007/s00251-006-0104-7
   Sobti RC, 2010, FOLIA BIOL-PRAGUE, V56, P110
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Swainson L, 2005, P NATL ACAD SCI USA, V102, P12867, DOI 10.1073/pnas.0503603102
   Zhang PA, 2005, WORLD J GASTROENTERO, V11, P1594, DOI 10.3748/wjg.v11.i11.1594
NR 51
TC 13
Z9 14
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-2815
EI 1399-0039
J9 TISSUE ANTIGENS
JI Tissue Antigens
PD AUG
PY 2012
VL 80
IS 2
BP 143
EP 150
DI 10.1111/j.1399-0039.2012.01887.x
PG 8
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA 980LH
UT WOS:000306894200005
PM 22587568
DA 2020-11-26
ER

PT J
AU Garcia, FB
   Kashima, S
   Rodrigues, ES
   Silva, IT
   Malta, TM
   Nicolete, LDF
   Covas, DT
   Moraes-Souza, H
AF Garcia, Fernanda Bernadelli
   Kashima, Simone
   Rodrigues, Evandra Strazza
   Silva, Israel Tojal
   Malta, Tathiane Maistro
   de Figueiredo Nicolete, Larissa Deadame
   Covas, Dimas Tadeu
   Moraes-Souza, Helio
TI Distribution of QPY and RAH haplotypes of granzyme B gene in distinct
   Brazilian populations
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA English
DT Article
DE Granzyme B; SNP; QPY haplotype; RAH haplotype; Brazilian population;
   Population distribution
ID HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; LYMPHOCYTES; APOPTOSIS; ALLELE;
   DEATH
AB Introduction: The cytolysis mediated by granules is one of the most important effector functions of cytotoxic T lymphocytes and natural killer cells. Recently, three single nucleotide polymorphisms (SNPs) were identified at exons 2, 3, and 5 of the granzyme B gene, resulting in a haplotype in which three amino acids of mature protein Q48P88Y245 are changed to R48A88H245, which leads to loss of cytotoxic activity of the protein. In this study, we evaluated the frequency of these polymorphisms in Brazilian populations. Methods: We evaluated the frequency of these polymorphisms in Brazilian ethnic groups (white, Afro-Brazilian, and Asian) by sequencing these regions. Results: The allelic and genotypic frequencies of SNP 2364A/G at exon 2 in Afro-Brazilian individuals (42.3% and 17.3%) were significantly higher when compared with those in whites and Asians (p < 0.0001 and p = 0.0007, respectively). The polymorphisms 2933C/G and 4243C/T also were more frequent in Afro-Brazilians but without any significant difference regarding the other groups. The Afro-Brazilian group presented greater diversity of haplotypes, and the RAH haplotype seemed to be more frequent in this group (25%), followed by the whites (20.7%) and by the Asians (11.9%), similar to the frequency presented in the literature. Conclusions: There is a higher frequency of polymorphisms in Afro-Brazilians, and the RAH haplotype was more frequent in these individuals. We believe that further studies should aim to investigate the correlation of this haplotype with diseases related to immunity mediated by cytotoxic lymphocytes, and if this correlation is confirmed, novel treatment strategies might be elaborated.
C1 [Garcia, Fernanda Bernadelli; Moraes-Souza, Helio] Univ Fed Triangulo Mineiro, Disciplina Hematol & Hemoterapia, BR-38025440 Uberaba, MG, Brazil.
   [Kashima, Simone; Rodrigues, Evandra Strazza; Silva, Israel Tojal; Malta, Tathiane Maistro; Covas, Dimas Tadeu] Univ Sao Paulo, Ctr Reg Hemoterapia, BR-14049 Ribeirao Preto, SP, Brazil.
   [Kashima, Simone; Malta, Tathiane Maistro] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
   [de Figueiredo Nicolete, Larissa Deadame] Inst Pesquisas Patol Tropicais Rondonia, Porto Velho, RO, Brazil.
   [Covas, Dimas Tadeu] Univ Sao Paulo, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
   [Moraes-Souza, Helio] Hemoctr Reg Uberaba, Fundacao Hemominas, Uberaba, MG, Brazil.
RP Garcia, FB (corresponding author), Univ Fed Triangulo Mineiro, Disciplina Hematol & Hemoterapia, Av Getulio Guarita 250, BR-38025440 Uberaba, MG, Brazil.
EM nandadelli@yahoo.com.br
RI Moraes-Souza, Helio/O-7720-2015; Malta, Tathiane/N-1686-2013; Silva,
   Israel T/N-3858-2014; Rodrigues, Evandra/L-6094-2017; Covas, Dimas
   T/C-5431-2013; Kashima, Simone/G-4876-2012
OI Malta, Tathiane/0000-0003-1129-5791; Silva, Israel
   T/0000-0002-4687-1499; Rodrigues, Evandra/0000-0003-0964-9554; Covas,
   Dimas T/0000-0002-7364-2595; Moraes-Souza, Helio/0000-0001-8049-348X;
   Kashima, Simone/0000-0002-1487-0141
FU Center for Cell-Therapy (CTC); Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais
   (FAPEMIG)Minas Gerais State Research Foundation (FAPEMIG); Fundacao
   Hemocentro de Ribeirao Preto (FUNDHERP)
FX This study was supported by the Center for Cell-Therapy (CTC), Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Fundacao de Amparo
   a Pesquisa do Estado de Minas Gerais (FAPEMIG), and Fundacao Hemocentro
   de Ribeirao Preto (FUNDHERP).
CR Abe-Sandes K, 2004, HUM BIOL, V76, P77, DOI 10.1353/hub.2004.0014
   Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819
   Ericson KG, 2003, HUM GENET, V112, P98, DOI 10.1007/s00439-002-0841-0
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   Excoffier L, 1998, AM J HUM GENET, V62, P171, DOI 10.1086/301674
   Excoffier L, 2005, EVOL BIOINFORM, V1, P47, DOI 10.1177/117693430500100003
   Gaafar A, 2009, EXP HEMATOL, V37, P838, DOI 10.1016/j.exphem.2009.04.003
   GUO SW, 1992, BIOMETRICS, V48, P361, DOI 10.2307/2532296
   HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X
   McIlroy D, 2003, P NATL ACAD SCI USA, V100, P2562, DOI 10.1073/pnas.0437935100
   Mullbacher A, 1999, P NATL ACAD SCI USA, V96, P13950, DOI 10.1073/pnas.96.24.13950
   Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745
   POE M, 1991, J BIOL CHEM, V266, P98
   RAYMOND M, 1995, J HERED, V86, P248, DOI 10.1093/oxfordjournals.jhered.a111573
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Stepp SE, 1999, SCIENCE, V286, P1957, DOI 10.1126/science.286.5446.1957
   Sun JR, 2004, J BIOL CHEM, V279, P16907, DOI 10.1074/jbc.M400563200
   Trapani JA, 2002, NAT REV IMMUNOL, V2, P735, DOI 10.1038/nri911
NR 19
TC 0
Z9 0
U1 0
U2 3
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PD JUL-AUG
PY 2012
VL 45
IS 4
BP 496
EP 499
DI 10.1590/S0037-86822012005000001
PG 4
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 996OR
UT WOS:000308100800016
PM 22767096
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU de Oliveira, GLV
   Malmegrim, KCR
   Ferreira, AF
   Tognon, R
   Kashima, S
   Couri, CEB
   Covas, DT
   Voltarelli, JC
   de Castro, FA
AF de Oliveira, G. L. V.
   Malmegrim, K. C. R.
   Ferreira, A. F.
   Tognon, R.
   Kashima, S.
   Couri, C. E. B.
   Covas, D. T.
   Voltarelli, J. C.
   de Castro, F. A.
TI Up-regulation of fas and fasL pro-apoptotic genes expression in type 1
   diabetes patients after autologous haematopoietic stem cell
   transplantation
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE apoptosis-related genes expression; autologous haematopoietic stem cell
   transplantation; Bcl-2 family members; death receptors family members;
   inhibitory apoptosis proteins; type 1 diabetes
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; ANTI-THYMOCYTE GLOBULIN; BCL-2 FAMILY
   PROTEINS; MULTIPLE-SCLEROSIS; NOD MICE; T-CELLS; RHEUMATOID-ARTHRITIS;
   AUTOIMMUNE-DISEASES; CENTRAL TOLERANCE; B-CELLS
AB Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by T cell-mediated destruction of pancreatic beta cells, resulting in insulin deficiency and hyperglycaemia. Recent studies have described that apoptosis impairment during central and peripheral tolerance is involved in T1D pathogenesis. In this study, the apoptosis-related gene expression in T1D patients was evaluated before and after treatment with high-dose immunosuppression followed by autologous haematopoietic stem cell transplantation (HDI-AHSCT). We also correlated gene expression results with clinical response to HDI-AHSCT. We observed a decreased expression of bad, bax and fasL pro-apoptotic genes and an increased expression of a1, bcl-xL and cIAP-2 anti-apoptotic genes in patients' peripheral blood mononuclear cells (PBMCs) compared to controls. After HDI-AHSCT, we found an up-regulation of fas and fasL and a down-regulation of anti-apoptotic bcl-xL genes expression in post-HDI-AHSCT periods compared to pre-transplantation. Additionally, the levels of bad, bax, bok, fasL, bcl-xL and cIAP-1 genes expression were found similar to controls 2 years after HDI-AHSCT. Furthermore, over-expression of pro-apoptotic noxa at 540 days post-HDI-AHSCT correlated positively with insulin-free patients and conversely with glutamic acid decarboxylase autoantibodies (GAD65) autoantibody levels. Taken together, the results suggest that apoptosis-related genes deregulation in patients' PBMCs might be involved in breakdown of immune tolerance and consequently contribute to T1D pathogenesis. Furthermore, HDI-AHSCT modulated the expression of some apoptotic genes towards the levels similar to controls. Possibly, the expression of these apoptotic molecules could be applied as biomarkers of clinical remission of T1D patients treated with HDI-AHSCT therapy.
C1 [de Oliveira, G. L. V.; Ferreira, A. F.; Tognon, R.; Kashima, S.; de Castro, F. A.] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin Anal, Sao Paulo, Brazil.
   [de Oliveira, G. L. V.; Malmegrim, K. C. R.; Kashima, S.; Covas, D. T.; Voltarelli, J. C.] Univ Sao Paulo, Sch Med, Natl Inst Sci & Technol Stem Cells & Cell Therapy, Sao Paulo, Brazil.
   [Couri, C. E. B.; Covas, D. T.; Voltarelli, J. C.] Univ Sao Paulo, Sch Med, Dept Clin Med, Sao Paulo, Brazil.
RP de Castro, FA (corresponding author), Fac Ciencias Farmaceut Ribeirao Preto, Lab Hematol, Sala 50A,Bloco M,Ave Cafe S-N Ribeirao Preto, BR-14040903 Sao Paulo, Brazil.
EM castrofa@fcfrp.usp.br
RI Covas, Dimas T/C-5431-2013; Malmegrim, Kelen/H-1016-2015; Kashima,
   Simone/G-4876-2012; Malmegrim, Kelen/B-8514-2012; de Oliveira, Gislane
   L. V./I-4896-2013
OI Covas, Dimas T/0000-0002-7364-2595; Malmegrim,
   Kelen/0000-0002-9303-0086; Kashima, Simone/0000-0002-1487-0141; de
   Oliveira, Gislane L. V./0000-0002-0269-9973; Lelis Vilela de Oliveira,
   Gislane/0000-0002-8883-5541
FU Brazilian governmental agency: Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior (CAPES, Coordination of the Advancement of Higher
   Education); Brazilian governmental agency: Fundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP, Foundation for the Support of Research
   in the State of Sao Paulo); Fundacao Hemocentro de Ribeirao Preto
   (FUNDHERP, Ribeirao Preto Blood Bank Foundation)
FX We thank the Bone Marrow Transplantation group of the University
   Hospital of the School of Medicine of Ribeirao Preto for assistance in
   collecting peripheral blood samples. The authors of this study received
   financial support in the form of fellowship grants from Brazilian
   governmental agencies, as follows: from the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES, Coordination of the
   Advancement of Higher Education) to G. L. V. O.; Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP, Foundation for the Support of
   Research in the State of Sao Paulo) to K. C. R. M. A. F. F. and R. T.
   This study also received financial support in the form of general grants
   from Fundacao Hemocentro de Ribeirao Preto (FUNDHERP, Ribeirao Preto
   Blood Bank Foundation).
CR Abrahamsson S, 2008, AUTOIMMUNITY, V41, P577, DOI 10.1080/08916930802197081
   Albesiano E, 2003, BLOOD, V102, P3333, DOI 10.1182/blood-2003-05-1585
   Annaloro C, 2009, EXPERT REV HEMATOL, V2, P699, DOI 10.1586/EHM.09.60
   Aoki CA, 2005, AUTOIMMUN REV, V4, P373, DOI 10.1016/j.autrev.2005.02.002
   Arnold R, 2006, EUR J IMMUNOL, V36, P1654, DOI 10.1002/eji.200636197
   Couri CEB, 2011, CURR STEM CELL RES T, V6, P10
   Couri CEB, 2008, AUTOIMMUNITY, V41, P666, DOI 10.1080/08916930802200208
   Bouillet P, 2009, NAT REV IMMUNOL, V9, P514, DOI 10.1038/nri2570
   BOYUM A, 1974, TISSUE ANTIGENS, V4, P269
   Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   Couri CEB, 2006, BRAZ J MED BIOL RES, V39, P1271, DOI 10.1590/S0100-879X2006005000010
   Couri CEB, 2009, JAMA-J AM MED ASSOC, V301, P1573, DOI 10.1001/jama.2009.470
   Daneman D, 2006, LANCET, V367, P847, DOI 10.1016/S0140-6736(06)68341-4
   Decallonne B, 2003, J AUTOIMMUN, V20, P219, DOI 10.1016/S0896-8411(03)00025-8
   Dubey S, 2003, ANN HEMATOL, V82, P496, DOI 10.1007/s00277-003-0645-x
   Eguchi K, 2001, INTERNAL MED, V40, P275, DOI 10.2169/internalmedicine.40.275
   Eisenbarth GS, 2007, J CLIN ENDOCR METAB, V92, P2403, DOI 10.1210/jc.2007-0339
   EISENBARTH GS, 1985, DIABETES RES CLIN EX, V2, P271
   Filippi C, 2005, CELL IMMUNOL, V233, P125, DOI 10.1016/j.cellimm.2005.04.009
   Genestier L, 1998, BLOOD, V91, P2360, DOI 10.1182/blood.V91.7.2360.2360_2360_2368
   GIORDANO C, 1995, DIABETOLOGIA, V38, P1449, DOI 10.1007/BF00400606
   Gronski Matthew A., 2006, Review of Diabetic Studies, V3, P88, DOI 10.1900/RDS.2006.3.88
   Grullich C, 2009, BIOL BLOOD MARROW TR, V15, P173, DOI 10.1016/j.bbmt.2008.11.014
   Hayashi T, 2001, APOPTOSIS, V6, P31, DOI 10.1023/A:1009667926296
   International Diabetes Federation, 2011, IDF DIAB ATL
   Kishimoto H, 2001, NAT IMMUNOL, V2, P1025, DOI 10.1038/ni726
   Knip M, 2008, AUTOIMMUN REV, V7, P550, DOI 10.1016/j.autrev.2008.04.008
   Krammer PH, 2007, NAT REV IMMUNOL, V7, P532, DOI 10.1038/nri2115
   Kuhtrelber WM, 2003, J MOL ENDOCRINOL, V31, P373, DOI 10.1677/jme.0.0310373
   Lamhamedi-Cherradi SE, 1998, DIABETOLOGIA, V41, P178, DOI 10.1007/s001250050887
   Lehuen A, 2010, NAT REV IMMUNOL, V10, P501, DOI 10.1038/nri2787
   Liphaus BL, 2007, J RHEUMATOL, V34, P1580
   Liu HT, 2003, CURR OPIN PHARMACOL, V3, P317, DOI 10.1016/S1471-4892(03)00037-7
   Mathis D, 2001, NATURE, V414, P792, DOI 10.1038/414792a
   Mauricio D, 1998, DIABETES, V47, P1537, DOI 10.2337/diabetes.47.10.1537
   Munz C, 2009, NAT REV IMMUNOL, V9, P246, DOI 10.1038/nri2527
   Munoz LE, 2008, LUPUS, V17, P371, DOI 10.1177/0961203308089990
   Muraro PA, 2005, J EXP MED, V201, P805, DOI 10.1084/jem.20041679
   Muraro PA, 2010, CURR OPIN INVEST DR, V11, P1265
   Newton K, 1998, CURR OPIN GENET DEV, V8, P68, DOI 10.1016/S0959-437X(98)80064-6
   Opferman JT, 2008, CELL DEATH DIFFER, V15, P234, DOI 10.1038/sj.cdd.4402182
   Pope RM, 2002, NAT REV IMMUNOL, V2, P527, DOI 10.1038/nri846
   Rieux-Laucat F, 2003, CELL DEATH DIFFER, V10, P124, DOI 10.1038/sj.cdd.4401190
   Saudek Frantisek, 2004, Rev Diabet Stud, V1, P80, DOI 10.1900/RDS.2004.1.80
   SCHATZ DA, 1989, IMMUNOPHARM IMMUNOT, V11, P269, DOI 10.3109/08923978909005370
   Sharief MK, 2003, J NEUROIMMUNOL, V134, P158, DOI 10.1016/S0165-5728(02)00400-9
   Sharief MK, 2002, J NEUROIMMUNOL, V125, P155, DOI 10.1016/S0165-5728(02)00024-3
   Sia Charles, 2010, Rev Diabet Stud, V7, P6, DOI 10.1900/RDS.2010.7.6
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   Steck AK, 2011, CLIN CHEM, V57, P176, DOI 10.1373/clinchem.2010.148221
   Su X, 2000, J IMMUNOL, V164, P2523, DOI 10.4049/jimmunol.164.5.2523
   Sykes M, 2005, NATURE, V435, P620, DOI 10.1038/nature03728
   Tenev T, 2005, NAT CELL BIOL, V7, P70, DOI 10.1038/ncb1204
   Thomas David, 2005, Rev Diabet Stud, V2, P9, DOI 10.1900/RDS.2005.2.9
   Tischner D, 2010, Cell Death Dis, V1, pe48, DOI 10.1038/cddis.2010.27
   Todaro M, 2004, J CLIN IMMUNOL, V24, P1, DOI 10.1023/B:JOCI.0000018057.89066.c6
   Voltarelli JC, 2007, JAMA-J AM MED ASSOC, V297, P1568, DOI 10.1001/jama.297.14.1568
   Waiczies S, 2002, J NEUROIMMUNOL, V126, P213, DOI 10.1016/S0165-5728(02)00067-X
   Zucchelli S, 2005, IMMUNITY, V22, P385, DOI 10.1016/j.immuni.2005.01.015
NR 60
TC 18
Z9 19
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD JUN
PY 2012
VL 168
IS 3
BP 291
EP 302
DI 10.1111/j.1365-2249.2012.04583.x
PG 12
WC Immunology
SC Immunology
GA 929EM
UT WOS:000303044000006
PM 22519592
OA Green Published
DA 2020-11-26
ER

PT J
AU Pinto, MT
   Rodrigues, ES
   Malta, TM
   Azevedo, R
   Takayanagui, OM
   Valente, VB
   Ubiali, EMA
   Covas, DT
   Kashima, S
AF Pinto, Mariana Tomazini
   Rodrigues, Evandra Strazza
   Malta, Tathiane Maistro
   Azevedo, Rochele
   Takayanagui, Osvaldo Massaiti
   Valente, Vanderleia Barbaro
   Amorim Ubiali, Eugenia Maria
   Covas, Dimas Tadeu
   Kashima, Simone
TI HTLV-1/2 SEROPREVALENCE AND COINFECTION RATE IN BRAZILIAN FIRST-TIME
   BLOOD DONORS: AN 11-YEAR FOLLOW-UP
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE HTLV-1/2; Blood donors; Seroprevalence; HTLV coinfection
ID CELL LYMPHOTROPIC VIRUS; LEUKEMIA-VIRUS; TYPE-1 HTLV-1; RISK-FACTORS;
   SAO-PAULO; TAX GENE; INFECTION; SALVADOR; INDIVIDUALS; ASSOCIATION
AB The seroprevalence and geographic distribution of HTLV-1/2 among blood donors are extremely important to transfusion services. We evaluated the seroprevalence of HTLV-1/2 infection among first-time blood donor candidates in Ribeirao Preto city and region. From January 2000 to December 2010, 1,038,489 blood donations were obtained and 301,470 were first-time blood donations. All samples were screened with serological tests for HTLV-1/2 using enzyme immunoassay (EIA). In addition, the frequency of coinfection with hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), Chagas disease (CD) and syphilis was also determined. In-house PCR was used as confirmatory test for HTLV-1/2. A total of 296 (0.1%) first-time donors were serologically reactive for HTLV-1/2. Confirmatory PCR of 63 samples showed that 28 were HTLV-1 positive, 13 HTLV-2 positive, 19 negative and three indeterminate. Regarding HTLV coinfection rates, the most prevalent was with HBV (51.3%) and HCV (35.9%), but coinfection with HIV, CD and syphilis was also detected. The real number of HTLV-infected individual and coinfection rate in the population is underestimated and epidemiological studies like ours are very informative.
C1 [Pinto, Mariana Tomazini; Rodrigues, Evandra Strazza; Malta, Tathiane Maistro; Azevedo, Rochele; Valente, Vanderleia Barbaro; Amorim Ubiali, Eugenia Maria; Covas, Dimas Tadeu; Kashima, Simone] Reg Blood Ctr Ribeirao Preto, Ribeirao Preto, SP, Brazil.
   [Pinto, Mariana Tomazini; Rodrigues, Evandra Strazza; Malta, Tathiane Maistro; Kashima, Simone] Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
   [Takayanagui, Osvaldo Massaiti; Covas, Dimas Tadeu] Univ Sao Paulo, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
RP Kashima, S (corresponding author), Reg Blood Ctr Ribeirao Preto, Rua Tenente Catao Roxo 2501, Ribeirao Preto, SP, Brazil.
EM skashima@hemocentro.fmrp.usp.br
RI Takayanagui, Osvaldo M/C-8159-2013; Covas, Dimas T/C-5431-2013; Malta,
   Tathiane/N-1686-2013; Rodrigues, Evandra/L-6094-2017; Pinto,
   Mariana/B-6129-2017; Kashima, Simone/G-4876-2012
OI Takayanagui, Osvaldo M/0000-0002-8190-0275; Covas, Dimas
   T/0000-0002-7364-2595; Malta, Tathiane/0000-0003-1129-5791; Rodrigues,
   Evandra/0000-0003-0964-9554; Pinto, Mariana/0000-0002-5176-7776;
   Kashima, Simone/0000-0002-1487-0141
FU Fundacao Hemocentro de Ribeirao Preto (FUNDHERP); Centro Regional de
   Hemoterapia de Ribeirao Preto (CRH)
FX This work was supported by Fundacao Hemocentro de Ribeirao Preto
   (FUNDHERP) and Centro Regional de Hemoterapia de Ribeirao Preto (CRH).
CR Alcantara LC, 2003, JAIDS-J ACQ IMM DEF, V33, P536, DOI 10.1097/00126334-200308010-00016
   Bangham CRM, 2005, ONCOGENE, V24, P6035, DOI 10.1038/sj.onc.1208970
   Beilke MA, 2012, AIDS RES HUM RETROV, V28, P139, DOI [10.1089/aid.2011.0342, 10.1089/AID.2011.0342]
   Bittencourt AL, 2001, J ACQ IMMUN DEF SYND, V26, P490, DOI 10.1097/00126334-200104150-00016
   Borducchi D M, 1999, Rev Assoc Med Bras (1992), V45, P63, DOI 10.1590/S0104-42301999000100012
   Boschi-Pinto C, 2000, J INFECT DIS, V181, P35, DOI 10.1086/315177
   Brites C, 2009, AIDS REV, V11, P8
   Cardoso DF, 2009, REV INST MED TROP SP, V51, P325, DOI 10.1590/S0036-46652009000600003
   Carneiro-Proietti Anna Bárbara F., 2002, Rev. Soc. Bras. Med. Trop., V35, P499, DOI 10.1590/S0037-86822002000500013
   Casoli C, 2007, AIDS REV, V9, P140
   Catalan-Soares BC, 2001, REV BRAS EPIDEMIOL, V4, P81
   Catalan-Soares Bernadette, 2005, Cad. Saúde Pública, V21, P926, DOI 10.1590/S0102-311X2005000300027
   DETHE G, 1993, AIDS RES HUM RETROV, V9, P381, DOI 10.1089/aid.1993.9.381
   Dourado I, 1999, MEM I OSWALDO CRUZ, V94, P13, DOI 10.1590/S0074-02761999000100006
   Dourado I, 2003, JAIDS-J ACQ IMM DEF, V34, P527, DOI 10.1097/00126334-200312150-00013
   Eiraku N, 1996, J VIROL, V70, P1481, DOI 10.1128/JVI.70.3.1481-1492.1996
   FERREIRA OC, 1995, TRANSFUSION, V35, P258, DOI 10.1046/j.1537-2995.1995.35395184284.x
   Furukawa Y, 2000, J INFECT DIS, V182, P1343, DOI 10.1086/315897
   GalvaoCastro B, 1997, TRANSFUSION, V37, P242, DOI 10.1046/j.1537-2995.1997.37297203532.x
   Gudo ES, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-211
   KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847
   Kaplan JE, 1996, J ACQ IMMUN DEF SYND, V12, P193, DOI 10.1097/00042560-199606010-00014
   LAGRENADE L, 1990, LANCET, V336, P1345
   Lima MASD, 2005, J NEUROL NEUROSUR PS, V76, P294, DOI 10.1136/jnnp.2004.035709
   Mahieux R, 2005, Med Trop (Mars), V65, P525
   Mahieux R, 2009, PATHOL BIOL, V57, P161, DOI 10.1016/j.patbio.2008.02.015
   Mariette X, 2000, CLIN EXP RHEUMATOL, V18, P341
   de Lima LHM, 2009, CAD SAUDE PUBLICA, V25, P668, DOI 10.1590/S0102-311X2009000300021
   Mochizuki M, 1996, J ACQ IMMUN DEF SYND, V13, pS50, DOI 10.1097/00042560-199600001-00010
   MORGAN OS, 1989, LANCET, V2, P1184
   Moxoto I, 2007, REV SOC BRAS MED TRO, V40, P37, DOI 10.1590/S0037-86822007000100007
   Mufti GJ, 1998, BRIT J HAEMATOL, V100, P453, DOI 10.1046/j.1365-2141.1998.00582.x
   NISHIOKA K, 1989, LANCET, V1, P441
   OSAME M, 1986, LANCET, V1, P1031
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   Portelinha AM, 2009, MEM I OSWALDO CRUZ, V104, P960, DOI 10.1590/S0074-02762009000700003
   Saito M, 2004, J INFECT DIS, V189, P29, DOI 10.1086/380101
   Salles Nanci A., 2003, Rev Panam Salud Publica, V13, P111, DOI 10.1590/S1020-49892003000200011
   Soares BC, 2003, REV SAUDE PUBL, V37, P470, DOI 10.1590/s0034-89102003000400012
   SWITZER WM, 1995, J VIROL, V69, P621, DOI 10.1128/JVI.69.2.621-632.1995
   Victoria MB, 2010, BRAZ J INFECT DIS, V14, P135, DOI 10.1590/S1413-86702010000200004
   Wolfe ND, 2005, P NATL ACAD SCI USA, V102, P7994, DOI 10.1073/pnas.0501734102
   YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534
NR 43
TC 25
Z9 25
U1 0
U2 2
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
EI 1678-9946
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PD MAY-JUN
PY 2012
VL 54
IS 3
BP 123
EP 129
DI 10.1590/S0036-46652012000300002
PG 7
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 949AG
UT WOS:000304546500002
PM 22634882
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Tognon, R
   Gasparotto, EPL
   Neves, RP
   Nunes, NS
   Ferreira, AF
   Palma, PVB
   Kashima, S
   Covas, DT
   Santana, M
   Souto, EX
   Zanichelli, MA
   Simoes, BP
   de Souza, AM
   Castro, FA
AF Tognon, Raquel
   Gasparotto, Elainy P. L.
   Neves, Renata P.
   Nunes, Natalia S.
   Ferreira, Aline F.
   Palma, Patricia V. B.
   Kashima, Simone
   Covas, Dimas T.
   Santana, Mary
   Souto, Elizabeth X.
   Zanichelli, Maria Aparecida
   Simoes, Belinda P.
   de Souza, Ana Maria
   Castro, Fabiola A.
TI Deregulation of apoptosis-related genes is associated with PRV1
   overexpression and JAK2 V617F allele burden in Essential Thrombocythemia
   and Myelofibrosis
SO JOURNAL OF HEMATOLOGY & ONCOLOGY
LA English
DT Article
DE Chronic Myeloproliferative Neoplasms; Apoptosis; JAK2 V617F allele
   burden; PRV1; BCL2 family members
ID MESSENGER-RNA EXPRESSION; TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA;
   MYELOPROLIFERATIVE NEOPLASMS; ACTIVATING MUTATION; MCL-1;
   THROMBOPOIETIN; CLASSIFICATION; IDENTIFICATION; DIAGNOSIS
AB Background: Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF) are Chronic Myeloproliferative Neoplasms (MPN) characterized by clonal myeloproliferation/myeloaccumulation without cell maturation impairment. The JAK2 V617F mutation and PRV1 gene overexpression may contribute to MPN physiopathology. We hypothesized that deregulation of the apoptotic machinery may also play a role in the pathogenesis of ET and PMF. In this study we evaluated the apoptosis-related gene and protein expression of BCL2 family members in bone marrow CD34(+) hematopoietic stem cells (HSC) and peripheral blood leukocytes from ET and PMF patients. We also tested whether the gene expression results were correlated with JAK2 V617F allele burden percentage, PRV1 overexpression, and clinical and laboratory parameters.
   Results: By real time PCR assay, we observed that A1, MCL1, BIK and BID, as well as A1, BCLW and BAK gene expression were increased in ET and PMF CD34(+) cells respectively, while pro-apoptotic BAX and anti-apoptotic BCL2 mRNA levels were found to be lower in ET and PMF CD34(+) cells respectively, in relation to controls. In patients' leukocytes, we detected an upregulation of anti-apoptotic genes A1, BCL2, BCL-XL and BCLW. In contrast, pro-apoptotic BID and BIMEL expression were downregulated in ET leukocytes. Increased BCL-XL protein expression in PMF leukocytes and decreased BID protein expression in ET leukocytes were observed by Western Blot. In ET leukocytes, we found a correlation between JAK2 V617F allele burden and BAX, BIK and BAD gene expression and between A1, BAX and BIK and PRV1 gene expression. A negative correlation between PRV1 gene expression and platelet count was observed, as well as a positive correlation between PRV1 gene expression and splenomegaly.
   Conclusions: Our results suggest the participation of intrinsic apoptosis pathway in the MPN physiopathology. In addition, PRV1 and JAK2 V617F allele burden were linked to deregulation of the apoptotic machinery.
C1 [Tognon, Raquel; Gasparotto, Elainy P. L.; Neves, Renata P.; Nunes, Natalia S.; Ferreira, Aline F.; de Souza, Ana Maria; Castro, Fabiola A.] Univ Sao Paulo, Dept Clin Toxicol & Bromatol Anal, Ribeirao Preto Sch Pharmaceut Sci, BR-14049 Ribeirao Preto, Brazil.
   [Palma, Patricia V. B.; Kashima, Simone; Covas, Dimas T.] Univ Sao Paulo, Reg Blood Ctr Ribeirao Preto, Ribeirao Preto Sch Med, Clin Hosp, BR-14049 Ribeirao Preto, Brazil.
   [Santana, Mary; Souto, Elizabeth X.] Brigadeiro Hosp Sao Paulo, Sao Paulo, Brazil.
   [Zanichelli, Maria Aparecida] Inst Canc Treatment Children ITACI, Sao Paulo, Brazil.
   [Covas, Dimas T.; Simoes, Belinda P.] Univ Sao Paulo, Dept Clin Med, Ribeirao Preto Sch Med, BR-14049 Ribeirao Preto, Brazil.
RP Castro, FA (corresponding author), Univ Sao Paulo, Dept Clin Toxicol & Bromatol Anal, Ribeirao Preto Sch Pharmaceut Sci, BR-14049 Ribeirao Preto, Brazil.
EM castrofa@fcfrp.usp.br
RI Covas, Dimas T/C-5431-2013; Kashima, Simone/G-4876-2012; Simoes, Belinda
   P/M-7469-2016
OI Covas, Dimas T/0000-0002-7364-2595; Kashima, Simone/0000-0002-1487-0141;
   
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2008/52049-5,
   2010/01756-3, 2008/54387-5, 2006/50094-8]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq)
FX We are really grateful to Dr. Thomas Radimerski from Novartis Institute
   for Biomedical Research (Basel, Switzerland) for reviewing and
   discussing the manuscript results. We are also grateful to Luciana
   Ambrosio for technical assistance. AFF, NSN and RT are recipients of a
   fellowship from the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) (Process Numbers: 2008/52049-5, 2010/01756-3 and 2008/54387-5,
   respectively). EPLG, GLVO and RPN were recipients of fellowships from
   the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq).; This work was supported by FAPESP grants Numbers 2006/50094-8
   and 2008/54387-5.
CR Aichberger KJ, 2005, BLOOD, V105, P3303, DOI 10.1182/blood-2004-02-0749
   Anastasi J, 2009, HEMATOL ONCOL CLIN N, V23, P693, DOI 10.1016/j.hoc.2009.04.002
   Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456
   Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9
   Carbuccia N, 2009, LEUKEMIA, V23, P2183, DOI 10.1038/leu.2009.141
   Castro FA, 2005, ASH ANN M, V106, P2880
   Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007
   Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025
   Del Poeta G, 2008, CURR CANCER DRUG TAR, V8, P207
   Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069
   Dillon M, 2008, LEUKEMIA RES, V32, P811, DOI 10.1016/j.leukres.2007.09.018
   Economopoulou C, 2008, LEUKEMIA RES, V32, P61, DOI 10.1016/j.leukres.2007.04.012
   Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001
   Fabregat I, 2009, WORLD J GASTROENTERO, V15, P513, DOI 10.3748/wjg.15.513
   Frenzel A, 2009, APOPTOSIS, V14, P584, DOI 10.1007/s10495-008-0300-z
   Grand FH, 2009, BLOOD, V113, P6182, DOI 10.1182/blood-2008-12-194548
   Griesshammer M, 2004, ANN HEMATOL, V83, P364, DOI 10.1007/s00277-004-0864-9
   James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546
   Johansson P, 2003, EUR J HAEMATOL, V70, P358, DOI 10.1034/j.1600-0609.2003.00079.x
   Klippel S, 2003, BLOOD, V102, P3569, DOI 10.1182/blood-2003-03-0919
   Kralovics R, 2005, BLOOD, V106, P3374, DOI 10.1182/blood-2005-05-1889
   Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113
   Larsen TS, 2007, EUR J HAEMATOL, V79, P508, DOI 10.1111/j.1600-0609.2007.00960.x
   Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023
   Melis S, 2009, ACTA CLIN BELG, V64, P429, DOI 10.1179/acb.2009.070
   Mesa RA, 2006, LEUKEMIA, V20, P1800, DOI 10.1038/sj.leu.2404338
   Mnjoyan Z, 2006, HAEMATOLOGICA, V91, P411
   Olsson A, 2007, BRIT J CANCER, V97, P769, DOI 10.1038/sj.bjc.6603951
   Pikman Y, 2006, PLOS MED, V3, P1140, DOI 10.1371/journal.pmed.0030270
   Puigdecanet E, 2006, CANCER GENET CYTOGEN, V167, P39, DOI 10.1016/j.cancergencyto.2005.08.016
   Rubert J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-24
   Scott LM, 2007, NEW ENGL J MED, V356, P459, DOI 10.1056/NEJMoa065202
   Tefferi A, 2008, LEUKEMIA, V22, P14, DOI 10.1038/sj.leu.2404955
   Temerinac S, 2000, BLOOD, V95, P2569
   Thomadaki H, 2006, CRIT REV CL LAB SCI, V43, P1, DOI 10.1080/10408360500295626
   Tognon R, 2011, J CLIN PATHOL, V64, P75, DOI 10.1136/jcp.2010.080895
   Turkson J, 2004, EXPERT OPIN THER TAR, V8, P409, DOI 10.1517/14728222.8.5.409
   Vainchenker W, 2011, BLOOD
   Wuilleme-Toumi S, 2005, LEUKEMIA, V19, P1248, DOI 10.1038/sj.leu.2403784
   Zhang L, 2004, HAEMATOLOGICA, V89, P1199
   Zhao RX, 2005, J BIOL CHEM, V280, P22788, DOI 10.1074/jbc.C500138200
   Zivny J, 2010, CURR PHARM DESIGN, V16, P11, DOI 10.2174/138161210789941883
NR 42
TC 17
Z9 18
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1756-8722
J9 J HEMATOL ONCOL
JI J. Hematol. Oncol.
PD FEB 2
PY 2012
VL 5
AR 2
DI 10.1186/1756-8722-5-2
PG 11
WC Oncology; Hematology
SC Oncology; Hematology
GA 917FN
UT WOS:000302158000001
PM 22300941
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Cunha, LKH
   Kashima, S
   Amarante, MFC
   Haddad, R
   Rodrigues, ES
   Silva, KLT
   Lima, TA
   Castro, DB
   Brito, FC
   Almeida, EG
   Covas, DT
   Malheiro, A
AF Cunha, L. K. H.
   Kashima, S.
   Amarante, M. F. C.
   Haddad, R.
   Rodrigues, E. S.
   Silva, K. L. T.
   Lima, T. A.
   Castro, D. B.
   Brito, F. C.
   Almeida, E. G.
   Covas, D. T.
   Malheiro, A.
TI Distribution of human immunodeficiency virus type 1 subtypes in the
   State of Amazonas, Brazil, and subtype C identification
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE HIV-1; Subtypes; Phylogenetic analysis; Blood donors; Molecular and
   epidemiological characterization
ID MOLECULAR EPIDEMIOLOGY; PHYLOGENETIC ANALYSIS; GENETIC SUBTYPES;
   SOUTHERN BRAZIL; SAO-PAULO; HIV-1; INDIVIDUALS; RECOMBINANT; STRAINS;
   INFECTIONS
AB Few studies have reported the molecular epidemiological characterization of HIV-1 in the Northern region of Brazil. The present study reports the molecular and epidemiological characterization of 31 HIV-1 isolates from blood donors from the State of Amazonas who donated blood between April 2006 and March 2007. Serum/plasma samples from all donors were screened for HIV antibodies by ELISA and the results confirmed by Western blot analysis. Genomic DNA was extracted from the buffy coat using the Super Quik-Gene-DNA Isolation kit. Nested PCR was performed on the env, gag, and pol regions of HIV-1 using the Gene Amp PCR System 9700. Sequencing reactions were performed using the inner PCR primers and the DYEnamic (TM) ET Dye Terminator Kit, and phylogenetic analysis was performed using the gag, pol, and env gene sequences. We collected samples from 31 blood donors who tested positive for HIV-1 in confirmatory experiments. The male: female ratio of blood donors was 3.4:1, and the mean age was 32.4 years (range: 19 to 61 years). Phylogenetic analysis showed that subtype B is the most prevalent among Northern Brazilian HIV-1-seropositive blood donors. One HIV-1 subtype C and one circulating recombinant form (CRF_BF) of HIV-1 were identified in the State of Amazonas. This is the first study showing the occurrence of a possible "homogenous" subtype C in this region of Brazil. This finding could contribute to a better characterization of the HIV-1 strains that circulate in the country.
C1 [Silva, K. L. T.; Lima, T. A.; Castro, D. B.; Brito, F. C.; Almeida, E. G.; Malheiro, A.] Fundacao Hematol & Hemoterapia Amazonas, Diretoria Ensino & Pesquisa, BR-69040002 Manaus, Amazonas, Brazil.
   [Cunha, L. K. H.; Malheiro, A.] Univ Fed Amazonas, Dept Parasitol, Manaus, Amazonas, Brazil.
   [Kashima, S.; Amarante, M. F. C.; Haddad, R.; Rodrigues, E. S.; Covas, D. T.] Univ Sao Paulo, Fac Med Ribeirao Preto, Hemoctr Ribeirao Preto, Mol Biol Lab, Ribeirao Preto, SP, Brazil.
RP Malheiro, A (corresponding author), Fundacao Hematol & Hemoterapia Amazonas, Diretoria Ensino & Pesquisa, Av Constantino Nery 2943, BR-69040002 Manaus, Amazonas, Brazil.
EM malheiroadriana@yahoo.com.br
RI Rodrigues, Evandra/L-6094-2017; Covas, Dimas T/C-5431-2013; Haddad,
   Rodrigo/A-3460-2013; Kashima, Simone/G-4876-2012; Barros de Castro,
   Daniel/J-9358-2016
OI Rodrigues, Evandra/0000-0003-0964-9554; Covas, Dimas
   T/0000-0002-7364-2595; Haddad, Rodrigo/0000-0003-4699-164X; Kashima,
   Simone/0000-0002-1487-0141; Barros de Castro,
   Daniel/0000-0001-5969-544X; Castro Amarante, Maria
   Fernanda/0000-0003-2162-9505
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado do Amazonas; Center for
   Cell-Therapy (CTC)/Fundacao Hemocentro de Ribeirao Preto; FAPESPFundacao
   de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX We thank Rochele Azevedo, Andreia Monteiro Tarrago and Adriana Aparecida
   Marques for technical assistance. Research supported by CNPq, Fundacao
   de Amparo a Pesquisa do Estado do Amazonas, Center for Cell-Therapy
   (CTC)/Fundacao Hemocentro de Ribeirao Preto, and FAPESP.
CR Bello G, 2006, AIDS, V20, P763, DOI 10.1097/01.aids.0000216377.84313.52
   Brennan CA, 2007, AIDS RES HUM RETROV, V23, P1434, DOI 10.1089/aid.2007.0121
   Brigido LFM, 2005, AIDS RES HUM RETROV, V21, P673, DOI 10.1089/aid.2005.21.673
   Brigido LFM, 2007, AIDS RES HUM RETROV, V23, P1579, DOI 10.1089/aid.2007.0102
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Cabral VP, 2006, MEM I OSWALDO CRUZ, V101, P881, DOI 10.1590/S0074-02762006000800010
   Carrion G, 2004, AIDS RES HUM RETROV, V20, P1022, DOI 10.1089/aid.2004.20.1022
   Castro E, 2005, J CLIN VIROL, V32, P257, DOI 10.1016/j.jcv.2004.11.004
   Couto-Fernandez JC, 2006, AIDS RES HUM RETROV, V22, P207, DOI 10.1089/aid.2006.22.207
   Couto-Fernandez JC, 2005, MEM I OSWALDO CRUZ, V100, P73, DOI 10.1590/S0074-02762005000100014
   Ferreira JLD, 2008, MEM I OSWALDO CRUZ, V103, P800, DOI 10.1590/S0074-02762008000800010
   De Sa DJ, 2005, AIDS RES HUM RETROV, V21, P145, DOI 10.1089/aid.2005.21.145
   Guiniaraes ML, 2002, AIDS RES HUM RETROV, V18, P1261, DOI 10.1089/088922202320886307
   Joint United Nations Programme on HIV/AIDS (UNAIDS), REP GLOB AIDS EP
   Jones LR, 2009, AIDS RES HUM RETROV, V25, P951, DOI 10.1089/aid.2008.0293
   Koch WH, 2001, J CLIN MICROBIOL, V39, P1017, DOI 10.1128/JCM.39.3.1017-1020.2001
   Los Alamos Laboratory, CIRC REC FORMS CRFS
   LOUWAGIE J, 1993, AIDS RES HUM RETROV, V9, pS147
   LOUWAGIE J, 1993, AIDS, V7, P769, DOI 10.1097/00002030-199306000-00003
   Machado LFA, 2009, AIDS RES HUM RETROV, V25, P961, DOI 10.1089/aid.2009.0027
   MCCUTCHAN F, 1993, J ACQ IMMUN DEF SYND, V6, P685
   Montano SM, 2005, JAIDS-J ACQ IMM DEF, V40, P57, DOI 10.1097/01.qai.0000159667.72584.8b
   Robertson DL, 2000, SCIENCE, V288, P55, DOI 10.1126/science.288.5463.55d
   SABINO EC, 1994, J VIROL, V68, P6340, DOI 10.1128/JVI.68.10.6340-6346.1994
   Sanabani S, 2006, INFECT GENET EVOL, V6, P368, DOI 10.1016/j.meegid.2006.01.003
   Simon F, 1998, NAT MED, V4, P1032, DOI 10.1038/2017
   Soares EAJM, 2005, AIDS, V19, pS81, DOI 10.1097/01.aids.0000191497.00928.e4
   Soares EAJM, 2003, JAIDS-J ACQ IMM DEF, V34, P520, DOI 10.1097/00126334-200312150-00012
   Stefani MMA, 2007, J CLIN VIROL, V39, P205, DOI 10.1016/j.jcv.2007.04.012
   Takebe Y, 2004, PEDIATR INT, V46, P236, DOI 10.1046/j.1442-200x.2004.01869.x
   Thomson MM, 2005, AIDS REV, V7, P210
   *UNAIDS, LAT AM AIDS EP UPD R
   Vicente ACP, 2000, J ACQ IMMUN DEF SYND, V23, P327
NR 33
TC 9
Z9 9
U1 0
U2 3
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, 00, BRAZIL
SN 0100-879X
EI 1678-4510
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD FEB
PY 2012
VL 45
IS 2
BP 104
EP 112
DI 10.1590/S0100-879X2012007500003
PG 9
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 897OX
UT WOS:000300663200003
PM 22249428
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Slavov, SN
   Kashima, S
   Silva-Pinto, AC
   Covas, DT
AF Slavov, Svetoslav Nanev
   Kashima, Simone
   Silva-Pinto, Ana Cristina
   Covas, Dimas Tadeu
TI Genotyping of Human parvovirus B19 among Brazilian patients with
   hemoglobinopathies
SO CANADIAN JOURNAL OF MICROBIOLOGY
LA English
DT Article
DE Human parvovirus B19; sickle cell disease; thalassemia; real-time PCR
ID HUMAN PARVOVIRUS B19; REAL-TIME PCR; SEQUENCE VARIABILITY; HUMAN
   ERYTHROVIRUSES; DNA; SEROPREVALENCE; IDENTIFICATION; POPULATION;
   INFECTION; DIVERSITY
AB Human parvovirus B19 (B19V) infection can be a life-threatening condition among patients with hereditary (chronic) hemolytic anemias. Our objective was to characterize the infection molecularly among patients with sickle cell disease and thalassemia. Forty-seven patients (37 with sickle cell disease, and 10 with beta-thalassemia major) as well as 47 healthy blood donors were examined for B19V infection by anti-B19V IgG enzyme immunoassay, quantitative PCR, which detects all B19V genotypes, and DNA sequencing. B19V viremia was documented in nine patients (19.1%) as two displayed acute infection and the rest had a low titre viremia (mean 3.4 x 10(4) copies/mL). All donors were negative for B19V DNA. Anti-B19V IgG was detected in 55.3% of the patients and 57.4% among the donors. Based on partial NS1 fragments, all patient isolates were classified as genotype 1 and subgenotype 1A. The evolutionary events of the examined partial NS1 gene sequence were associated with a lack of positive selection. The quantification of all B19V genotypes by a single hydrolytic probe is a technically useful method, but it is difficult to establish relationships between B19V sequence characteristics and infection outcome.
C1 [Slavov, Svetoslav Nanev; Kashima, Simone; Silva-Pinto, Ana Cristina; Covas, Dimas Tadeu] Univ Sao Paulo, Fac Med Ribeirao Preto, Reg Blood Ctr Ribeirao Preto FUNDHERP, BR-14051140 Sao Paulo, Brazil.
RP Slavov, SN (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Reg Blood Ctr Ribeirao Preto FUNDHERP, 2051 Tenente Catao Roxo Str, BR-14051140 Sao Paulo, Brazil.
EM svetlyosf@yahoo.com
RI N, Svetoslav/M-5416-2017; Covas, Dimas T/C-5431-2013; Kashima,
   Simone/G-4876-2012
OI Covas, Dimas T/0000-0002-7364-2595; Slavov,
   Svetoslav/0000-0003-0805-6140; Kashima, Simone/0000-0002-1487-0141;
   Pinto, Ana/0000-0002-4104-2296
CR Baylis SA, 2004, J VIROL METHODS, V121, P7, DOI 10.1016/j.jviromet.2004.05.011
   Broliden K, 2006, J INTERN MED, V260, P285, DOI 10.1111/j.1365-2796.2006.01697.x
   Corcoran C, 2010, J CLIN MICROBIOL, V48, P137, DOI 10.1128/JCM.00610-09
   Dobec M, 2007, GYNECOL OBSTET INVES, V63, P53, DOI 10.1159/000095394
   Freitas RB, 2008, J CLIN VIROL, V43, P60, DOI 10.1016/j.jcv.2008.03.033
   Gallinella G, 2003, J CLIN VIROL, V28, P1, DOI 10.1016/S1386-6532(03)00120-3
   Hemauer A, 1996, J GEN VIROL, V77, P1781, DOI 10.1099/0022-1317-77-8-1781
   Hokynar K, 2004, J CLIN MICROBIOL, V42, P2013, DOI 10.1128/JCM.42.5.2013-2019.2004
   Huatuco EMM, 2008, REV SAUDE PUBL, V42, P443, DOI 10.1590/S0034-89102008000300008
   International Committee on Taxonomy of Viruses, 2007, VIR TAX 2007 REL
   Jitschin R, 2011, CLIN MICROBIOL INFEC, V17, P1336, DOI 10.1111/j.1469-0691.2010.03355.x
   Keller LW, 2009, ARCH VIROL, V154, P1685, DOI 10.1007/s00705-009-0482-x
   Kishore Janak, 2010, Asian J Transfus Sci, V4, P86, DOI 10.4103/0973-6247.67022
   KOCH WC, 1990, J CLIN MICROBIOL, V28, P65, DOI 10.1128/JCM.28.1.65-69.1990
   Lee TH, 2011, TRANSFUSION, V51, P1896, DOI 10.1111/j.1537-2995.2010.03035.x
   Liefeldt L, 2005, J MED VIROL, V75, P161, DOI 10.1002/jmv.20251
   Lindblom A, 2008, CLIN INFECT DIS, V46, P528, DOI 10.1086/526522
   Liu ZX, 2008, J VIROL METHODS, V149, P103, DOI 10.1016/j.jviromet.2007.12.017
   NASCIMENTO JP, 1990, REV I MED TROP, V32, P41, DOI 10.1590/S0036-46651990000100007
   Sanabani S, 2006, J CLIN MICROBIOL, V44, P604, DOI 10.1128/JCM.44.2.604-606.2006
   Servant A, 2002, J VIROL, V76, P9124, DOI 10.1128/JVI.76.18.9124-9134.2002
   Slavov SN, 2011, FEMS IMMUNOL MED MIC, V62, P247, DOI 10.1111/j.1574-695X.2011.00819.x
   van Rijckevorsel GGC, 2009, J MED VIROL, V81, P1305, DOI 10.1002/jmv.21528
   Young NS, 2004, NEW ENGL J MED, V350, P586, DOI 10.1056/NEJMra030840
NR 24
TC 13
Z9 15
U1 0
U2 2
PU CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS
PI OTTAWA
PA 1200 MONTREAL ROAD, BUILDING M-55, OTTAWA, ON K1A 0R6, CANADA
SN 0008-4166
J9 CAN J MICROBIOL
JI Can. J. Microbiol.
PD FEB
PY 2012
VL 58
IS 2
BP 200
EP 205
DI 10.1139/W11-119
PG 6
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Immunology; Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Immunology; Microbiology
GA 885PO
UT WOS:000299791500012
PM 22280886
DA 2020-11-26
ER

PT J
AU Gasparotto, EPL
   Tognon, R
   Ferreira, AF
   Oliveira, GLV
   Palma, PVB
   Zanichelli, MA
   Souto, EX
   Velano, CEE
   Simoes, BP
   Carrara, RDV
   Kashima, S
   Covas, DT
   de Castro, FA
   de Souza, AM
AF Lino Gasparotto, Elainy Patricia
   Tognon, Raquel
   Ferreira, Aline Fernanda
   Vilela Oliveira, Gislane Lelis
   Bonini Palma, Patricia Vianna
   Zanichelli, Maria Aparecida
   Souto, Elizabeth Xisto
   Engel Velano, Carlos Eduardo
   Simoes, Belinda Pinto
   Viu Carrara, Rita de Cassia
   Kashima, Simone
   Covas, Dimas Tadeu
   de Castro, Fabiola Attie
   de Souza, Ana Maria
TI Deregulated expression of A1, Bcl-2, Bcl-x(L), and Mcl-1 antiapoptotic
   proteins and Bid, Bad, and Bax proapoptotic genes in polycythemia vera
   patients
SO BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Polycythemia vera; Gene mutation; Gene expression; Apoptosis; Bcl-2
   family members
ID HEALTH-ORGANIZATION CRITERIA; TYROSINE KINASE JAK2; MYELOPROLIFERATIVE
   NEOPLASMS; ESSENTIAL THROMBOCYTHEMIA; MYELOID-LEUKEMIA; DOWN-REGULATION;
   ALLELE BURDEN; APOPTOSIS; CELLS; MUTATION
AB Apoptosis deregulation might have a role in the pathophysiology of polycythemia vera (PV). This study evaluated Bcl-2 molecule expression in CD34(+) cells and leukocytes in 12 PV patients. Gene expression was investigated by real time PCR using SybrGreen Quantitect kit and protein expression was evaluated by western-blotting. JAK2 V617F mutation was detected according to Baxter et al (2005). CD34(+) cells from PV patients presented higher levels of A1 and Mc1-1 expression (median: 22.6 and 5.2, respectively) in comparison with controls (0.9 and 0.5, p=0.004 and p=0.020); while Bcl-2 and Bcl-x(L) expression decreased in PV patients (0.18 and 1.19) compared with controls (1.39 and 2.01, p=0.006 and p=0.020). CD34(+) cells in PV patients showed an elevated Bid expression (14.4) in comparison with healthy subjects (1.0; p=0.002). Patients' leukocytes showed an A1 augmentation (7.41, p=0.001) and a reduced expression of Bar (0.19; p=0.040) and Bad (0.2; p=0.030). There was no correlation between JAK2 V617F allele burden and molecular expression. PV patients showed alterations in Bcl-2 members' expression, which may interfere with control of apoptotic machinery and contribute to disease pathogenesis.
C1 [Lino Gasparotto, Elainy Patricia; Tognon, Raquel; Ferreira, Aline Fernanda; Vilela Oliveira, Gislane Lelis; de Castro, Fabiola Attie; de Souza, Ana Maria] Univ Sao Paulo, Dept Clin Anal Toxicol & Food Sci, Fac Pharmaceut Sci Ribeirao Preto, BR-14040903 Ribeirao Preto, SP, Brazil.
   [Zanichelli, Maria Aparecida; Souto, Elizabeth Xisto] Brigadeiro Hosp, Sao Paulo, Brazil.
   [Engel Velano, Carlos Eduardo; Simoes, Belinda Pinto; Covas, Dimas Tadeu] Univ Sao Paulo, Dept Clin Med, Fac Med Ribeirao Preto, BR-14040903 Ribeirao Preto, SP, Brazil.
   [Bonini Palma, Patricia Vianna; Viu Carrara, Rita de Cassia; Kashima, Simone; Covas, Dimas Tadeu] Univ Sao Paulo, Hemotherapy Ctr Ribeirao Preto, Sch Med Ribeirao Preto, BR-14040903 Ribeirao Preto, SP, Brazil.
RP de Souza, AM (corresponding author), Univ Sao Paulo, Dept Anal Clin Toxicol & Bromatol, Fac Ciencias Farmaceut Ribeirao Preto, Ave Cafe S-N, BR-14040903 Ribeirao Preto, SP, Brazil.
EM amsouza@fcfrp.usp.br
RI Simoes, Belinda P/M-7469-2016; Covas, Dimas T/C-5431-2013; CASTRO,
   FABIOLA/D-4693-2012; Kashima, Simone/G-4876-2012; de Oliveira,
   Gislane/I-4896-2013
OI Covas, Dimas T/0000-0002-7364-2595; Kashima, Simone/0000-0002-1487-0141;
   Lelis Vilela de Oliveira, Gislane/0000-0002-8883-5541; de Oliveira,
   Gislane/0000-0002-0269-9973
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq,
   National Council for Scientific and Technological Development)National
   Council for Scientific and Technological Development (CNPq);
   FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [06/50094-8]
FX The authors would like to thank Marcella Grando and Zita M. O. Gregorio
   for technical assistance. We are also grateful to Amelia Regina de
   Albuquerque for assisting in the creation of the figures. E.L.P.G. is
   the recipient of a fellowship from the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq, National Council for
   Scientific and Technological Development. Funding: This work was
   supported by a FAPESP grant (No. 06/50094-8).
CR Aichberger KJ, 2005, BLOOD, V105, P3303, DOI 10.1182/blood-2004-02-0749
   Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664
   Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9
   Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3
   BOYUM A, 1976, SCAND J IMMUNOL, P9
   Brien G, 2007, ONCOGENE, V26, P5828, DOI 10.1038/sj.onc.1210363
   Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007
   Del Poeta G, 2008, CURR CANCER DRUG TAR, V8, P207
   Economopoulou C, 2008, LEUKEMIA RES, V32, P61, DOI 10.1016/j.leukres.2007.04.012
   Finazzi G, 2008, LEUKEMIA, V22, P1494, DOI 10.1038/leu.2008.177
   Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608
   Fulda S, 2000, CANCER RES, V60, P3947
   Gangat N, 2008, EUR J HAEMATOL, V80, P197, DOI 10.1111/j.1600-0609.2007.01003.x
   Garcon L, 2006, BLOOD, V108, P1551, DOI 10.1182/blood-2005-10-009514
   Inoue S, 2008, LEUKEMIA, V22, P819, DOI 10.1038/leu.2008.1
   James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546
   Jin ZY, 2005, CANCER BIOL THER, V4, P139, DOI 10.4161/cbt.4.2.1508
   Kalousek I, 2007, ANTI-CANCER DRUG, V18, P763, DOI 10.1097/CAD.0b013e3280adc905
   Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200
   Kitada S, 2004, JNCI-J NATL CANCER I, V96, P642, DOI 10.1093/jnci/djh153
   Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113
   Laubach JP, 2009, EXP HEMATOL, V37, P1411, DOI 10.1016/j.exphem.2009.09.009
   Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023
   Levine RL, 2007, NAT REV CANCER, V7, P673, DOI 10.1038/nrc2210
   LI J., 2006, WORLD J SURG ONCOL, V4, P1
   Nussenzveig RH, 2007, EXP HEMATOL, V35, P32, DOI 10.1016/j.exphem.2006.11.012
   Passamonti F, 2009, HAEMATOL-HEMATOL J, V94, P7, DOI 10.3324/haematol.2008.001271
   Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016
   Simpson LA, 2006, BLOOD, V107, P4695, DOI 10.1182/blood-2005-10-4025
   Spivak JL, 2002, BLOOD, V100, P4272, DOI 10.1182/blood-2001-12-0349
   Tefferi A, 2008, LEUKEMIA, V22, P14, DOI 10.1038/sj.leu.2404955
   Thomadaki H, 2006, CRIT REV CL LAB SCI, V43, P1, DOI 10.1080/10408360500295626
   Vainchenker W, 2011, BLOOD, V118, P1723, DOI 10.1182/blood-2011-02-292102
   Wadleigh M, 2010, INT J HEMATOL, V91, P174, DOI 10.1007/s12185-010-0529-5
   Wang MH, 2007, NEUROSCI RES, V59, P40, DOI 10.1016/j.neures.2007.05.010
   Yan N, 2005, ANNU REV CELL DEV BI, V21, P35, DOI 10.1146/annurev.cellbio.21.012704.131040
   Zeuner A, 2006, BLOOD, V107, P3495, DOI 10.1182/blood-2005-07-3037
   Zhang YY, 2004, STEM CELLS, V22, P1015, DOI 10.1634/stemcells.22-6-1015
NR 38
TC 9
Z9 10
U1 0
U2 0
PU UNIV SAO PAULO, CONJUNTO QUIMICAS
PI SAO PAULO
PA SERVICO PUBLICACOES E CIRCULACAO, CAIXA POSTAL 66083, SAO PAULO, 00000,
   BRAZIL
SN 1984-8250
EI 2175-9790
J9 BRAZ J PHARM SCI
JI Braz. J. Pharm. Sci.
PD OCT-DEC
PY 2011
VL 47
IS 4
BP 873
EP 886
DI 10.1590/S1984-82502011000400025
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 922BE
UT WOS:000302521000025
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Slavov, SN
   Kashima, S
   Pinto, ACS
   Covas, DT
AF Slavov, Svetoslav N.
   Kashima, Simone
   Silva Pinto, Ana Cristina
   Covas, Dimas Tadeu
TI Human parvovirus B19: general considerations and impact on patients with
   sickle-cell disease and thalassemia and on blood transfusions
SO FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY
LA English
DT Review
DE parvovirus B19; clinical conditions; sickle-cell disease; blood
   transfusion
ID ORGANIZATION INTERNATIONAL STANDARD; ACUTE CHEST SYNDROME; SEVERE
   ANEMIA; APLASTIC CRISIS; MOLECULAR CHARACTERIZATION; CLINICAL
   PRESENTATIONS; BACULOVIRUS EXPRESSION; GENETIC DIVERSITY;
   HYDROPS-FETALIS; CAPSID PROTEINS
AB Human parvovirus B19 (B19V) is a small (22-24 nm) nonenveloped DNA virus belonging to the genus Erythrovirus (family Parvoviridae). Although it generally causes self-limiting conditions in healthy people, B19V infection may have a different outcome in patients with inherited hemolytic anemias. In such high-risk individuals, the high-titer replication may result in bone marrow suppression, triggering a life-threatening drop of hemoglobin values (profound anemia, aplastic crisis). To date there is no consensus concerning a B19V screening program either for the blood donations used in the hemotherapy or for high-risk patients. Moreover, questions such as the molecular mechanisms by which B19V produces latency and persistent replication, the primary site (sites) of B19V infection and B19V immunopathology are far from being known. This review summarizes general aspects of B19V molecular characteristics, pathogenesis and diagnostic approaches with a focus on the role of this pathogen in blood transfusions and in patients with some hemoglobinopathies (sickle-cell disease, thalassemia).
C1 [Slavov, Svetoslav N.; Kashima, Simone; Silva Pinto, Ana Cristina; Covas, Dimas Tadeu] Univ Sao Paulo, Fac Med Ribeirao Preto, Reg Blood Ctr Ribeirao Preto, Ribeirao Preto, SP, Brazil.
   [Kashima, Simone] Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
RP Slavov, SN (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Reg Blood Ctr Ribeirao Preto, Rua Tenente Catao Roxo 2051, Ribeirao Preto, SP, Brazil.
EM svetlyosf@yahoo.com
RI N, Svetoslav/M-5416-2017; Covas, Dimas T/C-5431-2013; Kashima,
   Simone/G-4876-2012
OI Covas, Dimas T/0000-0002-7364-2595; Kashima, Simone/0000-0002-1487-0141;
   Slavov, Svetoslav/0000-0003-0805-6140; Pinto, Ana/0000-0002-4104-2296
CR Amaku M, 2009, MEM I OSWALDO CRUZ, V104, P897, DOI 10.1590/S0074-02762009000600013
   ANDERSON MJ, 1983, LANCET, V1, P1378
   ANDERSON MJ, 1985, J INFECT DIS, V152, P257, DOI 10.1093/infdis/152.2.257
   Assanasen C, 2003, J PEDIAT HEMATOL ONC, V25, P978, DOI 10.1097/00043426-200312000-00015
   Azzi A, 1999, TRANSFUS MED REV, V13, P194, DOI 10.1016/S0887-7963(99)80033-9
   AZZI A, 1992, AM J HEMATOL, V39, P228, DOI 10.1002/ajh.2830390315
   Bakhshi S, 2002, ARCH DIS CHILD, V87, P541, DOI 10.1136/adc.87.6.541
   Baylis SA, 2010, VOX SANG, V98, P441, DOI 10.1111/j.1423-0410.2009.01288.x
   Bekhit MT, 2009, FETAL DIAGN THER, V25, P153, DOI 10.1159/000209200
   Biesma DH, 1997, NETH J MED, V50, P81, DOI 10.1016/S0300-2977(96)00076-9
   Blumel J, 2002, TRANSFUSION, V42, P1011, DOI 10.1046/j.1537-2995.2002.00158.x
   Bonsch C, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000669
   Bonsch C, 2008, J VIROL, V82, P11784, DOI 10.1128/JVI.01399-08
   Broliden K, 2006, J INTERN MED, V260, P285, DOI 10.1111/j.1365-2796.2006.01697.x
   Broliden K, 2001, PEDIATR TRANSPLANT, V5, P320, DOI 10.1034/j.1399-3046.2001.00035.x
   BROWN CS, 1990, VIRUS RES, V15, P197, DOI 10.1016/0168-1702(90)90028-A
   BROWN K, 2004, PRINCIPLES PRACTICE, P703
   Brown K. E., 2009, Principles and practice of clinical virology, P853, DOI 10.1002/9780470741405.ch35
   BROWN T, 1984, LANCET, V2, P1033
   Cassinotti P, 1997, J MED VIROL, V53, P229, DOI 10.1002/(SICI)1096-9071(199711)53:3&lt;229::AID-JMV8&gt;3.0.CO;2-A
   CASSINOTTI P, 1995, ANN RHEUM DIS, V54, P498, DOI 10.1136/ard.54.6.498
   Cassinotti P, 2000, EUR J CLIN MICROBIOL, V19, P886, DOI 10.1007/s100960000384
   CHARACHE S, 1979, ARCH INTERN MED, V139, P67, DOI 10.1001/archinte.139.1.67
   Chen AY, 2010, FUTURE VIROL, V5, P731, DOI 10.2217/FVL.10.56
   Chen HT, 2009, J VIROL METHODS, V158, P100, DOI 10.1016/j.jviromet.2009.02.005
   Chiorini JA, 1996, CURR TOP MICROBIOL, V218, P25
   CLEWLEY JP, 1984, J GEN VIROL, V65, P241, DOI 10.1099/0022-1317-65-1-241
   Cohen BJ, 1997, TRANSFUSION, V37, P947, DOI 10.1046/j.1537-2995.1997.37997454023.x
   Corcoran A, 2000, J VIROL, V74, P9903, DOI 10.1128/JVI.74.21.9903-9910.2000
   Corcoran A, 2004, J MED MICROBIOL, V53, P459, DOI 10.1099/jmm.0.05485-0
   Corcoran A, 2004, J INFECT DIS, V189, P1873, DOI 10.1086/382963
   Corsini J, 1997, J VIROL, V71, P9008, DOI 10.1128/JVI.71.12.9008-9015.1997
   COSSART YE, 1975, LANCET, V1, P72
   Daly P, 2002, J CLIN MICROBIOL, V40, P1958, DOI 10.1128/JCM.40.6.1958-1962.2002
   DEISS V, 1990, VIROLOGY, V175, P247, DOI 10.1016/0042-6822(90)90205-6
   Doyle S, 2011, METHODS MOL BIOL, V665, P213, DOI 10.1007/978-1-60761-817-1_13
   Escher F, 2008, MED SCI MONITOR, V14, pCR333
   Fartoukh M, 2006, HAEMATOLOGICA, V91, P53
   Fattet S, 2004, J PEDIAT HEMATOL ONC, V26, P497, DOI 10.1097/01.mph.0000134463.09543.99
   Ferguson M, 1997, BIOLOGICALS, V25, P283, DOI 10.1006/biol.1997.0098
   Ferry T, 2010, CLIN INFECT DIS, V50, P115, DOI 10.1086/649004
   Franssila R, 2005, CLIN EXP IMMUNOL, V142, P53, DOI [10.1111/j.1365-2249.2005.02886.x, 10.1111/j.1365-2249.2005.02886.X]
   Freitas RB, 2008, J CLIN VIROL, V43, P60, DOI 10.1016/j.jcv.2008.03.033
   Geng YS, 2007, TRANSFUSION, V47, P883, DOI 10.1111/j.1537-2995.2007.01205.x
   GODEAU B, 1991, AM J MED, V91, P557, DOI 10.1016/0002-9343(91)90198-7
   Grabarczyk P, 2011, J MED VIROL, V83, P142, DOI 10.1002/jmv.21947
   GRAY JJ, 1993, J VIROL METHODS, V44, P11, DOI 10.1016/0166-0934(93)90003-A
   Guan WX, 2008, J VIROL, V82, P9951, DOI 10.1128/JVI.01162-08
   Guillaume MP, 2002, CLIN RHEUMATOL, V21, P306, DOI 10.1007/s100670200080
   Gupta R, 2005, HAEMATOLOGICA, V90, P114
   Gustafsson I, 2010, CLIN INFECT DIS, V50, P1426, DOI 10.1086/652286
   Heegaard ED, 2002, J MED VIROL, V66, P246, DOI 10.1002/jmv.2137
   Heegaard ED, 2002, CLIN MICROBIOL REV, V15, P485, DOI 10.1128/CMR.15.3.485-505.2002
   Hemauer A, 1996, J GEN VIROL, V77, P1781, DOI 10.1099/0022-1317-77-8-1781
   Hourfar MK, 2011, TRANSFUSION, V51, P129, DOI 10.1111/j.1537-2995.2010.02780.x
   Hsu Shih-Tien, 2007, Taiwan J Obstet Gynecol, V46, P417, DOI 10.1016/S1028-4559(08)60014-5
   *ICTV, 2007, VIR TAX 2007 REL
   Ingrassia F, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-87
   IWA N, 1995, DIAGN CYTOPATHOL, V13, P139, DOI 10.1002/dc.2840130212
   Jitschin R, 2011, CLIN MICROBIOL INFEC, V17, P1336, DOI 10.1111/j.1469-0691.2010.03355.x
   Jones MS, 2005, J VIROL, V79, P8230, DOI 10.1128/JVI.79.13.8230-8236.2005
   JONES PH, 1990, J TROP MED HYG, V93, P67
   Jordan J, 1998, VOX SANG, V75, P97, DOI 10.1159/000030968
   Kaufmann B, 2004, P NATL ACAD SCI USA, V101, P11628, DOI 10.1073/pnas.0402992101
   KE L, 2011, TRANSFUSION, DOI DOI 10.1111/J.1537-2995.2011.03067.X
   Kelly HA, 2000, EPIDEMIOL INFECT, V124, P449, DOI 10.1017/S0950268899003817
   KERR JR, 1995, LANCET, V345, P1118, DOI 10.1016/S0140-6736(95)90850-1
   Kerr S, 1999, J MED VIROL, V57, P179, DOI 10.1002/(SICI)1096-9071(199902)57:2&lt;179::AID-JMV16&gt;3.0.CO;2-T
   KINNEY JS, 1988, J INFECT DIS, V157, P663, DOI 10.1093/infdis/157.4.663
   Klein HG, 1999, ANESTHESIOLOGY, V91, P861, DOI 10.1097/00000542-199909000-00040
   Koduri PR, 1996, ANN HEMATOL, V72, P49
   Kooistra K, 2011, VOX SANG, V100, P261, DOI 10.1111/j.1423-0410.2010.01423.x
   KOPPELMAN MH, 2010, TRANSFUSION, DOI DOI 10.1111/J.1537-2995.2010.02995.X
   Krishnamurti L, 2007, PEDIATR BLOOD CANCER, V49, P1019, DOI 10.1002/pbc.20855
   Kudesia G, 2005, CLIN DIAGNOSTIC VIRO, P90
   KURTZMAN GJ, 1989, J CLIN INVEST, V84, P1114, DOI 10.1172/JCI114274
   Lamont RF, 2010, B J OBSTE GYNAECOL, V118, P175
   Landolsi H, 2009, Pathol Biol (Paris), V57, pe1, DOI 10.1016/j.patbio.2007.11.001
   Lefrere JJ, 2005, BLOOD, V106, P2890, DOI 10.1182/blood-2005-03-1053
   LEFRERE JJ, 1986, AM J HEMATOL, V23, P271, DOI 10.1002/ajh.2830230311
   LEFRERE JJ, 1986, J CLIN PATHOL, V39, P1277, DOI 10.1136/jcp.39.11.1277
   LEFRERE JJ, 1986, J INFECTION, V13, P45, DOI 10.1016/S0163-4453(86)92279-6
   Lowenthal EA, 1996, AM J HEMATOL, V51, P207, DOI 10.1002/(SICI)1096-8652(199603)51:3<207::AID-AJH5>3.0.CO;2-0
   Lunardi C, 2008, AUTOIMMUN REV, V8, P116, DOI 10.1016/j.autrev.2008.07.005
   LYON DJ, 1989, LANCET, V1, P1085
   Manaresi E, 2001, J MED VIROL, V64, P67, DOI 10.1002/jmv.1019
   Michel PO, 2008, J VIROL METHODS, V152, P1, DOI 10.1016/j.jviromet.2008.06.006
   Modrow S, 2011, VOX SANG, V100, P351, DOI 10.1111/j.1423-0410.2010.01445.x
   Moffatt S, 1998, J VIROL, V72, P3018, DOI 10.1128/JVI.72.4.3018-3028.1998
   MORI J, 1987, J GEN VIROL, V68, P2797, DOI 10.1099/0022-1317-68-11-2797
   Morita E, 2001, J VIROL, V75, P7555, DOI 10.1128/JVI.75.16.7555-7563.2001
   Munro K, 2003, PEDIATR CARDIOL, V24, P473, DOI 10.1007/s00246-002-0173-9
   Newton CRJC, 1997, TROP MED INT HEALTH, V2, P165, DOI 10.1046/j.1365-3156.1997.d01-238.x
   Norja P, 2006, P NATL ACAD SCI USA, V103, P7450, DOI 10.1073/pnas.0602259103
   OZAWA K, 1986, SCIENCE, V233, P883, DOI 10.1126/science.3738514
   OZAWA K, 1987, J VIROL, V61, P2395, DOI 10.1128/JVI.61.8.2395-2406.1987
   Pallier C, 1997, J VIROL, V71, P9482, DOI 10.1128/JVI.71.12.9482-9489.1997
   Pankuweit S, 2005, J VET MED B, V52, P344, DOI 10.1111/j.1439-0450.2005.00873.x
   Parsyan A, 2007, J GEN VIROL, V88, P428, DOI 10.1099/vir.0.82496-0
   Pasquinelli G, 2009, J CLIN VIROL, V44, P33, DOI 10.1016/j.jcv.2008.10.008
   Pasvol G, 2006, J INFECT DIS, V194, P141, DOI 10.1086/505086
   PATTISON JR, 1981, LANCET, V1, P664
   Prowse C, 1997, VOX SANG, V72, P1, DOI 10.1046/j.1423-0410.1997.00001.x
   Quek L, 2010, BRIT J HAEMATOL, V149, P289, DOI 10.1111/j.1365-2141.2009.08062.x
   Rayburg M, 2010, AM J HEMATOL, V85, P182, DOI 10.1002/ajh.21605
   REED JL, 2000, INFECT DIS REV, V2, P169
   REID DM, 1985, LANCET, V1, P422
   Reitblat T, 2000, AM J MED, V109, P512, DOI 10.1016/S0002-9343(00)00561-1
   Ros C, 2006, VIROLOGY, V345, P137, DOI 10.1016/j.virol.2005.09.030
   SAARINEN UM, 1986, BLOOD, V67, P1411
   Saldanha J, 2002, VOX SANG, V82, P24, DOI 10.1046/j.1423-0410.2002.00132.x
   Saldanha J, 2001, J CLIN VIROL, V20, P7, DOI 10.1016/S1386-6532(00)00149-9
   SALIMANS MMM, 1989, J VIROL METHODS, V23, P19, DOI 10.1016/0166-0934(89)90085-2
   Sanphasitvong Wanviput, 2005, Southeast Asian Journal of Tropical Medicine and Public Health, V36, P1216
   Santagostino E, 1997, TRANSFUSION, V37, P517, DOI 10.1046/j.1537-2995.1997.37597293884.x
   SATAKE M, 2011, TRANSFUSION, DOI DOI 10.1111/J.1537-2995.2010.03047.X
   Scarlata F, 2002, CLIN INFECT DIS, V35, P1449, DOI 10.1086/344452
   SERJEANT GR, 1981, LANCET, V2, P595
   Servant A, 2002, J VIROL, V76, P9124, DOI 10.1128/JVI.76.18.9124-9134.2002
   Servey JT, 2007, AM FAM PHYSICIAN, V75, P373
   Shackelton LA, 2006, J VIROL, V80, P3666, DOI 10.1128/JVI.80.7.3666-3669.2006
   SIMEONI S, 2010, MOL DETECTION HUMAN, P831
   Simmonds P, 2008, J GEN VIROL, V89, P2299, DOI 10.1099/vir.0.2008/001180-0
   Smith-Whitley K, 2004, BLOOD, V103, P422, DOI 10.1182/blood-2003-01-0069
   Sol N, 1999, J VIROL, V73, P8762, DOI 10.1128/JVI.73.10.8762-8770.1999
   Soliman OE, 2009, J PEDIAT HEMATOL ONC, V31, P173, DOI 10.1097/MPH.0b013e3181983b2d
   STAMAND J, 1991, VIROLOGY, V183, P133, DOI 10.1016/0042-6822(91)90126-V
   Stramer SL, 2009, TRANSFUSION, V49, p1S, DOI 10.1111/j.1537-2995.2009.02279.x
   SUMMERS J, 1983, J GEN VIROL, V64, P2527, DOI 10.1099/0022-1317-64-11-2527
   Toan NL, 2006, J GEN VIROL, V87, P2941, DOI 10.1099/vir.0.82037-0
   Tolaymat A, 1999, PEDIATR NEPHROL, V13, P340, DOI 10.1007/s004670050622
   Tolfvenstam T, 2009, SEMIN FETAL NEONAT M, V14, P218, DOI 10.1016/j.siny.2009.01.007
   Toyokawa Yasuhiko, 2007, Mod Rheumatol, V17, P333, DOI 10.1007/s10165-007-0584-9
   *US FDA, 2008, NUCL AC TEST NAT RED
   VANELSACKERNIELE AMW, 1989, BRIT J OBSTET GYNAEC, V96, P768
   von Landenberg P, 2003, ARTHRITIS RHEUM-US, V48, P1939, DOI 10.1002/art.11038
   Wan CH, 2002, J GEN VIROL, V83, P2075, DOI 10.1099/0022-1317-83-8-2075
   Watanabe D, 2011, J INFECT CHEMOTHER, V17, P283, DOI 10.1007/s10156-010-0111-3
   Weigel-Kelley KA, 2003, BLOOD, V102, P3927, DOI 10.1182/blood-2003-05-1522
   Weigel-Kelley KA, 2006, HUM GENE THER, V17, P909, DOI 10.1089/hum.2006.17.909
   WEILAND HT, 1989, BRIT J HAEMATOL, V71, P300, DOI 10.1111/j.1365-2141.1989.tb04276.x
   WHITE DG, 1985, LANCET, V1, P419
   WHITE DO, 1994, MED VIROLOGY, P285
   Wierenga KJJ, 2001, J PEDIATR-US, V139, P438, DOI 10.1067/mpd.2001.117070
   WIERENGA KJJ, 1995, LANCET, V346, P475, DOI 10.1016/S0140-6736(95)91324-6
   Wildig J, 2006, J INFECT DIS, V194, P146, DOI 10.1086/505082
   WILLIAMS MD, 1990, VOX SANG, V58, P177, DOI 10.1111/j.1423-0410.1990.tb02086.x
   Yaegashi N, 1998, J INFECTION, V37, P28, DOI 10.1016/S0163-4453(98)90346-2
   Yates AM, 2009, PEDIATR BLOOD CANCER, V53, P479, DOI 10.1002/pbc.22035
   Yeats J, 1999, EUR J HAEMATOL, V63, P276, DOI 10.1111/j.1600-0609.1999.tb01892.x
   Yu MYW, 2010, TRANSFUSION, V50, P1712, DOI 10.1111/j.1537-2995.2010.02591.x
   Yunoki M, 2005, BRIT J HAEMATOL, V128, P401, DOI 10.1111/j.1365-2141.2004.05309.x
   Zaki MES, 2010, INT J LAB HEMATOL, V32, P159, DOI 10.1111/j.1751-553X.2009.01150.x
   Zaki ME, 2006, HEMATOLOGY, V11, P261, DOI 10.1080/10245330600841089
   ZANELLA A, 1995, TRANSFUSION, V35, P769, DOI 10.1046/j.1537-2995.1995.35996029163.x
   Zhi N, 2006, J VIROL, V80, P5941, DOI 10.1128/JVI.02430-05
NR 156
TC 26
Z9 28
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0928-8244
EI 1574-695X
J9 FEMS IMMUNOL MED MIC
JI FEMS Immunol. Med. Microbiol.
PD AUG
PY 2011
VL 62
IS 3
BP 247
EP 262
DI 10.1111/j.1574-695X.2011.00819.x
PG 16
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 792UM
UT WOS:000292775900001
PM 21585562
OA Bronze
DA 2020-11-26
ER

PT J
AU Haddad, R
   Kashima, S
   Rodrigues, ES
   Palma, PVB
   Zago, MA
   Covas, DT
AF Haddad, Rodrigo
   Kashima, Simone
   Rodrigues, Evandra Strazza
   Bonini Palma, Patricia Vianna
   Zago, Marco Antonio
   Covas, Dimas Tadeu
TI Inhibition of Expression of HTLV-1 Structural Genes Mediated by Short
   Hairpin RNA In Vitro
SO ANTICANCER RESEARCH
LA English
DT Article
DE HTLV-1; gag and env genes; RNA interference; shRNA
ID CELL LEUKEMIA-VIRUS; T-CELLS; RETROVIRUS; INFECTION; LYMPHOMA; EFFICACY;
   PCR; TAX
AB Background: Human T-lymphotropic virus 1 (HTLV-1) is associated with the T-cell malignancy known as adult T-cell leukemia! lymphoma (ATLL) and with a disorder called HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Currently, the treatment of these diseases is based on symptom relief. RNA interference (RNAi) technology has been described as an efficient mechanism for development of new therapeutic methods. Thus, the aim of this study was to evaluate the inhibition of HTLV-1 structural proteins using short hairpin RNAs (shRNAs) expressed by non-viral vectors. Materials and Methods: Reporter plasmids that express enhanced green fluorescent protein-Gag (EGFP-Gag) and EGFP-Env fusion proteins and vectors that express shRNAs corresponding to the HTLV-1 gag and env genes were constructed. shRNA vectors and reporter plasmids were simultaneously transfected into HEK 293 cells. Results: Fluorescence microscopy, flow cytometry and real-time PCR showed that shRNAs were effective in inhibiting the fusion proteins. Conclusion: These shRNAs are effective against the expression of structural genes and may provide an approach to the development of new therapeutic agents.
C1 [Haddad, Rodrigo; Kashima, Simone; Rodrigues, Evandra Strazza; Bonini Palma, Patricia Vianna; Zago, Marco Antonio; Covas, Dimas Tadeu] Univ Sao Paulo, Fundacao Hemoctr Ribeirao Preto, BR-14051140 Ribeirao Preto, SP, Brazil.
   [Haddad, Rodrigo; Kashima, Simone; Zago, Marco Antonio; Covas, Dimas Tadeu] Univ Sao Paulo, Fac Med Ribeirao Preto, BR-14051140 Ribeirao Preto, SP, Brazil.
   [Kashima, Simone] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, BR-14051140 Ribeirao Preto, SP, Brazil.
RP Covas, DT (corresponding author), Univ Sao Paulo, Fundacao Hemoctr Ribeirao Preto, Rua Tenente Catao Roxo 2501, BR-14051140 Ribeirao Preto, SP, Brazil.
EM dimas@fmrp.usp.br
RI Rodrigues, Evandra/L-6094-2017; ZAGO, MARCO A/E-9442-2017; Kashima,
   Simone/G-4876-2012; Haddad, Rodrigo/A-3460-2013; Covas, Dimas
   T/C-5431-2013
OI Rodrigues, Evandra/0000-0003-0964-9554; Kashima,
   Simone/0000-0002-1487-0141; Haddad, Rodrigo/0000-0003-4699-164X; Covas,
   Dimas T/0000-0002-7364-2595
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Centro de Terapia
   Celular/Fundacao Hemocentro de Ribeirao Preto (CTC/FUNDHERP); Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)National
   Council for Scientific and Technological Development (CNPq)
FX We thank Sandra Navarro for the artwork. This study was supported by
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Centro de
   Terapia Celular/Fundacao Hemocentro de Ribeirao Preto (CTC/FUNDHERP) and
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq).
CR Bitko V, 2001, BMC Microbiol, V1, P34, DOI 10.1186/1471-2180-1-34
   Blot V, 2004, J CELL SCI, V117, P2357, DOI 10.1242/jcs.01095
   Gallo RC, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-17
   Haddad R, 2011, J VIROL METHODS, V173, P92, DOI 10.1016/j.jviromet.2011.01.012
   Hara T, 2008, CANCER SCI, V99, P1155, DOI 10.1111/j.1349-7006.2008.00798.x
   Hieshima K, 2008, J IMMUNOL, V180, P931, DOI 10.4049/jimmunol.180.2.931
   Ishitsuka K, 2008, EUR J HAEMATOL, V80, P185, DOI 10.1111/j.1600-0609.2007.01016.x
   Kim DH, 2005, NAT BIOTECHNOL, V23, P222, DOI 10.1038/nbt1051
   LE B, 2001, VIRUS RES, V78, P5
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X
   Nagai M, 2003, J NEUROVIROL, V9, P228, DOI 10.1080/13550280390194028
   Oh U, 2008, NEUROL CLIN, V26, P781, DOI 10.1016/j.ncl.2008.03.008
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   Ratner L, 2004, FRONT BIOSCI-LANDMRK, V9, P2852, DOI 10.2741/1442
   Rossi JJ, 2006, BIOTECHNIQUES, V40, P25, DOI 10.2144/000112167
   Sashital DG, 2010, CURR OPIN STRUC BIOL, V20, P90, DOI 10.1016/j.sbi.2009.12.001
   Schubert S, 2005, J MOL BIOL, V348, P883, DOI 10.1016/j.jmb.2005.03.011
   SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618
   Shrey K, 2009, BIOCHEM BIOPH RES CO, V386, P273, DOI 10.1016/j.bbrc.2009.06.018
   Siolas D, 2005, NAT BIOTECHNOL, V23, P227, DOI 10.1038/nbt1052
   Tan FL, 2004, CELL RES, V14, P460, DOI 10.1038/sj.cr.7290248
   Tiemann K, 2009, EMBO MOL MED, V1, P142, DOI 10.1002/emmm.200900023
   Verdonck K, 2007, LANCET INFECT DIS, V7, P266, DOI 10.1016/S1473-3099(07)70081-6
   Yasunaga Jun-ichirou, 2007, Cancer Control, V14, P133
NR 26
TC 0
Z9 0
U1 0
U2 1
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD JUN
PY 2011
VL 31
IS 6
BP 2173
EP 2177
PG 5
WC Oncology
SC Oncology
GA 791AE
UT WOS:000292631300021
PM 21737637
DA 2020-11-26
ER

PT J
AU Haddad, R
   Kashima, S
   Rodrigues, ES
   Azevedo, R
   Palma, PVB
   de Magalhaes, DAR
   Zago, MA
   Covas, DT
AF Haddad, Rodrigo
   Kashima, Simone
   Rodrigues, Evandra Strazza
   Azevedo, Rochele
   Bonini Palma, Patricia Vianna
   Rosa de Magalhaes, Danielle Aparecida
   Zago, Marco Antonio
   Covas, Dimas Tadeu
TI Silencing of HTLV-1 gag and env genes by small interfering RNAs in HEK
   293 cells
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE HTLV-1; Gag; Env; RNA interference; siRNA
ID ANTIVIRAL DEFENSE-MECHANISM; HEPATITIS-B-VIRUS; LEUKEMIA-VIRUS; T-CELLS;
   EXPRESSION; INHIBITION; REPLICATION; TAX; INFECTION
AB Since the discovery of RNAi technology, several functional genomic and disease therapy studies have been conducted using this technique in the field of oncology and virology. RNAi-based antiviral therapies are being studied for the treatment of retroviruses such as HIV-1. These studies include the silencing of regulatory, infectivity and structural genes. The HTLV-1 structural genes are responsible for the synthesis of proteins involved in the entry, assembly and release of particles during viral infection. To examine the possibility of silencing HTLV-1 genes gag and env by RNA interference technology, these genes were cloned into reporter plasmids. These vectors expressed the target mRNAs fused to EGFP reporter genes. Three small interference RNAs (siRNAs) corresponding to gag and three corresponding to env were designed to analyze the effect of silencing by RNAi technology. The plasmids and siRNAs were co-transfected into HEK 293 cells. The results demonstrated that the expression of the HTLV-1 gag and env genes decreased significantly in vitro. Thus, siRNAs can be used to inhibit HTLV-1 structural genes in transformed cells, which could provide a tool for clarifying the roles of HTLV-1 structural genes, as well as a therapy for this infection. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Haddad, Rodrigo; Kashima, Simone; Rodrigues, Evandra Strazza; Azevedo, Rochele; Bonini Palma, Patricia Vianna; Rosa de Magalhaes, Danielle Aparecida; Zago, Marco Antonio; Covas, Dimas Tadeu] Univ Sao Paulo, Fundacao Hemoctr Ribeirao Preto, BR-14051140 Sao Paulo, Brazil.
   [Haddad, Rodrigo; Kashima, Simone; Zago, Marco Antonio; Covas, Dimas Tadeu] Univ Sao Paulo, Fac Med Ribeirao Preto, BR-14049900 Sao Paulo, Brazil.
   [Kashima, Simone] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, BR-14040903 Sao Paulo, Brazil.
RP Covas, DT (corresponding author), Univ Sao Paulo, Fundacao Hemoctr Ribeirao Preto, Rua Tenente Catao Roxo 2501, BR-14051140 Sao Paulo, Brazil.
EM dimas@fmrp.usp.br
RI Rodrigues, Evandra/L-6094-2017; Covas, Dimas T/C-5431-2013; ZAGO, MARCO
   A/E-9442-2017; Kashima, Simone/G-4876-2012; Haddad, Rodrigo/A-3460-2013
OI Rodrigues, Evandra/0000-0003-0964-9554; Covas, Dimas
   T/0000-0002-7364-2595; Kashima, Simone/0000-0002-1487-0141; Haddad,
   Rodrigo/0000-0003-4699-164X
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Centro de Terapia
   Celular da Fundacao Hemocentro de Ribeirao Preto (CTC/FUNDHERP);
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq)
FX This work was financially supported by Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP), Centro de Terapia Celular da Fundacao
   Hemocentro de Ribeirao Preto (CTC/FUNDHERP) and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq). The authors would like
   to thank Sandra Navarro for the artwork and Svetoslav N. Slavov for
   revising the English text.
CR Bitko V, 2001, BMC Microbiol, V1, P34, DOI 10.1186/1471-2180-1-34
   Blot V, 2004, J CELL SCI, V117, P2357, DOI 10.1242/jcs.01095
   Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798
   Cooper Sarah A, 2009, Pract Neurol, V9, P16, DOI 10.1136/jnnp.2008.167155
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Haasnoot J, 2007, NAT BIOTECHNOL, V25, P1435, DOI 10.1038/nbt1369
   Hara T, 2008, CANCER SCI, V99, P1155, DOI 10.1111/j.1349-7006.2008.00798.x
   Hayafune Masaaki, 2006, Antiviral Chemistry & Chemotherapy, V17, P241
   Hieshima K, 2008, J IMMUNOL, V180, P931, DOI 10.4049/jimmunol.180.2.931
   Holen T, 2002, NUCLEIC ACIDS RES, V30, P1757, DOI 10.1093/nar/30.8.1757
   Ishitsuka K, 2008, EUR J HAEMATOL, V80, P185, DOI 10.1111/j.1600-0609.2007.01016.x
   Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896
   Jung KJ, 2008, J VIROL, V82, P8537, DOI 10.1128/JVI.00690-08
   Kronke J, 2004, J VIROL, V78, P3436, DOI 10.1128/JVI.78.7.3436-3446.2004
   Kurreck J, 2009, ANGEW CHEM INT EDIT, V48, P1378, DOI 10.1002/anie.200802092
   Le Blanc I, 2001, VIRUS RES, V78, P5, DOI 10.1016/S0168-1702(01)00278-7
   Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500
   Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X
   Manel N, 2005, ONCOGENE, V24, P6016, DOI 10.1038/sj.onc.1208972
   Nagai M, 2003, J NEUROVIROL, V9, P228, DOI 10.1080/13550280390194028
   Naito Y, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-80
   Nomura M, 2004, J VIROL, V78, P3827, DOI 10.1128/JVI.78.8.3827-3836.2004
   Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725
   Oh U, 2008, NEUROL CLIN, V26, P781, DOI 10.1016/j.ncl.2008.03.008
   Park WS, 2003, GENE THER, V10, P2046, DOI 10.1038/sj.gt.3302099
   Park WS, 2002, NUCLEIC ACIDS RES, V30, P4830, DOI 10.1093/nar/gkf627
   Qu ZX, 2004, J BIOL CHEM, V279, P44563, DOI 10.1074/jbc.M403689200
   Rana TM, 2007, NAT REV MOL CELL BIO, V8, P23, DOI 10.1038/nrm2085
   Ratner L, 2004, FRONT BIOSCI-LANDMRK, V9, P2852, DOI 10.2741/1442
   Sakamoto N, 2008, J GASTROEN HEPATOL, V23, P1437, DOI 10.1111/j.1440-1746.2007.05076.x
   Schubert S, 2005, J MOL BIOL, V348, P883, DOI 10.1016/j.jmb.2005.03.011
   Segers GC, 2007, P NATL ACAD SCI USA, V104, P12902, DOI 10.1073/pnas.0702500104
   SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618
   Shi Y, 2005, CELL RES, V15, P193, DOI 10.1038/sj.cr.7290286
   Tomita M, 2009, INT J CANCER, V124, P2607, DOI 10.1002/ijc.24257
   Verdonck K, 2007, LANCET INFECT DIS, V7, P266, DOI 10.1016/S1473-3099(07)70081-6
   Voinnet O, 2001, TRENDS GENET, V17, P449, DOI 10.1016/S0168-9525(01)02367-8
   Wang XH, 2006, SCIENCE, V312, P452, DOI 10.1126/science.1125694
   Waterhouse PM, 2001, NATURE, V411, P834, DOI 10.1038/35081168
   Wilkins C, 2005, NATURE, V436, P1044, DOI 10.1038/nature03957
   Wu CJ, 2005, ANTIVIR RES, V65, P45, DOI 10.1016/j.antiviral.2004.09.005
   Wu KL, 2005, VIRUS RES, V112, P100, DOI 10.1016/j.virusres.2005.04.001
   Ma Y, 2007, WORLD J GASTROENTERO, V13, P5169, DOI 10.3748/wjg.v13.i39.5169
   Yasunaga Jun-ichirou, 2007, Cancer Control, V14, P133
   Ying RS, 2007, ANTIVIR RES, V73, P24, DOI 10.1016/j.antiviral.2006.05.022
   Zhou HB, 2007, ANTIVIR RES, V76, P186, DOI 10.1016/j.antiviral.2007.07.002
NR 47
TC 2
Z9 2
U1 0
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD APR
PY 2011
VL 173
IS 1
BP 92
EP 98
DI 10.1016/j.jviromet.2011.01.012
PG 7
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 753GF
UT WOS:000289759600014
PM 21277903
OA Green Published
DA 2020-11-26
ER

PT J
AU Haddad, R
   Alves, DCC
   Rocha, MC
   Azevedo, R
   Pombo-de-Oliveira, MD
   Takayanagui, OM
   Donadi, EA
   Covas, DT
   Kashima, S
AF Haddad, Rodrigo
   Ciliao Alves, Daiani Cristina
   Rocha-Junior, Mauricio Cristiano
   Azevedo, Rochele
   Pombo-de-Oliveira, Maria do Socorro
   Takayanagui, Oswaldo Massaiti
   Donadi, Eduardo Antonio
   Covas, Dimas Tadeu
   Kashima, Simone
TI HLA-G 14-bp Insertion/Deletion Polymorphism Is a Risk Factor for HTLV-1
   Infection
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID VIRUS TYPE-I; VERTICAL TRANSMISSION; G EXPRESSION; G GENE; TROPHOBLAST;
   DELETION; ANTIGEN; ASSAY
AB About 95% of HTLV-1 infected patients remain asymptomatic throughout life, and the risk factors associated with the development of related diseases, such as HAM/TSP and ATL, are not fully understood. The human leukocyte antigen-G molecule (HLA-G), a nonclassical HLA class I molecule encoded by MHC, is expressed in several pathological conditions, including viral infection, and is related to immunosuppressive effects that allow the virus-infected cells to escape the antiviral defense of the host. The 14-bp insertion/deletion polymorphism of exon 8 HLA-G gene influences the stability of the transcripts and could be related to HTLV-1-infected cell protection and to the increase of proviral load. The present study analyzed by conventional PCR the 14-bp insertion/deletion polymorphism of exon 8 HLA-G gene in 150 unrelated healthy subjects, 82 HTLV-1 infected patients with symptoms (33 ATL and 49 HAM), and 56 asymptomatic HTLV-1 infected patients (HAC). In addition, the proviral load was determined by quantitative real-time PCR in all infected groups and correlated with 14-bp insertion/deletion genotypes. The heterozygote genotype frequencies were significantly higher in HAM, in the symptomatic group, and in infected patients compared to control (p < 0.05). The proviral load was higher in the symptomatic group than the HAC group (p < 0.0005). The comparison of proviral load and genotypes showed that -14-bp/-14-bp genotype had a higher proviral load than +14-bp/-14-bp and +14-bp/+14-bp genotypes. Although HLA-G 14-bp polymorphism does not appear to be associated
C1 [Haddad, Rodrigo; Rocha-Junior, Mauricio Cristiano; Azevedo, Rochele; Covas, Dimas Tadeu; Kashima, Simone] Univ Sao Paulo, Hemoctr Ribeirao Preto, Sao Paulo, Brazil.
   [Haddad, Rodrigo; Ciliao Alves, Daiani Cristina; Takayanagui, Oswaldo Massaiti; Donadi, Eduardo Antonio; Covas, Dimas Tadeu] Univ Sao Paulo, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
   [Rocha-Junior, Mauricio Cristiano; Kashima, Simone] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Sao Paulo, Brazil.
   [Pombo-de-Oliveira, Maria do Socorro] Fundacao Oswaldo Cruz, INCA, Rio De Janeiro, Brazil.
RP Kashima, S (corresponding author), Fundacao Hemoctr Ribeirao Preto, Mol Biol Lab, Rua Tenente Catao Roxo 2501, BR-14051140 Sao Paulo, Brazil.
EM skashima@hemocentro.fmrp.usp.br
RI Kashima, Simone/G-4876-2012; Covas, Dimas T/C-5431-2013; Takayanagui,
   Osvaldo M/C-8159-2013; donadi, eduardo A/H-7080-2013; Pombo-de-Oliveira,
   Maria S./I-8884-2014; Haddad, Rodrigo/A-3460-2013; Pombo-de-Oliveira,
   Maria do Socorro/I-8884-2014
OI Kashima, Simone/0000-0002-1487-0141; Covas, Dimas T/0000-0002-7364-2595;
   Takayanagui, Osvaldo M/0000-0002-8190-0275; donadi, eduardo
   A/0000-0002-9457-9601; Pombo-de-Oliveira, Maria S./0000-0002-1507-004X;
   Haddad, Rodrigo/0000-0003-4699-164X; Pombo-de-Oliveira, Maria do
   Socorro/0000-0003-3986-8993
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); Centro de Terapia
   Celular da Fundacao Hemocentro de Ribeirao Preto (CTC/FUNDHERP);
   Instituto Nacional de Celulas Tronco e Terapia Celular (INCTC)
FX This work was supported financially by Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP), Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Centro de Terapia Celular da Fundacao
   Hemocentro de Ribeirao Preto (CTC/FUNDHERP), and Instituto Nacional de
   Celulas Tronco e Terapia Celular (INCTC).
CR Asquith B, 2005, J GEN VIROL, V86, P1515, DOI 10.1099/vir.0.80766-0
   Asquith B, 2007, IMMUNOL CELL BIOL, V85, P280, DOI 10.1038/sj.icb.7100050
   Carosella ED, 2008, TRENDS IMMUNOL, V29, P125, DOI 10.1016/j.it.2007.11.005
   Carosella ED, 2003, ADV IMMUNOL, V81, P199, DOI 10.1016/S0065-2776(03)81006-4
   Caumartin J, 2007, EMBO J, V26, P1423, DOI 10.1038/sj.emboj.7601570
   Cooper Sarah A, 2009, Pract Neurol, V9, P16, DOI 10.1136/jnnp.2008.167155
   Cordero EAA, 2009, TISSUE ANTIGENS, V74, P308, DOI 10.1111/j.1399-0039.2009.01331.x
   ELLIS SA, 1986, IMMUNOLOGY, V59, P595
   Fabris A, 2009, AIDS, V23, P177, DOI 10.1097/QAD.0b013e32832027bf
   Fuzzi B, 2002, EUR J IMMUNOL, V32, P311, DOI 10.1002/1521-4141(200202)32:2<311::AID-IMMU311>3.0.CO;2-8
   GERAGHTY DE, 1987, P NATL ACAD SCI USA, V84, P9145, DOI 10.1073/pnas.84.24.9145
   GESSAIN A, 1985, LANCET, V2, P407
   Hiby SE, 1999, TISSUE ANTIGENS, V53, P1, DOI 10.1034/j.1399-0039.1999.530101.x
   Hviid TV, 2002, TISSUE ANTIGENS, V60, P122, DOI 10.1034/j.1399-0039.2002.600202.x
   Hviid TVF, 2003, IMMUNOGENETICS, V55, P63, DOI 10.1007/s00251-003-0547-z
   Komatsu F, 1999, ONCOL RES, V11, P213
   KOVATS S, 1990, SCIENCE, V248, P220, DOI 10.1126/science.2326636
   LaGrenade L, 1996, J ACQ IMMUN DEF SYND, V13, pS46, DOI 10.1097/00042560-199600001-00009
   Lajoie J, 2010, HUM IMMUNOL, V71, P182, DOI 10.1016/j.humimm.2009.11.007
   LeMaoult J, 2007, BLOOD, V109, P2040, DOI 10.1182/blood-2006-05-024547
   Mariette X, 2000, CLIN EXP RHEUMATOL, V18, P341
   Martinetti M, 2006, INT J IMMUNOPATH PH, V19, P369, DOI 10.1177/039463200601900213
   MCMASTER MT, 1995, J IMMUNOL, V154, P3771
   Miley WJ, 2000, AIDS RES HUM RETROV, V16, P665, DOI 10.1089/088922200308891
   Mochizuki M, 1996, J ACQ IMMUN DEF SYND, V13, pS50, DOI 10.1097/00042560-199600001-00010
   MORGAN OS, 1989, LANCET, V2, P1184
   Nagai M, 2003, J NEUROVIROL, V9, P228, DOI 10.1080/13550280390194028
   Nagai M, 1998, J NEUROVIROL, V4, P586, DOI 10.3109/13550289809114225
   NISHIOKA K, 1989, LANCET, V1, P441
   OSAME M, 1986, LANCET, V1, P1031
   Ratner L, 2004, FRONT BIOSCI-LANDMRK, V9, P2852, DOI 10.2741/1442
   RAYMOND M, 1995, J HERED, V86, P248, DOI 10.1093/oxfordjournals.jhered.a111573
   Rouas-Freiss N, 2005, CANCER RES, V65, P10139, DOI 10.1158/0008-5472.CAN-05-0097
   RouasFreiss N, 1997, P NATL ACAD SCI USA, V94, P11520, DOI 10.1073/pnas.94.21.11520
   Rousseau P, 2003, HUM IMMUNOL, V64, P1005, DOI 10.1016/j.humimm.2003.08.347
   Segat L, 2009, AIDS, V23, P1916, DOI 10.1097/QAD.0b013e32832f8104
   Tripathi P, 2004, TISSUE ANTIGENS, V64, P706, DOI 10.1111/j.1399-0039.2004.00308.x
   Verdonck K, 2007, LANCET INFECT DIS, V7, P266, DOI 10.1016/S1473-3099(07)70081-6
   Zheng XQ, 2009, TISSUE ANTIGENS, V74, P317, DOI 10.1111/j.1399-0039.2009.01312.x
NR 39
TC 16
Z9 17
U1 0
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD MAR
PY 2011
VL 27
IS 3
BP 283
EP 288
DI 10.1089/aid.2010.0165
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 733DO
UT WOS:000288241600009
PM 20977358
DA 2020-11-26
ER

PT J
AU Fontes, AM
   Kashima, S
   Bonfim-Silva, R
   Azevedo, R
   Abraham, KJ
   Albuquerque, SRL
   Bordin, JO
   Langhi, DM
   Covas, DT
AF Fontes, Aparecida Maria
   Kashima, Simone
   Bonfim-Silva, Ricardo
   Azevedo, Rochele
   Abraham, Kuruvilla Joseph
   Lopes Albuquerque, Sergio Roberto
   Bordin, Jose Orlando
   Langhi Junior, Dante Mario
   Covas, Dimas Tadeu
TI Association between Knops blood group polymorphisms and susceptibility
   to malaria in an endemic area of the Brazilian Amazon
SO GENETICS AND MOLECULAR BIOLOGY
LA English
DT Article
DE Brazilian Amazon population; CR1 haplotypes; Knops blood group
   polymorphism; malaria
ID CELL SURFACE-ANTIGENS; TRANSFUSION-COMMITTEE; WEST-AFRICA;
   IDENTIFICATION; REGION; TERMINOLOGY; KENYA; CR-1
AB Complement receptor 1 (CR1) gene polymorphisms that are associated with Knops blood group antigens may influence the binding of Plasmodium parasites to erythrocytes, thereby affecting susceptibility to malaria. The aim of this study was to evaluate the genotype and allele and haplotype frequencies of single-nucleotide polymorphisms (SNPs) of Knops blood group antigens and examine their association with susceptibility to malaria in an endemic area of Brazil. One hundred and twenty-six individuals from the Brazilian Amazon were studied. The CR1-genomic fragment was amplified by PCR and six SNPs and haplotypes were identified after DNA sequence analysis. Allele and haplotype frequencies revealed that the Kn(b) allele and H8 haplotype were possibly associated with susceptibility to Plasmodium falciparum. The odds ratios were reasonably high, suggesting a potentially important association between two Knops blood antigens (Kn(b) and KAM(+)) that confer susceptibility to P. falciparum in individuals from the Brazilian Amazon.
C1 [Fontes, Aparecida Maria; Kashima, Simone; Bonfim-Silva, Ricardo; Azevedo, Rochele; Covas, Dimas Tadeu] Univ Sao Paulo, Hemoctr Ribeirao Preto, Inst Nacl Ciencia & Tecnol Celulas Tronco & Terap, Hosp Clin,Fac Med Ribeirao Preto, BR-14051140 Ribeirao Preto, SP, Brazil.
   [Kashima, Simone] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, BR-14051140 Ribeirao Preto, SP, Brazil.
   [Abraham, Kuruvilla Joseph] Iowa State Univ, Dept Anim Sci, Ames, IA USA.
   [Lopes Albuquerque, Sergio Roberto] Hemoctr Amazonas, Manaus, Amazonas, Brazil.
   [Bordin, Jose Orlando] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Langhi Junior, Dante Mario] Fac Ciencias Med, Sao Paulo, Brazil.
RP Fontes, AM (corresponding author), Univ Sao Paulo, Ctr Reg Hemoterapia, Inst Nacl Ciencia & Tecnol Celulas Tronco & Terap, Hosp Clin,Fac Med Ribeirao Preto, R Tenente Catao Roxo 2501, BR-14051140 Ribeirao Preto, SP, Brazil.
EM fontesam@hemocentro.fmrp.usp.br
RI Langhi, Dante/L-7916-2017; Fontes, Aparecida Maria/ABF-2892-2020;
   Kashima, Simone/G-4876-2012; Fontes, Aparecida M/F-5627-2013; Covas,
   Dimas T/C-5431-2013; Silva, Ricardo Bonfim/A-8868-2013; kar, paritosh
   kumar/U-6713-2019
OI Langhi, Dante/0000-0002-4642-8091; Fontes, Aparecida
   Maria/0000-0002-4878-417X; Kashima, Simone/0000-0002-1487-0141; Fontes,
   Aparecida M/0000-0002-4878-417X; Covas, Dimas T/0000-0002-7364-2595;
   Silva, Ricardo Bonfim/0000-0002-4128-0497; 
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); National Institute of
   Science and Tecnology in Stem Cell and Cell Therapy/Fundacao Hemocentro
   de Ribeirao Preto (INCTC/FUNDHERP-HC-FMRP/USP); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), BrazilNational Council
   for Scientific and Technological Development (CNPq) [314458/2009-3];
   USDA-NIFAUnited States Department of Agriculture (USDA)
   [2009-35205-05100]
FX We thank Adriana Aparecida Marques for technical assistance, and Evandra
   Strazza Rodrigues and Danielle Aparecida Rosa de Magalhaes for help with
   data analysis and useful scientific discussions. This work was supported
   by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), the
   National Institute of Science and Tecnology in Stem Cell and Cell
   Therapy/Fundacao Hemocentro de Ribeirao Preto
   (INCTC/FUNDHERP-HC-FMRP/USP) and Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq) for scholarship grant (no
   314458/2009-3), Brazil. K.J.A. was supported by a USDA-NIFA grant (no.
   2009-35205-05100).
CR Barreiro LB, 2008, NAT GENET, V40, P340, DOI 10.1038/ng.78
   Covas DT, 2007, TRANSFUSION, V47, P147, DOI 10.1111/j.1537-2995.2007.01077.x
   Daniels G, 2007, VOX SANG, V92, P250, DOI 10.1111/j.1423-0410.2007.00887.x
   Daniels GL, 2004, VOX SANG, V87, P304, DOI 10.1111/j.1423-0410.2004.00564.x
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   Excoffier L, 2005, EVOL BIOINFORM, V1, P47, DOI 10.1177/117693430500100003
   de Oliveira MRF, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-277
   Gandhi M, 2009, J VECTOR DIS, V46, P288
   Jallow M, 2009, NAT GENET, V41, P657, DOI 10.1038/ng.388
   Kappe SHI, 2010, SCIENCE, V328, P862, DOI 10.1126/science.1184785
   LUZZATTO L, 1974, B WORLD HEALTH ORGAN, V50, P195
   Marth GT, 1999, NAT GENET, V23, P452, DOI 10.1038/70570
   Moulds JM, 2000, GENES IMMUN, V1, P325, DOI 10.1038/sj.gene.6363676
   Moulds JM, 2004, TRANSFUSION, V44, P164, DOI 10.1111/j.1537-2995.2004.00615.x
   Moulds JM, 2002, TRANSFUSION, V42, P251, DOI 10.1046/j.1537-2995.2002.00002.x
   Moulds JM, 2001, BLOOD, V97, P2879, DOI 10.1182/blood.V97.9.2879
   Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745
   ROWE A, 1995, INFECT IMMUN, V63, P2323, DOI 10.1128/IAI.63.6.2323-2326.1995
   Rowe JA, 2000, J IMMUNOL, V165, P6341, DOI 10.4049/jimmunol.165.11.6341
   Rowe JA, 1997, NATURE, V388, P292, DOI 10.1038/40888
   Thathy V, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-54
   Zimmerman PA, 2003, GENES IMMUN, V4, P368, DOI 10.1038/sj.gene.6363980
NR 23
TC 5
Z9 5
U1 0
U2 4
PU SOC BRASIL GENETICA
PI RIBEIRAO PRET
PA RUA CAP ADELMIO NORBET DA SILVA, 736, ALTO DA BOA VISTA, 14025-670
   RIBEIRAO PRET, BRAZIL
SN 1415-4757
EI 1678-4685
J9 GENET MOL BIOL
JI Genet. Mol. Biol.
PY 2011
VL 34
IS 4
BP 539
EP 545
DI 10.1590/S1415-47572011005000051
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 858IL
UT WOS:000297789600002
PM 22215954
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Tognon, R
   Gasparotto, EPL
   Leroy, JMG
   Oliveira, GLV
   Neves, RP
   Carrara, RDV
   Kashima, S
   Covas, DT
   Santana, M
   Souto, EX
   Zanichelli, MA
   Velano, CEE
   Simoes, BP
   Alberto, FL
   Miyashiro, K
   de Souza, AM
   Amarante-Mendes, GP
   de Castro, FA
AF Tognon, Raquel
   Lino Gasparotto, Elainy Patricia
   Gisele Leroy, Janine Marie
   Vilela Oliveira, Gislane Lelis
   Neves, Renata Peres
   Viu Carrara, Rita de Cassia
   Kashima, Simone
   Covas, Dimas Tadeu
   Santana, Mary
   Souto, Elizabeth Xisto
   Zanichelli, Maria Aparecida
   Engel Velano, Carlos Eduardo
   Simoes, Belinda Pinto
   Alberto, Fernando Lopes
   Miyashiro, Kozue
   de Souza, Ana Maria
   Amarante-Mendes, Gustavo Pessini
   de Castro, Fabiola Attie
TI Differential expression of apoptosis-related genes from death receptor
   pathway in chronic myeloproliferative diseases
SO JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article
ID V617F MUTATION STATUS; TYROSINE KINASE JAK2; C-FLIP EXPRESSION;
   POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; IDIOPATHIC MYELOFIBROSIS;
   MEDIATED APOPTOSIS; ALLELE BURDEN; FAS-LIGAND; RESISTANCE
AB Background Chronic myeloproliferative disorders (MPDs) are clonal haematopoietic stem cell malignancies characterised by an accumulation of mature myeloid cells in bone marrow and peripheral blood. Deregulation of the apoptotic machinery may be associated with MPD physiopathology.
   Aims To evaluate expression of death receptors' family members, mononuclear cell apoptosis resistance, and JAK2 allele burden.
   Subjects and Methods Bone marrow haematopoietic progenitor CD34 cells were separated using the Ficoll-hypaque protocol followed by the Miltenyi CD34 isolation kit, and peripheral blood leukocytes were separated by the Haes-Steril method. Total RNA was extracted by the Trizol method, the High Capacity Kit was used to synthesise cDNA, and real-time PCR was performed using SybrGreen in ABIPrism 7500 equipment. The results of gene expression quantification are given as 2(-Delta Delta Ct). The JAK2 V617F mutation was detected by real-time allelic discrimination PCR assay. Peripheral blood mononuclear cells (PBMCs) were isolated by the Ficoll-hypaque protocol and cultured in the presence of apoptosis inducers.
   Results In CD34 cells, there was mRNA overexpression for fas, faim and c-flip in polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF), as well as fasl in PMF, and dr4 levels were increased in ET. In leukocytes, fas, c-flip and trail levels were increased in PV, and dr5 expression was decreased in ET. There was an association between dr5 and fasl expression and JAK2V617F mutation. PBMCs from patients with PV, ET or PMF showed resistance to apoptosis inducers.
   Conclusions The results indicate deregulation of apoptosis gene expression, which may be associated with MPD pathogenesis leading to accumulation of myeloid cells in MPDs.
C1 [de Castro, Fabiola Attie] Univ Sao Paulo, Fac Ciencias Farmaceut, Hematol Lab,Ribeirao Preto Sch Pharmaceut Sci, Dept Clin Toxicol & Bromatol Anal, BR-14040903 Ribeirao Preto, SP, Brazil.
   [Viu Carrara, Rita de Cassia; Kashima, Simone; Covas, Dimas Tadeu] Univ Sao Paulo, Hosp Clin, Ribeirao Preto Sch Med, Ribeirao Preto Ctr Transfus Med, BR-14040903 Ribeirao Preto, SP, Brazil.
   [Santana, Mary; Souto, Elizabeth Xisto; Zanichelli, Maria Aparecida] Brigadeiro Hosp Sao Paulo, Sao Paulo, Brazil.
   [Engel Velano, Carlos Eduardo; Simoes, Belinda Pinto] Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Clin Med, BR-14040903 Ribeirao Preto, SP, Brazil.
   [Alberto, Fernando Lopes; Miyashiro, Kozue] Fleury Med & Hlth, Sao Paulo, Brazil.
   [Gisele Leroy, Janine Marie; Amarante-Mendes, Gustavo Pessini] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Sao Paulo, Brazil.
RP de Castro, FA (corresponding author), Univ Sao Paulo, Fac Ciencias Farmaceut, Hematol Lab,Ribeirao Preto Sch Pharmaceut Sci, Dept Clin Toxicol & Bromatol Anal, Av Cafe S-N, BR-14040903 Ribeirao Preto, SP, Brazil.
EM castrofa@fcfrp.usp.br
RI Kashima, Simone/G-4876-2012; Covas, Dimas T/C-5431-2013; de Oliveira,
   Gislane L. V./I-4896-2013; CASTRO, FABIOLA/D-4693-2012; Simoes, Belinda
   P/M-7469-2016; Mendes, Gustavo P Amarante/C-8187-2012; SIMOES,
   BELINDA/A-1896-2014
OI Kashima, Simone/0000-0002-1487-0141; Covas, Dimas T/0000-0002-7364-2595;
   de Oliveira, Gislane L. V./0000-0002-0269-9973; Mendes, Gustavo P
   Amarante/0000-0002-7851-6205; Lelis Vilela de Oliveira,
   Gislane/0000-0002-8883-5541; SIMOES, BELINDA/0000-0003-4508-8934
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [08/54387-5,
   06/50094-8]; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES)CAPES
FX RT is the recipient of a fellowship from the Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) (No 08/54387-5), EPLG and RPN
   are recipients of fellowships from the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), and GLVO is the
   recipient of a fellowship from the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES). This work was supported by a FAPESP
   grant (No 06/50094-8).
CR Alenzi FQB, 2002, EXP HEMATOL, V30, P1428, DOI 10.1016/S0301-472X(02)00957-8
   Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359-6101(03)00029-7
   Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926
   Barcena A, 1996, BLOOD, V88, P2013, DOI 10.1182/blood.V88.6.2013.bloodjournal8862013
   Barosi G, 2007, BLOOD, V110, P4030, DOI 10.1182/blood-2007-07-099184
   Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9
   Bogani C, 2007, HAEMATOLOGICA, V92, P258, DOI 10.3324/haematol.10527
   Campbell PJ, 2006, BLOOD, V107, P2098, DOI 10.1182/blood-2005-08-3395
   Castro FA, 2005, BLOOD, V106, p807A, DOI 10.1182/blood.V106.11.2880.2880
   Ciurea SO, 2007, BLOOD, V110, P986, DOI 10.1182/blood-2006-12-064626
   Contini P, 2007, LEUKEMIA, V21, P253, DOI 10.1038/sj.leu.2404494
   Cooper WA, 2008, CANCER, V113, P135, DOI 10.1002/cncr.23528
   De Maria R, 1999, BLOOD, V93, P796, DOI 10.1182/blood.V93.3.796.403k23_796_803
   Debatin KM, 2003, SEMIN CANCER BIOL, V13, P149, DOI 10.1016/S1044-579X(02)00132-3
   Delhommeau F, 2006, CELL MOL LIFE SCI, V63, P2939, DOI 10.1007/s00018-006-6272-7
   Delhommeau F, 2007, BLOOD, V109, P71, DOI 10.1182/blood-2006-03-007146
   Deligezer U, 2007, PATHOL ONCOL RES, V13, P290, DOI 10.1007/BF02940307
   Economopoulou C, 2008, LEUKEMIA RES, V32, P61, DOI 10.1016/j.leukres.2007.04.012
   Han J, 2008, J BIOL CHEM, V283, P19665, DOI 10.1074/jbc.M710169200
   Hara K, 2001, EUR J HAEMATOL, V66, P70, DOI 10.1034/j.1600-0609.2001.00266.x
   Huo J, 2009, CELL DEATH DIFFER, V16, P1062, DOI 10.1038/cdd.2009.26
   Ishii T, 2006, BLOOD, V108, P3128, DOI 10.1182/blood-2006-04-017392
   James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546
   Jin ZY, 2005, CANCER BIOL THER, V4, P139, DOI 10.4161/cbt.4.2.1508
   Jones AV, 2005, BLOOD, V106, P2162, DOI 10.1182/blood-2005-03-1320
   Komura E, 2003, EXP HEMATOL, V31, P622, DOI 10.1016/S0301-472X(03)00085-7
   Kralovics R, 2003, BLOOD, V102, P1869, DOI 10.1182/blood-2003-03-0744
   Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113
   Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728
   Larsen TS, 2007, EUR J HAEMATOL, V79, P508, DOI 10.1111/j.1600-0609.2007.00960.x
   Laubach JP, 2009, EXP HEMATOL, V37, P1411, DOI 10.1016/j.exphem.2009.09.009
   LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187
   Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023
   Levine RL, 2007, NAT REV CANCER, V7, P673, DOI 10.1038/nrc2210
   Lippert E, 2006, BLOOD, V108, P1865, DOI 10.1182/blood-2006-01-013540
   Mesa RA, 2006, LEUKEMIA, V20, P1800, DOI 10.1038/sj.leu.2404338
   Pardanani A, 2007, STEM CELLS, V25, P2358, DOI 10.1634/stemcells.2007-0175
   Passamonti F, 2006, BLOOD, V107, P3676, DOI 10.1182/blood-2005-09-3826
   Pearl-Yafe M, 2007, EXP HEMATOL, V35, P1601, DOI 10.1016/j.exphem.2007.07.010
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Reilly JT, 2006, HEMATOL ONCOL, V24, P56, DOI 10.1002/hon.771
   Rothstein TL, 2000, IMMUNOL REV, V176, P116
   Sanlioglu AD, 2007, INT J RADIAT ONCOL, V69, P716, DOI 10.1016/j.ijrobp.2007.03.057
   Schimmer AD, 2001, BLOOD, V98, P3541, DOI 10.1182/blood.V98.13.3541
   Schneider TJ, 1999, J EXP MED, V189, P949, DOI 10.1084/jem.189.6.949
   Segura MF, 2007, J NEUROSCI, V27, P11228, DOI 10.1523/JNEUROSCI.3462-07.2007
   Sirhan S, 2008, AM J HEMATOL, V83, P363, DOI 10.1002/ajh.21149
   Skurk C, 2004, J BIOL CHEM, V279, P1513, DOI 10.1074/jbc.M304736200
   Sole C, 2004, J CELL BIOL, V167, P479, DOI 10.1083/jcb.200403093
   Speletas M, 2007, LEUKEMIA RES, V31, P1053, DOI 10.1016/j.leukres.2006.09.005
   Spivak JL, 2004, SEMIN HEMATOL, V41, P1, DOI 10.1053/j.seminhematol.2004.02.011
   Starck L, 2005, EUR J IMMUNOL, V35, P1257, DOI 10.1002/eji.200425686
   Tefferi A, 2008, LEUKEMIA, V22, P14, DOI 10.1038/sj.leu.2404955
   Tenedini E, 2004, BLOOD, V104, P3126, DOI 10.1182/blood-2003-07-2597
   Ugo V, 2004, EXP HEMATOL, V32, P179, DOI 10.1016/j.exphem.2003.11.003
   Walczak H, 1999, NAT MED, V5, P157
   Wang MH, 2007, NEUROSCI RES, V59, P40, DOI 10.1016/j.neures.2007.05.010
   Wang WL, 2002, J BIOL CHEM, V277, P21723, DOI 10.1074/jbc.M202224200
   Wang XO, 2008, J OPT NETW, V7, P1, DOI 10.1364/JON.7.000001
   Wickremasinghe RG, 1999, BLOOD, V93, P3587, DOI 10.1182/blood.V93.11.3587.411k46_3587_3600
   Zeuner A, 2006, BLOOD, V107, P3495, DOI 10.1182/blood-2005-07-3037
   Zhao RX, 2005, J BIOL CHEM, V280, P22788, DOI 10.1074/jbc.C500138200
NR 62
TC 20
Z9 21
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0021-9746
EI 1472-4146
J9 J CLIN PATHOL
JI J. Clin. Pathol.
PD JAN
PY 2011
VL 64
IS 1
BP 75
EP 82
DI 10.1136/jcp.2010.080895
PG 8
WC Pathology
SC Pathology
GA 694IG
UT WOS:000285288800014
PM 21045235
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Tognon, R
   Gasparotto, E
   Neves, R
   Kashima, S
   Covas, D
   Palma, P
   Santana, M
   Souto, E
   Zanichelli, MA
   Velano, C
   Simoes, B
   Souza, AM
   Castro, F
AF Tognon, R.
   Gasparotto, E.
   Neves, R.
   Kashima, S.
   Covas, D.
   Palma, P.
   Santana, M.
   Souto, E.
   Zanichelli, M. A.
   Velano, C.
   Simoes, B.
   Souza, A. M.
   Castro, F.
TI JAK2V617F ALLELE BURDEN IS ASSOCIATED WITH APOPTOSIS-RELATED GENES
   EXPRESSION IN ESSENTIAL THROMBOCYTHEMIA
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 15th Annual Meeting of the European-Hematology-Association
CY JUN 10-13, 2010
CL Barcelona, SPAIN
SP European Hematol Assoc
C1 [Tognon, R.; Gasparotto, E.; Neves, R.; Souza, A. M.; Castro, F.] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, BR-14049 Ribeirao Preto, Brazil.
   [Kashima, S.; Covas, D.; Palma, P.] Univ Sao Paulo, Ctr Reg Hemoterapia Ribeirao Preto, HCFMRP, Ribeirao Preto, Brazil.
   [Santana, M.; Souto, E.; Zanichelli, M. A.] Hosp Brigadeiro, Sao Paulo, Brazil.
   [Velano, C.; Simoes, B.] Univ Sao Paulo, Dept Clin Med, Fac Med Ribeirao Preto, Ribeirao Preto, Brazil.
RI Kashima, Simone/G-4876-2012; CASTRO, FABIOLA/D-4693-2012; Simoes,
   Belinda P/M-7469-2016; Covas, Dimas T/C-5431-2013
OI Kashima, Simone/0000-0002-1487-0141; Covas, Dimas T/0000-0002-7364-2595
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
EI 1592-8721
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2010
VL 95
SU 2
MA 0407
BP 165
EP 166
PG 2
WC Hematology
SC Hematology
GA 614IY
UT WOS:000279051300405
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Ferreira, A
   Simoes, BP
   Silva, W
   Silva, IT
   Zanichelli, MA
   Colassanti, MD
   Hamerschlak, N
   Covas, D
   Kashima, S
   Souza, AM
   Castro, F
AF Ferreira, A.
   Simoes, B. Pinto
   Silva, W., Jr.
   Silva, I. Tojal
   Zanichelli, M. A.
   Colassanti, M. D.
   Hamerschlak, N.
   Covas, D.
   Kashima, S.
   Souza, A. M.
   Castro, F.
TI MIRNA-29C EXPRESSION IS ASSOCIATED WITH IMATINIB RESISTANCE AND MCL-1
   ANTI-APOPTOIC GENE EXPRESSION IN CHRONIC MYELOID LEUKEMIA PATIENTS
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
C1 [Ferreira, A.; Simoes, B. Pinto; Silva, W., Jr.; Silva, I. Tojal; Kashima, S.] Univ Sao Paulo, BR-14049 Ribeirao Preto, Brazil.
   [Zanichelli, M. A.; Colassanti, M. D.] Hosp Brigadeiro, Sao Paulo, Brazil.
   [Hamerschlak, N.] Brasileira Hosp Albert Einstein, Sociedade Beneficente Israelita, Sao Paulo, Brazil.
   [Covas, D.] Univ Sao Paulo, Fac Med, Ribeirao Preto, Brazil.
   [Souza, A. M.; Castro, F.] Univ Sao Paulo, Fac Ciencias Farmaceut, Ribeirao Preto, Brazil.
RI Covas, Dimas T/C-5431-2013; Silva, Israel T/N-3858-2014; Hamerschlak,
   Nelson/M-8060-2015; Simoes, Belinda P/M-7469-2016; Kashima,
   Simone/G-4876-2012
OI Covas, Dimas T/0000-0002-7364-2595; Silva, Israel T/0000-0002-4687-1499;
   Hamerschlak, Nelson/0000-0002-5140-5310; Kashima,
   Simone/0000-0002-1487-0141
NR 0
TC 0
Z9 0
U1 0
U2 2
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
EI 1592-8721
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2010
VL 95
SU 2
MA 1709
BP 668
EP 668
PG 1
WC Hematology
SC Hematology
GA 614IY
UT WOS:000279051302341
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Trindade, B
   Nicollete, L
   Malta, T
   Sorgi, C
   Takayanagui, O
   Covas, D
   Kashima, S
   Faccioli, L
AF Trindade, B.
   Nicollete, L.
   Malta, T.
   Sorgi, C.
   Takayanagui, O.
   Covas, D.
   Kashima, S.
   Faccioli, L.
TI ELEVATED LEUKOTRIENE B4 PRODUCTION BY PERIPHERAL BLOOD MONONUCLEAR CELLS
   FROM HTLV-1 INFECTED INDIVIDUALS
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
C1 [Trindade, B.; Nicollete, L.; Malta, T.; Sorgi, C.; Takayanagui, O.; Faccioli, L.] Univ Sao Paulo, BR-14049 Ribeirao Preto, Brazil.
   [Covas, D.; Kashima, S.] Fundacao Hemocentro Ribeirao Preto, Ribeirao Preto, Brazil.
RI Sorgi, Carlos Arterio/AAA-6284-2020; Sorgi, Carlos A/B-9732-2012;
   Kashima, Simone/G-4876-2012; Takayanagui, Osvaldo M/C-8159-2013; Sorgi,
   Carlos/F-6780-2012; Sorgi, Carlos/ABE-4246-2020; Covas, Dimas
   T/C-5431-2013
OI Sorgi, Carlos Arterio/0000-0001-7528-9935; Kashima,
   Simone/0000-0002-1487-0141; Takayanagui, Osvaldo M/0000-0002-8190-0275;
   Covas, Dimas T/0000-0002-7364-2595
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
EI 1592-8721
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2010
VL 95
SU 2
MA 1713
BP 669
EP 669
PG 1
WC Hematology
SC Hematology
GA 614IY
UT WOS:000279051302345
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Prata, KD
   Orellana, MD
   De Santis, GC
   Kashima, S
   Fontes, AM
   Carrara, RDV
   Palma, PVB
   Neder, L
   Covas, DT
AF Prata, Karen de Lima
   Orellana, Maristela Delgado
   De Santis, Gil Cunha
   Kashima, Simone
   Fontes, Aparecida Maria
   Viu Carrara, Rita de Cassia
   Bonini Palma, Patricia Vianna
   Neder, Luciano
   Covas, Dimas Tadeu
TI Effects of high-dose chemotherapy on bone marrow multipotent mesenchymal
   stromal cells isolated from lymphoma patients
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Article
ID HEMATOPOIETIC STEM-CELLS; THERAPY POSITION STATEMENT; ACUTE MYELOGENOUS
   LEUKEMIA; ONCOHEMATOLOGICAL DISEASES; PROLIFERATION KINETICS;
   INTERNATIONAL-SOCIETY; FUNCTIONAL-PROPERTIES; PROGENITOR CELLS;
   GENE-EXPRESSION; CANCER PATIENTS
AB Objective. High-dose chemotherapy (HDCT) followed by autologous stem cell transplantation is a widely applied treatment for hematological and autoimmune diseases. Little is known about the effects of this therapy on multipotent mesenchymal stromal cells (MSCs). We aimed to characterize, morphologically and functionally, MSCs isolated from bone marrow aspirates of patients after HDCT.
   Materials and Methods. We studied 12 consecutive lymphoma patients submitted to BEAM conditioning regimen followed by autologous stem cell transplantation 28 to 1836 days before the sample collection. Thirteen normal donors were used as control. MSCs were isolated by adherence to plastic and expanded ex vivo by culture in flasks containing a minimum essential medium plus 15% fetal bovine serum.
   Results. The cell population isolated showed a typical MSC morphology, immunophenotype, and differentiation capacity into adipogenic, osteogenic, and chondrogenic lineages. The MSCs obtained from patients with Hodgkin's disease and non-Hodgkin's lymphoma showed decreased fibroblastoid colony-forming unit count (p = 0.023) and increased doubling time (p = 0.031) related to the control group. The total cell expansion of MSCs from normal subjects was marginally superior to the patient group (p = 0.064). There were no differences in gene expression profile, MSCs plasticity, or hematopoiesis support capability between control and patient group.
   Conclusions. Results suggest that HDCT applied to lymphoma patients damaged MSCs, which was demonstrated by their reduced clonogenic potential, doubling time, and cell expansion rates when compared to controls. (C) 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.
C1 [Prata, Karen de Lima; Neder, Luciano; Covas, Dimas Tadeu] USP, Fac Med, BR-14051140 Ribeirao Preto, SP, Brazil.
   [Prata, Karen de Lima; Orellana, Maristela Delgado; De Santis, Gil Cunha; Kashima, Simone; Fontes, Aparecida Maria; Viu Carrara, Rita de Cassia; Bonini Palma, Patricia Vianna; Covas, Dimas Tadeu] Ctr Cell Therapy & Reg Blood Ctr, Natl Inst Sci & Technol Stem Cell & Cell Therapy, Ribeirao Preto, Brazil.
RP Covas, DT (corresponding author), USP, FMRP, Ctr Reg Hemoterapia, Rua Tenente Catao Roxo 2501, BR-14051140 Ribeirao Preto, SP, Brazil.
EM dimas@fmrp.usp.br
RI Covas, Dimas T/C-5431-2013; Orellana, Maristela/L-5542-2014; Prata,
   Karen/I-4568-2013; Fontes, Aparecida Maria/ABF-2892-2020; Fontes,
   Aparecida M/F-5627-2013; Kashima, Simone/G-4876-2012
OI Covas, Dimas T/0000-0002-7364-2595; Orellana,
   Maristela/0000-0003-0159-4472; Fontes, Aparecida
   Maria/0000-0002-4878-417X; Fontes, Aparecida M/0000-0002-4878-417X;
   Kashima, Simone/0000-0002-1487-0141
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) (Sao
   Paulo, SP, Brazil)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq) (Brasilia, DF, Brazil)National Council for Scientific and
   Technological Development (CNPq); Financiadora de Estudos e Projetos
   (FINEP) (Rio de Janeiro, RJ, Brazil)Ciencia Tecnologia e Inovacao
   (FINEP)
FX The authors would like to thank Abel Dorigan Neto, Ana Flavia Gembre,
   Ana Maria A. Dorigan, Ane Rose L. da Silva, Fabiana R. de Morais,
   Fernanda U.F. Melo, Karina R. Solano, Luciene Medeiros, Luiz Alberto M.
   de Andrade, and Valeria M. Motta for the laboratory assistance, Antonio
   D. Campos, M.D., Ph.D. and his assistant Sidney Porcincula for helping
   with the statistical analysis, Prof. Dr. Ademilson E. S. Egea and his
   assistant Jairo de Souza for helping with cell irradiation and
   Alessandra Almeida for the language review. The authors are also
   grateful to the patients and to Luciana C.O. de Oliveira, M.D., M.S.
   responsible for the ambulatory where patients are assisted. This work
   was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) (Sao Paulo, SP, Brazil), Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq) (Brasilia, DF, Brazil), and Financiadora
   de Estudos e Projetos (FINEP) (Rio de Janeiro, RJ, Brazil).
CR Arthur A, 2009, J CELL PHYSIOL, V218, P237, DOI 10.1002/jcp.21592
   Banfi A, 2000, EXP HEMATOL, V28, P707, DOI 10.1016/S0301-472X(00)00160-0
   Banfi A, 2001, LEUKEMIA LYMPHOMA, V42, P863, DOI 10.3109/10428190109097705
   Cao J, 2008, CANCER LETT, V263, P197, DOI 10.1016/j.canlet.2008.01.011
   CarloStella C, 1997, BONE MARROW TRANSPL, V20, P465, DOI 10.1038/sj.bmt.1700916
   Carrara RCV, 2007, BRAZ J MED BIOL RES, V40, P57, DOI 10.1590/S0100-879X2006005000055
   Conget PA, 1999, J CELL PHYSIOL, V181, P67, DOI 10.1002/(SICI)1097-4652(199910)181:1<67::AID-JCP7>3.3.CO;2-3
   Covas DT, 2008, EXP HEMATOL, V36, P642, DOI 10.1016/j.exphem.2007.12.015
   Covas DT, 2003, BRAZ J MED BIOL RES, V36, P1179, DOI 10.1590/S0100-879X2003000900006
   Dazzi F, 2006, BLOOD REV, V20, P161, DOI 10.1016/j.blre.2005.11.002
   Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301-472X(00)00482-3
   Domenech J, 1998, LEUKEMIA LYMPHOMA, V29, P533, DOI 10.3109/10428199809050913
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Fouillard L, 2007, LEUKEMIA, V21, P568, DOI 10.1038/sj.leu.2404550
   Fouillard L, 2003, LEUKEMIA, V17, P474, DOI 10.1038/sj.leu.2402786
   Galotto M, 1999, EXP HEMATOL, V27, P1460, DOI 10.1016/S0301-472X(99)00076-4
   Gutierrez-Rodriguez M, 2000, STEM CELLS, V18, P46, DOI 10.1634/stemcells.18-1-46
   Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Isaikina Y., 2006, Experimental Oncology, V28, P146
   Isaikina Ya., 2008, Experimental Oncology, V30, P121
   Javazon EH, 2004, EXP HEMATOL, V32, P414, DOI 10.1016/j.exphem.2004.02.004
   Koc ON, 2002, BONE MARROW TRANSPL, V30, P215, DOI 10.1038/sj.bmt.1703650
   Koc ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307
   Lazarus HM, 2005, BIOL BLOOD MARROW TR, V11, P389, DOI 10.1016/j.bbmt.2005.02.001
   Le Blanc K, 2007, LEUKEMIA, V21, P1733, DOI 10.1038/sj.leu.2404777
   LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140-6736(08)60690-X
   Lee ST, 2002, BRIT J HAEMATOL, V118, P1128, DOI 10.1046/j.1365-2141.2002.03767.x
   Meirelles LD, 2008, STEM CELLS, V26, P2287, DOI 10.1634/stemcells.2007-1122
   Minguell JJ, 2001, EXP BIOL MED, V226, P507
   Mueller LP, 2006, STEM CELLS, V24, P2753, DOI 10.1634/stemcells.2006-0108
   Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Ringden O, 2007, LEUKEMIA, V21, P2271, DOI 10.1038/sj.leu.2404833
   Schwartz GN, 1998, BONE MARROW TRANSPL, V22, P457, DOI 10.1038/sj.bmt.1701364
   Short B, 2003, ARCH MED RES, V34, P565, DOI 10.1016/j.arcmed.2003.09.007
   Silva WA, 2003, STEM CELLS, V21, P661, DOI 10.1634/stemcells.21-6-661
   Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005
   Stute N, 2004, EXP HEMATOL, V32, P1212, DOI 10.1016/j.exphem.2004.09.003
   Tondreau T, 2004, CYTOTHERAPY, V6, P372, DOI 10.1080/14653240410004943
   Wexler SA, 2003, BRIT J HAEMATOL, V121, P368, DOI 10.1046/j.1365-2141.2003.04284.x
NR 41
TC 23
Z9 23
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0301-472X
J9 EXP HEMATOL
JI Exp. Hematol.
PD APR
PY 2010
VL 38
IS 4
BP 292
EP 300
DI 10.1016/j.exphem.2010.01.006
PG 9
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA 575GF
UT WOS:000276054300004
PM 20138957
DA 2020-11-26
ER

PT J
AU Victoria, MB
   Victoria, FD
   Torres, KL
   Kashima, S
   Covas, DT
   Malheiro, A
AF Victoria, Marilu Barbieri
   Victoria, Flamir da Silva
   Torres, Katia Luz
   Kashima, Simone
   Covas, Dimas Tadeu
   Malheiro, Adriana
TI Epidemiology of HIV/HCV coinfection in patients cared for at the
   Tropical Medicine Foundation of Amazonas
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE coinfection; hepatitis C; HIV; epidemiology; transmission
ID HEPATITIS-C VIRUS; NATURAL-HISTORY; LIVER-DISEASE; HIV-INFECTION;
   RISK-FACTORS; MANAGEMENT; IMPACT; HCV
AB The association of HIV infection and hepatitis C virus (HCV) infection often occurs because both viruses share the same transmission routes, increasing the possibility of HIV/HCV coinfection. World prevalence greater than 30% of coinfected cases is estimated, and it can reach 90% depending on the transmission route. With the aim of determining the frequency and profile of HIV/HCV coinfected patients, a descriptive analysis was carried out with patients with HIV/AIDS whose serology was positive for hepatitis C virus (HCV), cared for at the Fundacao de Medicina Tropical do Amazonas from 2000 to 2007. In the present study, of the 2,653 AIDS cases notified in SINAN, 1,582 patients underwent serology test for hepatitis C, and a frequency of 4.42% (n = 70) of HIV/HCV coinfected patients was identified in the period studied. The most frequent infection route was sexual transmission (84.3%), 68.6% among heterosexual individuals. Most patients were males (72.9%), aged between 25 and 40 years (60.1%), of low income (50% earning up to one minimum wage), and low educational level (80% had completed only middle school). A high percentage of deaths were observed during the study (34.3%). The results indicate a low seroprevalence of HIV/HCV coinfection in this population, in which sexual transmission, characterized by sexual promiscuity among heterosexual individuals, is the major transmission route of the virus rather than the use of injection drugs, as shown in world statistics.
C1 [Malheiro, Adriana] Univ Fed Amazonas, Manaus, Amazonas, Brazil.
   [Kashima, Simone; Covas, Dimas Tadeu] Univ Sao Paulo, HCFMRP, Ctr Reg Hematol, Fundacao Hemoctr Ribeirao Preto, Sao Paulo, Brazil.
RP Victoria, MB (corresponding author), Rua Rio Javari 200-400, BR-69053110 Manaus, Amazonas, Brazil.
EM mariluvictoria@vivax.com.br
RI Kashima, Simone/G-4876-2012; Covas, Dimas T/C-5431-2013
OI Kashima, Simone/0000-0002-1487-0141; Covas, Dimas T/0000-0002-7364-2595
CR AGUIAR JI, 2005, REV PANAMERICANA INF, V7, P29
   Alter MJ, 2006, J HEPATOL, V44, pS6, DOI 10.1016/j.jhep.2005.11.004
   Amaral ISA, 2007, REV PARA MED, V21, P15
   *BRASIL MIN SAUD, 2008, B EPID
   *BRASIL MIN SAUD, 2007, B EP AIDS AM
   Brito A M, 2001, Rev Soc Bras Med Trop, V34, P207, DOI 10.1590/S0037-86822001000200010
   Busch M. P., 2000, Transfusion (Bethesda), V40, P143
   CARVALHO FHP, 2006, REV MED, V20, P11
   CHAMOT E, 1990, AIDS, V4, P1275, DOI 10.1097/00002030-199012000-00016
   Cheng DM, 2007, ALCOHOL CLIN EXP RES, V31, P829, DOI 10.1111/j.1530-0277.2007.00381.x
   CORVINO SM, 2007, REV BRAS EPIDEMIOL, V10
   *GOV EST AM, 2007, B EPID AIDS AM
   *IBGE, CENS DEM 2008
   Lakshmi V, 2007, Indian J Med Microbiol, V25, P140
   Larsen C, 2008, EUROSURVEILLANCE, V13, P109
   LUIZ RR, 2001, B EPIDEMIOLOGICO AID, V14
   Mast EE, 2005, J INFECT DIS, V192, P1880, DOI 10.1086/497701
   Silva ACM, 2006, REV SAUDE PUBL, V40, P482, DOI 10.1590/S0034-89102006000300017
   Mendoza RJ, 2001, NEUROREHAB NEURAL RE, V15, P9, DOI 10.1177/154596830101500102
   Mohsen AH, 2002, GUT, V51, P601, DOI 10.1136/gut.51.4.601
   Monteiro Maria Rita de Cassia Costa, 2004, Rev. Soc. Bras. Med. Trop., V37, P40, DOI 10.1590/S0037-86822004000700006
   Monto A, 2008, J ADDICT DIS, V27, P49, DOI 10.1300/J069v27n02_06
   Pol S, 2008, CLIN INFECT DIS, V47, P94, DOI 10.1086/588669
   de Carvalho FHP, 2009, REV SAUDE PUBL, V43, P133, DOI 10.1590/S0034-89102009000100017
   Pottes Fábia Alexandra, 2007, Rev. bras. epidemiol., V10, P338, DOI 10.1590/S1415-790X2007000300005
   Rodriguez-Rosado R, 1998, AIDS, V12, P1256, DOI 10.1097/00002030-199810000-00025
   *SBI, 2006, B AT SOC BRAS INF HE
   *SBI, 2008, I CONS SOC BRAS INF, P35
   Soriano V, 2004, J VIRAL HEPATITIS, V11, P2, DOI 10.1046/j.1365-2893.2003.00491.x
   Soriano V, 1999, EUR J EPIDEMIOL, V15, P1, DOI 10.1023/A:1007506617734
   SZWARCWALD CL, 2000, CAD SAUDE PUBLICA S1, V16, pS7
   Thomas DL, 2000, JAMA-J AM MED ASSOC, V284, P450, DOI 10.1001/jama.284.4.450
   Tovo Cristiane Valle, 2007, Arq. Gastroenterol., V44, P113, DOI 10.1590/S0004-28032007000200005
   van de Laar TJW, 2007, J INFECT DIS, V196, P230, DOI 10.1086/518796
   Varella Rafael Brandão, 2006, Rev. bras. epidemiol., V9, P447, DOI 10.1590/S1415-790X2006000400005
NR 35
TC 11
Z9 12
U1 0
U2 0
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD MAR-APR
PY 2010
VL 14
IS 2
BP 135
EP 140
DI 10.1590/S1413-86702010000200004
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 613DY
UT WOS:000278959300004
PM 20563438
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Costa, GCS
   Alcantara, LCJ
   Azevedo, R
   Muricy, G
   Kashima, SH
   Covas, DT
   Galvao-Castro, B
   Gadelha, SR
AF Costa, G. C. S.
   Alcantara, L. C. J.
   Azevedo, R.
   Muricy, G.
   Kashima, S. H.
   Covas, D. T.
   Galvao-Castro, B.
   Gadelha, S. R.
TI Frequency distribution of XbaIG > T and HaeIIIT > C GLUT1 polymorphisms
   among different Brazilian ethnic groups
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE GLUT1; Polymorphisms; Brazilian populations
ID DEPENDENT DIABETES-MELLITUS; NEPHROPATHY; SUSCEPTIBILITY; GENE;
   POPULATIONS; INTERLEUKIN-6
AB GLUT is the major glucose transporter in mammalian cells. Single nucleotide polymorphisms (SNP) at GLUT1 promoter and regulatory regions have been associated to the risk of developing nephropathy in different type 1 and type 2 diabetic populations. It has been demonstrated that differences in allelic and genotypic frequencies of GLUT1 gene (SLC2A1) polymorphisms occur among different populations. Therefore, ethnic differences in distribution of GLUT1 gene polymorphisms may be an important factor in determining gene-disease association. In this study, we investigated the XbaIG > T and HaeIIIT > C polymorphisms in six different Brazilian populations: 102 individuals from Salvador population (Northern Brazil), 56 European descendants from Joinville (South Brazil), 85 Indians from Tiryi tribe (North Brazil) and 127 samples from Southern Brazil: 44 from European descendants, 42 from African descendants and 41 from Japanese descendants. Genotype frequencies from both sites did not differ significantly from those expected under the Hardy-Weinberg equilibrium. We verified that the allele frequencies of both polymorphisms were heterogeneous in these six Brazilian ethnic groups.
C1 [Gadelha, S. R.] Univ Estadual Santa Cruz, BR-45650000 Ilheus, BA, Brazil.
   [Costa, G. C. S.; Alcantara, L. C. J.; Muricy, G.; Galvao-Castro, B.; Gadelha, S. R.] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Lab Avancado Saude Publ, Salvador, BA, Brazil.
   [Alcantara, L. C. J.; Muricy, G.; Galvao-Castro, B.; Gadelha, S. R.] Escola Bahiana Med & Saude Publ, Salvador, BA, Brazil.
   [Azevedo, R.; Kashima, S. H.; Covas, D. T.] Univ Sao Paulo, Fac Med Ribeirao Preto, Banco Sangue Reg Ribeirao Preto, Mol Biol Lab, Sao Paulo, Brazil.
RP Gadelha, SR (corresponding author), Univ Estadual Santa Cruz, Campus Prof Soane Nazare de Andrade,Km 16 Rodovia, BR-45650000 Ilheus, BA, Brazil.
EM srgmello@uesc.br
RI Kashima, Simone/G-4876-2012; Covas, Dimas T/C-5431-2013; Gadelha,
   Sandra/X-3373-2019
OI Kashima, Simone/0000-0002-1487-0141; Covas, Dimas T/0000-0002-7364-2595;
   Gadelha, Sandra/0000-0002-3079-488X; Alcantara, Luiz/0000-0002-6769-9931
FU Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB)
FX This work was partially supported by the Fundacao de Amparo a Pesquisa
   do Estado da Bahia (FAPESB). We thank Mauricio Barreto, Gloria Teixeira,
   Ozenilda Carvalho and Ivo Brito for providing the samples from Salvador
   general population, Joinville and Tiryio, respectively.
CR ABESANDES K, 2002, THESIS USP RIBEIRAO
   Alves-Silva J, 2000, AM J HUM GENET, V67, P444, DOI 10.1086/303004
   AZEVEDO ES, 1982, HUM BIOL, V54, P329
   Brosius FC, 2005, PEDIATR NEPHROL, V20, P447, DOI 10.1007/s00467-004-1748-x
   Callegari-Jacques Sidia M., 1999, Ciencia e Cultura (Sao Paulo), V51, P166
   Cox ED, 2001, TRANSPLANTATION, V72, P720, DOI 10.1097/00007890-200108270-00027
   Dornelles CL, 1999, GENET MOL BIOL, V22, P151, DOI 10.1590/S1415-47571999000200003
   Gadelha SR, 2005, HUM BIOL, V77, P509, DOI 10.1353/hub.2005.0061
   Grimaldi R, 2002, HUM GENET, V111, P102, DOI 10.1007/s00439-002-0747-x
   Grzeszczak W, 2001, KIDNEY INT, V59, P631, DOI 10.1046/j.1523-1755.2001.059002631.x
   Gutierrez C, 1998, DIABETES RES CLIN PR, V41, P113, DOI 10.1016/S0168-8227(98)00050-3
   Hodgkinson AD, 2005, J DIABETES COMPLICAT, V19, P65, DOI 10.1016/j.jdiacomp.2004.07.002
   Liu Z, 1998, Zhonghua Yi Xue Za Zhi, V78, P662
   Liu ZH, 1999, KIDNEY INT, V55, P1843, DOI 10.1046/j.1523-1755.1999.00449.x
   Makni K, 2008, ANN HUM BIOL, V35, P490, DOI 10.1080/03014460802247142
   Meenagh A, 2002, HUM IMMUNOL, V63, P1055, DOI 10.1016/S0198-8859(02)00440-8
   Ng DPK, 2002, DIABETES, V51, P2264, DOI 10.2337/diabetes.51.7.2264
   PANASCI LC, 1997, ANAL BIOCHEM, V83, P677
   Pontiroli AE, 1996, ACTA DIABETOL, V33, P193
   RAYMOND M, 1995, J HERED, V86, P248, DOI 10.1093/oxfordjournals.jhered.a111573
   SALZANO FM, 1967, POPULACOES BRASILEIR, P32
   Shindo N, 2002, AIDS RES HUM RETROV, V18, P71, DOI 10.1089/088922202753394736
   TAO T, 1995, DIABETOLOGIA, V38, P942, DOI 10.1007/BF00400583
   Teixeira Maria da Glória, 2002, Cad. Saúde Pública, V18, P1189, DOI 10.1590/S0102-311X2002000500011
NR 24
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD JAN
PY 2010
VL 37
IS 1
BP 75
EP 79
DI 10.1007/s11033-009-9528-0
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 540GI
UT WOS:000273319000012
PM 19347605
OA Green Published
DA 2020-11-26
ER

PT J
AU Nicolete, LDF
   Zanette, DL
   Covas, DT
   Silva, IT
   Takayanagui, OM
   Azevedo, R
   Kashima, S
   Malta, TM
AF Nicolete, L. D. F.
   Zanette, D. L.
   Covas, D. T.
   Silva, I. T.
   Takayanagui, O. M.
   Azevedo, R.
   Kashima, S.
   Malta, T. M.
TI Deregulation of HSA-MIR-125B in Human T-Cell Lymphotropic Virus Type 1
   Infection
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT 14th International Conference on Human Retrovirology HTLV and Related
   Retroviruses
CY JUL 01-04, 2009
CL Salvador, BRAZIL
C1 Fac Ciencias Farmaceut Ribeirao Preto, Ribeirao Preto, Brazil.
   Fundacao Hemoctr Ribeirao Preto, Ribeirao Preto, Brazil.
RI Silva, Israel T/N-3858-2014; Kashima, Simone/G-4876-2012; Covas, Dimas
   T/C-5431-2013; Takayanagui, Osvaldo M/C-8159-2013; ZANETTE,
   DALILA/Q-3541-2016
OI Silva, Israel T/0000-0002-4687-1499; Kashima,
   Simone/0000-0002-1487-0141; Covas, Dimas T/0000-0002-7364-2595;
   Takayanagui, Osvaldo M/0000-0002-8190-0275; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV
PY 2009
VL 25
IS 11
BP 1206
EP +
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 524ZF
UT WOS:000272182200041
DA 2020-11-26
ER

PT J
AU Rego, FFA
   Azevedo, R
   Mota-Miranda, AC
   Carvalho, VJU
   Kusterer, LEFL
   Kashima, S
   Galvao-Castro, B
   Alcantara, LCJ
AF Rego, F. F. A.
   Azevedo, R.
   Mota-Miranda, A. C.
   Carvalho, V. J. U.
   Kusterer, L. E. F. L.
   Kashima, S.
   Galvao-Castro, B.
   Alcantara, L. C. J.
TI Analysis of the HTLV-1 Intra-Host Variations in Peripheral Blood and
   Saliva of Infected Individuals
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT 14th International Conference on Human Retrovirology HTLV and Related
   Retroviruses
CY JUL 01-04, 2009
CL Salvador, BRAZIL
C1 [Rego, F. F. A.; Mota-Miranda, A. C.; Carvalho, V. J. U.; Kusterer, L. E. F. L.; Galvao-Castro, B.; Alcantara, L. C. J.] Bahia Fdn Dev Sci, Bahia Sch Med & Publ Hlth, Salvador, BA, Brazil.
   [Rego, F. F. A.; Mota-Miranda, A. C.; Galvao-Castro, B.; Alcantara, L. C. J.] Fundacao Oswaldo Cruz, Goncalo Moniz Res Ctr, Adv Publ Hlth Lab, Salvador, BA, Brazil.
   [Azevedo, R.; Kashima, S.] Univ Sao Paulo, Reg Blood Ctr Ribeirao Preto, BR-05508 Sao Paulo, Brazil.
RI Kashima, Simone/G-4876-2012
OI Kashima, Simone/0000-0002-1487-0141
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV
PY 2009
VL 25
IS 11
BP 1244
EP 1244
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 524ZF
UT WOS:000272182200129
DA 2020-11-26
ER

PT J
AU Pinto, MT
   Covas, DT
   Nicolete, LDF
   Takayanagui, OM
   Azevedo, R
   Panepucci, RA
   Kashima, S
   Malta, TM
AF Pinto, M. T.
   Covas, D. T.
   Nicolete, L. D. F.
   Takayanagui, O. M.
   Azevedo, R.
   Panepucci, R. A.
   Kashima, S.
   Malta, T. M.
TI Microarrays Analysis of Gene Expression in CD4+T Cells Isolated from
   HTLV-1 Infected Individuals
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT 14th International Conference on Human Retrovirology HTLV and Related
   Retroviruses
CY JUL 01-04, 2009
CL Salvador, BRAZIL
DE HTLV-1; CD4(+) T cells; gene expression; microarrays; HAM/TSP
C1 Hemoctr Ribeira Preto, Ribeirao Preto, Brazil.
   Fac Ciencias Farmaceut Ribeirao Preto, Ribeirao Preto, Brazil.
RI Kashima, Simone/G-4876-2012; Panepucci, Rodrigo A/C-2365-2012; Covas,
   Dimas T/C-5431-2013; Takayanagui, Osvaldo M/C-8159-2013
OI Kashima, Simone/0000-0002-1487-0141; Panepucci, Rodrigo
   A/0000-0002-1119-4352; Covas, Dimas T/0000-0002-7364-2595; Takayanagui,
   Osvaldo M/0000-0002-8190-0275
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV
PY 2009
VL 25
IS 11
BP 1265
EP 1265
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 524ZF
UT WOS:000272182200181
DA 2020-11-26
ER

PT J
AU Malta, TM
   Santos, ARD
   Pinheiro, DG
   Covas, DT
   Silva, IT
   Nicolete, LDF
   Takayanagui, OM
   Azevedo, R
   Panepucci, RA
   Kashima, S
AF Malta, T. M.
   Santos, A. R. D.
   Pinheiro, D. G.
   Covas, D. T.
   Silva, I. T.
   Nicolete, L. D. F.
   Takayanagui, O. M.
   Azevedo, R.
   Panepucci, R. A.
   Kashima, S.
TI Identification of Activated Genes in CD8+T Cells Isolated from HTLV-1
   Infected Individuals
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT 14th International Conference on Human Retrovirology HTLV and Related
   Retroviruses
CY JUL 01-04, 2009
CL Salvador, BRAZIL
DE HTLV-1; SAGE; CD8 T cells
C1 USP, Fac Ciencias Farmaceut Ribeirao Preto, Ribeirao Preto, Brazil.
   BRA, Hemoctr Ribeirao Preto, Ribeirao Preto, Brazil.
RI Silva, Israel T/N-3858-2014; Pinheiro, Daniel/H-4604-2012; Takayanagui,
   Osvaldo M/C-8159-2013; Kashima, Simone/G-4876-2012; Covas, Dimas
   T/C-5431-2013; Panepucci, Rodrigo A/C-2365-2012
OI Silva, Israel T/0000-0002-4687-1499; Pinheiro,
   Daniel/0000-0001-7062-5936; Takayanagui, Osvaldo M/0000-0002-8190-0275;
   Kashima, Simone/0000-0002-1487-0141; Covas, Dimas T/0000-0002-7364-2595;
   Panepucci, Rodrigo A/0000-0002-1119-4352
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV
PY 2009
VL 25
IS 11
BP 1269
EP 1269
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 524ZF
UT WOS:000272182200189
DA 2020-11-26
ER

PT J
AU Haddad, R
   Rodrigues, ES
   Azevedo, R
   Takayanagui, OM
   Fontes, AM
   Palma, PVB
   Kashima, S
   Covas, DT
   Zago, MA
AF Haddad, R.
   Rodrigues, E. S.
   Azevedo, R.
   Takayanagui, O. M.
   Fontes, A. M.
   Palma, P. V. B.
   Kashima, S.
   Covas, D. T.
   Zago, M. A.
TI Inhibition of GAG and ENV Proteins Expression of HTLV-1 by shRNAs in
   HEK-293 Cells
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT 14th International Conference on Human Retrovirology HTLV and Related
   Retroviruses
CY JUL 01-04, 2009
CL Salvador, BRAZIL
C1 [Haddad, R.; Rodrigues, E. S.; Azevedo, R.; Fontes, A. M.; Palma, P. V. B.; Kashima, S.; Covas, D. T.; Zago, M. A.] Hemoctr Ribeirao Preto, Ribeirao Preto, Brazil.
   [Haddad, R.; Takayanagui, O. M.; Fontes, A. M.; Kashima, S.; Covas, D. T.; Zago, M. A.] Univ Sao Paulo, Fac Med Ribeirao Preto, BR-05508 Sao Paulo, Brazil.
   [Kashima, S.] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, BR-09500900 Sao Paulo, Brazil.
RI Kashima, Simone/G-4876-2012; Haddad, Rodrigo/A-3460-2013; Covas, Dimas
   T/C-5431-2013; ZAGO, MARCO A/E-9442-2017; Takayanagui, Osvaldo
   M/C-8159-2013; Fontes, Aparecida M/F-5627-2013; Rodrigues,
   Evandra/L-6094-2017; Fontes, Aparecida Maria/ABF-2892-2020
OI Kashima, Simone/0000-0002-1487-0141; Haddad,
   Rodrigo/0000-0003-4699-164X; Covas, Dimas T/0000-0002-7364-2595;
   Takayanagui, Osvaldo M/0000-0002-8190-0275; Fontes, Aparecida
   M/0000-0002-4878-417X; Rodrigues, Evandra/0000-0003-0964-9554; Fontes,
   Aparecida Maria/0000-0002-4878-417X
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV
PY 2009
VL 25
IS 11
BP 1273
EP 1274
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 524ZF
UT WOS:000272182200201
DA 2020-11-26
ER

PT J
AU Rodrigues, ES
   Kashima, S
   Malta, TM
   Nicolete, LDF
   Garcia, FB
   Da Silva, IT
   Takayanagui, OM
   Covas, DT
AF Rodrigues, E. S.
   Kashima, S.
   Malta, T. M.
   Nicolete, L. D. F.
   Garcia, F. B.
   Da Silva, I. T.
   Takayanagui, O. M.
   Covas, D. T.
TI Perforin and Granzyme B Gene Variations and Their Association with the
   Progression of the Disease in HTLV-1 Infected Individuals
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT 14th International Conference on Human Retrovirology HTLV and Related
   Retroviruses
CY JUL 01-04, 2009
CL Salvador, BRAZIL
DE Perforin; Granzyme B; genetic polymorphism; HTLV-1
C1 [Rodrigues, E. S.; Kashima, S.; Malta, T. M.; Nicolete, L. D. F.; Garcia, F. B.; Da Silva, I. T.; Covas, D. T.] Univ Sao Paulo, Reg Blood Ctr Ribeirao Preto, BR-05508 Sao Paulo, Brazil.
   [Takayanagui, O. M.; Covas, D. T.] Univ Sao Paulo, Fac Med Ribeirao Preto, BR-05508 Sao Paulo, Brazil.
   [Kashima, S.; Malta, T. M.; Nicolete, L. D. F.] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, BR-05508 Sao Paulo, Brazil.
RI Covas, Dimas T/C-5431-2013; Takayanagui, Osvaldo M/C-8159-2013; Kashima,
   Simone/G-4876-2012; Rodrigues, Evandra/L-6094-2017
OI Covas, Dimas T/0000-0002-7364-2595; Takayanagui, Osvaldo
   M/0000-0002-8190-0275; Kashima, Simone/0000-0002-1487-0141; Rodrigues,
   Evandra/0000-0003-0964-9554
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV
PY 2009
VL 25
IS 11
BP 1277
EP 1277
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 524ZF
UT WOS:000272182200209
DA 2020-11-26
ER

PT J
AU de Andrade, AV
   de Almeida, D
   Fontes, A
   Orellana, M
   Kashima, S
   Magalhaes, DA
   Caruso, S
   Palma, PV
   de Oliveira, F
   Farias, KCR
   da Meirelles, L
   Covas, D
AF de Andrade, Ana Valeria
   de Almeida, Danilo
   Fontes, Aparecida
   Orellana, Maristela
   Kashima, Simone
   Magalhaes, Danielle Aparecida
   Caruso, Samia
   Palma, Patricia Vianna
   de Oliveira, Fabio
   Ribeiro Farias, Kelen Cristina
   da Meirelles, Lindolfo
   Covas, Dimas
TI Umbilical cord vein-derived mesenchymal stem cells: a potential
   alternative to bone marrow-derived mesenchymal stem cells
SO HUMAN GENE THERAPY
LA English
DT Meeting Abstract
CT Combined Meeting of the 17th
   European-Society-of-Gene-and-Cell-Therapy/16th
   German-Society-for-Gene-Therapy/4th
   German-Society-for-Stem-Cell-Research
CY NOV 21-25, 2009
CL Hannover, GERMANY
SP Int Soc Cellular Therapy, European Branch, European Soc Gene & Cell Therapy, German Soc Gene Therapy, German Soc Stem Cell Res, BD Biosci, Biotech GmbH, Genethon, Cellectis, EUFETS, Lonza, Oxford BioMedica, Peprotech, Plasmidfactory, Regenx Biosci, Rentschler, Sartorius Stedim, StemCell Technologies
C1 [de Andrade, Ana Valeria; de Almeida, Danilo; Covas, Dimas] Fac Med Ribeirao Preto, Ribeirao Preto, Brazil.
   [Fontes, Aparecida; Orellana, Maristela; Kashima, Simone; Magalhaes, Danielle Aparecida; Caruso, Samia; Palma, Patricia Vianna; de Oliveira, Fabio; Ribeiro Farias, Kelen Cristina; da Meirelles, Lindolfo] Reg Bloodctr Ribeirao Preto, Ribeirao Preto, Brazil.
EM anavaleria@usp.br
RI Malmegrim, Kelen/B-8514-2012; Fontes, Aparecida Maria/ABF-2892-2020;
   Kashima, Simone/G-4876-2012; Fontes, Aparecida M/F-5627-2013; Covas,
   Dimas T/C-5431-2013; Orellana, Maristela/L-5542-2014; Malmegrim,
   Kelen/H-1016-2015
OI Fontes, Aparecida Maria/0000-0002-4878-417X; Kashima,
   Simone/0000-0002-1487-0141; Fontes, Aparecida M/0000-0002-4878-417X;
   Covas, Dimas T/0000-0002-7364-2595; Orellana,
   Maristela/0000-0003-0159-4472; Malmegrim, Kelen/0000-0002-9303-0086
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
J9 HUM GENE THER
JI Hum. Gene Ther.
PD NOV
PY 2009
VL 20
IS 11
BP 1487
EP 1487
PG 1
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 515BJ
UT WOS:000271441000393
DA 2020-11-26
ER

PT J
AU Ferreira, AF
   Silva, WA
   Silva, IT
   Azevedo, R
   Tognon, R
   Zanichelli, MA
   Hamerschlak, N
   Amarante-Mendes, GP
   Covas, DT
   Kashima, S
   Souza, AM
   Castro, FA
AF Ferreira, A. F.
   Silva-, W. A., Jr.
   Silva, I. T.
   Azevedo, R.
   Tognon, R.
   Zanichelli, M. A.
   Hamerschlak, N.
   Amarante-Mendes, G. P.
   Covas, D. T.
   Kashima, S.
   Souza, A. M.
   Castro, F. A.
TI BCR-ABL ONCOPROTEIN MODULATES MIRNA INVOLVED IN APOPTOSIS REGULATION
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Ferreira, A. F.] Univ Sao Paulo, BR-14049 Ribeirao Preto, Brazil.
   [Silva-, W. A., Jr.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Genet, Ribeirao Preto, Brazil.
   [Silva, I. T.; Azevedo, R.; Covas, D. T.; Kashima, S.] Univ Sao Paulo, Ctr Reg Hemoterapia Ribeirao Preto HCFMRP, Ribeirao Preto, Brazil.
   [Tognon, R.; Souza, A. M.; Castro, F. A.] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Ribeirao Preto, Brazil.
   [Zanichelli, M. A.] Hosp Brigadeiro, Sao Paulo, Brazil.
   [Hamerschlak, N.] Soc Beneficente Israelita, Sao Paulo, Brazil.
   [Hamerschlak, N.] Brasileira Hosp Albert Einstein, Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Ciencias Biomed, Dept Imunol, BR-09500900 Sao Paulo, Brazil.
RI Hamerschlak, Nelson/M-8060-2015; Kashima, Simone/G-4876-2012; Silva,
   Israel T/N-3858-2014; Mendes, Gustavo P Amarante/C-8187-2012; CASTRO,
   FABIOLA/D-4693-2012; Covas, Dimas T/C-5431-2013; Silva, Wilson
   Araujo/E-9487-2011
OI Hamerschlak, Nelson/0000-0002-5140-5310; Kashima,
   Simone/0000-0002-1487-0141; Silva, Israel T/0000-0002-4687-1499; Mendes,
   Gustavo P Amarante/0000-0002-7851-6205; Covas, Dimas
   T/0000-0002-7364-2595; Silva, Wilson Araujo/0000-0001-9364-2886
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
EI 1592-8721
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
SU 2
MA 0321
BP 126
EP 127
PG 2
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931900323
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Tognon, R
   Gasparotto, EPL
   Ferreira, AF
   Carrara, RCV
   Kashima, S
   Covas, DT
   Santana, M
   Souto, EX
   Zanichelli, MA
   Velano, CEE
   Simoes, BP
   Souza, AM
   Castro, FA
AF Tognon, R.
   Gasparotto, E. P. L.
   Ferreira, A. F.
   Carrara, R. C. V.
   Kashima, S.
   Covas, D. T.
   Santana, M.
   Souto, E. X.
   Zanichelli, M. A.
   Velano, C. E. E.
   Simoes, B. P.
   Souza, A. M.
   Castro, F. A.
TI CIAP-1 AND CIAP-2 ANTI-APOPTOTIC MOLECULES ARE OVEREXPRESSED IN
   ESSENTIAL THROMBOCYTHEMIA AND MYELOFIBROSIS
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Tognon, R.; Gasparotto, E. P. L.; Ferreira, A. F.; Souza, A. M.; Castro, F. A.] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, BR-14049 Ribeirao Preto, Brazil.
   [Carrara, R. C. V.; Kashima, S.; Covas, D. T.] Univ Sao Paulo, Ctr Reg Hemoterapia Ribeirao Preto HCFMRP, Ribeirao Preto, Brazil.
   [Santana, M.; Souto, E. X.; Zanichelli, M. A.] Hosp Brigadeiro, Sao Paulo, Brazil.
   [Velano, C. E. E.; Simoes, B. P.] Univ Sao Paulo, Fac Med Ribeirao Preto, Ribeirao Preto, Brazil.
RI Kashima, Simone/G-4876-2012; Covas, Dimas T/C-5431-2013; CASTRO,
   FABIOLA/D-4693-2012; Simoes, Belinda P/M-7469-2016
OI Kashima, Simone/0000-0002-1487-0141; Covas, Dimas T/0000-0002-7364-2595;
   
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
EI 1592-8721
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
SU 2
MA 0873
BP 351
EP 352
PG 2
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931900872
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Kashima, S
   Rodrigues, ES
   Azevedo, F
   Castelli, ED
   Mendes, CT
   Yoshioka, FKN
   da Silva, IT
   Takayanagui, OM
   Covas, DT
AF Kashima, Simone
   Rodrigues, Evandra Strazza
   Azevedo, FRochele
   Castelli, Erick da Cruz
   Mendes-Junior, Celso Teixeira
   Nascimento Yoshioka, France Keiko
   da Silva, Israel Tojal
   Takayanagui, Osvaldo Massaiti
   Covas, Dimas Tadeu
TI DC-SIGN (CD209) gene promoter polymorphisms in a Brazilian population
   and their association with human T-cell lymphotropic virus type 1
   infection
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID HUMAN DENDRITIC CELLS; TUBERCULOSIS; DISEASE; SUSCEPTIBILITY; LEUKEMIA;
   HTLV-1; RETROVIRUS; ANTIBODIES; VARIANTS; RECEPTOR
AB This study evaluated four polymorphisms located in the DC-SIGN (CD209) gene promoter region (positions -336, -332 -201 and -139) in DNA samples from four Brazilian ethnic groups (Caucasians, Afro-Brazilian, Asians and Amerindians) to establish the population distribution of these single-nucleotide polymorphisms (SNPs) and correlated DC-SIGN polymorphisms and infection in samples from human T-cell lymphotropic virus type 1 (HTLV-1)-infected individuals. To identify CD209 SNPs, 452 bp of the CD209 promoter region were sequenced and the genotype and allelic frequencies were evaluated. This is the first study to show genetic polymorphism in the CD209 gene in distinct Brazilian ethnic groups with the distribution of allelic and genotypic frequency. The results showed that -336A and -139A SNPs were quite common in Asians and that the -201T allele was not observed in Caucasians, Asians or Amerindians. No significant differences were observed between individuals with HTLV-1 disease and asymptomatic patients. However, the -336A variant was more frequent in HTLV-1 -infected patients [HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), 80%; healthy asymptomatic HTLV-1 carriers, 90 %] than in the control group (70 %) [P=0.0197, odds ratio (OR)=2.511, 95 % confidence interval (CI)=1.218-5.179). In addition, the -139A allele was found to be associated with protection against HTLV-1 infection (P=0.0037, OR=0.3758, 95% CI=0.1954-0.7229) when the HTLV-1 -infected patients as a whole were compared with the healthy-control group. These observations suggest that the -139A allele may be associated with HTLV-1 infection, although no significant association was observed among asymptomatic and HAM/TSP patients. In conclusion, the variation observed in SNPs -336 and -139 indicates that this lectin may be of crucial importance in the susceptibility/transmission of HTLV-1 infections.
C1 [Kashima, Simone; Rodrigues, Evandra Strazza; Azevedo, FRochele; Nascimento Yoshioka, France Keiko; da Silva, Israel Tojal; Covas, Dimas Tadeu] Univ Sao Paulo, Reg Blood Ctr Ribeirao Preto, BR-05508 Sao Paulo, Brazil.
   [Kashima, Simone] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, BR-05508 Sao Paulo, Brazil.
   [Castelli, Erick da Cruz] Univ Sao Paulo, Fac Med Ribeirao Preto, Div Clin Immunol, BR-05508 Sao Paulo, Brazil.
   [Mendes-Junior, Celso Teixeira] Univ Sao Paulo, Sch Philosophy Sci & Literature, Dept Chem, BR-05508 Sao Paulo, Brazil.
RP Covas, DT (corresponding author), Univ Sao Paulo, Reg Blood Ctr Ribeirao Preto, BR-05508 Sao Paulo, Brazil.
EM dimas@fmrp.usp.br
RI Silva, Israel T/N-3858-2014; Mendes-Junior, Celso Teixeira/B-1994-2010;
   Takayanagui, Osvaldo M/C-8159-2013; Rodrigues, Evandra/L-6094-2017;
   Castelli, Erick C./B-4250-2010; Covas, Dimas T/C-5431-2013; Kashima,
   Simone/G-4876-2012
OI Silva, Israel T/0000-0002-4687-1499; Mendes-Junior, Celso
   Teixeira/0000-0002-7337-1203; Takayanagui, Osvaldo
   M/0000-0002-8190-0275; Rodrigues, Evandra/0000-0003-0964-9554; Castelli,
   Erick C./0000-0003-2142-7196; Covas, Dimas T/0000-0002-7364-2595;
   Kashima, Simone/0000-0002-1487-0141
FU Center for Cell Therapy (CTC); Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP); Fundacao Haemocentro de Ribeirao Preto (FUNDHERP)
FX We are grateful to the staff and blood donors of the Regional Blood
   Center of Ribeirao Preto and to the patients from the Neurology
   Department of the University Hospital. The authors thank Mrs Adriana
   Aparecida Marques for technical assistance with the sequencing
   reactions. This study was supported by the Center for Cell Therapy
   (CTC), Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) and
   Fundacao Haemocentro de Ribeirao Preto (FUNDHERP).
CR Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Barreiro LB, 2006, PLOS MED, V3, P230, DOI 10.1371/journal.pmed.0030020
   Barreiro LB, 2007, HUM IMMUNOL, V68, P106, DOI 10.1016/j.humimm.2006.10.020
   Barreiro LB, 2006, HUM IMMUNOL, V67, P102, DOI 10.1016/j.humimm.2006.02.028
   Boily-Larouche G, 2007, HUM IMMUNOL, V68, P523, DOI 10.1016/j.humimm.2007.02.002
   Ceccaldi PE, 2006, J VIROL, V80, P4771, DOI 10.1128/JVI.80.10.4771-4780.2006
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   Excoffier L, 1998, AM J HUM GENET, V62, P171, DOI 10.1086/301674
   EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921
   Excoffier L, 2005, EVOL BIOINFORM, V1, P47, DOI 10.1177/117693430500100003
   GESSAIN A, 1985, LANCET, V2, P407
   Gomez LM, 2006, HUM IMMUNOL, V67, P808, DOI 10.1016/j.humimm.2006.07.003
   GUO SW, 1992, BIOMETRICS, V48, P361, DOI 10.2307/2532296
   Halary F, 2002, IMMUNITY, V17, P653, DOI 10.1016/S1074-7613(02)00447-8
   HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476
   Jones KS, 2008, NAT MED, V14, P429, DOI 10.1038/nm1745
   Koizumi Y, 2007, AIDS RES HUM RETROV, V23, P713, DOI 10.1089/aid.2006.0225
   LAGRENADE L, 1990, LANCET, V336, P1345
   Marth GT, 1999, NAT GENET, V23, P452, DOI 10.1038/70570
   Martin MP, 2004, J VIROL, V78, P14053, DOI 10.1128/JVI.78.24.14053-14056.2004
   MOCHIZUKI M, 1992, J INFECT DIS, V166, P943, DOI 10.1093/infdis/166.4.943
   MORGAN OS, 1989, LANCET, V2, P1184
   Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745
   Nunez C, 2006, WORLD J GASTROENTERO, V12, P4397, DOI 10.3748/wjg.v12.i27.4397
   Olesen R, 2007, GENES IMMUN, V8, P456, DOI 10.1038/sj.gene.6364410
   OSAME M, 1986, LANCET, V1, P1031
   Plancoulaine S, 2006, HUM MOL GENET, V15, P3306, DOI 10.1093/hmg/ddl406
   POCIOT F, 1992, EUR J CLIN INVEST, V22, P396, DOI 10.1111/j.1365-2362.1992.tb01480.x
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   Raymond M, 1995, EVOLUTION, V49, P1280, DOI 10.1111/j.1558-5646.1995.tb04456.x
   RAYMOND M, 1995, J HERED, V86, P248, DOI 10.1093/oxfordjournals.jhered.a111573
   Sakuntabhai A, 2005, NAT GENET, V37, P507, DOI 10.1038/ng1550
   Soilleux EJ, 2002, J LEUKOCYTE BIOL, V71, P445
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468
   Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840
   Turner DM, 1997, EUR J IMMUNOGENET, V24, P1, DOI 10.1111/j.1365-2370.1997.tb00001.x
   Vannberg FO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001388
   Wichukchinda N, 2007, AIDS RES HUM RETROV, V23, P686, DOI 10.1089/aid.2006.0212
   YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031
NR 42
TC 18
Z9 19
U1 0
U2 2
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD APR
PY 2009
VL 90
BP 927
EP 934
DI 10.1099/vir.0.008367-0
PN 4
PG 8
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA 429DF
UT WOS:000264900300017
PM 19264667
OA Green Published, Other Gold
DA 2020-11-26
ER

PT J
AU Sorgi, CA
   Secatto, A
   Fontanari, C
   Turato, WM
   Belanger, C
   de Medeiros, AI
   Kashima, S
   Marleau, S
   Covas, DT
   Bozza, PT
   Faccioli, LH
AF Sorgi, Carlos Arterio
   Secatto, Adriana
   Fontanari, Caroline
   Turato, Walter Miguel
   Belanger, Caroline
   de Medeiros, Alexandra Ivo
   Kashima, Simone
   Marleau, Sylvie
   Covas, Dimas Tadeu
   Bozza, Patricia Torres
   Faccioli, Lucia Helena
TI Histoplasma capsulatum Cell Wall beta-Glucan Induces Lipid Body
   Formation through CD18, TLR2, and Dectin-1 Receptors: Correlation with
   Leukotriene B-4 Generation and Role in HIV-1 Infection
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID COLONY-STIMULATING FACTOR; PLATELET-ACTIVATING-FACTOR;
   HUMAN-IMMUNODEFICIENCY-VIRUS; ALVEOLAR MACROPHAGE PHAGOCYTOSIS;
   NECROSIS-FACTOR-ALPHA; IN-VIVO; HOST-DEFENSE; 5-LIPOXYGENASE METABOLISM;
   PULMONARY HISTOPLASMOSIS; INFLAMMATORY RESPONSES
AB Histoplasma capsulatum (Hc) is a facultative, intracellular parasite of worldwide significance. Infection with Hc produces a broad spectrum of diseases and may progress to a life-threatening systemic disease, particularly in individuals with HIV infection. Resolution of histoplasmosis is associated with the activation of cell-mediated immunity, and leukotriene B-4 plays an important role in this event. Lipid bodies (LBs) are increasingly being recognized as multifunctional organelles with roles in inflammation and infection. In this study, we investigated LB formation in histoplasmosis and its putative function in innate immunity. LB formation in leukocytes harvested from Hc-infected C57BL/6 mice peaks on day 2 postinfection and correlates with enhanced generation of lipid mediators, including leukotriene B-4 and PGE(2). Pretreatment of leukocytes with platelet-activating factor and BLT1 receptor antagonists showed that both lipid mediators are involved in cell signaling for LB formation. Alveolar leukocytes cultured with live or dead Hc also presented an increase in LB numbers. The yeast alkali-insoluble fraction 1, which contains mainly beta-glucan isolated from the Hc cell wall, induced a dose- and time-dependent increase in LB numbers, indicating that beta-glucan plays a signaling role in LB formation. In agreement with this hypothesis, beta-glucan-elicited LB formation was inhibited in leukocytes from 5-LO-/-, CD18(low) and TLR2(-/-) mice, as well as in leukocytes pretreated with anti-Dectin-1 Ab. Interestingly, human monocytes from HIV-1-infected patients failed to produce LBs after beta-glucan stimulation. These results demonstrate that Hc induces LB formation, an event correlated with eicosanoid production, and suggest a role for these lipid-enriched organelles in host defense during fungal infection. The Journal of Immunology, 2009, 182: 4025-4035.
C1 [Sorgi, Carlos Arterio; Secatto, Adriana; Fontanari, Caroline; Turato, Walter Miguel; de Medeiros, Alexandra Ivo; Faccioli, Lucia Helena] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Dept Anal Clin Toxicol & Bromatol, Sao Paulo, Brazil.
   [Belanger, Caroline; Marleau, Sylvie] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada.
   [Kashima, Simone] Univ Sao Paulo, Fundacao Hemoctr Ribeirao Preto, Sao Paulo, Brazil.
   [Covas, Dimas Tadeu] Univ Sao Paulo, Dept Clin Med, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
   [Bozza, Patricia Torres] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
RP Faccioli, LH (corresponding author), Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Dept Anal Clin Toxicol & Bromatol, Av Cafe S-N, Sao Paulo, Brazil.
EM faccioli@fcfrp.usp.br
RI Kashima, Simone/G-4876-2012; Lucia, Faccioli/G-8976-2015; Sorgi,
   Carlos/F-6780-2012; Sorgi, Carlos/ABE-4246-2020; Covas, Dimas
   T/C-5431-2013; Sorgi, Carlos Arterio/AAA-6284-2020; Sorgi,
   Carlos/O-2839-2017; Medeiros, Alexandra I. AIM/J-6103-2012
OI Kashima, Simone/0000-0002-1487-0141; Lucia,
   Faccioli/0000-0002-4999-8305; Covas, Dimas T/0000-0002-7364-2595; Sorgi,
   Carlos Arterio/0000-0001-7528-9935; Sorgi, Carlos/0000-0001-7528-9935;
   Medeiros, Alexandra I. AIM/0000-0001-6048-3647; Bozza,
   Patricia/0000-0001-8349-9529
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [02/12856-2]; Conselho Nacional
   de Desenvolvimento Cientifico e TccnologicoNational Council for
   Scientific and Technological Development (CNPq); Fundacao de Apoio
   Ensino; Pesquisa e Assistencia; Faculdade de Medicina de Ribeirao Preto;
   Universidade de Sao Paulo
FX This study was supported by grants front the Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (Grant 02/12856-2), Conselho Nacional de
   Desenvolvimento Cientifico e Tccnologico, and Fundacao de Apoio Ensino,
   Pesquisa e Assistencia, Faculdade de Medicina de Ribeirao Preto,
   Universidade de Sao Paulo.
CR Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593
   Allendoerfer R, 1998, J IMMUNOL, V160, P6072
   Aronoff DM, 2004, J IMMUNOL, V173, P559, DOI 10.4049/jimmunol.173.1.559
   Bandeira-Melo C, 2001, J BIOL CHEM, V276, P22779, DOI 10.1074/jbc.M101436200
   Bartemes KR, 1999, J IMMUNOL, V162, P2982
   Bittencourt VCB, 2006, J BIOL CHEM, V281, P22614, DOI 10.1074/jbc.M511417200
   Bozza PT, 2007, PHARMACOL THERAPEUT, V113, P30, DOI 10.1016/j.pharmthera.2006.06.006
   Bozza PT, 2005, MEM I OSWALDO CRUZ, V100, P113, DOI 10.1590/S0074-02762005000900020
   Bozza PT, 1997, J EXP MED, V186, P909, DOI 10.1084/jem.186.6.909
   Bozza PT, 1996, J EXP MED, V183, P1515, DOI 10.1084/jem.183.4.1515
   Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470
   Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620
   Cano M V, 2001, Semin Respir Infect, V16, P109
   Casotti Janaina Aparecida Schineider, 2006, Braz J Infect Dis, V10, P327, DOI 10.1590/S1413-86702006000500005
   *CDC, 1986, ANN INTERN MED, V105, P234
   Coffey MJ, 1998, J CLIN INVEST, V102, P663, DOI 10.1172/JCI2117
   Coffey MJ, 1996, J IMMUNOL, V157, P393
   Coffey MJ, 1999, BLOOD, V94, P3897, DOI 10.1182/blood.V94.11.3897.423k12_3897_3905
   D'Avila H, 2006, J IMMUNOL, V176, P3087, DOI 10.4049/jimmunol.176.5.3087
   Deepe GS, 1999, J IMMUNOL, V163, P4985
   DEMITSU T, 1989, INT J IMMUNOPHARMACO, V11, P801, DOI 10.1016/0192-0561(89)90134-3
   Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871
   Hahn PY, 2003, J BIOL CHEM, V278, P2043, DOI 10.1074/jbc.M209715200
   HOBER D, 1993, MICROBIOL IMMUNOL, V37, P785, DOI 10.1111/j.1348-0421.1993.tb01706.x
   HORIE S, 1994, J IMMUNOL, V152, P5457
   Kimberg M, 2008, MED MYCOL, V46, P631, DOI 10.1080/13693780802140907
   Lebron F, 2003, J BIOL CHEM, V278, P25001, DOI 10.1074/jbc.M301426200
   Lima RG, 2006, AIDS RES HUM RETROV, V22, P763, DOI 10.1089/aid.2006.22.763
   Mancuso P, 1998, INFECT IMMUN, V66, P5140, DOI 10.1128/IAI.66.11.5140-5146.1998
   Maya-Monteiro CM, 2008, J BIOL CHEM, V283, P2203, DOI 10.1074/jbc.M706706200
   McCann F, 2005, INFECT IMMUN, V73, P6340, DOI 10.1128/IAI.73.10.6340-6349.2005
   Medeiros AI, 2004, INFECT IMMUN, V72, P1637, DOI 10.1128/IAI.72.3.1637-1644.2004
   Medeiros AI, 1999, BRIT J PHARMACOL, V128, P1529, DOI 10.1038/sj.bjp.0702912
   Medeiros AI, 2002, SCAND J IMMUNOL, V56, P392, DOI 10.1046/j.1365-3083.2002.01142.x
   Melo RCN, 2003, TISSUE CELL, V35, P59, DOI 10.1016/S0040-8166(02)00105-2
   Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3
   Newman SL, 1999, TRENDS MICROBIOL, V7, P67, DOI 10.1016/S0966-842X(98)01431-0
   Pacheco P, 2002, J IMMUNOL, V169, P6498, DOI 10.4049/jimmunol.169.11.6498
   Pacheco P, 2007, J IMMUNOL, V179, P8500, DOI 10.4049/jimmunol.179.12.8500
   Peters-Golden M, 2000, AM J RESP CRIT CARE, V161, pS36, DOI 10.1164/ajrccm.161.supplement_1.ltta-8
   PITRAK DL, 1993, J INFECT DIS, V167, P1406, DOI 10.1093/infdis/167.6.1406
   Serezani CH, 2007, AM J RESP CELL MOL, V37, P562, DOI 10.1165/rcmb.2007-0153OC
   Silva AR, 2002, J IMMUNOL, V168, P4112, DOI 10.4049/jimmunol.168.8.4112
   SMITH JG, 1990, J INFECT DIS, V162, P1349, DOI 10.1093/infdis/162.6.1349
   Soberman RJ, 2003, J CLIN INVEST, V111, P1107, DOI 10.1172/JCI200318338
   Vieira-De-Abreu A, 2005, AM J RESP CELL MOL, V33, P254, DOI 10.1165/rcmb.2005-0145OC
   Weller PF, 1999, INT ARCH ALLERGY IMM, V118, P450, DOI 10.1159/000024161
   Wheat J, 1996, Curr Top Med Mycol, V7, P7
   WHEAT LJ, 1990, MEDICINE, V69, P361, DOI 10.1097/00005792-199011000-00004
   WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889
   Yoon J, 2008, J IMMUNOL, V181, P2907, DOI 10.4049/jimmunol.181.4.2907
   ZHOU P, 1995, J IMMUNOL, V155, P785
NR 52
TC 42
Z9 42
U1 0
U2 7
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD APR 1
PY 2009
VL 182
IS 7
BP 4025
EP 4035
DI 10.4049/jimmunol.0801795
PG 11
WC Immunology
SC Immunology
GA 424NY
UT WOS:000264574600015
PM 19299700
OA Bronze
DA 2020-11-26
ER

PT J
AU Costa, GCS
   Azevedo, R
   Gadelha, SR
   Kashima, SH
   Muricy, G
   Olavarria, VN
   Covas, DT
   Takayanagui, OM
   Galvao-Castro, B
   Alcantara, LC
AF Souza Costa, Giselle Calasans
   Azevedo, Rochele
   Gadelha, Sandra Rocha
   Kashima, Simone Haddad
   Muricy, Gabriel
   Olavarria, Viviana Nila
   Covas, Dimas Tadeu
   Takayanagui, Osvaldo Massaiti
   Galvao-Castro, Bernardo
   Junior alcantara, Luiz Carlos
TI Polymorphisms at GLUT1 Gene Are Not Associated With the Development of
   TSP/HAM in Brazilian HTLV-1 Infected Individuals and the Discovery of a
   New Polymorphism at GLUT1 Gene
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE HTLV-1; GLUT1; polymorphisms
ID T-CELL LEUKEMIA; VIRUS TYPE-I; DIABETIC-NEPHROPATHY; ETHNIC-DIFFERENCES;
   PROVIRAL LOAD; SUSCEPTIBILITY; CYTOKINE; RISK; MYELOPATHY; EXPRESSION
AB The development of HTLV-1 associated clinical manifestations, such as TSP/HAM and ATLL, occur in 2-4% of the infected population and it is still unclear why this infection remains asymptomatic in most infected carriers. Recently, it has been demonstrated that HTLV uses the Glucose transporter type 1 (GLUT1) to infect T-CD4(+) lymphocytes and that single nucleotide polymorphisms (SNP) in the GLUT1 gene are associated with diabetic nephropathy in patients with diabetes mellitus in different populations. These polymorphisms could contribute to a higher GLUT1 protein expression on cellular membrane, facilitating the entry of HTLV and its transmission cell by cell. This could result in a higher provirus load and consequently in the development of TSP/HAM. To evaluate the role of GLUT1 gene polymorphisms in the development of TSP/HAM in HTLV-1 infected individuals, the g.22999G > T, g.15339T > C and c.-2841A > T sites were analyzed by PCR/RFLP or sequencing in 244 infected individuals and 102 normal controls. The proviral load of the HTLV-1 infected patients was also analyzed using Real Time Quantitative PCR. Genotypic and allelic frequencies of the three sites did not differ significantly between controls and HTLV-1 infected individuals. There was no difference in genotypic and allelic distributions among patients as to the presence or absence of HTLV-1 associated clinic manifestations. As regards the quantification of the provirus load, we observed a significant reduction in the asymptomatic individuals compared with the oligosymptomatic and TSP/HAM individuals. These results suggest that g.22999G > T, g.15339T > C, and c.-2841A > T SNP do not contribute to HTLV-1 infection nor to the genetic susceptibility of TSP/HAM in Brazilian HTLV-1 infected individuals. J. Med. Virol. 81:552557, 2009. (C) 2009 Wiley-Liss, Inc.
C1 [Souza Costa, Giselle Calasans; Gadelha, Sandra Rocha; Olavarria, Viviana Nila; Galvao-Castro, Bernardo; Junior alcantara, Luiz Carlos] Fundacao Oswaldo Cruz, Ctr Pesquisa Goncalo Moniz, Lab Avancado Saude Publ, BR-40296610 Salvador, BA, Brazil.
   [Azevedo, Rochele; Kashima, Simone Haddad; Covas, Dimas Tadeu] Hemoctr Ribeirao Preto, Sao Paulo, Brazil.
   [Muricy, Gabriel; Galvao-Castro, Bernardo; Junior alcantara, Luiz Carlos] Fundacao Bahiana Desenvolvimento Ciencias, Escola Bahiana Med & Saude Publ, Salvador, BA, Brazil.
   [Takayanagui, Osvaldo Massaiti] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Neurol Psiquiatria & Psicol Med, Sao Paulo, Brazil.
RP Alcantara, LC (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisa Goncalo Moniz, Lab Avancado Saude Publ, Rua Waldemar Falcao 121, BR-40296610 Salvador, BA, Brazil.
EM lalcan@bahia.fiocruz.br
RI Takayanagui, Osvaldo M/C-8159-2013; Gadelha, Sandra/X-3373-2019;
   Kashima, Simone/G-4876-2012; Covas, Dimas T/C-5431-2013
OI Takayanagui, Osvaldo M/0000-0002-8190-0275; Kashima,
   Simone/0000-0002-1487-0141; Covas, Dimas T/0000-0002-7364-2595;
   Alcantara, Luiz/0000-0002-6769-9931; Gadelha, Sandra/0000-0002-3079-488X
FU Fundacao de Amparo a Pesquisa do Estado da Bahia
FX Grant sponsor: Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB;
   partially supported).
CR AYRES M, 2005, BIOESTAT VERSA 4 0
   BANGHAM CR, 2003, SCIENCE, V299, P1713
   Coskun AK, 2005, J VIROL, V79, P4150, DOI 10.1128/JVI.79.7.4150-4158.2005
   Cox ED, 2001, TRANSPLANTATION, V72, P720, DOI 10.1097/00007890-200108270-00027
   D'Aiuto F, 2004, CYTOKINE, V28, P29, DOI 10.1016/j.cyto.2004.06.005
   Dehee A, 2002, J VIROL METHODS, V102, P37, DOI 10.1016/S0166-0934(01)00445-1
   Dourado I, 2003, JAIDS-J ACQ IMM DEF, V34, P527, DOI 10.1097/00126334-200312150-00013
   Fishman D, 1998, J CLIN INVEST, V102, P1369, DOI 10.1172/JCI2629
   Gadelha SR, 2008, J MED VIROL, V80, P2141, DOI 10.1002/jmv.21341
   Gadelha SR, 2005, HUM BIOL, V77, P509, DOI 10.1353/hub.2005.0061
   GESSAIN A, 1985, LANCET, V2, P407
   Grzeszczak W, 2001, KIDNEY INT, V59, P631, DOI 10.1046/j.1523-1755.2001.059002631.x
   Gutierrez C, 1998, DIABETES RES CLIN PR, V41, P113, DOI 10.1016/S0168-8227(98)00050-3
   Hayashi M, 2004, J ENDOCRINOL, V183, P145, DOI 10.1677/joe.1.05599
   Hodgkinson AD, 2005, J DIABETES COMPLICAT, V19, P65, DOI 10.1016/j.jdiacomp.2004.07.002
   Hoffmann SC, 2002, AM J TRANSPLANT, V2, P560, DOI 10.1034/j.1600-6143.2002.20611.x
   Kaplan JE, 1996, J ACQ IMMUN DEF SYND, V12, P193, DOI 10.1097/00042560-199606010-00014
   KITAJIMA I, 1989, ARTHRITIS RHEUM, V32, P1342, DOI 10.1002/anr.1780321030
   Kitamura A, 2002, DIABETIC MED, V19, P1000, DOI 10.1046/j.1464-5491.2002.00844.x
   LAGRENADE L, 1990, LANCET, V336, P1345
   Licastro F, 2003, NEUROBIOL AGING, V24, P921, DOI 10.1016/S0197-4580(03)00013-7
   Liu Z, 1998, Zhonghua Yi Xue Za Zhi, V78, P662
   Liu ZH, 1999, KIDNEY INT, V55, P1843, DOI 10.1046/j.1523-1755.1999.00449.x
   Manel N, 2005, J BIOL CHEM, V280, P29025, DOI 10.1074/jbc.M504549200
   MOCHIZUKI M, 1992, LANCET, V339, P1110, DOI 10.1016/0140-6736(92)90699-4
   MORGAN OS, 1989, LANCET, V2, P1184
   Nagai M, 1998, J NEUROVIROL, V4, P586, DOI 10.3109/13550289809114225
   Ng DPK, 2002, DIABETES, V51, P2264, DOI 10.2337/diabetes.51.7.2264
   Nishimura M, 2002, HUM IMMUNOL, V63, P696, DOI 10.1016/S0198-8859(02)00419-6
   OSAME M, 1986, LANCET, V1, P1031
   Plothow A, 2003, TRANSPLANT P, V35, P2908, DOI 10.1016/j.transproceed.2003.10.013
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   RAYMOND M, 1995, J HERED, V86, P248, DOI 10.1093/oxfordjournals.jhered.a111573
   Rosenwasser LJ, 1997, AM J RESP CRIT CARE, V156, pS152, DOI 10.1164/ajrccm.156.4.12tac-14
   Sabouri AH, 2004, J INFECT DIS, V190, P1279, DOI 10.1086/423942
   Takenouchi N, 2003, J NEUROVIROL, V9, P29, DOI 10.1080/13550280390173418
   Tomita M, 2007, BIOCHEM J, V406, P317, DOI 10.1042/BJ20070286
   YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031
NR 38
TC 2
Z9 2
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD MAR
PY 2009
VL 81
IS 3
BP 552
EP 557
DI 10.1002/jmv.21421
PG 6
WC Virology
SC Virology
GA 399JC
UT WOS:000262795200023
PM 19152396
OA Green Published
DA 2020-11-26
ER

PT J
AU Gadelha, SR
   Alcantara, LCJ
   Costa, GC
   Acosta, AX
   Rios, D
   Kashima, S
   Covas, DT
   Galvao-Castro, B
AF Gadelha, Sandra Rocha
   Junior Alcantara, Luiz Carlos
   Costa, Gisele Calazans
   Acosta, Angelina Xavier
   Rios, Domingos
   Kashima, Simone
   Covas, Dimas Tadeu
   Galvao-Castro, Bernardo
TI Correlation Between Polymorphisms at Interleukin-6 But Not at
   Interleukin-10 Promoter and the Risk of Human T Lymphotropic Virus Type
   I-Associated Myelopathy/Tropical Spastic Paraparesis in Brazilian
   Individuals
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE HTLV-1; interleukin-6; interleukin-10; polymorphisms; Brazilian
   populations
ID HTLV-I; CYTOKINE PRODUCTION; GENE PROMOTER; ETHNIC-DIFFERENCES; IL-6
   GENE; EXPRESSION; ALLELES; DISEASE; SUSCEPTIBILITY; TRANSCRIPTION
AB HTLV-1 is the etiologic agent of ATL and HAM/TSP. The majority of HTLV-1-infected individuals remain asymptomatic, indicating that the infection alone is not sufficient to cause the diseases. It has been reported that cytokine gene polymorphisms, including polymorphisms at IL-6 and IL-10 gene, might be important. We analyzed SNP in the promoter region of the IL-6: -174, -572, -597, and -634 positions, and IL-10: -592 position to evaluate the role of these polymorphisms in the HAM/TSP pathogenesis in 133 HTLV-1 infected individuals and in 100 healthy individuals from Salvador, Bahia, Brazil. The -634C allele frequencies were higher among HAM/TSP patients (21.2%) than among oligosymptomatic (6.5%; P=0.038) and asymptomatic (9.5%; P=0.025) subjects. Similarly, the -174G allele frequencies were higher in HAM/TSP patients than in oligosymptomatic patients (P=0.02). Moreover, the -634GC/-174GG genotype combination was identified at a higher frequency (38.5%) in the HAM/TSP patients than in subjects with other clinical status (8.7%; P=0.016 for oligosymptomatic and 15.5%, P=0.012 for asymptomatic patients). However, the multivariate logistic regression including the genotypes of the three studied loci showed that only -634 C IL-6 carriers remain as significant and independent TSP/HAM predictor (odds ratio [OR] = 5.31; 95% [CI] = 1.60-17.56; P=0.006). We suggest that -634 G C in IL-6 could contribute to HAM/TSP development and that identification of the collective influence of several cytokine is polymorphisms, their prevalence, and their interaction could help to better understand this disease. J. Med. Virol. 80:2141-2146, 2008. (C) 2008 Wiley-Liss, Inc.
C1 [Gadelha, Sandra Rocha; Junior Alcantara, Luiz Carlos; Costa, Gisele Calazans; Acosta, Angelina Xavier; Galvao-Castro, Bernardo] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Lab Avancado Saude Publ, Salvador, BA, Brazil.
   [Gadelha, Sandra Rocha; Junior Alcantara, Luiz Carlos; Galvao-Castro, Bernardo] Fundacao Desenvolvimento Ciencias, Escola Bahiana Med Saude Publ, Salvador, BA, Brazil.
   [Acosta, Angelina Xavier] Univ Fed Bahia, UFBA, Fac Med, Dept Pediat, BR-41170290 Salvador, BA, Brazil.
   [Kashima, Simone; Covas, Dimas Tadeu] Hemoctr Ribeirao Preto, Sao Paulo, Brazil.
RP Galvao-Castro, B (corresponding author), Fiocruz MS, CPqGM, LASP, 121 Rua Waldemar Falcao, BR-40296710 Salvador, BA, Brazil.
EM bgalvao@cpqgm.fiocruz.br
RI Gadelha, Sandra/X-3373-2019; Covas, Dimas T/C-5431-2013; Kashima,
   Simone/G-4876-2012
OI Covas, Dimas T/0000-0002-7364-2595; Gadelha, Sandra/0000-0002-3079-488X;
   Alcantara, Luiz/0000-0002-6769-9931; Kashima, Simone/0000-0002-1487-0141
CR ABRAMSON JH, 2001, COMPUTER PROGRAM EPI
   Belluco C, 2003, CLIN CANCER RES, V9, P2173
   Cox ED, 2001, TRANSPLANTATION, V72, P720, DOI 10.1097/00007890-200108270-00027
   Dourado I, 2003, JAIDS-J ACQ IMM DEF, V34, P527, DOI 10.1097/00126334-200312150-00013
   Ershler WB, 2000, ANNU REV MED, V51, P245, DOI 10.1146/annurev.med.51.1.245
   Fishman D, 1998, J CLIN INVEST, V102, P1369, DOI 10.1172/JCI2629
   Font J, 2002, RHEUMATOLOGY, V41, P1025, DOI 10.1093/rheumatology/41.9.1025
   Furukawa Y, 2003, J INFECT DIS, V187, P1116, DOI 10.1086/368379
   Gabay C, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1917
   Gadelha SR, 2005, HUM BIOL, V77, P509, DOI 10.1353/hub.2005.0061
   GalvaoCastro B, 1997, TRANSFUSION, V37, P242, DOI 10.1046/j.1537-2995.1997.37297203532.x
   GESSAIN A, 1985, LANCET, V2, P407
   Hoffmann SC, 2002, AM J TRANSPLANT, V2, P560, DOI 10.1034/j.1600-6143.2002.20611.x
   Ishihara K, 2002, CYTOKINE GROWTH F R, V13, P357, DOI 10.1016/S1359-6101(02)00027-8
   Jahromi MM, 2000, J INTERF CYTOK RES, V20, P885, DOI 10.1089/10799900050163253
   Jeffery KJM, 1999, P NATL ACAD SCI USA, V96, P3848, DOI 10.1073/pnas.96.7.3848
   Jenny NS, 2002, ARTERIOSCL THROM VAS, V22, P2066, DOI 10.1161/01.ATV.0000040224.49362.60
   Kitamura A, 2002, DIABETIC MED, V19, P1000, DOI 10.1046/j.1464-5491.2002.00844.x
   Kodama D, 2004, J NEUROIMMUNOL, V156, P188, DOI 10.1016/j.jneuroim.2004.07.007
   Kubaszek A, 2003, DIABETES, V52, P558, DOI 10.2337/diabetes.52.2.558
   Li XH, 2000, AIDS RES HUM RETROV, V16, P1583, DOI 10.1089/08892220050192994
   Licastro F, 2003, NEUROBIOL AGING, V24, P921, DOI 10.1016/S0197-4580(03)00013-7
   Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200
   Meenagh A, 2002, HUM IMMUNOL, V63, P1055, DOI 10.1016/S0198-8859(02)00440-8
   Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683
   Mori N, 1996, BLOOD, V88, P1035
   MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214
   Nishimura M, 2002, HUM IMMUNOL, V63, P696, DOI 10.1016/S0198-8859(02)00419-6
   Nishimura M, 2000, HUM IMMUNOL, V61, P1262, DOI 10.1016/S0198-8859(00)00182-8
   Nobuhara Y, 2006, IMMUNOGENETICS, V57, P944, DOI 10.1007/s00251-005-0075-0
   Orland JR, 2003, NEUROLOGY, V61, P1588, DOI 10.1212/01.WNL.0000096011.92542.DA
   OSAME M, 1986, LANCET, V1, P1031
   Plothow A, 2003, TRANSPLANT P, V35, P2908, DOI 10.1016/j.transproceed.2003.10.013
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P6815, DOI 10.1073/pnas.77.11.6815
   Rafatpanah H, 2004, HUM IMMUNOL, V65, P839, DOI 10.1016/j.humimm.2004.05.006
   RAYMOND M, 1995, J HERED, V86, P248, DOI 10.1093/oxfordjournals.jhered.a111573
   Rivera-Chavez FA, 2003, SHOCK, V20, P218, DOI 10.1097/00024382-200309000-00004
   Rosenwasser LJ, 1997, AM J RESP CRIT CARE, V156, pS152, DOI 10.1164/ajrccm.156.4.12tac-14
   Sabouri AH, 2004, J INFECT DIS, V190, P1279, DOI 10.1086/423942
   Saito M, 2005, J NEUROL SCI, V232, P29, DOI 10.1016/j.jns.2005.01.005
   Shin HD, 2000, P NATL ACAD SCI USA, V97, P14467, DOI 10.1073/pnas.97.26.14467
   Taylor A, 2006, IMMUNOLOGY, V117, P433, DOI 10.1111/j.1365-2567.2006.02321.x
   Terry CF, 2000, J BIOL CHEM, V275, P18138, DOI 10.1074/jbc.M000379200
   Warle MC, 2003, LIVER TRANSPLANT, V9, P170, DOI 10.1053/jlts.2002.50014
   Westendorp RGJ, 1997, LANCET, V349, P1912, DOI 10.1016/S0140-6736(05)63910-4
NR 45
TC 17
Z9 17
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD DEC
PY 2008
VL 80
IS 12
BP 2141
EP 2146
DI 10.1002/jmv.21341
PG 6
WC Virology
SC Virology
GA 368FH
UT WOS:000260606500013
PM 19040291
OA Green Published
DA 2020-11-26
ER

PT J
AU Mota-Miranda, AC
   Araujo, SP
   Dias, JP
   Colin, DD
   Kashima, S
   Covas, DT
   Tavares-Neto, J
   Galvao-Castro, B
   Alcantara, LCJ
AF Mota-Miranda, Aline Cristina
   Araujo, Sergio Pereira
   Dias, Juarez Pereira
   Colin, Denise Duizit
   Kashima, Simone
   Covas, Dimas Tadeu
   Tavares-Neto, Jose
   Galvao-Castro, Bernardo
   Junior Alcantara, Luiz Carlos
TI HTLV-1 infection in blood donors from the western Brazilian Amazon
   region: Seroprevalence and molecular study of viral isolates
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE LTR region; glycoproteins; phylogenetic analysis; protein sites
ID VIRUS TYPE-I; CELL LYMPHOTROPIC VIRUS; EPIDEMIOLOGY; AMERICA; ORIGIN;
   TYPE-1; GP46
AB To determine the seroprevalence of HTLV-1 in Brazil, and to review the virus molecular epidemiology in this Amazon population (Rio Branco-Acre), 219 blood donors were screened for HTLV-1. Only one case of infection (0.46% seroprevalence) was detected during July 2004 screening at the Acre Hospital Foundation (FUNDACRE). Neighbor-joining and Maximum Likelihood phylogenetic analyses of two (n = 2) complete LTR region sequences were performed with the PAUP* software. Since the HTLV-1 envelope surface (gp46) and transmembrane (gp21) glycoproteins are important for virus fitness, three envelope glycoproteins sequences (n = 3) were analyzed using the Prosite tool to determinate potential protein sites. Phylogenetic analysis demonstrated that the new isolate described in this study, and the unpublished LTR strain described in a previous report belong to the Transcontinental subgroup of the Cosmopolitan subtype, inside the Latin American cluster. A similar result was obtained when submitting, to the Automated Genotyping System, three LTR partial sequences from a previous study of the seroprevalence of HTLV-1 in the same Amazon population. In all analyzed env sequences, the potential protein site was found: two PKC phosphorylation sites at amino acid (aa) positions 310-312 and 342-344, one CK2 phosphorylation site at 194-197aa, three N-glycosylation sites at 222-225aa, 244-247aa and 272-275aa, and a single N-myristylation site at 327-338aa. In conclusion, potential protein sites described in HTLV-1 gp46 and gp21 confirm the presence of conserved sites in the HTLV-1 envelope proteins, likewise phylogenetic analysis suggests a possible recent introduction of the virus into North Brazil.
C1 [Mota-Miranda, Aline Cristina; Araujo, Sergio Pereira; Galvao-Castro, Bernardo; Junior Alcantara, Luiz Carlos] Fundacao Oswaldo Cruz, Adv Publ Hlth Lab, Goncalo Moniz Res Ctr, BR-40296610 Salvador, BA, Brazil.
   [Dias, Juarez Pereira; Tavares-Neto, Jose] Univ Fed Bahia, Salvador, BA, Brazil.
   [Colin, Denise Duizit] Fundaco Hosp Estadual Acre, Rio Branco, Acre, Brazil.
   [Kashima, Simone; Covas, Dimas Tadeu] Hemoctr Ribeirao Preto, Sao Paulo, Brazil.
   [Galvao-Castro, Bernardo; Junior Alcantara, Luiz Carlos] Fundacao Bahiana Desenvolvimento Ciencias, Escola Bahiana Med & Saude Publ, Salvador, BA, Brazil.
RP Alcantara, LCJ (corresponding author), Fundacao Oswaldo Cruz, Adv Publ Hlth Lab, Goncalo Moniz Res Ctr, Waldemar Falcao St 121, BR-40296610 Salvador, BA, Brazil.
EM lalcan@bahia.fiocruz.br
RI Covas, Dimas T/C-5431-2013; Kashima, Simone/G-4876-2012
OI Covas, Dimas T/0000-0002-7364-2595; Alcantara, Luiz/0000-0002-6769-9931;
   Kashima, Simone/0000-0002-1487-0141
FU Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB); PN-DST/AIDS,
   Ministerio da Saude, Brazil
FX Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB) (partial
   support); Grant sponsor: PN-DST/AIDS, Ministerio da Saude, Brazil
   (partial support).
CR Alcantara LC, 2003, JAIDS-J ACQ IMM DEF, V33, P536, DOI 10.1097/00126334-200308010-00016
   Alcantara LCJ, 2006, AIDS, V20, P780, DOI 10.1097/01.aids.0000216383.14808.13
   Bouamr F, 2003, BIOCHEMISTRY-US, V42, P6408, DOI 10.1021/bi020692z
   Carneiro-Proietti Anna Bárbara F., 2002, Rev. Soc. Bras. Med. Trop., V35, P499, DOI 10.1590/S0037-86822002000500013
   Colin Denise Duizit, 2003, Rev. Soc. Bras. Med. Trop., V36, P677, DOI 10.1590/S0037-86822003000600006
   Dourado I, 2003, JAIDS-J ACQ IMM DEF, V34, P527, DOI 10.1097/00126334-200312150-00013
   GalvaoCastro B, 1997, TRANSFUSION, V37, P242, DOI 10.1046/j.1537-2995.1997.37297203532.x
   GESSAIN A, 1985, LANCET, V2, P407
   ISHAK R, 1995, AIDS RES HUM RETROV, V11, P813, DOI 10.1089/aid.1995.11.813
   ISHAK R, 2003, CAD SAUDE PUBLICA, V19, P109
   Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7
   KUMAR S, 1994, COMPUT APPL BIOSCI, V10, P189
   MIURA T, 1994, P NATL ACAD SCI USA, V91, P1124, DOI 10.1073/pnas.91.3.1124
   Mota Augusto, 2006, Rev. Bras. Hematol. Hemoter., V28, P120, DOI 10.1590/S1516-84842006000200011
   Mota-Miranda AC, 2007, MEM I OSWALDO CRUZ, V102, P741, DOI [10.1590/S0074-02762007005000089, 10.1590/S0074-02762007000600014]
   NAGY K, 1983, INT J CANCER, V32, P321, DOI 10.1002/ijc.2910320310
   Nicholas KB, 1997, EMBNEW NEWS, V4, P14
   OSAME M, 1986, LANCET, V1, P1031
   Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357
   PALKER TJ, 1989, J IMMUNOL, V142, P971
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Proietti FA, 2005, ONCOGENE, V24, P6058, DOI 10.1038/sj.onc.1208968
   QUEIROZ AT, 2007, MEM I OSWALDO CRUZ, V102, P133, DOI DOI 10.1590/S0074-02762007005000005
   Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679
   Swofford DL, 1998, PAUP PHYLOGENETIC AN
   Vallinoto ACR, 1998, MEM I OSWALDO CRUZ, V93, P407, DOI 10.1590/S0074-02761998000300026
   Van Dooren S, 1998, J GEN VIROL, V79, P2695, DOI 10.1099/0022-1317-79-11-2695
   Yamashita M, 1999, VIROLOGY, V261, P59
   Yang YC, 1997, J MED VIROL, V51, P25, DOI 10.1002/(SICI)1096-9071(199701)51:1&lt;25::AID-JMV4&gt;3.0.CO;2-U
   Zehender G, 2007, AIDS RES HUM RETROV, V23, P1146, DOI 10.1089/aid.2007.0039
NR 31
TC 6
Z9 7
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2008
VL 80
IS 11
BP 1966
EP 1971
DI 10.1002/jmv.21300
PG 6
WC Virology
SC Virology
GA 354EX
UT WOS:000259622800015
PM 18814249
DA 2020-11-26
ER

PT J
AU Pimenta, FCF
   Haddad, SK
   de Medeiros, JG
   Costa, MJC
   Diniz, MFM
   Fernandes, MP
   de Araujo, LB
   Pombo-de-Oliveira, MS
AF Pimenta, Flavia C. F.
   Haddad, Simone Kashima
   de Medeiros Filho, Joao G.
   Costa, Maria Jose C.
   Diniz, Margareth F. M.
   Fernandes, Melina P.
   de Araujo, Lenisio B.
   Pombo-de-Oliveira, Maria S.
TI Prevalence ratio of HTLV-1 in nursing mothers from the state of Paraiba,
   northeastern Brazil
SO JOURNAL OF HUMAN LACTATION
LA English
DT Article
DE HTLV-1/II infection; breastfeeding infants; nursing mothers
ID T-CELL LEUKEMIA; VIRUS TYPE-1 HTLV-1; I INFECTION; TRANSMISSION;
   LEUKEMIA/LYMPHOMA; NATIONWIDE; DISEASES; JAPAN; RISK
AB The human T-cell lymphotropic virus type I (HTLV- 1) was the first human retrovirus known as a direct causal agent of a malignant disease. The vertical route of HTLV transmission is the most frequent pathway of the virus contamination. This study was performed to determine the prevalence ratio of HTLV- I infection among nursing women. From January 2004 to January 2005, blood samples from 1033 nursing mothers from Paraiba, Brazil were evaluated for HTLV antibodies by ELISA and HTLV-1 viral particles confirmed by polymerase chain reaction (PCR). HTLV antibodies were detected in 7 women. The overall seroprevalence ratio was 0.68% and HTLV-1 viral sequences were confirmed by PCR in 2 women. These preliminary data suggest that HTLV screening should be introduced as a mandatory test before breastfeeding and breast milk donation in Paraiba, Brazil. Additionally, counseling programs would help reduce the prevalence ratio of HTLV-1 infected individuals in this Brazilian region.
C1 [Pombo-de-Oliveira, Maria S.] Inst Nacl Canc, CPq, Div Expt Med, Pediat Leukemia & Lymphoma Grp, BR-20231050 Rio De Janeiro, Brazil.
   [Pimenta, Flavia C. F.] Univ Fed Paraiba, Dept Pediat Med, BR-58059900 Joao Pessoa, Paraiba, Brazil.
   [Haddad, Simone Kashima] Hemoctr, Mol Lab, Sao Paulo, Brazil.
   [de Medeiros Filho, Joao G.] Univ Fed Paraiba, Dept Pediat, BR-58059900 Joao Pessoa, Paraiba, Brazil.
   [Costa, Maria Jose C.] Univ Fed Paraiba, Dept Pharmaceut Sci, Serol Lab, BR-58059900 Joao Pessoa, Paraiba, Brazil.
   [de Araujo, Lenisio B.] Univ Fed Paraiba, Dept Surg, CCS, BR-58059900 Joao Pessoa, Paraiba, Brazil.
RP Pombo-de-Oliveira, MS (corresponding author), Inst Nacl Canc, CPq, Div Expt Med, Pediat Leukemia & Lymphoma Grp, Rua Andre Cavalcanti 37, BR-20231050 Rio De Janeiro, Brazil.
EM mpombo@inca.gov.br
RI Pombo-de-Oliveira, Maria S./I-8884-2014; Kashima, Simone/G-4876-2012
OI Pombo-de-Oliveira, Maria S./0000-0002-1507-004X; Kashima,
   Simone/0000-0002-1487-0141
CR ADE CA, 1993, J NEUROL SCI, V116, P165
   Ando Y, 2003, J INFECTION, V46, P177, DOI 10.1053/jinf.2002.1107
   BLATTNER WA, 1999, TXB AIDS MED, P1003
   Carvalho SMF, 1997, J ACQ IMMUNE DEFIC S, V15, P238
   Catalan-Soares Bernadette, 2005, Cad. Saúde Pública, V21, P926, DOI 10.1590/S0102-311X2005000300027
   De Oliveira MSP, 1999, INT J CANCER, V83, P291, DOI 10.1002/(SICI)1097-0215(19991029)83:3&lt;291::AID-IJC1&gt;3.0.CO;2-P
   GalvaoCastro B, 1997, TRANSFUSION, V37, P242, DOI 10.1046/j.1537-2995.1997.37297203532.x
   Kaplan JE, 1996, J ACQ IMMUN DEF SYND, V12, P193, DOI 10.1097/00042560-199606010-00014
   Kashima S, 2006, AIDS RES HUM RETROV, V22, P953, DOI 10.1089/aid.2006.22.953
   Kashiwagi K, 2004, AM J TROP MED HYG, V70, P158, DOI 10.4269/ajtmh.2004.70.158
   Lamounier Joel A., 2004, J. Pediatr. (Rio J.), V80, ps181, DOI 10.1590/S0021-75572004000700010
   Maia Paulo Ricardo da Silva, 2004, Cad. Saúde Pública, V20, P1700, DOI 10.1590/S0102-311X2004000600029
   MANNS A, 1992, INT J CANCER, V51, P886, DOI 10.1002/ijc.2910510609
   Pombo-de-Oliveira MS, 2002, LEUKEMIA RES, V26, P155, DOI 10.1016/S0145-2126(01)00108-4
   Pombo-de-Oliveira MS, 2001, LEUKEMIA LYMPHOMA, V42, P135, DOI 10.3109/10428190109097685
   Proietti FA, 2005, ONCOGENE, V24, P6058, DOI 10.1038/sj.onc.1208968
   SAKURAI H, 1992, LEUKEMIA RES, V16, P941, DOI 10.1016/0145-2126(92)90040-E
   Santos Jairo Vvo Dos, 1995, Revista do Instituto de Medicina Tropical de Sao Paulo, V37, P343
   TAJIMA K, 1990, INT J CANCER, V45, P237, DOI 10.1002/ijc.2910450206
   TAKEZAKI T, 1997, LEUKEMIA S3, V11, pS60
   Victora CG, 1998, AM J CLIN NUTR, V67, P452
   Vrielink H, 2004, TRANSFUS MED REV, V18, P46, DOI 10.1016/j.tmrv.2003.10.004
   Wiktor S Z, 1997, J Hum Virol, V1, P37
NR 23
TC 5
Z9 6
U1 0
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0890-3344
EI 1552-5732
J9 J HUM LACT
JI J. Hum. Lact.
PD AUG
PY 2008
VL 24
IS 3
BP 289
EP 292
DI 10.1177/0890334408316084
PG 4
WC Nursing; Obstetrics & Gynecology; Pediatrics
SC Nursing; Obstetrics & Gynecology; Pediatrics
GA 332PJ
UT WOS:000258095300011
PM 18689716
DA 2020-11-26
ER

PT J
AU Sorgi, C
   Medeiros, A
   Secatto, A
   Fontanari, C
   Turato, W
   Belanger, C
   Marleau, S
   Kashima, S
   Covos, D
   Bozza, P
   Faccioli, L
AF Sorgi, Carlos
   Medeiros, Alexandra
   Secatto, Adriana
   Fontanari, Caroline
   Turato, Walter
   Belanger, Caroline
   Marleau, Sylvie
   Kashima, Simone
   Covos, Dimas
   Bozza, Patricia
   Faccioli, Lucia
TI Histoplasma capsulatum cell wall beta-glucan induced lipid body
   formation and LTB4 generation through TLR2 and CD18 receptors
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies
CY JUN 05-09, 2008
CL Boston, MA
SP Federat Clinical Immunol Soc
C1 [Sorgi, Carlos; Medeiros, Alexandra; Secatto, Adriana; Fontanari, Caroline; Turato, Walter; Faccioli, Lucia] Univ Sao Paulo, FCFRP, BR-14049 Ribeirao Preto, Brazil.
   [Belanger, Caroline; Marleau, Sylvie] Univ Montreal, Montreal, PQ, Canada.
   [Bozza, Patricia] Fiocruz MS, BR-21045900 Rio De Janeiro, Brazil.
   [Kashima, Simone; Covos, Dimas] Univ Sao Paulo, FMRP, BR-14049 Ribeirao Preto, Brazil.
RI Kashima, Simone/G-4876-2012; Sorgi, Carlos/F-6780-2012; Sorgi, Carlos
   A/B-9732-2012; Sorgi, Carlos Arterio/AAA-6284-2020; Sorgi,
   Carlos/ABE-4246-2020
OI Kashima, Simone/0000-0002-1487-0141; Sorgi, Carlos
   Arterio/0000-0001-7528-9935; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PY 2008
VL 127
SU S
BP S30
EP S30
DI 10.1016/j.clim.2008.03.078
PG 1
WC Immunology
SC Immunology
GA 296HD
UT WOS:000255533200082
DA 2020-11-26
ER

PT J
AU Amarante, MFDC
   Kashima, S
   Covas, DT
AF Amarante, Maria Fernanda De Castro
   Kashima, Simone
   Covas, Dimas Tadeu
TI TT virus (TTV) genotyping in blood donors and multiple transfused
   patients in Brazil
SO VIRUS GENES
LA English
DT Article
DE TT virus; anellovirus; prevalence; phylogenetic analysis; genotypes;
   blood donors; multiple transfused patients
ID AGE-SPECIFIC PREVALENCE; DNA VIRUS; POSTTRANSFUSION HEPATITIS;
   INFECTION; TRANSMISSION; RECOMBINATION; REGION; SALIVA; SERUM; RISK
AB TT virus (TTV) is widely distributed in the general population. The objective of the present study was to investigate the prevalence and distribution of TTV genotypes among blood donor candidates and multiple transfused patients in the Southeast region of the state of Sao Paulo, Brazil. TTV-DNA detection by amplification of a segment of the ORF-1 region, presented a prevalence of 11.9% in 270 serum samples from blood donors, of 46.2% in 18 samples from patients with coagulopathies, and of 31.8% in 15 samples from patients with hemoglobinopathies. When specific primers for the non-coding (UTR) region of the TTV genome were used the prevalences were 50.5%, 95.0%, and 82.0% for blood donors, patients with coagulopathies and patients with hemoglobinopathies, respectively. Positive samples from 49 individuals were sequenced and partial segments of 230 base pairs referring to the ORF-1 region of the TTV genome were used for the determination of their genotypes with the aid of phylogenetic analysis. The most frequent genotype was 1 (74.0%), followed by genotype 2 (26.0%). These data indicate a high prevalence of this virus in the populations of blood donors and transfused patients, providing further evidence for the role of transfusions as an efficient pathway in the transmission chain.
C1 Reg Blood Ctr Ribeirao Preto, Mol Biol Lab, BR-14051140 Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
RP Amarante, MFDC (corresponding author), Reg Blood Ctr Ribeirao Preto, Mol Biol Lab, Rua Tenente Catao Roxo,2501,Ribeirao Preto, BR-14051140 Sao Paulo, Brazil.
EM mfcastro@hemocentro.fmrp.usp.br; skashima@hemocentro.fmrp.usp.br;
   dimas@fmrp.usp.br
RI Kashima, Simone/G-4876-2012; Covas, Dimas T/C-5431-2013; Amarante, Marla
   Karine/AAO-3735-2020; Amarante, Marla/F-4606-2015
OI Kashima, Simone/0000-0002-1487-0141; Covas, Dimas T/0000-0002-7364-2595;
   Amarante, Marla Karine/0000-0001-8218-8518; Amarante,
   Marla/0000-0001-8218-8518; Castro Amarante, Maria
   Fernanda/0000-0003-2162-9505
CR BASSIT Leda, 2002, Rev. Inst. Med. trop. S. Paulo, V44, P233, DOI 10.1590/S0036-46652002000400010
   Biagini P, 2006, J MED VIROL, V78, P298, DOI 10.1002/jmv.20539
   Biagini P, 1999, J GEN VIROL, V80, P419, DOI 10.1099/0022-1317-80-2-419
   Chen BP, 1999, BLOOD, V94, P4333, DOI 10.1182/blood.V94.12.4333.424k11_4333_4336
   Deng XW, 2000, J MED VIROL, V62, P531, DOI 10.1002/1096-9071(200012)62:4&lt;531::AID-JMV20&gt;3.0.CO;2-C
   Devalle S, 2004, J MED VIROL, V72, P166, DOI 10.1002/jmv.10564
   Erker JC, 1999, J GEN VIROL, V80, P1743, DOI 10.1099/0022-1317-80-7-1743
   Foschini MP, 2001, VIRCHOWS ARCH, V439, P752, DOI 10.1007/s004280100467
   Gallian P, 2000, J CLIN VIROL, V17, P43, DOI 10.1016/S1386-6532(00)00066-4
   Handa A, 2000, TRANSFUSION, V40, P245, DOI 10.1046/j.1537-2995.2000.40020245.x
   Inami T, 2000, J CLIN MICROBIOL, V38, P2407
   Kalkan A, 2005, JPN J INFECT DIS, V58, P222
   Kao JH, 1999, J MED VIROL, V59, P307, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;307::AID-JMV8&gt;3.0.CO;2-3
   Leary TP, 1999, J GEN VIROL, V80, P2115, DOI 10.1099/0022-1317-80-8-2115
   Lefrere JJ, 2000, BLOOD, V95, P347, DOI 10.1182/blood.V95.1.347.001k42_347_351
   Lemey P, 2002, VIRUS RES, V85, P47, DOI 10.1016/S0168-1702(02)00017-5
   Love A, 2000, TRANSFUSION, V40, P306, DOI 10.1046/j.1537-2995.2000.40030306.x
   Manni F, 2002, J MOL EVOL, V55, P563, DOI 10.1007/s00239-002-2352-y
   Mushahwar IK, 1999, P NATL ACAD SCI USA, V96, P3177, DOI 10.1073/pnas.96.6.3177
   Nishizawa T, 1997, BIOCHEM BIOPH RES CO, V241, P92, DOI 10.1006/bbrc.1997.7765
   Okamoto H, 1999, VIROLOGY, V259, P428, DOI 10.1006/viro.1999.9770
   Okamoto H, 1998, J MED VIROL, V56, P128, DOI 10.1002/(SICI)1096-9071(199810)56:2&lt;128::AID-JMV5&gt;3.0.CO;2-A
   Okamoto H, 1998, HEPATOL RES, V10, P1, DOI 10.1016/S1386-6346(97)00123-X
   Peng YH, 2002, ARCH VIROL, V147, P21, DOI 10.1007/s705-002-8301-7
   Pisani G, 2000, HAEMATOLOGICA, V85, P1218
   Prati D, 1999, BLOOD, V93, P1502, DOI 10.1182/blood.V93.5.1502.405a37_1502_1505
   Prescott LE, 1999, J GEN VIROL, V80, P1751, DOI 10.1099/0022-1317-80-7-1751
   Saback FL, 1999, J MED VIROL, V59, P318, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;318::AID-JMV10&gt;3.0.CO;2-Q
   Salakova M, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-56
   Schroter M, 1999, HEPATOL RES, V13, P205, DOI 10.1016/S1386-6346(98)00091-6
   Simmonds P, 1998, LANCET, V352, P191, DOI 10.1016/S0140-6736(98)03056-6
   Takahashi K, 1998, HEPATOL RES, V12, P233, DOI 10.1016/S1386-6346(98)00068-0
   Takamatsu J, 2001, HAEMOPHILIA, V7, P575, DOI 10.1046/j.1365-2516.2001.00567.x
   Takayama S, 1999, BIOCHEM BIOPH RES CO, V256, P208, DOI 10.1006/bbrc.1999.0270
   Touinssi M, 2001, J CLIN VIROL, V21, P135, DOI 10.1016/S1386-6532(01)00157-3
   Toyoda H, 2001, TRANSFUSION, V41, P1130, DOI 10.1046/j.1537-2995.2001.41091130.x
   Viazov S, 1998, J GEN VIROL, V79, P3085, DOI 10.1099/0022-1317-79-12-3085
   Werno AM, 2000, J MED VIROL, V62, P109, DOI 10.1002/1096-9071(200009)62:1&lt;109::AID-JMV17&gt;3.0.CO;2-H
   Worobey M, 2000, J VIROL, V74, P7666, DOI 10.1128/JVI.74.16.7666-7670.2000
   Yazici M, 2002, CLIN MICROBIOL INFEC, V8, P363, DOI 10.1046/j.1469-0691.2002.00423.x
   Yokozaki S, 1999, BRIT J HAEMATOL, V105, P1114, DOI 10.1046/j.1365-2141.1999.01452.x
NR 41
TC 8
Z9 11
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920-8569
EI 1572-994X
J9 VIRUS GENES
JI Virus Genes
PD DEC
PY 2007
VL 35
IS 3
BP 503
EP 509
DI 10.1007/s11262-007-0124-x
PG 7
WC Genetics & Heredity; Virology
SC Genetics & Heredity; Virology
GA 232ZM
UT WOS:000251060200005
PM 17570047
DA 2020-11-26
ER

PT J
AU Gasparotto, G
   Carrara, RV
   Zanichelli, MA
   Souto, EX
   Simoes, BP
   Vellano, C
   Covas, DT
   Kashima, S
   Souza, AM
   Castro, FA
AF Gasparotto, G.
   Carrara, R. V.
   Zanichelli, M. A.
   Souto, E. X.
   Simoes, B. P.
   Vellano, C.
   Covas, D. T.
   Kashima, S.
   Souza, A. M.
   Castro, F. A.
TI Differential expression of the FLICE-inhibitory protein, C-FLIP, in
   CD34(+) cells in chronic myelogenous leukemia, polycythemia vera and
   essential trombocythemia
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 12th Congress of the European-Hematology-Association
CY JUN 07-10, 2007
CL Vienna, AUSTRIA
SP European Hematol Assoc
C1 Univ Sao Paulo, FCFRP, BR-14049 Ribeirao Preto, Brazil.
   Ctr Reg Hemotherapy, Ribeirao Preto, Brazil.
   Hosp Brigadeiro, Sao Paulo, Brazil.
   Univ Sao Paulo, FMRP, BR-14049 Ribeirao Preto, Brazil.
RI Covas, Dimas T/C-5431-2013; Simoes, Belinda P/M-7469-2016; CASTRO,
   FABIOLA/D-4693-2012; Kashima, Simone/G-4876-2012
OI Covas, Dimas T/0000-0002-7364-2595; Kashima, Simone/0000-0002-1487-0141
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA STRADA NUOVA 134, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2007
VL 92
SU 1
MA 0963
BP 358
EP 359
PG 2
WC Hematology
SC Hematology
GA 177UB
UT WOS:000247176901181
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Russo-Carbolante, EMD
   Penteado, FC
   Medeiros, L
   Kashima, S
   Takayanagui, OM
   Covas, DT
AF Russo-Carbolante, Elisa Maria de Sousa
   Lobo Penteado, Flora Cristina
   Medeiros, Luciene
   Kashima, Simone
   Takayanagui, Oswaldo M.
   Covas, Dimas Tadeu
TI Cloning and expression of the transmembranic glycoprotein from human T
   cell lymphotropic virus in a prokaryotic system
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA Portuguese
DT Article
ID TROPICAL SPASTIC PARAPARESIS; II HTLV-II; INFECTION; ANTIBODIES;
   PREVALENCE; RETROVIRUS; MYELOPATHY; LEUKEMIA; LYMPHOMA; DISEASE
AB HTLV-1 is the virus that causes T cell lymphoma/leukemia in adults and a neurological disorder known as HTLV-associated myelopathy, or tropical spastic paraparesis. One of the transmission means is through contaminated blood and its byproducts. Because of the risk of HTLV-associated infections, screening for HTLV was introduced for Brazilian blood donors in 1993. Most of the diagnostic kits used in the national blood banks are bought from foreign companies. Brazil does not have the technology to produce this material and there is a need to produce diagnostic systems with national technology. In this study, we show the expression of gp21/HTLV-1 in Escherichia coli and its reactivity towards monoclonal antibodies and the antibodies of infected patients. Expressing these proteins is the first step towards obtaining diagnostic kits with Brazilian biotechnology.
C1 USP, Ctr Reg Hemoterapia, HCFMRP, BR-14051140 Ribeirao Preto, Brazil.
   Univ Estadual Paulista, Dept Anal Clin, Fac Ciencias Farmaceut Julio de Mesquita Filho, Araraquara, SP, Brazil.
   Univ Sao Paulo, Dept Neurol, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, Brazil.
   Univ Sao Paulo, Dept Clin Med, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, Brazil.
RP Russo-Carbolante, EMD (corresponding author), USP, Ctr Reg Hemoterapia, HCFMRP, R Tenente Catao Roxo 2501, BR-14051140 Ribeirao Preto, Brazil.
EM elisa@hemocentro.fmrp.usp.br
RI Russo, Elisa/A-2894-2016; Kashima, Simone/G-4876-2012; Covas, Dimas
   T/C-5431-2013; Takayanagui, Osvaldo M/C-8159-2013
OI Russo, Elisa/0000-0002-9274-7915; Kashima, Simone/0000-0002-1487-0141;
   Covas, Dimas T/0000-0002-7364-2595; Takayanagui, Osvaldo
   M/0000-0002-8190-0275
CR Andersson S, 1999, TRANSFUSION, V39, P845, DOI 10.1046/j.1537-2995.1999.39080845.x
   Carneiro-Proietti Anna Bárbara F., 2002, Rev. Soc. Bras. Med. Trop., V35, P499, DOI 10.1590/S0037-86822002000500013
   GESSAIN A, 1985, LANCET, V2, P407
   GESSAIN A, 1996, HUMAN T CELL LYMPHOT, P34
   Hall WW, 1996, J ACQ IMMUN DEF SYND, V13, pS204, DOI 10.1097/00042560-199600001-00031
   HARRINGTON WJ, 1993, ANN NEUROL, V33, P411, DOI 10.1002/ana.410330416
   Johnson JM, 2001, INT J EXP PATHOL, V82, P135, DOI 10.1046/j.1365-2613.2001.00191.x
   KHABBAZ RF, 1993, ANN INTERN MED, V118, P448
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   *MIN SAUD, 1995, PROGR NAC DOENC SEX
   Monteiro-De-Castro M S, 2001, Cad Saude Publica, V17, P1219, DOI 10.1590/S0102-311X2001000500022
   Murphy EL, 1997, J INFECT DIS, V176, P1468, DOI 10.1086/514143
   OSAME M, 1986, LANCET, V1, P1031
   PINHEIRO SRAA, 1995, ARQ NEURO-PSIQUIAT, V53, P777, DOI 10.1590/S0004-282X1995000500011
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   RODGERSJOHNSON P, 1985, LANCET, V2, P1247
   SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875
   SHEREMATA WA, 1993, VIRUS RES, V29, P71, DOI 10.1016/0168-1702(93)90126-8
   Silva EA, 2002, J MED VIROL, V66, P253, DOI 10.1002/jmv.2138
   TAKATSUKI K, 1985, CANCER RES, V45, P4644
   Thorstensson R, 2002, TRANSFUSION, V42, P780, DOI 10.1046/j.1537-2995.2002.00114.x
   YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031
   ZANINOVIC V, 1996, HTLV THRUTHS QUESTIO, P301
   ZEHENDER G, 1995, J INFECT DIS, V172, P1595, DOI 10.1093/infdis/172.6.1595
NR 24
TC 1
Z9 1
U1 0
U2 1
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PD MAY-JUN
PY 2007
VL 40
IS 3
BP 277
EP 281
PG 5
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 190BN
UT WOS:000248032900005
PM 17653460
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Franca, SC
   Kashima, S
   Roberto, PG
   Marins, M
   Ticli, FK
   Pereira, JO
   Astolfi-Filho, S
   Stabeli, RG
   Magro, AJ
   Fontes, MRM
   Sampaio, SV
   Soares, AM
AF Franca, Suzelei C.
   Kashima, Simone
   Roberto, Patricia G.
   Marins, Mozart
   Ticli, Fabio K.
   Pereira, Jose Odair
   Astolfi-Filho, Spartaco
   Stabeli, Rodrigo G.
   Magro, Angelo J.
   Fontes, Marcos R. M.
   Sampaio, Suely V.
   Soares, Andreimar M.
TI Molecular approaches for structural characterization of Bothrops L-amino
   acid oxidases with antiprotozoal activity: cDNA cloning, comparative
   sequence analysis, and molecular modeling
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE cloning; molecular characterization; three-dimensional modeling;
   phylogenetic analysis; parasiticide activities
ID AGKISTRODON-HALYS-BLOMHOFFII; APOPTOSIS-INDUCING FACTOR; SNAKE-VENOM;
   PLATELET-AGGREGATION; APOXIN I
AB Two L-amino acid oxidases (LAAOs) were identified by random sequencing of cDNA libraries from the venom glands of Bothrops moojeni (BmooLAAO) and Bothrops jararacussu (Bjussu LAAO). Phylogenetic analysis involving other SV-LAAOs showed sequence identities within the range 83-87% being closely related to those from Agkistrodon and Trimeresurus. Molecular modeling experiments indicated the FAD-binding, substrate-binding, and helical domains of Bmoo and Bjussu LAAOs. The RMS deviations obtained by the superposition of those domains and that from Calloselasma rhodostoma LAAO crystal structure confirm the high degree of structural similarity between these enzymes. Purified BjussuLAAO-I and BmooLAAO-I exhibited antiprotozoal activities which were demonstrated to be hydrogen-peroxide mediated. This is the first report on the isolation and identification of cDNAs encoding LAAOs from Bothrops venom. The findings here reported contribute to the overall structural elucidation of SV-LAAOs and will advance the understanding on their mode of action. (c) 2006 Elsevier Inc. All rights reserved.
C1 Univ Ribeirao Preto, UNAERP, Unidade Biotecnol Vegetal, Ribeirao Preto, SP, Brazil.
   Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin Toxicol & Bromatol, BR-14049 Ribeirao Preto, Brazil.
   Univ Fed Amazonas, UFAM, Fac Ciencias Agr, Inst Ciencias Biol, Manaus, Amazonas, Brazil.
   Univ Fed Rondonia, UNIR, IPEPATRO, Inst Pesquisas Patol Trop, Porto Velho, RO, Brazil.
   Univ Estadual Paulista, UNESP, IB, Dept Fis & Biofis, Botucatu, SP, Brazil.
RP Franca, SC (corresponding author), Univ Ribeirao Preto, UNAERP, Unidade Biotecnol Vegetal, Ribeirao Preto, SP, Brazil.
EM sfranca@unaerp.br
RI Magro, Angelo/J-9710-2012; Soares, Andreimar M/K-5556-2014; Fontes,
   Marcos R/B-1941-2009; Vilela, Suely/D-7429-2012; Marins,
   Mozart/U-7048-2017; Franca, Suzelei C/E-4069-2013; Kashima,
   Simone/G-4876-2012; Marins, Mozart/N-8248-2013; VILELA SAMPAIO,
   SUELY/C-3433-2013; Stabeli, Rodrigo Guerino/G-1721-2017
OI Fontes, Marcos R/0000-0002-4634-6221; Vilela, Suely/0000-0003-3274-180X;
   Franca, Suzelei C/0000-0003-4864-430X; Kashima,
   Simone/0000-0002-1487-0141; Stabeli, Rodrigo
   Guerino/0000-0002-0476-920X; ROBERTO, PATRICIA/0000-0001-8932-4666;
   Marins, Mozart/0000-0001-7389-4023; Magro, Angelo
   Jose/0000-0002-4253-6992; Soares, Andreimar/0000-0003-1032-2188
CR Brener Z, 1976, Rev Inst Med Trop Sao Paulo, V18, P450
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
   DeLano W. L., 2002, PYMOL MOL GRAPHICS S
   FELSENSTEIN J, 1997, PHYLIP PHYLOGENY INF
   Izidoro LFM, 2006, BIOORGAN MED CHEM, V14, P7034, DOI 10.1016/j.bmc.2006.06.025
   JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189
   Kashima S, 2004, BIOCHIMIE, V86, P211, DOI 10.1016/j.biochi.2004.02.002
   Moreira MEC, 1996, J CELL PHYSIOL, V167, P305, DOI 10.1002/(SICI)1097-4652(199605)167:2&lt;305::AID-JCP15&gt;3.0.CO;2-6
   Pawelek PD, 2000, EMBO J, V19, P4204, DOI 10.1093/emboj/19.16.4204
   Raibekas AA, 1998, BIOCHEM BIOPH RES CO, V248, P476, DOI 10.1006/bbrc.1998.9024
   Sakurai Y, 2003, BBA-PROTEINS PROTEOM, V1649, P51, DOI 10.1016/S1570-9639(03)00157-2
   Stabeli RG, 2004, BIOORGAN MED CHEM, V12, P2881, DOI 10.1016/j.bmc.2004.03.049
   STABILE RG, 2007, IN PRESS INT J BIOL
   Suhr SM, 1996, BIOCHEM BIOPH RES CO, V224, P134, DOI 10.1006/bbrc.1996.0996
   Takatsuka H, 2001, BBA-PROTEIN STRUCT M, V1544, P267, DOI 10.1016/S0167-4838(00)00229-6
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Torii S, 1997, J BIOL CHEM, V272, P9539, DOI 10.1074/jbc.272.14.9539
   Torii S, 2000, BIOCHEMISTRY-US, V39, P3197, DOI 10.1021/bi992416z
NR 18
TC 37
Z9 40
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 6
PY 2007
VL 355
IS 2
BP 302
EP 306
DI 10.1016/j.bbrc.2006.12.217
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 144DC
UT WOS:000244774700002
PM 17292326
DA 2020-11-26
ER

PT J
AU Kashima, S
   Rodrigues, ES
   Castelli, EC
   Azevedo, RC
   Yoshioka, FKN
   Silva, IT
   Takayanagui, OM
   Covas, DT
AF Kashima, Simone
   Rodrigues, Evandra S.
   Castelli, Erick C.
   Azevedo, Rochele C.
   Yoshioka, France K. N.
   Silva, Israel T.
   Takayanagui, Osvaldo M.
   Covas, Dimas T.
TI DC-SIGN (CD209) promoter region polymorphisms: Populational distribution
   in Brazilian ethnic groups and association with HTLV-1 infection
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT 13th International Conference on Human Retrovirology - HTLV and Related
   Viruses
CY MAY 21-25, 2007
CL Hakone, JAPAN
C1 Univ Sao Paulo, Reg Blood Ctr Ribeirao Preto, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med Rebeirao Preto, Sao Paulo, Brazil.
EM skashima@hemocentro.fmrp.usp.br
RI Kashima, Simone/G-4876-2012; Takayanagui, Osvaldo M/C-8159-2013; Covas,
   Dimas T/C-5431-2013; Rodrigues, Evandra/L-6094-2017
OI Kashima, Simone/0000-0002-1487-0141; Takayanagui, Osvaldo
   M/0000-0002-8190-0275; Covas, Dimas T/0000-0002-7364-2595; Rodrigues,
   Evandra/0000-0003-0964-9554
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD APR
PY 2007
VL 23
IS 4
BP 605
EP 605
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 160AN
UT WOS:000245909300082
DA 2020-11-26
ER

PT J
AU Monteiro, JP
   Ferraro, GA
   Oliveira, T
   Goldani, LZ
   Kashima, S
   Alcantara, LCJ
   Morgado, MG
   Bou-Habib, DC
   Galvao-Castro, B
AF Monteiro, Joana P.
   Ferraro, Geraldo A.
   Oliveira, Tulio
   Goldani, Luciano Z.
   Kashima, Simone
   Alcantara, Luiz C. J.
   Morgado, Mariza G.
   Bou-Habib, Dumith Chequer
   Galvao-Castro, Bernardo
TI Genetic and biologic characterization of HIV type 1 subtype C isolates
   from South Brazil
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; FULL-LENGTH SEQUENCE; DISEASE
   PROGRESSION; V3 LOOP; ENVELOPE; IDENTIFICATION; VACCINE; GP120
AB The molecular and biological properties of HIV-1 subtype C strains from South Brazil were investigated. We sequenced gag and env fragments of viruses from 22 HIV-1-infected individuals from Porto Alegre City, which has the highest frequency of subtype C in the country. The sequences were then compared with other subtype B, C, and F strains isolated in Brazil and other countries using phylogenetic methods. Amino acid signatures were identified and correlated with phenotypic characteristics. We identified six strains with subtype C (27.3%), eight subtype B (36.4%), one subtype F (4.5%), six C/B recombinants (27.3%), and one B/F recombinant (4.5%). The Brazilian subtype C sequences formed a unique phylogenetic group and presented 6 and 18 specific amino acid signatures in gag and env, respectively. Three distinct patterns of C/B recombinants presented characteristic Brazilian amino acid substitutions. Subtype C viruses were predominantly R5 and non-syncytium-inducing, while C/B recombinants were R5/X4 and syncytium-inducing viruses. These findings suggest that subtype C viruses circulating in Brazil are the result of a unique introduction into the country. Recombination events between subtypes B and C have been occurring frequently for more than 10 years in South Brazil. Biological characterization confirms the hypothesis that subtype C is distinct from the others in the evolution of coreceptor utilization.
C1 LASP CP GM FIOCRUZ, BR-40296710 Salvador, BA, Brazil.
   FBDC, EBMSP, Salvador, BA, Brazil.
   Univ Oxford, Dept Zool, Oxford, England.
   UFRS, Hosp Clin Porto Alegre, Unidade Med Interna, Porto Alegre, RS, Brazil.
   Univ Sao Paulo, Hemoctr Ribeirao Preto, Sao Paulo, Brazil.
   Fiocruz MS, Inst Oswaldo Cruz, Dept Imunol, Lab AIDS & Imunol Mol, Rio De Janeiro, RJ, Brazil.
   Fiocruz MS, Inst Oswaldo Cruz, Dept Imunol, Lab Imunol Clin, Rio De Janeiro, RJ, Brazil.
RP Galvao-Castro, B (corresponding author), LASP CP GM FIOCRUZ, Rua Waldemar Falcao 121, BR-40296710 Salvador, BA, Brazil.
EM bgalvao@cpqgm.fiocruz.br
RI Goldani, Luciano Zubaran/U-4617-2019; Kashima, Simone/G-4876-2012
OI Kashima, Simone/0000-0002-1487-0141; Alcantara, Luiz/0000-0002-6769-9931
CR Aulicino PC, 2005, AIDS RES HUM RETROV, V21, P894, DOI 10.1089/aid.2005.21.894
   Blackard JT, 1999, VIROLOGY, V254, P220, DOI 10.1006/viro.1998.9504
   Bongertz V, 2000, J ACQ IMMUN DEF SYND, V23, P184
   Brindeiro R, 1999, ANTIMICROB AGENTS CH, V43, P1674, DOI 10.1128/AAC.43.7.1674
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Carr JK, 1996, J VIROL, V70, P5935, DOI 10.1128/JVI.70.9.5935-5943.1996
   Carrillo A, 1996, J VIROL, V70, P1301, DOI 10.1128/JVI.70.2.1301-1309.1996
   Carrion G, 2004, AIDS RES HUM RETROV, V20, P1022, DOI 10.1089/aid.2004.20.1022
   Cecilia D, 2000, VIROLOGY, V271, P253, DOI 10.1006/viro.2000.0297
   Chackerian B, 1997, J VIROL, V71, P7719, DOI 10.1128/JVI.71.10.7719-7727.1997
   Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621
   Cornelissen M, 1996, J VIROL, V70, P8209, DOI 10.1128/JVI.70.11.8209-8212.1996
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655
   DEWOLF F, 1994, AIDS RES HUM RETROV, V10, P1387, DOI 10.1089/aid.1994.10.1387
   DOE B, 1994, EUR J IMMUNOL, V24, P2369, DOI 10.1002/eji.1830241017
   Esparza J, 2000, LANCET, V355, P2061, DOI 10.1016/S0140-6736(00)02360-6
   Ferraro GA, 2001, AIDS RES HUM RETROV, V17, P1241, DOI 10.1089/088922201750461294
   Gordon M, 2003, J VIROL, V77, P2587, DOI 10.1128/JVI.77.4.2587-2599.2003
   Guiniaraes ML, 2002, AIDS RES HUM RETROV, V18, P1261, DOI 10.1089/088922202320886307
   HALL TA, 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.5598/IMAFUNGUS.2011.02.02.06
   Heyndrickx L, 2000, J VIROL, V74, P363, DOI 10.1128/JVI.74.1.363-370.2000
   Hu QX, 2000, J VIROL, V74, P11858, DOI 10.1128/JVI.74.24.11858-11872.2000
   KORBER BTM, 1994, J VIROL, V68, P6730, DOI 10.1128/JVI.68.10.6730-6744.1994
   Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244
   Montano MA, 1997, J VIROL, V71, P8657, DOI 10.1128/JVI.71.11.8657-8665.1997
   Morgado MG, 2002, MEM I OSWALDO CRUZ, V97, P143, DOI 10.1590/S0074-02762002000200001
   Ndung'u T, 2001, J VIROL, V75, P4964, DOI 10.1128/JVI.75.11.4964-4972.2001
   Nicholas KB, 1997, GENEDOC ANAL VISUALI
   OSMANOV S, 1994, AIDS RES HUM RETROV, V10, P1327, DOI 10.1089/aid.1994.10.1327
   Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357
   Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679
   Rodrigues R, 2006, VIRUS RES, V116, P201, DOI 10.1016/j.virusres.2005.10.004
   RUBSAMENWAIGMANN H, 1994, AIDS RES HUM RETROV, V10, P1401, DOI 10.1089/aid.1994.10.1401
   Salemi M, 2005, J MOL EVOL, V60, P598, DOI 10.1007/s00239-004-0206-5
   SALMINEN MO, 1995, AIDS RES HUM RETROV, V11, P1423, DOI 10.1089/aid.1995.11.1423
   Salminen MO, 1996, AIDS RES HUM RETROV, V12, P1329, DOI 10.1089/aid.1996.12.1329
   Shankarappa R, 2001, J VIROL, V75, P10479, DOI 10.1128/JVI.75.21.10479-10487.2001
   Soares MA, 2003, AIDS, V17, P11, DOI 10.1097/00002030-200301030-00004
   Swofford DL, 1999, PAUP 4 0 PHYLOGENETI
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Yamaguchi-Kabata Y, 2000, J VIROL, V74, P4335, DOI 10.1128/JVI.74.9.4335-4350.2000
NR 42
TC 7
Z9 8
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD JAN
PY 2007
VL 23
IS 1
BP 135
EP 143
DI 10.1089/aid.2006.0064
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 133EM
UT WOS:000243995300018
PM 17263643
OA Green Published
DA 2020-11-26
ER

PT J
AU Carrara, RCV
   Orellana, MD
   Fontes, AM
   Palma, PVB
   Kashima, S
   Mendes, MR
   Coutinho, MA
   Voltarelli, JC
   Covas, DT
AF Carrara, R. C. V.
   Orellana, M. D.
   Fontes, A. M.
   Palma, P. V. B.
   Kashima, S.
   Mendes, M. R.
   Coutinho, M. A.
   Voltarelli, J. C.
   Covas, D. T.
TI Mesenchymal stem cells from patients with chronic myeloid leukemia do
   not express BCR-ABL and have absence of chimerism after allogeneic bone
   marrow transplant
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE mesenchymal stem cells; chimerism; allogeneic hematopoietic stem cell
   transplantation; chronic myeloid leukemia; bcr-abl gene
ID CHRONIC MYELOGENOUS LEUKEMIA; SEVERE APLASTIC-ANEMIA; PERIPHERAL-BLOOD;
   ENGRAFTMENT CAPACITY; DONOR ORIGIN; TISSUES; MODEL; CHROMOSOME;
   RADIATION; FAILURE
AB Bone marrow is a heterogeneous cell population which includes hematopoietic and mesenchymal progenitor cells. Dysregulated hematopoiesis occurs in chronic myelogenous leukemia (CML), being caused at least in part by abnormalities in the hematopoietic progenitors. However, the role of mesenchymal stem cells (MSCs) in CML has not been well characterized. The objectives of the present study were to observe the biological characteristics of MSCs from CML patients and to determine if MSCs originate in part from donors in CML patients after bone marrow transplantation (BMT). We analyzed MSCs from 5 untreated patients and from 3 CML patients after sex-mismatched allogeneic BMT. Flow cytometry analysis revealed the typical MSC phenotype and in vitro assays showed ability to differentiate into adipocytes and osteoblasts. Moreover, although some RTPCR data were contradictory, combined fluorescence in situ hybridization analysis showed that MSCs from CML patients do not express the bcr-abl gene. Regarding MSCs of donor origin, although it is possible to detect Y target sequence by nested PCR, the low frequency (0.14 and 0.34%) of XY cells in 2 MSC CML patients by fluorescence in situ hybridization analysis suggests the presence of contaminant hematopoietic cells and the absence of host-derived MSCs in CML patients. Therefore, we conclude that MSCs from CML patients express the typical MSC phenotype, can differentiate into osteogenic and adipogenic lineages and do not express the bcr-abl gene. MSCs cannot be found in recipients 12 to 20 months after BMT. The influence of MSCs on the dysregulation of hematopoiesis in CML patients deserves further investigation.
C1 USP, Ctr Reg Hemoterapia, FMRP, Dept Clin Med, BR-14051140 Ribeirao Preto, Brazil.
RP Covas, DT (corresponding author), USP, Ctr Reg Hemoterapia, FMRP, Dept Clin Med, Rua Tenente Catao Roxo 2501, BR-14051140 Ribeirao Preto, Brazil.
EM dimas@fmrp.usp.br
RI Fontes, Aparecida Maria/ABF-2892-2020; Orellana, Maristela/L-5542-2014;
   Kashima, Simone/G-4876-2012; Fontes, Aparecida M/F-5627-2013; Covas,
   Dimas T/C-5431-2013
OI Fontes, Aparecida Maria/0000-0002-4878-417X; Orellana,
   Maristela/0000-0003-0159-4472; Kashima, Simone/0000-0002-1487-0141;
   Fontes, Aparecida M/0000-0002-4878-417X; Covas, Dimas
   T/0000-0002-7364-2595
CR Awaya N, 2002, EXP HEMATOL, V30, P937, DOI 10.1016/S0301-472X(02)00821-4
   BHATIA R, 1995, BLOOD, V85, P3636, DOI 10.1182/blood.V85.12.3636.bloodjournal85123636
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471-4914(01)02016-0
   Chapel A, 2003, J GENE MED, V5, P1028, DOI 10.1002/jgm.452
   Cilloni D, 2000, BLOOD, V96, P3637
   Coutinho V, 1968, Rev Paul Med, V72, P9
   Covas DT, 2003, BRAZ J MED BIOL RES, V36, P1179, DOI 10.1590/S0100-879X2003000900006
   Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343
   Devine SM, 2003, BLOOD, V101, P2999, DOI 10.1182/blood-2002-06-1830
   Fang BJ, 2005, BLOOD, V105, P2733, DOI 10.1182/blood-2004-07-2514
   Gunsilius E, 2000, LANCET, V355, P1688, DOI 10.1016/S0140-6736(00)02241-8
   Hayakawa J, 2003, INT J HEMATOL, V77, P456, DOI 10.1007/BF02986613
   Kabarowski JHS, 2000, STEM CELLS, V18, P399, DOI 10.1002/stem.180399
   KEATING A, 1982, NATURE, V298, P280, DOI 10.1038/298280a0
   Mahmud N, 2004, EXP HEMATOL, V32, P494, DOI 10.1016/j.exphem.2004.02.010
   Minguell JJ, 2001, EXP BIOL MED, V226, P507
   Mitelman F, 1995, ISCN 1995 INT SYSTEM
   MOORHEAD PS, 1960, EXP CELL RES, V20, P613, DOI 10.1016/0014-4827(60)90138-5
   NOWELL PC, 1960, SCIENCE, V132, P1497
   Poloni A, 2006, LEUKEMIA, V20, P329, DOI 10.1038/sj.leu.2404018
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Rieger K, 2005, EXP HEMATOL, V33, P605, DOI 10.1016/j.exphem.2005.02.004
   Silva WA, 2003, STEM CELLS, V21, P661, DOI 10.1634/stemcells.21-6-661
   STORB R, 1989, BRIT J HAEMATOL, V72, P567, DOI 10.1111/j.1365-2141.1989.tb04325.x
   Stute N, 2002, J HEMATOTH STEM CELL, V11, P977, DOI 10.1089/152581602321080646
   Villaron EM, 2006, EXP HEMATOL, V34, P7, DOI 10.1016/j.exphem.2005.09.014
   Villaron EM, 2004, HAEMATOLOGICA, V89, P1421
   Zhao ZG, 2006, LEUKEMIA RES, V30, P993, DOI 10.1016/j.leukres.2005.12.010
NR 28
TC 18
Z9 21
U1 0
U2 5
PU ASSOC BRAS DIVULG CIENTIFICA
PI RIBEIRAO PRETO
PA FACULDADE MEDICINA, CASA 10, 14049 RIBEIRAO PRETO, RIBEIRAO PRETO, SP
   14049, BRAZIL
SN 0100-879X
EI 1414-431X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD JAN
PY 2007
VL 40
IS 1
BP 57
EP 67
DI 10.1590/S0100-879X2006005000055
PG 11
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 126AW
UT WOS:000243485600008
PM 17224997
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Kashima, S
   Alcantara, LC
   Takayanagui, OM
   Cunha, MAV
   Castro, BG
   Pombo-De-Oliveira, MS
   Zago, MA
   Covas, DT
AF Kashima, Simone
   Alcantara, Luiz Carlos
   Takayanagui, Osvaldo Massaiti
   Valtas Cunha, Marco Aurelio
   Castro, Bernardo Galvao
   Pombo-De-Oliveira, Maria Socorro
   Zago, Marco Antonio
   Covas, Dimas Tadeu
TI Distribution of human T cell lymphotropic virus type 1 (HTLV-1) subtypes
   in Brazil: Genetic characterization of LTR and tax region
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID TROPICAL SPASTIC PARAPARESIS; PHYLOGENETIC SUBTYPES; LEUKEMIA-LYMPHOMA;
   I INFECTION; EPIDEMIOLOGY; SEQUENCE; AMERICA; STRAINS; PYGMY;
   CLASSIFICATION
AB We report the molecular and epidemiological characterization of 128 human T cell lymphotropic virus type 1 (HTLV-1) isolates from Brazilian patients with different clinical manifestations of the infection. Thirty-two percent of the patients were asymptomatic, 44% had HTLV-1-associated myelopathy/ tropical spastic paraparesis (HAM/TSP), and 23% had adult T cell leukemia/lymphoma (ATLL). Phylogenetic analysis performed using part of the LTR region of the viral genome revealed that all Brazilian isolates belonged to the Cosmopolitan subtype, with the following distribution within the Transcontinental subgroup: 81.6% within the Latin American cluster and 15.8% outside the Latin American cluster. Two isolates belonged to the Japanese subgroup. Molecular analysis of the tax region showed a high nucleotide similarity (similar to 99%) with 41 prototype sequences, including the ATK-1 isolate. The mean number of nucleotide substitutions ranged from 1 to 8. Five specific nucleotide substitutions, C7401T, T7914C, C7920T, C7982T, and G8231A, were highly conserved among the Brazilian isolates (79.6%), with a frequency ranging from 81.6% to 100% in the sample group and from 18.4% to 24.1% in the prototypes used, suggesting the existence of a molecular signature. These changes were not correlated with a specific clinical status of the patients and could be a molecular characteristic of the HTLV-1 strains that circulate in Brazil.
C1 Reg Blood Ctr Ribeirao Preto, Mol Biol Lab, BR-14051140 Ribeirao Preto, Brazil.
   Fundacao Oswaldo Cruz, Goncalo Moniz Res Ctr, Adv Publ Hlth Lab, Salvador, BA, Brazil.
   Univ Sao Paulo, Dept Neurol, Sao Paulo, Brazil.
   Reg Blood Ctr Ribeirao Preto, Bioinformat Lab, BR-14051140 Ribeirao Preto, Brazil.
   Inst Nacl Canc, Rio De Janeiro, Brazil.
   Univ Sao Paulo, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
RP Kashima, S (corresponding author), Reg Blood Ctr Ribeirao Preto, Mol Biol Lab, Rue Tenente Catao Roxo,2501, BR-14051140 Ribeirao Preto, Brazil.
EM skashima@hemocentro.fmrp.usp.br
RI Kashima, Simone/G-4876-2012; Covas, Dimas T/C-5431-2013; Takayanagui,
   Osvaldo M/C-8159-2013; Pombo-de-Oliveira, Maria S./I-8884-2014; ZAGO,
   MARCO A/E-9442-2017
OI Kashima, Simone/0000-0002-1487-0141; Covas, Dimas T/0000-0002-7364-2595;
   Takayanagui, Osvaldo M/0000-0002-8190-0275; Pombo-de-Oliveira, Maria
   S./0000-0002-1507-004X; Alcantara, Luiz/0000-0002-6769-9931
CR Alcantara LCJ, 2003, AIDS RES HUM RETROV, V19, P519, DOI 10.1089/088922203766774577
   ARANGO C, 1988, ANN NEUROL, V23, pS161, DOI 10.1002/ana.410230736
   CARTIER L, 1989, J NEUROL NEUROSUR PS, V52, P304, DOI 10.1136/jnnp.52.3.304
   Chen JL, 1995, AIDS RES HUM RETROV, V11, P1529, DOI 10.1089/aid.1995.11.1529
   Dourado I, 2003, JAIDS-J ACQ IMM DEF, V34, P527, DOI 10.1097/00126334-200312150-00013
   Furukawa Y, 2000, J INFECT DIS, V182, P1343, DOI 10.1086/315897
   GalvaoCastro B, 1997, TRANSFUSION, V37, P242, DOI 10.1046/j.1537-2995.1997.37297203532.x
   GASMI M, 1994, AIDS RES HUM RETROV, V10, P1313, DOI 10.1089/aid.1994.10.1313
   GESSAIN A, 1993, J VIROL, V67, P1015, DOI 10.1128/JVI.67.2.1015-1023.1993
   GESSAIN A, 1985, LANCET, V2, P407
   GUDERIAN R, 1994, T ROY SOC TROP MED H, V88, P399, DOI 10.1016/0035-9203(94)90398-0
   HAHN BH, 1984, INT J CANCER, V34, P613, DOI 10.1002/ijc.2910340505
   KORBER B, 1992, AIDS RES HUM RETROV, V8, P1549, DOI 10.1089/aid.1992.8.1549
   Mboudjeka I, 1997, JPN J CANCER RES, V88, P619, DOI 10.1111/j.1349-7006.1997.tb00427.x
   MIURA T, 1994, P NATL ACAD SCI USA, V91, P1124, DOI 10.1073/pnas.91.3.1124
   MOREIRA ED, 1993, J ACQ IMMUN DEF SYND, V6, P959
   MUELLER N, 1991, CANCER CAUSE CONTROL, V2, P37, DOI 10.1007/BF00052359
   OSAME M, 1986, LANCET, V1, P1031
   Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Salemi M, 1998, VIROLOGY, V246, P277, DOI 10.1006/viro.1998.9215
   SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x
   UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481
   Van Dooren S, 1998, J GEN VIROL, V79, P2695, DOI 10.1099/0022-1317-79-11-2695
   VIDAL AU, 1994, J GEN VIROL, V75, P3655, DOI 10.1099/0022-1317-75-12-3655
   Wolfe ND, 2005, P NATL ACAD SCI USA, V102, P7994, DOI 10.1073/pnas.0501734102
   YAMASHITA M, 1995, VIRUS GENES, V10, P85, DOI 10.1007/BF01724300
   Yamashita M, 1999, VIROLOGY, V261, P59
NR 29
TC 21
Z9 21
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2006
VL 22
IS 10
BP 953
EP 959
DI 10.1089/aid.2006.22.953
PG 7
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 101FV
UT WOS:000241726000005
PM 17067264
OA Green Published
DA 2020-11-26
ER

PT J
AU Fontes, A
   Neder, L
   Orellana, M
   Prata, K
   Carrara, R
   Palma, P
   Kashima, S
   Zago, MA
   Covas, D
AF Fontes, Aparecida
   Neder, Luciano
   Orellana, Maristela
   Prata, Karen
   Carrara, Rita
   Palma, Patricia
   Kashima, Simone
   Zago, Marco A.
   Covas, Dimas
TI Morphologic and immunohistochemistry caracterization of human
   mesenchymal stem cells differentiated into osteocytes, adypocytes and
   chondrocytes from distinct sources
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 26th International Congress of the International-Academy-of-Pathology
CY SEP 16-21, 2006
CL Montreal, CANADA
SP Int Acad Pathol, United States & Canadian Acad Pathol
C1 Univ Sao Paulo, Ribeirao Preto Med Sch, BR-14049 Ribeirao Preto, Brazil.
RI Covas, Dimas T/C-5431-2013; ZAGO, MARCO A/E-9442-2017; Fontes, Aparecida
   Maria/ABF-2892-2020; Fontes, Aparecida M/F-5627-2013; Kashima,
   Simone/G-4876-2012; Prata, Karen/I-4568-2013
OI Covas, Dimas T/0000-0002-7364-2595; Fontes, Aparecida
   Maria/0000-0002-4878-417X; Fontes, Aparecida M/0000-0002-4878-417X;
   Kashima, Simone/0000-0002-1487-0141; 
NR 0
TC 0
Z9 0
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
J9 MODERN PATHOL
JI Mod. Pathol.
PD SEP
PY 2006
VL 19
SU 3
MA 523
BP 114
EP 114
PG 1
WC Pathology
SC Pathology
GA 077AF
UT WOS:000239999400524
DA 2020-11-26
ER

PT J
AU Carbolante, EM
   Medeiros, L
   Penteado, FL
   Kashima, SK
   Covas, D
AF Carbolante, EM
   Medeiros, L
   Penteado, FL
   Kashima, SK
   Covas, D
TI Heterologous expression of gp21 from HTLV-1 and immunoblotting with
   monoclonal and patient antibodies
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT 12th International Conference on Human Retrovirology - HTLV and Related
   Viruses
CY JUN 22-25, 2005
CL Montego Bay, JAMAICA
SP Int Retrovirol Assoc, Natl Inst Hlth, Univ W Indies, Natl Inst Allergy & Infect Dis, Natl Canc Inst, Natl Inst Neurol Dis & Stroke, BD Biosci, Bristol-Myers Squibb, Ohio State Univ, Ctr Retrovirus Res, Dept Vet Biosci, Genome Sci Lab Ltd, Horai Chem Co Ltd, Natl Inst Drug Abuse, Sci Supplies & Technol, Jamaica Med Fdn, J Wray & Nephew Ltd, Red Stripe, UCSF AIDS & Canc Specimen Resource
C1 Blood Ctr Ribeirao Preto, Ribeirao Preto, Brazil.
RI Kashima, Simone/G-4876-2012; Covas, Dimas T/C-5431-2013
OI Kashima, Simone/0000-0002-1487-0141; Covas, Dimas T/0000-0002-7364-2595
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD MAY
PY 2005
VL 21
IS 5
MA P100
BP 492
EP 492
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 936AV
UT WOS:000229825700181
DA 2020-11-26
ER

PT J
AU Azevedo, R
   Kashima, SK
   Hachiya, EM
   Costa, MR
   Takayanagui, OM
   De Oliveira, MP
   Zago, M
   Covas, D
AF Azevedo, R
   Kashima, SK
   Hachiya, EM
   Costa, MR
   Takayanagui, OM
   De Oliveira, MP
   Zago, M
   Covas, D
TI Interleukin-6 and lymphotoxin-alfa polymorphisms in HTLV-1 infection
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT 12th International Conference on Human Retrovirology - HTLV and Related
   Viruses
CY JUN 22-25, 2005
CL Montego Bay, JAMAICA
SP Int Retrovirol Assoc, Natl Inst Hlth, Univ W Indies, Natl Inst Allergy & Infect Dis, Natl Canc Inst, Natl Inst Neurol Dis & Stroke, BD Biosci, Bristol-Myers Squibb, Ohio State Univ, Ctr Retrovirus Res, Dept Vet Biosci, Genome Sci Lab Ltd, Horai Chem Co Ltd, Natl Inst Drug Abuse, Sci Supplies & Technol, Jamaica Med Fdn, J Wray & Nephew Ltd, Red Stripe, UCSF AIDS & Canc Specimen Resource
C1 Blood Ctr Ribeirao Preto Brazil, Mol Biol Lab, Ribeirao Preto, Brazil.
   Univ Sao Paulo, Ribeirao Preto, SP, Brazil.
   Natl Canc Inst, Rio De Janeiro, Brazil.
RI Kashima, Simone/G-4876-2012; Takayanagui, Osvaldo M/C-8159-2013; Covas,
   Dimas T/C-5431-2013
OI Kashima, Simone/0000-0002-1487-0141; Takayanagui, Osvaldo
   M/0000-0002-8190-0275; Covas, Dimas T/0000-0002-7364-2595
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD MAY
PY 2005
VL 21
IS 5
MA P113
BP 495
EP 496
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 936AV
UT WOS:000229825700194
DA 2020-11-26
ER

PT J
AU Kashima, S
   Azevedo, R
   Hachiya, EM
   Takayanagui, OM
   De Oliveira, MP
   Covas, DT
AF Kashima, S
   Azevedo, R
   Hachiya, EM
   Takayanagui, OM
   De Oliveira, MP
   Covas, DT
TI HTLV-1 proviral load by SYBR Green assay
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT 12th International Conference on Human Retrovirology - HTLV and Related
   Viruses
CY JUN 22-25, 2005
CL Montego Bay, JAMAICA
SP Int Retrovirol Assoc, Natl Inst Hlth, Univ W Indies, Natl Inst Allergy & Infect Dis, Natl Canc Inst, Natl Inst Neurol Dis & Stroke, BD Biosci, Bristol-Myers Squibb, Ohio State Univ, Ctr Retrovirus Res, Dept Vet Biosci, Genome Sci Lab Ltd, Horai Chem Co Ltd, Natl Inst Drug Abuse, Sci Supplies & Technol, Jamaica Med Fdn, J Wray & Nephew Ltd, Red Stripe, UCSF AIDS & Canc Specimen Resource
C1 Blood Ctr Ribeirao Preto, Mol Biol Lab, Sao Paulo, Brazil.
   Univ Sao Paulo, Sao Paulo, Brazil.
   Natl Canc Inst, Rio De Janeiro, Brazil.
RI Covas, Dimas T/C-5431-2013; Takayanagui, Osvaldo M/C-8159-2013; Kashima,
   Simone/G-4876-2012
OI Covas, Dimas T/0000-0002-7364-2595; Takayanagui, Osvaldo
   M/0000-0002-8190-0275; Kashima, Simone/0000-0002-1487-0141
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD MAY
PY 2005
VL 21
IS 5
MA P160
BP 509
EP 509
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 936AV
UT WOS:000229825700241
DA 2020-11-26
ER

PT J
AU Covas, DT
   Kashima, S
   Guerreiro, JF
   dos Santos, SEB
   Zago, MA
AF Covas, DT
   Kashima, S
   Guerreiro, JF
   dos Santos, SEB
   Zago, MA
TI Variation in the Fc gamma R3B gene among distinct Brazilian populations
SO TISSUE ANTIGENS
LA English
DT Article
DE Amerinds; Brazil; Fc gamma RIII alleles; granulocytes antigens;
   population genetics
ID POLYMERASE-CHAIN-REACTION; GAMMA RECEPTOR IIIB; FREQUENCIES; SH;
   NOMENCLATURE; NA1; POLYMORPHISM; EXPRESSION; ANTIGENS; AFRICAN
AB The FCGR3B gene codes for the FcgammaR3b receptor, which occurs in three polymorphic forms representing the human neutrophil antigens (HNA)-1a, HNA-1b, and HNA-1c. The alleles that code for these antigens are FCGR3B*1, FCGR3B*2, and FCGR3B*3, respectively. New variants of these alleles have been recently described. In order to study the frequency of these alleles and the occurrence of variant forms, we sequenced part of the FCGR3B gene in 149 individuals belonging to four distinct Brazilian populations, i.e., 60 Amerindians, 30 Whites of European descent, 30 Afro-Brazilians, and 30 Japanese. The FCGR3B*1 allele showed high frequency among Amerindians (0.850), with the value detected representing the highest frequency described thus far for this allele in population studies. Its frequency was 0.660 in the Japanese population studied, a value equal to that observed in Afro-Brazilians (0.600) and higher than that observed in Whites (0.480). The FCGR3B*3 allele was only found among Afro-Brazilians, where it occurred at a frequency of 0.080, which was lower than the frequency observed among Afro-North Americans (0.207) and Ugandans (0.166). Two variant haplotypes were detected among Amerindians and Afro-Brazilians, occurring in six individuals (four Amerindians and two Afro-Brazilians). The variant haplotype FCGR3B*1 A227G, which occurred in homozygosis in two Amerindians and in heterozygosis in two Afro-Brazilians, is described for the first time in the present report. In general, these data reveal variability in the frequency of alleles of the FCGR3B gene compared to other populations of the same genetic background in other regions of the world.
C1 Univ Sao Paulo, HCFMRP, Ctr Reg Hemoterapia Ribeirao Preto, BR-14051140 Ribeirao Preto, SP, Brazil.
   FAPESP, CTC, CEPID, Reg Blood Ctr Ribeirao Preto, Ribeirao Preto, SP, Brazil.
   Fed Univ Para, Human & Med Genet Lab, BR-66059 Belem, Para, Brazil.
RP Covas, DT (corresponding author), Univ Sao Paulo, HCFMRP, Ctr Reg Hemoterapia Ribeirao Preto, R Tenente Catao Roxo 2501, BR-14051140 Ribeirao Preto, SP, Brazil.
EM dimas@fmrp.usp.br
RI Kashima, Simone/G-4876-2012; Covas, Dimas T/C-5431-2013; ZAGO, MARCO
   A/E-9442-2017
OI Kashima, Simone/0000-0002-1487-0141; Covas, Dimas T/0000-0002-7364-2595;
   
CR Bux J, 1999, TRANSFUSION, V39, P662, DOI 10.1046/j.1537-2995.1999.39060662.x
   BUX J, 1995, TRANSFUSION, V35, P54, DOI 10.1046/j.1537-2995.1995.35195090663.x
   Bux J, 1997, BLOOD, V89, P1027, DOI 10.1182/blood.V89.3.1027
   Covas DT, 1997, VOX SANG, V73, P182, DOI 10.1046/j.1423-0410.1997.7330182.x
   Covas DT, 2000, EUR J HAEMATOL, V65, P128, DOI 10.1034/j.1600-0609.2000.90172.x
   Flesch BK, 2002, TRANSFUSION, V42, P469, DOI 10.1046/j.1525-1438.2002.00087.x
   Fujiwara K, 1999, VOX SANG, V77, P218, DOI 10.1159/000031130
   Gessner JE, 1998, ANN HEMATOL, V76, P231, DOI 10.1007/s002770050396
   Gittinger FS, 2002, TISSUE ANTIGENS, V60, P64, DOI 10.1034/j.1399-0039.2002.600108.x
   Guz K, 2000, TRANSFUSION, V40, P490, DOI 10.1046/j.1537-2995.2000.40040490.x
   Hessner MJ, 1996, TRANSFUSION, V36, P895, DOI 10.1046/j.1537-2995.1996.361097017176.x
   HUIZINGA TWJ, 1990, BLOOD, V75, P213
   Kissel K, 2000, TISSUE ANTIGENS, V56, P143, DOI 10.1034/j.1399-0039.2000.560205.x
   Koene HR, 1998, BLOOD, V91, P673, DOI 10.1182/blood.V91.2.673.673_673_679
   Kuwano ST, 2000, TRANSFUSION, V40, P1388, DOI 10.1046/j.1537-2995.2000.40111388.x
   Matsuo K, 2000, TRANSFUSION, V40, P645, DOI 10.1046/j.1537-2995.2000.40060645.x
   ORY PA, 1989, J CLIN INVEST, V84, P1688, DOI 10.1172/JCI114350
   QIU WQ, 1990, SCIENCE, V248, P732, DOI 10.1126/science.2139735
   Rascu A, 1997, ANN NY ACAD SCI, V815, P282, DOI 10.1111/j.1749-6632.1997.tb52070.x
   RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481
   Salas A, 2004, AM J HUM GENET, V74, P454, DOI 10.1086/382194
   Steffensen R, 2000, TRANSFUSION, V40, P491, DOI 10.1046/j.1537-2995.2000.40040491.x
   Steffensen R, 1999, TRANSFUSION, V39, P593, DOI 10.1046/j.1537-2995.1999.39060593.x
   Zago MA, 1996, HUM HERED, V46, P274, DOI 10.1159/000154364
NR 24
TC 14
Z9 14
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-2815
EI 1399-0039
J9 TISSUE ANTIGENS
JI Tissue Antigens
PD FEB
PY 2005
VL 65
IS 2
BP 178
EP 182
DI 10.1111/j.1399-0039.2005.00352.x
PG 5
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA 897QQ
UT WOS:000227020100007
PM 15713217
DA 2020-11-26
ER

PT J
AU Roberto, PG
   Kashima, S
   Soares, AM
   Chioato, L
   Faca, VM
   Fuly, AL
   Astolfi, S
   Pereira, JO
   Franca, SC
AF Roberto, PG
   Kashima, S
   Soares, AM
   Chioato, L
   Faca, VM
   Fuly, AL
   Astolfi, S
   Pereira, JO
   Franca, SC
TI Cloning and expression of an acidic platelet aggregation inhibitor
   phospholipase A(2) cDNA from Bothrops jararacussu venom gland
SO PROTEIN EXPRESSION AND PURIFICATION
LA English
DT Article
DE Bothrops jararacussu snake; ESTs; gene expression; acidic phospholipases
   A(2); platelet aggregation inhibitor
ID ESCHERICHIA-COLI; SNAKE-VENOM; FUNCTIONAL-CHARACTERIZATION;
   LYS(49)-PHOSPHOLIPASE A(2); SYNTHETIC GENE; LYS49; PURIFICATION;
   ACTIVATION; MECHANISM; SEQUENCE
AB The phospholipase A(2) (PLA(2), E.C. 3.1.1.4) superfamily is defined by enzymes that catalyze the hydrolysis of the sn-2 bond of phosphoglycerides. Most PLA(2)s from the venom of Bothrops species are basic proteins, which have been well characterized both structurally and functionally, however, little is known about acidic PLA(2)s from this venom. Nevertheless, it has been demonstrated that they are non-toxic, with high catalytic and hypotensive activities and show the ability to inhibit platelet aggregation. To further understand the function of these proteins, we have isolated a cDNA that encodes an acidic PLA2 from a cDNA library prepared from the poly(A)(+) RNA of venom gland of Bothrops jararacussu. The full-length nucleotide sequence of 366 base pairs encodes a predicted gene product with 122 amino acid with theoretical isoelectric point and size of 5.28 and 13,685 kDa, respectively. This acidic PLA(2) sequence was cloned into expression vector pET11a (+) and expressed as inclusion bodies in Escherichia coli BL21(DE3)pLysS. The N-terminal amino acid sequence of the 14 kDa recombinant protein was determined. The recombinant acidic PLA(2) protein was submitted to refolding and to be purified by RP-HPLC chromatography. The structure and function of the recombinant protein was compared to that of the native protein by circular dichroism (CD), enzymatic activity, edema-inducing, and platelet aggregation inhibition activities. (C) 2004 Elsevier Inc. All rights reserved.
C1 Univ Ribeirao Preto, UNAERP, Unidade Biotecnol, Ribeirao Preto, SP, Brazil.
   Univ Sao Paulo, FMRP, Dept Bioquim & Imunol, Ribeirao Preto, SP, Brazil.
   Univ Sao Paulo, Ctr Quim Proteinas, BR-14049 Ribeirao Preto, SP, Brazil.
   Univ Sao Paulo, Dept Biol Celular Mol & Bioagentes Patogen, BR-14049 Ribeirao Preto, SP, Brazil.
   Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Dept Bioquim Med, Rio De Janeiro, RJ, Brazil.
   Univ Fed Amazonas, Fac Ciencias Agrarias, Manaus, Amazonas, Brazil.
RP Soares, AM (corresponding author), Univ Ribeirao Preto, UNAERP, Unidade Biotecnol, Ribeirao Preto, SP, Brazil.
EM andreimar@unaerp.br; suzicf@odin.unaerp.br
RI Faca, Vitor/A-3989-2013; Fuly, Andre/U-1538-2019; Kashima,
   Simone/G-4876-2012; Soares, Andreimar M/K-5556-2014; Franca, Suzelei
   C/E-4069-2013
OI Kashima, Simone/0000-0002-1487-0141; Franca, Suzelei
   C/0000-0003-4864-430X; FACA, VITOR MARCEL/0000-0003-3205-7944; ROBERTO,
   PATRICIA/0000-0001-8932-4666; Soares, Andreimar/0000-0003-1032-2188
CR Andriao-Escarso SH, 2002, BIOCHEM PHARMACOL, V64, P723, DOI 10.1016/S0006-2952(02)01210-8
   Arni RK, 1996, TOXICON, V34, P827, DOI 10.1016/0041-0101(96)00036-0
   Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175
   Chang LS, 1996, BIOCHEM BIOPH RES CO, V225, P990, DOI 10.1006/bbrc.1996.1283
   Chioato L, 2002, BIOCHEM J, V366, P971, DOI 10.1042/BJ20020092
   Cura JE, 2002, CLIN CANCER RES, V8, P1033
   deAraujo HSS, 1996, ARCH BIOCHEM BIOPHYS, V326, P21, DOI 10.1006/abbi.1996.0042
   Fenard D, 1999, J CLIN INVEST, V104, P611, DOI 10.1172/JCI6915
   Fuly AL, 1997, THROMB HAEMOSTASIS, V78, P1372
   GUTIERREZ JM, 1988, TOXICON, V26, P411, DOI 10.1016/0041-0101(88)90010-4
   Gutierrez JM, 2002, REV BIOL TROP, V50, P377
   Kashima S, 2004, BIOCHIMIE, V86, P211, DOI 10.1016/j.biochi.2004.02.002
   Kashima S, 2002, BIOCHIMIE, V84, P675, DOI 10.1016/S0300-9084(02)01429-3
   KELLEY MJ, 1992, BIOCHIM BIOPHYS ACTA, V1118, P107, DOI 10.1016/0167-4838(92)90136-2
   KINI RM, 1989, TOXICON, V27, P613, DOI 10.1016/0041-0101(89)90013-5
   Kini RM, 1997, VENOM PHOSPHOLIPASE, P1
   Lizano S, 2001, INT J BIOCHEM CELL B, V33, P127, DOI 10.1016/S1357-2725(00)00073-X
   Othman R, 1996, BBA-LIPID LIPID MET, V1303, P92, DOI 10.1016/0005-2760(96)00083-5
   Ownby CL, 1998, J TOXICOL-TOXIN REV, V17, P213, DOI 10.3109/15569549809009250
   Paramo L, 1998, EUR J BIOCHEM, V253, P452, DOI 10.1046/j.1432-1327.1998.2530452.x
   RICKLES FR, 1983, BLOOD, V62, P14
   Roberto PG, 2004, PROTEIN J, V23, P273, DOI 10.1023/B:JOPC.0000027852.92208.60
   Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0
   Soares AM, 2000, ARCH BIOCHEM BIOPHYS, V378, P201, DOI 10.1006/abbi.2000.1790
   Soares AM, 2003, TOXICON, V42, P855, DOI 10.1016/j.toxicon.2003.11.004
   STEFANSSON S, 1990, BIOCHEMISTRY-US, V29, P7742, DOI 10.1021/bi00485a024
   Touqui Lhousseine, 2001, Current Molecular Medicine (Hilversum), V1, P739, DOI 10.2174/1566524013363258
   Ward RJ, 2002, BIOCHEM J, V362, P89, DOI 10.1042/0264-6021:3620089
   Ward RJ, 2001, PROTEIN EXPRES PURIF, V21, P134, DOI 10.1006/prep.2000.1353
   Yang WL, 2003, TOXICON, V41, P713, DOI 10.1016/S0041-0101(03)00047-3
   Zhong XY, 2001, J NAT TOXINS, V10, P17
NR 31
TC 18
Z9 22
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1046-5928
EI 1096-0279
J9 PROTEIN EXPRES PURIF
JI Protein Expr. Purif.
PD SEP
PY 2004
VL 37
IS 1
BP 102
EP 108
DI 10.1016/j.pep.2004.05.020
PG 7
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 847RR
UT WOS:000223413100014
PM 15294287
DA 2020-11-26
ER

PT J
AU Roberto, PG
   Kashima, S
   Marcussi, S
   Pereira, JO
   Astolfi, S
   Nomizo, A
   Giglio, JR
   Fontes, MRM
   Soares, AM
   Franca, SC
AF Roberto, Patricia G.
   Kashima, Simone
   Marcussi, Silvana
   Pereira, Jose O.
   Astolfi-Filho, Spartaco
   Nomizo, Auro
   Giglio, Jose R.
   Fontes, Marcos R. M.
   Soares, Andreimar M.
   Franca, Suzelei C.
TI Cloning and Identification of a Complete cDNA Coding for a Bactericidal
   and Antitumoral Acidic Phospholipase A(2) from Bothrops jararacussu
   Venom
SO PROTEIN JOURNAL
LA English
DT Article
DE Acidic phospholipases A(2); antitumoral effect; bactericidal; Bothrops
   jararacussu; BPB-chemical modification; cDNA; structural analysis
AB In order to better understand the function of acidic phospholipases A(2) (PLA(2)s) from snake venoms, expressed sequence tags (ESTs) that code for acidic PLA(2)s were isolated from a cDNA library prepared from the poly(A) + RNA of venomous glands of Bothrops jararacussu. The complete nucleotide sequence (366 bp), named BOJU-III, encodes the BthA-I-PLA(2) precursor, which includes a signal peptide and the mature protein with 16 and 122 amino acid residues, respectively. Multiple comparison of both the nucleotide and respective deduced amino acid sequence with EST and protein sequences from databases revealed that the full-length cDNA identified (BOJU III - AY145836) is related to an acidic PLA(2) sharing similarity, within the range 55-81%, with acidic phospholipases from snake venoms. Moreover, phylogenetic analysis of amino acid sequences of acidic PLA(2)s from several pit viper genera showed close evolutionary relationships among acidic PLA(2)s from Bothrops, Crotalus, and Trimeresurus. The molecular modeling showed structural similarity with other dimeric class II PLA(2)s from snake venoms. The native protein BthA-I-PLA(2), a nontoxic acidic PLA(2) directly isolated from Bothrops jararacussu snake venom, was purified and submitted to various bioassays. BthA-I-PLA(2) displayed high catalytic activity and induced Ca2+-dependent liposome disruption. Edema induced by this PLA(2) was inhibited by indomethacin and dexamethasone, thus suggesting involvement of the cyclo-oxygenase pathway. BthA-I-PLA(2) showed anticoagulant activity upon human plasma and inhibited phospholipid-dependent platelet aggregation induced by collagen or ADP. In addition, it displayed bactericidal activity against Escherichia coli and Staphylococcus aureus and antitumoral effect upon breast adrenocarcinoma as well as upon human leukemia T and Erlich ascitic tumor. Following chemical modification with p-bromophenacyl bromide, total loss of the enzymatic and pharmacological activities were observed. This is the first report on the isolation and identification of a cDNA encoding a complete acidic PLA(2) from Bothrops venom, exhibiting bactericidal and antitumoral effects.
C1 [Roberto, Patricia G.; Kashima, Simone; Marcussi, Silvana; Soares, Andreimar M.; Franca, Suzelei C.] Univ Ribeirao Preto, UNAERP, Unidade Biotecnol, Ribeirao Preto, SP, Brazil.
   [Pereira, Jose O.; Astolfi-Filho, Spartaco] Univ Fed Amazonas, Fac Ciencias Agr, Manaus, Amazonas, Brazil.
   [Nomizo, Auro] Univ Sao Paulo, FCFRP, Dept Anal Clin Toxicol & Bromatol, BR-14049 Ribeirao Preto, SP, Brazil.
   [Giglio, Jose R.] Univ Sao Paulo, FMRP, Dept Bioquim & Imunol, BR-14049 Ribeirao Preto, SP, Brazil.
   [Fontes, Marcos R. M.] Univ Estadual Paulista, IB, Dept Fis & Biofis, Botucatu, SP, Brazil.
RP Soares, AM (corresponding author), Univ Ribeirao Preto, UNAERP, Unidade Biotecnol, Ribeirao Preto, SP, Brazil.
EM andreimar@unaerp.br
RI Kashima, Simone/G-4876-2012; Franca, Suzelei C/E-4069-2013; Fontes,
   Marcos R/B-1941-2009; Soares, Andreimar M/K-5556-2014
OI Kashima, Simone/0000-0002-1487-0141; Franca, Suzelei
   C/0000-0003-4864-430X; Fontes, Marcos R/0000-0002-4634-6221; Soares,
   Andreimar/0000-0003-1032-2188; ROBERTO, PATRICIA/0000-0001-8932-4666
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); Universidade de
   Ribeirao Preto (UNAERP)
FX The authors express their gratitude to Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP), Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), and Universidade de Ribeirao Preto
   (UNAERP) for financial support. The skilfull technical assistance of E.
   G. Silva and the kind collaboration of Dr. A. L. Fuly (UFRJ, Brazil),
   Dr. S. H. Andriao-Escarso (FMRP-USP, Brazil), Prof. Dr. R. J. Ward
   (FFCLRP-USP, Brazil), and B. Lomonte (ICP-UCR, Costa Rica) is
   acknowledged. Molecular biology studies were part of the master's thesis
   in biotechnology of P. G. Roberto, and biochemical studies were part of
   S. Marcussi's master's thesis in biotechnology presented to the
   Universidade de Ribeirao Preto-SP. The sequence data reported in this
   paper will appear in GenBank under accession no. AY145836
CR ALVARADO J, 1988, REV BIOL TROP, V36, P563
   Andriao-Escarso SH, 2000, BIOCHIMIE, V82, P755, DOI 10.1016/S0300-9084(00)01150-0
   Andriao-Escarso SH, 2002, BIOCHEM PHARMACOL, V64, P723, DOI 10.1016/S0006-2952(02)01210-8
   Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175
   BULTRON E, 1993, BIOCHIM BIOPHYS ACTA, V1179, P253, DOI 10.1016/0167-4889(93)90080-9
   Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7
   Chaves F, 1998, TOXICON, V36, P1861, DOI 10.1016/S0041-0101(98)00107-X
   CHWETZOFF S, 1989, J BIOL CHEM, V264, P13289
   CORIN RE, 1993, INVEST NEW DRUG, V11, P11, DOI 10.1007/BF00873905
   Cummings BS, 2000, J PHARMACOL EXP THER, V294, P793
   Cura JE, 2002, CLIN CANCER RES, V8, P1033
   DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P103, DOI 10.1016/0005-2744(68)90248-9
   DIAZ C, 1991, BIOCHIM BIOPHYS ACTA, V1070, P455, DOI 10.1016/0005-2736(91)90086-N
   FELSENSTEIN J, 1997, PHYLIP PHYLOGENY INF
   Fully AL, 2002, BIOCHEM PHARMACOL, V63, P1589, DOI 10.1016/S0006-2952(02)00873-0
   Gutierrez J.M., 1997, VENOM PHOSPHOLIPASE, P321
   GUTIERREZ JM, 1988, TOXICON, V26, P411, DOI 10.1016/0041-0101(88)90010-4
   HOMSIBRANDEBURGO MI, 1988, TOXICON, V26, P615, DOI 10.1016/0041-0101(88)90244-9
   ITZHAKI RF, 1964, ANAL BIOCHEM, V9, P401, DOI 10.1016/0003-2697(64)90200-3
   Junqueira-de-Azevedo IDM, 2002, GENE, V299, P279, DOI 10.1016/S0378-1119(02)01080-6
   Kashima S, 2002, BIOCHIMIE, V84, P675, DOI 10.1016/S0300-9084(02)01429-3
   KASHIMA S, 2004, BIOCHIMIE IN PRESS, V86
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Kini RM, 1999, J MOL EVOL, V48, P125, DOI 10.1007/PL00006450
   LOMONTE B, 1992, COMP BIOCHEM PHYS B, V102, P325, DOI 10.1016/0305-0491(92)90129-F
   Lu QM, 2002, TOXICON, V40, P1313, DOI 10.1016/S0041-0101(02)00141-1
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   MOURADASILVA AM, 1995, J MOL EVOL, V41, P174, DOI 10.1007/BF00170670
   Ownby CL, 1999, TOXICON, V37, P411, DOI 10.1016/S0041-0101(98)00188-3
   Pan H, 1998, TOXICON, V36, P1155, DOI 10.1016/S0041-0101(98)00013-0
   Panini SR, 2001, J LIPID RES, V42, P1678
   Rodrigues VM, 1998, COMP BIOCHEM PHYS A, V121, P215, DOI 10.1016/S1095-6433(98)10136-8
   Rudrammaji LMS, 1998, TOXICON, V36, P921, DOI 10.1016/S0041-0101(97)00097-4
   Serrano SMT, 1999, ARCH BIOCHEM BIOPHYS, V367, P26, DOI 10.1006/abbi.1999.1230
   Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0
   Soares A.M., 1998, Journal of Venomous Animals and Toxins, V4, P137
   Soares AM, 1998, TOXICON, V36, P503, DOI 10.1016/S0041-0101(97)00133-5
   Soares AM, 2000, ARCH BIOCHEM BIOPHYS, V378, P201, DOI 10.1006/abbi.2000.1790
   Soares AM, 2003, TOXICON, V42, P855, DOI 10.1016/j.toxicon.2003.11.004
   Soares AM, 2001, ARCH BIOCHEM BIOPHYS, V387, P188, DOI 10.1006/abbi.2000.2244
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   TSAI IH, 1995, BIOCHEM J, V311, P895, DOI 10.1042/bj3110895
   Tsai IH, 2003, ARCH BIOCHEM BIOPHYS, V411, P289, DOI 10.1016/S0003-9861(02)00747-6
   Tsai IH, 2000, EUR J BIOCHEM, V267, P6684, DOI 10.1046/j.1432-1327.2000.01766.x
   VALIENTE C, 1992, TOXICON, V30, P815, DOI 10.1016/0041-0101(92)90379-J
   VESTERBERG O, 1972, BIOCHIM BIOPHYS ACTA, V257, P11, DOI 10.1016/0005-2795(72)90248-6
   Wang YM, 1996, TOXICON, V34, P1191, DOI 10.1016/0041-0101(96)00067-0
NR 47
TC 47
Z9 48
U1 1
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1572-3887
EI 1573-4943
J9 PROTEIN J
JI Protein J.
PD MAY
PY 2004
VL 23
IS 4
BP 273
EP 285
DI 10.1023/B:JOPC.0000027852.92208.60
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA V18VI
UT WOS:000208031900005
PM 15214498
DA 2020-11-26
ER

PT J
AU Kashima, S
   Roberto, PG
   Soares, AM
   Astolfi, S
   Pereira, JO
   Giuliati, S
   Faria, M
   Xavier, MAS
   Fontes, MRM
   Giglio, JR
   Franca, SC
AF Kashima, S
   Roberto, PG
   Soares, AM
   Astolfi, S
   Pereira, JO
   Giuliati, S
   Faria, M
   Xavier, MAS
   Fontes, MRM
   Giglio, JR
   Franca, SC
TI Analysis of Bothrops jararacussu venomous gland transcriptome focusing
   on structural and functional aspects: I - gene expression profile of
   highly expressed phospholipases A(2)
SO BIOCHIMIE
LA English
DT Article
DE Bothrops jararacussu; snake venom gland EST's; transcriptome; gene
   expression; toxins; enzymes; phospholipases A(2)
ID ANGIOTENSIN-CONVERTING ENZYME; SNAKE-VENOM; A(2) HOMOLOG; SEQUENCE TAGS;
   LYS49; MYOTOXIN; METALLOPROTEINASES; IDENTIFICATION; PURIFICATION; ROLES
AB Snake venom glands are a rich source of bioactive molecules such as peptides, proteins and enzymes that show important pharmacological activity leading to in local and systemic effects as pain, edema, bleeding and muscle necrosis. Most studies on pharmacologically active peptides and proteins from snake venoms have been concerned with isolation and structure elucidation through methods of classical biochemistry. As an attempt to examine the transcripts expressed in the venom gland of Bothrops jararacussu and to unveil the toxicological and pharmacological potential of its products at the molecular level, we generated 549 expressed sequence tags (ESTs) from a directional cDNA library. Sequences obtained from single-pass sequencing of randomly selected cDNA clones could be identified by similarities searches on existing databases, resulting in 197 sequences with significant similarity to phospholipase A(2) (PLA(2)), of which 83.2% were Lys49-PLA(2) homologs (BOJU-1), 0.1% were basic Asp49-PLA(2)s (BOJU-II) and 0.6% were acidic Asp49-PLA(2)s (BOJU-III). Adjoining this very abundant class of proteins we found 88 transcripts codifying for putative sequences of metalloproteases, which after clustering and assembling resulted in three full-length sequences: BOJUMET-I, BOJUMET-II and BOJUMET-III; as well as 25 transcripts related to C-type lectin like protein including a full-length cDNA of a putative galactose binding C-type lectin and a cluster of eight serine-proteases transcripts including a full-length cDNA of a putative serine protease. Among the full-length sequenced clones we identified a nerve growth factor (Bj-NGF) with 92% identity with a human NGF (NGHUBM) and an acidic phospholipase A2 (BthA-I-PLA(2)) displaying 85-93% identity with other snake venom toxins. Genetic distance among PLA(2)s from Bothrops species were evaluated by phylogenetic analysis. Furthermore, analysis of full-length putative Lys49-PLA(2) through molecular modeling showed conserved structural domains, allowing the characterization of those proteins as group II PLA(2)s. The constructed cDNA library provides molecular clones harboring sequences that can be used to probe directly the genetic material from gland venom of other snake species. Expression of complete cDNAs or their modified derivatives will be useful for elucidation of the structure-function relationships of these toxins and peptides of biotechnological interest. (C) 2004 Elsevier SAS. All rights reserved.
C1 Univ Ribeirao Preto, Unidade Biotecnol, BR-14096380 Ribeirao Preto, SP, Brazil.
   Univ Fed Amazonas, Inst Ciencias Biol, Fac Ciencias Agr, Manaus, Amazonas, Brazil.
   Univ Brasilia, Dept Biol Celular, Brasilia, DF, Brazil.
   Univ Estadual Paulista, Dept Fis & Biofis, Botucatu, SP, Brazil.
   Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Bioquim & Imunol, Ribeirao Preto, Brazil.
RP Soares, AM (corresponding author), Univ Ribeirao Preto, Unidade Biotecnol, BR-14096380 Ribeirao Preto, SP, Brazil.
EM andreimar@unaerp.br; suzicf@odin.unaerp.br
RI Soares, Andreimar M/K-5556-2014; Xavier, Mauro A. S./L-7158-2013;
   Kashima, Simone/G-4876-2012; Franca, Suzelei C/E-4069-2013; Fontes,
   Marcos R/B-1941-2009
OI Xavier, Mauro A. S./0000-0002-0512-1616; Kashima,
   Simone/0000-0002-1487-0141; Franca, Suzelei C/0000-0003-4864-430X;
   Fontes, Marcos R/0000-0002-4634-6221; ROBERTO,
   PATRICIA/0000-0001-8932-4666; Soares, Andreimar/0000-0003-1032-2188
CR ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873
   Andriao-Escarso SH, 2000, BIOCHIMIE, V82, P755, DOI 10.1016/S0300-9084(00)01150-0
   Andriao-Escarso SH, 2002, BIOCHEM PHARMACOL, V64, P723, DOI 10.1016/S0006-2952(02)01210-8
   AndriaoEscarso SH, 1997, TOXICON, V35, P1043, DOI 10.1016/S0041-0101(96)00222-X
   Angulo Y, 2002, INT J BIOCHEM CELL B, V34, P1268, DOI 10.1016/S1357-2725(02)00060-2
   Arni RK, 1996, TOXICON, V34, P827, DOI 10.1016/0041-0101(96)00036-0
   Azam A, 1996, GENE, V181, P113, DOI 10.1016/S0378-1119(96)00484-2
   Bailey P, 2001, Emerg Med (Fremantle), V13, P28, DOI 10.1046/j.1442-2026.2001.00174.x
   Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175
   Bortoleto RK, 2002, TOXICON, V40, P1307, DOI 10.1016/S0041-0101(02)00140-X
   Braud S, 2000, BIOCHIMIE, V82, P851, DOI 10.1016/S0300-9084(00)01178-0
   Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7
   Chioato L, 2002, BIOCHEM J, V366, P971, DOI 10.1042/BJ20020092
   da Silva Giotto MT, 1998, PROTEINS, V30, P442, DOI 10.1002/(SICI)1097-0134(19980301)30:4<442::AID-PROT11>3.0.CO;2-I
   DUPUREUR CM, 1992, BIOCHEMISTRY-US, V31, P10576, DOI 10.1021/bi00158a021
   Ferreira SH, 2000, SEMIN PERINATOL, V24, P7, DOI 10.1016/S0146-0005(00)80046-4
   FERREIRA SH, 1994, BRAZ J MED BIOL RES, V27, P1693
   Gutierrez J.M., 1997, VENOM PHOSPHOLIPASE, P321
   Gutierrez JM, 2000, BIOCHIMIE, V82, P841, DOI 10.1016/S0300-9084(00)01163-9
   HOMSIBRANDEBURGO MI, 1988, TOXICON, V26, P615, DOI 10.1016/0041-0101(88)90244-9
   Junqueira-de-Azevedo IDM, 2002, GENE, V299, P279, DOI 10.1016/S0378-1119(02)01080-6
   Kamiguti AS, 1998, BRAZ J MED BIOL RES, V31, P853, DOI 10.1590/S0100-879X1998000700001
   Kashima S, 2002, BIOCHIMIE, V84, P675, DOI 10.1016/S0300-9084(02)01429-3
   LI YS, 1994, BIOCHEMISTRY-US, V33, P14714, DOI 10.1021/bi00253a009
   LOMONTE B, 1994, J BIOL CHEM, V269, P29867
   Marsh NA, 2001, HAEMOSTASIS, V31, P211
   Matsui T, 2000, BBA-PROTEIN STRUCT M, V1477, P146, DOI 10.1016/S0167-4838(99)00268-X
   MOURADASILVA AM, 1995, J MOL EVOL, V41, P174, DOI 10.1007/BF00170670
   Paramo L, 1998, EUR J BIOCHEM, V253, P452, DOI 10.1046/j.1432-1327.1998.2530452.x
   Pereira MF, 1998, J PROTEIN CHEM, V17, P381, DOI 10.1023/A:1022563401413
   Soares AM, 2000, ARCH BIOCHEM BIOPHYS, V373, P7, DOI 10.1006/abbi.1999.1492
   Soares AM, 2000, ARCH BIOCHEM BIOPHYS, V378, P201, DOI 10.1006/abbi.2000.1790
   Soares AM, 2003, TOXICON, V42, P855, DOI 10.1016/j.toxicon.2003.11.004
   Soares AM, 2002, INT J BIOCHEM CELL B, V34, P668, DOI 10.1016/S1357-2725(01)00174-1
   Touqui Lhousseine, 2001, Current Molecular Medicine (Hilversum), V1, P739, DOI 10.2174/1566524013363258
   Ward RJ, 2002, BIOCHEM J, V362, P89, DOI 10.1042/0264-6021:3620089
   Ward RJ, 2001, PROTEIN EXPRES PURIF, V21, P134, DOI 10.1006/prep.2000.1353
   Ward RJ, 1998, PROTEIN ENG, V11, P285, DOI 10.1093/protein/11.4.285
NR 38
TC 82
Z9 87
U1 0
U2 6
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0300-9084
EI 1638-6183
J9 BIOCHIMIE
JI Biochimie
PD MAR
PY 2004
VL 86
IS 3
BP 211
EP 219
DI 10.1016/j.biochi.2004.02.002
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 822SY
UT WOS:000221561700008
PM 15134836
DA 2020-11-26
ER

PT J
AU Scrideli, CA
   Queiroz, RGP
   Kashima, S
   Sankarankutty, BOM
   Tone, LG
AF Scrideli, CA
   Queiroz, RGP
   Kashima, S
   Sankarankutty, BOM
   Tone, LG
TI T cell receptor gamma (TCRG) gene rearrangements in Brazilian children
   with acute lymphoblastic leukemia: analysis and implications for the
   study of minimal residual disease
SO LEUKEMIA RESEARCH
LA English
DT Article
DE acute lymphoblastic leukemia; T cell receptor gamma; minimal residual
   disease; childhood; junctional diversity
ID POLYMERASE-CHAIN-REACTION; STRONG PREDICTIVE FACTOR; ACUTE
   LYMPHOID-LEUKEMIA; B-LINEAGE; CLINICAL-SIGNIFICANCE; PCR ANALYSIS;
   CHILDHOOD; RELAPSE; IMMUNOGLOBULIN; CLONALITY
AB The high frequency of T cell receptor gamma (TCRG) gene rearrangements in both B-lineage and T cell acute lymphoblastic leukemia (ALL), its easy detection and the lower incidence of oligoclonality make this gene one of the main target for the detection of minimal residual disease by PCR in childhood ALL. We analyzed the frequency and type of TCRG rearrangements in DNA samples obtained from the bone marrow of 102 Brazilian children at diagnosis using PCR and automatic sequencing. TCRG rearrangements were found in 69% of patients with B-lineage ALL and in 94% of patients with T cell ALL. In contrast to other studies, rearrangements involving the Vgamma9 segment reported to be uncommon were the most frequent both in B-lineage and T cell ALL and involved 49/109 (45%) of the rearranged alleles. This fact should be considered when standardizing consensus primers for the study of minimal residual disease in different populations. (C) 2003 Elsevier Ltd. All rights reserved.
C1 Univ Sao Paulo, Dept Pediat, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil.
   Ribeirao Preto Hemocentro Fdn, Ribeirao Preto, SP, Brazil.
RP Tone, LG (corresponding author), Univ Sao Paulo, Dept Pediat, Fac Med Ribeirao Preto, Av Bandeirantes,3900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM lgtone@fmrp.usp.br
RI Scrideli, Carlos A/D-7618-2012; Tone, Luiz/D-3934-2012; Kashima,
   Simone/G-4876-2012
OI Scrideli, Carlos A/0000-0001-6618-789X; Kashima,
   Simone/0000-0002-1487-0141; Tone, Luiz Gonzaga/0000-0001-8821-4211
CR BEISHUIZEN A, 1994, BLOOD, V83, P2238, DOI 10.1182/blood.V83.8.2238.bloodjournal8382238
   BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x
   Biondi A, 2000, LEUKEMIA, V14, P1939, DOI 10.1038/sj.leu.2401922
   BOEHM TLJ, 1987, EUR J IMMUNOL, V17, P1593, DOI 10.1002/eji.1830171111
   BRANDALISE S, 1993, LEUKEMIA, V7, pS142
   BRISCO MJ, 1994, LANCET, V343, P196, DOI 10.1016/S0140-6736(94)90988-1
   Brumpt C, 2000, BLOOD, V96, P2254
   CAMPANA D, 1995, BLOOD, V85, P1416, DOI 10.1182/blood.V85.6.1416.bloodjournal8561416
   CATOVSKY D, 1991, ANN HEMATOL, V62, P16, DOI 10.1007/BF01714978
   Cave H, 1998, NEW ENGL J MED, V339, P591, DOI 10.1056/NEJM199808273390904
   CAVE H, 1994, BLOOD, V83, P1892
   CHEN Z, 1988, BLOOD, V72, P776
   Foroni L, 1999, BRIT J HAEMATOL, V105, P7
   GONZALEZSARMIENTO R, 1988, BLOOD, V72, P2038
   Goulden NJ, 1998, BRIT J HAEMATOL, V100, P235, DOI 10.1046/j.1365-2141.1998.00574.x
   GREENBERG JM, 1986, J IMMUNOL, V137, P2043
   Gruhn B, 1998, LEUKEMIA, V12, P675, DOI 10.1038/sj.leu.2400985
   HARA J, 1989, J CLIN INVEST, V83, P1277, DOI 10.1172/JCI114012
   HUCK S, 1988, EMBO J, V7, P719, DOI 10.1002/j.1460-2075.1988.tb02868.x
   Jacquy C, 1997, BRIT J HAEMATOL, V98, P140, DOI 10.1046/j.1365-2141.1997.1792996.x
   JANUSZKIEWICZ DA, 1994, ANN HEMATOL, V69, P107, DOI 10.1007/BF01695689
   KNEBA M, 1994, BLOOD, V84, P574
   KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0
   Langerak AW, 1999, LEUKEMIA, V13, P206, DOI 10.1038/sj.leu.2401276
   Langerak AW, 1997, LEUKEMIA, V11, P2192, DOI 10.1038/sj.leu.2400887
   LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0
   Nirmala K, 2002, LEUKEMIA RES, V26, P335, DOI 10.1016/S0145-2126(01)00130-8
   Peham M, 2002, BRIT J HAEMATOL, V117, P315, DOI 10.1046/j.1365-2141.2002.03428.x
   Pongers-Willemse MJ, 1999, LEUKEMIA, V13, P110, DOI 10.1038/sj.leu.2401245
   QUERTERMOUS T, 1986, SCIENCE, V231, P252, DOI 10.1126/science.3079918
   Roberts WM, 1997, NEW ENGL J MED, V336, P317, DOI 10.1056/NEJM199701303360501
   Sazawal S, 2000, LEUKEMIA RES, V24, P575, DOI 10.1016/S0145-2126(00)00025-4
   Scrideli C A, 2001, Sao Paulo Med J, V119, P175, DOI 10.1590/S1516-31802001000500005
   Scrideli CA, 2002, LEUKEMIA RES, V26, P431, DOI 10.1016/S0145-2126(01)00153-9
   Scrideli CA, 2002, J PEDIAT HEMATOL ONC, V24, P364, DOI 10.1097/00043426-200206000-00008
   Scrideli CA, 1997, J PEDIAT HEMATOL ONC, V19, P516, DOI 10.1097/00043426-199711000-00005
   Sykes PJ, 1997, LEUKEMIA, V11, P153, DOI 10.1038/sj.leu.2400542
   Szczepanski T, 2000, LEUKEMIA, V14, P1208, DOI 10.1038/sj.leu.2401765
   Szczepanski T, 1999, LEUKEMIA, V13, P196, DOI 10.1038/sj.leu.2401277
   TAYLOR JJ, 1991, BLOOD, V77, P1989
   TRAINOR KJ, 1991, BLOOD, V78, P192
   van der Velden VHJ, 2002, LEUKEMIA, V16, P928, DOI 10.1038/sj.leu.2402475
   van Dongen JJ, 1999, CHILDHOOD LEUKEMIAS, P145
   van Dongen JJM, 1998, LANCET, V352, P1731, DOI 10.1016/S0140-6736(98)04058-6
   VANDONGEN JJM, 1991, CLIN CHIM ACTA, V198, P1
NR 45
TC 11
Z9 11
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0145-2126
EI 1873-5835
J9 LEUKEMIA RES
JI Leuk. Res.
PD MAR
PY 2004
VL 28
IS 3
BP 267
EP 273
DI 10.1016/j.leukres.2003.07.001
PG 7
WC Oncology; Hematology
SC Oncology; Hematology
GA 775WA
UT WOS:000189082600011
PM 14687622
DA 2020-11-26
ER

PT J
AU Covas, DT
   Kashima, S
AF Covas, DT
   Kashima, S
TI Complete nucleotide sequences of the genomes of two Brazilian specimens
   of human T lymphotropic virus type 2 (HTLV-2)
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID II SUBTYPE-B; CELL LEUKEMIA; GUAYMI INDIANS; KAYAPO INDIANS; ISOLATE;
   IDENTIFICATION; INFECTION; RETROVIRUS; POPULATION; MYELOPATHY
AB We report the complete nucleotide sequences of the genomes of two human T cell lymphotropic viruses type 2 (HTLV-2) isolated from a Kayapo Indian (K96 isolate) and from an inhabitant of an urban region in the south of Brazil (RP329 isolate). The general structure of the K96 and RP329 genomes did not differ from that of other HTLV-2 genomes described in the literature. The K96 genome consisted of 8955 bp and the RP329 genome consisted of 8964 bp. The general similarity between the nucleotide sequences of the K96 and RP329 genomes was 99.4%. Comparison between the nucleotide sequences of the K96 and RP329 genomes and the nucleotide sequences of isolates considered to be HTLV-2 prototypes of subtype 2a (Mo isolate), 2b (NRA isolate), and 2d (Efe2 isolate) showed a global similarity of 98.8, 95.6, and 93.3%, respectively, for the RP329 isolate, and of 99.1, 95.6, and 93.3%, respectively, for the K96 isolate. Phylogenetic analysis permitted the classification of the K96 and RP329 isolates as HTLV-2 subtype 2a. Detailed phylogenetic analyses of the LTR, env, and Tax regions showed that the Brazilian isolates tend to form a distinct phylogenetic subgroup within subtype 2a, previously called HTLV-2c, which differs from the subtype 2a isolates found in North America, Europe, and Africa. The K96 genome is the first HTLV-2 genome obtained from a Brazilian Indian that was completely sequenced, whereas the RP329 genome represents the first specimen derived from an inhabitant of a Brazilian urban region who was not coinfected with HIV-1.
C1 Blood Ctr Ribeirao Preto, Ctr Cell Based Therapy, CEPID, FAPESP, BR-14051140 Ribeirao Preto, SP, Brazil.
   Univ Sao Paulo, Fac Med Ribeirao Preto, BR-14051140 Sao Paulo, Brazil.
RP Covas, DT (corresponding author), Blood Ctr Ribeirao Preto, Ctr Cell Based Therapy, CEPID, FAPESP, Rua Tenente Catao Roxo 2501, BR-14051140 Ribeirao Preto, SP, Brazil.
EM dimas@fmrp.usp.br
RI Kashima, Simone/G-4876-2012; Covas, Dimas T/C-5431-2013
OI Kashima, Simone/0000-0002-1487-0141; Covas, Dimas T/0000-0002-7364-2595
CR Biggar RJ, 1996, VIROLOGY, V216, P165, DOI 10.1006/viro.1996.0043
   BLACK FL, 1994, AIDS RES HUM RETROV, V10, P1165, DOI 10.1089/aid.1994.10.1165
   Black FL, 1997, HUM BIOL, V69, P467
   Dube S, 1999, VIROLOGY, V253, P181, DOI 10.1006/viro.1998.9515
   DUENASBARAJAS E, 1992, AIDS RES HUM RETROV, V8, P1851, DOI 10.1089/aid.1992.8.1851
   Eiraku N, 1996, J VIROL, V70, P1481, DOI 10.1128/JVI.70.3.1481-1492.1996
   FERRER JF, 1993, VIROLOGY, V197, P576, DOI 10.1006/viro.1993.1631
   GESSAIN A, 1985, LANCET, V2, P407
   GOUBAU P, 1993, AIDS RES HUM RETROV, V9, P709, DOI 10.1089/aid.1993.9.709
   HALL WW, 1992, J VIROL, V66, P2456, DOI 10.1128/JVI.66.4.2456-2463.1992
   HJELLE B, 1991, J INFECT DIS, V163, P435, DOI 10.1093/infdis/163.3.435
   ISHAK R, 1995, AIDS RES HUM RETROV, V11, P813, DOI 10.1089/aid.1995.11.813
   KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   KUMAR S, 2001, MEGA2 MOL EVOLUTIONA
   LAIRMORE MD, 1990, P NATL ACAD SCI USA, V87, P8840, DOI 10.1073/pnas.87.22.8840
   Letourneur F, 1998, J GEN VIROL, V79, P269, DOI 10.1099/0022-1317-79-2-269
   Lewis MJ, 2000, VIROLOGY, V271, P142, DOI 10.1006/viro.2000.0284
   MALONEY EM, 1992, J INFECT DIS, V166, P100, DOI 10.1093/infdis/166.1.100
   Murphy EL, 1997, NEUROLOGY, V48, P315, DOI 10.1212/WNL.48.2.315
   Murphy EL, 1999, ARCH INTERN MED, V159, P1485, DOI 10.1001/archinte.159.13.1485
   OSAME M, 1986, LANCET, V1, P1031
   PARDI D, 1993, J VIROL, V67, P4659, DOI 10.1128/JVI.67.8.4659-4664.1993
   Poiesz B, 2000, NEW ENGL J MED, V342, P930, DOI 10.1056/NEJM200003303421304
   POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0
   REEVES WC, 1990, AM J TROP MED HYG, V43, P410, DOI 10.4269/ajtmh.1990.43.410
   ROSENBLATT JD, 1986, NEW ENGL J MED, V315, P372, DOI 10.1056/NEJM198608073150606
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454
   Salemi M, 1998, J MOL EVOL, V46, P602, DOI 10.1007/PL00006340
   Salemi M, 1996, J GEN VIROL, V77, P1193, DOI 10.1099/0022-1317-77-6-1193
   Salemi M, 1999, P NATL ACAD SCI USA, V96, P13253, DOI 10.1073/pnas.96.23.13253
   Sambrook J., 1989, MOL CLONING LAB MANU, V1
   SHIMOTOHNO K, 1985, P NATL ACAD SCI USA, V82, P3101, DOI 10.1073/pnas.82.10.3101
   Switzer WM, 1996, AIDS RES HUM RETROV, V12, P635, DOI 10.1089/aid.1996.12.635
   Vandamme AM, 1998, J VIROL, V72, P4327, DOI 10.1128/JVI.72.5.4327-4340.1998
   Vandamme AM, 2000, GENE, V261, P171, DOI 10.1016/S0378-1119(00)00473-X
   YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031
NR 37
TC 8
Z9 9
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD AUG
PY 2003
VL 19
IS 8
BP 689
EP 697
DI 10.1089/088922203322280919
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 716GP
UT WOS:000185020700008
PM 13678471
DA 2020-11-26
ER

PT J
AU Alcantara, LC
   Van Dooren, S
   Goncalves, MS
   Kashima, S
   Costa, MCR
   Santos, FLN
   Bittencourt, AL
   Dourado, I
   Andrade, A
   Covas, DT
   Vandamme, AM
   Galvao-Castro, B
AF Alcantara, LC
   Van Dooren, S
   Goncalves, MS
   Kashima, S
   Costa, MCR
   Santos, FLN
   Bittencourt, AL
   Dourado, I
   Andrade, A
   Covas, DT
   Vandamme, AM
   Galvao-Castro, B
TI Globin haplotypes of human T-cell lymphotropic virus type I-infected
   individuals in Salvador, Bahia, Brazil, suggest a post-Columbian African
   origin of this virus
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HTLV-1; LTR; beta-globin haplotypes; Bantu; Salvador-Brazil; Southern
   Africa
ID POLYMERASE CHAIN-REACTION; BETA-S-CHROMOSOMES; HTLV-I; MOLECULAR
   EPIDEMIOLOGY; PHYLOGENETIC SUBTYPES; JAPANESE IMMIGRANTS; STRAINS;
   SEQUENCE; AMERICA; GENE
AB The city of Salvador, Bahia, Brazil, has sociodemographic characteristics similar to some African cities. Up to now, it has had the highest prevalence of human T-cell lymphotropic virus type I (HTLV-I) infection (1.74%) in the country. To investigate which strains of HTLV-I are circulating in Salvador, we studied isolates from 82 patients infected with HTLV-I: 19 from the general population, 21 from pregnant women, 16 from intravenous drug users, and 26 from patients and their family attending a neurologic clinic. Phylogenetic analysis from part of the LTR fragments showed that most of these isolates belonged to the Transcontinental subgroup of the Cosmopolitan subtype (HTLV-Ia). Only one sample from a pregnant woman was closely related to the Japanese subgroup, suggesting recent introduction of a Japanese HTLV-I lineage into Salvador. beta(A)-Globin haplotypes were examined in 34 infected individuals and found to be atypical, confirming the racial heterogeneity of this population. A total of 20 chromosomes were characterized as Central African Republic (CAR) haplotype (29.4%), 31 (45.6%) were characterized as Benin (BEN) haplotype, and 17 (25%) were characterized as Senegal (SEN) haplotype. Five patients' genotypes (14.7%) were CAR/CAR; 10 (29,4%), BEN/BEN; 9 (26.5%), CAR/BEN; 2 (5.9%), BEN/SEN; and 7 (20.6%), SEN/SEN. One patient's genotype (2.9%) was CAR/SEN. The beta(A)-globin haplotype distribution in Salvador is unusual compared with other Brazilian states. Our data support the hypothesis of multiple post-Columbian introductions of African HTLV-Ia strains-in Salvador, Bahia, Brazil.
C1 Oswaldo Cruz Fdn, Adv Publ Hlth Lab, Goncalo Moniz Res Ctr, BR-40295001 Salvador, BA, Brazil.
   Fdn Sci Dev, Bahia Sch Med & Publ Hlth, Salvador, BA, Brazil.
   Katholieke Univ Leuven, Rega Inst, Louvain, Belgium.
   Brazil Blood Ctr Ribeirao Preto, Ribeirao Preto, SP, Brazil.
   Univ Fed Bahia, Salvador, BA, Brazil.
RP Galvao-Castro, B (corresponding author), Oswaldo Cruz Fdn, Adv Publ Hlth Lab, Goncalo Moniz Res Ctr, Rua Waldemar Falcao 121,Brotas, BR-40295001 Salvador, BA, Brazil.
RI Van Dooren, Sonia/E-3113-2019; Santos, Fred/G-6077-2012; Dourado,
   Ines/Q-6535-2016; Kashima, Simone/G-4876-2012; Vandamme,
   Anne-Mieke/I-4127-2012; SANTOS, Fred/S-2954-2019; Covas, Dimas
   T/C-5431-2013; Goncalves, Marilda/B-5904-2014
OI Dourado, Ines/0000-0003-1675-2146; Kashima, Simone/0000-0002-1487-0141;
   Vandamme, Anne-Mieke/0000-0002-6594-2766; SANTOS,
   Fred/0000-0002-3944-0818; Covas, Dimas T/0000-0002-7364-2595; Alcantara,
   Luiz/0000-0002-6769-9931
CR Andrade TM, 1998, J ACQ IMMUN DEF SYND, V18, P186, DOI 10.1097/00042560-199806010-00011
   ANTONARAKIS SE, 1984, P NATL ACAD SCI-BIOL, V81, P853, DOI 10.1073/pnas.81.3.853
   AZEVEDO ES, 1981, HUM HERED, V31, P353, DOI 10.1159/000153237
   Bittencourt AL, 2001, J ACQ IMMUN DEF SYND, V26, P490, DOI 10.1097/00126334-200104150-00016
   CURTIN PD, 1969, SLAVE ATLANTIC TRADE
   DOURADO I, 2001, AIDS RES HUM RETR S9, V17, pO17
   Fatumbi Verger Pierre, 1968, FLUX REFLUX TRAITE N
   GalvaoCastro B, 1997, TRANSFUSION, V37, P242, DOI 10.1046/j.1537-2995.1997.37297203532.x
   GASMI M, 1994, AIDS RES HUM RETROV, V10, P1313, DOI 10.1089/aid.1994.10.1313
   GESSAIN A, 1993, J VIROL, V67, P1015, DOI 10.1128/JVI.67.2.1015-1023.1993
   GESSAIN A, 1994, AIDS RES HUM RETROV, V10, P103, DOI 10.1089/aid.1994.10.103
   GONCALVES MS, 1994, HUM HERED, V44, P322, DOI 10.1159/000154238
   GONCALVES MS, 2003, IN PRESS BRAZ J MED
   HAHN BH, 1984, INT J CANCER, V34, P613, DOI 10.1002/ijc.2910340505
   HATTORI Y, 1986, HEMOGLOBIN, V10, P623, DOI 10.3109/03630268609036566
   KITAGAWA T, 1986, JAMA-J AM MED ASSOC, V256, P2342, DOI 10.1001/jama.1986.03380170058009
   LANCLOS KD, 1991, BLOOD, V77, P2488
   LAPOUMEROULIE C, 1992, HUM GENET, V89, P333
   Mahieux R, 1997, J VIROL, V71, P1317, DOI 10.1128/JVI.71.2.1317-1333.1997
   Mboudjeka I, 1997, JPN J CANCER RES, V88, P619, DOI 10.1111/j.1349-7006.1997.tb00427.x
   MIURA T, 1994, P NATL ACAD SCI USA, V91, P1124, DOI 10.1073/pnas.91.3.1124
   MIURA T, 1997, J MOL EVOL, V44, P76
   MUELLER N, 1991, CANCER CAUSE CONTROL, V2, P37, DOI 10.1007/BF00052359
   NAGEL R L, 1984, Einstein Quarterly Journal of Biology and Medicine, V2, P53
   NAGEL RL, 1990, SEMIN HEMATOL, V27, P342
   NICHOLAS KB, 1997, GENEDOC ANAL VISUALI, P30
   PINSKY J, 1988, ESCRAVIDAO BRASIL, P24
   RODRIGUES N, 1977, OS AFRICANOS BRASIL, P13
   Salemi M, 1998, VIROLOGY, V246, P277, DOI 10.1006/viro.1998.9215
   SUTTON M, 1989, AM J HEMATOL, V32, P66, DOI 10.1002/ajh.2830320113
   Swofford David L., 1996, P407
   VALLEJO A, 1995, J VIROL METHODS, V51, P9, DOI 10.1016/0166-0934(94)00093-V
   Van Dooren S, 1998, J GEN VIROL, V79, P2695, DOI 10.1099/0022-1317-79-11-2695
   Vandamme AM, 1998, TRENDS MICROBIOL, V6, P477, DOI 10.1016/S0966-842X(98)01406-1
   Verger P., 1976, TRADE RELATIONS BIGH, p[12, 24]
   VIANA L, 1988, NEGRO BAHIA, P224
   VIDAL AU, 1994, J GEN VIROL, V75, P3655, DOI 10.1099/0022-1317-75-12-3655
   XIA X, 2000, DAMBE DATA ANAL MOL
   Yamashita M, 1999, VIROLOGY, V261, P59
   ZAGO MA, 1992, AM J PHYS ANTHROPOL, V88, P295, DOI 10.1002/ajpa.1330880304
NR 40
TC 19
Z9 21
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 1
PY 2003
VL 33
IS 4
BP 536
EP 542
DI 10.1097/00126334-200308010-00016
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 703LA
UT WOS:000184279800016
PM 12869844
OA Green Published
DA 2020-11-26
ER

PT J
AU Watanabe, MAE
   Cavassin, GGD
   Orellana, MD
   Milanezi, CM
   Voltarelli, JC
   Kashima, S
   Covas, DT
AF Watanabe, MAE
   Cavassin, GGD
   Orellana, MD
   Milanezi, CM
   Voltarelli, JC
   Kashima, S
   Covas, DT
TI SDF-1 gene polymorphisms and syncytia induction in Brazilian HIV-1
   infected individuals
SO MICROBIAL PATHOGENESIS
LA English
DT Article
DE SDF-1; syncytia; HIV; CD4; MT-2 cells
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 BIOLOGICAL PHENOTYPE; DISEASE
   PROGRESSION; INFECTION; ASSAY
AB Stromal-derived factor (SDF-1) is the principal ligand for CXCR4, a co-receptor with CD4 for T lymphocyte cell line-tropic human immunodeficiency virus-type 1 (HIV-1). A common polymorphism, SDF1-3' A, was identified in an evolutionary conserved segment of the 3' untranslated region of the SDF-1 gene. Sequence analysis revealed a common variant at position 801, a G --> A transition referred to as SDF1-3' A. Because this variant eliminates the Msp I restriction site PCR-restriction fragment length polymorphism (RFLP) analysis was used for rapid detection of genotypes. We genotyped 62 HIV infected patients and 60 non-HIV blood donors by RFLP analysis. We also assessed syncytia formation through co-culture of MT-2 cells with peripheral blood mononuclear cells from HIV patients. Syncytium-inducing HIV-1 variants have been shown to be clinically significant in the pathogenesis of HIV-1 infection. In our study, we detected a low frequency of 3'A/3'A (5%) in the blood donors but this genotype was absent in all HIV patients. We found that 41 (68%) HIV patients including syncytia inducing (SI) and non-syncytia inducing (NSI) groups contained the wild type (wt/wt) genotype for SDF-1. Our data indicate that there is no correlation between SDF-1 alleles and syncytium inducing HIV. (C) 2003 Elsevier Science Ltd. All rights reserved.
C1 Univ Estadual Londrina, Dept Pathol Sci, BR-86060220 Londrina, PR, Brazil.
   Ribeirao Preto Blood Ctr, Ribeirao Preto, SP, Brazil.
   Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Immunol, Ribeirao Preto, SP, Brazil.
RP Watanabe, MAE (corresponding author), Univ Estadual Londrina, Dept Pathol Sci, Rua Jonatas Serrano 600, BR-86060220 Londrina, PR, Brazil.
RI Orellana, Maristela/L-5542-2014; Kashima, Simone/G-4876-2012; Watanabe,
   Maria Angelica/AAO-4970-2020; Covas, Dimas T/C-5431-2013
OI Orellana, Maristela/0000-0003-0159-4472; Kashima,
   Simone/0000-0002-1487-0141; Covas, Dimas T/0000-0002-7364-2595
CR Balter M, 1998, SCIENCE, V279, P327, DOI 10.1126/science.279.5349.327
   Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571
   BOUCHER CAB, 1992, AIDS, V6, P1259, DOI 10.1097/00002030-199211000-00003
   BOZZETTE SA, 1993, J INFECT DIS, V168, P1374, DOI 10.1093/infdis/168.6.1374
   CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   JAPOUR AJ, 1994, J CLIN MICROBIOL, V32, P2291, DOI 10.1128/JCM.32.9.2291-2294.1994
   KOOT M, 1992, AIDS, V6, P49, DOI 10.1097/00002030-199201000-00006
   Lathey JL, 2001, J INFECT DIS, V184, P1402, DOI 10.1086/324427
   MICHAEL NL, 1996, SCIENCE, V242, P1168
   ROOT M, 1993, ANN INTERN MED, V118, P681
   SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992
   THORNHILL JL, 1997, ORAL DIS, V3, P3
   van Rij RP, 1998, AIDS, V12, pF85, DOI 10.1097/00002030-199809000-00001
   Winkler C, 1998, SCIENCE, V118, P681
NR 15
TC 40
Z9 40
U1 0
U2 3
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0882-4010
J9 MICROB PATHOGENESIS
JI Microb. Pathog.
PD JUL
PY 2003
VL 35
IS 1
BP 31
EP 34
DI 10.1016/S0882-4010(03)00088-3
PG 4
WC Immunology; Microbiology
SC Immunology; Microbiology
GA 705KR
UT WOS:000184394700004
PM 12860456
DA 2020-11-26
ER

PT J
AU Alcantara, LCJ
   Shindo, N
   Van Dooren, S
   Salemi, M
   Costa, MCR
   Kashima, S
   Covas, DT
   Vandamme, AM
   Galvao-Castro, B
AF Alcantara, LCJ
   Shindo, N
   Van Dooren, S
   Salemi, M
   Costa, MCR
   Kashima, S
   Covas, DT
   Vandamme, AM
   Galvao-Castro, B
TI Brazilian HTLV type 2a strains from intravenous drug users (IDUs) appear
   to have originated from two sources: Brazilian Amerindians and
   European/North American IDUs
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID VIRUS TYPE-II; COMPLETE NUCLEOTIDE-SEQUENCE; IDENTIFICATION; PHYLOGENY;
   INFECTION; SALVADOR; SUBTYPE; ISOLATE; INDIANS; KAYAPO
AB In Brazil, HTLV-2 has been detected in blood donors, in intravenous drug users (IDUs) from urban areas, and in Amerindians living in the Amazon basin. Of the three main HTLV-2 subtypes (2a, 2b, and 2d) only subtype 2a has been detected in Brazil. However, a molecular variant of subtype 2a (also called HTLV-2c) characterized by an extended Tax protein has been isolated from Brazilian blood donors, IDUs, and Indians. Here, we analyzed HTLV-2 isolates from 10 IDUs and a Chilean woman living in Salvador, Bahia, Brazil. Sequencing of env, pX, and long terminal repeat (LTR) genes demonstrated that 10 of the isolates are related to the Brazilian subtype 2a molecular variant described previously. We show that most HTLV-2a Brazilian strains comprise a phylogenetic group harboring a considerable degree of diversity within the env region but not within the LTR region. Interestingly, we demonstrated for the first time in Brazil the presence of a subtype 2a in IDUs that is closely related to the prototype Mo but distinct from the Brazilian 2a molecular variant.
C1 Oswaldo Cruz Fdn, Goncalo Moniz Res Ctr, Adv Publ Hlth Lab, BR-40295001 Salvador, BA, Brazil.
   Fdn Dev Sci, Bahia Sch Med & Publ Hlth, BR-40050420 Salvador, BA, Brazil.
   Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.
   Katholieke Univ Leuven, Rega Inst Med Res, B-5000 Namur, Belgium.
   Blood Ctr Ribeirao Preto, BR-14051140 Sao Paulo, Brazil.
RP Galvao-Castro, B (corresponding author), Oswaldo Cruz Fdn, Goncalo Moniz Res Ctr, Adv Publ Hlth Lab, Rua Waldemat Falcao 121, BR-40295001 Salvador, BA, Brazil.
RI Vandamme, Anne-Mieke/I-4127-2012; Van Dooren, Sonia/E-3113-2019; Covas,
   Dimas T/C-5431-2013; Kashima, Simone/G-4876-2012
OI Vandamme, Anne-Mieke/0000-0002-6594-2766; Covas, Dimas
   T/0000-0002-7364-2595; Kashima, Simone/0000-0002-1487-0141; Alcantara,
   Luiz/0000-0002-6769-9931
CR Andrade TM, 1998, J ACQ IMMUN DEF SYND, V18, P186, DOI 10.1097/00042560-199806010-00011
   Biggar RJ, 1996, VIROLOGY, V216, P165, DOI 10.1006/viro.1996.0043
   Eiraku N, 1996, J VIROL, V70, P1481, DOI 10.1128/JVI.70.3.1481-1492.1996
   Felsenstein J, 1989, PHYLIP PHYLOGENY INF
   Gomes I, 1999, J NEUROL SCI, V165, P84, DOI 10.1016/S0022-510X(99)00083-0
   ISHAK R, 1995, AIDS RES HUM RETROV, V11, P813, DOI 10.1089/aid.1995.11.813
   LEE H, 1993, VIROLOGY, V196, P57, DOI 10.1006/viro.1993.1454
   Lewis MJ, 2000, VIROLOGY, V271, P142, DOI 10.1006/viro.2000.0284
   Miura T, 1997, J MOL EVOL, V44, pS76, DOI 10.1007/PL00000053
   Nicholas KB, 1997, GENEDOC ANAL VISUALI
   SHIMOTOHNO K, 1985, P NATL ACAD SCI USA, V82, P3101, DOI 10.1073/pnas.82.10.3101
   Shindo N, 2002, AIDS RES HUM RETROV, V18, P71, DOI 10.1089/088922202753394736
   Switzer WM, 1996, AIDS RES HUM RETROV, V12, P635, DOI 10.1089/aid.1996.12.635
   SWITZER WM, 1995, J VIROL, V69, P621, DOI 10.1128/JVI.69.2.621-632.1995
   XIA X, 2000, DAMBE DATA ANAL MOL
NR 15
TC 24
Z9 27
U1 0
U2 2
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD JUN
PY 2003
VL 19
IS 6
BP 519
EP 523
DI 10.1089/088922203766774577
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 699KF
UT WOS:000184055500011
PM 12892061
OA Green Published
DA 2020-11-26
ER

PT J
AU Alcantara, LC
   Van Dooren, S
   Goncalves, M
   Kashima, S
   Costa, MC
   Santos, FL
   Bittencourt, AL
   Dourado, I
   Filho, AA
   Covas, DT
   Vandamme, A
   Galvao-Castro, B
AF Alcantara, LC
   Van Dooren, S
   Goncalves, M
   Kashima, S
   Costa, MC
   Santos, FL
   Bittencourt, AL
   Dourado, I
   Filho, AA
   Covas, DT
   Vandamme, A
   Galvao-Castro, B
TI Globin haplotypes of human T-cell lymphotropic virus type I (HTLV-I)
   infected individuals in Salvador, Bahia, Brazil suggest a postColumbian
   African origin of this virus.
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT 11th International Conference on Human Retrovirology: HTLV and Related
   Viruses
CY JUN 09-12, 2003
CL SAN FRANCISCO, CALIFORNIA
C1 Fdn Oswaldo Cruz, LASP CPqGM, Salvador, BA, Brazil.
   Escola Bahania Med Saude Publ, FDC, Salvador, BA, Brazil.
   Katholieke Univ Leuven, Louvain, Belgium.
   Fdn Oswaldo Cruz, CPqGM, Salvador, BA, Brazil.
   Blood Ctr Ribeirao Preto, Ribeirao Preto, Brazil.
   Univ Fed Bahia, Hosp Clin, Salvador, BA, Brazil.
   Univ Fed Bahia, Inst Saude Coletiva, Salvador, BA, Brazil.
RI Van Dooren, Sonia/E-3113-2019; Vandamme, Anne-Mieke/I-4127-2012;
   Kashima, Simone/G-4876-2012; Santos, Fred/G-6077-2012; Covas,
   Dimas/C-5431-2013
OI Vandamme, Anne-Mieke/0000-0002-6594-2766; Kashima,
   Simone/0000-0002-1487-0141; Covas, Dimas/0000-0002-7364-2595
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PY 2003
VL 19
SU S
MA O59
BP S23
EP S24
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 685TU
UT WOS:000183280000060
DA 2020-11-26
ER

PT J
AU Kashima, S
   Takayanagui, OM
   Hachiya, EM
   Carreto, R
   Alcantara, LC
   Castro, BG
   de Oliveira, MP
   Covas, DT
AF Kashima, S
   Takayanagui, OM
   Hachiya, EM
   Carreto, R
   Alcantara, LC
   Castro, BG
   de Oliveira, MP
   Covas, DT
TI Molecular characterization of Tax region in HTLV-I patients from Brazil.
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT 11th International Conference on Human Retrovirology: HTLV and Related
   Viruses
CY JUN 09-12, 2003
CL SAN FRANCISCO, CALIFORNIA
C1 Blood Ctr Ribeirao Preto, Ribeirao Preto, Brazil.
   Univ Sao Paulo, Ribeirao Preto, Brazil.
   Blood Ctr Ribeirao Preto, Mol Biol Lab, Ribeirao Preto, Brazil.
   Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   Natl Canc Inst, Rio De Janeiro, Brazil.
RI Kashima, Simone/G-4876-2012; Covas, Dimas T/C-5431-2013; Takayanagui,
   Osvaldo M/C-8159-2013
OI Kashima, Simone/0000-0002-1487-0141; Covas, Dimas T/0000-0002-7364-2595;
   Takayanagui, Osvaldo M/0000-0002-8190-0275
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PY 2003
VL 19
SU S
MA P3
BP S29
EP S29
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 685TU
UT WOS:000183280000079
DA 2020-11-26
ER

PT J
AU Watanabe, MAE
   Milanezi, CM
   Silva, WA
   Angulo, ID
   Santis, G
   Kashima, S
   da Costa, JAC
   Neto, MM
   Covas, DT
AF Watanabe, MAE
   Milanezi, CM
   Silva, WA
   Angulo, ID
   Santis, G
   Kashima, S
   da Costa, JAC
   Neto, MM
   Covas, DT
TI Molecular investigation of GB virus c RNA in hemodialysis and
   thalassemics patients from Brazil
SO RENAL FAILURE
LA English
DT Article
DE HGV; HBV; HCV; blood-borne diseases; chronic renal failure; thalassemia;
   GBV-C/HGV; HCV; HBV; blood donors
ID HEPATITIS-G VIRUS; C/HEPATITIS-G VIRUS; HIGH PREVALENCE; BLOOD-DONORS;
   INFECTION; TRANSMISSION; CLONING; DISEASE; C/HGV
AB The GB virus C (GBV_C)/hepatitis G virus (HGV) is a-member of the Flaviviridae family. Based on the clinical and epidemiological profiles, this. virus could be acquired mainly by. parenteral transmission through contaminated blood.. We therefore investigated the presence of GBV-C/HGV and its relation with the other blood borne viruses as hepatitis B and C viruses (HBV, HCV) in hemodialysis and thalassemic individuals and blood donors,from Ribeirao Preto-Brazil. Detection of blood borne virus markers including HBV surface antigen (HbsAg), HBV core antibody (anti-Hbc) and HCV antibody was carried out. HIV-1, HIV-2, HTLV-1 and HTLV-2 were also investigated. GBV-C/HGV RNA was detected by reverse transcriptase and polymerase chain reaction (RT-PCR). Ninety-four serum samples from patients with chronic renal failure were analyzed. GBV-C/HGV RNA was identified in 12 (12.8%) patients, anti-HCV antibodies in 28 (29.8%), anti-Hbc in 9 (9.6%), anti-HIV in 1 (1%), HBsAg in 33 (35.1%), and HBsAg/anti-HBc was observed in 2 (2.1%) patients. Thirty-six (38.3%) samples were non-reactive. Seven of the 12 GBV-C/HGV RNA infected samples were co-infected with other viruses: 3 (25%) with HBsAg, 2 (16.7%) with anti-HCV and 2 (16.7%) with anti-HBc/anti-HCV/HBsAg. Among the 42 thalassemic patients, GBV-C/HGV RNA was detected in 6/42 patients (14.2%). Three patients presented GBV-C/HGV, with other blood borne markers. We also detected GBV-C/HGV in 6/50 (12%) blood donors. In these GBV-C/HGV positive thalassemics patients, 50% (3/6) were young individuals (lesser 15 years old) and 67% (4/6) were female patients. The presence of GBV-C RNA in the absence of hepatitis B and C infection in the young patients and healthy donors could be indicate that this virus is capable of independent transmission and does not contribute to liver disease.
C1 Univ Estadual Londrina, Dept Pathol Sci, Londrina, Brazil.
   Univ Sao Paulo, Fac Med, Dept Immunol, Ribeirao Preto, SP, Brazil.
   Univ Sao Paulo, Fac Med, Dept Nephrol, Ribeirao Preto, SP, Brazil.
   Ribeirao Preto Blood Ctr, Ribeirao Preto, SP, Brazil.
   Univ Sao Paulo, Fac Med, Dept Clin Med, BR-05508 Sao Paulo, Brazil.
   Ribeirao Preto Blood Ctr, Ribeirao Preto, SP, Brazil.
RP Watanabe, MAE (corresponding author), Univ Estadual Londrina, Dept Ciencias Patol, Campus Univ, BR-86051970 Londrina, PR, Brazil.
EM maewat@sercomtel.com.br
RI Silva, Wilson Araujo/E-9487-2011; Kashima, Simone/G-4876-2012; Covas,
   Dimas T/C-5431-2013; NETO, MIGUEL MOYSES/AAA-2514-2019; Watanabe, Maria
   Angelica/AAO-4970-2020; Costa, Jose A C/J-5997-2017
OI Silva, Wilson Araujo/0000-0001-9364-2886; Kashima,
   Simone/0000-0002-1487-0141; Covas, Dimas T/0000-0002-7364-2595; Costa,
   Jose A C/0000-0002-7400-5598
CR Aikawa T, 1996, NEW ENGL J MED, V334, P195, DOI 10.1056/NEJM199601183340316
   Alter HJ, 1997, NEW ENGL J MED, V336, P747, DOI 10.1056/NEJM199703133361102
   Alter HJ, 1996, NEW ENGL J MED, V334, P1536, DOI 10.1056/NEJM199606063342310
   Bowden S, 2001, J GASTROEN HEPATOL, V16, P124, DOI 10.1046/j.1440-1746.2001.02405.x
   Casteling A, 1998, J MED VIROL, V55, P103, DOI 10.1002/(SICI)1096-9071(199806)55:2&lt;103::AID-JMV4&gt;3.0.CO;2-6
   Cutuli N, 2000, VOX SANG, V79, P247
   Gallian P, 1998, J MED VIROL, V56, P310, DOI 10.1002/(SICI)1096-9071(199812)56:4&lt;310::AID-JMV4&gt;3.0.CO;2-4
   Ibanez A, 1998, J MED VIROL, V55, P293, DOI 10.1002/(SICI)1096-9071(199808)55:4&lt;293::AID-JMV7&gt;3.0.CO;2-W
   Kallinowski B, 1998, NEPHROL DIAL TRANSPL, V13, P93, DOI 10.1093/ndt/13.1.93
   Kao JH, 1999, J INFECT DIS, V180, P191, DOI 10.1086/314850
   Kato T, 1998, J MED VIROL, V55, P109, DOI 10.1002/(SICI)1096-9071(199806)55:2&lt;109::AID-JMV5&gt;3.0.CO;2-6
   Kinoshita T, 1997, J INFECT DIS, V175, P454, DOI 10.1093/infdis/175.2.454
   Kondili LA, 2001, INFECTION, V29, P219, DOI 10.1007/s15010-001-9172-7
   Lampe E, 1998, CLIN DIAGN VIROL, V9, P1, DOI 10.1016/S0928-0197(97)10017-4
   Lampe E, 1998, J MED VIROL, V56, P39, DOI 10.1002/(SICI)1096-9071(199809)56:1&lt;39::AID-JMV7&gt;3.0.CO;2-O
   Lampe E, 1997, J MED VIROL, V52, P61, DOI 10.1002/(SICI)1096-9071(199705)52:1&lt;61::AID-JMV10&gt;3.0.CO;2-3
   Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A
   Lin HH, 1998, J INFECT DIS, V177, P1202, DOI 10.1086/515264
   Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505
   Liu HF, 1998, J MED VIROL, V55, P118, DOI 10.1002/(SICI)1096-9071(199806)55:2&lt;118::AID-JMV6&gt;3.0.CO;2-5
   Masuko K, 1996, NEW ENGL J MED, V334, P1485, DOI 10.1056/NEJM199606063342301
   Matzkies F K, 2000, Clin Lab, V46, P247
   Moatter T, 1999, Indian J Pathol Microbiol, V42, P475
   Moaven LD, 1996, MED J AUSTRALIA, V165, P84, DOI 10.5694/j.1326-5377.1996.tb124854.x
   Oshita M, 1998, J MED VIROL, V55, P98, DOI 10.1002/(SICI)1096-9071(199806)55:2&lt;98::AID-JMV3&gt;3.0.CO;2-I
   Pavesi A, 2001, J MOL EVOL, V53, P104, DOI 10.1007/s002390010198
   Radkowski M, 1998, INFECTION, V26, P113, DOI 10.1007/BF02767771
   SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564
   Tong CYW, 1997, BRIT J HAEMATOL, V99, P295, DOI 10.1046/j.1365-2141.1997.3783178.x
   Wang JT, 1998, TRANSFUSION, V38, P290, DOI 10.1046/j.1537-2995.1998.38398222874.x
   Watanabe T, 1997, NEPHRON, V76, P171, DOI 10.1159/000190165
NR 31
TC 8
Z9 8
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0886-022X
EI 1525-6049
J9 RENAL FAILURE
JI Ren. Fail.
PY 2003
VL 25
IS 1
BP 67
EP 75
DI 10.1081/JDI-120017469
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA 647YD
UT WOS:000181120900008
PM 12617334
DA 2020-11-26
ER

PT J
AU Januario, AH
   Rodrigues, E
   Pietro, RCLR
   Kashima, S
   Sato, DN
   Franca, SC
AF Januario, AH
   Rodrigues, E
   Pietro, RCLR
   Kashima, S
   Sato, DN
   Franca, SC
TI Antimycobacterial physalins from Physalis angulata L. (Solanaceae)
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE physalis angulata; physalins; antimycobacterial
ID MYCOBACTERIUM-TUBERCULOSIS
AB Crude extracts and fractions from aerial parts of Physalis angulata have been bioassayed for antimycobacterial activity. Fraction Al-29-12 containing physalins B, F and D exhibited a minimum inhibitory concentration value (MIC) against Mycobacterium tuberculosis H(37)Rv strain of 32 mug/mL. Purified physalin B and physalin D were also tested showing MIC values against Mycobacterium tuberculosis H37Rv strain of >128 mug/mL and 32 mug/mL respectively, suggesting that physalin D plays a relevant role in the antimycobacterial activity displayed. Structural elucidation of both physalins D and B was based on detailed C-13 and H-1 NMR spectral analysis with the aid of 2D-correlation spectroscopy (H-1-H-1, COSY, HSQC and HMBC). The assignment of the C-13 chemical shift for physalin D is reported here for the first time. Copyright (C) 2002 John Wiley Sons, Ltd.
C1 Univ Ribeirao Preto, UNAERP, Unidade Biotecnol Vegetal, Ribeirao Preto, Brazil.
   Univ Fed Sao Carlos, Dept Quim, BR-13560 Sao Carlos, SP, Brazil.
   Univ Ribeirao Preto, UNAERP, Dept Ciencias Farmaceut, Ribeirao Preto, Brazil.
   Inst Adolfo Lutz Registro, Ribeirao Preto, SP, Brazil.
RP Januario, AH (corresponding author), Univ Ribeirao Preto, UNAERP, Unidade Biotecnol Vegetal, Ribeirao Preto, Brazil.
RI Kashima, Simone/G-4876-2012; Franca, Suzelei C/E-4069-2013; Januario,
   Ana Helena/U-2283-2019; Pietro, Rosemeire/N-1811-2019; Pietro, Rosemeire
   Cristina Linhari Rodrigues/G-8996-2015; Rodrigues-Filho,
   Edson/M-7657-2019; Januario, Ana Helena AH/G-9375-2012; Rodrigues-Filho,
   Edson/C-5024-2009
OI Kashima, Simone/0000-0002-1487-0141; Franca, Suzelei
   C/0000-0003-4864-430X; Pietro, Rosemeire/0000-0001-7859-8127;
   Rodrigues-Filho, Edson/0000-0003-4305-0326; Januario, Ana
   Helena/0000-0002-3815-6903
CR ANTOUN MD, 1981, J NAT PROD, V44, P579, DOI 10.1021/np50017a013
   CHIANG HC, 1992, ANTICANCER RES, V12, P837
   CHIANG HC, 1992, ANTICANCER RES, V12, P1155
   Cohn DL, 1997, CLIN INFECT DIS, V24, pS121, DOI 10.1093/clinids/24.Supplement_1.S121
   Collins LA, 1997, ANTIMICROB AGENTS CH, V41, P1004, DOI 10.1128/AAC.41.5.1004
   Cox JS, 1999, NATURE, V402, P79
   Franca SC, 1999, ACTA HORTIC, P389, DOI 10.17660/ActaHortic.1999.502.64
   JUANG JK, 1989, BIOCHEM BIOPH RES CO, V159, P1128, DOI 10.1016/0006-291X(89)92226-2
   KAWAI M, 1987, PHYTOCHEMISTRY, V26, P3313, DOI 10.1016/S0031-9422(00)82495-4
   Makino B, 1995, J NAT PROD, V58, P1668, DOI 10.1021/np50125a004
   Phetsuksiri B, 1999, ANTIMICROB AGENTS CH, V43, P1042, DOI 10.1128/AAC.43.5.1042
   Pietro RCLR, 2000, PHYTOMEDICINE, V7, P335, DOI 10.1016/S0944-7113(00)80052-5
   Santos EMG, 1989, PLANTAS MED AMAZONIA, P45
NR 13
TC 61
Z9 70
U1 1
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD AUG
PY 2002
VL 16
IS 5
BP 445
EP 448
DI 10.1002/ptr.939
PG 4
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 587VR
UT WOS:000177655800009
PM 12203265
DA 2020-11-26
ER

PT J
AU Kashima, S
   Soares, AM
   Roberto, PG
   Pereira, JO
   Astolfi, S
   Cintra, AO
   Fontes, MRM
   Giglio, JR
   Franca, SD
AF Kashima, S
   Soares, AM
   Roberto, PG
   Pereira, JO
   Astolfi, S
   Cintra, AO
   Fontes, MRM
   Giglio, JR
   Franca, SD
TI cDNA sequence and molecular modeling of a nerve growth factor from
   Bothrops jararacussu venomous gland
SO BIOCHIMIE
LA English
DT Article
DE nerve growth factor (NGF); Bothrops jararacussu snake; cDNA; molecular
   model
ID AMINO-ACID-SEQUENCE; NAJA-NAJA-ATRA; CRYSTAL-STRUCTURE; FACTOR
   PRECURSOR; BINDING DOMAIN; SNAKE-VENOMS; PURIFICATION; CLONING; TRKA;
   NGF
AB The complete nucleotide sequence of a nerve growth factor precursor from Bothrops jararacussu snake (Bj-NGF) was determined by DNA sequencing of a clone from cDNA library prepared from the poly(A) + RNA of the venom gland of B.jararacussu. cDNA encoding Bj-NGF precursor contained 723 bp in length, which encoded a prepro-NGF molecule with 241 amino acid residues. The mature Bj-NGF molecule was composed of I 18 amino acid residues with theoretical pI and molecular weight of 8.31 and 13,537, respectively. Its amino acid sequence showed 97%, 96%, 93%, 86%, 78%, 74%, 76%, 76% and 55% sequential similarities with NGFs from Crotalus durissus terrificus, Agkistrodon halys pallas, Daboia (Vipera) russelli russelli, Bungarus multicinctus, Naja sp., mouse, human, bovine and cat, respectively. Phylogenetic analyses based on the amino acid sequences of 15 NGFs separate the Elapidae family (Naja and Bungarus) from those Crotalidae snakes (Bothrops, Crotalus and Agkistrodon). The three-dimensional structure of mature Bj-NGF was modeled based on the crystal structure of the human NGF. The model reveals that the core of NGF, formed by a pair of P-sheets, is highly conserved and the major mutations are both at the three beta-hairpin loops and at the reverse turn. (C) 2002 Societe francaise de biochimie et biologic moleculaire/Editions scientifiques et medicales Elsevier SAS. All rights reserved.
C1 Univ Ribeirao Preto, Dept Biotecnol, UNAERP, BR-14096380 Ribeirao Preto, SP, Brazil.
   Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Bioquim & Imunol, Ribeirao Preto, Brazil.
   Univ Sao Paulo, FCFRP, Dept Anal Clin Toxicol & Bromatol, BR-14049 Ribeirao Preto, Brazil.
   Univ Amazonas, Inst Ciencias Biol, Fac Ciencias Agr, Manaus, Amazonas, Brazil.
   Univ Estadual Paulista Julio Mesquita Filho, IB, Dept Fis & Biofis, Botucatu, SP, Brazil.
RP Franca, SD (corresponding author), Univ Ribeirao Preto, Dept Biotecnol, UNAERP, Av Costabile Romano 2201, BR-14096380 Ribeirao Preto, SP, Brazil.
RI Kashima, Simone/G-4876-2012; Franca, Suzelei C/E-4069-2013; Soares,
   Andreimar M/K-5556-2014; Fontes, Marcos R/B-1941-2009
OI Kashima, Simone/0000-0002-1487-0141; Franca, Suzelei
   C/0000-0003-4864-430X; Fontes, Marcos R/0000-0002-4634-6221; Soares,
   Andreimar/0000-0003-1032-2188; ROBERTO, PATRICIA/0000-0001-8932-4666
CR Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7
   DANSE JM, 1993, GROWTH FACTORS, V8, P77, DOI 10.3109/08977199309029136
   Felsenstein J, PHYLIP PHYLOGENY INF
   FURUKAWA S, 1978, BIOCHIM BIOPHYS ACTA, V533, P383, DOI 10.1016/0005-2795(78)90384-7
   Guo LY, 1999, TOXICON, V37, P465, DOI 10.1016/S0041-0101(98)00177-9
   HOGUEANGELETTI RA, 1976, BIOCHEMISTRY-US, V15, P26, DOI 10.1021/bi00646a005
   IBANEZ CF, 1990, EMBO J, V9, P1477, DOI 10.1002/j.1460-2075.1990.tb08265.x
   INOUE S, 1991, FEBS LETT, V279, P38, DOI 10.1016/0014-5793(91)80244-W
   JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189
   Kostiza T, 1996, TOXICON, V34, P787, DOI 10.1016/0041-0101(96)00023-2
   KOSTIZA T, 1995, TOXICON, V33, P1249, DOI 10.1016/0041-0101(95)00086-2
   KOYAMA J, 1992, BIOCHIM BIOPHYS ACTA, V1160, P287, DOI 10.1016/0167-4838(92)90090-Z
   Lipps BV, 1998, J NAT TOXINS, V7, P121
   Lipps BV, 2000, J NAT TOXINS, V9, P13
   LOUGHLIN SE, 1993, NEUROTROPHIC FACTORS
   MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0
   ODA T, 1989, BIOCHEM INT, V19, P909
   PEARCE FL, 1986, J PHYSIOL-LONDON, V372, P379, DOI 10.1113/jphysiol.1986.sp016014
   SELBY MJ, 1987, J NEUROSCI RES, V18, P293, DOI 10.1002/jnr.490180205
   SIIGUR E, 1985, COMP BIOCHEM PHYS B, V81, P211, DOI 10.1016/0305-0491(85)90185-3
   SIIGUR J, 1986, COMP BIOCHEM PHYS B, V83, P621, DOI 10.1016/0305-0491(86)90306-8
   SMITH PJ, 1992, COMP BIOCHEM PHYS B, V103, P975, DOI 10.1016/0305-0491(92)90225-G
   SUTER U, 1991, EMBO J, V10, P2395, DOI 10.1002/j.1460-2075.1991.tb07778.x
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Ultsch MH, 1999, J MOL BIOL, V290, P149, DOI 10.1006/jmbi.1999.2816
   Wiesmann C, 1999, NATURE, V401, P184
   Xu TR, 1999, COMP BIOCHEM PHYS C, V124, P149, DOI 10.1016/S0742-8413(99)00047-X
NR 27
TC 14
Z9 15
U1 0
U2 0
PU EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS CEDEX 15
PA 23 RUE LINOIS, 75724 PARIS CEDEX 15, FRANCE
SN 0300-9084
J9 BIOCHIMIE
JI Biochimie
PD JUL
PY 2002
VL 84
IS 7
BP 675
EP 680
AR PII S0300-9084(02)01429-3
DI 10.1016/S0300-9084(02)01429-3
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 617BK
UT WOS:000179339600009
PM 12453640
DA 2020-11-26
ER

PT J
AU Scrideli, CA
   Kashima, S
   Cipolloti, R
   Defavery, R
   Tone, LG
AF Scrideli, CA
   Kashima, S
   Cipolloti, R
   Defavery, R
   Tone, LG
TI Clonal evolution as the limiting factor in the detection of minimal
   residual disease by polymerase chain reaction in children in Brazil with
   acute lymphoid leukemia
SO JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
LA English
DT Article
DE childhood acute lymphoblastic leukemia; polymerase chain reaction; TCR
   gamma; clonal evolution
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; IMMUNOGLOBULIN HEAVY-CHAIN; ISOLATED
   EXTRAMEDULLARY RELAPSE; GENE REARRANGEMENTS; CHILDHOOD; STABILITY;
   PROGRESSION; DNA
AB Background: The purpose of this investigation was to analyze the incidence of clonal evolution in children in Brazil children with acute lymphoblastic leukemia and its interference with the detection of minimal residual disease by polymerase chain reaction using clone-specific primers.
   Patients and Methods: The authors analyzed DNA samples from 12 children with acute lymphoblastic leukemia at diagnosis and after relapse using polymerase chain reaction and automatic sequencing to determine the presence of T-cell receptor gamma (TCRgamma) gene rearrangements. A clone-specific primer was synthesized based on the sequence obtained at diagnosis for each patient and at relapse for those with clonal evolution for the Study of minimal residual disease.
   Results: A change of the original clone was detected in 3 of 12 patients (25%), involving the same rearrangement detected at diagnosis, suggesting the development of subclones. Minimal residual disease was detected at the end of treatment or before the relapse in all patients who had maintained the same rearrangements detected at diagnosis. Minimal residual disease was investigated at the end of treatment in two of the three patients with clonal evolution and was not detected with the use of clone-specific primers.
   Conclusions: These data suggest that clonal evolution for TCRgamma gene rearrangements was not a rare event among children in Brazil and, when present, interfered with the detection of minimal residual disease.
C1 Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat & Puericultura, BR-14049900 Ribeirao Preto, SP, Brazil.
   Fundacao Hemoctr Ribeirao Preto, Sao Paulo, Brazil.
RP Tone, LG (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat & Puericultura, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM lgtone@fmrp.usp.br
RI Scrideli, Carlos A/D-7618-2012; Tone, Luiz/D-3934-2012; Kashima,
   Simone/G-4876-2012
OI Scrideli, Carlos A/0000-0001-6618-789X; Kashima,
   Simone/0000-0002-1487-0141; Tone, Luiz Gonzaga/0000-0001-8821-4211
CR BEISHUIZEN A, 1994, BLOOD, V83, P2238, DOI 10.1182/blood.V83.8.2238.bloodjournal8382238
   BRANDALISE S, 1993, LEUKEMIA, V7, pS142
   BUNIN NJ, 1990, LEUKEMIA, V4, P727
   CAMPANA D, 1999, CHILDHOOD LEUKEMIAS, V22, P413
   Cave H, 1998, NEW ENGL J MED, V339, P591, DOI 10.1056/NEJM199808273390904
   Choi Y, 1996, BLOOD, V87, P2506, DOI 10.1182/blood.V87.6.2506.bloodjournal8762506
   Foroni L, 1999, BRIT J HAEMATOL, V105, P7
   Frost L, 1997, BRIT J HAEMATOL, V98, P992, DOI 10.1046/j.1365-2141.1997.3103129.x
   GOULDEN N, 1994, BRIT J HAEMATOL, V87, P282, DOI 10.1111/j.1365-2141.1994.tb04910.x
   Goulden NJ, 1998, BRIT J HAEMATOL, V100, P235, DOI 10.1046/j.1365-2141.1998.00574.x
   Gruhn B, 1998, LEUKEMIA, V12, P675, DOI 10.1038/sj.leu.2400985
   Height SE, 1996, BLOOD, V87, P5242, DOI 10.1182/blood.V87.12.5242.bloodjournal87125242
   ITO Y, 1993, J CLIN ONCOL, V11, P546, DOI 10.1200/JCO.1993.11.3.546
   KATZ F, 1989, BRIT J HAEMATOL, V73, P173, DOI 10.1111/j.1365-2141.1989.tb00249.x
   KITCHINGMAN GR, 1986, BLOOD, V67, P698
   Kuang SQ, 1996, CANCER GENET CYTOGEN, V88, P110, DOI 10.1016/0165-4608(95)00286-3
   Lal A, 1998, J CLIN PATHOL-MOL PA, V51, P277, DOI 10.1136/mp.51.5.277
   Lo Nigro L, 1999, LEUKEMIA, V13, P190
   MARSHALL GM, 1995, LEUKEMIA, V9, P1847
   OREILLY J, 1995, LEUKEMIA, V9, P624
   RAGHAVACHAR A, 1988, EUR J PEDIATR, V147, P503, DOI 10.1007/BF00441975
   Rosenquist R, 1999, EUR J HAEMATOL, V63, P171
   ROVERA G, 1991, NEW ENGL J MED, V324, P774
   SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875
   Scrideli CA, 1997, J PEDIAT HEMATOL ONC, V19, P516, DOI 10.1097/00043426-199711000-00005
   SCRIDELI CA, 1999, MED PEDIATR ONCOL, V33, P235
   STEENBERGEN EJ, 1993, BLOOD, V82, P581, DOI 10.1182/blood.V82.2.581.bloodjournal822581
   STEWARD CG, 1994, BLOOD, V83, P1355
   Szczepanski T, 1999, LEUKEMIA, V13, P196, DOI 10.1038/sj.leu.2401277
   TAYLOR JJ, 1994, LEUKEMIA, V8, P60
   TRAINOR KJ, 1991, BLOOD, V78, P192
   van Dongen JJM, 1998, LANCET, V352, P1731, DOI 10.1016/S0140-6736(98)04058-6
   WASSERMAN R, 1992, BLOOD, V79, P223
NR 33
TC 6
Z9 6
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1077-4114
EI 1536-3678
J9 J PEDIAT HEMATOL ONC
JI J. Pediatr. Hematol. Oncol.
PD JUN-JUL
PY 2002
VL 24
IS 5
BP 364
EP 367
DI 10.1097/00043426-200206000-00008
PG 4
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 570ZR
UT WOS:000176690800006
PM 12142784
DA 2020-11-26
ER

PT J
AU Scrideli, CA
   Kashima, S
   Cipolloti, R
   Defavery, R
   Bernardes, JE
   Tone, LG
AF Scrideli, CA
   Kashima, S
   Cipolloti, R
   Defavery, R
   Bernardes, JE
   Tone, LG
TI Minimal residual disease in Brazilian children with acute lymphoid
   leukemia: comparison of three detection methods by PCR
SO LEUKEMIA RESEARCH
LA English
DT Article
DE childhood ALL; minimal residual disease; PCR; TCR gamma; clonal
   evolution; monoclonality
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; POLYMERASE-CHAIN-REACTION; STRONG
   PREDICTIVE FACTOR; GENE REARRANGEMENT; INDUCTION THERAPY; FOLLOW-UP;
   CHILDHOOD; RELAPSE; END; REMISSION
AB The minimal residual disease (MRD) detection by the polymerase chain reaction (PCR) in children with acute lymphoblastic leukemia has been pointed to be an adverse prognostic factor. Detection methods based on this technique using clone-specific primers are cumbersome and time consuming. The detection of monoclonal gene rearrangements of gamma T-cell receptors (TCRgamma) is a simpler although less sensitive method. In the present study, we analyzed the presence of MRD during four different phases of treatment (week 4; 3-6, 12-24 months, and end of treatment) in 34 Brazilian children with lymphoid leukemia by three detection methods based on the PCR technique: (1) using consensus primers for the detection of a clonal population for TCRgamma (2) clone-specific primers for the junctional region of TCRgamma; and (3) a semi-nested reaction with an initial cycle with consensus primers followed by a second cycle with clone-specific primers. MRD presence was associated with a shorter event-free survival and was the major independent prognostic factor in most of the phases analyzed. The use of consensus primers for the detection of TCRgamma clonality, although less sensitive, proved to be a simpler, faster and less costly method whose positivity was associated with more than 90% relapse rates during all phases analyzed. (C) 2002 Elsevier Science Ltd. All rights reserved.
C1 Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat & Puericultura, BR-14049900 Ribeirao Preto, SP, Brazil.
   Fdn Hemoctr Ribeirao Preto, Ribeirao Preto, SP, Brazil.
RP Tone, LG (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat & Puericultura, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM lgtone@fmrp.usp.br
RI Tone, Luiz/D-3934-2012; Kashima, Simone/G-4876-2012; Scrideli, Carlos
   A/D-7618-2012
OI Kashima, Simone/0000-0002-1487-0141; Scrideli, Carlos
   A/0000-0001-6618-789X; Tone, Luiz Gonzaga/0000-0001-8821-4211
CR Biondi A, 2000, LEUKEMIA, V14, P1939, DOI 10.1038/sj.leu.2401922
   BRANDALISE S, 1993, LEUKEMIA, V7, pS142
   BRISCO MJ, 1993, LEUKEMIA, V7, P1514
   Brisco MJ, 2001, LEUKEMIA, V15, P385, DOI 10.1038/sj.leu.2402044
   BRISCO MJ, 1994, LANCET, V343, P196, DOI 10.1016/S0140-6736(94)90988-1
   CAMPANA D, 1999, CHILDHOOD LEUKEMIAS, P413
   Cave H, 1998, NEW ENGL J MED, V339, P591, DOI 10.1056/NEJM199808273390904
   Coustan-Smith E, 2000, BLOOD, V96, P2691, DOI 10.1182/blood.V96.8.2691
   DEANE M, 1990, BRIT J HAEMATOL, V74, P251, DOI 10.1111/j.1365-2141.1990.tb02579.x
   FARDEL S, 1999, ARCH PATHOL LAB MED, V123, P1030
   Foroni L, 1999, BRIT J HAEMATOL, V105, P7
   Goulden NJ, 1998, BRIT J HAEMATOL, V100, P235, DOI 10.1046/j.1365-2141.1998.00574.x
   Greaves M, 1997, NEW ENGL J MED, V336, P367, DOI 10.1056/NEJM199701303360510
   Gruhn B, 1998, LEUKEMIA, V12, P675, DOI 10.1038/sj.leu.2400985
   ITO Y, 1993, J CLIN ONCOL, V11, P546, DOI 10.1200/JCO.1993.11.3.546
   Jacquy C, 1997, BRIT J HAEMATOL, V98, P140, DOI 10.1046/j.1365-2141.1997.1792996.x
   Kuang SQ, 1996, CANCER GENET CYTOGEN, V88, P110, DOI 10.1016/0165-4608(95)00286-3
   Lo Nigro L, 1999, LEUKEMIA, V13, P190
   Neale GAM, 1999, LEUKEMIA, V13, P1221, DOI 10.1038/sj.leu.2401459
   NIZET Y, 1991, BRIT J HAEMATOL, V79, P205, DOI 10.1111/j.1365-2141.1991.tb04523.x
   PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1
   Pinkel D, 1996, J CLIN ONCOL, V14, P4, DOI 10.1200/JCO.1996.14.1.4
   POTTER MN, 1993, BRIT J HAEMATOL, V83, P412, DOI 10.1111/j.1365-2141.1993.tb04665.x
   Pui CH, 2000, LEUKEMIA, V14, P783, DOI 10.1038/sj.leu.2401780
   Roberts WM, 1997, NEW ENGL J MED, V336, P317, DOI 10.1056/NEJM199701303360501
   SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875
   Scrideli CA, 1997, J PEDIAT HEMATOL ONC, V19, P516, DOI 10.1097/00043426-199711000-00005
   SCRIDELI CA, 1999, MED PEDIATR ONCOL, V33, P235
   STEWARD CG, 1994, BLOOD, V83, P1355
   Sykes PJ, 1997, LEUKEMIA, V11, P153, DOI 10.1038/sj.leu.2400542
   Szczepanski T, 1999, LEUKEMIA, V13, P196, DOI 10.1038/sj.leu.2401277
   TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0
   TRAINOR KJ, 1991, BLOOD, V78, P192
   van Dongen JJ, 1999, CHILDHOOD LEUKEMIAS, P145
   van Dongen JJM, 1998, LANCET, V352, P1731, DOI 10.1016/S0140-6736(98)04058-6
   VANDONGEN JJM, 1991, CLIN CHIM ACTA, V198, P1
   Viana MB, 1998, INT J CANCER, V78, P56, DOI 10.1002/(SICI)1097-0215(1998)78:11+<56::AID-IJC16>3.0.CO;2-X
   VIANA MB, 1994, ARCH DIS CHILD, V71, P304, DOI 10.1136/adc.71.4.304
   WASSERMAN R, 1992, J CLIN ONCOL, V10, P1879, DOI 10.1200/JCO.1992.10.12.1879
   YAMADA M, 1990, NEW ENGL J MED, V323, P448, DOI 10.1056/NEJM199008163230705
   YOKOTA S, 1991, BLOOD, V77, P331
NR 41
TC 7
Z9 7
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0145-2126
EI 1873-5835
J9 LEUKEMIA RES
JI Leuk. Res.
PD MAY
PY 2002
VL 26
IS 5
BP 431
EP 438
AR PII S0145-2126(01)00153-9
DI 10.1016/S0145-2126(01)00153-9
PG 8
WC Oncology; Hematology
SC Oncology; Hematology
GA 546TG
UT WOS:000175289700002
PM 11916514
DA 2020-11-26
ER

PT J
AU Shindo, N
   Alcantara, LCJ
   Van Dooren, S
   Salemi, M
   Costa, MCR
   Kashima, S
   Covas, DT
   Teva, A
   Pellegrini, M
   Brito, I
   Vandamme, AM
   Galvao-Castro, B
AF Shindo, N
   Alcantara, LCJ
   Van Dooren, S
   Salemi, M
   Costa, MCR
   Kashima, S
   Covas, DT
   Teva, A
   Pellegrini, M
   Brito, I
   Vandamme, AM
   Galvao-Castro, B
TI Human retroviruses (HIV and HTLV) in Brazilian Indians:
   Seroepidemiological study and molecular epidemiology of HTLV type 2
   isolates
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID VIRUS TYPE-II; T-CELL LEUKEMIA; COMPLETE NUCLEOTIDE-SEQUENCE; GUAYMI
   INDIANS; KAYAPO INDIANS; LYMPHOMA VIRUS; DRUG-ABUSERS; PAN-PANISCUS;
   INFECTION; IDENTIFICATION
AB To investigate serological, epidemiological, and molecular aspects of HTLV-1, HTLV-2, and HIV-1 infections in Amerindian populations in Brazil, we tested 683 and 321 sera from Tiriyo and Waiampi Indians, respectively. Both HIV-1 and HTLV-2 infections were detected at low prevalence among the Tiriyos whereas only HTLV-1 was present among the Waiampis, also at low prevalence. Analysis of the nucleotide sequence of the 631 bp of the env gene obtained from the three HTLV-2 isolates detected among the Tiriyos demonstrated by restriction fragment length polymorphism that these viruses belong to subtype IIa. Phylogenetic analysis of this same fragment showed that these sequences cluster closer to HTLV-2 isolates from intravenous drug users living in urban areas of southern Brazil than to the same gene sequence studied in another Brazilian tribe, the Kayapos. Our results confirm the distribution of Brazilian HTLV-2 sequences in a unique cluster I and cluster IIa and suggest that there is a considerable degree of diversity within this cluster. We also report for the first time HIV-1 infection among Brazilian Amerindians.
C1 Fundacao Oswaldo Cruz, Goncalo Moniz Res Ctr, Adv Publ Hlth Lab, BR-40295001 Salvador, BA, Brazil.
   Fdn Dev Sci, Bahi Sch Med & Publ Hlth, BR-40290000 Salvador, BA, Brazil.
   Univ Fed Rio de Janeiro, BR-27941590 Rio De Janeiro, Brazil.
   Katholieke Univ Leuven, Rega Inst, B-3000 Louvain, Belgium.
   Blood Ctr Ribeirao Preto, BR-14051140 Sao Paulo, Brazil.
   Fundacao Oswaldo Cruz, IOS, BR-21045400 Rio De Janeiro, Brazil.
   Brazilian Minist Hlth, CN DST AIDS, BR-70750543 Brasilia, DF, Brazil.
RP Shindo, N (corresponding author), Univ Washington, Dept Microbiol, Box 35870,1959 Pacific Ave, Seattle, WA 98195 USA.
EM nshindo@u.washington.edu
RI Covas, Dimas T/C-5431-2013; Van Dooren, Sonia/E-3113-2019; Vandamme,
   Anne-Mieke/I-4127-2012; Kashima, Simone/G-4876-2012
OI Covas, Dimas T/0000-0002-7364-2595; Vandamme,
   Anne-Mieke/0000-0002-6594-2766; Kashima, Simone/0000-0002-1487-0141;
   Alcantara, Luiz/0000-0002-6769-9931
CR ANDRADASERPA MJ, 1988, IMMUNOL LETT, V18, P15, DOI 10.1016/0165-2478(88)90063-6
   Biggar RJ, 1996, VIROLOGY, V216, P165, DOI 10.1006/viro.1996.0043
   BIGLIONE M, 1993, J ACQ IMMUN DEF SYND, V6, P631
   BLACK FL, 1994, AIDS RES HUM RETROV, V10, P1165, DOI 10.1089/aid.1994.10.1165
   *BRAZ MIN HLTH NAT, 1997, REL VIAG TERR IND TU
   DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655
   Digilio L, 1997, J VIROL, V71, P3684, DOI 10.1128/JVI.71.5.3684-3692.1997
   DUBE DK, 1993, J VIROL, V67, P1175, DOI 10.1128/JVI.67.3.1175-1184.1993
   DUENASBARAJAS E, 1992, AIDS RES HUM RETROV, V8, P1851, DOI 10.1089/aid.1992.8.1851
   Eiraku N, 1996, J VIROL, V70, P1481, DOI 10.1128/JVI.70.3.1481-1492.1996
   FEIGAL E, 1991, J INFECT DIS, V164, P36, DOI 10.1093/infdis/164.1.36
   Felsenstein J, 1989, PHYLIP PHYLOGENY INF
   FERRER JF, 1993, VIROLOGY, V197, P576, DOI 10.1006/viro.1993.1631
   FUJIYAMA C, 1993, J INFECT DIS, V168, P1075, DOI 10.1093/infdis/168.4.1075
   Fujiyoshi T, 1999, AIDS RES HUM RETROV, V15, P1235, DOI 10.1089/088922299310124
   FUKUSHIMA Y, 1995, AIDS RES HUM RETROV, V11, P637, DOI 10.1089/aid.1995.11.637
   GESSAIN A, 1985, LANCET, V2, P407
   GLVAOCASTRO B, 1986, LANCET, V1, P976
   Hall BG, 1996, MOL BIOL EVOL, V13, P1
   HALL WW, 1994, SEMIN VIROL, V5, P165, DOI 10.1006/smvy.1994.1017
   HALL WW, 1992, J VIROL, V66, P2456, DOI 10.1128/JVI.66.4.2456-2463.1992
   HENEINE W, 1991, NEW ENGL J MED, V324, P565, DOI 10.1056/NEJM199102213240815
   HINUMA Y, 1993, LEUKEMIA RES, V17, P379, DOI 10.1016/0145-2126(93)90027-I
   IJICHI S, 1993, JPN J CANCER RES, V84, P1215, DOI 10.1111/j.1349-7006.1993.tb02824.x
   ISHAK R, 1995, AIDS RES HUM RETROV, V11, P813, DOI 10.1089/aid.1995.11.813
   LAIRMORE MD, 1990, P NATL ACAD SCI USA, V87, P8840, DOI 10.1073/pnas.87.22.8840
   LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084
   LEE H, 1993, VIROLOGY, V196, P57, DOI 10.1006/viro.1993.1454
   LEVINE PH, 1993, AIDS RES HUM RETROV, V9, P123, DOI 10.1089/aid.1993.9.123
   Lewis MJ, 2000, VIROLOGY, V271, P142, DOI 10.1006/viro.2000.0284
   MALONEY EM, 1992, J INFECT DIS, V166, P100, DOI 10.1093/infdis/166.1.100
   MIURA T, 1997, J MOL EVOL, V44, P76
   MUELLER N, 1991, CANCER CAUSE CONTROL, V2, P37, DOI 10.1007/BF00052359
   Murphy EL, 1996, J ACQ IMMUN DEF SYND, V13, pS215, DOI 10.1097/00042560-199600001-00032
   NAKAUCHI CM, 1990, MEM I OSWALDO CRUZ, V85, P29, DOI 10.1590/S0074-02761990000100004
   OSAME M, 1986, LANCET, V1, P1031
   PARDI D, 1993, J VIROL, V67, P7663, DOI 10.1128/JVI.67.12.7663-7667.1993
   SALZANO FM, 1977, AM J PHYS ANTHROPOL, V47, P337, DOI 10.1002/ajpa.1330470214
   SHIMOTOHNO K, 1985, P NATL ACAD SCI USA, V82, P3101, DOI 10.1073/pnas.82.10.3101
   Switzer WM, 1996, AIDS RES HUM RETROV, V12, P635, DOI 10.1089/aid.1996.12.635
   SWITZER WM, 1995, J VIROL, V69, P621, DOI 10.1128/JVI.69.2.621-632.1995
   TAKAHASHI H, 1993, AIDS RES HUM RETROV, V9, P721, DOI 10.1089/aid.1993.9.721
   Talarmin A, 1999, J GEN VIROL, V80, P3083, DOI 10.1099/0022-1317-80-12-3083
   TEDDER RS, 1984, LANCET, V2, P125
   Van Brussel M, 1998, VIROLOGY, V243, P366, DOI 10.1006/viro.1998.9075
   Vandamme AM, 1998, J VIROL, V72, P4327, DOI 10.1128/JVI.72.5.4327-4340.1998
NR 46
TC 37
Z9 45
U1 0
U2 4
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD JAN 1
PY 2002
VL 18
IS 1
BP 71
EP 77
DI 10.1089/088922202753394736
PG 7
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 513FN
UT WOS:000173367400008
PM 11804558
OA Green Published
DA 2020-11-26
ER

PT J
AU Batista, WC
   Kashima, S
   Marques, AC
   Figueiredo, LTM
AF Batista, WC
   Kashima, S
   Marques, AC
   Figueiredo, LTM
TI Phylogenetic analysis of Brazilian Flavivirus using nucleotide sequences
   of parts of NS5 gene and 3 ' non-coding regions
SO VIRUS RESEARCH
LA English
DT Article
DE Brazilian Flavivirus; Flavivirus genome; Flavivirus phylogeny
ID POLYMERASE-CHAIN-REACTION; YELLOW-FEVER VIRUS; ENCEPHALITIS-VIRUS;
   3'-NONCODING REGION; IDENTIFICATION; STRAINS
AB Viruses of the genus Flavivirus, which are arboviruses, of the Flaviviridae family, are amongst the most important agents of infectious disease in Brazil, causing human infections with a high morbility and mortality. In this work, the phylogeny of 14 virus amplicon sequences that were obtained by RT-PCR with universal primers for mosquito-borne Flavivirus were studied. The amplicons included a region of the Flavivirus genome of 129 nucleotides at the 3' terminus of the NS5 gene and the 145 initial nucleotides of the 3' non-coding region (NS5-3'NCR). Based on phylogenetic trees, most Brazilian Flaviviruses were grouped into two main branches, including a yellow-fever branch and a second main branch divided into a dengue branch that in its turn is subdivided into serotype 1, 2 and 4 branches, and another (Japanese Encephalitis Virus Complex) blanch including SLE and Ilheus. Rocio and Cacipacore viruses were included in the Japanese Encephalitis Virus Complex branch in one of the two phylogenetic trees. Iguape virus appears in phylogenetic trees as a separate distant branch. (C) 2001 Elsevier Science B.V. All rights reserved.
C1 Univ Sao Paulo, Sch Med Ribeirao Preto, Virus Res Unit, Ribeirao Preto, Brazil.
   Hemoctr Fdn Ribeirao Preto, Ribeirao Preto, Brazil.
   Univ Sao Paulo, IB, Dept Zool, BR-14049 Ribeirao Preto, Brazil.
RP Figueiredo, LTM (corresponding author), Fac Med Ribeirao Preto, Unidade Multidept Pesquisa Virol, Av Bandeirantes 3-900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM ltmfigue@fmrp.usp.br
RI Kashima, Simone/G-4876-2012; Figueiredo, Luiz T/E-3702-2012; Marques,
   Antonio Carlos/E-8049-2011
OI Kashima, Simone/0000-0002-1487-0141; Marques, Antonio
   Carlos/0000-0002-2884-0541
CR *AM COMM ARTHR BOR, 1985, INT CAT ARB INCL CER
   CAUSEY OR, 1961, AM J TROP MED HYG, V10, P227, DOI 10.4269/ajtmh.1961.10.227
   Cruz ACR, 1997, INTERVIROLOGY, V40, P220, DOI 10.1159/000150550
   Degallier Nicolas, 1992, Ciencia e Cultura (Sao Paulo), V44, P143
   DEUBEL V, 1998, VIROLOGY, V65, P234
   Figueiredo L T, 1990, Rev Soc Bras Med Trop, V23, P13, DOI 10.1590/S0037-86821990000100003
   Figueiredo L. T., 1998, OVERVIEW ARBOVIROLOG, P154
   Figueiredo LTM, 1998, AM J TROP MED HYG, V59, P357, DOI 10.4269/ajtmh.1998.59.357
   FIGUEIREDO LTM, 1992, REV INST MED TROP SP, V34, P121, DOI 10.1590/S0036-46651992000200007
   FONSECA BAL, 1996, TRATADO INFECT, P251
   FU JL, 1992, VIROLOGY, V188, P953, DOI 10.1016/0042-6822(92)90560-C
   HALSTEAD SB, 1998, EMERG INFECT DIS, P65
   Kuno G, 1998, J VIROL, V72, P73, DOI 10.1128/JVI.72.1.73-83.1998
   LOPES ODS, 1978, AM J EPIDEMIOL, V107, P444
   LOPES ODS, 1979, AM J TROP MED HYG, V28, P583
   MACKOW E, 1987, VIROLOGY, V159, P217, DOI 10.1016/0042-6822(87)90458-2
   MEYER D, 1997, ELEMENTOS BASICOS SI, P188
   NI HL, 1994, J GEN VIROL, V75, P1505, DOI 10.1099/0022-1317-75-6-1505
   OSANAI CH, 1986, REV INST MED TROP SP, V23, P53
   PINHEIRO FP, 1981, AM J TROP MED HYG, V30, P145, DOI 10.4269/ajtmh.1981.30.145
   PINHEIRO FP, 1981, CRC HDB SERIES ZOONO, P168
   Proutski V, 1997, NUCLEIC ACIDS RES, V25, P1194, DOI 10.1093/nar/25.6.1194
   RICE CM, 1985, SCIENCE, V229, P726, DOI 10.1126/science.4023707
   RICE CM, 1995, VIROLOGY, P931
   SCHATZMAYR H G, 1986, Memorias do Instituto Oswaldo Cruz, V81, P245, DOI 10.1590/S0074-02761986000200019
   Sneath PHA, 1973, NUMERICAL TAXONOMY
   Swofford D., 1999, PHYLOGENETIC ANAL US
   TANAKA M, 1993, J VIROL METHODS, V41, P311, DOI 10.1016/0166-0934(93)90020-R
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Travassos da Rosa J.F.S., 1998, OVERVIEW ARBOVIROLOG, P19
   Vasconcelos P., 1998, OVERVIEW ARBOVIROLOG, P72
   Vasconcelos Pedro F. Da C., 1995, Revista do Instituto de Medicina Tropical de Sao Paulo, V37, P253
   Vasconcelos PFC, 1992, CIENC CULT-SAO PAULO, V43, P117
   VASCONCELOS PFC, 1993, BRASIL REV I MED TRO, V35, P141
   WALLNER G, 1995, VIROLOGY, V213, P169, DOI 10.1006/viro.1995.1557
   Wang E, 1996, VIROLOGY, V225, P274, DOI 10.1006/viro.1996.0601
   WENGLER G, 1991, ARCH VIROL, V2, P230
   ZAGNE SMO, 1994, T ROY SOC TROP MED H, V88, P677, DOI 10.1016/0035-9203(94)90225-9
NR 38
TC 12
Z9 13
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD MAY
PY 2001
VL 75
IS 1
BP 35
EP 42
DI 10.1016/S0168-1702(01)00222-2
PG 8
WC Virology
SC Virology
GA 422JX
UT WOS:000168115700004
PM 11311426
DA 2020-11-26
ER

PT J
AU Alcantara, LCJ
   Shindo, N
   Van Dooren, S
   Kashima, S
   Costa, MCR
   Andrade, T
   Andrade, A
   Bittencourt, A
   Dourado, I
   Covas, DT
   Vandamme, AM
   Galvao-Castro, B
AF Alcantara, LCJ
   Shindo, N
   Van Dooren, S
   Kashima, S
   Costa, MCR
   Andrade, T
   Andrade, A
   Bittencourt, A
   Dourado, I
   Covas, DT
   Vandamme, AM
   Galvao-Castro, B
TI Molecular epidemiology of human T-cell lymphotropic virus type I
   (HTLV-I) in northeast of Brazil.
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
C1 Oswaldo Cruz Fdn, Goncalo Moniz Res Ctr, Adv Publ Hlth Lab, Salvador, BA, Brazil.
   Fdn Dev Sci, Bahia Sch Med & Publ Hlth, Salvador, BA, Brazil.
   Catholic Univ Leuven, Rega Inst, Louvain, Belgium.
   Blood Ctr Fdn Ribeirao Preto, Sao Paulo, Brazil.
   Univ Fed Bahia, BR-41170290 Salvador, BA, Brazil.
RI Van Dooren, Sonia/E-3113-2019; Vandamme, Anne-Mieke/I-4127-2012; Covas,
   Dimas T/C-5431-2013; Kashima, Simone/G-4876-2012
OI Vandamme, Anne-Mieke/0000-0002-6594-2766; Covas, Dimas
   T/0000-0002-7364-2595; Kashima, Simone/0000-0002-1487-0141
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PY 2001
VL 17
SU 1
BP S33
EP S33
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 446EE
UT WOS:000169499300108
DA 2020-11-26
ER

PT J
AU Kashima, S
   Alcantara, LCJ
   Takayanagui, OM
   Carreto, R
   Galvao-Castro, B
   Covas, DT
AF Kashima, S
   Alcantara, LCJ
   Takayanagui, OM
   Carreto, R
   Galvao-Castro, B
   Covas, DT
TI Phylogenetic analysis of human T-cell lymphotropic viruses type I
   (HTLV-I)
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
C1 Blood Ctr Ribeirao Preto, Ribeirao Preto, Brazil.
   Osvaldo Cruz Fdn, Salvador, BA, Brazil.
   USP, Fac Med Ribeirao Preto, BR-09500900 Sao Paulo, Brazil.
RI Kashima, Simone/G-4876-2012; Covas, Dimas T/C-5431-2013; Takayanagui,
   Osvaldo M/C-8159-2013
OI Kashima, Simone/0000-0002-1487-0141; Covas, Dimas T/0000-0002-7364-2595;
   Takayanagui, Osvaldo M/0000-0002-8190-0275
NR 0
TC 2
Z9 2
U1 0
U2 0
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PY 2001
VL 17
SU 1
BP S38
EP S38
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 446EE
UT WOS:000169499300126
DA 2020-11-26
ER

PT J
AU Shindo, N
   Alcantara, LCJ
   Van Dooren, S
   Salemi, M
   Costa, MCR
   Kashima, S
   Covas, DT
   Teva, A
   Brito, I
   Vandamme, AM
   Galvao-Castro, B
AF Shindo, N
   Alcantara, LCJ
   Van Dooren, S
   Salemi, M
   Costa, MCR
   Kashima, S
   Covas, DT
   Teva, A
   Brito, I
   Vandamme, AM
   Galvao-Castro, B
TI Human retroviruses (HIV and HTLV) in Brazilian Indians:
   Seroepidemiological study and molecular epidemiology of HTLV-II
   isolates.
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
C1 Oswaldo Cruz Fdn, Goncalo Moniz Res Ctr, Adv Publ Hlth Lab, Salvador, BA, Brazil.
   Escola Bahiana Med & Saude Publ, FDC, Salvador, BA, Brazil.
   Catholic Univ Leuven, Rega Inst, Louvain, Belgium.
   Blood Ctr Ribeirao Preto, Sao Paulo, Brazil.
   Oswaldo Cruz Fdn, IOC, Rio De Janeiro, Brazil.
   Brazilian Hlth Minist, CN DST AIDS, Salvador, BA, Brazil.
RI Vandamme, Anne-Mieke/I-4127-2012; Kashima, Simone/G-4876-2012; Van
   Dooren, Sonia/E-3113-2019; Covas, Dimas T/C-5431-2013
OI Vandamme, Anne-Mieke/0000-0002-6594-2766; Kashima,
   Simone/0000-0002-1487-0141; Covas, Dimas T/0000-0002-7364-2595
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PY 2001
VL 17
SU 1
BP S41
EP S41
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 446EE
UT WOS:000169499300140
DA 2020-11-26
ER

PT J
AU Pietro, RCLR
   Kashima, S
   Sato, DN
   Januario, AH
   Franca, SC
AF Pietro, RCLR
   Kashima, S
   Sato, DN
   Januario, AH
   Franca, SC
TI In vitro antimycobacterial activities of Physalis angulata L.
SO PHYTOMEDICINE
LA English
DT Article
DE Physalis angulata; plant extract; antimycobacterial; Mycobacterium
   tuberculosis; mycobacteria
ID ALAMAR-BLUE ASSAY; MYCOBACTERIUM-TUBERCULOSIS; ALKEKENGI; DISEASES;
   ANALOGS; PLANTS; SYSTEM; AVIUM
AB The HIV-tuberculosis co-infection has caused an impact on tuberculosis epidemiology all over the world and the efficacies of the therapeutic schemes traditionally prescribed in the treatment of tuberculosis, such as isoniazid, rifampicin and pyrazinamide, have decreased due to the appearance of multidrug-resistant M. tuberculosis strains (MDR). This work is part of research on natural antimicrobial agents from plant: extracts through bioassay-guided fractionation, by in vitro determination of the minimum inhibitory concentration (MIC) using the microdilution method with Alamar blue oxidation-reduction dye. Crude CHCl3 Physalis angulata extracts and physalin-containing fractions displayed antimycobacterial activity against Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium kansasii, Mycobacterium malmoense and Mycobacterium intracellulare.
C1 Univ Ribeirao Preto, UNAERP, Dept Ciencias Farmaceut, BR-14096380 Ribeirao Preto, SP, Brazil.
   Adolfo Lutz Inst, Ribeirao Preto, SP, Brazil.
   Univ Ribeirao Preto, UNAERP, Dept Biotecnol Vegetal, BR-14096380 Ribeirao Preto, SP, Brazil.
RP Pietro, RCLR (corresponding author), Univ Ribeirao Preto, UNAERP, Dept Ciencias Farmaceut, Ave Costabile Romano 2201, BR-14096380 Ribeirao Preto, SP, Brazil.
EM rpietro@online.unaerp.br
RI Kashima, Simone/G-4876-2012; Pietro, Rosemeire Cristina Linhari
   Rodrigues/G-8996-2015; Januario, Ana Helena AH/G-9375-2012; Pietro,
   Rosemeire/N-1811-2019; Januario, Ana Helena/U-2283-2019; Franca, Suzelei
   C/E-4069-2013
OI Kashima, Simone/0000-0002-1487-0141; Pietro,
   Rosemeire/0000-0001-7859-8127; Franca, Suzelei C/0000-0003-4864-430X;
   Januario, Ana Helena/0000-0002-3815-6903
CR Baker CN, 1996, J CLIN MICROBIOL, V34, P2654, DOI 10.1128/JCM.34.11.2654-2659.1996
   BASEY K, 1992, PHYTOCHEMISTRY, V31, P4173, DOI 10.1016/0031-9422(92)80437-J
   Burman WJ, 1997, AM J MED SCI, V313, P355, DOI 10.1097/00000441-199706000-00008
   CACERES A, 1995, J ETHNOPHARMACOL, V48, P85, DOI 10.1016/0378-8741(95)01288-O
   Cantrell CL, 1998, PHYTOMEDICINE, V5, P137, DOI 10.1016/S0944-7113(98)80011-1
   CHIANG HC, 1992, ANTICANCER RES, V12, P837
   Cohn DL, 1997, CLIN INFECT DIS, V24, pS121, DOI 10.1093/clinids/24.Supplement_1.S121
   Collins LA, 1997, ANTIMICROB AGENTS CH, V41, P1004, DOI 10.1128/AAC.41.5.1004
   DHOPLE AM, 1995, TUBERCLE LUNG DIS, V76, P136, DOI 10.1016/0962-8479(95)90556-1
   DOOLEY SW, 1992, ANN INTERN MED, V117, P257, DOI 10.7326/0003-4819-117-3-257
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677
   Franca SC, 1999, ACTA HORTIC, P389, DOI 10.17660/ActaHortic.1999.502.64
   Franzblau SG, 1998, J CLIN MICROBIOL, V36, P362, DOI 10.1128/JCM.36.2.362-366.1998
   Freiburghaus F, 1996, J ETHNOPHARMACOL, V55, P1, DOI 10.1016/S0378-8741(96)01463-8
   KAWAI M, 1992, PHYTOCHEMISTRY, V31, P4299, DOI 10.1016/0031-9422(92)80462-N
   KAWAI M, 1987, PHYTOCHEMISTRY, V26, P3313, DOI 10.1016/S0031-9422(00)82495-4
   LIN YS, 1992, AM J CHINESE MED, V20, P233, DOI 10.1142/S0192415X92000242
   Makino B, 1995, J NAT PROD, V58, P1668, DOI 10.1021/np50125a004
   SUNAYAMA R, 1993, PHYTOCHEMISTRY, V34, P529, DOI 10.1016/0031-9422(93)80040-Y
   TIBALLI RN, 1995, J CLIN MICROBIOL, V33, P915, DOI 10.1128/JCM.33.4.915-917.1995
   White MJ, 1996, J NEUROSCI METH, V70, P195, DOI 10.1016/S0165-0270(96)00118-5
   *WHO, 1997, WHOTB97, P225
   WOLINSKY E, 1979, AM REV RESPIR DIS, V119, P107
   YAJKO DM, 1995, J CLIN MICROBIOL, V33, P2324, DOI 10.1128/JCM.33.9.2324-2327.1995
   YAMAMOTO S, 1995, ANTIMICROB AGENTS CH, V39, P2088, DOI 10.1128/AAC.39.9.2088
NR 25
TC 41
Z9 46
U1 1
U2 8
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944-7113
EI 1618-095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD JUL
PY 2000
VL 7
IS 4
BP 335
EP 338
DI 10.1016/S0944-7113(00)80052-5
PG 4
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 348AB
UT WOS:000088960500012
PM 10969728
DA 2020-11-26
ER

PT J
AU Figueiredo, LTM
   Batista, WC
   Kashima, S
   Nassar, ED
AF Figueiredo, LTM
   Batista, WC
   Kashima, S
   Nassar, ED
TI Identification of Brazilian flaviviruses by a simplified reverse
   transcription polymerase chain reaction method using Flavivirus
   universal primers
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID DENGUE HEMORRHAGIC-FEVER; RAPID IDENTIFICATION; NUCLEOTIDE-SEQUENCE;
   YELLOW-FEVER; VIRUS; EXPRESSION; DIAGNOSIS; GENOME
AB We report a simplified reverse transcription-polymerase chain reaction (RT-PCR) method for identification of Brazilian flaviviruses based on the patterns of electrophoretic separation of the amplicons. The RT-PCR was done on the culture fluids of Aedes albopictus C6/36 cells infected with Brazilian flaviviruses, without previous extraction of viral RNA, using Flavivirus universal primers that anneal to highly conserved sequences within the nonstructural protein 5 and 3'- non translated region of the virus genome. Genomes of 13 Brazilian Flavivirus isolates were amplified. It was not possible to amplify the genome of Bussuquara virus. Analysis of the RT-PCR products gave reproducible results and three distinct amplicon patterns were observed. Cacipacore (800-850 basepairs [bp]) and yellow fever viruses (600 bp) yielded a single amplicon; dengue virus types 1 and 2 (650 and 550 bp), dengue virus type 4 (550 and 450 bp), Iguape (650-600 bp and 750-700 bp), St. Louis encephalitis (700 and 650-600 bp), and Rocio viruses (600 and 500-550 bp) yielded two amplicons; and Ilheus virus yielded five amplicons, two larger than 1,000 bp, one 650-700 bp, one 550-600 bp, and one 450-500 bp. The analysis of amplicon DNA sequences of six viruses showed homology with the 3'- nontranslated region of Flavivirus genome. The use of the Flavivirus universal primers in this simple RT-PCR technique is suitable as a screening test for the genus Flavivirus, with the exception of Bussuquara virus, in Brazilian isolates in tissue culture fluid.
C1 Univ Sao Paulo, Fac Med Ribeirao Preto, Unidade Multidisciplinar Pesquisa Virol, BR-14049900 Ribeirao Preto, SP, Brazil.
   Fundacao Hemoctr Ribeirao Preto, BR-14051140 Ribeirao Preto, SP, Brazil.
   Adolfo Lutz Inst, Serv Virol, BR-01246902 Sao Paulo, Brazil.
RP Figueiredo, LTM (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Unidade Multidisciplinar Pesquisa Virol, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
RI Figueiredo, Luiz T/E-3702-2012; Kashima, Simone/G-4876-2012
OI Kashima, Simone/0000-0002-1487-0141
CR *AM COMM ARTHR BOR, 1985, INT CAT ARB INCL CER
   ANDERSON CR, 1961, AM J TROP MED HYG, V10, P574, DOI 10.4269/ajtmh.1961.10.574
   Beaty B.J., 1995, DIAGNOSTIC PROCEDURE, P189
   CALISHER CH, 1989, J GEN VIROL, V70, P37, DOI 10.1099/0022-1317-70-1-37
   CAUSEY OR, 1961, AM J TROP MED HYG, V10, P227, DOI 10.4269/ajtmh.1961.10.227
   Cha Rita S., 1995, P37
   CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245
   Degallier Nicolas, 1992, Ciencia e Cultura (Sao Paulo), V44, P143
   DEUBEL V, 1986, VIROLOGY, V155, P365, DOI 10.1016/0042-6822(86)90200-X
   Figueiredo L T, 1990, Rev Soc Bras Med Trop, V23, P13, DOI 10.1590/S0037-86821990000100003
   FIGUEIREDO LTM, 1992, REV INST MED TROP SP, V34, P121, DOI 10.1590/S0036-46651992000200007
   FIGUEIREDO LTM, 1996, VIRUS REV RES, V1, P9
   HENCHAL EA, 1991, AM J TROP MED HYG, V45, P418, DOI 10.4269/ajtmh.1991.45.418
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   LIU HS, 1995, J VIROL METHODS, V51, P55, DOI 10.1016/0166-0934(94)00111-S
   LOPES ODS, 1978, AM J EPIDEMIOL, V107, P444
   LOPES ODS, 1979, AM J TROP MED HYG, V28, P583
   MORITA K, 1991, J CLIN MICROBIOL, V29, P2107, DOI 10.1128/JCM.29.10.2107-2110.1991
   MORITA K, 1994, J MED VIROL, V44, P54, DOI 10.1002/jmv.1890440111
   Osanai C H, 1983, Rev Inst Med Trop Sao Paulo, V25, P53
   PINHEIRO FP, 1981, AM J TROP MED HYG, V30, P145, DOI 10.4269/ajtmh.1981.30.145
   PINHEIRO FP, 1981, CRC HDB SERIES ZOONO, P168
   RICE CM, 1985, SCIENCE, V229, P726, DOI 10.1126/science.4023707
   RICE CM, 1995, VIROLOGY, P931
   Robertson SE, 1996, JAMA-J AM MED ASSOC, V276, P1157, DOI 10.1001/jama.276.14.1157
   SCHATZMAYR H G, 1986, Memorias do Instituto Oswaldo Cruz, V81, P245, DOI 10.1590/S0074-02761986000200019
   TANAKA M, 1991, Tropical Medicine, V33, P23
   TANAKA M, 1993, J VIROL METHODS, V41, P311, DOI 10.1016/0166-0934(93)90020-R
   Vasconcelos Pedro F. Da C., 1995, Revista do Instituto de Medicina Tropical de Sao Paulo, V37, P253
   Vasconcelos Pedro Fernando Da Costa, 1993, Revista do Instituto de Medicina Tropical de Sao Paulo, V35, P141, DOI 10.1590/S0036-46651993000200005
   Vasconcelos PFC, 1992, CIENC CULT-SAO PAULO, V43, P117
   WENGLER G, 1991, ARCH VIROL, V2, P230
   ZAGNE SMO, 1994, T ROY SOC TROP MED H, V88, P677, DOI 10.1016/0035-9203(94)90225-9
NR 33
TC 18
Z9 20
U1 0
U2 5
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD SEP
PY 1998
VL 59
IS 3
BP 357
EP 362
DI 10.4269/ajtmh.1998.59.357
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 119RJ
UT WOS:000075910700003
PM 9749625
OA Bronze
DA 2020-11-26
ER

PT J
AU Covas, DT
   Biscaro, TA
   Kashima, S
   Duarte, T
   Machado, AA
AF Covas, DT
   Biscaro, TA
   Kashima, S
   Duarte, T
   Machado, AA
TI High frequency of the GWG (Pro trp) envelope variant of HIV-1 in
   southeast Brazil
SO JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY
LA English
DT Article
DE HIV-1 V3 loop; genetic variability; RFLP; Brazil
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PRINCIPAL NEUTRALIZING DETERMINANT;
   SUBTYPE-B STRAINS; V3 LOOP; TYPE-1; SEQUENCE; REGION; GLYCOPROTEIN;
   INFECTIVITY; ANTIBODIES
AB The HIV-1 variant that contains the GWG amino acid sequence in the crown of the principal neutralizing determinant (PND) has been detected in a few patients in Japan, France, and Brazil by direct sequencing. We describe for the first time the use of restriction fragment length polymorphism (RFLP) and limited DNA sequencing of the C2-V3 region of the HN-I envelope (env) gene to determine the prevalence of the variant in 75 HIV-l-infected Brazilian patients. Overall prevalence of the GWC sequence as indicated by RFLP was 57% (43 of 75). The prevalence in females (72%) was higher than that in males (32%) and newborns (40%). Two GFG sequences and I CLG sequence were also detected. This finding is relevant for the planning of vaccines and for studies of the epidemiology of HN-I in Brazil.
C1 Univ Sao Paulo, Fac Med Ribeirao Preto, Ribeirao Preto, Brazil.
   Univ Sao Paulo, Fac Med Ribeirao Preto, Ribeirao Preto, Brazil.
RP Covas, DT (corresponding author), Fdn Hemoctr Ribeirao Preto, R Tenente Catao Roxo 2501, BR-14051140 Ribeirao Preto, SP, Brazil.
RI Covas, Dimas T/C-5431-2013; Kashima, Simone/G-4876-2012; Duarte,
   Geraldo/J-7906-2012
OI Covas, Dimas T/0000-0002-7364-2595; Kashima, Simone/0000-0002-1487-0141;
   Machado, Alcyone/0000-0002-5677-7332
CR BROLIDEN PA, 1992, P NATL ACAD SCI USA, V89, P461, DOI 10.1073/pnas.89.2.461
   BUCK CB, 1996, IMMUNOLOGY HIV INFEC, P23
   FISHER AG, 1988, NATURE, V334, P444, DOI 10.1038/334444a0
   GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344
   GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478
   GRIMAILA RJ, 1992, J VIROL, V66, P1875, DOI 10.1128/JVI.66.4.1875-1883.1992
   HATTORI T, 1991, AIDS RES HUM RETROV, V7, P825, DOI 10.1089/aid.1991.7.825
   HOLMES EC, 1992, P NATL ACAD SCI USA, V89, P4838
   HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842
   IVANOFF LA, 1991, AIDS RES HUM RETROV, V7, P595, DOI 10.1089/aid.1991.7.595
   IVANOFF LA, 1992, VIROLOGY, V187, P423, DOI 10.1016/0042-6822(92)90444-T
   KUMAR S, 1993, MEGA MOL EVOLUTIONAR
   LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685
   Lasky M, 1997, AIDS, V11, P43, DOI 10.1097/00002030-199701000-00007
   LEONARD CK, 1990, J BIOL CHEM, V265, P10373
   MATSUSHITA S, 1988, J VIROL, V62, P2107, DOI 10.1128/JVI.62.6.2107-2114.1988
   MORGADO MG, 1994, AIDS RES HUM RETROV, V10, P569, DOI 10.1089/aid.1994.10.569
   MYERS G, 1996, HUMAN RETROVIRUSES A
   OU CY, 1993, LANCET, V341, P1171, DOI 10.1016/0140-6736(93)91001-3
   PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932
   PANG S, 1991, J ACQ IMMUN DEF SYND, V4, P1082
   POTTS KE, 1993, AIDS, V7, P1191, DOI 10.1097/00002030-199309000-00007
   RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198
   SAMBROOK J, 1989, MOL CLONING LAB MANU, P45
   SIMMONDS P, 1990, J VIROL, V64, P5840, DOI 10.1128/JVI.64.12.5840-5850.1990
   WESTERVELT P, 1992, J VIROL, V66, P2577, DOI 10.1128/JVI.66.4.2577-2582.1992
   WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316
   Yamaguchi Y, 1997, P NATL ACAD SCI USA, V94, P1264, DOI 10.1073/pnas.94.4.1264
NR 28
TC 19
Z9 21
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA
SN 1077-9450
J9 J ACQ IMMUN DEF SYND
JI J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.
PD SEP 1
PY 1998
VL 19
IS 1
BP 74
EP 79
DI 10.1097/00042560-199809010-00012
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 114QX
UT WOS:000075621300012
PM 9732073
DA 2020-11-26
ER

PT J
AU Kashima, S
   Kitagawa, M
AF Kashima, S
   Kitagawa, M
TI The longest suspension bridge (vol 277, pg 88, 1997)
SO SCIENTIFIC AMERICAN
LA English
DT Correction
CR Kashima S, 1997, SCI AM, V277, P88, DOI 10.1038/scientificamerican1297-88
NR 1
TC 0
Z9 0
U1 0
U2 0
PU SCI AMERICAN INC
PI NEW YORK
PA 415 MADISON AVE, NEW YORK, NY 10017 USA
SN 0036-8733
J9 SCI AM
JI Sci.Am.
PD MAR
PY 1998
VL 278
IS 3
BP 10
EP 10
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA YX866
UT WOS:000072087500010
DA 2020-11-26
ER

PT J
AU Kashima, S
   Kitagawa, M
AF Kashima, S
   Kitagawa, M
TI The longest suspension bridge
SO SCIENTIFIC AMERICAN
LA English
DT Article
RP Kashima, S (corresponding author), HONSHU SHIKOKU BRIDGE AUTHOR,CONSTRUCT BUR 1,KOBE,HYOGO,JAPAN.
CR Gimsing N.J, 1997, CABLE SUPPORTED BRID
   Irvine H.M., 1992, CABLE STRUCTURES
   MATSUDA K, 1997, IHI ENG REV TOKYO, V30, P93
   TAKE N, 1997, TECHNOLOGY REPORTS O, V47, P79
   1993, J EC J, V31, P13
NR 5
TC 1
Z9 1
U1 0
U2 0
PU SCI AMERICAN INC
PI NEW YORK
PA 415 MADISON AVE, NEW YORK, NY 10017
SN 0036-8733
J9 SCI AM
JI Sci.Am.
PD DEC
PY 1997
VL 277
IS 6
BP 88
EP &
DI 10.1038/scientificamerican1297-88
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA YG852
UT WOS:A1997YG85200030
DA 2020-11-26
ER

EF